-- Generated by Craft v2.6.2791 on Jul 15, 2016, 5:57:54 PM.

--
-- Disable foreign key checks and autocommit.
--

SET FOREIGN_KEY_CHECKS = 0;
SET SQL_MODE = "NO_AUTO_VALUE_ON_ZERO";
SET AUTOCOMMIT = 0;
SET NAMES utf8;


DROP TABLE IF EXISTS `craft_assetfiles`;


--
-- Schema for table `craft_assetfiles`
--
CREATE TABLE `craft_assetfiles` (
  `id` int(11) NOT NULL,
  `sourceId` int(11) DEFAULT NULL,
  `folderId` int(11) NOT NULL,
  `filename` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `kind` varchar(50) COLLATE utf8_unicode_ci NOT NULL DEFAULT 'unknown',
  `width` int(11) unsigned DEFAULT NULL,
  `height` int(11) unsigned DEFAULT NULL,
  `size` bigint(20) unsigned DEFAULT NULL,
  `dateModified` datetime DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_assetfiles_filename_folderId_unq_idx` (`filename`,`folderId`),
  KEY `craft_assetfiles_sourceId_fk` (`sourceId`),
  KEY `craft_assetfiles_folderId_fk` (`folderId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_assetfiles`
--

INSERT INTO `craft_assetfiles` (`id`, `sourceId`, `folderId`, `filename`, `kind`, `width`, `height`, `size`, `dateModified`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('31', '1', '1', 'texture_1.png', 'image', '500', '750', '470172', '2016-06-14 20:20:18', '2016-06-14 20:20:18', '2016-06-14 20:45:49', '4622e9d3-4506-4352-bde1-024ed1f3c910'),
 ('34', '3', '3', 'texture_1.png', 'image', '500', '750', '470172', '2016-06-14 20:21:32', '2016-06-14 20:21:32', '2016-06-14 20:45:49', 'edbc53f3-9611-473a-8ed9-41704f83615c'),
 ('51', '1', '1', 'marble.jpg', 'image', '4000', '2250', '1280149', '2016-06-16 18:43:09', '2016-06-16 18:43:10', '2016-06-16 18:43:10', '1996d27c-bb44-4800-8383-e70c9333e76b'),
 ('80', '1', '1', 'texture_2_160707_220422.jpg', 'image', '1470', '584', '96838', '2016-07-07 22:04:22', '2016-07-07 22:04:25', '2016-07-07 22:04:25', '0b65ba52-4990-463d-b669-5f31463f883e'),
 ('83', '1', '1', 'stock-photo-light-micrograph-of-white-adipose-tissue-adipocytes-fat-cells-contain-a-large-lipid-droplet-the-267094196.jpg', 'image', '450', '380', '82963', '2016-07-08 19:37:25', '2016-07-08 19:37:25', '2016-07-08 19:37:25', 'bef3c975-e54f-4874-815d-748813a3b348'),
 ('87', '1', '1', 'cover_homepage.jpg', 'image', '1600', '800', '193578', '2016-07-11 17:23:22', '2016-07-11 17:23:22', '2016-07-11 17:23:22', 'f749aa28-f02d-4108-a796-b61e81d41be0'),
 ('88', '1', '1', 'cover-about.jpg', 'image', '1600', '800', '203147', '2016-07-11 17:23:23', '2016-07-11 17:23:23', '2016-07-11 17:23:23', '11c45eea-bd14-4c31-a6b8-41a6f654fa08'),
 ('89', '1', '1', 'header_section-healthcare_services.jpg', 'image', '1600', '300', '61183', '2016-07-11 17:23:24', '2016-07-11 17:23:24', '2016-07-11 17:23:24', '607bec27-684a-4e5d-91e6-d8c9d9104050'),
 ('90', '1', '1', 'header_section-legacy_companies.jpg', 'image', '1600', '300', '175486', '2016-07-11 17:23:24', '2016-07-11 17:23:24', '2016-07-11 17:23:24', 'e398dacd-a0d3-43cf-bb08-ce1a69310870'),
 ('92', '1', '1', 'header_section-medical_devices.jpg', 'image', '1600', '300', '86761', '2016-07-11 17:23:25', '2016-07-11 17:23:25', '2016-07-11 17:23:25', 'a8989a02-4df7-4383-83fd-016e6c175d52'),
 ('93', '1', '1', 'header_section-news.jpg', 'image', '1600', '300', '131541', '2016-07-11 17:23:26', '2016-07-11 17:23:26', '2016-07-11 17:23:26', '1bf871c4-6a82-4a33-a452-fe1cf8364676'),
 ('94', '1', '1', 'header_section-press.jpg', 'image', '1600', '300', '72200', '2016-07-11 17:23:26', '2016-07-11 17:23:26', '2016-07-11 17:23:26', '85e3d825-3a4e-46c1-90c5-5fa2a68432f8'),
 ('95', '1', '1', 'header_section-therapeutics.jpg', 'image', '1600', '300', '150654', '2016-07-11 17:23:27', '2016-07-11 17:23:27', '2016-07-11 17:23:27', 'df34d8d2-4f5c-401a-842d-b85bda52f685'),
 ('112', '1', '1', 'icon_atp_logo.svg', 'image', '280', '122', '165332', '2016-07-11 20:42:52', '2016-07-11 20:42:52', '2016-07-11 20:42:52', 'bd77e8da-6ed3-477b-8de5-43c63daf8d08'),
 ('136', '1', '1', 'footer.jpg', 'image', '640', '275', '29790', '2016-07-11 21:17:42', '2016-07-11 21:17:42', '2016-07-11 21:50:45', '03450e1a-e1d2-4876-bcab-8093ea3aca3e'),
 ('202', '2', '2', 'icon_atp_logo.svg', 'image', '280', '122', '165332', '2016-07-11 21:57:43', '2016-07-11 21:57:43', '2016-07-11 21:57:43', 'a191e8cc-34a7-454c-a9d3-026b47399a98'),
 ('361', '2', '2', 'Braeburn_transparent.png', 'image', '506', '282', '25647', '2016-07-13 16:24:30', '2016-07-13 16:24:30', '2016-07-13 16:24:30', 'a39ee913-c145-491d-a38b-63983187b42c'),
 ('362', '2', '2', 'SyntimmuneLogo.png', 'image', '800', '106', '33474', '2016-07-13 16:24:30', '2016-07-13 16:24:30', '2016-07-13 16:24:30', '441174d3-be2b-4ca1-8555-98b77f50520c'),
 ('363', '2', '2', 'TripleCare_transparent.PNG', 'image', '1291', '953', '62675', '2016-07-13 16:24:33', '2016-07-13 16:24:33', '2016-07-13 16:24:33', '71ac665e-e023-4061-9cc5-4c892687f344'),
 ('364', '2', '2', 'Aileron_logo_4C.png', 'image', '731', '600', '48505', '2016-07-13 16:24:34', '2016-07-13 16:24:34', '2016-07-13 16:24:34', '8c800801-ba60-4a58-adb6-ad3077e14745'),
 ('365', '2', '2', 'Tokai_Pharmaceuticals_Logo_PMS.PNG', 'image', '588', '139', '6422', '2016-07-13 16:24:34', '2016-07-13 16:24:34', '2016-07-13 16:24:34', '569b5b2d-d2f7-454b-8269-93dcf149c4bd'),
 ('366', '2', '2', 'CleanSlate_Transparent.png', 'image', '450', '180', '10078', '2016-07-13 16:24:34', '2016-07-13 16:24:34', '2016-07-13 16:24:34', '65e86697-242a-4a7e-b229-0b64a024b8a0'),
 ('367', '2', '2', 'Gloucestor_transparent.png', 'image', '232', '105', '41053', '2016-07-13 16:24:34', '2016-07-13 16:24:35', '2016-07-13 16:24:35', 'fee7393a-b111-45bb-b6ec-9fb854030310'),
 ('369', '2', '2', 'HeartWare_transparent.png', 'image', '300', '86', '103589', '2016-07-13 16:24:36', '2016-07-13 16:24:36', '2016-07-13 16:24:36', '9082b7bc-1b65-4414-bf3a-05a3ae590b75'),
 ('370', '2', '2', 'SGX_transparent.png', 'image', '297', '215', '13924', '2016-07-13 16:24:36', '2016-07-13 16:24:36', '2016-07-13 16:24:36', '1f0d8872-9569-4c21-93a5-e042d045d02d'),
 ('371', '2', '2', 'Tendyne_transparent.png', 'image', '241', '49', '4311', '2016-07-13 16:24:36', '2016-07-13 16:24:36', '2016-07-13 16:24:36', '6b9e012f-de1e-4c80-a73d-fd7fe6fdd06e'),
 ('372', '2', '2', 'vytronus_transparent.png', 'image', '1547', '432', '234288', '2016-07-13 16:24:37', '2016-07-13 16:24:37', '2016-07-13 16:24:37', 'c39e19ba-9b3e-498e-aaea-47b66ffacb0a'),
 ('373', '2', '2', 'CureForward_transparent.png', 'image', '813', '280', '912380', '2016-07-13 16:24:38', '2016-07-13 16:24:38', '2016-07-13 16:24:38', '3463b4e1-cb0f-47e8-ac1e-3374fdb3e033'),
 ('374', '2', '2', 'Qualderm_transparent.png', 'image', '608', '211', '40633', '2016-07-13 16:24:40', '2016-07-13 16:24:40', '2016-07-13 16:24:40', 'e283a2c4-eec6-442a-9fbe-d4c48ca49382'),
 ('375', '2', '2', 'Tusker_transparent.png', 'image', '2581', '898', '333884', '2016-07-13 16:24:42', '2016-07-13 16:24:43', '2016-07-13 16:24:43', 'f4f8ef00-84af-47c4-82ce-b1e0c4328a2a'),
 ('377', '1', '1', 'icon_atp_logo-white.svg', 'image', '280', '122', '163739', '2016-07-13 17:00:51', '2016-07-13 17:00:51', '2016-07-13 17:10:22', '617f2978-1725-418f-9bc4-80e2cbd6cc94'),
 ('380', '2', '2', 'CoelacanthChemicalCorporation.png', 'image', '600', '148', '8266', '2016-07-13 17:17:59', '2016-07-13 17:17:59', '2016-07-13 17:17:59', '6e35accd-9ffb-4eb3-aaa3-04f1f5b69bd3'),
 ('381', '2', '2', 'Gala_Logo.png', 'image', '661', '287', '105699', '2016-07-13 17:18:00', '2016-07-13 17:18:00', '2016-07-13 17:18:00', 'c4a162b9-97a8-4d79-95d2-41b7d18097f8'),
 ('382', '2', '2', 'cyrano.png', 'image', '244', '71', '7364', '2016-07-13 17:18:00', '2016-07-13 17:18:00', '2016-07-13 17:18:00', '70a6a5d6-36d6-454a-8247-d87b94933321'),
 ('387', '1', '1', 'header_section-legal-1.jpg', 'image', '1600', '300', '146418', '2016-07-14 19:36:49', '2016-07-14 19:36:49', '2016-07-14 19:36:49', '0f2a32f0-3824-41a9-a389-e5f3e8baa79f'),
 ('388', '1', '1', 'Menu-Background.png', 'image', '640', '1100', '284837', '2016-07-15 16:57:28', '2016-07-15 16:57:28', '2016-07-15 16:57:28', '07b4b0af-b420-4118-a4a0-517333d429c5');



DROP TABLE IF EXISTS `craft_assetfolders`;


--
-- Schema for table `craft_assetfolders`
--
CREATE TABLE `craft_assetfolders` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `parentId` int(11) DEFAULT NULL,
  `sourceId` int(11) DEFAULT NULL,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `path` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_assetfolders_name_parentId_sourceId_unq_idx` (`name`,`parentId`,`sourceId`),
  KEY `craft_assetfolders_parentId_fk` (`parentId`),
  KEY `craft_assetfolders_sourceId_fk` (`sourceId`)
) ENGINE=InnoDB AUTO_INCREMENT=8 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_assetfolders`
--

INSERT INTO `craft_assetfolders` (`id`, `parentId`, `sourceId`, `name`, `path`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', NULL, '1', 'Site Assets', '', '2016-06-14 19:24:49', '2016-06-14 19:24:49', 'eebb19a8-5b96-4873-b63e-1eb0d9619b67'),
 ('2', NULL, '2', 'Company Logos', '', '2016-06-14 19:25:09', '2016-06-14 19:25:09', 'dcb6b1c6-480a-4136-8874-8abc95aebe5b'),
 ('3', NULL, '3', 'News Assets', '', '2016-06-14 19:25:31', '2016-06-14 19:25:31', '870090ee-ea1b-4534-92d4-9e33c4105d12'),
 ('5', NULL, NULL, 'Temporary source', NULL, '2016-07-11 15:30:42', '2016-07-11 15:30:42', 'fd6af4aa-7985-47de-8bbe-7c470c6494a2'),
 ('6', '5', NULL, 'user_1', NULL, '2016-07-11 15:30:42', '2016-07-11 15:30:42', '58a0faa0-d2df-4d8c-bc41-122c73d86249'),
 ('7', '6', NULL, 'field_124', 'field_124/', '2016-07-11 15:30:42', '2016-07-11 15:30:42', '93157121-3826-4204-99ab-d305633ef08f');



DROP TABLE IF EXISTS `craft_assetindexdata`;


--
-- Schema for table `craft_assetindexdata`
--
CREATE TABLE `craft_assetindexdata` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `sessionId` varchar(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '',
  `sourceId` int(10) NOT NULL,
  `offset` int(10) NOT NULL,
  `uri` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `size` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `recordId` int(10) DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_assetindexdata_sessionId_sourceId_offset_unq_idx` (`sessionId`,`sourceId`,`offset`),
  KEY `craft_assetindexdata_sourceId_fk` (`sourceId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_assetsources`;


--
-- Schema for table `craft_assetsources`
--
CREATE TABLE `craft_assetsources` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `handle` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `type` varchar(150) COLLATE utf8_unicode_ci NOT NULL,
  `settings` text COLLATE utf8_unicode_ci,
  `sortOrder` smallint(6) unsigned DEFAULT NULL,
  `fieldLayoutId` int(10) DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_assetsources_name_unq_idx` (`name`),
  UNIQUE KEY `craft_assetsources_handle_unq_idx` (`handle`),
  KEY `craft_assetsources_fieldLayoutId_fk` (`fieldLayoutId`)
) ENGINE=InnoDB AUTO_INCREMENT=4 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_assetsources`
--

INSERT INTO `craft_assetsources` (`id`, `name`, `handle`, `type`, `settings`, `sortOrder`, `fieldLayoutId`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', 'Site Assets', 'siteAssets', 'Local', '{\"path\":\"assets\\/images\\/site\\/_1600x800_crop_center-center\\/\",\"publicURLs\":\"1\",\"url\":\"{basePath}assets\\/images\\/site\\/\"}', '1', '270', '2016-06-14 19:24:49', '2016-07-13 18:59:45', '6288a61a-84b5-4c64-a807-7d3b05cc0282'),
 ('2', 'Company Logos', 'companyLogos', 'Local', '{\"path\":\"assets\\/images\\/company\\/\",\"publicURLs\":\"1\",\"url\":\"{baseUrl}\\/assets\\/images\\/company\\/\"}', '2', '229', '2016-06-14 19:25:09', '2016-07-11 21:57:34', '7e6eec57-4905-4d00-9fda-08d7759763d8'),
 ('3', 'News Assets', 'newsAssets', 'Local', '{\"path\":\"{basePath}\\/assets\\/images\\/news\\/\",\"publicURLs\":\"1\",\"url\":\"{baseUrl}\\/assets\\/images\\/news\\/\"}', '3', '84', '2016-06-14 19:25:31', '2016-06-14 20:15:55', '516153fc-d971-4b19-8219-cfe04301193b');



DROP TABLE IF EXISTS `craft_assettransformindex`;


--
-- Schema for table `craft_assettransformindex`
--
CREATE TABLE `craft_assettransformindex` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `fileId` int(11) NOT NULL,
  `filename` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `format` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `location` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `sourceId` int(11) DEFAULT NULL,
  `fileExists` tinyint(1) DEFAULT NULL,
  `inProgress` tinyint(1) DEFAULT NULL,
  `dateIndexed` datetime DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  KEY `craft_assettransformindex_sourceId_fileId_location_idx` (`sourceId`,`fileId`,`location`)
) ENGINE=InnoDB AUTO_INCREMENT=43 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_assettransforms`;


--
-- Schema for table `craft_assettransforms`
--
CREATE TABLE `craft_assettransforms` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `handle` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `mode` enum('stretch','fit','crop') COLLATE utf8_unicode_ci NOT NULL DEFAULT 'crop',
  `position` enum('top-left','top-center','top-right','center-left','center-center','center-right','bottom-left','bottom-center','bottom-right') COLLATE utf8_unicode_ci NOT NULL DEFAULT 'center-center',
  `height` int(10) DEFAULT NULL,
  `width` int(10) DEFAULT NULL,
  `format` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `quality` int(10) DEFAULT NULL,
  `dimensionChangeTime` datetime DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_assettransforms_name_unq_idx` (`name`),
  UNIQUE KEY `craft_assettransforms_handle_unq_idx` (`handle`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_categories`;


--
-- Schema for table `craft_categories`
--
CREATE TABLE `craft_categories` (
  `id` int(11) NOT NULL,
  `groupId` int(11) NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  KEY `craft_categories_groupId_fk` (`groupId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_categorygroups`;


--
-- Schema for table `craft_categorygroups`
--
CREATE TABLE `craft_categorygroups` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `structureId` int(11) NOT NULL,
  `fieldLayoutId` int(11) DEFAULT NULL,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `handle` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `hasUrls` tinyint(1) unsigned NOT NULL DEFAULT '1',
  `template` varchar(500) COLLATE utf8_unicode_ci DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_categorygroups_name_unq_idx` (`name`),
  UNIQUE KEY `craft_categorygroups_handle_unq_idx` (`handle`),
  KEY `craft_categorygroups_structureId_fk` (`structureId`),
  KEY `craft_categorygroups_fieldLayoutId_fk` (`fieldLayoutId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_categorygroups_i18n`;


--
-- Schema for table `craft_categorygroups_i18n`
--
CREATE TABLE `craft_categorygroups_i18n` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `groupId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `urlFormat` text COLLATE utf8_unicode_ci,
  `nestedUrlFormat` text COLLATE utf8_unicode_ci,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_categorygroups_i18n_groupId_locale_unq_idx` (`groupId`,`locale`),
  KEY `craft_categorygroups_i18n_locale_fk` (`locale`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_content`;


--
-- Schema for table `craft_content`
--
CREATE TABLE `craft_content` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `elementId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `title` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `field_blurb` text COLLATE utf8_unicode_ci,
  `field_publishedDate` datetime DEFAULT NULL,
  `field_aboutTitle` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `field_aboutText` text COLLATE utf8_unicode_ci,
  `field_teamMemberBio` text COLLATE utf8_unicode_ci,
  `field_companyBio` text COLLATE utf8_unicode_ci,
  `field_teamMemberShortDescription` varchar(200) COLLATE utf8_unicode_ci DEFAULT NULL,
  `field_companyShortDescription` text COLLATE utf8_unicode_ci,
  `field_footerCopy` text COLLATE utf8_unicode_ci,
  `field_teamMemberPosition` text COLLATE utf8_unicode_ci,
  `field_trajectorySectionTitle` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `field_partnershipSectionTitle` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `field_twitterShortDescription` varchar(115) COLLATE utf8_unicode_ci DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_content_elementId_locale_unq_idx` (`elementId`,`locale`),
  KEY `craft_content_title_idx` (`title`),
  KEY `craft_content_locale_fk` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=259 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_content`
--

INSERT INTO `craft_content` (`id`, `elementId`, `locale`, `title`, `field_blurb`, `field_publishedDate`, `field_aboutTitle`, `field_aboutText`, `field_teamMemberBio`, `field_companyBio`, `field_teamMemberShortDescription`, `field_companyShortDescription`, `field_footerCopy`, `field_teamMemberPosition`, `field_trajectorySectionTitle`, `field_partnershipSectionTitle`, `field_twitterShortDescription`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '1', 'en_us', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-10 14:33:29', '2016-07-11 20:08:13', '0bcd8afd-acaa-44d7-88e6-3cae2ec96878'),
 ('4', '4', 'en_us', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '<h2>Do you have a&nbsp;</h2>\r\n\r\n<h2>revolutionary innovation?&nbsp;</h2>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<h2><em><a href=\"{entry:10:url}\">Let\'s talk.</a></em></h2>', NULL, NULL, NULL, NULL, '2016-06-10 18:12:53', '2016-07-13 18:21:00', 'a8dbaa83-ce02-44b2-94ee-762d24a61bb1'),
 ('8', '9', 'en_us', 'Home', '<p>We use a <em>long term investment philosophy</em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.</p>', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Charting a trajectory', 'Partnerships', NULL, '2016-06-14 15:24:07', '2016-07-13 21:11:57', '5adca0e1-3d73-44e4-b672-e24ab2573408'),
 ('9', '10', 'en_us', 'Contact', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-14 15:24:20', '2016-07-13 21:20:34', '599dfda3-d068-4295-991c-e3aa42eb7387'),
 ('11', '12', 'en_us', 'Team', NULL, NULL, 'About Apple Tree Partners (ATP)', 'Founded in 1999, we are a venture capital firm that invests in and starts new therapeutic, medtech, and healthcare service companies. With a history of well-known successes in long-term investment strategies, our managers can build with confidence, knowing that we are funding them to grow and develop their businesses.', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-14 15:25:54', '2016-07-14 16:36:39', '870dc90f-8b9f-4704-867c-ed5070e175de'),
 ('12', '13', 'en_us', 'Portfolio', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-14 15:26:11', '2016-07-13 21:16:21', 'c4957ce5-05f9-48bb-b5f9-129a68b9168c'),
 ('13', '14', 'en_us', 'CleanSlate Centers names Gregory C. Marotta President & CEO', NULL, '2016-06-13 04:00:00', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'CleanSlate Centers names Gregory C. Marotta President & CEO', '2016-06-14 15:37:22', '2016-07-15 16:27:09', '2fed676c-d7da-4e4c-81b7-2bfe72f43415'),
 ('14', '27', 'en_us', 'Aileron Therapeutics', NULL, NULL, NULL, NULL, NULL, '<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. ALRN-6924, in Phase 1, is a p53 re-activator for the treatment of cancer, the only p53 molecule in development that targets both MDM2 and MDMX.</p>', NULL, '<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform.</p>', NULL, NULL, NULL, NULL, NULL, '2016-06-14 16:14:38', '2016-07-13 16:33:56', '8ab06d0d-bee3-4b4a-984b-193881ad2520'),
 ('15', '29', 'en_us', 'Seth L. Harrison, MD', NULL, NULL, NULL, NULL, '<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York. </p>\n\n<p><br /></p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.</p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<p><br /></p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br /></p>', NULL, 'Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991.', NULL, NULL, 'Managing Partner', NULL, NULL, NULL, '2016-06-14 16:15:24', '2016-07-13 17:29:25', '62378845-fa8f-48b4-9ef9-12e79603d932'),
 ('16', '31', 'en_us', 'Texture 1', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-14 20:20:18', '2016-06-14 20:45:49', '369a0514-2bd7-4388-afa1-49c91a0d6b51'),
 ('19', '34', 'en_us', 'Texture 1', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-14 20:21:32', '2016-06-14 20:45:49', 'c90e964e-dc7f-4ac6-aea2-bcffcf3db6aa'),
 ('21', '51', 'en_us', 'Marble', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-16 18:43:10', '2016-06-16 18:43:10', '1c995825-3e53-48af-994b-0a9ca5ec88ac'),
 ('22', '52', 'en_us', 'Mass.-based addiction treatment center expands nationally as opioid epidemic rages on', NULL, '2016-06-15 04:00:00', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Mass.-based addiction treatment center expands nationally as opioid epidemic rages on', '2016-06-16 20:31:27', '2016-07-15 16:27:02', '2da50663-a4e5-4ab3-86ef-cd643d89516c'),
 ('23', '53', 'en_us', 'Diane M. Daych', NULL, NULL, NULL, NULL, '<p>Diane has over 25 years of investing, advisory and operating experience, with over 20 years focused on the healthcare services industry. She joined Apple Tree Partners in 2013 to lead their healthcare services investing. From 2010 to 2012, she was a Managing Director and Co-Head, Private Equity of the Marwood Group. Additionally, since 2000, Diane has been a partner and principal at CCP Equity Partners (“CCP”) and its predecessor firm, Conning Capital Partners, where she invested in growth companies that offer specialized solutions for the financing, management and delivery of health care in industries such as managed care, disease and care management, outpatient services, information technology and healthcare-related ancillary and outsourcing services. Prior to joining CCP in 2000, she held a senior development role at Mariner Health, a post acute care company, where she worked with operating management to develop the strategies and structures for physician practice management acquisitions and joint ventures. Prior to Mariner, Diane held senior operating roles at Medical Care America (MCA), one of the largest operators of free standing ambulatory surgery centers at that time.</p>\n\n<p><br /></p>\n\n\n\n\n\n\n\n\n\n\n\n<p>Diane currently sits on the Board of directors of TripleCare, CleanSlate Addiction Treatment Centers, QualDerm Partners, Prism Education Group, the Tuck School’s MBA Advisory Board and The Healthcare Private Equity Association (HCPEA). She was previously on the Board of directors of Cogent Healthcare, Relay Health, Zoologic and an observer for Evolution Benefits and Vantage Oncology. She also previously sat on the Board of directors of the Women’s Association of Venture and Equity (WAVE), and she is a past president of the Hartford Chapter of the Connecticut Venture Group and sat on its statewide Board for several years. She received an MBA from the Tuck School at Dartmouth College and a BA in Economics from Lehigh University.</p>', NULL, 'Diane has over 25 years of investing, advisory and operating experience, with over 20 years focused on the healthcare services industry.', NULL, NULL, 'Partner', NULL, NULL, NULL, '2016-06-17 17:12:03', '2016-07-13 17:46:39', 'd8eeaf20-59d4-4609-92b7-a1be954ba4d0'),
 ('24', '55', 'en_us', 'Sami Hamadé', NULL, NULL, NULL, NULL, '<p>With over 20 years of operating and investing experience across a broad spectrum of therapeutic areas, Sami is a prominent figure in the medical technology sector and will be leading Apple Tree’s efforts in this area. His interests include therapeutic devices, sensors and healthcare IT solutions.</p>\n\n<p><br /></p>\n\n\n\n\n\n<p>Prior to joining Apple Tree Partners, Sami was a Partner at Aberdare Ventures where he oversaw the sale of Ablation Frontiers to Medtronic and participated in a number of key investments including NxThera Inc., Nevro and Sonitus.</p>\n\n\n\n\n\n\n\n<p><br /></p>\n\n\n\n\n\n<p>In prior years, Sami was Vice President at the Guidant Corporation and head of the Compass Group, where he was responsible for Guidant’s venture capital, business development and M&amp;A activities. Successful investments included Cardionet Inc (Nasdaq: BEAT), Evalve (Acquired by ABT), Cryovascular (Acquired by BSX), Remon medical (Acquired by BSX) Cardiomems (Acquired by St. Jude Medical) and Spiration Inc (Acquired by Olympus).</p>\n\n\n\n\n\n\n\n<p><br /></p>\n\n\n\n\n\n<p>Earlier in his career, Sami played a critical operating role at Advanced Cardiovascular Systems (ACS), the pioneering company in the then emerging field of interventional cardiology which subsequently became a central part of Guidant’s multi-billion dollar leadership position in the stent market.  He was also a senior executive in Guidant’s peripheral business. Sami has been a regular guest lecturer at the Stanford Business School and Biodesign programs. He is also an inventor and recipient of the prestigious Boss Kettering Award for innovation.</p>\n\n\n\n\n\n\n\n<p><br /></p>\n\n\n\n\n\n<p>Sami holds a Bachelor’s Degree in Engineering from the American University of Beirut, a Masters Degree in Engineering from the University of Michigan, Ann Arbor and an MBA from the Stanford Graduate School of Business.</p>\n\n\n\n\n\n\n\n<p><br /></p>\n\n\n\n\n\n<p>Board responsibilities include: Gala Therapeutics, VytronUS.</p>', NULL, 'With over 20 years of operating and investing experience across a broad spectrum of therapeutic areas, Sami leads ATP\'s medical technology investments.', NULL, NULL, 'Partner', NULL, NULL, NULL, '2016-06-17 17:12:30', '2016-07-13 17:30:51', 'c5123c2a-2765-448a-b17d-78e0e0f88050'),
 ('25', '57', 'en_us', 'David J. McIntyre', NULL, NULL, NULL, NULL, '<p>David has over 20 years of experience as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries, including medical devices. With professional qualifications in finance and law, David has held senior financial, legal and operational roles.</p>\n\n<p><br /></p>\n\n\n\n\n\n<p>More recently, David was Executive Vice President, Chief Financial Officer of HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) from 2005 through 2011, and assumed the additional responsibilities of Chief Operating Officer during HeartWare’s global commercialization phase for the period from 2008 through 2011.</p>\n\n\n\n\n\n<p><br /></p>\n\n\n\n\n\n\n\n<p>Prior to HeartWare, David practiced as a senior attorney in private practice specializing in corporate, mergers and acquisitions and equity capital markets with Baker &amp; McKenzie and KPMG as well as holding various senior financial roles in multi-national companies including Coal &amp; Allied Limited, a publicly traded subsidiary of the Rio Tinto Group of companies.</p>\n\n\n\n\n\n<p><br /></p>\n\n\n\n\n\n\n\n<p>David holds a Bachelor of Economics (Accounting) from the University of Sydney (Australia), a Bachelor of Law from the University of Technology, Sydney (Australia) and a Masters of Business Administration (Fuqua Scholar) from Duke University. He is also a Certified Practicing Accountant (CPA) and is admitted as a Legal Practitioner of the Supreme Court of New South Wales (in Australia).</p>\n\n\n\n\n\n<p><br /></p>\n\n\n\n\n\n\n\n<p>Board responsibilities include: VytronUS, QualDerm, Tusker Medical, Braeburn Pharmaceuticals, Gala Therapeutics and previously Tendyne (acquired by Abbott).</p>', NULL, 'David has over 20 years of experience as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries, including medical devices.', NULL, NULL, 'Partner', NULL, NULL, NULL, '2016-06-17 17:13:00', '2016-07-13 17:33:12', '43566325-8e00-464b-bb49-db3c71a432ad'),
 ('26', '61', 'en_us', 'Company ', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-21 15:51:04', '2016-06-21 15:51:04', 'ce8d2c6d-3f46-429c-932c-16ef8103cb45'),
 ('27', '65', 'en_us', 'CleanSlate Centers', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-23 18:55:51', '2016-06-23 18:55:51', '2b5ce03e-736a-4545-811f-0ef45a0ff336'),
 ('28', '66', 'en_us', 'Legal', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-27 16:01:14', '2016-07-14 19:37:10', '58e3d7b7-a6cc-4e47-badf-4c46e90b3df9'),
 ('29', '70', 'en_us', 'Therapuetics', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-28 15:58:42', '2016-06-28 15:58:42', 'b539d1c0-7783-4047-93ae-ce164a5991ce'),
 ('30', '71', 'en_us', 'Company Name', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-28 16:26:33', '2016-06-28 16:26:33', '81a6c11e-ae2e-4c39-8172-a79be2d277c2'),
 ('31', '72', 'en_us', 'Company ', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-28 16:26:39', '2016-06-28 16:26:39', '5dd5c5ee-ebcb-4e24-b62b-3a45acd8452f'),
 ('32', '73', 'en_us', 'Company Name 2', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-28 16:28:32', '2016-06-28 16:28:32', 'd2070da3-e991-4163-a81b-945adb530d67'),
 ('33', '75', 'en_us', 'Press', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-06 21:31:22', '2016-07-14 20:30:23', '2508e8fe-83c1-48e2-ba10-2a5983d5e7c9'),
 ('34', '80', 'en_us', 'Texture 2', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-07 22:04:23', '2016-07-07 22:04:23', 'ba77884d-19ed-4a55-b7ed-fd91cdc62fab'),
 ('37', '83', 'en_us', 'Stock Photo Light Micrograph Of White Adipose Tissue Adipocytes Fat Cells Contain A Large Lipid Droplet The 267094196', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-08 19:37:25', '2016-07-08 19:37:25', '08093779-6af0-41cd-863f-4cb3edc2b1f9'),
 ('41', '87', 'en_us', 'Cover Homepage', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 17:23:22', '2016-07-11 17:23:22', '32f22f56-b2e0-4ec8-ba19-5d565dd6d590'),
 ('42', '88', 'en_us', 'Cover About', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 17:23:23', '2016-07-11 17:23:23', '25fffb28-67f3-43d1-8204-aca5a841f99e'),
 ('43', '89', 'en_us', 'Header Section Healthcare Services', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 17:23:24', '2016-07-11 17:23:24', '079b18ef-48e2-4dff-b913-f25927b91984'),
 ('44', '90', 'en_us', 'Header Section Legacy Companies', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 17:23:24', '2016-07-11 17:23:24', '045ec096-e3dd-454c-b1b6-9b37bbaf3e79'),
 ('46', '92', 'en_us', 'Header Section Medical Devices', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 17:23:25', '2016-07-11 17:23:25', 'd93a1ad0-740c-43b3-b93b-7c60f4647594'),
 ('47', '93', 'en_us', 'Header Section News', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 17:23:26', '2016-07-11 17:23:26', '300642fd-3a57-4ce8-b205-f9b7505f4a56'),
 ('48', '94', 'en_us', 'Header Section Press', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 17:23:26', '2016-07-11 17:23:26', '00652d92-cb1c-4e42-94a4-eb62acbbdd47'),
 ('49', '95', 'en_us', 'Header Section Therapeutics', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 17:23:27', '2016-07-11 17:23:27', '5adb79c9-e742-4383-8f30-5ec473b51488'),
 ('50', '96', 'en_us', 'Healthcare Services', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 19:00:38', '2016-07-11 19:00:38', 'a117fc53-5bae-4581-9a5d-8b0137afb051'),
 ('51', '97', 'en_us', 'Medical Devices', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 19:01:28', '2016-07-11 19:01:28', '9554074f-f7d3-4cb3-a9d7-5e6bc66bb45f'),
 ('52', '98', 'en_us', 'Medtech', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 19:02:51', '2016-07-11 19:02:51', '17eb5933-9594-4bb8-9ae9-75587b8dde39'),
 ('53', '99', 'en_us', 'Lauren Farrell', NULL, NULL, NULL, NULL, '<p>Lauren has over 20 years accounting and finance experience including roles in public accounting, financial management and reporting, and strategic financial consulting across multiple industries. Prior to joining Apple Tree Partners, Lauren was Vice President and Chief Accounting Officer at HeartWare International, Inc. (NASDAQ:HTWR) from 2006 to 2013, where she led the Company’s financial management and reporting activities. From 2005 to 2006, Lauren was Chief Financial Officer at Ambient Corporation. From January 2001 to July 2004, Lauren served as Vice President at Bingham Strategic Advisors providing M&amp;A advisory services.</p>\n\n<p><br /></p>\n\n\n\n\n\n\n\n<p>Lauren is a Certified Public Accountant and holds a Bachelors of Science in Accounting and a Masters of Business Administration from Bentley University.</p>', NULL, 'Lauren has over 20 years accounting and finance experience including roles in public accounting, financial management and reporting, and strategic financial consulting across multiple industries.', NULL, NULL, 'Chief Financial Officer', NULL, NULL, NULL, '2016-07-11 19:05:03', '2016-07-13 17:50:10', '17404add-7dc3-46fa-b62a-5ca5149bd8d3'),
 ('54', '100', 'en_us', 'Therapeutics', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 19:05:31', '2016-07-11 19:05:31', 'aa0d755e-8695-4085-847c-9e7da95c2d48'),
 ('55', '101', 'en_us', 'Finance & Administration', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 19:06:46', '2016-07-11 19:06:46', '26faa890-303f-4f90-adf5-d7ee0e383159'),
 ('56', '102', 'en_us', 'Julie Gionfriddo', NULL, NULL, NULL, NULL, '<p>Julie Gionfriddo joined Apple Tree Partners in 2014 and has spent nearly 18 years prior focused on private equity. Prior to joining Apple Tree, Julie was a vice president within the private equity secondary group at Landmark Partners, where she was involved in transaction origination, underwriting, and negotiation of private equity investments, as well as investor relations and marketing.</p><p><br /></p>\n\n<p>Julie serves on the board of directors for the Women’s Association of Venture and Equity. Julie also serves on the Board of Fellows and the Women’s Leadership Council for Trinity College. She received her BA and MA in Economics from Trinity College.</p>', NULL, 'Julie Gionfriddo joined Apple Tree Partners in 2014 and has spent nearly 18 years prior focused on private equity.', NULL, NULL, 'Principal', NULL, NULL, NULL, '2016-07-11 19:07:46', '2016-07-13 17:47:35', '21542be8-2351-40bc-b4de-d006492b39c9'),
 ('57', '105', 'en_us', 'Sam Hall, Ph.D.', NULL, NULL, NULL, NULL, '<p>Sam Hall has experience in the life sciences across roles as a private equity investor, investment banker and basic scientist. Prior to joining Apple Tree in 2013, he was a researcher at the University of Cambridge in the UK, where his work focused on novel therapeutic strategies for autoimmune diseases. Previously, Sam was a member of the investment team at Symphony Capital, a private equity firm dedicated to investments in biopharmaceutical development. Prior to Symphony, he served as a member of the healthcare investment banking team at Citigroup, where he advised leading biotechnology, medical device and healthcare services businesses on numerous completed strategic and debt and equity financing engagements.</p>\n\n<p><br /></p><p>Sam holds an A.B. in Molecular Biology from Princeton University and completed his M.Phil. and Ph.D. research at the University of Cambridge, where he was a Taylor Research Scholar and was awarded an NSF Graduate Research Fellowship for his work.</p>\n\n\n\n<p><br /></p>\n\n\n\n\n\n<p>Board responsibilities include: Syntimmune (Director), Stoke Therapeutics (Director).</p>', NULL, 'Sam Hall has experience in the life sciences across roles as a private equity investor, investment banker and basic scientist.', NULL, NULL, 'Principal', NULL, NULL, NULL, '2016-07-11 19:12:55', '2016-07-13 16:54:50', 'dcbeb63b-4db5-44d6-8102-30af5ce5d9fa'),
 ('58', '106', 'en_us', 'Aaron Kantoff', NULL, NULL, NULL, NULL, '<p>Aaron has significant early and late-stage biotech experience, serving financial analysis and restructuring. Prior to joining Apple Tree in 2011, Aaron was a partner at Recess Global, LLC, an investment company, focused on funding startups. Prior to starting Recess Global, LLC, Aaron was a member of the investment banking team at Rothschild Inc., in the Restructuring Group. Selected transactions that he worked on at Rothschild, Inc. include: advising the U.S Treasury on restructuring of Chrysler Group, LLC; assisting Milacron Inc. with the Section 363 sale of assets; working with Delphi Automotive on its in-court Chapter 11 bankruptcy; developing the Penton Media \"Pre-packaged\" Chapter 11 filing. In addition to his role with Apple Tree, Aaron has also served as Executive Director of Business Development &amp; Corporate Strategy of Braeburn Pharmaceuticals.</p>\n\n<p><br /></p><p>Aaron holds a Bachelor of Science in Finance and International Business from the New York University Stern School of Business.</p>\n\n\n\n<p><br /></p>\n\n\n\n\n\n<p>Board responsibilities include: Cure Forward (Director), Corvidia (Board Observer), and Syntimmune (Board Observer).</p>', NULL, 'Aaron has significant early and late-stage biotech experience, serving financial analysis and restructuring.', NULL, NULL, 'Principal', NULL, NULL, NULL, '2016-07-11 19:13:57', '2016-07-13 16:56:01', 'd161afae-c3ac-44df-9d9f-4231161ed33d'),
 ('59', '107', 'en_us', 'Jonathan Waldstreicher, MD', NULL, NULL, NULL, NULL, '<p>Jonathan Waldstreicher joined Apple Tree in 2013 to invest in medical devices. After incubating an interventional pulmonary technology for two years, Jon founded Gala Therapeutics in Silicon Valley and assumed the CEO role to further its development.</p><p><br /></p>\n\n<p>Prior to joining Apple Tree, Jon was a Director, Global Surgery R&amp;D, at Johnson &amp; Johnson where he initiated and led an investment strategy and R&amp;D development program in a new growth platform technology area. He started at Johnson &amp; Johnson as an Associate Director in the Corporate Office of Science &amp; Technology where he executed numerous seed grants to startup companies and participated in technical diligence of venture capital investments. Before medical school, Jon worked in Equity Research at Bear Stearns.</p>\n\n\n\n<p><br /></p>\n\n\n\n\n\n<p>Jon received a B.A. from Brandeis University in Economics and an M.D. and M.B.A. from Tufts University School of Medicine where he was awarded the Norman Stearns award for highest achievement and overall excellence within the dual degree program. Between his third and fourth year of medical school, Jon worked as a fellow at the Corporate Office of Science &amp; Technology at J&amp;J. He completed a General Surgery Internship at Tufts Medical Center in Boston.</p>\n\n\n\n<p><br /></p>\n\n\n\n\n\n<p>Board responsibilities include: Gala Therapeutics, VytronUS (Board Observer).</p>', NULL, 'Jonathan Waldstreicher joined Apple Tree in 2013 to invest in medical devices.', NULL, NULL, 'Principal', NULL, NULL, NULL, '2016-07-11 19:15:07', '2016-07-13 17:36:08', '350865a9-7d63-4777-a172-0c6ba5d29e9e'),
 ('60', '108', 'en_us', 'Keting Chu, MD, Ph.D.', NULL, NULL, NULL, NULL, '<p>Keting Chu joined Apple Tree Partners in 2016 as a Venture Partner. Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture philanthropy.</p><p><br /></p>\n\n<p>Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS). There she was responsible for venture philanthropy, also known as the Therapy Acceleration program. At LLS, Keting led the investment of Celator, Stemline, Constellation, Affimed, arGen-X, Kite Pharma, Kiadis, OncoPepe, Valor and a number of projects within academic institutions. Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc. Prior to co-founding DigitAB, Keting was the Co-Founder and CEO of BioCubed Corporation, Vice President of Biology and Head of R&amp;D at Five Prime Therapeutics during its founding stage and the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical and clinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases.</p>\n\n\n\n\n\n\n\n<p><br /></p>\n\n\n\n\n\n\n\n\n\n<p>Keting received her MD in Sun Yat-sen Medical University specialized in infectious diseases in China, Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF). She also conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.</p>', NULL, 'Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development.', NULL, NULL, 'Venture Partner', NULL, NULL, NULL, '2016-07-11 19:15:57', '2016-07-13 17:25:02', 'eb3e3380-3997-41cf-accc-14953d51b454'),
 ('61', '109', 'en_us', 'Paul DaSilva-Jardine, Ph.D.', NULL, NULL, NULL, NULL, '<p>Paul DaSilva-Jardine joined Apple Tree Partners in 2016 as a Venture Partner. Paul has over 25 years of drug discovery and development experience in the Cardiovascular, Metabolic and Endocrine diseases space. Prior to joining Apple Tree, Paul spent over 25 years at Pfizer Research and Development where he participated in the discovery and development of over fifty drug candidates including the first, lasofoxifene, a SERM which received authorization from European Medicines Agency. Paul held various leadership positions at Pfizer R&amp;D including Vice President, Head of CVMED Chemistry, and Vice President in the CVMED Research Unit which was responsible for drug development from Idea to Phase 2 Proof of Concept.</p><p><br /></p>\n\n<p>Paul earned his PhD and completed post-doctoral studies in Synthetic Organic Chemistry with Professor Corey at Harvard University.</p>', NULL, 'Paul has over 25 years of drug discovery and development experience in the Cardiovascular, Metabolic and Endocrine diseases space.', NULL, NULL, 'Venture Partner', NULL, NULL, NULL, '2016-07-11 20:30:09', '2016-07-13 17:26:39', '614ea527-6a91-4655-86f3-7766641a1dae'),
 ('62', '110', 'en_us', 'David de Graaf, Ph.D.', NULL, NULL, NULL, NULL, '<p>David de Graaf joined Apple Tree Partners in 2015 as a Venture Partner. David is a scientist and entrepreneur with broad experience ranging from operational leadership to the development of new companies. Most recently, David was Entrepreneur in Residence for Flagship Ventures and Executive Chairman of Selventa, a Flagship portfolio company which he restarted and rebranded. As CEO, David brought Selventa to revenue stage and financial independence with a line of services and products in the personalized medicine space. Before Selventa, David held roles of increasing responsibility at AstraZeneca, Pfizer, and Boehringer-Ingleheim with a focus on the early portfolio in a variety of therapeutic areas. He brought pathway biology to AstraZeneca, building functions for pathway analysis in the UK and the US. He headed Systems Biology at Pfizer with a focus on biotherapeutics and predictive toxicology and at Boehringer-Ingelheim, as Vice President of Biotherapeutics and Integrative Biology, he built a new biotherapeutics capability which brought a handful of candidates to the clinic in auto-immune diseases and oncology. David’s academic career initially brought him to the Whitehead/MIT center for Functional Genomics as one of the founding scientists to work with Prof. Eric Lander, after his postdoctoral work at the Weizmann Institute in Israel.</p>\n\n<p>David also serves on a variety of boards, ranging from the Swiss Institute of Bioinformatics to Chugai PharmaBody. David holds a PhD in Mammalian Genetics from the University of Illinois at Chicago and a Masters in Evolutionary Genetics form the University of Utrecht.</p>', NULL, '<p>David is a scientist and entrepreneur with broad experience ranging from operational leadership to the development of new companies.</p>', NULL, NULL, 'Venture Partner', NULL, NULL, NULL, '2016-07-11 20:31:07', '2016-07-11 20:33:17', 'c7e88f7d-0a91-4a37-9f1e-40c8e7366221'),
 ('63', '111', 'en_us', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 20:41:13', '2016-07-15 17:08:20', 'f375cc7a-37a6-4d47-b0f6-6d3712536775'),
 ('64', '112', 'en_us', 'Icon Atp Logo', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 20:42:52', '2016-07-11 20:42:52', '74b44de1-b941-4ea8-892a-6e30fb38c965'),
 ('65', '113', 'en_us', 'Behshad Sheldon', NULL, NULL, NULL, NULL, '<p>Behshad has more than 25 years of experience leading pharmaceutical development and commercialization in the United States and globally. She currently also serves as the President and Chief Executive Officer of Braeburn Pharmaceuticals, a portfolio company of Apple Tree Partners. Prior to joining Braeburn, Behshad spent 10 years at Otsuka Pharmaceuticals, having co-founded the Otsuka Princeton office in 2002. Ms. Sheldon last served as a member of the board of directors of the Otsuka R&amp;D organization, contributing to the oversight of 18 pre-approval programs for 13 products in CNS, cardio-renal, pain, dermatology, and oncology. Simultaneously, she served as senior vice president, patient &amp; branding strategy in the commercial organization, where she was responsible for global and United States marketing, alliance management, and early development strategy. Prior to Otsuka, Behshad held positions with increasing responsibility at SmithKline Beecham and Bristol-Myers Squibb. Throughout her 27-year career, Behshad has driven the success of blockbuster products such as Glucophage, Plavix, and Abilify, and has contributed to several strategic alliances and acquisitions, including the landmark 2011 agreement between Otsuka and Lundbeck involving 5 CNS products. Behshad holds a BS degree in Neuroscience from the University of Rochester.</p>\n\n<p><br /></p>\n\n<p>Board responsibilities include: CleanSlate Addiction Treatment Centers (Board Observer).</p>', NULL, 'Behshad has more than 25 years of experience leading pharmaceutical development and commercialization in the United States and globally.', NULL, NULL, 'Venture Partner', NULL, NULL, NULL, '2016-07-11 20:44:31', '2016-07-13 17:28:32', '2acaa8c8-aea3-4856-a53b-9b6037873192'),
 ('66', '114', 'en_us', 'Mikael Dolsten, MD, Ph.D.', NULL, NULL, NULL, NULL, '<p>Mikael Dolsten, M.D., Ph.D. became the Chairman of Apple Tree Partner’s Translational Advisory Board in 2016. Mikael is currently the President of Pfizer Worldwide Research and Development (WRD) and Executive Vice President of Pfizer Inc. Dr. Dolsten is also a member of the Pfizer Executive Leadership Team and co-chairs the company’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&amp;D priorities.</p><p><br /></p>\n\n<p>Prior to joining Pfizer in 2009, Dr. Dolsten was President of Wyeth Research responsible for global research and development activities. Before joining Wyeth, he served as Executive Vice President for Worldwide Research at Boehringer Ingelheim. His earlier career as a research leader included VP leadership positions with AstraZeneca, Pharmacia and Upjohn. Mikael has also served as a Private Equity partner at Orbimed, the world’s largest healthcare focused investment company. In addition, he gained leadership experience from five large-scale M&amp;A transactions.</p>\n\n\n\n\n\n<p><br /></p>\n\n\n\n\n\n\n\n<p>Mikael is a governor of the New York Academy of Sciences, a member of the board of Karyopharm Therapeutics Inc., a member of the Biomedical Advisory Council of The Pharmaceutical Research and Manufacturers of America (PhRMA), co-lead for the industry-NIH Accelerating Medicine Partnership (AMP) Executive Committee and serves on the PhRMA Foundation Board of Directors. He has been a board member of a Swedish Business School for Innovation and Chamber of Commerce. Dr. Dolsten is a named inventor on several patents and has published approximately 150 articles in international journals, with particular contributions in areas such as molecular cell biology, immunology and oncology.</p>\n\n\n\n\n\n<p><br /></p>\n\n\n\n\n\n\n\n<p>Dr. Dolsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund, Sweden.</p>', NULL, 'Mikael is currently the President of Pfizer Worldwide Research and Development (WRD) and Executive Vice President of Pfizer Inc.', NULL, NULL, 'Chairman, Translational Advisory Board', NULL, NULL, NULL, '2016-07-11 20:46:13', '2016-07-13 20:16:47', '1872da8c-ce1f-4d65-bbe6-81bf90a2c75f'),
 ('68', '116', 'en_us', 'Amir Abolfathi', NULL, NULL, NULL, NULL, '<p>Amir has over 26 years of operating experience in the healthcare industry focused on developing and commercializing cardiovascular devices, dental products, hearing prosthetics, and genomic diagnostics &amp; analytics. Amir was the inventor and founder of Sonitus Medical in 2006, a novel non-surgical hearing prosthetic designed for treatment of unilateral deafness, and Sonitus Technologies in 2010, which is currently developing the first truly covert two-way communication device.</p><p><br /></p>\n\n<p>Prior to Sonitus, Amir served for six years as an Officer, Executive Vice President of R&amp;D at Align Technology Inc. (NASDAQ: ALGN), creators of a unique, invisible orthodontic product called Invisalign. Previously, Amir was the first member of the senior management team at Embolic Protection Inc., where he was a consulting VP of Operations. EPI was successfully acquired by Boston Scientific in 2001.</p>\n\n<p><br /></p>\n\n\n\n<p>In early 1995, Amir co-founded EndoTex Interventional Systems, developers of minimally invasive solutions for treatment of carotid artery disease, which was also acquired by Boston Scientific in 2006. Amir has also held various management and engineering positions at Pfizer, Guidant, and Baxter-Edwards. He has over 100+ issued patents. Cleveland Clinic Foundation and Popular Science recognized one of his inventions as Top 10 Inventions of the Year in 2010.</p>\n\n<p><br /></p>\n\n\n\n<p>Amir currently sits on the Board of Directors of Sonitus Technologies and Rodo Medical. He is also a business adviser to Guardant Health. He was previously on the Board of Directors of NextBio, acquired by Illumina in 2013, and an adviser to On-Pharma, acquired by Valeant Pharmaceutical in 2014.</p>\n\n<p><br /></p>\n\n\n\n<p>Amir received a MS in Engineering Management from University of Southern California and BS in Biomedical Engineering from University of California, San Diego. He is a member of the University of California, San Diego Jacobs School Council of Advisers.</p>', NULL, 'Amir has over 26 years of operating experience in the healthcare industry focused on developing and commercializing medical devices. ', NULL, NULL, 'Entrepreneur-in-Residence, Ear, Nose & Throat', NULL, NULL, NULL, '2016-07-11 20:47:37', '2016-07-13 17:44:33', 'b13d4e5b-0f57-4efb-afb0-3bcb866c7b64'),
 ('69', '117', 'en_us', 'bubble gum', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 20:54:41', '2016-07-11 20:54:41', 'ed933a20-70cd-4ac2-8fbe-76a683c5fb16'),
 ('70', '118', 'en_us', 'swimming', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 20:54:46', '2016-07-11 20:54:46', 'eb1aa60e-aa9d-49e3-b675-02e5ab471f07'),
 ('71', '119', 'en_us', '!@#$%^&*()', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 20:54:56', '2016-07-11 20:54:56', '32af26c2-75db-412f-a0e0-b24962a06532'),
 ('72', '120', 'en_us', '123456789', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 20:55:03', '2016-07-11 20:55:03', '49b518ef-c2c9-4b52-910a-026cc99067fb'),
 ('73', '121', 'en_us', 'abcdefghijklmnopqrstuvwxyz', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 20:55:14', '2016-07-11 20:55:14', '4edd0dc1-e543-48d5-8568-d3c351cc40bf'),
 ('74', '122', 'en_us', 'New Tag', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 20:55:48', '2016-07-11 20:55:48', 'e7cdf1ff-b03d-4047-b913-55d4cf3cfa28'),
 ('75', '123', 'en_us', 'Andreas Loew, Ph.D.', NULL, NULL, NULL, NULL, '<p>Andreas Loew is an Entrepreneur-in-Residence focused on creating novel biotherapeutics to combat cancer and auto-immune disease. Andreas has over fifteen years of experience in the biopharmaceutical industry, most recently as the global head of new technologies in the biologics center at the Novartis Institutes for Biomedical Research (NIBR). At NIBR, Andreas established a group to lead drug discovery efforts in multiple disease indications across a large spectrum of biotherapeutics including multi-specific antibodies, therapeutic proteins and chimeric antigen receptors (CARs). Prior to joining Novartis, Andreas provided structure-based drug design support at Abbott both for small molecules and anti-body based therapies including HUMIRA®.</p><p><br /></p>\n\n<p>Andreas earned his master degrees in Chemistry at the University of Kaiserslautern, Germany and a PhD degree in Biochemistry at the University of Bayreuth, Germany. He conducted post-doctoral research in protein biochemistry and x-ray structural biology in Yee-Kin Ho’s laboratory at the University of Illinois, Chicago, at Steven Sprang’s laboratory at the University of Texas, Medical Center, Dallas and in Tom Blundell’s laboratory at Birkbeck College, London, UK.</p>', NULL, 'Andreas Loew is an Entrepreneur-in-Residence focused on creating novel biotherapeutics to combat cancer and auto-immune disease.', NULL, NULL, 'Entrepreneur-in-Residence, Biotherapeutics', NULL, NULL, NULL, '2016-07-11 20:56:15', '2016-07-13 17:27:41', '0bde0cba-4ca3-4e79-98b1-2c402dfa31e2'),
 ('76', '124', 'en_us', 'New Tag', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 20:57:14', '2016-07-11 20:57:14', 'c8ed1ae8-3a76-4ede-9e49-6e05e7d1c6c3'),
 ('77', '125', 'en_us', 'Chris Cain, Ph.D.', NULL, NULL, NULL, NULL, '<p>Chris joined Apple Tree Partners in 2016 as an Associate focused on therapeutics. Prior to joining Apple Tree Partners, Chris was an Associate at RA Capital Management, LLC, a crossover fund invested in healthcare and the life sciences. Previously, Chris was a writer and editor at BioCentury Publications and the Science-Business eXchange (SciBX), a translational science journal co-published with Nature Publishing Group, where he evaluated the clinical and commercial potential of novel molecular targets and drug platforms emerging from academic labs. Prior to BioCentury, Chris was a researcher at the University of California, San Francisco, where his work focused on understanding the transcriptional regulation and evolution of morphological change in fungi including the pathogen Candida albicans.</p>\n\n<p><br /></p><p>Chris holds a B.A. in Biology from the University of California, Santa Barbara, College of Creative Studies. He earned his Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco, where he was awarded a Genentech Graduate Fellowship.</p>', NULL, 'Chris joined Apple Tree Partners in 2016 as an Associate focused on therapeutics.', NULL, NULL, 'Associate', NULL, NULL, NULL, '2016-07-11 20:58:38', '2016-07-13 16:56:41', '24dd3415-5c4e-4e8e-9520-c52136646907'),
 ('78', '126', 'en_us', 'Jernej Godec, Ph.D.', NULL, NULL, NULL, NULL, '<p>Jernej joined Apple Tree Partners in 2016 as an Associate focused on therapeutics. His work focuses on the development of breakthrough companies with transformative therapies. Prior to joining Apple Tree Partners, he completed his doctorate in Immunology at Harvard University. He was jointly mentored by Arlene Sharpe at Harvard Medical School and Nicholas Haining at the Dana-Farber Cancer Institute, where he studied how co-inhibitory receptors and transcriptional programs orchestrate differentiation of cytotoxic T lymphocytes. He published his work in top peer-reviewed journals, including <em>Cell</em>, <em>Immunity</em>, and<em>Nature Immunology</em>. While at Harvard, he was also on the leadership board of the Harvard Biotechnology Club.</p>\n\n<p><br /></p>\n\n<p>While in graduate school, Jernej co-founded Mifcor, a biotechnology company focused on developing new therapies for ischemic disease. As the co-founder and CSO, he successfully helped raise funding and lead the scientific strategy for preclinical drug development. Concurrently, he completed the Flagship VentureLabs fellows program and during the last year of his doctorate continued working with Flagship Ventures. As a consultant, he assisted in developing innovative concepts with accompanying intellectual property, marketable products, and founding strategy for new companies.</p>\n\n\n\n<p><br /></p>\n\n\n\n\n\n<p>Jernej received his B.A. with honors in Molecular and Cell Biology at the University of California at Berkeley where his research focused on innate immunity and bacterial pathogenesis. During his time at Cal, he was an All-American student-athlete in swimming and competed in two Olympic Games for his home country of Slovenia.</p>', NULL, 'Jernej\'s work focuses on the development of breakthrough companies with transformative therapies.', NULL, NULL, 'Associate', NULL, NULL, NULL, '2016-07-11 21:00:05', '2016-07-13 17:23:31', '8a61c6d6-6d8a-4d4b-a417-be7d0db14cc8'),
 ('79', '127', 'en_us', 'Stephanie Papes', NULL, NULL, NULL, NULL, '<p>Stephanie joined Apple Tree Partners in 2014 as an Associate focused on healthcare services and IT investments. Prior to joining Apple Tree Partners, Stephanie was as an Investment Banking Analyst in the Financial Sponsors Group of Wells Fargo Securities in San Francisco, CA and New York, NY. In this role, she was responsible for supporting the leveraged finance origination process for private equity transactions. Stephanie previously worked within Duke University Health System, where she assisted in the initial implementation stages of a $500 million EHR rollout and on a pilot program for an innovative bundled payment model, among other projects. She also worked in Washington, DC during the passing of the Affordable Care Act, where she served health systems in government funding requests and health policy consulting.</p><p><br /></p>\n\n<p>Stephanie graduated from Duke University with highest distinction in studies of Public Policy, Economics and Biology. She was a Civic Engagement Scholar, Dean’s Research Fellow, South Asian Studies Fellow and Sanford School of Public Policy Grant Recipient. Stephanie\'s Honors thesis focused on provider financial incentives in rural India, and she continues to conduct international nonprofit work in Delhi and West Bengal.</p>\n\n<p><br /></p>\n\n\n\n<p>Board responsibilities include: CleanSlate (Board Observer), TripleCare (Board Observer), QualDerm (Board Observer), Cure Forward (Director).</p>', NULL, 'Stephanie joined Apple Tree Partners in 2014 as an Associate focused on healthcare services and IT investments.', NULL, NULL, 'Associate', NULL, NULL, NULL, '2016-07-11 21:01:24', '2016-07-13 17:48:41', 'ae8f20f0-586e-433c-a79c-84974b2a0715'),
 ('80', '128', 'en_us', 'Joshua Sherman', NULL, NULL, NULL, NULL, '<p>Josh joined Apple Tree Partners in 2014 as an Associate focused on the Life Science, Pharmaceutical and Medical Device industries. He has a strong interest in the healthcare space and benefits greatly from his background in both science and finance.</p>\n\n<p><br /></p><p>Prior to joining Apple Tree Partners, Josh was an Analyst in the Healthcare Investment Banking Group at Barclays where he developed broad industry knowledge and M&amp;A experience. He was also formerly an Analyst at Morgan Stanley in the Financial Institutions Group where he focused on transactions in the Insurance and Asset Management space.</p>\n\n\n\n<p><br /></p>\n\n\n\n\n\n<p>Josh graduated from The University of Pennsylvania in 2012 earning dual-degrees as a member of the Vagelos Life Sciences &amp; Management Program. He holds a B.S. in Economics (Concentration in Finance) from The Wharton School and a B.A. in Biology from The College of Arts and Sciences. Josh grew up in New York City, is fluent in French, and enjoys travel and tennis.</p>', NULL, 'Josh joined Apple Tree Partners in 2014 as an Associate focused on the Life Science, Pharmaceutical and Medical Device industries.', NULL, NULL, 'Associate', NULL, NULL, NULL, '2016-07-11 21:03:01', '2016-07-13 17:37:59', '1083ca64-7ed1-4b40-9938-97f189894d37'),
 ('81', '129', 'en_us', 'test', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 21:04:23', '2016-07-11 21:04:23', 'b1693007-ad99-415e-9615-dd82a2a5cdef'),
 ('84', '136', 'en_us', 'Footer', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 21:17:42', '2016-07-11 21:50:45', 'dffc194d-3a8b-4e4f-9eb0-b24e4b68d501'),
 ('87', '141', 'en_us', 'Kristin Howell', NULL, NULL, NULL, NULL, '', NULL, '', NULL, NULL, 'Fund Accountant', NULL, NULL, NULL, '2016-07-11 21:24:27', '2016-07-11 21:24:27', '07decc31-34ae-4ad8-8669-93841f9c2006'),
 ('88', '142', 'en_us', 'Maja Nowak', NULL, NULL, NULL, NULL, '', NULL, '', NULL, NULL, 'Accounting Manager', NULL, NULL, NULL, '2016-07-11 21:24:48', '2016-07-12 00:28:47', '5e3ae8b5-7ca4-4ecd-b40b-0cd977904a7c'),
 ('89', '143', 'en_us', 'Shivranie Singh', NULL, NULL, NULL, NULL, '', NULL, '', NULL, NULL, 'Accounts Payable', NULL, NULL, NULL, '2016-07-11 21:25:07', '2016-07-12 00:28:23', 'ee316b9b-0419-4551-b51d-758ebd4f8391'),
 ('90', '144', 'en_us', 'Steph Lazarus', NULL, NULL, NULL, NULL, '', NULL, '', NULL, NULL, 'Senior Executive Assistant', NULL, NULL, NULL, '2016-07-11 21:25:28', '2016-07-11 21:25:28', '84436979-d240-43f7-adcf-61f263a600dd'),
 ('91', '145', 'en_us', 'Lisa Cagney', NULL, NULL, NULL, NULL, '', NULL, '', NULL, NULL, 'Executive Assistant (Therapeutics)', NULL, NULL, NULL, '2016-07-11 21:25:55', '2016-07-12 00:28:30', 'bb0be9f5-a50f-452e-9db1-3ee2ac200434'),
 ('92', '146', 'en_us', 'Salam Farhat', NULL, NULL, NULL, NULL, '', NULL, '', NULL, NULL, 'Executive Assistant (Medical Devices and Healthcare Services)', NULL, NULL, NULL, '2016-07-11 21:26:11', '2016-07-12 00:28:03', 'aca6bc0d-a8a5-484e-9b1d-560c070c727b'),
 ('140', '200', 'en_us', 'Braeburn Pharmaceuticals', NULL, NULL, NULL, NULL, NULL, '<p>Braeburn Pharmaceuticals is developing a portfolio of long-acting therapeutic treatment options for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Long-acting implantable and injectable therapies can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. The current portfolio includes: Probuphine®, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia.</p>', NULL, '<p>Braeburn Pharmaceuticals is developing a portfolio of long-acting therapeutic treatment options for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia.</p>', NULL, NULL, NULL, NULL, NULL, '2016-07-11 21:56:47', '2016-07-13 16:33:35', 'a016c616-0bf5-4fd9-af94-ebaa756db83e'),
 ('141', '202', 'en_us', 'Icon Atp Logo', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 21:57:43', '2016-07-11 21:57:43', 'd2d35a99-10ea-470e-a29c-0e77555c65a4'),
 ('143', '204', 'en_us', 'CleanSlate Addiction Treatment Centers', NULL, NULL, NULL, NULL, NULL, '<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania. CleanSlate provides medication-assisted treatment and related therapies using the highest quality, evidence-based practices for patients who have addiction and associated disorders.</p>', NULL, '<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania. </p>', NULL, NULL, NULL, NULL, NULL, '2016-07-11 21:58:40', '2016-07-13 16:33:16', '62e171b6-dc74-4e16-9308-7eb342be9eb5'),
 ('165', '227', 'en_us', 'testing', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 22:01:54', '2016-07-11 22:01:54', 'be5228d8-476c-4ba3-bcb5-0eb6a4767348'),
 ('166', '228', 'en_us', 'testing', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 22:03:14', '2016-07-11 22:03:14', '1887d28f-df9a-4317-9177-817dde2d3603'),
 ('167', '229', 'en_us', 'Coelacanth Chemical Corporation', NULL, NULL, NULL, NULL, NULL, '<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \"click\" chemistry.</p>\n\n<p><em>Acquired by Lexicon Genetics July 2001</em></p>', NULL, '<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \"click\" chemistry.</p>', NULL, NULL, NULL, NULL, NULL, '2016-07-11 22:03:23', '2016-07-13 21:14:28', '13477181-9712-4a3f-8645-e738630d5618'),
 ('168', '232', 'en_us', 'Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis,', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 22:17:15', '2016-07-11 22:17:15', 'dc6c34c7-2b7e-46cf-9ce4-88affad93d69'),
 ('169', '233', 'en_us', 'New Tag', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 22:18:44', '2016-07-11 22:18:44', 'f0714ceb-b247-41c8-841c-ff8b0db14e63'),
 ('171', '238', 'en_us', 'New Tag', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 22:21:22', '2016-07-11 22:21:22', '0dc81bda-f431-4d0f-b0b3-99645203f97a'),
 ('172', '239', 'en_us', 'Corvidia', NULL, NULL, NULL, NULL, NULL, '<p>Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company has identified mechanistically-driven responder populations in a variety of cardio-metabolic and cardio-renal disorders.</p>', NULL, '<p>Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies.</p>', NULL, NULL, NULL, NULL, NULL, '2016-07-11 22:21:39', '2016-07-13 16:32:34', '11eeb05c-1cfe-4b31-96d7-b0b3a3b17b1e'),
 ('174', '242', 'en_us', 'Gala Therapeutics', NULL, NULL, NULL, NULL, NULL, '<p>Gala Therapeutics is an early stage medical device company developing a novel catheter based approach to treating pulmonary disease including chronic bronchitis, COPD, and asthma.</p>', NULL, '<p>Gala Therapeutics is an early stage medical device company developing a novel catheter based approach to treating pulmonary disease including chronic bronchitis, COPD, and asthma.</p>', NULL, NULL, NULL, NULL, NULL, '2016-07-11 22:29:19', '2016-07-13 17:19:52', 'c29ea01b-4d7d-4b00-865a-3fb311f9f7ad'),
 ('175', '244', 'en_us', 'Cure Forward', NULL, NULL, NULL, NULL, NULL, '<p>Cure Forward connects cancer patients with clinical trial administrators working to reduce trial recruitment times and increase participation. Cure Forward’s online portal, in addition to providing access to clinical trials, can also help patients retrieve molecular diagnostic test results ordered by physicians, access educational information, connect with other patients, and investigate treatment options.</p>', NULL, '<p>Cure Forward connects cancer patients with clinical trial administrators working to reduce trial recruitment times and increase participation.</p>', NULL, NULL, NULL, NULL, NULL, '2016-07-11 22:35:10', '2016-07-13 16:31:58', '560c334a-70e7-4386-9a7e-186d9d634e78'),
 ('176', '246', 'en_us', 'Cyrano Sciences', NULL, NULL, NULL, NULL, NULL, '<p>An electronic nose for homeland defense applications.</p>\n\n<p><em>Acquired by Smiths Detection March 2004</em></p>', NULL, '<p>An electronic nose for homeland defense applications.</p><p><br /></p>\n\n<p><em>Acquired by Smiths Detection March 2004</em><br /></p>', NULL, NULL, NULL, NULL, NULL, '2016-07-11 22:36:11', '2016-07-13 21:17:31', '3be235e8-cba8-47a1-a871-516b1fde9528'),
 ('177', '248', 'en_us', 'Gloucester Pharmaceuticals', NULL, NULL, NULL, NULL, NULL, '<p>Creators of ISTODAX® (romidepsin) for T-cell lymphoma and other malignancies.</p>\n\n<p><em>Acquired by Celgene January 2010</em></p>', NULL, '<p>Creators of ISTODAX® (romidepsin) for T-cell lymphoma and other malignancies.</p>\n\n<p><em>Acquired by Celgene January 2010</em></p>', NULL, NULL, NULL, NULL, NULL, '2016-07-11 22:37:48', '2016-07-13 16:31:14', '4134e5df-80f4-4413-9652-085f015bea27'),
 ('178', '250', 'en_us', 'HeartWare International', NULL, NULL, NULL, NULL, NULL, '<p>HeartWare (HTWR)develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.</p>\n\n<p><em>IPO January 2005 ASX; listed on NASDAQ September 2013</em></p>', NULL, '<p>HeartWare (HTWR)develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.</p>', NULL, NULL, NULL, NULL, NULL, '2016-07-11 22:40:09', '2016-07-13 16:30:56', 'e399b5b3-b64c-4ce4-bd3c-6f6a1ed50480'),
 ('181', '255', 'en_us', 'New Tag', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 23:15:08', '2016-07-11 23:15:08', '04d38488-06d2-484b-804d-c1b6cedeb2dc'),
 ('182', '256', 'en_us', 'thisisreallyreallyreallyreallyreallyreallyreallylongandkajs;dlfkja;sldfjk;aslkjf;laskjdf;lasjdf;laskjflkasjdf;lkjasdf;lkasdf;klasdjf;lkasjdf;klasjdf;kasf;kasjf;kldsfj;aslkdfj;aklfj;aslkjf;sadlkfj', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 23:24:25', '2016-07-11 23:24:25', 'fdd55547-783f-4311-b932-2bb9eae740a2'),
 ('183', '257', 'en_us', 'will this appear on the top of the page?? ', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 23:37:38', '2016-07-11 23:37:38', 'd13683dc-9398-43de-a12b-8777512aa841'),
 ('192', '266', 'en_us', 'where do you belong?? ', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 23:40:12', '2016-07-11 23:40:12', '3a1b4e14-508b-468b-b220-063309b3939f'),
 ('200', '275', 'en_us', 'QualDerm Partners', NULL, NULL, NULL, NULL, NULL, '<p>QualDerm Partners provides strategic leadership and practice management services through partnerships with highly qualified dermatologists throughout the Southeastern US. The company alleviates practice administrative burdens, empowering providers to focus solely on delivering exceptional patient care.</p>', NULL, '<p>QualDerm Partners provides strategic leadership and practice management services through partnerships with highly qualified dermatologists throughout the Southeastern US. </p>', NULL, NULL, NULL, NULL, NULL, '2016-07-11 23:47:20', '2016-07-13 16:30:36', '0f3e2a14-2252-4261-b6ba-adc656ba1b33'),
 ('204', '280', 'en_us', 'principal', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-11 23:58:00', '2016-07-11 23:58:00', '2c8ef137-c1a9-4668-a43d-e37c9552d755'),
 ('205', '281', 'en_us', 'SGX Pharmaceuticals', NULL, NULL, NULL, NULL, NULL, '<p>A biotechnology company focused on discovery and development of small molecule therapeutics generated by its proprietary Fragments of Active Structures (FAST) medicinal chemistry platform.</p>\n\n<p><em>IPO February 2006 (acquired by Eli Lilly July 2008)</em></p>', NULL, '<p>A biotechnology company focused on discovery and development of small molecule therapeutics generated by its proprietary Fragments of Active Structures (FAST) medicinal chemistry platform.</p>', NULL, NULL, NULL, NULL, NULL, '2016-07-12 00:07:33', '2016-07-13 16:30:19', 'ba0fa6b1-226c-421e-8627-e5aa88794e24'),
 ('207', '284', 'en_us', 'Syntimmune', NULL, NULL, NULL, NULL, NULL, '<p>Syntimmune is developing novel antibody therapies for inflammatory diseases and severe toxicities. Syntimmune’s lead program, SYNT-001, specifically blocks FcRn-IgG interaction, resulting in the rapid clearance of pathogenic IgG important in a variety of antibody-mediated diseases.</p>', NULL, '<p>Syntimmune is developing novel antibody therapies for inflammatory diseases and severe toxicities.</p>', NULL, NULL, NULL, NULL, NULL, '2016-07-12 00:09:32', '2016-07-13 16:29:54', '88ab13a7-84e5-4543-9884-2ff92b593cab'),
 ('209', '287', 'en_us', 'Tendyne', NULL, NULL, NULL, NULL, NULL, '<p>Tendyne is focused on the development and commercialization of minimally invasive therapies for the treatment of mitral regurgitation. Tendyne’s first product is a percutaneous transcatheter mitral valve prosthesis.</p>\n\n<p><em>Acquired by Abbott August 2015</em></p>', NULL, '<p>Exited</p><p>Tendyne is focused on the development and commercialization of minimally invasive therapies for the treatment of mitral regurgitation. </p>', NULL, NULL, NULL, NULL, NULL, '2016-07-12 00:15:28', '2016-07-13 16:38:44', '2befc627-4cab-42b3-98f5-ce5d8e5912cf'),
 ('211', '290', 'en_us', 'Tokai Pharmaceuticals', NULL, NULL, NULL, NULL, NULL, '<p>Tokai (TKAI) is developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. The company is conducting a pivotal clinical trial of its lead drug candidate, galeterone, in patients with metastatic castration-resistant prostate cancer (mCRPC) whose tumors express the AR-V7 splice variant, which is a truncated form of the androgen receptor associated with non-responsiveness to commonly-used oral therapies for mCRPC. This trial is the first precision medicine based pivotal clinical trial in prostate cancer.</p>', NULL, '<p>Tokai (TKAI) is developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases.</p>', NULL, NULL, NULL, NULL, NULL, '2016-07-12 00:17:23', '2016-07-13 16:29:12', '4a8cf4bc-fc6e-4eca-be18-5bedd2e8473c'),
 ('213', '293', 'en_us', 'TripleCare', NULL, NULL, NULL, NULL, NULL, '<p>TripleCare provides acute hospital-level care to patients residing in skilled nursing facilities (“SNFs”) using state-of-the-art telemedicine technology. The company expands patient access to care after hours and on weekends by providing physicians, equipment, and software to SNFs, with the goal of treating patients in place. The company presently operates across over thirty-five facilities in six states.</p>', NULL, '<p>TripleCare provides acute hospital-level care to patients residing in skilled nursing facilities (“SNFs”) using state-of-the-art telemedicine technology.</p>', NULL, NULL, NULL, NULL, NULL, '2016-07-12 00:19:59', '2016-07-13 16:28:41', '0cd65f37-8205-47ca-b722-03d016c5fdd7'),
 ('215', '296', 'en_us', 'Tusker Medical', NULL, NULL, NULL, NULL, NULL, '<p>Tusker Medical is an early stage medical device company developing innovative ear, nose and throat treatments. Tusker is currently developing a suite of pediatric-focused technologies designed to enable placement of tubes within the comfort of an office environment, eliminating the need for general anesthetics.</p>', NULL, '<p>Tusker Medical is an early stage medical device company developing innovative ear, nose and throat treatments.</p>', NULL, NULL, NULL, NULL, NULL, '2016-07-12 00:23:01', '2016-07-13 21:08:08', '0347cdcb-7ac7-48ff-b6f8-0242eba216a2'),
 ('216', '298', 'en_us', 'VytronUS', NULL, NULL, NULL, NULL, NULL, '<p>VytronUS is a clinical stage company redefining ablation by using a next generation ultrasound based robotic catheter to treat complex cardiac arrhythmias including atrial fibrillation. The company has developed an endocardial ablation platform based on Low-Intensity Collimated Ultrasound (LICU™). LICU is capable of quickly producing high-resolution maps of cardiac anatomy and allows for non-contact energy delivery to create durable continuous linear lesions. VytronUS will help simplify the procedure and improve efficacy by leading to more predictable outcomes.</p>', NULL, '<p>VytronUS is a clinical stage company redefining ablation by using a next generation ultrasound based robotic catheter to treat complex cardiac arrhythmias including atrial fibrillation.</p>', NULL, NULL, NULL, NULL, NULL, '2016-07-12 00:24:36', '2016-07-13 16:27:51', '63f1a33d-aea2-40a0-b93a-9ac1bc601183');
INSERT INTO `craft_content` (`id`, `elementId`, `locale`, `title`, `field_blurb`, `field_publishedDate`, `field_aboutTitle`, `field_aboutText`, `field_teamMemberBio`, `field_companyBio`, `field_teamMemberShortDescription`, `field_companyShortDescription`, `field_footerCopy`, `field_teamMemberPosition`, `field_trajectorySectionTitle`, `field_partnershipSectionTitle`, `field_twitterShortDescription`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('217', '311', 'en_us', 'TripleCare', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:44:54', '2016-07-12 04:44:54', 'd0a793e3-2bb7-476b-b2c3-ae96c9525407'),
 ('218', '312', 'en_us', 'High-Tech Healthcare Helps Eliminate Unnecessary Hospital Visits', NULL, '2016-07-06 04:00:00', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'High-Tech Healthcare Helps Eliminate Unnecessary Hospital Visits', '2016-07-12 04:45:30', '2016-07-15 16:26:54', 'acde4de3-a504-4f41-ab14-96cfbe35b450'),
 ('219', '314', 'en_us', 'Cure Forward Announces First Trial Recruitment Collaboration That Will Expand Patient Access to Innovative Treatments', NULL, '2016-06-28 04:00:00', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Cure Forward Announces First Trial Recruitment Collaboration That expands Patient Access to Innovative Treatments', '2016-07-12 04:47:22', '2016-07-15 16:26:47', 'e76c0cbf-5116-4cdc-aa74-de983d3f87e2'),
 ('220', '318', 'en_us', 'Heartware', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:49:55', '2016-07-12 04:49:55', 'dd7e8400-af2e-4bda-b4a6-c49e56ddd2e3'),
 ('221', '319', 'en_us', 'Medtronic to Expand Heart Failure Portfolio with Acquisition of HeartWare International', NULL, '2016-06-27 04:00:00', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Medtronic to Expand Heart Failure Portfolio with Acquisition of HeartWare International', '2016-07-12 04:50:11', '2016-07-15 16:25:52', '8510689a-e080-4d83-a316-27417af413a8'),
 ('222', '325', 'en_us', 'Cure Forward', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:50:44', '2016-07-12 04:50:44', 'f1934033-4c4d-43bc-ba63-f0dfbff537f3'),
 ('223', '326', 'en_us', 'Braeburn', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:52:34', '2016-07-12 04:52:34', '49ef6bea-a491-4654-adbc-de59d9c0aa07'),
 ('224', '327', 'en_us', 'FDA approves first buprenorphine implant for treatment of opioid dependence', NULL, '2016-05-26 04:00:00', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'FDA approves first buprenorphine implant for treatment of opioid dependence', '2016-07-12 04:52:37', '2016-07-15 16:25:44', '8a80fcbc-4c25-48b2-907f-4c1b95de4be0'),
 ('225', '329', 'en_us', 'Dermatology Services Company QualDerm Unveils $31.8M Growth Investment', NULL, '2016-04-20 04:00:00', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Dermatology Services Company QualDerm Unveils $31.8M Growth Investment', '2016-07-12 04:55:12', '2016-07-15 16:25:37', '6b4924c1-40f8-4d69-9f48-15baa18e544c'),
 ('226', '337', 'en_us', 'Syntimmune', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:56:48', '2016-07-12 04:56:48', '8d319c3c-c379-4114-a2db-95603b55fd16'),
 ('227', '338', 'en_us', 'Syntimmune Secures Second Tranche of $26 Million Series A Financing', NULL, '2016-03-22 04:00:00', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Syntimmune Secures Second Tranche of $26 Million Series A Financing', '2016-07-12 04:56:51', '2016-07-15 16:25:30', '62ff58cd-2541-4695-94d8-f73ec21c00fa'),
 ('228', '342', 'en_us', 'Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain', NULL, '2016-02-22 05:00:00', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Chronic Pain', '2016-07-12 04:59:33', '2016-07-15 16:25:20', '6aa1c50e-bd11-46ff-b553-7aa0e7aa2844'),
 ('229', '350', 'en_us', 'Corvidia', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 05:01:52', '2016-07-12 05:01:52', '0a5c8975-9009-4d00-bb56-912526433b2b'),
 ('230', '351', 'en_us', 'Corvidia Therapeutics Raises $26M in a Series A Financing, Led by Sofinnova Partners and Apple Tree Partners', NULL, '2016-02-17 05:00:00', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Corvidia Therapeutics Raises $26M in a Series A Financing, Led by Sofinnova Partners and Apple Tree Partners', '2016-07-12 05:01:56', '2016-07-15 16:24:52', '8e3d06ca-1943-4080-821c-59a45b46ece6'),
 ('231', '361', 'en_us', 'Braeburn Transparent', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:24:30', '2016-07-13 16:24:30', 'be16e88e-9d9f-4bd7-8e5c-bddb5c27ce29'),
 ('232', '362', 'en_us', 'Syntimmune Logo', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:24:30', '2016-07-13 16:24:30', '67d57d9b-62dc-4c83-b038-2774898037c9'),
 ('233', '363', 'en_us', 'Triple Care Transparent', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:24:33', '2016-07-13 16:24:33', 'c8e81f90-cac3-463d-acf0-6606a4667417'),
 ('234', '364', 'en_us', 'Aileron Logo 4 C', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:24:34', '2016-07-13 16:24:34', '8340636c-c2d1-49b5-89d6-731c63873317'),
 ('235', '365', 'en_us', 'Tokai Pharmaceuticals Logo Pms', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:24:34', '2016-07-13 16:24:34', 'a3632d25-fc6e-40f7-8526-32a2c05c58c3'),
 ('236', '366', 'en_us', 'Clean Slate Transparent', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:24:34', '2016-07-13 16:24:34', 'ef166199-09b9-4668-bc56-c7ed0ddd8e26'),
 ('237', '367', 'en_us', 'Gloucestor Transparent', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:24:34', '2016-07-13 16:24:34', '51716487-f5bc-4554-af69-0d3d2fed47d6'),
 ('239', '369', 'en_us', 'Heart Ware Transparent', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:24:36', '2016-07-13 16:24:36', '323f8f97-b49c-41dd-8b13-83f7bb195ebc'),
 ('240', '370', 'en_us', 'Sgx Transparent', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:24:36', '2016-07-13 16:24:36', '80940d36-5814-4f73-a089-78c29b11f12f'),
 ('241', '371', 'en_us', 'Tendyne Transparent', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:24:36', '2016-07-13 16:24:36', 'f8453c5e-30a6-4d82-b88e-a82956161db8'),
 ('242', '372', 'en_us', 'Vytronus Transparent', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:24:37', '2016-07-13 16:24:37', 'c3093137-4d03-4212-b9f6-5643b1b9a032'),
 ('243', '373', 'en_us', 'Cure Forward Transparent', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:24:38', '2016-07-13 16:24:38', '31d2bce1-46df-453f-af60-ab6e658e100b'),
 ('244', '374', 'en_us', 'Qualderm Transparent', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:24:40', '2016-07-13 16:24:40', 'b069e992-9faa-491b-a893-4b2aa43fbcea'),
 ('245', '375', 'en_us', 'Tusker Transparent', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:24:43', '2016-07-13 16:24:43', '49f8c459-647b-4476-8473-fa82e4e00c8d'),
 ('246', '376', 'en_us', 'Legacy Investment', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 16:29:09', '2016-07-13 16:29:09', 'dd3e5fdb-4911-46aa-a589-717f8dbf7e5d'),
 ('247', '377', 'en_us', 'Icon Atp Logo White', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 17:00:51', '2016-07-13 17:10:22', '33d46799-8296-4ce4-9622-5061501150c2'),
 ('248', '379', 'en_us', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 17:09:06', '2016-07-13 17:10:34', '1ac8a3ce-f9b4-4d4e-be37-24c055e93012'),
 ('249', '380', 'en_us', 'Coelacanth Chemical Corporation', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 17:17:59', '2016-07-13 17:17:59', '7316e129-99cc-4ec2-843d-635c8aced6fd'),
 ('250', '381', 'en_us', 'Gala Logo', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 17:18:00', '2016-07-13 17:18:00', '049f9040-1c44-4f91-b8fd-6a5f63b58345'),
 ('251', '382', 'en_us', 'Cyrano', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 17:18:00', '2016-07-13 17:18:00', 'cb70ace1-26c2-420c-b5e2-d469c07d7cb5'),
 ('252', '383', 'en_us', 'Corvidia', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 21:52:58', '2016-07-13 21:52:58', '93a451a1-771b-4caf-b933-2a8a76ca9342'),
 ('253', '384', 'en_us', 'Braeburn', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 21:53:09', '2016-07-13 21:53:09', '8795a149-2661-40c2-bf2a-ee5eb535b423'),
 ('254', '385', 'en_us', 'Syntimmune', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 21:53:19', '2016-07-13 21:53:19', '64299a97-980b-4719-a40c-ff52fca2ec51'),
 ('255', '386', 'en_us', 'CleanSlate', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-13 21:53:45', '2016-07-13 21:53:45', 'efeab4a5-be0c-4939-9e3e-ab6c4b5642de'),
 ('256', '387', 'en_us', 'Header Section Legal 1', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-14 19:36:49', '2016-07-14 19:36:49', '1000abe3-72fd-4803-8daa-520d5d846814'),
 ('257', '388', 'en_us', 'Menu Background', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-15 16:57:28', '2016-07-15 16:57:28', 'afcb224c-f39d-4a7c-aa55-baf959bb1e6f'),
 ('258', '389', 'en_us', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-15 17:08:03', '2016-07-15 17:08:27', 'ac7bc4e4-627c-4e60-b601-e0bcb85f0e72');



DROP TABLE IF EXISTS `craft_deprecationerrors`;


--
-- Schema for table `craft_deprecationerrors`
--
CREATE TABLE `craft_deprecationerrors` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `key` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `fingerprint` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `lastOccurrence` datetime NOT NULL,
  `file` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `line` smallint(6) unsigned NOT NULL,
  `class` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `method` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `template` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `templateLine` smallint(6) unsigned DEFAULT NULL,
  `message` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `traces` text COLLATE utf8_unicode_ci,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_deprecationerrors_key_fingerprint_unq_idx` (`key`,`fingerprint`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_elementindexsettings`;


--
-- Schema for table `craft_elementindexsettings`
--
CREATE TABLE `craft_elementindexsettings` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `type` varchar(150) COLLATE utf8_unicode_ci NOT NULL,
  `settings` text COLLATE utf8_unicode_ci,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_elementindexsettings_type_unq_idx` (`type`)
) ENGINE=InnoDB AUTO_INCREMENT=3 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_elementindexsettings`
--

INSERT INTO `craft_elementindexsettings` (`id`, `type`, `settings`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', 'Entry', '{\"sources\":{\"singles\":{\"tableAttributes\":{\"1\":\"link\"}}}}', '2016-06-27 16:19:47', '2016-06-27 16:19:47', '7e3bb8fd-d5a6-48ab-ba0d-b520ab69a50f'),
 ('2', 'Category', '{\"sources\":{\"group:1\":{\"tableAttributes\":{\"1\":\"link\"}}}}', '2016-07-05 21:13:16', '2016-07-05 21:13:16', 'a2ea2a24-00f1-4a31-8809-05d77b79ca86');



DROP TABLE IF EXISTS `craft_elements`;


--
-- Schema for table `craft_elements`
--
CREATE TABLE `craft_elements` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `type` varchar(150) COLLATE utf8_unicode_ci NOT NULL,
  `enabled` tinyint(1) unsigned NOT NULL DEFAULT '1',
  `archived` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  KEY `craft_elements_type_idx` (`type`),
  KEY `craft_elements_enabled_idx` (`enabled`),
  KEY `craft_elements_archived_dateCreated_idx` (`archived`,`dateCreated`)
) ENGINE=InnoDB AUTO_INCREMENT=390 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_elements`
--

INSERT INTO `craft_elements` (`id`, `type`, `enabled`, `archived`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', 'User', '1', '0', '2016-06-10 14:33:29', '2016-07-11 20:08:13', '7c14b495-9870-4428-b743-5f1a5c95483d'),
 ('4', 'GlobalSet', '1', '0', '2016-06-10 18:12:53', '2016-07-13 18:21:00', '95400eb6-e74b-497f-8030-ef0500f70dbf'),
 ('9', 'Entry', '1', '0', '2016-06-14 15:24:07', '2016-07-13 21:11:57', '0fe7f798-1edb-4373-a5c4-6aa1bf9e71bb'),
 ('10', 'Entry', '1', '0', '2016-06-14 15:24:20', '2016-07-13 21:20:34', 'ca79abdb-27aa-4c54-b772-066d6a788800'),
 ('12', 'Entry', '1', '0', '2016-06-14 15:25:54', '2016-07-14 16:36:39', 'f04b2b8c-e6af-4d0a-a6f6-0700d7d7dc96'),
 ('13', 'Entry', '1', '0', '2016-06-14 15:26:11', '2016-07-13 21:16:21', '7fd8a92a-3ed2-4ab8-9d4f-174395612895'),
 ('14', 'Entry', '1', '0', '2016-06-14 15:37:22', '2016-07-15 16:27:09', 'b027e4c7-9264-4f6e-9c88-8280f959398a'),
 ('15', 'MatrixBlock', '1', '0', '2016-06-14 15:37:22', '2016-07-15 16:27:09', 'f06e1a3c-2ca0-4682-9e32-24f5bd8d955b'),
 ('16', 'MatrixBlock', '1', '0', '2016-06-14 15:37:22', '2016-07-15 16:27:09', '51eafe80-044d-4ba8-a1f3-f6b66831d9fd'),
 ('17', 'MatrixBlock', '1', '0', '2016-06-14 15:37:22', '2016-07-15 16:27:09', 'df5eeb1c-1ee9-48ce-8828-e9a6f5d2a5fb'),
 ('18', 'MatrixBlock', '1', '0', '2016-06-14 15:37:22', '2016-07-15 16:27:09', 'a45e2d3e-1482-4d43-8f8e-7f2e95510fe3'),
 ('19', 'MatrixBlock', '1', '0', '2016-06-14 15:52:39', '2016-07-13 21:16:21', '014fd936-60e0-4ece-882d-01cc037bbd04'),
 ('20', 'MatrixBlock', '1', '0', '2016-06-14 15:52:39', '2016-07-13 21:16:21', 'a217b2f0-3b4c-491d-b5e5-509bf6ae6549'),
 ('21', 'MatrixBlock', '1', '0', '2016-06-14 15:52:39', '2016-07-13 21:16:21', 'cd893a92-a5c7-4668-82aa-d2253f846620'),
 ('22', 'MatrixBlock', '1', '0', '2016-06-14 15:52:39', '2016-07-13 21:16:21', '1fbf3450-bb80-4177-b8d1-a1cceb124796'),
 ('23', 'MatrixBlock', '1', '0', '2016-06-14 16:06:35', '2016-07-14 16:36:40', '4a1bde3c-f07b-413f-9ff0-592f478d7f7a'),
 ('24', 'MatrixBlock', '1', '0', '2016-06-14 16:06:35', '2016-07-14 16:36:40', '2d7a659b-663d-4201-8c93-5f69ab5003a2'),
 ('25', 'MatrixBlock', '1', '0', '2016-06-14 16:06:35', '2016-07-14 16:36:40', '09899778-0953-44e1-995e-92b77b399520'),
 ('26', 'MatrixBlock', '1', '0', '2016-06-14 16:06:35', '2016-07-14 16:36:40', 'b44ba764-9336-48ac-8b21-46ad38403aa2'),
 ('27', 'Entry', '1', '0', '2016-06-14 16:14:38', '2016-07-13 16:33:56', 'a1377456-c6ba-4fc0-a800-79630dbcf314'),
 ('28', 'MatrixBlock', '1', '0', '2016-06-14 16:14:38', '2016-07-13 16:33:56', '53772b22-28ff-4c9f-9c38-71e00eb6c0b1'),
 ('29', 'Entry', '1', '0', '2016-06-14 16:15:24', '2016-07-13 17:29:25', 'ced3b2fc-16c0-40cd-aa48-3932c45e0498'),
 ('31', 'Asset', '1', '0', '2016-06-14 20:20:18', '2016-06-14 20:45:49', 'a5a04d66-5afd-4cb1-a3b4-57e01d6bebf5'),
 ('34', 'Asset', '1', '0', '2016-06-14 20:21:32', '2016-06-14 20:45:49', '10049595-ff98-4715-aab7-4e9700a355ea'),
 ('36', 'MatrixBlock', '1', '0', '2016-06-15 18:44:39', '2016-07-13 21:11:57', 'ad810ff7-d196-447a-9a1b-a898bd634f6c'),
 ('37', 'MatrixBlock', '1', '0', '2016-06-15 19:06:53', '2016-07-13 21:11:57', 'fe27b3fd-cd2c-4bee-a471-c14aff8aa216'),
 ('38', 'MatrixBlock', '1', '0', '2016-06-15 19:06:53', '2016-07-13 21:11:57', '7dab4243-ae05-4d08-b8c7-95047120afd2'),
 ('39', 'MatrixBlock', '1', '0', '2016-06-15 19:06:53', '2016-07-13 21:11:57', 'c3c69086-d1dd-4e12-9f2e-ea4b87f1d920'),
 ('40', 'MatrixBlock', '1', '0', '2016-06-15 19:06:53', '2016-07-13 21:11:57', '556f9571-7563-4a8d-9e8a-7e10326c6f54'),
 ('41', 'MatrixBlock', '1', '0', '2016-06-15 19:36:44', '2016-07-13 21:20:34', 'fcfb89a3-5d39-4077-bece-26282bdda194'),
 ('42', 'MatrixBlock', '1', '0', '2016-06-15 20:03:58', '2016-07-13 21:20:34', 'e935cf5f-4014-43c2-b5d8-4a21df0a7ec5'),
 ('43', 'MatrixBlock', '1', '0', '2016-06-15 20:03:58', '2016-07-13 21:20:34', 'd42645f4-3ffa-453f-b59f-434a4a45d347'),
 ('44', 'MatrixBlock', '1', '0', '2016-06-15 20:23:24', '2016-07-13 18:21:00', '4a73050e-e628-4920-9092-9090e126bf30'),
 ('46', 'MatrixBlock', '1', '0', '2016-06-15 20:24:14', '2016-07-13 18:21:00', '80500033-3477-4542-b78c-d22c76087728'),
 ('47', 'MatrixBlock', '1', '0', '2016-06-15 20:24:14', '2016-07-13 18:21:00', 'de8462e2-73f8-4daf-a8dc-8c033abf4cb5'),
 ('48', 'MatrixBlock', '1', '0', '2016-06-15 20:30:16', '2016-07-13 18:21:00', 'dc48c2fd-4783-422d-a82d-44c8258cfbbe'),
 ('49', 'MatrixBlock', '1', '0', '2016-06-15 20:30:16', '2016-07-13 18:21:00', '6c78a766-476d-4123-8eda-822888ac32ec'),
 ('50', 'MatrixBlock', '1', '0', '2016-06-15 20:30:16', '2016-07-13 18:21:00', '1efeec63-5482-4fb9-ac35-9ac6700814b5'),
 ('51', 'Asset', '1', '0', '2016-06-16 18:43:10', '2016-06-16 18:43:10', '5babf8d3-4b00-48cd-8566-9fe5da487bae'),
 ('52', 'Entry', '1', '0', '2016-06-16 20:31:27', '2016-07-15 16:27:02', '46a6b0ed-9569-49fe-a2a0-2c546701f921'),
 ('53', 'Entry', '1', '0', '2016-06-17 17:12:03', '2016-07-13 17:46:39', '443ab548-af9a-4e03-ab82-f6c856a56d26'),
 ('55', 'Entry', '1', '0', '2016-06-17 17:12:30', '2016-07-13 17:30:51', 'c7767a82-0628-4e29-b77d-d16bb01469c3'),
 ('57', 'Entry', '1', '0', '2016-06-17 17:13:00', '2016-07-13 17:33:12', '9c997704-2a20-469e-b34e-b825c47c4c3f'),
 ('59', 'MatrixBlock', '1', '0', '2016-06-20 19:49:21', '2016-07-15 16:27:02', 'db2b885d-4f0c-4eb8-b19c-3b06eed4e923'),
 ('60', 'MatrixBlock', '1', '0', '2016-06-20 19:49:21', '2016-07-15 16:27:02', 'd0195d05-8dd1-4f0d-a7c0-529516f5d73b'),
 ('61', 'Tag', '1', '0', '2016-06-21 15:51:04', '2016-06-21 15:51:04', '965e160e-8cf5-4cb8-9700-e28182775dc4'),
 ('62', 'MatrixBlock', '1', '0', '2016-06-22 14:39:26', '2016-07-13 21:11:57', 'a77a0628-c377-4fa9-88dd-2251e847d3ac'),
 ('63', 'MatrixBlock', '1', '0', '2016-06-22 14:39:26', '2016-07-13 21:11:57', '595b4cb9-2941-4bef-85c4-48a1ba219f78'),
 ('64', 'MatrixBlock', '1', '0', '2016-06-22 14:39:26', '2016-07-13 21:11:57', '7c88298a-81ab-40d3-bbd7-d731657e4d3d'),
 ('65', 'Tag', '1', '0', '2016-06-23 18:55:51', '2016-06-23 18:55:51', '739e73e6-f821-4eb2-98a8-8d61c09c7ff5'),
 ('66', 'Entry', '1', '0', '2016-06-27 16:01:14', '2016-07-14 19:37:10', 'a0e3ac1f-dbed-47da-82d5-33c5ad623e22'),
 ('67', 'MatrixBlock', '1', '0', '2016-06-27 16:58:18', '2016-07-14 19:37:10', '95afc8b5-895e-427a-9e9c-d7a54ca27920'),
 ('68', 'MatrixBlock', '1', '0', '2016-06-27 16:58:18', '2016-07-14 19:37:10', '340765d8-6a25-4366-b155-ab2c289d826e'),
 ('69', 'MatrixBlock', '1', '0', '2016-06-27 16:58:18', '2016-07-14 19:37:10', '7622631a-c580-4d39-95b8-d95e00dad276'),
 ('70', 'Tag', '1', '0', '2016-06-28 15:58:42', '2016-06-28 15:58:42', 'cc7d9f56-02ff-4cf0-9787-f15bdce85c42'),
 ('71', 'Tag', '1', '0', '2016-06-28 16:26:33', '2016-06-28 16:26:33', 'b4d4d4ee-17c2-4ab9-9f5c-d8bacc0cc9b9'),
 ('72', 'Tag', '1', '0', '2016-06-28 16:26:39', '2016-06-28 16:26:39', 'cf93a5e6-27a3-4c29-845b-6c840443c217'),
 ('73', 'Tag', '1', '0', '2016-06-28 16:28:32', '2016-06-28 16:28:32', '8ebb9d1c-5e5f-4357-9fce-e78cfde12355'),
 ('74', 'MatrixBlock', '1', '0', '2016-06-28 20:56:54', '2016-07-13 21:11:57', 'eaaa6612-e6be-46ff-ba96-1335021ea12d'),
 ('75', 'Entry', '1', '0', '2016-07-06 21:31:22', '2016-07-14 20:30:23', '6b10739c-2512-4c54-8ad5-f240e1d802e1'),
 ('76', 'MatrixBlock', '1', '0', '2016-07-06 21:49:07', '2016-07-14 20:30:23', 'a7192583-2838-4011-8950-7ad1533f6ef0'),
 ('77', 'MatrixBlock', '1', '0', '2016-07-06 21:49:07', '2016-07-14 20:30:23', '324c31fb-ce37-4ac8-a854-59c0e8c4aa0e'),
 ('78', 'MatrixBlock', '1', '0', '2016-07-06 21:49:07', '2016-07-14 20:30:23', 'bf83d125-bb84-4847-9d73-ca30063e75da'),
 ('79', 'MatrixBlock', '1', '0', '2016-07-06 22:06:29', '2016-07-14 20:30:23', '1a2d2ce4-f53d-4ece-8a73-0cc3ed1ba249'),
 ('80', 'Asset', '1', '0', '2016-07-07 22:04:23', '2016-07-07 22:04:23', '0f70b0b9-6af1-4d08-8e1d-7f4a147129d8'),
 ('83', 'Asset', '1', '0', '2016-07-08 19:37:25', '2016-07-08 19:37:25', '2c61e09b-929b-4a2a-814b-8b7c55312da9'),
 ('87', 'Asset', '1', '0', '2016-07-11 17:23:22', '2016-07-11 17:23:22', 'd5bb072c-cfd0-4751-8b7c-98ad00ccc28f'),
 ('88', 'Asset', '1', '0', '2016-07-11 17:23:23', '2016-07-11 17:23:23', '8611495c-1a5e-4fb8-a3dc-0dc6ff3ef0ab'),
 ('89', 'Asset', '1', '0', '2016-07-11 17:23:24', '2016-07-11 17:23:24', 'bf86ff5d-df07-4dfa-a847-abe6b7ae32ea'),
 ('90', 'Asset', '1', '0', '2016-07-11 17:23:24', '2016-07-11 17:23:24', 'd7eee969-0b43-4897-9534-efae548084d9'),
 ('92', 'Asset', '1', '0', '2016-07-11 17:23:25', '2016-07-11 17:23:25', '964d9630-7592-4932-8a31-bf1fe3179013'),
 ('93', 'Asset', '1', '0', '2016-07-11 17:23:26', '2016-07-11 17:23:26', '447e3008-ca6e-49a7-8b99-9bcd398ce93c'),
 ('94', 'Asset', '1', '0', '2016-07-11 17:23:26', '2016-07-11 17:23:26', '1db73480-0ba9-46ff-90a5-5043c705cd0d'),
 ('95', 'Asset', '1', '0', '2016-07-11 17:23:27', '2016-07-11 17:23:27', '1426fbd4-28a9-4b1c-afd0-b25d2c20848b'),
 ('96', 'Tag', '1', '0', '2016-07-11 19:00:38', '2016-07-11 19:00:38', 'f8228756-3699-4014-83eb-a57e0cf73949'),
 ('97', 'Tag', '1', '0', '2016-07-11 19:01:28', '2016-07-11 19:01:28', '075df45c-374d-44d3-bb63-307374569eb6'),
 ('98', 'Tag', '1', '0', '2016-07-11 19:02:51', '2016-07-11 19:02:51', '8c74e931-d562-4930-946a-fb06f54e0b02'),
 ('99', 'Entry', '1', '0', '2016-07-11 19:05:03', '2016-07-13 17:50:10', 'd0649f8a-e4db-43a4-b02a-8d655ae5cc79'),
 ('100', 'Tag', '1', '0', '2016-07-11 19:05:31', '2016-07-11 19:05:31', '49e8805d-7873-4684-895e-c549d6556135'),
 ('101', 'Tag', '1', '0', '2016-07-11 19:06:46', '2016-07-11 19:06:46', '3eb3380d-65f9-410a-8dc0-c9b540dd233c'),
 ('102', 'Entry', '1', '0', '2016-07-11 19:07:46', '2016-07-13 17:47:35', 'd64329b6-3601-4795-83d3-b107f0fee81b'),
 ('105', 'Entry', '1', '0', '2016-07-11 19:12:55', '2016-07-13 16:54:50', 'b0c96068-2f1a-473b-ba1b-f827fc2025ac'),
 ('106', 'Entry', '1', '0', '2016-07-11 19:13:57', '2016-07-13 16:56:01', '71fa296f-b84c-4849-beee-35823d556f82'),
 ('107', 'Entry', '1', '0', '2016-07-11 19:15:07', '2016-07-13 17:36:08', '147f5f1a-0d9e-4093-ab0c-de90ad5f9258'),
 ('108', 'Entry', '1', '0', '2016-07-11 19:15:57', '2016-07-13 17:25:02', '866cb5bb-8c24-4582-9725-5e19ff92f9d5'),
 ('109', 'Entry', '1', '0', '2016-07-11 20:30:09', '2016-07-13 17:26:39', '12481a1e-84d5-43c3-84ca-fd2131bf65d8'),
 ('110', 'Entry', '1', '0', '2016-07-11 20:31:07', '2016-07-11 20:33:17', '18c26038-bcc4-4cf0-b129-4140ac8fa15e'),
 ('111', 'GlobalSet', '1', '0', '2016-07-11 20:41:13', '2016-07-15 17:08:20', '41578684-cc96-4dee-9160-2626d28de83b'),
 ('112', 'Asset', '1', '0', '2016-07-11 20:42:52', '2016-07-11 20:42:52', '1fd88f01-0998-499c-a385-2b32ebfa0ac3'),
 ('113', 'Entry', '1', '0', '2016-07-11 20:44:31', '2016-07-13 17:28:32', '0150706d-2d6c-4540-a599-0ed37bf6ff65'),
 ('114', 'Entry', '1', '0', '2016-07-11 20:46:13', '2016-07-13 20:16:47', '6386e7da-a68e-4f51-9fa9-5e9e6ca995a2'),
 ('116', 'Entry', '1', '0', '2016-07-11 20:47:37', '2016-07-13 17:44:33', '05ecc4a9-0a30-4070-bb1a-e5fdb8575a2a'),
 ('117', 'Tag', '1', '0', '2016-07-11 20:54:41', '2016-07-11 20:54:41', '3b9be28b-6d58-4184-bbf5-3c472a8c1834'),
 ('118', 'Tag', '1', '0', '2016-07-11 20:54:46', '2016-07-11 20:54:46', '7e3b7a60-c7fc-4f9a-ac0a-ee4fae0af2a8'),
 ('119', 'Tag', '1', '0', '2016-07-11 20:54:56', '2016-07-11 20:54:56', 'bf10bfe5-fe78-4ba7-a533-5819ef5ec594'),
 ('120', 'Tag', '1', '0', '2016-07-11 20:55:03', '2016-07-11 20:55:03', 'fbcc6666-4b91-4e76-9b8b-ea1aef2e5684'),
 ('121', 'Tag', '1', '0', '2016-07-11 20:55:14', '2016-07-11 20:55:14', '243a2e41-931c-4b6b-ae0b-ce426e2da3f2'),
 ('122', 'Tag', '1', '0', '2016-07-11 20:55:48', '2016-07-11 20:55:48', 'ec96f485-caba-44ef-aa1a-79817a8c345b'),
 ('123', 'Entry', '1', '0', '2016-07-11 20:56:15', '2016-07-13 17:27:41', 'b6199632-98ef-48bd-a64a-e3f69190cd73'),
 ('124', 'Tag', '1', '0', '2016-07-11 20:57:14', '2016-07-11 20:57:14', 'c7bb7ac7-a412-4f85-b078-fd09ba64e330');
INSERT INTO `craft_elements` (`id`, `type`, `enabled`, `archived`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('125', 'Entry', '1', '0', '2016-07-11 20:58:38', '2016-07-13 16:56:41', 'fdae6416-293c-4c35-b9bd-2ac3b64ad6ee'),
 ('126', 'Entry', '1', '0', '2016-07-11 21:00:05', '2016-07-13 17:23:31', '7a61260c-0bac-4dbc-9cf9-24d0eca3d092'),
 ('127', 'Entry', '1', '0', '2016-07-11 21:01:24', '2016-07-13 17:48:41', 'a811f9cb-7f75-4e28-ad14-bb0f489ada8a'),
 ('128', 'Entry', '1', '0', '2016-07-11 21:03:01', '2016-07-13 17:37:59', '8a98d755-59ff-49bd-9795-77f9ad2c9a09'),
 ('129', 'Tag', '1', '0', '2016-07-11 21:04:23', '2016-07-11 21:04:23', '9533aa17-cab5-4b96-bb61-a12c5d1c6124'),
 ('136', 'Asset', '1', '0', '2016-07-11 21:17:42', '2016-07-11 21:50:45', '9c70e128-420c-42bb-9c86-a71c6b6cd904'),
 ('141', 'Entry', '1', '0', '2016-07-11 21:24:27', '2016-07-11 21:24:27', 'e12dbdf5-0eb6-4203-ae20-6d8a1befc53e'),
 ('142', 'Entry', '1', '0', '2016-07-11 21:24:48', '2016-07-12 00:28:47', 'b044a6d5-ae36-4d79-b897-08c50dd21381'),
 ('143', 'Entry', '1', '0', '2016-07-11 21:25:07', '2016-07-12 00:28:23', '3872efcc-8ed2-47b7-bd7f-59ad22cb5b1f'),
 ('144', 'Entry', '1', '0', '2016-07-11 21:25:28', '2016-07-11 21:25:28', 'f67753e5-4b5c-46f5-8910-1e73c89cf413'),
 ('145', 'Entry', '1', '0', '2016-07-11 21:25:55', '2016-07-12 00:28:30', 'a459b5a6-2caa-4fec-b800-72bbf7d275c7'),
 ('146', 'Entry', '1', '0', '2016-07-11 21:26:11', '2016-07-12 00:28:03', '75536e6f-0a8c-4922-9a45-c30f6e18e142'),
 ('200', 'Entry', '1', '0', '2016-07-11 21:56:47', '2016-07-13 16:33:35', '552a990d-4e31-4676-9e2b-f99e13d72418'),
 ('201', 'MatrixBlock', '1', '0', '2016-07-11 21:57:13', '2016-07-13 16:33:35', '43f32295-ccd9-4935-9484-30d5d6042a03'),
 ('202', 'Asset', '1', '0', '2016-07-11 21:57:43', '2016-07-11 21:57:43', '666b0b4b-b6c8-4c5d-8150-cf49c50c6ef1'),
 ('204', 'Entry', '1', '0', '2016-07-11 21:58:40', '2016-07-13 16:33:16', '20883c19-7616-4b9f-8f03-40a6724874ea'),
 ('205', 'MatrixBlock', '1', '0', '2016-07-11 21:58:40', '2016-07-13 16:33:16', '491649dc-2436-48c3-b666-0c6267e95c94'),
 ('227', 'Tag', '1', '0', '2016-07-11 22:01:54', '2016-07-11 22:01:54', 'b0bb0a56-1e2d-4987-ba0d-5706872d6f11'),
 ('228', 'Tag', '1', '0', '2016-07-11 22:03:14', '2016-07-11 22:03:14', '42e57a81-066b-4f6a-ac89-4ee0a4f773f1'),
 ('229', 'Entry', '1', '0', '2016-07-11 22:03:23', '2016-07-13 21:14:28', '02ad480b-0df8-4870-b54c-3f0a8f8ce91d'),
 ('230', 'MatrixBlock', '1', '0', '2016-07-11 22:03:47', '2016-07-13 21:14:28', '09a4bef1-17e6-46a7-b13b-0142e3550dae'),
 ('232', 'Tag', '1', '0', '2016-07-11 22:17:15', '2016-07-11 22:17:15', '4370dc6d-52d2-4690-953a-3091b26c265f'),
 ('233', 'Tag', '1', '0', '2016-07-11 22:18:44', '2016-07-11 22:18:44', '1708fc7c-a8e5-4f25-bf7d-08d089c0ed6b'),
 ('238', 'Tag', '1', '0', '2016-07-11 22:21:22', '2016-07-11 22:21:22', '0046c3c6-d07d-4fd6-9900-6d0d08fe5dd6'),
 ('239', 'Entry', '1', '0', '2016-07-11 22:21:39', '2016-07-13 16:32:34', 'f1b0a4a2-6948-432b-b552-a9efb7ece630'),
 ('240', 'MatrixBlock', '1', '0', '2016-07-11 22:21:39', '2016-07-13 16:32:34', '351c85f6-051a-45b2-9dd9-54419bf7e55a'),
 ('242', 'Entry', '1', '0', '2016-07-11 22:29:19', '2016-07-13 17:19:52', '7ecfaf9b-d857-4241-aefb-aafbc34707e0'),
 ('243', 'MatrixBlock', '1', '0', '2016-07-11 22:29:19', '2016-07-13 17:19:52', 'c5652e41-5097-4aea-a96c-354ae1e42319'),
 ('244', 'Entry', '1', '0', '2016-07-11 22:35:10', '2016-07-13 16:31:58', '58e6d7f8-ed81-4876-a2ab-4aa858c9ef47'),
 ('245', 'MatrixBlock', '1', '0', '2016-07-11 22:35:11', '2016-07-13 16:31:59', '8090ea40-30c7-46b1-b050-b88d4c600f14'),
 ('246', 'Entry', '1', '0', '2016-07-11 22:36:11', '2016-07-13 21:17:31', '0abb8ad3-53d6-4a02-80af-922730ea58a2'),
 ('247', 'MatrixBlock', '1', '0', '2016-07-11 22:36:11', '2016-07-13 21:17:31', 'a13fbe09-242d-4e58-ba1a-4cfe57e64c55'),
 ('248', 'Entry', '1', '0', '2016-07-11 22:37:48', '2016-07-13 16:31:14', 'd569cf88-abc9-4451-923a-4e9be6b78097'),
 ('249', 'MatrixBlock', '1', '0', '2016-07-11 22:37:48', '2016-07-13 16:31:14', 'a23eb83e-8f2c-494b-83f2-55d227282828'),
 ('250', 'Entry', '1', '0', '2016-07-11 22:40:09', '2016-07-13 16:30:56', '8e1a6e17-e9f2-4541-bdc8-4f3be4ee59d1'),
 ('255', 'Tag', '1', '0', '2016-07-11 23:15:08', '2016-07-11 23:15:08', '1b41037a-6644-40f1-b20a-3abca02b028b'),
 ('256', 'Tag', '1', '0', '2016-07-11 23:24:25', '2016-07-11 23:24:25', '25d59a4a-e657-4b66-b46b-a1dd9e458c29'),
 ('257', 'Tag', '1', '0', '2016-07-11 23:37:38', '2016-07-11 23:37:38', 'fd4f77b1-db21-4fff-a2ee-9abbb9e3345b'),
 ('266', 'Tag', '1', '0', '2016-07-11 23:40:12', '2016-07-11 23:40:12', '5967f21f-e9b9-498d-a404-f5542cc942f6'),
 ('268', 'MatrixBlock', '1', '0', '2016-07-11 23:41:01', '2016-07-13 16:30:57', 'dd20ce1f-d072-4f4d-93cd-8fa2d1dde6b1'),
 ('275', 'Entry', '1', '0', '2016-07-11 23:47:20', '2016-07-13 16:30:36', '79cd2140-9ae8-4b88-ae3b-7645a221f8fe'),
 ('276', 'MatrixBlock', '1', '0', '2016-07-11 23:47:20', '2016-07-13 16:30:36', 'd30fe568-9918-4f4b-a2ee-904b195c9b4b'),
 ('280', 'Tag', '1', '0', '2016-07-11 23:58:00', '2016-07-11 23:58:00', 'ccf10a7b-6527-4554-9c62-9fbf3902b7d9'),
 ('281', 'Entry', '1', '0', '2016-07-12 00:07:33', '2016-07-13 16:30:19', '7978cfac-e635-44ca-bf4b-7579d106d377'),
 ('282', 'MatrixBlock', '1', '0', '2016-07-12 00:07:33', '2016-07-13 16:30:20', 'c9659469-d184-4d72-be76-c0567356d86a'),
 ('284', 'Entry', '1', '0', '2016-07-12 00:09:32', '2016-07-13 16:29:54', '7f8df590-bad8-469e-9580-56a8ccdfae0f'),
 ('285', 'MatrixBlock', '1', '0', '2016-07-12 00:09:32', '2016-07-13 16:29:54', '2759ae92-7e7f-40c1-b0cf-ae6ab4ee810d'),
 ('287', 'Entry', '1', '0', '2016-07-12 00:15:28', '2016-07-13 16:38:44', '8b4ede4f-4047-4a28-a953-798acd0de5b9'),
 ('288', 'MatrixBlock', '1', '0', '2016-07-12 00:15:28', '2016-07-13 16:38:44', '789b4266-732f-48a6-8ae1-26df428a8ea9'),
 ('290', 'Entry', '1', '0', '2016-07-12 00:17:23', '2016-07-13 16:29:12', '122bb634-9575-442a-bf1b-7224519461e3'),
 ('291', 'MatrixBlock', '1', '0', '2016-07-12 00:17:23', '2016-07-13 16:29:12', '047fd0ea-bcb1-4cd9-9886-f276d9937423'),
 ('293', 'Entry', '1', '0', '2016-07-12 00:19:59', '2016-07-13 16:28:41', 'bd24038d-860c-4a8f-8b86-1a4c969a687e'),
 ('294', 'MatrixBlock', '1', '0', '2016-07-12 00:19:59', '2016-07-13 16:28:41', '75f15bb6-2a8c-4509-ae33-ace3a488ccba'),
 ('296', 'Entry', '1', '0', '2016-07-12 00:23:01', '2016-07-13 21:08:08', 'f2cea4a4-e0ad-4760-84e2-375fa0e7220e'),
 ('297', 'MatrixBlock', '1', '0', '2016-07-12 00:23:01', '2016-07-13 21:08:08', 'a5cbf3b5-c0cd-486d-981e-9efdc44e950a'),
 ('298', 'Entry', '1', '0', '2016-07-12 00:24:36', '2016-07-13 16:27:51', '25b537be-9674-48fe-b34d-ef0d62b51d1b'),
 ('299', 'MatrixBlock', '1', '0', '2016-07-12 00:24:36', '2016-07-13 16:27:51', '8f4f2710-a48e-4485-b7e2-f2268bc26ce3'),
 ('300', 'MatrixBlock', '1', '0', '2016-07-12 04:16:32', '2016-07-14 19:37:10', '99c85bf6-efda-4bf2-9a0d-26de4c83431e'),
 ('301', 'MatrixBlock', '1', '0', '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'f726d25f-9fe4-4f2d-9799-6775f3bc6ec4'),
 ('302', 'MatrixBlock', '1', '0', '2016-07-12 04:16:32', '2016-07-14 19:37:10', '823195c0-e184-4202-9734-47a65290e08f'),
 ('303', 'MatrixBlock', '1', '0', '2016-07-12 04:16:32', '2016-07-14 19:37:10', '9075f686-0284-40be-a962-8a48f1cd72fb'),
 ('304', 'MatrixBlock', '1', '0', '2016-07-12 04:16:32', '2016-07-14 19:37:10', '03552bb4-4fbf-4bc6-beb4-6e4a3b98576f'),
 ('305', 'MatrixBlock', '1', '0', '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'a03954fb-6675-4d1a-a4cb-540f81eacecd'),
 ('306', 'MatrixBlock', '1', '0', '2016-07-12 04:16:32', '2016-07-14 19:37:10', '10efb9fa-49d9-4901-a2bc-eef593821deb'),
 ('307', 'MatrixBlock', '1', '0', '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'e220174a-dfe1-4860-ac9a-f6bbffb2cfbf'),
 ('308', 'MatrixBlock', '1', '0', '2016-07-12 04:16:32', '2016-07-14 19:37:10', '774a128e-3099-4dce-a187-9104f5d75e4f'),
 ('309', 'MatrixBlock', '1', '0', '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'd9ca61ad-c234-4777-9245-db1aa66a1494'),
 ('310', 'MatrixBlock', '1', '0', '2016-07-12 04:16:32', '2016-07-14 19:37:10', '403dd314-82d0-45bf-98b3-170ef40dcf28'),
 ('311', 'Tag', '1', '0', '2016-07-12 04:44:54', '2016-07-12 04:44:54', 'd1d81ba2-f44a-4636-8697-4443367e0b4a'),
 ('312', 'Entry', '1', '0', '2016-07-12 04:45:30', '2016-07-15 16:26:54', 'e104752d-5e0e-4a2c-b5c2-0ea59011c024'),
 ('313', 'MatrixBlock', '1', '0', '2016-07-12 04:45:30', '2016-07-15 16:26:54', '567dc366-7325-4784-8d73-158375dc10ef'),
 ('314', 'Entry', '1', '0', '2016-07-12 04:47:22', '2016-07-15 16:26:47', 'b97dfc4d-898c-457f-85b0-8eef171914c9'),
 ('315', 'MatrixBlock', '1', '0', '2016-07-12 04:47:22', '2016-07-15 16:26:47', '5ce897b8-8619-4dda-a87f-0a53a45308c7'),
 ('316', 'MatrixBlock', '1', '0', '2016-07-12 04:47:22', '2016-07-15 16:26:47', '802cbbda-05f4-45b1-b5e4-0cfd3e0d4a77'),
 ('317', 'MatrixBlock', '1', '0', '2016-07-12 04:47:22', '2016-07-15 16:26:47', '9d01fd5c-77df-4bdd-8d15-522e5befe93e'),
 ('318', 'Tag', '1', '0', '2016-07-12 04:49:55', '2016-07-12 04:49:55', 'a2d461ef-c7f8-43fb-92be-b2bb6a6e278a'),
 ('319', 'Entry', '1', '0', '2016-07-12 04:50:11', '2016-07-15 16:25:52', '4ded1b99-edef-49a7-82a5-4ecb4c7bc342'),
 ('320', 'MatrixBlock', '1', '0', '2016-07-12 04:50:11', '2016-07-15 16:25:52', '2415e504-96c5-4941-826e-2d6f2d4ccaf0'),
 ('321', 'MatrixBlock', '1', '0', '2016-07-12 04:50:11', '2016-07-15 16:25:52', 'de412522-42ab-4dc1-8a60-c8b1fa47a7d3'),
 ('322', 'MatrixBlock', '1', '0', '2016-07-12 04:50:11', '2016-07-15 16:25:52', '34fd0ab3-0042-4d42-9ad8-a32edf5276f2'),
 ('323', 'MatrixBlock', '1', '0', '2016-07-12 04:50:11', '2016-07-15 16:25:52', 'd898ae20-d8c9-4db8-a10d-08247622769f'),
 ('324', 'MatrixBlock', '1', '0', '2016-07-12 04:50:11', '2016-07-15 16:25:52', '7e8da695-3b54-4deb-af52-e397a0dbdcec'),
 ('325', 'Tag', '1', '0', '2016-07-12 04:50:44', '2016-07-12 04:50:44', '82680501-6320-4abe-a185-37a3dfae49df'),
 ('326', 'Tag', '1', '0', '2016-07-12 04:52:34', '2016-07-12 04:52:34', '4f7212c7-d4c8-463e-b1f7-390422e67531'),
 ('327', 'Entry', '1', '0', '2016-07-12 04:52:37', '2016-07-15 16:25:44', 'a85d97e4-04a8-46f4-921f-512ee414732f'),
 ('328', 'MatrixBlock', '1', '0', '2016-07-12 04:52:37', '2016-07-15 16:25:44', '0f69fd9f-f53b-455e-aaae-7d1d7b2c2276'),
 ('329', 'Entry', '1', '0', '2016-07-12 04:55:12', '2016-07-15 16:25:37', '08b6f720-1393-4a86-84e3-88f3b9a2114e'),
 ('330', 'MatrixBlock', '1', '0', '2016-07-12 04:55:12', '2016-07-15 16:25:37', '7b7d55b2-7049-455f-bdbb-8741c16ca6b8'),
 ('331', 'MatrixBlock', '1', '0', '2016-07-12 04:55:12', '2016-07-15 16:25:37', '75922293-3114-44eb-8f5e-43f6b67f3627'),
 ('332', 'MatrixBlock', '1', '0', '2016-07-12 04:55:12', '2016-07-15 16:25:37', 'b6c2c9c8-b17a-491d-8c21-ea8142dc46e5'),
 ('333', 'MatrixBlock', '1', '0', '2016-07-12 04:55:12', '2016-07-15 16:25:37', '3588c92a-d2dc-483a-b6d0-025cf8e411fa'),
 ('334', 'MatrixBlock', '1', '0', '2016-07-12 04:55:12', '2016-07-15 16:25:37', '12f38555-9be3-4123-a3fa-af0803495cc5'),
 ('335', 'MatrixBlock', '1', '0', '2016-07-12 04:55:12', '2016-07-15 16:25:37', '067c8e7b-f9ee-4b4d-b9d5-003e311ac584'),
 ('336', 'MatrixBlock', '1', '0', '2016-07-12 04:55:12', '2016-07-15 16:25:37', 'ee7100a6-f1fd-4ad8-80d6-63783b6c98cd'),
 ('337', 'Tag', '1', '0', '2016-07-12 04:56:48', '2016-07-12 04:56:48', '64b462ea-61b6-41db-b892-482cac5762a9'),
 ('338', 'Entry', '1', '0', '2016-07-12 04:56:51', '2016-07-15 16:25:30', 'eab99d53-2144-472c-a7fc-5b74d305fef0'),
 ('339', 'MatrixBlock', '1', '0', '2016-07-12 04:56:51', '2016-07-15 16:25:30', 'dea180e5-ca48-478b-b802-d12d0fad6c87'),
 ('340', 'MatrixBlock', '1', '0', '2016-07-12 04:56:51', '2016-07-15 16:25:30', 'c84a8ffd-5366-4400-a741-2d5ba7304109'),
 ('341', 'MatrixBlock', '1', '0', '2016-07-12 04:56:51', '2016-07-15 16:25:30', 'c6b040fe-1e6a-446e-88ea-701abeaa449b'),
 ('342', 'Entry', '1', '0', '2016-07-12 04:59:33', '2016-07-15 16:25:20', '8185bf3b-bb77-4828-bec4-a6d537975794');
INSERT INTO `craft_elements` (`id`, `type`, `enabled`, `archived`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('343', 'MatrixBlock', '1', '0', '2016-07-12 04:59:33', '2016-07-15 16:25:20', '57d0ea3d-b4ae-438f-bfb4-c646dc3ebd21'),
 ('344', 'MatrixBlock', '1', '0', '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'caf6e5bf-139d-4d03-afa1-cb0323346d3c'),
 ('345', 'MatrixBlock', '1', '0', '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'ec41a557-d962-48df-b69e-6c48151bcdc5'),
 ('346', 'MatrixBlock', '1', '0', '2016-07-12 04:59:33', '2016-07-15 16:25:20', '07933a75-f339-4b4f-9f06-a752973aa6d5'),
 ('347', 'MatrixBlock', '1', '0', '2016-07-12 04:59:33', '2016-07-15 16:25:20', '29247312-ad81-464f-b7ec-e89efd848728'),
 ('348', 'MatrixBlock', '1', '0', '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'ccf175da-67af-48a9-9b26-92491b5a729c'),
 ('349', 'MatrixBlock', '1', '0', '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'ac06db4a-03b9-45e5-8970-b56dbaef379e'),
 ('350', 'Tag', '1', '0', '2016-07-12 05:01:52', '2016-07-12 05:01:52', '2b325236-37de-4b09-880f-b1929ee49602'),
 ('351', 'Entry', '1', '0', '2016-07-12 05:01:56', '2016-07-15 16:24:52', 'e59ca5cb-c68c-4caf-a132-801d0038b8af'),
 ('352', 'MatrixBlock', '1', '0', '2016-07-12 05:01:56', '2016-07-15 16:24:52', '58281319-f57d-40fb-a30b-0aa9d8ebbe2f'),
 ('353', 'MatrixBlock', '1', '0', '2016-07-12 05:01:56', '2016-07-15 16:24:52', 'e249b9c5-5c1d-425a-8c36-d1e547fcd021'),
 ('354', 'MatrixBlock', '1', '0', '2016-07-12 05:01:56', '2016-07-15 16:24:52', '6b1ffe6e-ca3d-4c74-998e-47b7a658da91'),
 ('355', 'MatrixBlock', '1', '0', '2016-07-12 05:01:56', '2016-07-15 16:24:52', '39ef22b5-4b41-43e6-8ff1-854b954c038a'),
 ('356', 'MatrixBlock', '1', '0', '2016-07-12 05:01:56', '2016-07-15 16:24:52', '6f7fca18-d166-4e4a-a571-fbd28be38001'),
 ('357', 'MatrixBlock', '1', '0', '2016-07-13 00:53:43', '2016-07-13 21:11:57', '80232e82-e4d8-4627-8b0b-a0cc30b75ed8'),
 ('361', 'Asset', '1', '0', '2016-07-13 16:24:30', '2016-07-13 16:24:30', '469af177-0fe6-42e4-9279-85830ab8c98b'),
 ('362', 'Asset', '1', '0', '2016-07-13 16:24:30', '2016-07-13 16:24:30', '2ed88a9b-e035-4595-a600-55443409fb59'),
 ('363', 'Asset', '1', '0', '2016-07-13 16:24:33', '2016-07-13 16:24:33', '056ab573-ba6c-4c48-ba01-73485260357e'),
 ('364', 'Asset', '1', '0', '2016-07-13 16:24:34', '2016-07-13 16:24:34', '9a2e6c4f-3f1f-4298-a9ab-a0361584470e'),
 ('365', 'Asset', '1', '0', '2016-07-13 16:24:34', '2016-07-13 16:24:34', '1114c250-273a-4b52-bf4f-e5363f57077d'),
 ('366', 'Asset', '1', '0', '2016-07-13 16:24:34', '2016-07-13 16:24:34', '5f7ba2eb-3653-4875-a8da-f72f08b4042d'),
 ('367', 'Asset', '1', '0', '2016-07-13 16:24:34', '2016-07-13 16:24:34', '0224b5e1-54ed-40cd-a15e-9281440b7319'),
 ('369', 'Asset', '1', '0', '2016-07-13 16:24:36', '2016-07-13 16:24:36', 'e3f58aa1-372f-4fda-b199-1cb1bb47c174'),
 ('370', 'Asset', '1', '0', '2016-07-13 16:24:36', '2016-07-13 16:24:36', 'eea88f96-f3fa-427e-af3c-bc0fd8c9531c'),
 ('371', 'Asset', '1', '0', '2016-07-13 16:24:36', '2016-07-13 16:24:36', '285eff61-626e-4c88-8dfc-f08ea26324a0'),
 ('372', 'Asset', '1', '0', '2016-07-13 16:24:37', '2016-07-13 16:24:37', '394c5eaa-7d75-4591-a445-2d09da4c341e'),
 ('373', 'Asset', '1', '0', '2016-07-13 16:24:38', '2016-07-13 16:24:38', 'c0a8d610-dd2d-4fa4-8aa0-fd589fa02e10'),
 ('374', 'Asset', '1', '0', '2016-07-13 16:24:40', '2016-07-13 16:24:40', '16a44b20-0bca-4201-9022-b8c37c136fc3'),
 ('375', 'Asset', '1', '0', '2016-07-13 16:24:43', '2016-07-13 16:24:43', '78ba1213-e229-4bcd-b9b2-ec8b94ba15c0'),
 ('376', 'Tag', '1', '0', '2016-07-13 16:29:09', '2016-07-13 16:29:09', '586997c7-7907-413c-b294-348dd605752c'),
 ('377', 'Asset', '1', '0', '2016-07-13 17:00:51', '2016-07-13 17:10:22', '7f4389ea-0529-438f-ab14-9fed317604c5'),
 ('379', 'GlobalSet', '1', '0', '2016-07-13 17:09:06', '2016-07-13 17:10:34', 'df5b0e88-a9ac-4650-be10-d38fb5f615d3'),
 ('380', 'Asset', '1', '0', '2016-07-13 17:17:59', '2016-07-13 17:17:59', 'de02e836-2933-428e-a961-acdfb3ab8556'),
 ('381', 'Asset', '1', '0', '2016-07-13 17:18:00', '2016-07-13 17:18:00', '5c89c9b5-69a4-45bc-b9be-d3a34aaf5495'),
 ('382', 'Asset', '1', '0', '2016-07-13 17:18:00', '2016-07-13 17:18:00', '3c72e8c8-aae0-4927-a2c1-01b24fcb158a'),
 ('383', 'Tag', '1', '0', '2016-07-13 21:52:58', '2016-07-13 21:52:58', '377e9dc9-720f-4310-91ee-5386d765eec5'),
 ('384', 'Tag', '1', '0', '2016-07-13 21:53:09', '2016-07-13 21:53:09', 'ac82c8cf-214a-4ed0-9c1f-573008781436'),
 ('385', 'Tag', '1', '0', '2016-07-13 21:53:19', '2016-07-13 21:53:19', '77ee2c49-8375-4cbf-9074-f6bea37f34b0'),
 ('386', 'Tag', '1', '0', '2016-07-13 21:53:45', '2016-07-13 21:53:45', 'b17375cd-7cfa-4b71-b448-241cdd0cd0fd'),
 ('387', 'Asset', '1', '0', '2016-07-14 19:36:49', '2016-07-14 19:36:49', '57d80089-ada7-4ca1-98e5-4d80ddef79bd'),
 ('388', 'Asset', '1', '0', '2016-07-15 16:57:28', '2016-07-15 16:57:28', 'e5b8d1fb-d2d1-47cb-9f6d-23e419fa4156'),
 ('389', 'GlobalSet', '1', '0', '2016-07-15 17:08:03', '2016-07-15 17:08:27', 'a034b77d-200f-4f70-8db3-4f01a24d85a2');



DROP TABLE IF EXISTS `craft_elements_i18n`;


--
-- Schema for table `craft_elements_i18n`
--
CREATE TABLE `craft_elements_i18n` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `elementId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `slug` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `uri` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `enabled` tinyint(1) unsigned NOT NULL DEFAULT '1',
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_elements_i18n_elementId_locale_unq_idx` (`elementId`,`locale`),
  UNIQUE KEY `craft_elements_i18n_uri_locale_unq_idx` (`uri`,`locale`),
  KEY `craft_elements_i18n_slug_locale_idx` (`slug`,`locale`),
  KEY `craft_elements_i18n_enabled_idx` (`enabled`),
  KEY `craft_elements_i18n_locale_fk` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=390 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_elements_i18n`
--

INSERT INTO `craft_elements_i18n` (`id`, `elementId`, `locale`, `slug`, `uri`, `enabled`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '1', 'en_us', '', NULL, '1', '2016-06-10 14:33:29', '2016-07-11 20:08:13', '54414488-fea0-4bc5-916a-402f9d5d6945'),
 ('4', '4', 'en_us', '', NULL, '1', '2016-06-10 18:12:53', '2016-07-13 18:21:00', '13484aae-f582-444c-adc5-8a9960211ba4'),
 ('9', '9', 'en_us', 'home', '__home__', '1', '2016-06-14 15:24:07', '2016-07-13 21:11:57', '407f078c-c7f1-4526-8f3c-b23110f5f5ca'),
 ('10', '10', 'en_us', 'contact', 'contact', '1', '2016-06-14 15:24:20', '2016-07-13 21:20:34', '4871975e-54f5-4ff9-9f16-9c9fac78dbd2'),
 ('12', '12', 'en_us', 'team', 'team', '1', '2016-06-14 15:25:54', '2016-07-14 16:36:40', 'a6487452-3e27-4324-a6c3-b97d8fdac5dd'),
 ('13', '13', 'en_us', 'portfolio', 'portfolio', '1', '2016-06-14 15:26:11', '2016-07-13 21:16:21', '84c64a06-507c-4f18-babd-a03075af0501'),
 ('14', '14', 'en_us', 'cleanslate', 'news/cleanslate', '1', '2016-06-14 15:37:22', '2016-07-15 16:27:09', '7c7dd205-9e63-4abf-a1c5-c0517babb509'),
 ('15', '15', 'en_us', '', NULL, '1', '2016-06-14 15:37:22', '2016-07-15 16:27:09', 'd2d567c3-b77f-4897-b123-f7fafda8141a'),
 ('16', '16', 'en_us', '', NULL, '1', '2016-06-14 15:37:22', '2016-07-15 16:27:09', '5f60d69f-9471-4044-b9a2-d09bb9fa0bb5'),
 ('17', '17', 'en_us', '', NULL, '1', '2016-06-14 15:37:22', '2016-07-15 16:27:09', 'a583dd45-3fde-446e-b627-3608b437b55e'),
 ('18', '18', 'en_us', '', NULL, '1', '2016-06-14 15:37:22', '2016-07-15 16:27:09', '1053d27a-635c-45e4-86de-69f537b42645'),
 ('19', '19', 'en_us', '', NULL, '1', '2016-06-14 15:52:39', '2016-07-13 21:16:21', '9f14b7cf-c149-4f49-b6de-6921a73194a6'),
 ('20', '20', 'en_us', '', NULL, '1', '2016-06-14 15:52:39', '2016-07-13 21:16:21', '4e9900d9-6fd3-449c-8509-1edf086beece'),
 ('21', '21', 'en_us', '', NULL, '1', '2016-06-14 15:52:39', '2016-07-13 21:16:21', 'a5b8cdc7-a500-4e85-aa63-c09f8eef8cbd'),
 ('22', '22', 'en_us', '', NULL, '1', '2016-06-14 15:52:39', '2016-07-13 21:16:21', '691c3d8f-44e1-4931-a7a0-b13de0e726ae'),
 ('23', '23', 'en_us', '', NULL, '1', '2016-06-14 16:06:35', '2016-07-14 16:36:40', '30b01c11-791c-4d68-8fba-32ec26b4fa31'),
 ('24', '24', 'en_us', '', NULL, '1', '2016-06-14 16:06:35', '2016-07-14 16:36:40', '2698f834-1fe4-4138-a455-ed8764957fc4'),
 ('25', '25', 'en_us', '', NULL, '1', '2016-06-14 16:06:35', '2016-07-14 16:36:40', '07fc9094-4c3f-45a4-85df-e3e60dd2fb4d'),
 ('26', '26', 'en_us', '', NULL, '1', '2016-06-14 16:06:35', '2016-07-14 16:36:40', 'ab32c9e8-7b7b-4142-8a75-dd3fcf9ce275'),
 ('27', '27', 'en_us', 'aileron-therapeutics', 'portfolio/aileron-therapeutics', '1', '2016-06-14 16:14:38', '2016-07-13 16:33:56', '384eae37-6705-42d0-8139-3554db403176'),
 ('28', '28', 'en_us', '', NULL, '1', '2016-06-14 16:14:38', '2016-07-13 16:33:56', 'aa1c77b2-a63a-4718-99b9-3ab886fc6269'),
 ('29', '29', 'en_us', 'seth-l-harrison', 'team/seth-l-harrison', '1', '2016-06-14 16:15:24', '2016-07-13 17:29:25', 'b9e70a75-81e9-4259-94b4-b850663a8235'),
 ('31', '31', 'en_us', 'texture-1', NULL, '1', '2016-06-14 20:20:18', '2016-06-14 20:45:49', '5a4e74cb-f6ed-43b1-9654-53b5d5e33d45'),
 ('34', '34', 'en_us', 'texture-1', NULL, '1', '2016-06-14 20:21:32', '2016-06-14 20:45:49', '76755daf-15fc-4339-9a0c-c234ff9d0aad'),
 ('36', '36', 'en_us', '', NULL, '1', '2016-06-15 18:44:39', '2016-07-13 21:11:57', '9a628fc9-c19d-4c24-b10f-606499d919ff'),
 ('37', '37', 'en_us', '', NULL, '1', '2016-06-15 19:06:53', '2016-07-13 21:11:57', '726763fa-88dc-4693-abcb-ed296baff247'),
 ('38', '38', 'en_us', '', NULL, '1', '2016-06-15 19:06:53', '2016-07-13 21:11:57', 'd5de1190-856d-45f3-ba7a-736b04fd26bd'),
 ('39', '39', 'en_us', '', NULL, '1', '2016-06-15 19:06:53', '2016-07-13 21:11:57', '549d8b25-29e6-4e86-94a2-656c68fe0468'),
 ('40', '40', 'en_us', '', NULL, '1', '2016-06-15 19:06:53', '2016-07-13 21:11:57', '801cad79-e827-4382-9a7c-9a6a45dd1e6c'),
 ('41', '41', 'en_us', '', NULL, '1', '2016-06-15 19:36:44', '2016-07-13 21:20:34', '46d12ede-72ba-4092-83a7-db70ec0f578a'),
 ('42', '42', 'en_us', '', NULL, '1', '2016-06-15 20:03:58', '2016-07-13 21:20:34', '1237244a-8a0f-4eeb-8261-b01f76ee080d'),
 ('43', '43', 'en_us', '', NULL, '1', '2016-06-15 20:03:58', '2016-07-13 21:20:34', 'ae67439d-8f8c-47d2-8b87-8a953df64330'),
 ('44', '44', 'en_us', '', NULL, '1', '2016-06-15 20:23:24', '2016-07-13 18:21:00', 'e3959695-243b-446d-be08-4f003b7cad60'),
 ('46', '46', 'en_us', '', NULL, '1', '2016-06-15 20:24:14', '2016-07-13 18:21:00', '9e2a573b-6306-4d29-8090-ea05895a4d1f'),
 ('47', '47', 'en_us', '', NULL, '1', '2016-06-15 20:24:14', '2016-07-13 18:21:00', '302b7276-2e0c-4b9c-9489-a48c64c64249'),
 ('48', '48', 'en_us', '', NULL, '1', '2016-06-15 20:30:16', '2016-07-13 18:21:00', '49953b06-a266-4ee5-bd6a-d313a75fabd2'),
 ('49', '49', 'en_us', '', NULL, '1', '2016-06-15 20:30:16', '2016-07-13 18:21:00', '7d4e32fc-6594-49ec-b8e5-cc4f8e5521fa'),
 ('50', '50', 'en_us', '', NULL, '1', '2016-06-15 20:30:16', '2016-07-13 18:21:00', '0dac031d-e3c4-49f3-904b-fb1084346b09'),
 ('51', '51', 'en_us', 'marble', NULL, '1', '2016-06-16 18:43:10', '2016-06-16 18:43:10', 'c02f0fe8-6b69-48b6-afd6-e114cdaaddf6'),
 ('52', '52', 'en_us', 'mass-based-addiction-treatment-center-expands-nationally-as-opioid-epidemic-rages-on', 'news/mass-based-addiction-treatment-center-expands-nationally-as-opioid-epidemic-rages-on', '1', '2016-06-16 20:31:27', '2016-07-15 16:27:02', 'e514d055-a3b8-402b-a4f4-7cd909410454'),
 ('53', '53', 'en_us', 'diane-m-daych', 'team/diane-m-daych', '1', '2016-06-17 17:12:03', '2016-07-13 17:46:39', '5abc6c68-0096-4347-b2fd-44569e6767a6'),
 ('55', '55', 'en_us', 'sami-hamadé', 'team/sami-hamadé', '1', '2016-06-17 17:12:30', '2016-07-13 17:30:51', '31342964-b58c-46cc-9c20-59fda5d89fc4'),
 ('57', '57', 'en_us', 'david-j-mcintyre', 'team/david-j-mcintyre', '1', '2016-06-17 17:13:00', '2016-07-13 17:33:12', 'd6fe1c49-5530-479d-8bd6-6d6e07a01618'),
 ('59', '59', 'en_us', '', NULL, '1', '2016-06-20 19:49:21', '2016-07-15 16:27:02', 'c2ac8b05-9cbe-4409-89ac-ea9cfff60863'),
 ('60', '60', 'en_us', '', NULL, '1', '2016-06-20 19:49:21', '2016-07-15 16:27:02', 'e8ac81c8-9524-427e-be2c-92019407d63e'),
 ('61', '61', 'en_us', 'company', NULL, '1', '2016-06-21 15:51:04', '2016-06-21 15:51:04', '85e861b6-5b6e-4df8-96ea-5a3a36623cfb'),
 ('62', '62', 'en_us', '', NULL, '1', '2016-06-22 14:39:26', '2016-07-13 21:11:57', 'f3afe3fe-c932-4606-9ec6-4e6681b0520f'),
 ('63', '63', 'en_us', '', NULL, '1', '2016-06-22 14:39:26', '2016-07-13 21:11:57', '7cf364ee-3a47-454d-98e0-1da9b6f72b10'),
 ('64', '64', 'en_us', '', NULL, '1', '2016-06-22 14:39:26', '2016-07-13 21:11:57', '2c9d5690-469a-436a-83e2-f6499bf80dd5'),
 ('65', '65', 'en_us', 'cleanslate-centers', NULL, '1', '2016-06-23 18:55:51', '2016-06-23 18:55:51', 'acfb50b7-f3cc-4e04-987b-ead5ab8b6aa6'),
 ('66', '66', 'en_us', 'legal', 'legal', '1', '2016-06-27 16:01:14', '2016-07-14 19:37:10', '7d882c06-7657-41ed-8fce-0a94a96ac6e4'),
 ('67', '67', 'en_us', '', NULL, '1', '2016-06-27 16:58:18', '2016-07-14 19:37:10', '891c0355-e8e3-471e-9e49-297c37c30dbd'),
 ('68', '68', 'en_us', '', NULL, '1', '2016-06-27 16:58:18', '2016-07-14 19:37:10', '3417f15b-faa7-4982-91f7-676565105a23'),
 ('69', '69', 'en_us', '', NULL, '1', '2016-06-27 16:58:18', '2016-07-14 19:37:10', '858f844d-619b-44d5-a762-3c7337d8caee'),
 ('70', '70', 'en_us', 'therapuetics', NULL, '1', '2016-06-28 15:58:42', '2016-06-28 15:58:42', '3f6e0431-8c0a-4b1f-86d7-8d4ad5ffae6b'),
 ('71', '71', 'en_us', 'company-name', NULL, '1', '2016-06-28 16:26:33', '2016-06-28 16:26:33', 'b1fbfb3c-8563-4514-ac62-3ba2d4103762'),
 ('72', '72', 'en_us', 'company', NULL, '1', '2016-06-28 16:26:39', '2016-06-28 16:26:39', '73adfe57-46ec-4ca4-b26c-cdb27b078b96'),
 ('73', '73', 'en_us', 'company-name-2', NULL, '1', '2016-06-28 16:28:32', '2016-06-28 16:28:32', '3721cc3c-f8e1-40d2-884e-45fc8ec5c38d'),
 ('74', '74', 'en_us', '', NULL, '1', '2016-06-28 20:56:54', '2016-07-13 21:11:57', 'bf23e0ac-732b-49c6-8c52-2303bdfd8c0a'),
 ('75', '75', 'en_us', 'press', 'press', '1', '2016-07-06 21:31:22', '2016-07-14 20:30:23', 'e01d0237-81ee-47f7-8af0-ce3d6926acab'),
 ('76', '76', 'en_us', '', NULL, '1', '2016-07-06 21:49:07', '2016-07-14 20:30:23', '71a4d1ac-6181-4bba-8de7-95f63d147688'),
 ('77', '77', 'en_us', '', NULL, '1', '2016-07-06 21:49:07', '2016-07-14 20:30:23', 'f8fd6a97-9657-46f5-8ffa-de961bccdfc8'),
 ('78', '78', 'en_us', '', NULL, '1', '2016-07-06 21:49:07', '2016-07-14 20:30:23', '2c3ee97f-fbf5-4683-a436-eb5654a213eb'),
 ('79', '79', 'en_us', '', NULL, '1', '2016-07-06 22:06:29', '2016-07-14 20:30:23', 'f1e62a97-163b-49c9-880b-0ac222b2373b'),
 ('80', '80', 'en_us', 'texture-2', NULL, '1', '2016-07-07 22:04:24', '2016-07-07 22:04:24', '3feaeb05-992e-4bb3-8be2-ac8c37c8cb10'),
 ('83', '83', 'en_us', 'stock-photo-light-micrograph-of-white-adipose-tissue-adipocytes-fat-cells-contain-a-large-lipid-droplet-the-267094196', NULL, '1', '2016-07-08 19:37:25', '2016-07-08 19:37:25', '09b31b77-b88f-4c1e-ab5b-79110b33648c'),
 ('87', '87', 'en_us', 'cover-homepage', NULL, '1', '2016-07-11 17:23:22', '2016-07-11 17:23:22', '76b47b2b-2331-41f6-a372-37c237a0347b'),
 ('88', '88', 'en_us', 'cover-about', NULL, '1', '2016-07-11 17:23:23', '2016-07-11 17:23:23', '9c6aaf87-07d4-4178-8f97-cc5ad09be21d'),
 ('89', '89', 'en_us', 'header-section-healthcare-services', NULL, '1', '2016-07-11 17:23:24', '2016-07-11 17:23:24', '229ae9c5-7694-4ddd-b0c7-581e73f63f43'),
 ('90', '90', 'en_us', 'header-section-legacy-companies', NULL, '1', '2016-07-11 17:23:24', '2016-07-11 17:23:24', '346ae952-80ee-44ff-ba07-ef1e5d1d390b'),
 ('92', '92', 'en_us', 'header-section-medical-devices', NULL, '1', '2016-07-11 17:23:25', '2016-07-11 17:23:25', 'a657387e-a2b4-4812-b0d9-e0a0d55d2b83'),
 ('93', '93', 'en_us', 'header-section-news', NULL, '1', '2016-07-11 17:23:26', '2016-07-11 17:23:26', '995a5efd-1193-4c29-babb-30b2cb7d3e91'),
 ('94', '94', 'en_us', 'header-section-press', NULL, '1', '2016-07-11 17:23:26', '2016-07-11 17:23:26', '43f58531-db1d-4962-aaeb-e95128bd80c3'),
 ('95', '95', 'en_us', 'header-section-therapeutics', NULL, '1', '2016-07-11 17:23:27', '2016-07-11 17:23:27', 'fac5baac-c47e-44d8-9a26-71fcbf1afb80'),
 ('96', '96', 'en_us', 'healthcare-services', NULL, '1', '2016-07-11 19:00:38', '2016-07-11 19:00:38', '3c82cddc-f493-4290-970e-f3f6b3ee406a'),
 ('97', '97', 'en_us', 'medical-devices', NULL, '1', '2016-07-11 19:01:28', '2016-07-11 19:01:28', 'b73516f0-db50-4202-96a5-bde63a8321be'),
 ('98', '98', 'en_us', 'medtech', NULL, '1', '2016-07-11 19:02:51', '2016-07-11 19:02:51', '249f0d3c-99aa-4d52-97d0-6a665a97eac1'),
 ('99', '99', 'en_us', 'lauren-farrell', 'team/lauren-farrell', '1', '2016-07-11 19:05:03', '2016-07-13 17:50:10', 'a4a9028c-67c0-43f7-948b-6a6c2a782fd2'),
 ('100', '100', 'en_us', 'therapeutics', NULL, '1', '2016-07-11 19:05:31', '2016-07-11 19:05:31', '3958f26b-6959-4639-a570-b583cc2b9f89'),
 ('101', '101', 'en_us', 'finance-administration', NULL, '1', '2016-07-11 19:06:46', '2016-07-11 19:06:46', '1b55087b-e3b2-4df4-9b8a-effa94642ded'),
 ('102', '102', 'en_us', 'julie-gionfriddo', 'team/julie-gionfriddo', '1', '2016-07-11 19:07:46', '2016-07-13 17:47:35', 'b28573db-6bd9-4d2d-b229-88cd69ff902b'),
 ('105', '105', 'en_us', 'sam-hall', 'team/sam-hall', '1', '2016-07-11 19:12:55', '2016-07-13 16:54:50', '76160485-fb67-4a47-970b-3309f55e5b26'),
 ('106', '106', 'en_us', 'aaron-kantoff', 'team/aaron-kantoff', '1', '2016-07-11 19:13:57', '2016-07-13 16:56:01', '0bb91c5f-8dc3-4095-a570-29a04a517351'),
 ('107', '107', 'en_us', 'jonathan-waldstreicher-md', 'team/jonathan-waldstreicher-md', '1', '2016-07-11 19:15:07', '2016-07-13 17:36:08', 'b633055d-0aa6-4bfe-81e4-aac987e73794'),
 ('108', '108', 'en_us', 'keting-chu', 'team/keting-chu', '1', '2016-07-11 19:15:57', '2016-07-13 17:25:02', 'a3d99421-808a-430f-9eed-fc61c412c988'),
 ('109', '109', 'en_us', 'paul-dasilva-jardine', 'team/paul-dasilva-jardine', '1', '2016-07-11 20:30:09', '2016-07-13 17:26:39', '95c1019d-1cb6-4779-b10d-9151248dae26'),
 ('110', '110', 'en_us', 'david-de-graaf', 'team/david-de-graaf', '1', '2016-07-11 20:31:07', '2016-07-11 20:33:17', '64529cb7-8340-4b27-9121-986cae23abda'),
 ('111', '111', 'en_us', '', NULL, '1', '2016-07-11 20:41:13', '2016-07-15 17:08:20', '5726ec2a-f57f-4f21-b6d1-fc201bb79532'),
 ('112', '112', 'en_us', 'icon-atp-logo', NULL, '1', '2016-07-11 20:42:52', '2016-07-11 20:42:52', '1ea4d4c9-0088-4881-9fda-5f5c53a8431c'),
 ('113', '113', 'en_us', 'behshad-sheldon', 'team/behshad-sheldon', '1', '2016-07-11 20:44:31', '2016-07-13 17:28:32', '9ad73a1b-3f2a-40ec-a3fc-3918c6206b2d'),
 ('114', '114', 'en_us', 'mikael-dolsten', 'team/mikael-dolsten', '1', '2016-07-11 20:46:13', '2016-07-13 20:16:47', '45cfa9e1-4d5e-4ddc-bb0f-ae2ccefc16b1'),
 ('116', '116', 'en_us', 'amir-abolfathi', 'team/amir-abolfathi', '1', '2016-07-11 20:47:37', '2016-07-13 17:44:33', 'f1886450-734e-4349-b132-16bf1da2108c'),
 ('117', '117', 'en_us', 'bubble-gum', NULL, '1', '2016-07-11 20:54:41', '2016-07-11 20:54:41', '30bf0bd4-a14e-40a2-8a6c-b9bb083db0b5'),
 ('118', '118', 'en_us', 'swimming', NULL, '1', '2016-07-11 20:54:46', '2016-07-11 20:54:46', 'c4b4d2c4-303c-4666-83db-51bfbd14b414'),
 ('119', '119', 'en_us', '', NULL, '1', '2016-07-11 20:54:56', '2016-07-11 20:54:56', 'df992a77-c6a6-42b8-9fb7-a08764bc5bb5'),
 ('120', '120', 'en_us', '123456789', NULL, '1', '2016-07-11 20:55:03', '2016-07-11 20:55:03', '3c406ec8-a68f-4b86-920d-9e08427d5ab8'),
 ('121', '121', 'en_us', 'abcdefghijklmnopqrstuvwxyz', NULL, '1', '2016-07-11 20:55:14', '2016-07-11 20:55:14', '7a2dc31d-5c66-4323-993a-fe3e7aed19d5'),
 ('122', '122', 'en_us', 'new-tag', NULL, '1', '2016-07-11 20:55:48', '2016-07-11 20:55:48', '0641a4b1-2cfb-4c5d-9b4c-77e86001be31'),
 ('123', '123', 'en_us', 'andreas-loew', 'team/andreas-loew', '1', '2016-07-11 20:56:15', '2016-07-13 17:27:41', '932c02b3-0c91-46f6-9092-1b4c8cc99c8c'),
 ('124', '124', 'en_us', 'new-tag', NULL, '1', '2016-07-11 20:57:14', '2016-07-11 20:57:14', '57e50363-36da-43e0-a4ba-13e54d3a6c68');
INSERT INTO `craft_elements_i18n` (`id`, `elementId`, `locale`, `slug`, `uri`, `enabled`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('125', '125', 'en_us', 'chris-cain', 'team/chris-cain', '1', '2016-07-11 20:58:38', '2016-07-13 16:56:41', '47991256-8718-4481-b5c1-0d6dd8a3a9c1'),
 ('126', '126', 'en_us', 'jernej-godec-ph-d', 'team/jernej-godec-ph-d', '1', '2016-07-11 21:00:05', '2016-07-13 17:23:31', '24d02312-9be8-4c97-a0aa-b80b35055070'),
 ('127', '127', 'en_us', 'stephanie-papes', 'team/stephanie-papes', '1', '2016-07-11 21:01:24', '2016-07-13 17:48:41', 'c2b852c5-287f-4785-9450-418ea86bc9e1'),
 ('128', '128', 'en_us', 'joshua-sherman', 'team/joshua-sherman', '1', '2016-07-11 21:03:01', '2016-07-13 17:37:59', '72e59c45-301e-478e-ad42-931f5f5c064a'),
 ('129', '129', 'en_us', 'test', NULL, '1', '2016-07-11 21:04:23', '2016-07-11 21:04:23', '99bb79d8-1a22-4004-8b3d-27e0671d6311'),
 ('136', '136', 'en_us', 'footer', NULL, '1', '2016-07-11 21:17:42', '2016-07-11 21:50:45', '763cbe58-5dcf-40da-b29e-0580be47e2a1'),
 ('141', '141', 'en_us', 'kristin-howell', 'team/kristin-howell', '1', '2016-07-11 21:24:27', '2016-07-11 21:24:27', '93f7f368-be20-432f-8539-0eb706cb8541'),
 ('142', '142', 'en_us', 'maja-nowak', 'team/maja-nowak', '1', '2016-07-11 21:24:48', '2016-07-12 00:28:47', '472f535f-0e9f-4f3a-a3a3-5a109b5db45f'),
 ('143', '143', 'en_us', 'shivranie-singh', 'team/shivranie-singh', '1', '2016-07-11 21:25:07', '2016-07-12 00:28:23', '5ed1d4f7-b875-499a-8b20-5baed21bab68'),
 ('144', '144', 'en_us', 'steph-lazarus', 'team/steph-lazarus', '1', '2016-07-11 21:25:28', '2016-07-11 21:25:28', '26129937-cda6-4ff2-8917-df246b783584'),
 ('145', '145', 'en_us', 'lisa-cagney', 'team/lisa-cagney', '1', '2016-07-11 21:25:55', '2016-07-12 00:28:30', '18452341-1eba-4a5d-a2f3-01678e5c41c3'),
 ('146', '146', 'en_us', 'salam-farhat', 'team/salam-farhat', '1', '2016-07-11 21:26:11', '2016-07-12 00:28:03', '1f2280b1-56cb-44f7-b725-38c41ba76c0a'),
 ('200', '200', 'en_us', 'braeburn-pharmaceuticals', 'portfolio/braeburn-pharmaceuticals', '1', '2016-07-11 21:56:47', '2016-07-13 16:33:35', 'bb4b5565-f041-4794-8c04-1ec877258668'),
 ('201', '201', 'en_us', '', NULL, '1', '2016-07-11 21:57:13', '2016-07-13 16:33:35', '0dd7e157-69ce-4ad0-a965-4e48bc950c6e'),
 ('202', '202', 'en_us', 'icon-atp-logo', NULL, '1', '2016-07-11 21:57:43', '2016-07-11 21:57:43', 'ad6f542c-f0e1-4450-9bbf-807a377c776d'),
 ('204', '204', 'en_us', 'cleanslate-addiction-treatment-centers', 'portfolio/cleanslate-addiction-treatment-centers', '1', '2016-07-11 21:58:40', '2016-07-13 16:33:16', 'e0064a30-6458-4a05-85f9-7b0ba75360b2'),
 ('205', '205', 'en_us', '', NULL, '1', '2016-07-11 21:58:40', '2016-07-13 16:33:16', 'f89fa27b-abe6-46d9-8e06-f52b2b980f0a'),
 ('227', '227', 'en_us', 'testing', NULL, '1', '2016-07-11 22:01:54', '2016-07-11 22:01:54', '21a451d7-e5e3-4a20-b4a7-6edf5708e26d'),
 ('228', '228', 'en_us', 'testing', NULL, '1', '2016-07-11 22:03:14', '2016-07-11 22:03:14', 'b2ac63b1-cfae-432c-a9ce-ea4dd5ca1a10'),
 ('229', '229', 'en_us', 'http-www-appletreepartners-com-portfolio-detail-coelacanth-acquired-by-lexicon-genetics', 'portfolio/http-www-appletreepartners-com-portfolio-detail-coelacanth-acquired-by-lexicon-genetics', '1', '2016-07-11 22:03:23', '2016-07-13 21:14:28', '071cf5de-5735-4bf7-ab3c-70b73fed86fe'),
 ('230', '230', 'en_us', '', NULL, '1', '2016-07-11 22:03:47', '2016-07-13 21:14:28', '66702b6e-fc8b-43cb-8e3a-3b334d8ece36'),
 ('232', '232', 'en_us', 'lorem-ipsum-dolor-sit-amet-consectetuer-adipiscing-elit-aenean-commodo-ligula-eget-dolor-aenean-massa-cum-sociis-natoque-penatibus-et-magnis-dis-parturient-montes-nascetur-ridiculus-mus-donec-quam-felis-ultricies-nec-pellentesque-eu-pretium-quis', NULL, '1', '2016-07-11 22:17:15', '2016-07-11 22:17:15', '70f1748e-405a-4510-8d08-ffbfb184d39f'),
 ('233', '233', 'en_us', 'new-tag', NULL, '1', '2016-07-11 22:18:44', '2016-07-11 22:18:44', '3d1667bd-15e8-41b0-9a58-862fcc4302e1'),
 ('238', '238', 'en_us', 'new-tag', NULL, '1', '2016-07-11 22:21:22', '2016-07-11 22:21:22', '92301018-4e48-4799-b3ec-3a02d8cbba4a'),
 ('239', '239', 'en_us', 'corvidia', 'portfolio/corvidia', '1', '2016-07-11 22:21:39', '2016-07-13 16:32:34', 'f98f9e8b-c746-470a-8ccf-ffc47e08cbc2'),
 ('240', '240', 'en_us', '', NULL, '1', '2016-07-11 22:21:39', '2016-07-13 16:32:34', '03075cef-80e4-44c0-98da-f0e0aa9114a2'),
 ('242', '242', 'en_us', 'gala-therapeutics', 'portfolio/gala-therapeutics', '1', '2016-07-11 22:29:19', '2016-07-13 17:19:52', 'a5d4c3ef-9b9a-41d3-883a-91fb2e6b41ef'),
 ('243', '243', 'en_us', '', NULL, '1', '2016-07-11 22:29:19', '2016-07-13 17:19:52', 'a0149c30-6b57-46bc-b69a-33a957e9ca69'),
 ('244', '244', 'en_us', 'cure-forward', 'portfolio/cure-forward', '1', '2016-07-11 22:35:11', '2016-07-13 16:31:59', '377ada72-161f-4ab9-8426-9b8562727916'),
 ('245', '245', 'en_us', '', NULL, '1', '2016-07-11 22:35:11', '2016-07-13 16:31:59', 'c687b787-a606-4fcf-90a5-f9caca5b850e'),
 ('246', '246', 'en_us', 'cyrano-sciences', 'portfolio/cyrano-sciences', '1', '2016-07-11 22:36:11', '2016-07-13 21:17:31', 'd908c9c5-3068-4bf1-b6c8-926bed143c8e'),
 ('247', '247', 'en_us', '', NULL, '1', '2016-07-11 22:36:11', '2016-07-13 21:17:31', 'ffdf1e46-75d2-4961-bee3-68f4e96736f9'),
 ('248', '248', 'en_us', 'gloucester-pharmaceuticals', 'portfolio/gloucester-pharmaceuticals', '1', '2016-07-11 22:37:48', '2016-07-13 16:31:14', '1603f5bd-516c-4001-a629-d83ce71d9ddf'),
 ('249', '249', 'en_us', '', NULL, '1', '2016-07-11 22:37:48', '2016-07-13 16:31:14', '54ab92f8-4531-4ffc-8df9-cbb5d056d347'),
 ('250', '250', 'en_us', 'heartware-international', 'portfolio/heartware-international', '1', '2016-07-11 22:40:09', '2016-07-13 16:30:57', '6bc1032f-52e3-4429-ae5b-ad521c189ff3'),
 ('255', '255', 'en_us', 'new-tag', NULL, '1', '2016-07-11 23:15:08', '2016-07-11 23:15:08', 'b92a5afe-3680-400e-94bd-24bad44174c8'),
 ('256', '256', 'en_us', 'thisisreallyreallyreallyreallyreallyreallyreallylongandkajs-dlfkja-sldfjk-aslkjf-laskjdf-lasjdf-laskjflkasjdf-lkjasdf-lkasdf-klasdjf-lkasjdf-klasjdf-kasf-kasjf-kldsfj-aslkdfj-aklfj-aslkjf-sadlkfj', NULL, '1', '2016-07-11 23:24:25', '2016-07-11 23:24:25', 'd1e08af6-8d06-43a0-8391-d21dbe7c3c15'),
 ('257', '257', 'en_us', 'will-this-appear-on-the-top-of-the-page', NULL, '1', '2016-07-11 23:37:38', '2016-07-11 23:37:38', '8e3013bd-277a-4125-aacf-e6967402f85e'),
 ('266', '266', 'en_us', 'where-do-you-belong', NULL, '1', '2016-07-11 23:40:12', '2016-07-11 23:40:12', '23b63bbe-5cb2-4062-b820-16d6236c770b'),
 ('268', '268', 'en_us', '', NULL, '1', '2016-07-11 23:41:01', '2016-07-13 16:30:57', '27b51f07-e653-4bf4-a4fb-2aeccbe6b917'),
 ('275', '275', 'en_us', 'qualderm-partners', 'portfolio/qualderm-partners', '1', '2016-07-11 23:47:20', '2016-07-13 16:30:36', 'a7176f5c-603d-4a61-b906-92c2254c090c'),
 ('276', '276', 'en_us', '', NULL, '1', '2016-07-11 23:47:20', '2016-07-13 16:30:36', '0960055d-b024-4aee-abff-703023210515'),
 ('280', '280', 'en_us', 'principal', NULL, '1', '2016-07-11 23:58:00', '2016-07-11 23:58:00', '93801f7e-e637-4216-8ca2-a4eb99fc5e1b'),
 ('281', '281', 'en_us', 'sgx-pharmaceuticals', 'portfolio/sgx-pharmaceuticals', '1', '2016-07-12 00:07:33', '2016-07-13 16:30:19', 'ed7bdc11-47cb-47f2-a68c-ebe064ee9817'),
 ('282', '282', 'en_us', '', NULL, '1', '2016-07-12 00:07:33', '2016-07-13 16:30:20', 'cc37f926-e710-4fa6-9236-380aafddb9d5'),
 ('284', '284', 'en_us', 'syntimmune', 'portfolio/syntimmune', '1', '2016-07-12 00:09:32', '2016-07-13 16:29:54', '0d04f5ec-502b-4a91-9946-a9133a97eadd'),
 ('285', '285', 'en_us', '', NULL, '1', '2016-07-12 00:09:32', '2016-07-13 16:29:54', 'a73daf9b-64c1-485c-8eab-6e736069b9a2'),
 ('287', '287', 'en_us', 'tendyne', 'portfolio/tendyne', '1', '2016-07-12 00:15:28', '2016-07-13 16:38:44', '2a42fd5d-fde4-4f1d-8631-4fddb3a50005'),
 ('288', '288', 'en_us', '', NULL, '1', '2016-07-12 00:15:28', '2016-07-13 16:38:44', '5bd199e7-abb9-4939-8ec2-1b508ae6ba32'),
 ('290', '290', 'en_us', 'tokai-pharmaceuticals', 'portfolio/tokai-pharmaceuticals', '1', '2016-07-12 00:17:23', '2016-07-13 16:29:12', 'a0b0567c-4792-4558-962f-4ab3b13c9ed8'),
 ('291', '291', 'en_us', '', NULL, '1', '2016-07-12 00:17:23', '2016-07-13 16:29:12', '68ed7801-4c2d-4ac7-8d0f-37774e97ee9d'),
 ('293', '293', 'en_us', 'triplecare', 'portfolio/triplecare', '1', '2016-07-12 00:19:59', '2016-07-13 16:28:41', '84f0b16c-e969-4e1f-990a-327ccc5f4b14'),
 ('294', '294', 'en_us', '', NULL, '1', '2016-07-12 00:19:59', '2016-07-13 16:28:41', '69ae7c5b-ec7f-4ed0-b253-8b4c532696d0'),
 ('296', '296', 'en_us', 'tusker-medical', 'portfolio/tusker-medical', '1', '2016-07-12 00:23:01', '2016-07-13 21:08:08', 'ab6275ce-28c6-4fb7-abb0-4544ac405127'),
 ('297', '297', 'en_us', '', NULL, '1', '2016-07-12 00:23:01', '2016-07-13 21:08:08', '8f61c8bf-aed3-43a0-ad4d-ecd43868e4ee'),
 ('298', '298', 'en_us', 'vytronus', 'portfolio/vytronus', '1', '2016-07-12 00:24:36', '2016-07-13 16:27:51', '709125e5-f128-4ae9-b798-302cabce7843'),
 ('299', '299', 'en_us', '', NULL, '1', '2016-07-12 00:24:36', '2016-07-13 16:27:51', '2e3135fd-f9ee-4a22-a52e-147f846c9b7a'),
 ('300', '300', 'en_us', '', NULL, '1', '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'd9d8c6a5-8d60-4d84-add3-a6935ad38315'),
 ('301', '301', 'en_us', '', NULL, '1', '2016-07-12 04:16:32', '2016-07-14 19:37:10', '571483ba-4f46-4141-8350-293a8808d293'),
 ('302', '302', 'en_us', '', NULL, '1', '2016-07-12 04:16:32', '2016-07-14 19:37:10', '07b768f7-9d95-4578-b978-ff666de2b965'),
 ('303', '303', 'en_us', '', NULL, '1', '2016-07-12 04:16:32', '2016-07-14 19:37:10', '7ce8dfcb-a58a-4c03-be42-451db2f33044'),
 ('304', '304', 'en_us', '', NULL, '1', '2016-07-12 04:16:32', '2016-07-14 19:37:10', '0871d771-93ff-412f-9e55-e66c200d032d'),
 ('305', '305', 'en_us', '', NULL, '1', '2016-07-12 04:16:32', '2016-07-14 19:37:10', '7401fa84-435e-49fd-b6ff-e824cee1224e'),
 ('306', '306', 'en_us', '', NULL, '1', '2016-07-12 04:16:32', '2016-07-14 19:37:10', '2599a7c3-f63e-49ce-94f5-67b309c78f8b'),
 ('307', '307', 'en_us', '', NULL, '1', '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'fe9cb6b1-1e2f-41b1-81e1-9d4070b74433'),
 ('308', '308', 'en_us', '', NULL, '1', '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'a6240262-36b6-4176-9804-b2a037431e90'),
 ('309', '309', 'en_us', '', NULL, '1', '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'c9309353-0159-4743-b3ed-7c915a6c23bd'),
 ('310', '310', 'en_us', '', NULL, '1', '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'b8c8cfa0-3532-4bba-a2d0-5fe260a038c5'),
 ('311', '311', 'en_us', 'triplecare', NULL, '1', '2016-07-12 04:44:54', '2016-07-12 04:44:54', '39fa33ef-0bd9-4c1a-b4d2-c34582a373ff'),
 ('312', '312', 'en_us', 'high-tech-healthcare-helps-eliminate-unnecessary-hospital-visits', 'news/high-tech-healthcare-helps-eliminate-unnecessary-hospital-visits', '1', '2016-07-12 04:45:30', '2016-07-15 16:26:54', '49a00aed-6a14-4142-b8d5-e74bc4ea4277'),
 ('313', '313', 'en_us', '', NULL, '1', '2016-07-12 04:45:30', '2016-07-15 16:26:54', '85b83dff-d53a-4c77-9394-37e349b61ad2'),
 ('314', '314', 'en_us', 'cure-forward-announces-first-trial-recruitment-collaboration-that-will-expand-patient-access-to-innovative-treatments', 'news/cure-forward-announces-first-trial-recruitment-collaboration-that-will-expand-patient-access-to-innovative-treatments', '1', '2016-07-12 04:47:22', '2016-07-15 16:26:47', '3d57ccee-2338-41e0-8e17-8a1f0bfbf4e6'),
 ('315', '315', 'en_us', '', NULL, '1', '2016-07-12 04:47:22', '2016-07-15 16:26:47', 'faad0268-173c-4440-b3fb-9859acc166ae'),
 ('316', '316', 'en_us', '', NULL, '1', '2016-07-12 04:47:22', '2016-07-15 16:26:47', 'b11c5593-1292-4797-820a-ae3eb39337ca'),
 ('317', '317', 'en_us', '', NULL, '1', '2016-07-12 04:47:22', '2016-07-15 16:26:47', '5d9f7c76-80bf-4b56-8a69-bdf8ffbcf483'),
 ('318', '318', 'en_us', 'heartware', NULL, '1', '2016-07-12 04:49:55', '2016-07-12 04:49:55', '7feedfc2-caa7-47b0-bfcc-2afe74d297e6'),
 ('319', '319', 'en_us', 'medtronic-to-expand-heart-failure-portfolio-with-acquisition-of-heartware-international', 'news/medtronic-to-expand-heart-failure-portfolio-with-acquisition-of-heartware-international', '1', '2016-07-12 04:50:11', '2016-07-15 16:25:52', 'd6437d40-e09d-4043-aa5a-6b50039709bc'),
 ('320', '320', 'en_us', '', NULL, '1', '2016-07-12 04:50:11', '2016-07-15 16:25:52', '5f6af6fa-2427-423f-932d-958e4f63f7b2'),
 ('321', '321', 'en_us', '', NULL, '1', '2016-07-12 04:50:11', '2016-07-15 16:25:52', 'd8b26139-14b4-4496-b609-58772a1f0f17'),
 ('322', '322', 'en_us', '', NULL, '1', '2016-07-12 04:50:11', '2016-07-15 16:25:52', 'd18a5467-ecf8-4aca-86fc-1451d95ac32d'),
 ('323', '323', 'en_us', '', NULL, '1', '2016-07-12 04:50:11', '2016-07-15 16:25:52', 'ca0a9a89-76e0-4bfb-a418-ee810bf989e7'),
 ('324', '324', 'en_us', '', NULL, '1', '2016-07-12 04:50:11', '2016-07-15 16:25:52', 'd63eae31-4a47-499a-81c7-bff859918caa'),
 ('325', '325', 'en_us', 'cure-forward', NULL, '1', '2016-07-12 04:50:44', '2016-07-12 04:50:44', '61fe0825-960c-421a-8dda-df596f2dc0e1'),
 ('326', '326', 'en_us', 'braeburn', NULL, '1', '2016-07-12 04:52:34', '2016-07-12 04:52:34', '72af0665-581c-4e84-8b1c-b2a2ac42aa5c'),
 ('327', '327', 'en_us', 'fda-approves-first-buprenorphine-implant-for-treatment-of-opioid-dependence', 'news/fda-approves-first-buprenorphine-implant-for-treatment-of-opioid-dependence', '1', '2016-07-12 04:52:37', '2016-07-15 16:25:44', 'e0171ff8-540f-4b9f-ba2b-b39eb5d0d579'),
 ('328', '328', 'en_us', '', NULL, '1', '2016-07-12 04:52:37', '2016-07-15 16:25:44', '4f587a1d-7727-41cd-9f00-f3e82f76d82d'),
 ('329', '329', 'en_us', 'dermatology-services-company-qualderm-unveils-31-8m-growth-investment', 'news/dermatology-services-company-qualderm-unveils-31-8m-growth-investment', '1', '2016-07-12 04:55:12', '2016-07-15 16:25:37', '4a7f4cdb-f7c4-4f74-a853-c4f8eac5af9c'),
 ('330', '330', 'en_us', '', NULL, '1', '2016-07-12 04:55:12', '2016-07-15 16:25:37', 'e3fa4690-5b39-4399-a202-f880a6da2d99'),
 ('331', '331', 'en_us', '', NULL, '1', '2016-07-12 04:55:12', '2016-07-15 16:25:37', 'c307c82c-c375-4b0e-8028-016b72afc585'),
 ('332', '332', 'en_us', '', NULL, '1', '2016-07-12 04:55:12', '2016-07-15 16:25:37', '3c284648-3ee0-4aa6-8320-3987200bd401'),
 ('333', '333', 'en_us', '', NULL, '1', '2016-07-12 04:55:12', '2016-07-15 16:25:37', '81ca909b-c51d-4d22-a784-7747f71595d8'),
 ('334', '334', 'en_us', '', NULL, '1', '2016-07-12 04:55:12', '2016-07-15 16:25:37', '7d2cb91e-710a-42d2-b863-f50b21325277'),
 ('335', '335', 'en_us', '', NULL, '1', '2016-07-12 04:55:12', '2016-07-15 16:25:37', '0a578518-38e1-4827-b8b0-22f6ecc82ed2'),
 ('336', '336', 'en_us', '', NULL, '1', '2016-07-12 04:55:12', '2016-07-15 16:25:37', '00f2326e-3d98-4b97-a48f-851716aed74f'),
 ('337', '337', 'en_us', 'syntimmune', NULL, '1', '2016-07-12 04:56:48', '2016-07-12 04:56:48', 'b20a9440-7042-46e6-ad61-134f460f200e'),
 ('338', '338', 'en_us', 'syntimmune-secures-second-tranche-of-26-million-series-a-financing', 'news/syntimmune-secures-second-tranche-of-26-million-series-a-financing', '1', '2016-07-12 04:56:51', '2016-07-15 16:25:30', '02d9933c-6a8d-49c0-b700-1b89fd389daa'),
 ('339', '339', 'en_us', '', NULL, '1', '2016-07-12 04:56:51', '2016-07-15 16:25:30', 'fd5372a6-365a-4c50-ae86-9f03b4ca5097'),
 ('340', '340', 'en_us', '', NULL, '1', '2016-07-12 04:56:51', '2016-07-15 16:25:30', '289b64b3-9d08-44de-afcf-d052ab55f4e3'),
 ('341', '341', 'en_us', '', NULL, '1', '2016-07-12 04:56:51', '2016-07-15 16:25:30', '00f4ad60-9989-4b10-a09d-9f1be05f5dd9'),
 ('342', '342', 'en_us', 'braeburn-and-camurus-announce-initiation-of-a-phase-2-study-in-opioid-dependent-patients-with-moderate-to-severe-chronic-pain', 'news/braeburn-and-camurus-announce-initiation-of-a-phase-2-study-in-opioid-dependent-patients-with-moderate-to-severe-chronic-pain', '1', '2016-07-12 04:59:33', '2016-07-15 16:25:20', '34a72a58-7555-4e24-82cc-09fd6abc913c');
INSERT INTO `craft_elements_i18n` (`id`, `elementId`, `locale`, `slug`, `uri`, `enabled`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('343', '343', 'en_us', '', NULL, '1', '2016-07-12 04:59:33', '2016-07-15 16:25:20', '5e6782a7-dc30-4f70-bc75-d3ce37a39a7e'),
 ('344', '344', 'en_us', '', NULL, '1', '2016-07-12 04:59:33', '2016-07-15 16:25:20', '1dd7015b-db48-449f-8b35-8e6c693660d9'),
 ('345', '345', 'en_us', '', NULL, '1', '2016-07-12 04:59:33', '2016-07-15 16:25:20', '59f2e1ec-3654-4df6-8add-10ccec6a273c'),
 ('346', '346', 'en_us', '', NULL, '1', '2016-07-12 04:59:33', '2016-07-15 16:25:20', '52defeb2-8bb9-4053-b2cb-a2b3658f3a0b'),
 ('347', '347', 'en_us', '', NULL, '1', '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'aba8205d-a620-4077-a99d-4cc6953c6ee6'),
 ('348', '348', 'en_us', '', NULL, '1', '2016-07-12 04:59:33', '2016-07-15 16:25:20', '9dad56a2-8465-40c8-84d6-5508deb3d8c2'),
 ('349', '349', 'en_us', '', NULL, '1', '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'd311c2a7-0b73-4bee-9427-1f22fa8ca312'),
 ('350', '350', 'en_us', 'corvidia', NULL, '1', '2016-07-12 05:01:52', '2016-07-12 05:01:52', 'ebf6159c-2e3c-42ee-86d2-5855ff53abfa'),
 ('351', '351', 'en_us', 'corvidia-therapeutics-raises-26m-in-a-series-a-financing-led-by-sofinnova-partners-and-apple-tree-partners', 'news/corvidia-therapeutics-raises-26m-in-a-series-a-financing-led-by-sofinnova-partners-and-apple-tree-partners', '1', '2016-07-12 05:01:56', '2016-07-15 16:24:52', '791129bc-18e2-4dea-be99-06bc5ec43be4'),
 ('352', '352', 'en_us', '', NULL, '1', '2016-07-12 05:01:56', '2016-07-15 16:24:52', 'f2a8b76f-d65d-4cbc-b692-36f23d9c43b1'),
 ('353', '353', 'en_us', '', NULL, '1', '2016-07-12 05:01:56', '2016-07-15 16:24:52', '1a712f36-89f7-497b-a6fd-0ba4cbfd0612'),
 ('354', '354', 'en_us', '', NULL, '1', '2016-07-12 05:01:56', '2016-07-15 16:24:52', 'd47c6ea0-6014-43eb-a22d-54ac04c89a67'),
 ('355', '355', 'en_us', '', NULL, '1', '2016-07-12 05:01:56', '2016-07-15 16:24:52', 'd700901f-c62f-4e17-adc2-3ea55227e3f1'),
 ('356', '356', 'en_us', '', NULL, '1', '2016-07-12 05:01:56', '2016-07-15 16:24:52', '655b005f-3bcb-47c6-ae40-915d84542f04'),
 ('357', '357', 'en_us', '', NULL, '1', '2016-07-13 00:53:43', '2016-07-13 21:11:57', '3dbba1df-4c4d-41e5-92a3-62dbcbb2742a'),
 ('361', '361', 'en_us', 'braeburn-transparent', NULL, '1', '2016-07-13 16:24:30', '2016-07-13 16:24:30', 'e5986883-57a4-499a-b287-8059f6ebf826'),
 ('362', '362', 'en_us', 'syntimmune-logo', NULL, '1', '2016-07-13 16:24:30', '2016-07-13 16:24:30', '2700fc2b-f275-494e-b683-367fee29e381'),
 ('363', '363', 'en_us', 'triple-care-transparent', NULL, '1', '2016-07-13 16:24:33', '2016-07-13 16:24:33', '91ad7a0a-9840-43fc-bbeb-5fd80cdeeaaf'),
 ('364', '364', 'en_us', 'aileron-logo-4-c', NULL, '1', '2016-07-13 16:24:34', '2016-07-13 16:24:34', '624b5969-c98f-4f5b-91c3-e944abe6fad1'),
 ('365', '365', 'en_us', 'tokai-pharmaceuticals-logo-pms', NULL, '1', '2016-07-13 16:24:34', '2016-07-13 16:24:34', '7b7a64fe-61b4-4aaf-b1b3-27d99b2b537b'),
 ('366', '366', 'en_us', 'clean-slate-transparent', NULL, '1', '2016-07-13 16:24:34', '2016-07-13 16:24:34', 'dd5db306-22ad-4b2e-a150-6ccd405a999d'),
 ('367', '367', 'en_us', 'gloucestor-transparent', NULL, '1', '2016-07-13 16:24:35', '2016-07-13 16:24:35', '35c18b2f-2671-4aa3-b554-4333280b9abe'),
 ('369', '369', 'en_us', 'heart-ware-transparent', NULL, '1', '2016-07-13 16:24:36', '2016-07-13 16:24:36', 'befe5037-bfe2-4ff0-8109-44276d88a9cd'),
 ('370', '370', 'en_us', 'sgx-transparent', NULL, '1', '2016-07-13 16:24:36', '2016-07-13 16:24:36', 'e54e928e-bb97-4915-a679-08721fb23220'),
 ('371', '371', 'en_us', 'tendyne-transparent', NULL, '1', '2016-07-13 16:24:36', '2016-07-13 16:24:36', 'a7296c35-0f23-4442-ae02-953a4b8bd783'),
 ('372', '372', 'en_us', 'vytronus-transparent', NULL, '1', '2016-07-13 16:24:37', '2016-07-13 16:24:37', '4cea05cf-828e-4f50-8635-b6a065029a7a'),
 ('373', '373', 'en_us', 'cure-forward-transparent', NULL, '1', '2016-07-13 16:24:38', '2016-07-13 16:24:38', '048b23a4-c57a-4996-bb87-073514f007ee'),
 ('374', '374', 'en_us', 'qualderm-transparent', NULL, '1', '2016-07-13 16:24:40', '2016-07-13 16:24:40', 'b7944aea-3481-4fca-bc66-79ca299fff1f'),
 ('375', '375', 'en_us', 'tusker-transparent', NULL, '1', '2016-07-13 16:24:43', '2016-07-13 16:24:43', '2d7268dc-5cc7-4b44-b3ef-48f4c01c6bd6'),
 ('376', '376', 'en_us', 'legacy-investment', NULL, '1', '2016-07-13 16:29:09', '2016-07-13 16:29:09', '023044ac-23ed-4707-9466-98cf034bc039'),
 ('377', '377', 'en_us', 'icon-atp-logo-white', NULL, '1', '2016-07-13 17:00:51', '2016-07-13 17:10:22', 'be05da0d-f87f-474a-bdc9-eae727cc409e'),
 ('379', '379', 'en_us', '', NULL, '1', '2016-07-13 17:09:06', '2016-07-13 17:10:34', 'ce7cd3c0-35ea-4f38-afc3-948aa304bb53'),
 ('380', '380', 'en_us', 'coelacanth-chemical-corporation', NULL, '1', '2016-07-13 17:17:59', '2016-07-13 17:17:59', '5c554614-7967-48ca-91d5-33ce9da62354'),
 ('381', '381', 'en_us', 'gala-logo', NULL, '1', '2016-07-13 17:18:00', '2016-07-13 17:18:00', '6450b0c7-0b28-4418-8f89-7e9ed323db53'),
 ('382', '382', 'en_us', 'cyrano', NULL, '1', '2016-07-13 17:18:00', '2016-07-13 17:18:00', 'fcd0642f-948a-4776-a98b-4b995f41be13'),
 ('383', '383', 'en_us', 'corvidia', NULL, '1', '2016-07-13 21:52:58', '2016-07-13 21:52:58', '21e67f0c-de85-45fb-a827-7248d0b3f50c'),
 ('384', '384', 'en_us', 'braeburn', NULL, '1', '2016-07-13 21:53:09', '2016-07-13 21:53:09', 'ceaebf78-5eba-4b6c-a91d-80eeee0828d5'),
 ('385', '385', 'en_us', 'syntimmune', NULL, '1', '2016-07-13 21:53:19', '2016-07-13 21:53:19', '1afc6eff-3fd6-4dc6-ab3b-1b7d2e5d6419'),
 ('386', '386', 'en_us', 'cleanslate', NULL, '1', '2016-07-13 21:53:45', '2016-07-13 21:53:45', '5cb3ae93-4396-481d-b17c-bff5aab47866'),
 ('387', '387', 'en_us', 'header-section-legal-1', NULL, '1', '2016-07-14 19:36:49', '2016-07-14 19:36:49', '5290ad31-fa5b-4972-b7bf-624757f74aa3'),
 ('388', '388', 'en_us', 'menu-background', NULL, '1', '2016-07-15 16:57:28', '2016-07-15 16:57:28', '783a3584-5acc-48c1-b9c4-d8c0987cd161'),
 ('389', '389', 'en_us', '', NULL, '1', '2016-07-15 17:08:03', '2016-07-15 17:08:27', '814e5341-2253-4007-8bd1-2d1ff6d43423');



DROP TABLE IF EXISTS `craft_emailmessages`;


--
-- Schema for table `craft_emailmessages`
--
CREATE TABLE `craft_emailmessages` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `key` char(150) COLLATE utf8_unicode_ci NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `subject` varchar(1000) COLLATE utf8_unicode_ci NOT NULL,
  `body` text COLLATE utf8_unicode_ci NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_emailmessages_key_locale_unq_idx` (`key`,`locale`),
  KEY `craft_emailmessages_locale_fk` (`locale`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_entries`;


--
-- Schema for table `craft_entries`
--
CREATE TABLE `craft_entries` (
  `id` int(11) NOT NULL,
  `sectionId` int(11) NOT NULL,
  `typeId` int(11) DEFAULT NULL,
  `authorId` int(11) DEFAULT NULL,
  `postDate` datetime DEFAULT NULL,
  `expiryDate` datetime DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  KEY `craft_entries_sectionId_idx` (`sectionId`),
  KEY `craft_entries_typeId_idx` (`typeId`),
  KEY `craft_entries_postDate_idx` (`postDate`),
  KEY `craft_entries_expiryDate_idx` (`expiryDate`),
  KEY `craft_entries_authorId_fk` (`authorId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_entries`
--

INSERT INTO `craft_entries` (`id`, `sectionId`, `typeId`, `authorId`, `postDate`, `expiryDate`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('9', '6', '6', NULL, '2016-06-14 15:25:35', NULL, '2016-06-14 15:24:07', '2016-07-13 21:11:57', 'bf07f3bc-7dc0-49f2-97a1-618ec5cb0fbd'),
 ('10', '7', NULL, NULL, '2016-06-14 15:24:20', NULL, '2016-06-14 15:24:20', '2016-07-13 21:20:34', '8749bb97-9835-4f7e-ae10-1c5e2cfbf112'),
 ('12', '9', '9', NULL, '2016-06-15 17:12:51', NULL, '2016-06-14 15:25:54', '2016-07-14 16:36:40', '4bd4468a-f46b-4567-aae5-1122e4ed5ce5'),
 ('13', '10', '10', NULL, '2016-06-15 17:13:21', NULL, '2016-06-14 15:26:11', '2016-07-13 21:16:21', '97e0f294-e0be-4e6e-aed9-edc18886cea7'),
 ('14', '8', '8', '1', '2016-06-14 15:36:00', NULL, '2016-06-14 15:37:22', '2016-07-15 16:27:09', '4fcedf1a-062d-4e2d-bc83-16508808e484'),
 ('27', '13', '13', '1', '2016-06-14 16:14:00', NULL, '2016-06-14 16:14:38', '2016-07-13 16:33:56', 'd5b31d23-0109-49ea-9724-66fd40a9e15e'),
 ('29', '12', '12', '1', '2016-06-14 16:15:00', NULL, '2016-06-14 16:15:24', '2016-07-13 17:29:25', '2f3c9e02-48dc-407e-8249-8290597ff83f'),
 ('52', '8', '8', '1', '2016-06-16 20:31:00', NULL, '2016-06-16 20:31:27', '2016-07-15 16:27:02', '42f7c774-6d24-4906-a158-61a25ec129f4'),
 ('53', '12', '12', '1', '2016-06-17 17:12:00', NULL, '2016-06-17 17:12:03', '2016-07-13 17:46:39', '1e54615d-a462-4f54-8190-eed01c287e97'),
 ('55', '12', '12', '1', '2016-06-17 17:12:00', NULL, '2016-06-17 17:12:30', '2016-07-13 17:30:51', 'a097d507-d62c-4784-b2a4-fd2f2c214936'),
 ('57', '12', '12', '1', '2016-06-17 17:13:00', NULL, '2016-06-17 17:13:00', '2016-07-13 17:33:12', '78ffcae6-7ae5-44c8-89c3-5b34fb92d07a'),
 ('66', '14', '14', NULL, '2016-06-27 16:01:30', NULL, '2016-06-27 16:01:14', '2016-07-14 19:37:10', '5f9baf84-8f70-442f-a11e-e3bd44a4fd07'),
 ('75', '15', NULL, NULL, '2016-07-06 21:31:22', NULL, '2016-07-06 21:31:22', '2016-07-14 20:30:23', '5f36029d-ea2b-4a13-b8b6-f8ae7e951d0e'),
 ('99', '12', '12', '1', '2016-07-11 19:05:00', NULL, '2016-07-11 19:05:04', '2016-07-13 17:50:10', '93c8916d-dfdf-4ac3-bb96-ed80cd6abeca'),
 ('102', '12', '12', '1', '2016-07-11 19:07:00', NULL, '2016-07-11 19:07:46', '2016-07-13 17:47:35', 'e642607e-d652-4919-b18d-52ca20549ed2'),
 ('105', '12', '12', '1', '2016-07-11 19:12:00', NULL, '2016-07-11 19:12:55', '2016-07-13 16:54:50', 'cfa28569-2694-405f-b26e-19ff4aae3d17'),
 ('106', '12', '12', '1', '2016-07-11 19:13:00', NULL, '2016-07-11 19:13:57', '2016-07-13 16:56:01', '26519d76-1dd7-4d97-836a-606160ce18d2'),
 ('107', '12', '12', '1', '2016-07-11 19:15:00', NULL, '2016-07-11 19:15:07', '2016-07-13 17:36:08', '8f478064-e2ed-4ae5-9afb-0e1bf861e0cc'),
 ('108', '12', '12', '1', '2016-07-11 19:15:00', NULL, '2016-07-11 19:15:57', '2016-07-13 17:25:02', '5fcbc465-a045-4261-99af-524a6b0f2cd4'),
 ('109', '12', '12', '1', '2016-07-11 20:30:00', NULL, '2016-07-11 20:30:09', '2016-07-13 17:26:39', '91322c82-c57f-4386-8b23-374059889593'),
 ('110', '12', '12', '1', '2016-07-11 20:31:00', NULL, '2016-07-11 20:31:07', '2016-07-11 20:33:17', '99d9ae41-bc1f-4913-8e4e-ae966fc96e74'),
 ('113', '12', '12', '1', '2016-07-11 20:44:00', NULL, '2016-07-11 20:44:31', '2016-07-13 17:28:32', 'c82c039a-7bea-48a2-81e5-88144c03ba6a'),
 ('114', '12', '12', '1', '2016-07-11 20:46:00', NULL, '2016-07-11 20:46:13', '2016-07-13 20:16:47', 'c2ceae72-00ac-4102-8678-b494f3e4de30'),
 ('116', '12', '12', '1', '2016-07-11 20:47:00', NULL, '2016-07-11 20:47:37', '2016-07-13 17:44:33', '3ae0b416-bfd5-43c1-ba30-c5d68f5b5f45'),
 ('123', '12', '12', '1', '2016-07-11 20:56:00', NULL, '2016-07-11 20:56:15', '2016-07-13 17:27:41', 'eeb7a63d-b2f3-4e1c-a576-dcb0a291f938'),
 ('125', '12', '12', '1', '2016-07-11 20:58:00', NULL, '2016-07-11 20:58:38', '2016-07-13 16:56:41', '5a915ccb-3c92-457d-84eb-c871475267e2'),
 ('126', '12', '12', '1', '2016-07-11 21:00:00', NULL, '2016-07-11 21:00:05', '2016-07-13 17:23:31', '1c50c2f0-2d1f-48f9-a2a7-2146201387da'),
 ('127', '12', '12', '1', '2016-07-11 21:01:00', NULL, '2016-07-11 21:01:24', '2016-07-13 17:48:41', '36519769-47fb-4c13-915a-a71e2038319f'),
 ('128', '12', '12', '1', '2016-07-11 21:03:00', NULL, '2016-07-11 21:03:01', '2016-07-13 17:37:59', '41241427-9072-458f-a915-dbc471fdbbe8'),
 ('141', '12', '12', '1', '2016-07-11 21:24:27', NULL, '2016-07-11 21:24:27', '2016-07-11 21:24:27', 'b39686d9-7824-42af-b203-e3b09a137718'),
 ('142', '12', '12', '1', '2016-07-11 21:24:00', NULL, '2016-07-11 21:24:48', '2016-07-12 00:28:47', '4d69014a-c76f-4c83-844c-3a5b98b82881'),
 ('143', '12', '12', '1', '2016-07-11 21:25:00', NULL, '2016-07-11 21:25:07', '2016-07-12 00:28:23', '71df8432-0fdd-4480-9f3d-dd2ec26c9737'),
 ('144', '12', '12', '1', '2016-07-11 21:25:28', NULL, '2016-07-11 21:25:28', '2016-07-11 21:25:28', 'd686a719-b1e4-4a84-9d54-eccd2bd922be'),
 ('145', '12', '12', '1', '2016-07-11 21:25:00', NULL, '2016-07-11 21:25:55', '2016-07-12 00:28:30', '01af65eb-276f-485a-873d-6ada7bf17b0e'),
 ('146', '12', '12', '1', '2016-07-11 21:26:00', NULL, '2016-07-11 21:26:11', '2016-07-12 00:28:03', '461d4935-f7c2-47f9-9df8-e4b7666896a5'),
 ('200', '13', '13', '1', '2016-07-11 21:56:00', NULL, '2016-07-11 21:56:47', '2016-07-13 16:33:35', '02272d41-f102-4def-9d9c-611ede4d68d6'),
 ('204', '13', '13', '1', '2016-07-11 21:58:00', NULL, '2016-07-11 21:58:40', '2016-07-13 16:33:16', 'eb6b7c97-4ac0-4fd0-89de-36e963f7d600'),
 ('229', '13', '13', '1', '2016-07-11 22:03:00', NULL, '2016-07-11 22:03:23', '2016-07-13 21:14:28', '81f07237-d9c2-47ec-99b7-7b40fbc48921'),
 ('239', '13', '13', '1', '2016-07-11 22:21:00', NULL, '2016-07-11 22:21:39', '2016-07-13 16:32:34', '471bd8c8-391e-4911-99f4-dc032193dbfe'),
 ('242', '13', '13', '1', '2016-07-11 22:29:00', NULL, '2016-07-11 22:29:19', '2016-07-13 17:19:52', '01253c92-df42-479d-b868-f4a6ccea43cf'),
 ('244', '13', '13', '1', '2016-07-11 22:35:00', NULL, '2016-07-11 22:35:11', '2016-07-13 16:31:59', 'ca7df762-ccf2-481b-9701-23332a55e2c5'),
 ('246', '13', '13', '1', '2016-07-11 22:36:00', NULL, '2016-07-11 22:36:11', '2016-07-13 21:17:31', 'c0aea63e-a6ec-4c49-9ef2-847e0b7a38ab'),
 ('248', '13', '13', '1', '2016-07-11 22:37:00', NULL, '2016-07-11 22:37:48', '2016-07-13 16:31:14', 'e57f1788-f478-4cbf-b30a-384d54be19e9'),
 ('250', '13', '13', '1', '2016-07-11 22:40:00', NULL, '2016-07-11 22:40:09', '2016-07-13 16:30:57', '35131a07-edf6-47e2-8183-e4c9c32068f4'),
 ('275', '13', '13', '1', '2016-07-11 23:47:00', NULL, '2016-07-11 23:47:20', '2016-07-13 16:30:36', '9bfcf5fb-e710-4f5a-8b0d-184703558ce4'),
 ('281', '13', '13', '1', '2016-07-12 00:07:00', NULL, '2016-07-12 00:07:33', '2016-07-13 16:30:20', '198ae420-1105-4553-ad80-f2ef2ee4585c'),
 ('284', '13', '13', '1', '2016-07-12 00:09:00', NULL, '2016-07-12 00:09:32', '2016-07-13 16:29:54', 'ad850917-756c-47a1-bfda-28ddaa22310f'),
 ('287', '13', '13', '1', '2016-07-12 00:15:00', NULL, '2016-07-12 00:15:28', '2016-07-13 16:38:45', '0258fb12-8976-4457-8eda-d08421a7ddd8'),
 ('290', '13', '13', '1', '2016-07-12 00:17:00', NULL, '2016-07-12 00:17:23', '2016-07-13 16:29:12', 'a68db894-c26c-49b3-aadc-92b9d464a8d0'),
 ('293', '13', '13', '1', '2016-07-12 00:19:00', NULL, '2016-07-12 00:19:59', '2016-07-13 16:28:42', 'a9025253-05bb-4c7a-8d61-32a9a405b797'),
 ('296', '13', '13', '1', '2016-07-12 00:23:00', NULL, '2016-07-12 00:23:01', '2016-07-13 21:08:08', '8e5003f2-d499-466e-9de1-72ce73c1a614'),
 ('298', '13', '13', '1', '2016-07-12 00:24:00', NULL, '2016-07-12 00:24:36', '2016-07-13 16:27:51', '9ae167f1-3871-437c-b728-dbc4abf95a32'),
 ('312', '8', '8', '1', '2016-07-12 04:45:00', NULL, '2016-07-12 04:45:30', '2016-07-15 16:26:54', '146adf4b-707d-4fae-aa1a-08ecdd8e2801'),
 ('314', '8', '8', '1', '2016-07-12 04:47:00', NULL, '2016-07-12 04:47:22', '2016-07-15 16:26:47', 'dac5ec7b-9d5c-44bf-aa27-eb763576e04d'),
 ('319', '8', '8', '1', '2016-07-12 04:50:00', NULL, '2016-07-12 04:50:11', '2016-07-15 16:25:52', '47dbbe42-5c77-4c02-a4bd-08658278df25'),
 ('327', '8', '8', '1', '2016-07-12 04:52:00', NULL, '2016-07-12 04:52:37', '2016-07-15 16:25:44', 'ba67a6af-8943-417c-bf16-6119acff7fba'),
 ('329', '8', '8', '1', '2016-07-12 04:55:00', NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', 'dbceb75d-f8d7-445a-bc06-45e083671991'),
 ('338', '8', '8', '1', '2016-07-12 04:56:00', NULL, '2016-07-12 04:56:51', '2016-07-15 16:25:30', '040fb07b-ec9f-4659-ba75-f58689192fca'),
 ('342', '8', '8', '1', '2016-07-12 04:59:00', NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'ad51a75a-15ac-4402-8ce3-85f884ad430a'),
 ('351', '8', '8', '1', '2016-07-12 05:01:00', NULL, '2016-07-12 05:01:56', '2016-07-15 16:24:52', 'e8fab628-0583-4bd0-8adc-504d233ae723');



DROP TABLE IF EXISTS `craft_entrydrafts`;


--
-- Schema for table `craft_entrydrafts`
--
CREATE TABLE `craft_entrydrafts` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `entryId` int(11) NOT NULL,
  `sectionId` int(11) NOT NULL,
  `creatorId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `notes` tinytext COLLATE utf8_unicode_ci,
  `data` mediumtext COLLATE utf8_unicode_ci NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  KEY `craft_entrydrafts_entryId_locale_idx` (`entryId`,`locale`),
  KEY `craft_entrydrafts_sectionId_fk` (`sectionId`),
  KEY `craft_entrydrafts_creatorId_fk` (`creatorId`),
  KEY `craft_entrydrafts_locale_fk` (`locale`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_entrytypes`;


--
-- Schema for table `craft_entrytypes`
--
CREATE TABLE `craft_entrytypes` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `sectionId` int(11) NOT NULL,
  `fieldLayoutId` int(11) DEFAULT NULL,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `handle` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `hasTitleField` tinyint(1) unsigned NOT NULL DEFAULT '1',
  `titleLabel` varchar(255) COLLATE utf8_unicode_ci DEFAULT 'Title',
  `titleFormat` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `sortOrder` smallint(6) unsigned DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_entrytypes_name_sectionId_unq_idx` (`name`,`sectionId`),
  UNIQUE KEY `craft_entrytypes_handle_sectionId_unq_idx` (`handle`,`sectionId`),
  KEY `craft_entrytypes_sectionId_fk` (`sectionId`),
  KEY `craft_entrytypes_fieldLayoutId_fk` (`fieldLayoutId`)
) ENGINE=InnoDB AUTO_INCREMENT=16 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_entrytypes`
--

INSERT INTO `craft_entrytypes` (`id`, `sectionId`, `fieldLayoutId`, `name`, `handle`, `hasTitleField`, `titleLabel`, `titleFormat`, `sortOrder`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('6', '6', '262', 'Home', 'home', '0', NULL, '{section.name|raw}', NULL, '2016-06-14 15:24:07', '2016-07-13 15:02:39', 'b18d49a7-8e24-4d59-94ff-1a736278e5da'),
 ('7', '7', '93', 'Contact', 'contact', '0', NULL, '{section.name|raw}', NULL, '2016-06-14 15:24:20', '2016-06-15 19:29:46', 'b4e1f1b8-c14e-4bc4-971c-7046b2a24a09'),
 ('8', '8', '278', 'Article', 'article', '1', 'Article Title', NULL, NULL, '2016-06-14 15:25:04', '2016-07-15 16:24:40', 'f9432d59-2320-468e-8760-cd124353e1f3'),
 ('9', '9', '62', 'Team', 'team', '0', NULL, '{section.name|raw}', NULL, '2016-06-14 15:25:54', '2016-06-14 16:05:47', '110cb1ad-9b36-4652-8424-f5c017dda498'),
 ('10', '10', '49', 'Portfolio', 'portfolio', '0', NULL, '{section.name|raw}', NULL, '2016-06-14 15:26:11', '2016-06-14 15:47:44', '25f20546-ae04-443e-8911-ea1f900d138b'),
 ('12', '12', '222', 'Team Member', 'teamMember', '1', 'Team Member Name', NULL, NULL, '2016-06-14 15:27:43', '2016-07-11 19:21:06', 'f4b101ce-acc5-43c4-a3fd-184cc7cfd364'),
 ('13', '13', '223', 'Company', 'company', '1', 'Company Name', NULL, NULL, '2016-06-14 15:28:12', '2016-07-11 19:26:30', '2f78f2c1-60b5-4262-ace1-ee090bf3a415'),
 ('14', '14', '221', 'Legal', 'legal', '0', NULL, '{section.name|raw}', NULL, '2016-06-27 16:01:14', '2016-07-11 19:18:59', '744fe177-663a-4d95-8853-d8cfdad2c985'),
 ('15', '15', '225', 'Press', 'press', '0', NULL, '{section.name|raw}', NULL, '2016-07-06 21:31:22', '2016-07-11 19:33:14', '5c0444ac-5f79-43cc-b600-e1d7f167233d');



DROP TABLE IF EXISTS `craft_entryversions`;


--
-- Schema for table `craft_entryversions`
--
CREATE TABLE `craft_entryversions` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `entryId` int(11) NOT NULL,
  `sectionId` int(11) NOT NULL,
  `creatorId` int(11) DEFAULT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `num` smallint(6) unsigned NOT NULL,
  `notes` tinytext COLLATE utf8_unicode_ci,
  `data` mediumtext COLLATE utf8_unicode_ci NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  KEY `craft_entryversions_entryId_locale_idx` (`entryId`,`locale`),
  KEY `craft_entryversions_sectionId_fk` (`sectionId`),
  KEY `craft_entryversions_creatorId_fk` (`creatorId`),
  KEY `craft_entryversions_locale_fk` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=438 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_entryversions`
--

INSERT INTO `craft_entryversions` (`id`, `entryId`, `sectionId`, `creatorId`, `locale`, `num`, `notes`, `data`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('7', '9', '6', '1', 'en_us', '1', NULL, '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917847,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":[]}', '2016-06-14 15:24:07', '2016-06-14 15:24:07', '3fd9aad4-168f-4204-933c-f4cf19df140b'),
 ('8', '10', '7', '1', 'en_us', '1', NULL, '{\"typeId\":\"7\",\"authorId\":null,\"title\":\"Contact\",\"slug\":\"contact\",\"postDate\":1465917860,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":[]}', '2016-06-14 15:24:20', '2016-06-14 15:24:20', 'ae13831a-090f-43c8-bd0f-f83071e4a6e6'),
 ('10', '12', '9', '1', 'en_us', '1', NULL, '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1465917954,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":[]}', '2016-06-14 15:25:54', '2016-06-14 15:25:54', '5c0f23d9-031c-485a-8582-081581eb0709'),
 ('11', '13', '10', '1', 'en_us', '1', NULL, '{\"typeId\":\"10\",\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1465917971,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":[]}', '2016-06-14 15:26:11', '2016-06-14 15:26:11', '9f904369-d0fd-4de6-94b2-8662e384768c'),
 ('12', '14', '8', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"News\",\"slug\":\"news\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"new1\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"new2\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"new3\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"new4\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"21\":\"CleanSlatPresident and CEO of the CleanSlate Research and Education Foundation.\",\"19\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"20\":{\"date\":\"6\\/14\\/2016\"},\"36\":\"\"}}', '2016-06-14 15:37:22', '2016-06-14 15:37:22', 'ff284d0c-a84a-4aea-b698-f0cfdca99b3a'),
 ('13', '14', '8', '1', 'en_us', '2', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"news\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"21\":\"CleanSlatPresident and CEO of the CleanSlate Research and Education Foundation.\",\"19\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"20\":{\"date\":\"6\\/14\\/2016\"},\"36\":\"\"}}', '2016-06-14 15:39:19', '2016-06-14 15:39:19', '771619a2-b972-4bf5-b474-ce7cd0ae51ee'),
 ('14', '14', '8', '1', 'en_us', '3', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"news\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"21\":\"CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation.\",\"19\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"20\":{\"date\":\"6\\/14\\/2016\"},\"36\":\"\"}}', '2016-06-14 15:39:29', '2016-06-14 15:39:29', 'fd4d9ddc-0456-46ef-b13d-dbda85f15434'),
 ('15', '13', '10', '1', 'en_us', '2', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1465917971,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"new1\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":\"\"}},\"new2\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":\"\"}},\"new3\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseDescription\":\"\",\"company\":\"\"}},\"new4\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"\",\"expertiseDescription\":\"\",\"company\":\"\"}}}}}', '2016-06-14 15:52:39', '2016-06-14 15:52:39', 'a0c93a3f-3f67-4f35-bae7-d0235d8d1096'),
 ('16', '13', '10', '1', 'en_us', '3', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1465917971,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"19\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":\"\"}},\"20\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":\"\"}},\"21\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":\"\"}},\"22\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Legacy Investments\",\"expertiseDescription\":\"\",\"company\":\"\"}}}}}', '2016-06-14 15:54:55', '2016-06-14 15:54:55', '39fa0ce7-a752-420a-bb76-bf9daaf3fdc9'),
 ('17', '12', '9', '1', 'en_us', '2', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1465917954,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":\"\",\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":\"\"}}', '2016-06-14 16:05:36', '2016-06-14 16:05:36', '5261dc8e-9ab2-44e9-b389-23a8ab0005c6'),
 ('18', '12', '9', '1', 'en_us', '3', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1465917954,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":\"\",\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"new4\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"Description\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":\"\"}},\"new1\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"Description\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":\"\"}},\"new2\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"Description\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":\"\"}},\"new3\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"Description\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":\"\"}}}}}', '2016-06-14 16:06:35', '2016-06-14 16:06:35', '3eb635f4-869c-4236-8701-ab0ccc674b90'),
 ('19', '27', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Aileron Therapeutics\",\"slug\":\"aileron-therapeutics\",\"postDate\":1465920878,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. ALRN-6924, in Phase 1, is a p53 re-activator for the treatment of cancer, the only p53 molecule in development that targets both MDM2 and MDMX.<\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.aileronrx.com\\/\",\"linkedin\":\"\",\"email\":\"http:\\/\\/aileronrx.com\\/contact.php\"}}},\"66\":\"\",\"60\":\" Aileron Therapeutics\"}}', '2016-06-14 16:14:38', '2016-06-14 16:14:38', '97a07728-bc36-4ad1-a65f-c4d608f7648c'),
 ('20', '29', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD, Managing Partner\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920924,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.<\\/p>\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<\\/p>\",\"57\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\"}}},\"55\":\"\"}}', '2016-06-14 16:15:24', '2016-06-14 16:15:24', 'cabe24b5-7028-430e-acbf-9c42b8a05680'),
 ('21', '12', '9', '1', 'en_us', '4', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1465917954,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":\"\",\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"Description\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"Description\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"Description\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"Description\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\"]}}}}}', '2016-06-14 16:15:57', '2016-06-14 16:15:57', 'ef851a1f-6c13-4222-8a7f-d9c5949b4ff5'),
 ('22', '14', '8', '1', 'en_us', '4', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"news\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"21\":\"CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation.\",\"20\":{\"date\":\"6\\/14\\/2016\"},\"36\":\"\"}}', '2016-06-14 16:18:43', '2016-06-14 16:18:43', '233d61f6-34fd-461c-adf5-430db2990695'),
 ('23', '29', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD, Managing Partner\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.<\\/p>\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\"}}}}}', '2016-06-14 16:18:50', '2016-06-14 16:18:50', '0e032b57-73f3-4681-905a-3ade70fca11d'),
 ('24', '27', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Aileron Therapeutics\",\"slug\":\"aileron-therapeutics\",\"postDate\":1465920840,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. ALRN-6924, in Phase 1, is a p53 re-activator for the treatment of cancer, the only p53 molecule in development that targets both MDM2 and MDMX.<\\/p>\",\"62\":{\"28\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.aileronrx.com\\/\",\"linkedin\":\"\",\"email\":\"http:\\/\\/aileronrx.com\\/contact.php\"}}},\"66\":\"\"}}', '2016-06-14 16:19:06', '2016-06-14 16:19:06', 'f78f7d41-a102-4930-ad6b-06c9fc85e986'),
 ('25', '14', '8', '1', 'en_us', '5', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"cleanslate\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"21\":\"CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation.\",\"20\":{\"date\":\"6\\/14\\/2016\"},\"36\":\"\"}}', '2016-06-15 18:08:18', '2016-06-15 18:08:18', '8dfcd949-26f9-40c4-8ca5-5f95a141567a'),
 ('26', '14', '8', '1', 'en_us', '6', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"cleanslate\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"21\":\"CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation.\",\"20\":{\"date\":\"6\\/14\\/2016\"},\"36\":\"\"}}', '2016-06-15 18:09:39', '2016-06-15 18:09:39', 'd7aa1828-0c7b-4543-86e6-23d1c007d9eb'),
 ('27', '9', '6', '1', 'en_us', '2', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":\"\",\"4\":\"\",\"3\":[\"31\"],\"9\":\"\"}}', '2016-06-15 18:43:01', '2016-06-15 18:43:01', '25101568-3375-438e-a1ff-82763cd21d35'),
 ('28', '9', '6', '1', 'en_us', '3', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"new1\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"\"}}},\"4\":\" We are Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, we closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\",\"3\":[\"31\"],\"9\":\"\"}}', '2016-06-15 18:44:39', '2016-06-15 18:44:39', '1440c724-f40c-4046-98a9-f02d2d6f6fab'),
 ('29', '9', '6', '1', 'en_us', '4', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"new1\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"new2\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\" We are Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, we closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\",\"3\":[\"31\"],\"9\":{\"new1\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"1.5 Billion Invested\"}},\"new2\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"1 Billion invested\"}}}}}', '2016-06-15 19:06:53', '2016-06-15 19:06:53', '008d9d78-fed5-48bb-b6ea-f04115a09c66'),
 ('30', '9', '6', '1', 'en_us', '5', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\" We are Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, we closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\",\"69\":[\"14\"],\"3\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"1.5 Billion Invested\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"1 Billion invested\"}}}}}', '2016-06-15 19:19:53', '2016-06-15 19:19:53', 'd15b537f-12ac-40ef-ac92-31f92e53e035'),
 ('31', '10', '7', '1', 'en_us', '2', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Contact\",\"slug\":\"contact\",\"postDate\":1465917860,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"70\":{\"new1\":{\"type\":\"locations\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"New York City\",\"address\":\"230 Park Avenue, Suite 2800\\r\\nNew York, New York 10169\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\"}}}}}', '2016-06-15 19:36:44', '2016-06-15 19:36:44', '496525c4-ac58-4eb0-97e3-9742e9cb4d94'),
 ('32', '10', '7', '1', 'en_us', '3', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Contact\",\"slug\":\"contact\",\"postDate\":1465917860,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"70\":{\"41\":{\"type\":\"locations\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"New York City\",\"address\":\"230 Park Avenue, Suite 2800\\r\\nNew York, New York 10169\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\"}},\"new1\":{\"type\":\"locations\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Cambridge \",\"address\":\"000 Street Name, Suite Number\\r\\nCitry, State, Zip Code\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\"}},\"new2\":{\"type\":\"locations\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Los Altos\",\"address\":\"000 Street Name, Suite Number\\r\\nCitry, State, Zip Code\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\"}}}}}', '2016-06-15 20:03:58', '2016-06-15 20:03:58', '1f1a3a83-6133-4d79-8d0a-9c29aab681fe'),
 ('33', '9', '6', '1', 'en_us', '6', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\" We are Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, we closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\",\"69\":[\"14\"],\"3\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"1.5 Billion Invested\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"1 Billion invested\"}}}}}', '2016-06-15 20:06:53', '2016-06-15 20:06:53', 'b6d0c59c-18c0-4394-9a03-ce8d7e4c17e5'),
 ('34', '13', '10', '1', 'en_us', '4', '', '{\"typeId\":\"10\",\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1466010801,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"19\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":\"\"}},\"20\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":\"\"}},\"21\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":\"\"}},\"22\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Legacy Investments\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":\"\"}}}}}', '2016-06-15 20:08:13', '2016-06-15 20:08:13', '2fcb312e-b090-4eb9-ae55-55f8d17df889'),
 ('35', '27', '13', '1', 'en_us', '3', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Aileron Therapeutics\",\"slug\":\"aileron-therapeutics\",\"postDate\":1465920840,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. ALRN-6924, in Phase 1, is a p53 re-activator for the treatment of cancer, the only p53 molecule in development that targets both MDM2 and MDMX.<\\/p>\",\"62\":{\"28\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.aileronrx.com\\/\",\"linkedin\":\"\",\"email\":\"http:\\/\\/aileronrx.com\\/contact.php\"}}},\"66\":\"\"}}', '2016-06-15 20:08:20', '2016-06-15 20:08:20', 'f34af91d-9d02-4660-85f1-5433a8e4ae49'),
 ('36', '13', '10', '1', 'en_us', '5', '', '{\"typeId\":\"10\",\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1466010801,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"19\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}},\"20\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}},\"21\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}},\"22\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Legacy Investments\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}}}}}', '2016-06-15 20:11:47', '2016-06-15 20:11:47', 'd950a790-0ec6-4231-9d13-c88476909f3e'),
 ('37', '12', '9', '1', 'en_us', '5', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":\"\",\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"Description\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"Description\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"Description\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"Description\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\"]}}}}}', '2016-06-15 20:13:04', '2016-06-15 20:13:04', '7e55ba66-ac86-42fe-96f5-71639f7f1cfe'),
 ('38', '9', '6', '1', 'en_us', '7', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\" We are Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, we closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\",\"69\":[\"14\"],\"3\":[\"51\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"1.5 Billion Invested\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"1 Billion invested\"}}}}}', '2016-06-16 18:43:17', '2016-06-16 18:43:17', '9386d41e-a621-49d2-aafc-022e54a7933e'),
 ('39', '9', '6', '1', 'en_us', '8', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\" We are Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, we closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\",\"69\":[\"14\"],\"3\":[\"51\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"1.5 Billion Invested\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"1 Billion invested\"}}}}}', '2016-06-16 20:08:24', '2016-06-16 20:08:24', '6ce19671-265e-4fd1-a4bf-991c106191fd'),
 ('40', '52', '8', '1', 'en_us', '1', NULL, '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Mass.-based addiction treatment center expands nationally as opioid epidemic rages on\",\"slug\":\"mass-based-addiction-treatment-center-expands-nationally-as-opioid-epidemic-rages-on\",\"postDate\":1466109087,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":\"\",\"21\":\"Two more opiate and alcohol treatment centers will be popping up in Massachusetts, as Northampton-based CleanSlate Centers looks to expand in the Bay State and nationally.\",\"68\":\"1\",\"20\":{\"date\":\"6\\/16\\/2016\"},\"36\":\"\"}}', '2016-06-16 20:31:27', '2016-06-16 20:31:27', '10d71b51-16e5-484a-a92c-34b8e0dd98c4'),
 ('41', '9', '6', '1', 'en_us', '9', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\" We are Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, we closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"1.5 Billion Invested\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"1 Billion invested\"}}}}}', '2016-06-16 20:32:16', '2016-06-16 20:32:16', 'e60690d3-d78a-49d8-b31e-e7ea471533f1'),
 ('42', '12', '9', '1', 'en_us', '6', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"31\"],\"38\":\"<p><em><\\/em>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\"]}}}}}', '2016-06-17 15:24:57', '2016-06-17 15:24:57', 'b41282a2-cb6a-4248-8b73-0ad87e03477d'),
 ('43', '29', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD, Managing Partner\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.<\\/p>\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"seth@gmail.com\",\"linkedin\":\"linkedin\"}}},\"67\":\"\"}}', '2016-06-17 17:07:40', '2016-06-17 17:07:40', '6f41841f-593d-45bf-a7e0-e0487f0e52e4'),
 ('44', '29', '12', '1', 'en_us', '4', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD, Managing Partner\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.<\\/p>\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"seth@gmail.com\",\"linkedin\":\"linkedin\"}}},\"67\":\"\"}}', '2016-06-17 17:07:41', '2016-06-17 17:07:41', '4bece047-d5d6-4951-905b-7b3710b38609'),
 ('45', '29', '12', '1', 'en_us', '5', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD, Managing Partner\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.<\\/p>\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"seth@gmail.com\",\"linkedin\":\"linkedin\"}}},\"67\":\"\"}}', '2016-06-17 17:08:15', '2016-06-17 17:08:15', 'b871df89-ddf4-4e28-9a63-74700b8e726e'),
 ('46', '53', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Diane M. Daych\",\"slug\":\"diane-m-daych\",\"postDate\":1466183523,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"\",\"57\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"diane@gmail.com\",\"linkedin\":\"linkedin\"}}},\"67\":\"\"}}', '2016-06-17 17:12:03', '2016-06-17 17:12:03', '48094b12-9de5-4492-af46-9751e8303fb6'),
 ('47', '55', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Sami Hamad\\u00e9\",\"slug\":\"sami-hamad\\u00e9\",\"postDate\":1466183550,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"\",\"57\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"sami@gmail.com\",\"linkedin\":\"linkedin\"}}},\"67\":\"\"}}', '2016-06-17 17:12:30', '2016-06-17 17:12:30', 'b3a1edd0-e824-4edf-9c85-74d5371f6e68'),
 ('48', '57', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"David J. McIntyre\",\"slug\":\"david-j-mcintyre\",\"postDate\":1466183580,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"\",\"57\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"david@gmail.com\",\"linkedin\":\"linkedin\"}}},\"67\":\"\"}}', '2016-06-17 17:13:00', '2016-06-17 17:13:00', 'a9d7267c-c312-47ef-aeb8-405499b3f12e'),
 ('49', '12', '9', '1', 'en_us', '7', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"31\"],\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"57\",\"55\",\"53\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\"]}}}}}', '2016-06-17 17:13:37', '2016-06-17 17:13:37', '1c5c777a-1864-4761-afec-3983e8fbbdaa'),
 ('50', '27', '13', '1', 'en_us', '4', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Aileron Therapeutics\",\"slug\":\"aileron-therapeutics\",\"postDate\":1465920840,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. ALRN-6924, in Phase 1, is a p53 re-activator for the treatment of cancer, the only p53 molecule in development that targets both MDM2 and MDMX.<\\/p>\",\"62\":{\"28\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.aileronrx.com\\/\",\"linkedin\":\"linkedin\",\"email\":\"http:\\/\\/aileronrx.com\\/contact.php\"}}},\"66\":\"\"}}', '2016-06-17 18:35:36', '2016-06-17 18:35:36', 'c39d78d6-50eb-4745-b9a5-9713658766a9'),
 ('51', '52', '8', '1', 'en_us', '2', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Mass.-based addiction treatment center expands nationally as opioid epidemic rages on\",\"slug\":\"mass-based-addiction-treatment-center-expands-nationally-as-opioid-epidemic-rages-on\",\"postDate\":1466109060,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"new1\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"Two more opiate and alcohol treatment centers will be popping up in Massachusetts, as Northampton-based CleanSlate Centers looks to expand in the Bay State and nationally.\"}},\"new2\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\",\"position\":\"left\"}}},\"21\":\"<p>Two more opiate and alcohol treatment centers will be popping up in Massachusetts, as Northampton-based CleanSlate Centers looks to expand in the Bay State and nationally.<\\/p>\",\"68\":\"1\",\"20\":{\"date\":\"6\\/16\\/2016\"},\"36\":\"\"}}', '2016-06-20 19:49:21', '2016-06-20 19:49:21', '7f1541b5-b70d-457f-af0e-01e3c704aeac'),
 ('52', '9', '6', '1', 'en_us', '10', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\" We are Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, we closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"1.5 Billion Invested\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"1 Billion invested\"}}}}}', '2016-06-21 15:36:20', '2016-06-21 15:36:20', '17c4da66-1880-462f-8b0b-bada8c922b77'),
 ('53', '27', '13', '1', 'en_us', '5', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Aileron Therapeutics\",\"slug\":\"aileron-therapeutics\",\"postDate\":1465920840,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. ALRN-6924, in Phase 1, is a p53 re-activator for the treatment of cancer, the only p53 molecule in development that targets both MDM2 and MDMX.<\\/p>\",\"62\":{\"28\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.aileronrx.com\\/\",\"linkedin\":\"linkedin\",\"email\":\"http:\\/\\/aileronrx.com\\/contact.php\"}}},\"66\":\"\",\"81\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide&nbsp;drug platform.<\\/p>\"}}', '2016-06-21 19:50:54', '2016-06-21 19:50:54', '7d49b089-4700-4b7e-97e0-b99e73f28631'),
 ('54', '57', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"David J. McIntyre\",\"slug\":\"david-j-mcintyre\",\"postDate\":1466183580,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"\",\"57\":{\"58\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"david@gmail.com\",\"linkedin\":\"linkedin\"}}},\"67\":\"\",\"80\":\"<p>Short description for the team member<\\/p>\"}}', '2016-06-21 19:51:14', '2016-06-21 19:51:14', 'a47a854d-a6f6-4e01-92ee-38905357f6b1'),
 ('55', '29', '12', '1', 'en_us', '6', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD, Managing Partner\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.<\\/p>\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"seth@gmail.com\",\"linkedin\":\"linkedin\"}}},\"67\":\"\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals,<\\/p>\"}}', '2016-06-21 19:55:22', '2016-06-21 19:55:22', 'ccd7a47e-1d81-4db6-adaf-3eb8c60ab86c'),
 ('56', '9', '6', '1', 'en_us', '11', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\" We are Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, we closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"new1\":{\"type\":\"partnerships\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/p>\"}},\"new2\":{\"type\":\"partnerships\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<p>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/p>\"}},\"new3\":{\"type\":\"partnerships\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<p>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/p>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"1.5 Billion Invested\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"1 Billion invested\"}}}}}', '2016-06-22 14:39:26', '2016-06-22 14:39:26', '43d39896-48c3-4af0-90d3-a960ebe0ef14'),
 ('57', '9', '6', '1', 'en_us', '12', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\" We are Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, we closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/h3>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/h3>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/h3>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"1.5 Billion Invested\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"1 Billion invested\"}}}}}', '2016-06-22 16:42:43', '2016-06-22 16:42:43', 'ce8b7a7d-d7dc-451f-bd7a-5d03eee75bb2'),
 ('58', '52', '8', '1', 'en_us', '3', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Mass.-based addiction treatment center expands nationally as opioid epidemic rages on\",\"slug\":\"mass-based-addiction-treatment-center-expands-nationally-as-opioid-epidemic-rages-on\",\"postDate\":1466109060,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"59\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"Two more opiate and alcohol treatment centers will be popping up in Massachusetts, as Northampton-based CleanSlate Centers looks to expand in the Bay State and nationally.\"}},\"60\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\",\"position\":\"left\"}}},\"21\":\"<p>Two more opiate and alcohol treatment centers will be popping up in Massachusetts, as Northampton-based CleanSlate Centers looks to expand in the Bay State and nationally.<\\/p>\",\"68\":\"1\",\"20\":{\"date\":\"6\\/16\\/2016\"},\"36\":[\"65\"]}}', '2016-06-23 18:55:56', '2016-06-23 18:55:56', '17399229-be60-4a0b-894f-9b6c40b931ae'),
 ('59', '14', '8', '1', 'en_us', '7', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"cleanslate\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"21\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation.<\\/p>\",\"68\":\"\",\"20\":{\"date\":\"6\\/14\\/2016\"},\"36\":[\"65\"]}}', '2016-06-23 19:06:39', '2016-06-23 19:06:39', '35d06f97-6b6a-480c-a4f7-5c70d984ee85'),
 ('60', '52', '8', '1', 'en_us', '4', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Mass.-based addiction treatment center expands nationally as opioid epidemic rages on\",\"slug\":\"mass-based-addiction-treatment-center-expands-nationally-as-opioid-epidemic-rages-on\",\"postDate\":1466109060,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"59\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"Two more opiate and alcohol treatment centers will be popping up in Massachusetts, as Northampton-based CleanSlate Centers looks to expand in the Bay State and nationally.\"}},\"60\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\",\"position\":\"left\"}}},\"21\":\"<p>Two more opiate and alcohol treatment centers will be popping up in Massachusetts, as Northampton-based CleanSlate Centers looks to expand in the Bay State and nationally.<\\/p>\",\"68\":\"1\",\"20\":{\"date\":\"6\\/16\\/2016\"},\"36\":\"\"}}', '2016-06-24 15:35:29', '2016-06-24 15:35:29', 'a4b73335-0151-4c15-9774-c6efe538b7a9'),
 ('61', '66', '14', '1', 'en_us', '1', '', '{\"typeId\":\"14\",\"authorId\":null,\"title\":\"Legal\",\"slug\":\"legal\",\"postDate\":1467043290,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"86\":{\"new1\":{\"type\":\"legalHeader\",\"enabled\":\"1\",\"fields\":{\"legalHeader\":\"Legal\",\"position\":\"full\"}},\"new2\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"\",\"legalCopy\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.\",\"position\":\"left\"}},\"new3\":{\"type\":\"legalLink\",\"enabled\":\"1\",\"fields\":{\"linkCopy\":\"Do you have a question? Contact us.\",\"linkPosition\":\"left\"}}}}}', '2016-06-27 16:58:18', '2016-06-27 16:58:18', '542e52ac-eab9-44cc-a877-2e9c749a1c36'),
 ('62', '66', '14', '1', 'en_us', '2', '', '{\"typeId\":\"14\",\"authorId\":null,\"title\":\"Legal\",\"slug\":\"legal\",\"postDate\":1467043290,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"86\":{\"67\":{\"type\":\"legalHeader\",\"enabled\":\"1\",\"fields\":{\"legalHeader\":\"Legal\",\"position\":\"full\"}},\"68\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"\",\"legalCopy\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.\",\"position\":\"left\"}},\"69\":{\"type\":\"legalLink\",\"enabled\":\"1\",\"fields\":{\"linkCopy\":\"Do you have a question? Contact us.\",\"linkPosition\":\"left\"}}}}}', '2016-06-27 17:07:00', '2016-06-27 17:07:00', '3e15ccef-157e-4f22-80a7-ca6bb109fa49'),
 ('63', '66', '14', '1', 'en_us', '3', '', '{\"typeId\":\"14\",\"authorId\":null,\"title\":\"Legal\",\"slug\":\"legal\",\"postDate\":1467043290,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"86\":{\"67\":{\"type\":\"legalHeader\",\"enabled\":\"1\",\"fields\":{\"legalHeader\":\"Legal\",\"position\":\"full\"}},\"68\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"\",\"legalCopy\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.\",\"position\":\"left\"}},\"69\":{\"type\":\"legalLink\",\"enabled\":\"1\",\"fields\":{\"linkCopy\":\"Do you have a question? Contact us.\",\"linkPosition\":\"left\"}}}}}', '2016-06-27 17:22:24', '2016-06-27 17:22:24', '9300e31a-cd98-4f10-be76-c17f652f45a4'),
 ('64', '66', '14', '1', 'en_us', '4', '', '{\"typeId\":\"14\",\"authorId\":null,\"title\":\"Legal\",\"slug\":\"legal\",\"postDate\":1467043290,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"86\":{\"67\":{\"type\":\"legalHeader\",\"enabled\":\"1\",\"fields\":{\"legalHeader\":\"Legal\",\"position\":\"full\"}},\"68\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Terms of Use\",\"legalCopy\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.\",\"position\":\"left\"}},\"69\":{\"type\":\"legalLink\",\"enabled\":\"1\",\"fields\":{\"linkCopy\":\"Do you have a question? Contact us.\",\"linkPosition\":\"left\"}}}}}', '2016-06-27 18:06:45', '2016-06-27 18:06:45', 'ac40cccf-22ba-46d6-bbd3-b6bef14d5c28'),
 ('65', '9', '6', '1', 'en_us', '13', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\" We are Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, we closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3><a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\" target=\\\"_blank\\\">Lorem ipsum dolor<\\/a> sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/h3>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/h3>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/h3>\"}}},\"99\":\"\",\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"1.5 Billion Invested\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"1 Billion invested\"}}}}}', '2016-06-27 21:44:44', '2016-06-27 21:44:44', '08b1fc4a-8e4d-4990-bb7b-efa6bd88b86a'),
 ('66', '57', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"David J. McIntyre\",\"slug\":\"david-j-mcintyre\",\"postDate\":1466183580,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"\",\"57\":{\"58\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"david@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"(123) 456-7890\"}}},\"80\":\"<p>Short description for the team member<\\/p>\"}}', '2016-06-27 21:54:17', '2016-06-27 21:54:17', '29c34e6b-2d16-47bc-84e0-f33a5c26959e'),
 ('67', '55', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Sami Hamad\\u00e9\",\"slug\":\"sami-hamad\\u00e9\",\"postDate\":1466183520,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"\",\"57\":{\"56\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"sami@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"(123) 456-7890\"}}},\"80\":\"\"}}', '2016-06-27 21:54:23', '2016-06-27 21:54:23', '8f59162e-6026-433c-9898-1c4def5c969c'),
 ('68', '10', '7', '1', 'en_us', '4', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Contact\",\"slug\":\"contact\",\"postDate\":1465917860,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"70\":{\"41\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"New York City\",\"cityImage\":\"\",\"address\":\"230 Park Avenue, Suite 2800\\r\\nNew York, New York 10169\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk\"}},\"42\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Cambridge \",\"cityImage\":\"\",\"address\":\"000 Street Name, Suite Number\\r\\nCitry, State, Zip Code\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk\"}},\"43\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Los Altos\",\"cityImage\":\"\",\"address\":\"000 Street Name, Suite Number\\r\\nCitry, State, Zip Code\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk\"}}}}}', '2016-06-27 22:10:23', '2016-06-27 22:10:23', '82c8500a-fba8-46a3-9fdd-2528b09202f0'),
 ('69', '27', '13', '1', 'en_us', '6', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Aileron Therapeutics\",\"slug\":\"aileron-therapeutics\",\"postDate\":1465920840,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. ALRN-6924, in Phase 1, is a p53 re-activator for the treatment of cancer, the only p53 molecule in development that targets both MDM2 and MDMX.<\\/p>\",\"62\":{\"28\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.aileronrx.com\\/\",\"linkedin\":\"linkedin\"}}},\"66\":\"\",\"81\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide&nbsp;drug platform.<\\/p>\",\"103\":[\"70\"]}}', '2016-06-28 15:58:45', '2016-06-28 15:58:45', 'b782b04b-0e17-4c16-9eed-313aa1b721e7'),
 ('70', '29', '12', '1', 'en_us', '7', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD, Managing Partner\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.<\\/p>\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"seth@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"\"}}},\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals,<\\/p>\",\"104\":[\"71\",\"72\"]}}', '2016-06-28 16:26:42', '2016-06-28 16:26:42', '2cdc1dce-0594-4e0d-8675-3048c7ebd9dc'),
 ('71', '29', '12', '1', 'en_us', '8', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD, Managing Partner\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.<\\/p>\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"seth@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"\"}}},\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals,<\\/p>\",\"104\":[\"71\",\"73\"]}}', '2016-06-28 16:28:34', '2016-06-28 16:28:34', '61b27bb6-1fba-4e02-8860-24f5b4ad24ef'),
 ('72', '9', '6', '1', 'en_us', '14', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\" We are Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. \",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3><a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\" target=\\\"_blank\\\">Lorem ipsum dolor<\\/a> sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/h3>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/h3>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/h3>\"}}},\"99\":\"\",\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"1.5 Billion Invested\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"1 Billion invested\"}}}}}', '2016-06-28 17:24:13', '2016-06-28 17:24:13', '407bbe20-6390-410e-991b-3eff0aea34c3'),
 ('73', '9', '6', '1', 'en_us', '15', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\" We are Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. \",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3><a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\" target=\\\"_blank\\\">Lorem ipsum dolor<\\/a> sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/h3>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/h3>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/h3>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"1.5 Billion Invested\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"1 Billion invested\"}}}}}', '2016-06-28 17:32:08', '2016-06-28 17:32:08', '4fbe8db1-43a1-4d4e-9f9d-49d15ee77c88'),
 ('74', '9', '6', '1', 'en_us', '16', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\" We are Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. \",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3><a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\" target=\\\"_blank\\\">Lorem ipsum dolor<\\/a> sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/h3>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/h3>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/h3>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\"}},\"new1\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\"}}}}}', '2016-06-28 20:56:54', '2016-06-28 20:56:54', 'c85d76d0-fc43-4246-acaa-98323bf5e163'),
 ('75', '9', '6', '1', 'en_us', '17', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"We use long term investment philosophy to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer. \",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3><a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\" target=\\\"_blank\\\">Lorem ipsum dolor<\\/a> sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/h3>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/h3>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/h3>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\"}}}}}', '2016-06-29 16:01:58', '2016-06-29 16:01:58', '0b42840a-1ef3-4db0-bd0c-4db87ade1eda'),
 ('76', '9', '6', '1', 'en_us', '18', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use <em>long term investment philosophy<\\/em> to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3><a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\" target=\\\"_blank\\\">Lorem ipsum dolor<\\/a> sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/h3>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/h3>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/h3>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\"}}}}}', '2016-06-29 16:02:55', '2016-06-29 16:02:55', '9f06c556-a4d4-4060-80d2-bd786ca0c2a0'),
 ('77', '9', '6', '1', 'en_us', '19', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use long term investment philosophy to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3><a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\" target=\\\"_blank\\\">Lorem ipsum dolor<\\/a> sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/h3>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/h3>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/h3>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\"}}}}}', '2016-06-29 16:05:05', '2016-06-29 16:05:05', '1d0b3f5d-fdf7-4490-bda9-e8d2359b353b'),
 ('78', '9', '6', '1', 'en_us', '20', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use <em>long term investment philosophy<\\/em> to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3><a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\" target=\\\"_blank\\\">Lorem ipsum dolor<\\/a> sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/h3>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/h3>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/h3>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\"}}}}}', '2016-06-29 16:07:29', '2016-06-29 16:07:29', '3a25bbd7-8eec-4910-a6fb-38c6e1d4fdca'),
 ('79', '9', '6', '1', 'en_us', '21', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"We use long term investment philosophy to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3><a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\" target=\\\"_blank\\\">Lorem ipsum dolor<\\/a> sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/h3>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/h3>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/h3>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\"}}}}}', '2016-06-29 16:09:09', '2016-06-29 16:09:09', '9bf21f05-82fd-40d0-a28e-dbb894b0a816'),
 ('80', '9', '6', '1', 'en_us', '22', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"We use <em>long term investment philosophy<em> to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3><a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\" target=\\\"_blank\\\">Lorem ipsum dolor<\\/a> sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/h3>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/h3>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/h3>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\"}}}}}', '2016-06-29 16:09:41', '2016-06-29 16:09:41', 'b6406f0d-6d27-4ad1-adfb-780f78c66617'),
 ('81', '9', '6', '1', 'en_us', '23', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"We use <em>long term investment philosophy<\\/em> to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3><a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\" target=\\\"_blank\\\">Lorem ipsum dolor<\\/a> sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/h3>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/h3>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/h3>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\"}}}}}', '2016-06-29 16:09:46', '2016-06-29 16:09:46', 'acae9e59-e5fe-49a2-9584-9c6686166288'),
 ('82', '9', '6', '1', 'en_us', '24', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"We use long term investment philosophy to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3><a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\" target=\\\"_blank\\\">Lorem ipsum dolor<\\/a> sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/h3>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/h3>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h3>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/h3>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\"}}}}}', '2016-06-29 16:10:05', '2016-06-29 16:10:05', '928700b4-cb4f-4f30-a142-5d5a5d7c4323'),
 ('83', '9', '6', '1', 'en_us', '25', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"We use long term investment philosophy to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\" target=\\\"_blank\\\">Lorem ipsum dolor<\\/a> sit amet, consectetur adipiscing elit. Suspendisse aliquet facilisis justo in lacinia. Sed ipsum quam, dignissim et leo accumsan, varius dignissim justo. Cras tristique urna non turpis blandit hendrerit. Pellentesque aliquet augue purus, nec semper orci hendrerit et. Curabitur ullamcorper nec metus vitae condimentum.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1>Sed non luctus metus, vitae hendrerit lorem. Aenean iaculis bibendum leo ut maximus. Integer posuere rutrum imperdiet. Donec vehicula felis non urna accumsan euismod. Cras et ullamcorper lorem. Pellentesque ornare mauris in orci tincidunt aliquet. Curabitur at nunc tincidunt, elementum felis ac,<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1>Mauris id orci nec justo blandit molestie consectetur eu metus. Phasellus congue turpis vel lobortis feugiat. Nam at lobortis ipsum. Mauris felis ex, commodo quis porttitor nec, placerat at felis.<\\/h1>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\"}}}}}', '2016-06-29 16:28:09', '2016-06-29 16:28:09', '70957235-0a07-46c8-a24a-6b1d94e4c6de'),
 ('84', '9', '6', '1', 'en_us', '26', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"We use long term investment philosophy to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\"}}}}}', '2016-06-29 16:29:35', '2016-06-29 16:29:35', 'b422ea82-a82a-4ec2-9d82-500cc108172d'),
 ('85', '9', '6', '1', 'en_us', '27', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key&nbsp;successes.&nbsp;It&nbsp;should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"We use long term investment philosophy to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\"}}}}}', '2016-06-29 22:35:15', '2016-06-29 22:35:15', '76686190-5713-417c-b645-f86b2f168192'),
 ('86', '9', '6', '1', 'en_us', '28', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key&nbsp;successes.&nbsp;It&nbsp;should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"We use long term investment philosophy to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\",\"trajectoryBody\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\",\"trajectoryBody\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\",\"trajectoryBody\":\"\"}}}}}', '2016-06-29 22:37:26', '2016-06-29 22:37:26', 'a2d28608-f84a-497e-ae9b-4e91f6902cd2'),
 ('87', '29', '12', '1', 'en_us', '9', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.<\\/p>\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"seth@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"\"}}},\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals,<\\/p>\",\"104\":[\"71\",\"73\"]}}', '2016-07-01 20:01:03', '2016-07-01 20:01:03', 'c39fc883-7ce9-42c2-8039-0c88ad40e2eb'),
 ('88', '29', '12', '1', 'en_us', '10', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.<\\/p>\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"seth@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"\"}}},\"109\":\"MD, Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals,<\\/p>\",\"104\":[\"71\",\"73\"]}}', '2016-07-01 20:01:50', '2016-07-01 20:01:50', '38e3c35c-16e0-4642-b0fa-da5351b0eae2'),
 ('89', '55', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Sami Hamad\\u00e9\",\"slug\":\"sami-hamad\\u00e9\",\"postDate\":1466183520,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"\",\"57\":{\"56\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"sami@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"(123) 456-7890\"}}},\"109\":\"Partner\",\"80\":\"\",\"104\":\"\"}}', '2016-07-01 20:02:04', '2016-07-01 20:02:04', '3b187cab-9af9-43c1-8600-a145d98ec3ee'),
 ('90', '53', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Diane M. Daych\",\"slug\":\"diane-m-daych\",\"postDate\":1466183520,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"\",\"57\":{\"54\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"diane@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"\"}}},\"109\":\"Partner\",\"80\":\"\",\"104\":\"\"}}', '2016-07-01 20:02:15', '2016-07-01 20:02:15', '506e3c34-c426-4f34-adc4-c811304d3b82'),
 ('91', '57', '12', '1', 'en_us', '4', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"David J. McIntyre\",\"slug\":\"david-j-mcintyre\",\"postDate\":1466183580,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"\",\"57\":{\"58\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"david@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"(123) 456-7890\"}}},\"109\":\"Partner\",\"80\":\"<p>Short description for the team member<\\/p>\",\"104\":\"\"}}', '2016-07-01 20:02:20', '2016-07-01 20:02:20', '1c430a23-c4e8-41db-b4c4-7a38075bb52b'),
 ('92', '29', '12', '1', 'en_us', '11', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.<\\/p>\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"seth@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"\"}}},\"109\":\"MD, Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies.&nbsp;<\\/p>\",\"104\":[\"71\",\"73\"]}}', '2016-07-05 18:24:07', '2016-07-05 18:24:07', '5a128c5c-c2a9-4318-bca2-61522ab29c53'),
 ('93', '12', '9', '1', 'en_us', '8', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"31\"],\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus.&nbsp;<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"57\",\"55\",\"53\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\"]}}}}}', '2016-07-05 18:57:27', '2016-07-05 18:57:27', '79d3045f-7c37-420c-b6a9-c0fff4e4947f'),
 ('94', '12', '9', '1', 'en_us', '9', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"31\"],\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue.&nbsp;<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"57\",\"55\",\"53\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\"]}}}}}', '2016-07-05 18:57:44', '2016-07-05 18:57:44', 'c98a4b73-9f37-4f03-a1c6-267c3b316f6a'),
 ('95', '29', '12', '1', 'en_us', '12', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"seth@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"\"}}},\"109\":\"MD, Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies.&nbsp;<\\/p>\",\"104\":[\"71\",\"73\"]}}', '2016-07-05 19:09:53', '2016-07-05 19:09:53', 'c5b47b5e-91ce-4312-9732-ea0d773b9943'),
 ('96', '29', '12', '1', 'en_us', '13', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"seth@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"(123) 456-7849\"}}},\"109\":\"MD, Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies.&nbsp;<\\/p>\",\"104\":[\"71\",\"73\"]}}', '2016-07-05 19:10:06', '2016-07-05 19:10:06', 'd1b98f76-0687-495d-b68f-082b29e019fa'),
 ('97', '29', '12', '1', 'en_us', '14', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"seth@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"(123) 456-7849\"}}},\"110\":[\"75\"],\"109\":\"MD, Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies.&nbsp;<\\/p>\",\"104\":[\"71\",\"73\"]}}', '2016-07-05 21:17:40', '2016-07-05 21:17:40', 'ab78ab93-c8e8-4308-b2d6-3bf673ca5fa6'),
 ('98', '29', '12', '1', 'en_us', '15', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"seth@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"(123) 456-7849\"}}},\"110\":[\"70\"],\"109\":\"MD, Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies.&nbsp;<\\/p>\",\"104\":[\"71\",\"73\"]}}', '2016-07-05 21:50:35', '2016-07-05 21:50:35', '6a001de2-6e33-4fb3-b84b-2548bb18fdf3'),
 ('99', '9', '6', '1', 'en_us', '29', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key&nbsp;successes.&nbsp;It&nbsp;should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use <em>long term investment philosophy<\\/em> to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"51\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"99\":[\"31\"],\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\",\"trajectoryBody\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\",\"trajectoryBody\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\",\"trajectoryBody\":\"\"}}}}}', '2016-07-06 14:37:47', '2016-07-06 14:37:47', '9b74cca7-c1b1-433b-a64d-467555cfcd57'),
 ('100', '52', '8', '1', 'en_us', '5', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Mass.-based addiction treatment center expands nationally as opioid epidemic rages on\",\"slug\":\"mass-based-addiction-treatment-center-expands-nationally-as-opioid-epidemic-rages-on\",\"postDate\":1466109060,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"59\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"Two more opiate and alcohol treatment centers will be popping up in Massachusetts, as Northampton-based CleanSlate Centers looks to expand in the Bay State and nationally.\"}},\"60\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\",\"position\":\"left\"}}},\"20\":{\"date\":\"6\\/16\\/2016\"},\"36\":[\"65\"]}}', '2016-07-06 16:00:30', '2016-07-06 16:00:30', '365bb696-add7-4cb6-896a-ccdef42c87b9'),
 ('101', '10', '7', '1', 'en_us', '5', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Contact\",\"slug\":\"contact\",\"postDate\":1465917860,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"70\":{\"41\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"New York City\",\"cityImage\":\"\",\"address\":\"230 Park Avenue, Suite 2800\\r\\nNew York, New York 10169\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}},\"42\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Cambridge \",\"cityImage\":\"\",\"address\":\"000 Street Name, Suite Number\\r\\nCitry, State, Zip Code\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk\",\"locationLatitude\":\"0\",\"locationLongitude\":\"0\"}},\"43\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Los Altos\",\"cityImage\":\"\",\"address\":\"000 Street Name, Suite Number\\r\\nCitry, State, Zip Code\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk\",\"locationLatitude\":\"0\",\"locationLongitude\":\"0\"}}}}}', '2016-07-06 19:14:39', '2016-07-06 19:14:39', '6d5f15bd-513b-467e-a299-a330b438bb2d'),
 ('102', '10', '7', '1', 'en_us', '6', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Contact\",\"slug\":\"contact\",\"postDate\":1465917860,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"70\":{\"41\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"New York City\",\"cityImage\":\"\",\"address\":\"230 Park Avenue, Suite 2800\\r\\nNew York, New York 10169\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}},\"42\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Cambridge \",\"cityImage\":\"\",\"address\":\"000 Street Name, Suite Number\\r\\nCitry, State, Zip Code\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}},\"43\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Los Altos\",\"cityImage\":\"\",\"address\":\"000 Street Name, Suite Number\\r\\nCitry, State, Zip Code\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk\",\"locationLatitude\":\"0\",\"locationLongitude\":\"0\"}}}}}', '2016-07-06 19:15:01', '2016-07-06 19:15:01', 'af17613d-9129-498e-a5f9-a23b076abb16'),
 ('103', '10', '7', '1', 'en_us', '7', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Contact\",\"slug\":\"contact\",\"postDate\":1465917860,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"70\":{\"41\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"New York City\",\"cityImage\":\"\",\"address\":\"230 Park Avenue, Suite 2800\\r\\nNew York, New York 10169\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}},\"42\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Cambridge \",\"cityImage\":\"\",\"address\":\"000 Street Name, Suite Number\\r\\nCitry, State, Zip Code\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}},\"43\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Los Altos\",\"cityImage\":\"\",\"address\":\"000 Street Name, Suite Number\\r\\nCitry, State, Zip Code\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}}}}}', '2016-07-06 19:17:06', '2016-07-06 19:17:06', '52d476f0-eb27-45a7-be06-8c81dc41a66d'),
 ('104', '10', '7', '1', 'en_us', '8', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Contact\",\"slug\":\"contact\",\"postDate\":1465917860,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"70\":{\"41\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"New York City\",\"cityImage\":\"\",\"address\":\"230 Park Avenue, Suite 2800\\r\\nNew York, New York 10169\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}},\"42\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Cambridge \",\"cityImage\":\"\",\"address\":\"000 Street Name, Suite Number\\r\\nCitry, State, Zip Code\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}},\"43\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Los Altos\",\"cityImage\":\"\",\"address\":\"000 Street Name, Suite Number\\r\\nCitry, State, Zip Code\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}}}}}', '2016-07-06 19:47:42', '2016-07-06 19:47:42', '02e00ef2-d840-4b3f-9de4-bf4929ae131f'),
 ('105', '75', '15', '1', 'en_us', '1', NULL, '{\"typeId\":\"15\",\"authorId\":null,\"title\":\"Press\",\"slug\":\"press\",\"postDate\":1467840682,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":[]}', '2016-07-06 21:31:22', '2016-07-06 21:31:22', '23638283-f30d-40ec-8a7b-e806d83da946'),
 ('106', '75', '15', '1', 'en_us', '2', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Press\",\"slug\":\"press\",\"postDate\":1467840682,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"113\":{\"new1\":{\"type\":\"pressInfo\",\"enabled\":\"1\",\"fields\":{\"pressHeader\":\"Press\",\"pressDescription\":\"Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam.\",\"pressLink\":\"<p>Didn\\u2019t find what you were looking for? <em>Get in touch.<\\/em><\\/p>\"}},\"new2\":{\"type\":\"brandAssets\",\"enabled\":\"1\",\"fields\":{\"brandAssetsHeader\":\"Brand Assets\",\"logoOptions\":\"\"}},\"new3\":{\"type\":\"pressTeam\",\"enabled\":\"1\",\"fields\":{\"pressTeamHeader\":\"Headshots and Bios\",\"headshotBioNames\":\"\",\"headshotsBioPdfs\":\"\"}}}}}', '2016-07-06 21:49:08', '2016-07-06 21:49:08', '2ab99d8f-a0f2-443b-b1e7-47a8e1f63718'),
 ('107', '75', '15', '1', 'en_us', '3', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Press\",\"slug\":\"press\",\"postDate\":1467840682,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"113\":{\"76\":{\"type\":\"pressInfo\",\"enabled\":\"1\",\"fields\":{\"pressHeader\":\"Press\",\"pressDescription\":\"Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam.\",\"pressLink\":\"<p>Didn\\u2019t find what you were looking for? <em>Get in touch.<\\/em><\\/p>\"}},\"77\":{\"type\":\"brandAssets\",\"enabled\":\"1\",\"fields\":{\"brandAssetsHeader\":\"Brand Assets\",\"logoOptions\":\"\"}},\"78\":{\"type\":\"pressTeam\",\"enabled\":\"1\",\"fields\":{\"pressTeamHeader\":\"Headshots and Bios\",\"headshotBioNames\":\"\",\"headshotAndBio\":\"\"}},\"new1\":{\"type\":\"pressNews\",\"enabled\":\"1\",\"fields\":{\"pressNewsHeader\":\"Recent News\"}}}}}', '2016-07-06 22:06:29', '2016-07-06 22:06:29', 'efccec8b-51b2-4298-9ece-daed383da42a');
INSERT INTO `craft_entryversions` (`id`, `entryId`, `sectionId`, `creatorId`, `locale`, `num`, `notes`, `data`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('108', '75', '15', '1', 'en_us', '4', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Press\",\"slug\":\"press\",\"postDate\":1467840682,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"113\":{\"76\":{\"type\":\"pressInfo\",\"enabled\":\"1\",\"fields\":{\"pressHeader\":\"Press\",\"pressDescription\":\"Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam.\",\"pressLink\":\"<p>Didn\\u2019t find what you were looking for? <em>Get in touch.<\\/em><\\/p>\"}},\"77\":{\"type\":\"brandAssets\",\"enabled\":\"1\",\"fields\":{\"brandAssetsHeader\":\"Brand Assets\",\"logoOptions\":\"\"}},\"78\":{\"type\":\"pressTeam\",\"enabled\":\"1\",\"fields\":{\"pressTeamHeader\":\"Headshots and Bios\",\"headshotBioNames\":\"\",\"headshotAndBio\":\"\"}},\"79\":{\"type\":\"pressNews\",\"enabled\":\"1\",\"fields\":{\"pressNewsHeader\":\"Recent News\"}}}}}', '2016-07-06 22:10:41', '2016-07-06 22:10:41', 'a8c42a0a-7fc6-4687-87fa-b576c7c85c3e'),
 ('109', '12', '9', '1', 'en_us', '10', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"31\"],\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue.&nbsp;<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"teamImage\":[\"51\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"57\",\"55\",\"53\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\"]}}}}}', '2016-07-11 15:14:00', '2016-07-11 15:14:00', '8bf45a70-371c-4d25-be69-a3579a85faff'),
 ('110', '12', '9', '1', 'en_us', '11', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"31\"],\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue.&nbsp;<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"teamImage\":[\"51\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"57\",\"55\",\"53\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":[\"80\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\"]}}}}}', '2016-07-11 15:14:09', '2016-07-11 15:14:09', 'd90d4f42-ffd2-4209-816b-760ad5ff212d'),
 ('111', '12', '9', '1', 'en_us', '12', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"31\"],\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue.&nbsp;<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"teamImage\":[\"51\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"57\",\"55\",\"53\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":[\"80\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\"]}}}}}', '2016-07-11 15:23:38', '2016-07-11 15:23:38', '7fdcfb3c-899f-42c5-bc6c-fa22fd4b999b'),
 ('112', '12', '9', '1', 'en_us', '13', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"31\"],\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue.&nbsp;<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"teamImage\":[\"84\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"57\",\"55\",\"53\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\"]}}}}}', '2016-07-11 15:31:27', '2016-07-11 15:31:27', '11d2b3a9-ee95-4898-8898-fa47551b9c91'),
 ('113', '12', '9', '1', 'en_us', '14', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"31\"],\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue.&nbsp;<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"teamImage\":[\"85\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"57\",\"55\",\"53\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\"]}}}}}', '2016-07-11 15:33:04', '2016-07-11 15:33:04', 'eac075db-20e0-4b8b-b1e6-bddf7d4d1bf9'),
 ('114', '12', '9', '1', 'en_us', '15', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"31\"],\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue.&nbsp;<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"teamImage\":[\"51\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"57\",\"55\",\"53\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\"]}}}}}', '2016-07-11 15:47:28', '2016-07-11 15:47:28', '8ff12204-478d-4f06-8a40-11733edfd5a4'),
 ('115', '12', '9', '1', 'en_us', '16', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"31\"],\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue.&nbsp;<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"teamImage\":[\"51\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"57\",\"55\",\"53\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":[\"80\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\"]}}}}}', '2016-07-11 16:04:02', '2016-07-11 16:04:02', '554f77a8-2b6e-49b9-824e-06c74d055612'),
 ('116', '13', '10', '1', 'en_us', '6', '', '{\"typeId\":\"10\",\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1466010801,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"19\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseImage\":[\"51\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}},\"20\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseImage\":\"\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}},\"21\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseImage\":\"\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}},\"22\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Legacy Investments\",\"expertiseImage\":\"\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}}}}}', '2016-07-11 16:21:18', '2016-07-11 16:21:18', '67e405f1-a225-4620-84fc-50549a6a5cb8'),
 ('117', '13', '10', '1', 'en_us', '7', '', '{\"typeId\":\"10\",\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1466010801,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"19\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseImage\":[\"51\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}},\"20\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseImage\":\"\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}},\"21\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseImage\":\"\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}},\"22\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Legacy Investments\",\"expertiseImage\":\"\",\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}}}}}', '2016-07-11 16:21:55', '2016-07-11 16:21:55', '352ab53a-0b0c-466b-876d-753db39c8e03'),
 ('118', '9', '6', '1', 'en_us', '30', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key&nbsp;successes.&nbsp;It&nbsp;should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should&nbsp;describe&nbsp;why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use <em>long term investment philosophy<\\/em> to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\",\"trajectoryBody\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.5\",\"trajectoryDescription\":\"$1.5 billion capital pool\",\"trajectoryBody\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"\",\"trajectoryBody\":\"\"}}}}}', '2016-07-11 17:47:07', '2016-07-11 17:47:07', '035772ea-b719-422a-910f-162d041b4bab'),
 ('119', '12', '9', '1', 'en_us', '17', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"95\"],\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue.&nbsp;<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"teamImage\":[\"51\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"57\",\"55\",\"53\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":[\"80\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\"]}}}}}', '2016-07-11 18:18:47', '2016-07-11 18:18:47', '6d68b299-cfa6-43dc-b2ec-45b6e9b217ba'),
 ('120', '13', '10', '1', 'en_us', '8', '', '{\"typeId\":\"10\",\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1466010801,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"19\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseImage\":[\"95\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}},\"20\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseImage\":[\"92\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}},\"21\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseImage\":[\"89\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}},\"22\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Legacy Investments\",\"expertiseImage\":[\"90\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}}}}}', '2016-07-11 18:19:48', '2016-07-11 18:19:48', 'd125a33e-1272-4415-8f3f-43b8d585d257'),
 ('121', '12', '9', '1', 'en_us', '18', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"95\"],\"38\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue.&nbsp;<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"teamImage\":[\"89\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"57\",\"55\",\"53\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":[\"95\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":[\"92\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":[\"89\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\"]}}}}}', '2016-07-11 18:21:24', '2016-07-11 18:21:24', '120ee796-f587-42b5-b185-ba3b34d86e2c'),
 ('122', '29', '12', '1', 'en_us', '16', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p><p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n<p><br><\\/p><p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"(123) 456-7849\"}}},\"110\":[\"70\"],\"109\":\"Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies.&nbsp;<\\/p>\",\"104\":\"\"}}', '2016-07-11 18:55:21', '2016-07-11 18:55:21', '9df6be8b-cbe8-48f8-9c9a-6fa177e3bb5d'),
 ('123', '29', '12', '1', 'en_us', '17', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"(123) 456-7849\"}}},\"110\":[\"70\"],\"109\":\"Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies.&nbsp;<\\/p>\",\"104\":\"\"}}', '2016-07-11 18:58:36', '2016-07-11 18:58:36', '341c439d-a719-435d-821c-6935f55adf57'),
 ('124', '53', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Diane M. Daych\",\"slug\":\"diane-m-daych\",\"postDate\":1466183520,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Diane has over 25 years of investing, advisory and operating experience, with over 20 years focused on the healthcare services industry. She joined Apple Tree Partners in 2013 to lead their healthcare services investing. From 2010 to 2012, she was a Managing Director and Co-Head, Private Equity of the Marwood Group. Additionally, since 2000, Diane has been a partner and principal at CCP Equity Partners (\\u201cCCP\\u201d) and its predecessor firm, Conning Capital Partners, where she invested in growth companies that offer specialized solutions for the financing, management and delivery of health care in industries such as managed care, disease and care management, outpatient services, information technology and healthcare-related ancillary and outsourcing services. Prior to joining CCP in 2000, she held a senior development role at Mariner Health, a post acute care company, where she worked with operating management to develop the strategies and structures for physician practice management acquisitions and joint ventures. Prior to Mariner, Diane held senior operating roles at Medical Care America (MCA), one of the largest operators of free standing ambulatory surgery centers at that time.<\\/p>\\r\\n\\r\\n<p><br><\\/p><p>Diane currently sits on the Board of directors of TripleCare, CleanSlate Addiction Treatment Centers, QualDerm Partners, Prism Education Group, the Tuck School\\u2019s MBA Advisory Board and The Healthcare Private Equity Association (HCPEA). She was previously on the Board of directors of Cogent Healthcare, Relay Health, Zoologic and an observer for Evolution Benefits and Vantage Oncology. She also previously sat on the Board of directors of the Women\\u2019s Association of Venture and Equity (WAVE), and she is a past president of the Hartford Chapter of the Connecticut Venture Group and sat on its statewide Board for several years. She received an MBA from the Tuck School at Dartmouth College and a BA in Economics from Lehigh University.<\\/p>\",\"57\":{\"54\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"diane@gmail.com\",\"linkedin\":\"linkedin\",\"phone\":\"\"}}},\"110\":[\"96\"],\"109\":\"Partner\",\"80\":\"<p>Diane has over 25 years of investing, advisory and operating experience, with over 20 years focused on the healthcare services industry.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:01:00', '2016-07-11 19:01:00', 'e50f2e41-ae15-4ab8-8da7-42d3e045378f'),
 ('125', '55', '12', '1', 'en_us', '4', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Sami Hamad\\u00e9\",\"slug\":\"sami-hamad\\u00e9\",\"postDate\":1466183520,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>With over 20 years of operating and investing experience across a broad spectrum of therapeutic areas, Sami is a prominent figure in the medical technology sector and will be leading Apple Tree\\u2019s efforts in this area. His interests include therapeutic devices, sensors and healthcare IT solutions.<\\/p>\\r\\n\\r\\n<p><br><\\/p><p>Prior to joining Apple Tree Partners, Sami was a Partner at Aberdare Ventures where he oversaw the sale of Ablation Frontiers to Medtronic and participated in a number of key investments including NxThera Inc., Nevro and Sonitus.<\\/p>\\r\\n\\r\\n<p><br><\\/p><p>In prior years, Sami was Vice President at the Guidant Corporation and head of the Compass Group, where he was responsible for Guidant\\u2019s venture capital, business development and M&A activities. Successful investments included Cardionet Inc (Nasdaq: BEAT), Evalve (Acquired by ABT), Cryovascular (Acquired by BSX), Remon medical (Acquired by BSX) Cardiomems (Acquired by St. Jude Medical) and Spiration Inc (Acquired by Olympus).<\\/p>\\r\\n\\r\\n<p><br><\\/p><p>Earlier in his career, Sami played a critical operating role at Advanced Cardiovascular Systems (ACS), the pioneering company in the then emerging field of interventional cardiology which subsequently became a central part of Guidant\\u2019s multi-billion dollar leadership position in the stent market.\\u2028 He was also a senior executive in Guidant\\u2019s peripheral business. Sami has been a regular guest lecturer at the Stanford Business School and Biodesign programs. He is also an inventor and recipient of the prestigious Boss Kettering Award for innovation.<\\/p>\\r\\n\\r\\n<p><br><\\/p><p>Sami holds a Bachelor\\u2019s Degree in Engineering from the American University of Beirut, a Masters Degree in Engineering from the University of Michigan, Ann Arbor and an MBA from the Stanford Graduate School of Business.<\\/p>\\r\\n\\r\\n<p><br><\\/p><p>Board responsibilities include: Gala Therapeutics, VytronUS.<\\/p>\",\"57\":{\"56\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"98\"],\"109\":\"Partner\",\"80\":\"<p>With over 20 years of operating and investing experience across a broad spectrum of therapeutic areas, Sami is a prominent figure in the medical technology sector and will be leading Apple Tree\\u2019s efforts in this area.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:02:54', '2016-07-11 19:02:54', '214cbbca-8058-4be0-a703-cfcddeab6113'),
 ('126', '29', '12', '1', 'en_us', '18', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"70\"],\"109\":\"Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies.&nbsp;<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:03:03', '2016-07-11 19:03:03', '97a0852b-4191-4e06-9b66-fab54662656b'),
 ('127', '53', '12', '1', 'en_us', '4', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Diane M. Daych\",\"slug\":\"diane-m-daych\",\"postDate\":1466183520,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Diane has over 25 years of investing, advisory and operating experience, with over 20 years focused on the healthcare services industry. She joined Apple Tree Partners in 2013 to lead their healthcare services investing. From 2010 to 2012, she was a Managing Director and Co-Head, Private Equity of the Marwood Group. Additionally, since 2000, Diane has been a partner and principal at CCP Equity Partners (\\u201cCCP\\u201d) and its predecessor firm, Conning Capital Partners, where she invested in growth companies that offer specialized solutions for the financing, management and delivery of health care in industries such as managed care, disease and care management, outpatient services, information technology and healthcare-related ancillary and outsourcing services. Prior to joining CCP in 2000, she held a senior development role at Mariner Health, a post acute care company, where she worked with operating management to develop the strategies and structures for physician practice management acquisitions and joint ventures. Prior to Mariner, Diane held senior operating roles at Medical Care America (MCA), one of the largest operators of free standing ambulatory surgery centers at that time.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Diane currently sits on the Board of directors of TripleCare, CleanSlate Addiction Treatment Centers, QualDerm Partners, Prism Education Group, the Tuck School\\u2019s MBA Advisory Board and The Healthcare Private Equity Association (HCPEA). She was previously on the Board of directors of Cogent Healthcare, Relay Health, Zoologic and an observer for Evolution Benefits and Vantage Oncology. She also previously sat on the Board of directors of the Women\\u2019s Association of Venture and Equity (WAVE), and she is a past president of the Hartford Chapter of the Connecticut Venture Group and sat on its statewide Board for several years. She received an MBA from the Tuck School at Dartmouth College and a BA in Economics from Lehigh University.<\\/p>\",\"57\":{\"54\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"96\"],\"109\":\"Partner\",\"80\":\"<p>Diane has over 25 years of investing, advisory and operating experience, with over 20 years focused on the healthcare services industry.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:03:23', '2016-07-11 19:03:23', '3dcbd527-067a-43b9-a358-b9d6ba5eaa50'),
 ('128', '53', '12', '1', 'en_us', '5', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Diane M. Daych\",\"slug\":\"diane-m-daych\",\"postDate\":1466183520,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Diane has over 25 years of investing, advisory and operating experience, with over 20 years focused on the healthcare services industry. She joined Apple Tree Partners in 2013 to lead their healthcare services investing. From 2010 to 2012, she was a Managing Director and Co-Head, Private Equity of the Marwood Group. Additionally, since 2000, Diane has been a partner and principal at CCP Equity Partners (\\u201cCCP\\u201d) and its predecessor firm, Conning Capital Partners, where she invested in growth companies that offer specialized solutions for the financing, management and delivery of health care in industries such as managed care, disease and care management, outpatient services, information technology and healthcare-related ancillary and outsourcing services. Prior to joining CCP in 2000, she held a senior development role at Mariner Health, a post acute care company, where she worked with operating management to develop the strategies and structures for physician practice management acquisitions and joint ventures. Prior to Mariner, Diane held senior operating roles at Medical Care America (MCA), one of the largest operators of free standing ambulatory surgery centers at that time.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Diane currently sits on the Board of directors of TripleCare, CleanSlate Addiction Treatment Centers, QualDerm Partners, Prism Education Group, the Tuck School\\u2019s MBA Advisory Board and The Healthcare Private Equity Association (HCPEA). She was previously on the Board of directors of Cogent Healthcare, Relay Health, Zoologic and an observer for Evolution Benefits and Vantage Oncology. She also previously sat on the Board of directors of the Women\\u2019s Association of Venture and Equity (WAVE), and she is a past president of the Hartford Chapter of the Connecticut Venture Group and sat on its statewide Board for several years. She received an MBA from the Tuck School at Dartmouth College and a BA in Economics from Lehigh University.<\\/p>\",\"57\":{\"54\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"96\"],\"109\":\"Partner\",\"80\":\"<p>Diane has over 25 years of investing, advisory and operating experience, with over 20 years focused on the healthcare services industry.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:03:27', '2016-07-11 19:03:27', 'c110fe82-12d2-47ba-aa65-412ff4ab2682'),
 ('129', '57', '12', '1', 'en_us', '5', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"David J. McIntyre\",\"slug\":\"david-j-mcintyre\",\"postDate\":1466183580,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>David has over 20 years of experience as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries, including medical devices. With professional qualifications in finance and law, David has held senior financial, legal and operational roles.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>More recently, David was Executive Vice President, Chief Financial Officer of HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) from 2005 through 2011, and assumed the additional responsibilities of Chief Operating Officer during HeartWare\\u2019s global commercialization phase for the period from 2008 through 2011.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Prior to HeartWare, David practiced as a senior attorney in private practice specializing in corporate, mergers and acquisitions and equity capital markets with Baker & McKenzie and KPMG as well as holding various senior financial roles in multi-national companies including Coal & Allied Limited, a publicly traded subsidiary of the Rio Tinto Group of companies.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>David holds a Bachelor of Economics (Accounting) from the University of Sydney (Australia), a Bachelor of Law from the University of Technology, Sydney (Australia) and a Masters of Business Administration (Fuqua Scholar) from Duke University. He is also a Certified Practicing Accountant (CPA) and is admitted as a Legal Practitioner of the Supreme Court of New South Wales (in Australia).<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Board responsibilities include: VytronUS, QualDerm, Tusker Medical, Braeburn Pharmaceuticals, Gala Therapeutics and previously Tendyne (acquired by Abbott).<\\/p>\",\"57\":{\"58\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":\"\",\"109\":\"Partner\",\"80\":\"<p>David has over 20 years of experience as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries, including medical devices.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:04:13', '2016-07-11 19:04:13', '2394e20f-edde-4d0a-932b-235917c40559'),
 ('130', '99', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Lauren Farrell\",\"slug\":\"lauren-farrell\",\"postDate\":1468263903,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Lauren has over 20 years accounting and finance experience including roles in public accounting, financial management and reporting, and strategic financial consulting across multiple industries. Prior to joining Apple Tree Partners, Lauren was Vice President and Chief Accounting Officer at HeartWare International, Inc. (NASDAQ:HTWR) from 2006 to 2013, where she led the Company\\u2019s financial management and reporting activities. From 2005 to 2006, Lauren was Chief Financial Officer at Ambient Corporation. From January 2001 to July 2004, Lauren served as Vice President at Bingham Strategic Advisors providing M&A advisory services.<\\/p>\\r\\n\\r\\n<p><br><\\/p><p>Lauren is a Certified Public Accountant and holds a Bachelors of Science in Accounting and a Masters of Business Administration from Bentley University.<\\/p>\",\"57\":\"\",\"110\":\"\",\"109\":\"Chief Financial Officer\",\"80\":\"<p>Lauren has over 20 years accounting and finance experience including roles in public accounting, financial management and reporting, and strategic financial consulting across multiple industries.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:05:04', '2016-07-11 19:05:04', '4642bf4b-1c90-4857-a00a-769cb8a3a73d'),
 ('131', '29', '12', '1', 'en_us', '19', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison-md-managing-partner\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"100\"],\"109\":\"Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies.&nbsp;<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:05:37', '2016-07-11 19:05:37', 'e752d2d1-f8ac-426e-88bc-8f2e16948485'),
 ('132', '55', '12', '1', 'en_us', '5', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Sami Hamad\\u00e9\",\"slug\":\"sami-hamad\\u00e9\",\"postDate\":1466183520,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>With over 20 years of operating and investing experience across a broad spectrum of therapeutic areas, Sami is a prominent figure in the medical technology sector and will be leading Apple Tree\\u2019s efforts in this area. His interests include therapeutic devices, sensors and healthcare IT solutions.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n<p>Prior to joining Apple Tree Partners, Sami was a Partner at Aberdare Ventures where he oversaw the sale of Ablation Frontiers to Medtronic and participated in a number of key investments including NxThera Inc., Nevro and Sonitus.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n<p>In prior years, Sami was Vice President at the Guidant Corporation and head of the Compass Group, where he was responsible for Guidant\\u2019s venture capital, business development and M&A activities. Successful investments included Cardionet Inc (Nasdaq: BEAT), Evalve (Acquired by ABT), Cryovascular (Acquired by BSX), Remon medical (Acquired by BSX) Cardiomems (Acquired by St. Jude Medical) and Spiration Inc (Acquired by Olympus).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n<p>Earlier in his career, Sami played a critical operating role at Advanced Cardiovascular Systems (ACS), the pioneering company in the then emerging field of interventional cardiology which subsequently became a central part of Guidant\\u2019s multi-billion dollar leadership position in the stent market.\\u2028 He was also a senior executive in Guidant\\u2019s peripheral business. Sami has been a regular guest lecturer at the Stanford Business School and Biodesign programs. He is also an inventor and recipient of the prestigious Boss Kettering Award for innovation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n<p>Sami holds a Bachelor\\u2019s Degree in Engineering from the American University of Beirut, a Masters Degree in Engineering from the University of Michigan, Ann Arbor and an MBA from the Stanford Graduate School of Business.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n<p>Board responsibilities include: Gala Therapeutics, VytronUS.<\\/p>\",\"57\":{\"56\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"97\"],\"109\":\"Partner\",\"80\":\"<p>With over 20 years of operating and investing experience across a broad spectrum of therapeutic areas, Sami is a prominent figure in the medical technology sector and will be leading Apple Tree\\u2019s efforts in this area.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:05:58', '2016-07-11 19:05:58', '08c70713-f843-4a02-bfd0-5da4981447b2'),
 ('133', '29', '12', '1', 'en_us', '20', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"30\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"100\"],\"109\":\"Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies.&nbsp;<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:06:05', '2016-07-11 19:06:05', '5f1068ca-309d-4018-9d5e-126b302b6bea'),
 ('134', '53', '12', '1', 'en_us', '6', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Diane M. Daych\",\"slug\":\"diane-m-daych\",\"postDate\":1466183520,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Diane has over 25 years of investing, advisory and operating experience, with over 20 years focused on the healthcare services industry. She joined Apple Tree Partners in 2013 to lead their healthcare services investing. From 2010 to 2012, she was a Managing Director and Co-Head, Private Equity of the Marwood Group. Additionally, since 2000, Diane has been a partner and principal at CCP Equity Partners (\\u201cCCP\\u201d) and its predecessor firm, Conning Capital Partners, where she invested in growth companies that offer specialized solutions for the financing, management and delivery of health care in industries such as managed care, disease and care management, outpatient services, information technology and healthcare-related ancillary and outsourcing services. Prior to joining CCP in 2000, she held a senior development role at Mariner Health, a post acute care company, where she worked with operating management to develop the strategies and structures for physician practice management acquisitions and joint ventures. Prior to Mariner, Diane held senior operating roles at Medical Care America (MCA), one of the largest operators of free standing ambulatory surgery centers at that time.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Diane currently sits on the Board of directors of TripleCare, CleanSlate Addiction Treatment Centers, QualDerm Partners, Prism Education Group, the Tuck School\\u2019s MBA Advisory Board and The Healthcare Private Equity Association (HCPEA). She was previously on the Board of directors of Cogent Healthcare, Relay Health, Zoologic and an observer for Evolution Benefits and Vantage Oncology. She also previously sat on the Board of directors of the Women\\u2019s Association of Venture and Equity (WAVE), and she is a past president of the Hartford Chapter of the Connecticut Venture Group and sat on its statewide Board for several years. She received an MBA from the Tuck School at Dartmouth College and a BA in Economics from Lehigh University.<\\/p>\",\"57\":{\"54\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"96\"],\"109\":\"Partner\",\"80\":\"<p>Diane has over 25 years of investing, advisory and operating experience, with over 20 years focused on the healthcare services industry.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:06:14', '2016-07-11 19:06:14', 'ef26c6be-a089-4a54-8ebc-a9fd132fd218'),
 ('135', '57', '12', '1', 'en_us', '6', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"David J. McIntyre\",\"slug\":\"david-j-mcintyre\",\"postDate\":1466183580,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>David has over 20 years of experience as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries, including medical devices. With professional qualifications in finance and law, David has held senior financial, legal and operational roles.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n<p>More recently, David was Executive Vice President, Chief Financial Officer of HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) from 2005 through 2011, and assumed the additional responsibilities of Chief Operating Officer during HeartWare\\u2019s global commercialization phase for the period from 2008 through 2011.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Prior to HeartWare, David practiced as a senior attorney in private practice specializing in corporate, mergers and acquisitions and equity capital markets with Baker & McKenzie and KPMG as well as holding various senior financial roles in multi-national companies including Coal & Allied Limited, a publicly traded subsidiary of the Rio Tinto Group of companies.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>David holds a Bachelor of Economics (Accounting) from the University of Sydney (Australia), a Bachelor of Law from the University of Technology, Sydney (Australia) and a Masters of Business Administration (Fuqua Scholar) from Duke University. He is also a Certified Practicing Accountant (CPA) and is admitted as a Legal Practitioner of the Supreme Court of New South Wales (in Australia).<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Board responsibilities include: VytronUS, QualDerm, Tusker Medical, Braeburn Pharmaceuticals, Gala Therapeutics and previously Tendyne (acquired by Abbott).<\\/p>\",\"57\":{\"58\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"97\"],\"109\":\"Partner\",\"80\":\"<p>David has over 20 years of experience as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries, including medical devices.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:06:34', '2016-07-11 19:06:34', 'db74ed37-2e87-4029-93d6-641185257729'),
 ('136', '99', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Lauren Farrell\",\"slug\":\"lauren-farrell\",\"postDate\":1468263900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Lauren has over 20 years accounting and finance experience including roles in public accounting, financial management and reporting, and strategic financial consulting across multiple industries. Prior to joining Apple Tree Partners, Lauren was Vice President and Chief Accounting Officer at HeartWare International, Inc. (NASDAQ:HTWR) from 2006 to 2013, where she led the Company\\u2019s financial management and reporting activities. From 2005 to 2006, Lauren was Chief Financial Officer at Ambient Corporation. From January 2001 to July 2004, Lauren served as Vice President at Bingham Strategic Advisors providing M&A advisory services.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n<p>Lauren is a Certified Public Accountant and holds a Bachelors of Science in Accounting and a Masters of Business Administration from Bentley University.<\\/p>\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Chief Financial Officer\",\"80\":\"<p>Lauren has over 20 years accounting and finance experience including roles in public accounting, financial management and reporting, and strategic financial consulting across multiple industries.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:06:54', '2016-07-11 19:06:54', '818433fc-b9ee-4df5-8ca6-85cae828a317'),
 ('137', '102', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Julie Gionfriddo\",\"slug\":\"julie-gionfriddo\",\"postDate\":1468264066,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Julie Gionfriddo joined Apple Tree Partners in 2014 and has spent nearly 18 years prior focused on private equity. Prior to joining Apple Tree, Julie was a vice president within the private equity secondary group at Landmark Partners, where she was involved in transaction origination, underwriting, and negotiation of private equity investments, as well as investor relations and marketing.<\\/p>\\r\\n\\r\\n<p>Julie serves on the board of directors for the Women\\u2019s Association of Venture and Equity. Julie also serves on the Board of Fellows and the Women\\u2019s Leadership Council for Trinity College. She received her BA and MA in Economics from Trinity College.<\\/p>\",\"57\":\"\",\"110\":[\"96\"],\"109\":\"Principal\",\"80\":\"<p>Julie Gionfriddo joined Apple Tree Partners in 2014 and has spent nearly 18 years prior focused on private equity<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:07:46', '2016-07-11 19:07:46', '2f174af0-5bd4-4445-929e-02a727e011ec'),
 ('138', '29', '12', '1', 'en_us', '21', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies.&nbsp;<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:08:01', '2016-07-11 19:08:01', 'fcd075eb-dbef-4d56-9691-a0409a0b9108'),
 ('139', '66', '14', '1', 'en_us', '5', '', '{\"typeId\":\"14\",\"authorId\":null,\"title\":\"Legal\",\"slug\":\"legal\",\"postDate\":1467043290,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"86\":{\"67\":{\"type\":\"legalHeader\",\"enabled\":\"1\",\"fields\":{\"legalHeader\":\"Legal\",\"position\":\"full\"}},\"new1\":{\"type\":\"legalHeaderImage\",\"enabled\":\"1\",\"fields\":{\"legalHeaderImage\":[\"91\"]}},\"68\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Terms of Use\",\"legalCopy\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.\",\"position\":\"left\"}},\"69\":{\"type\":\"legalLink\",\"enabled\":\"1\",\"fields\":{\"linkCopy\":\"Do you have a question? Contact us.\",\"linkPosition\":\"left\"}}}}}', '2016-07-11 19:09:20', '2016-07-11 19:09:20', 'fd62764c-6e4c-47d7-a4e1-9ff61ab02a90'),
 ('140', '29', '12', '1', 'en_us', '22', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"100\"],\"109\":\"Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies.&nbsp;<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:11:39', '2016-07-11 19:11:39', '5285100f-96f3-41bb-af47-c0d652fb2e9e'),
 ('141', '105', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Sam Hall, Ph.D.\",\"slug\":\"sam-hall\",\"postDate\":1468264375,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Sam Hall has experience in the life sciences across roles as a private equity investor, investment banker and basic scientist. Prior to joining Apple Tree in 2013, he was a researcher at the University of Cambridge in the UK, where his work focused on novel therapeutic strategies for autoimmune diseases. Previously, Sam was a member of the investment team at Symphony Capital, a private equity firm dedicated to investments in biopharmaceutical development. Prior to Symphony, he served as a member of the healthcare investment banking team at Citigroup, where he advised leading biotechnology, medical device and healthcare services businesses on numerous completed strategic and debt and equity financing engagements.<\\/p>\\r\\n\\r\\n<p>Sam holds an A.B. in Molecular Biology from Princeton University and completed his M.Phil. and Ph.D. research at the University of Cambridge, where he was a Taylor Research Scholar and was awarded an NSF Graduate Research Fellowship for his work.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Board responsibilities include: Syntimmune (Director), Stoke Therapeutics (Director).<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Principal\",\"80\":\"<p>Sam Hall has experience in the life sciences across roles as a private equity investor, investment banker and basic scientist.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:12:55', '2016-07-11 19:12:55', '90dbd5e5-411e-4f3c-ab9a-b74416879c77'),
 ('142', '106', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Aaron Kantoff\",\"slug\":\"aaron-kantoff\",\"postDate\":1468264437,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Aaron has significant early and late-stage biotech experience, serving financial analysis and restructuring. Prior to joining Apple Tree in 2011, Aaron was a partner at Recess Global, LLC, an investment company, focused on funding startups. Prior to starting Recess Global, LLC, Aaron was a member of the investment banking team at Rothschild Inc., in the Restructuring Group. Selected transactions that he worked on at Rothschild, Inc. include: advising the U.S Treasury on restructuring of Chrysler Group, LLC; assisting Milacron Inc. with the Section 363 sale of assets; working with Delphi Automotive on its in-court Chapter 11 bankruptcy; developing the Penton Media \\\"Pre-packaged\\\" Chapter 11 filing. In addition to his role with Apple Tree, Aaron has also served as Executive Director of Business Development & Corporate Strategy of Braeburn Pharmaceuticals.<\\/p>\\r\\n\\r\\n<p>Aaron holds a Bachelor of Science in Finance and International Business from the New York University Stern School of Business.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Board responsibilities include: Cure Forward (Director), Corvidia (Board Observer), and Syntimmune (Board Observer).<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Principal\",\"80\":\"<p>Aaron has significant early and late-stage biotech experience, serving financial analysis and restructuring.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:13:57', '2016-07-11 19:13:57', 'b4819ecc-a128-42e8-bb7b-6cbcc223c909'),
 ('143', '107', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Jonathan Waldstreicher, MD\",\"slug\":\"jonathan-waldstreicher-md\",\"postDate\":1468264507,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Jonathan Waldstreicher joined Apple Tree in 2013 to invest in medical devices. After incubating an interventional pulmonary technology for two years, Jon founded Gala Therapeutics in Silicon Valley and assumed the CEO role to further its development.<\\/p>\\r\\n\\r\\n<p>Prior to joining Apple Tree, Jon was a Director, Global Surgery R&D, at Johnson & Johnson where he initiated and led an investment strategy and R&D development program in a new growth platform technology area. He started at Johnson & Johnson as an Associate Director in the Corporate Office of Science & Technology where he executed numerous seed grants to startup companies and participated in technical diligence of venture capital investments. Before medical school, Jon worked in Equity Research at Bear Stearns.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Jon received a B.A. from Brandeis University in Economics and an M.D. and M.B.A. from Tufts University School of Medicine where he was awarded the Norman Stearns award for highest achievement and overall excellence within the dual degree program. Between his third and fourth year of medical school, Jon worked as a fellow at the Corporate Office of Science & Technology at J&J. He completed a General Surgery Internship at Tufts Medical Center in Boston.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Board responsibilities include: Gala Therapeutics, VytronUS (Board Observer).<\\/p>\",\"57\":\"\",\"110\":[\"97\"],\"109\":\"Principal\",\"80\":\"<p>Jonathan Waldstreicher joined Apple Tree in 2013 to invest in medical devices.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:15:07', '2016-07-11 19:15:07', '143432fe-0480-413d-8cd3-ec9890745e5f'),
 ('144', '108', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Keting Chu, MD, Ph.D.\",\"slug\":\"keting-chu\",\"postDate\":1468264557,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Keting Chu joined Apple Tree Partners in 2016 as a Venture Partner. Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture philanthropy.<\\/p>\\r\\n\\r\\n<p>Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS). There she was responsible for venture philanthropy, also known as the Therapy Acceleration program. At LLS, Keting led the investment of Celator, Stemline, Constellation, Affimed, arGen-X, Kite Pharma, Kiadis, OncoPepe, Valor and a number of projects within academic institutions. Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc. Prior to co-founding DigitAB, Keting was the Co-Founder and CEO of BioCubed Corporation, Vice President of Biology and Head of R&D at Five Prime Therapeutics during its founding stage and the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical and clinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Keting received her MD in Sun Yat-sen Medical University specialized in infectious diseases in China, Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF). She also conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.<\\/p>\",\"57\":\"\",\"110\":\"\",\"109\":\"Venture Partner\",\"80\":\"<p>Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture philanthropy.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:15:57', '2016-07-11 19:15:57', '8c1f84fa-c510-43eb-a22e-8bb033b88271'),
 ('145', '108', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Keting Chu, MD, Ph.D.\",\"slug\":\"keting-chu\",\"postDate\":1468264500,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"56\":\"<p>Keting Chu joined Apple Tree Partners in 2016 as a Venture Partner. Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture philanthropy.<\\/p>\\r\\n\\r\\n<p>Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS). There she was responsible for venture philanthropy, also known as the Therapy Acceleration program. At LLS, Keting led the investment of Celator, Stemline, Constellation, Affimed, arGen-X, Kite Pharma, Kiadis, OncoPepe, Valor and a number of projects within academic institutions. Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc. Prior to co-founding DigitAB, Keting was the Co-Founder and CEO of BioCubed Corporation, Vice President of Biology and Head of R&D at Five Prime Therapeutics during its founding stage and the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical and clinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Keting received her MD in Sun Yat-sen Medical University specialized in infectious diseases in China, Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF). She also conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Venture Partner\",\"80\":\"<p>Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture philanthropy.<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:16:22', '2016-07-11 19:16:22', '7328dd71-d994-403c-8cf4-7271cbd766fb'),
 ('146', '66', '14', '1', 'en_us', '6', '', '{\"typeId\":\"14\",\"authorId\":null,\"title\":\"Legal\",\"slug\":\"legal\",\"postDate\":1467043290,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"128\":[\"91\"],\"86\":{\"67\":{\"type\":\"legalHeader\",\"enabled\":\"1\",\"fields\":{\"legalHeader\":\"Legal\",\"position\":\"full\"}},\"68\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Terms of Use\",\"legalCopy\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.\",\"position\":\"left\"}},\"69\":{\"type\":\"legalLink\",\"enabled\":\"1\",\"fields\":{\"linkCopy\":\"Do you have a question? Contact us.\",\"linkPosition\":\"left\"}}}}}', '2016-07-11 19:19:09', '2016-07-11 19:19:09', '0dbaaee6-8b30-4c24-8f4f-cd7420fd22f5'),
 ('147', '29', '12', '1', 'en_us', '23', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"104\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"100\"],\"109\":\"Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies.&nbsp;<\\/p>\",\"104\":\"\"}}', '2016-07-11 19:21:34', '2016-07-11 19:21:34', 'b242a704-0dba-4955-b923-0b803b7a6c0b'),
 ('148', '27', '13', '1', 'en_us', '7', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Aileron Therapeutics\",\"slug\":\"aileron-therapeutics\",\"postDate\":1465920840,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. ALRN-6924, in Phase 1, is a p53 re-activator for the treatment of cancer, the only p53 molecule in development that targets both MDM2 and MDMX.<\\/p>\",\"62\":{\"28\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.aileronrx.com\\/\",\"linkedin\":\"linkedin\"}}},\"130\":[\"90\"],\"66\":\"\",\"81\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide&nbsp;drug platform.<\\/p>\",\"103\":[\"70\"]}}', '2016-07-11 19:26:41', '2016-07-11 19:26:41', 'ef4684c2-8841-4537-8ac8-b9bba719994f'),
 ('149', '52', '8', '1', 'en_us', '6', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Mass.-based addiction treatment center expands nationally as opioid epidemic rages on\",\"slug\":\"mass-based-addiction-treatment-center-expands-nationally-as-opioid-epidemic-rages-on\",\"postDate\":1466109060,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"59\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"Two more opiate and alcohol treatment centers will be popping up in Massachusetts, as Northampton-based CleanSlate Centers looks to expand in the Bay State and nationally.\"}},\"60\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"90\"],\"20\":{\"date\":\"6\\/16\\/2016\"},\"36\":[\"65\"]}}', '2016-07-11 19:30:23', '2016-07-11 19:30:23', '63be9a22-cfdb-4485-a112-06d0a0c9f03a'),
 ('150', '75', '15', '1', 'en_us', '5', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Press\",\"slug\":\"press\",\"postDate\":1467840682,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"132\":[\"94\"],\"113\":{\"76\":{\"type\":\"pressInfo\",\"enabled\":\"1\",\"fields\":{\"pressHeader\":\"Press\",\"pressDescription\":\"Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam.\",\"pressLink\":\"<p>Didn\\u2019t find what you were looking for? <em>Get in touch.<\\/em><\\/p>\"}},\"77\":{\"type\":\"brandAssets\",\"enabled\":\"1\",\"fields\":{\"brandAssetsHeader\":\"Brand Assets\",\"logoOptions\":\"\"}},\"78\":{\"type\":\"pressTeam\",\"enabled\":\"1\",\"fields\":{\"pressTeamHeader\":\"Headshots and Bios\",\"headshotBioNames\":\"\",\"headshotAndBio\":\"\"}},\"79\":{\"type\":\"pressNews\",\"enabled\":\"1\",\"fields\":{\"pressNewsHeader\":\"Recent News\"}}}}}', '2016-07-11 19:33:23', '2016-07-11 19:33:23', 'f0006b50-941a-4e82-a290-e70d87d1ab49'),
 ('151', '109', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Paul DaSilva-Jardine, Ph.D.\",\"slug\":\"paul-dasilva-jardine\",\"postDate\":1468269009,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":\"\",\"56\":\"<p>Paul DaSilva-Jardine joined Apple Tree Partners in 2016 as a Venture Partner. Paul has over 25 years of drug discovery and development experience in the Cardiovascular, Metabolic and Endocrine diseases space. Prior to joining Apple Tree, Paul spent over 25 years at Pfizer Research and Development where he participated in the discovery and development of over fifty drug candidates including the first, lasofoxifene, a SERM which received authorization from European Medicines Agency. Paul held various leadership positions at Pfizer R&D including Vice President, Head of CVMED Chemistry, and Vice President in the CVMED Research Unit which was responsible for drug development from Idea to Phase 2 Proof of Concept.<\\/p>\\r\\n\\r\\n<p>Paul earned his PhD and completed post-doctoral studies in Synthetic Organic Chemistry with Professor Corey at Harvard University.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Venture Partner\",\"80\":\"<p>Paul has over 25 years of drug discovery and development experience in the Cardiovascular, Metabolic and Endocrine diseases space.&nbsp;<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:30:09', '2016-07-11 20:30:09', '19bef338-0eda-4f5b-8390-3804ac6d0542'),
 ('152', '110', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"David de Graaf, Ph.D.\",\"slug\":\"david-de-graaf-ph-d\",\"postDate\":1468269067,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":\"\",\"56\":\"<p>David de Graaf joined Apple Tree Partners in 2015 as a Venture Partner. David is a scientist and entrepreneur with broad experience ranging from operational leadership to the development of new companies. Most recently, David was Entrepreneur in Residence for Flagship Ventures and Executive Chairman of Selventa, a Flagship portfolio company which he restarted and rebranded. As CEO, David brought Selventa to revenue stage and financial independence with a line of services and products in the personalized medicine space. Before Selventa, David held roles of increasing responsibility at AstraZeneca, Pfizer, and Boehringer-Ingleheim with a focus on the early portfolio in a variety of therapeutic areas. He brought pathway biology to AstraZeneca, building functions for pathway analysis in the UK and the US. He headed Systems Biology at Pfizer with a focus on biotherapeutics and predictive toxicology and at Boehringer-Ingelheim, as Vice President of Biotherapeutics and Integrative Biology, he built a new biotherapeutics capability which brought a handful of candidates to the clinic in auto-immune diseases and oncology. David\\u2019s academic career initially brought him to the Whitehead\\/MIT center for Functional Genomics as one of the founding scientists to work with Prof. Eric Lander, after his postdoctoral work at the Weizmann Institute in Israel.<\\/p>\\r\\n\\r\\n<p>David also serves on a variety of boards, ranging from the Swiss Institute of Bioinformatics to Chugai PharmaBody. David holds a PhD in Mammalian Genetics from the University of Illinois at Chicago and a Masters in Evolutionary Genetics form the University of Utrecht.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Venture Partner\",\"80\":\"<p>David is a scientist and entrepreneur with broad experience ranging from operational leadership to the development of new companies.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:31:07', '2016-07-11 20:31:07', '17a30c8e-6a5c-41b7-8ce1-28e573461398'),
 ('153', '110', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"David de Graaf, Ph.D.\",\"slug\":\"david-de-graaf\",\"postDate\":1468269060,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":\"\",\"56\":\"<p>David de Graaf joined Apple Tree Partners in 2015 as a Venture Partner. David is a scientist and entrepreneur with broad experience ranging from operational leadership to the development of new companies. Most recently, David was Entrepreneur in Residence for Flagship Ventures and Executive Chairman of Selventa, a Flagship portfolio company which he restarted and rebranded. As CEO, David brought Selventa to revenue stage and financial independence with a line of services and products in the personalized medicine space. Before Selventa, David held roles of increasing responsibility at AstraZeneca, Pfizer, and Boehringer-Ingleheim with a focus on the early portfolio in a variety of therapeutic areas. He brought pathway biology to AstraZeneca, building functions for pathway analysis in the UK and the US. He headed Systems Biology at Pfizer with a focus on biotherapeutics and predictive toxicology and at Boehringer-Ingelheim, as Vice President of Biotherapeutics and Integrative Biology, he built a new biotherapeutics capability which brought a handful of candidates to the clinic in auto-immune diseases and oncology. David\\u2019s academic career initially brought him to the Whitehead\\/MIT center for Functional Genomics as one of the founding scientists to work with Prof. Eric Lander, after his postdoctoral work at the Weizmann Institute in Israel.<\\/p>\\r\\n\\r\\n<p>David also serves on a variety of boards, ranging from the Swiss Institute of Bioinformatics to Chugai PharmaBody. David holds a PhD in Mammalian Genetics from the University of Illinois at Chicago and a Masters in Evolutionary Genetics form the University of Utrecht.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Venture Partner\",\"80\":\"<p>David is a scientist and entrepreneur with broad experience ranging from operational leadership to the development of new companies.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:31:48', '2016-07-11 20:31:48', '39210009-5f5a-4761-86e8-4c0a6971a4ff'),
 ('154', '110', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"David de Graaf, Ph.D.\",\"slug\":\"david-de-graaf\",\"postDate\":1468269060,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":\"\",\"56\":\"<p>David de Graaf joined Apple Tree Partners in 2015 as a Venture Partner. David is a scientist and entrepreneur with broad experience ranging from operational leadership to the development of new companies. Most recently, David was Entrepreneur in Residence for Flagship Ventures and Executive Chairman of Selventa, a Flagship portfolio company which he restarted and rebranded. As CEO, David brought Selventa to revenue stage and financial independence with a line of services and products in the personalized medicine space. Before Selventa, David held roles of increasing responsibility at AstraZeneca, Pfizer, and Boehringer-Ingleheim with a focus on the early portfolio in a variety of therapeutic areas. He brought pathway biology to AstraZeneca, building functions for pathway analysis in the UK and the US. He headed Systems Biology at Pfizer with a focus on biotherapeutics and predictive toxicology and at Boehringer-Ingelheim, as Vice President of Biotherapeutics and Integrative Biology, he built a new biotherapeutics capability which brought a handful of candidates to the clinic in auto-immune diseases and oncology. David\\u2019s academic career initially brought him to the Whitehead\\/MIT center for Functional Genomics as one of the founding scientists to work with Prof. Eric Lander, after his postdoctoral work at the Weizmann Institute in Israel.<\\/p>\\r\\n\\r\\n<p>David also serves on a variety of boards, ranging from the Swiss Institute of Bioinformatics to Chugai PharmaBody. David holds a PhD in Mammalian Genetics from the University of Illinois at Chicago and a Masters in Evolutionary Genetics form the University of Utrecht.<\\/p>\",\"57\":\"\",\"110\":\"\",\"109\":\"Venture Partner\",\"80\":\"<p>David is a scientist and entrepreneur with broad experience ranging from operational leadership to the development of new companies.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:32:25', '2016-07-11 20:32:25', 'ee74799b-067b-49e7-8ed2-97d66fab9697'),
 ('155', '110', '12', '1', 'en_us', '4', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"David de Graaf, Ph.D.\",\"slug\":\"david-de-graaf\",\"postDate\":1468269060,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":\"\",\"56\":\"<p>David de Graaf joined Apple Tree Partners in 2015 as a Venture Partner. David is a scientist and entrepreneur with broad experience ranging from operational leadership to the development of new companies. Most recently, David was Entrepreneur in Residence for Flagship Ventures and Executive Chairman of Selventa, a Flagship portfolio company which he restarted and rebranded. As CEO, David brought Selventa to revenue stage and financial independence with a line of services and products in the personalized medicine space. Before Selventa, David held roles of increasing responsibility at AstraZeneca, Pfizer, and Boehringer-Ingleheim with a focus on the early portfolio in a variety of therapeutic areas. He brought pathway biology to AstraZeneca, building functions for pathway analysis in the UK and the US. He headed Systems Biology at Pfizer with a focus on biotherapeutics and predictive toxicology and at Boehringer-Ingelheim, as Vice President of Biotherapeutics and Integrative Biology, he built a new biotherapeutics capability which brought a handful of candidates to the clinic in auto-immune diseases and oncology. David\\u2019s academic career initially brought him to the Whitehead\\/MIT center for Functional Genomics as one of the founding scientists to work with Prof. Eric Lander, after his postdoctoral work at the Weizmann Institute in Israel.<\\/p>\\r\\n\\r\\n<p>David also serves on a variety of boards, ranging from the Swiss Institute of Bioinformatics to Chugai PharmaBody. David holds a PhD in Mammalian Genetics from the University of Illinois at Chicago and a Masters in Evolutionary Genetics form the University of Utrecht.<\\/p>\",\"57\":\"\",\"110\":\"\",\"109\":\"Venture Partner\",\"80\":\"<p>David is a scientist and entrepreneur with broad experience ranging from operational leadership to the development of new companies.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:33:17', '2016-07-11 20:33:17', '1a34b904-36d4-41d1-b798-e6dd1bb6bd93'),
 ('156', '29', '12', '1', 'en_us', '24', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"104\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"100\"],\"109\":\"Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies.&nbsp;<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:33:22', '2016-07-11 20:33:22', '870a0f75-b13b-414a-8d0c-670f5f02e3d3'),
 ('157', '55', '12', '1', 'en_us', '6', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Sami Hamad\\u00e9\",\"slug\":\"sami-hamad\\u00e9\",\"postDate\":1466183520,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"92\"],\"56\":\"<p>With over 20 years of operating and investing experience across a broad spectrum of therapeutic areas, Sami is a prominent figure in the medical technology sector and will be leading Apple Tree\\u2019s efforts in this area. His interests include therapeutic devices, sensors and healthcare IT solutions.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Prior to joining Apple Tree Partners, Sami was a Partner at Aberdare Ventures where he oversaw the sale of Ablation Frontiers to Medtronic and participated in a number of key investments including NxThera Inc., Nevro and Sonitus.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>In prior years, Sami was Vice President at the Guidant Corporation and head of the Compass Group, where he was responsible for Guidant\\u2019s venture capital, business development and M&A activities. Successful investments included Cardionet Inc (Nasdaq: BEAT), Evalve (Acquired by ABT), Cryovascular (Acquired by BSX), Remon medical (Acquired by BSX) Cardiomems (Acquired by St. Jude Medical) and Spiration Inc (Acquired by Olympus).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Earlier in his career, Sami played a critical operating role at Advanced Cardiovascular Systems (ACS), the pioneering company in the then emerging field of interventional cardiology which subsequently became a central part of Guidant\\u2019s multi-billion dollar leadership position in the stent market.\\u2028 He was also a senior executive in Guidant\\u2019s peripheral business. Sami has been a regular guest lecturer at the Stanford Business School and Biodesign programs. He is also an inventor and recipient of the prestigious Boss Kettering Award for innovation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Sami holds a Bachelor\\u2019s Degree in Engineering from the American University of Beirut, a Masters Degree in Engineering from the University of Michigan, Ann Arbor and an MBA from the Stanford Graduate School of Business.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Board responsibilities include: Gala Therapeutics, VytronUS.<\\/p>\",\"57\":{\"56\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"97\"],\"109\":\"Partner\",\"80\":\"<p>With over 20 years of operating and investing experience across a broad spectrum of therapeutic areas, Sami is a prominent figure in the medical technology sector and will be leading Apple Tree\\u2019s efforts in this area.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:33:33', '2016-07-11 20:33:33', '79da2731-a771-4b52-b236-00e21013b078'),
 ('158', '53', '12', '1', 'en_us', '7', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Diane M. Daych\",\"slug\":\"diane-m-daych\",\"postDate\":1466183520,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"89\"],\"56\":\"<p>Diane has over 25 years of investing, advisory and operating experience, with over 20 years focused on the healthcare services industry. She joined Apple Tree Partners in 2013 to lead their healthcare services investing. From 2010 to 2012, she was a Managing Director and Co-Head, Private Equity of the Marwood Group. Additionally, since 2000, Diane has been a partner and principal at CCP Equity Partners (\\u201cCCP\\u201d) and its predecessor firm, Conning Capital Partners, where she invested in growth companies that offer specialized solutions for the financing, management and delivery of health care in industries such as managed care, disease and care management, outpatient services, information technology and healthcare-related ancillary and outsourcing services. Prior to joining CCP in 2000, she held a senior development role at Mariner Health, a post acute care company, where she worked with operating management to develop the strategies and structures for physician practice management acquisitions and joint ventures. Prior to Mariner, Diane held senior operating roles at Medical Care America (MCA), one of the largest operators of free standing ambulatory surgery centers at that time.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Diane currently sits on the Board of directors of TripleCare, CleanSlate Addiction Treatment Centers, QualDerm Partners, Prism Education Group, the Tuck School\\u2019s MBA Advisory Board and The Healthcare Private Equity Association (HCPEA). She was previously on the Board of directors of Cogent Healthcare, Relay Health, Zoologic and an observer for Evolution Benefits and Vantage Oncology. She also previously sat on the Board of directors of the Women\\u2019s Association of Venture and Equity (WAVE), and she is a past president of the Hartford Chapter of the Connecticut Venture Group and sat on its statewide Board for several years. She received an MBA from the Tuck School at Dartmouth College and a BA in Economics from Lehigh University.<\\/p>\",\"57\":{\"54\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"96\"],\"109\":\"Partner\",\"80\":\"<p>Diane has over 25 years of investing, advisory and operating experience, with over 20 years focused on the healthcare services industry.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:33:49', '2016-07-11 20:33:49', '421d45f4-2ae4-417b-b9b2-21e10dacdb5b'),
 ('159', '57', '12', '1', 'en_us', '7', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"David J. McIntyre\",\"slug\":\"david-j-mcintyre\",\"postDate\":1466183580,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"92\"],\"56\":\"<p>David has over 20 years of experience as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries, including medical devices. With professional qualifications in finance and law, David has held senior financial, legal and operational roles.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>More recently, David was Executive Vice President, Chief Financial Officer of HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) from 2005 through 2011, and assumed the additional responsibilities of Chief Operating Officer during HeartWare\\u2019s global commercialization phase for the period from 2008 through 2011.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Prior to HeartWare, David practiced as a senior attorney in private practice specializing in corporate, mergers and acquisitions and equity capital markets with Baker & McKenzie and KPMG as well as holding various senior financial roles in multi-national companies including Coal & Allied Limited, a publicly traded subsidiary of the Rio Tinto Group of companies.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>David holds a Bachelor of Economics (Accounting) from the University of Sydney (Australia), a Bachelor of Law from the University of Technology, Sydney (Australia) and a Masters of Business Administration (Fuqua Scholar) from Duke University. He is also a Certified Practicing Accountant (CPA) and is admitted as a Legal Practitioner of the Supreme Court of New South Wales (in Australia).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Board responsibilities include: VytronUS, QualDerm, Tusker Medical, Braeburn Pharmaceuticals, Gala Therapeutics and previously Tendyne (acquired by Abbott).<\\/p>\",\"57\":{\"58\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"97\"],\"109\":\"Partner\",\"80\":\"<p>David has over 20 years of experience as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries, including medical devices.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:39:19', '2016-07-11 20:39:19', '33d450bb-2103-4434-8a7f-e343b20244ca'),
 ('160', '99', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Lauren Farrell\",\"slug\":\"lauren-farrell\",\"postDate\":1468263900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":\"\",\"56\":\"<p>Lauren has over 20 years accounting and finance experience including roles in public accounting, financial management and reporting, and strategic financial consulting across multiple industries. Prior to joining Apple Tree Partners, Lauren was Vice President and Chief Accounting Officer at HeartWare International, Inc. (NASDAQ:HTWR) from 2006 to 2013, where she led the Company\\u2019s financial management and reporting activities. From 2005 to 2006, Lauren was Chief Financial Officer at Ambient Corporation. From January 2001 to July 2004, Lauren served as Vice President at Bingham Strategic Advisors providing M&A advisory services.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Lauren is a Certified Public Accountant and holds a Bachelors of Science in Accounting and a Masters of Business Administration from Bentley University.<\\/p>\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Chief Financial Officer\",\"80\":\"<p>Lauren has over 20 years accounting and finance experience including roles in public accounting, financial management and reporting, and strategic financial consulting across multiple industries.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:39:34', '2016-07-11 20:39:34', '1c423fdf-d1cd-4e98-ba79-7cdcc30934fc'),
 ('161', '102', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Julie Gionfriddo\",\"slug\":\"julie-gionfriddo\",\"postDate\":1468264020,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"89\"],\"56\":\"<p>Julie Gionfriddo joined Apple Tree Partners in 2014 and has spent nearly 18 years prior focused on private equity. Prior to joining Apple Tree, Julie was a vice president within the private equity secondary group at Landmark Partners, where she was involved in transaction origination, underwriting, and negotiation of private equity investments, as well as investor relations and marketing.<\\/p>\\r\\n\\r\\n<p>Julie serves on the board of directors for the Women\\u2019s Association of Venture and Equity. Julie also serves on the Board of Fellows and the Women\\u2019s Leadership Council for Trinity College. She received her BA and MA in Economics from Trinity College.<\\/p>\",\"57\":\"\",\"110\":[\"96\"],\"109\":\"Principal\",\"80\":\"<p>Julie Gionfriddo joined Apple Tree Partners in 2014 and has spent nearly 18 years prior focused on private equity<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:40:01', '2016-07-11 20:40:01', 'bf1bee69-8b2f-4bf4-90d8-cd0dc5886bcb'),
 ('162', '102', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Julie Gionfriddo\",\"slug\":\"julie-gionfriddo\",\"postDate\":1468264020,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"89\"],\"56\":\"<p>Julie Gionfriddo joined Apple Tree Partners in 2014 and has spent nearly 18 years prior focused on private equity. Prior to joining Apple Tree, Julie was a vice president within the private equity secondary group at Landmark Partners, where she was involved in transaction origination, underwriting, and negotiation of private equity investments, as well as investor relations and marketing.<\\/p>\\r\\n\\r\\n<p>Julie serves on the board of directors for the Women\\u2019s Association of Venture and Equity. Julie also serves on the Board of Fellows and the Women\\u2019s Leadership Council for Trinity College. She received her BA and MA in Economics from Trinity College.<\\/p>\",\"57\":\"\",\"110\":[\"96\"],\"109\":\"Principal\",\"80\":\"<p>Julie Gionfriddo joined Apple Tree Partners in 2014 and has spent nearly 18 years prior focused on private equity<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:40:04', '2016-07-11 20:40:04', 'c7948256-cbb0-410b-94d2-bdd3f943014f'),
 ('163', '105', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Sam Hall, Ph.D.\",\"slug\":\"sam-hall\",\"postDate\":1468264320,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Sam Hall has experience in the life sciences across roles as a private equity investor, investment banker and basic scientist. Prior to joining Apple Tree in 2013, he was a researcher at the University of Cambridge in the UK, where his work focused on novel therapeutic strategies for autoimmune diseases. Previously, Sam was a member of the investment team at Symphony Capital, a private equity firm dedicated to investments in biopharmaceutical development. Prior to Symphony, he served as a member of the healthcare investment banking team at Citigroup, where he advised leading biotechnology, medical device and healthcare services businesses on numerous completed strategic and debt and equity financing engagements.<\\/p>\\r\\n\\r\\n<p>Sam holds an A.B. in Molecular Biology from Princeton University and completed his M.Phil. and Ph.D. research at the University of Cambridge, where he was a Taylor Research Scholar and was awarded an NSF Graduate Research Fellowship for his work.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Board responsibilities include: Syntimmune (Director), Stoke Therapeutics (Director).<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Principal\",\"80\":\"<p>Sam Hall has experience in the life sciences across roles as a private equity investor, investment banker and basic scientist.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:40:14', '2016-07-11 20:40:14', 'dcc1e7bc-ebda-4d2d-8d52-5a5f00b8d778'),
 ('164', '106', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Aaron Kantoff\",\"slug\":\"aaron-kantoff\",\"postDate\":1468264380,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Aaron has significant early and late-stage biotech experience, serving financial analysis and restructuring. Prior to joining Apple Tree in 2011, Aaron was a partner at Recess Global, LLC, an investment company, focused on funding startups. Prior to starting Recess Global, LLC, Aaron was a member of the investment banking team at Rothschild Inc., in the Restructuring Group. Selected transactions that he worked on at Rothschild, Inc. include: advising the U.S Treasury on restructuring of Chrysler Group, LLC; assisting Milacron Inc. with the Section 363 sale of assets; working with Delphi Automotive on its in-court Chapter 11 bankruptcy; developing the Penton Media \\\"Pre-packaged\\\" Chapter 11 filing. In addition to his role with Apple Tree, Aaron has also served as Executive Director of Business Development & Corporate Strategy of Braeburn Pharmaceuticals.<\\/p>\\r\\n\\r\\n<p>Aaron holds a Bachelor of Science in Finance and International Business from the New York University Stern School of Business.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Board responsibilities include: Cure Forward (Director), Corvidia (Board Observer), and Syntimmune (Board Observer).<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Principal\",\"80\":\"<p>Aaron has significant early and late-stage biotech experience, serving financial analysis and restructuring.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:40:23', '2016-07-11 20:40:23', '510eeae2-5862-4c60-ba1e-3a7ca4d52705'),
 ('165', '108', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Keting Chu, MD, Ph.D.\",\"slug\":\"keting-chu\",\"postDate\":1468264500,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Keting Chu joined Apple Tree Partners in 2016 as a Venture Partner. Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture philanthropy.<\\/p>\\r\\n\\r\\n<p>Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS). There she was responsible for venture philanthropy, also known as the Therapy Acceleration program. At LLS, Keting led the investment of Celator, Stemline, Constellation, Affimed, arGen-X, Kite Pharma, Kiadis, OncoPepe, Valor and a number of projects within academic institutions. Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc. Prior to co-founding DigitAB, Keting was the Co-Founder and CEO of BioCubed Corporation, Vice President of Biology and Head of R&D at Five Prime Therapeutics during its founding stage and the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical and clinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Keting received her MD in Sun Yat-sen Medical University specialized in infectious diseases in China, Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF). She also conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Venture Partner\",\"80\":\"<p>Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture philanthropy.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:40:35', '2016-07-11 20:40:35', '9ec3e8ae-4e57-4793-981a-15f99f676c60'),
 ('166', '107', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Jonathan Waldstreicher, MD\",\"slug\":\"jonathan-waldstreicher-md\",\"postDate\":1468264500,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"92\"],\"56\":\"<p>Jonathan Waldstreicher joined Apple Tree in 2013 to invest in medical devices. After incubating an interventional pulmonary technology for two years, Jon founded Gala Therapeutics in Silicon Valley and assumed the CEO role to further its development.<\\/p>\\r\\n\\r\\n<p>Prior to joining Apple Tree, Jon was a Director, Global Surgery R&D, at Johnson & Johnson where he initiated and led an investment strategy and R&D development program in a new growth platform technology area. He started at Johnson & Johnson as an Associate Director in the Corporate Office of Science & Technology where he executed numerous seed grants to startup companies and participated in technical diligence of venture capital investments. Before medical school, Jon worked in Equity Research at Bear Stearns.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Jon received a B.A. from Brandeis University in Economics and an M.D. and M.B.A. from Tufts University School of Medicine where he was awarded the Norman Stearns award for highest achievement and overall excellence within the dual degree program. Between his third and fourth year of medical school, Jon worked as a fellow at the Corporate Office of Science & Technology at J&J. He completed a General Surgery Internship at Tufts Medical Center in Boston.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Board responsibilities include: Gala Therapeutics, VytronUS (Board Observer).<\\/p>\",\"57\":\"\",\"110\":[\"97\"],\"109\":\"Principal\",\"80\":\"<p>Jonathan Waldstreicher joined Apple Tree in 2013 to invest in medical devices.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:40:45', '2016-07-11 20:40:45', '167dc836-e24e-4e1d-9740-d4213b562098'),
 ('167', '109', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Paul DaSilva-Jardine, Ph.D.\",\"slug\":\"paul-dasilva-jardine\",\"postDate\":1468269000,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Paul DaSilva-Jardine joined Apple Tree Partners in 2016 as a Venture Partner. Paul has over 25 years of drug discovery and development experience in the Cardiovascular, Metabolic and Endocrine diseases space. Prior to joining Apple Tree, Paul spent over 25 years at Pfizer Research and Development where he participated in the discovery and development of over fifty drug candidates including the first, lasofoxifene, a SERM which received authorization from European Medicines Agency. Paul held various leadership positions at Pfizer R&D including Vice President, Head of CVMED Chemistry, and Vice President in the CVMED Research Unit which was responsible for drug development from Idea to Phase 2 Proof of Concept.<\\/p>\\r\\n\\r\\n<p>Paul earned his PhD and completed post-doctoral studies in Synthetic Organic Chemistry with Professor Corey at Harvard University.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Venture Partner\",\"80\":\"<p>Paul has over 25 years of drug discovery and development experience in the Cardiovascular, Metabolic and Endocrine diseases space.&nbsp;<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:40:53', '2016-07-11 20:40:53', '1edcebd9-c8e0-4296-822c-11799d67ba31'),
 ('168', '113', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Behshad Sheldon\",\"slug\":\"behshad-sheldon\",\"postDate\":1468269871,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Behshad has more than 25 years of experience leading pharmaceutical development and commercialization in the United States and globally. She currently also serves as the President and Chief Executive Officer of Braeburn Pharmaceuticals, a portfolio company of Apple Tree Partners. Prior to joining Braeburn, Behshad spent 10 years at Otsuka Pharmaceuticals, having co-founded the Otsuka Princeton office in 2002. Ms. Sheldon last served as a member of the board of directors of the Otsuka R&D organization, contributing to the oversight of 18 pre-approval programs for 13 products in CNS, cardio-renal, pain, dermatology, and oncology. Simultaneously, she served as senior vice president, patient & branding strategy in the commercial organization, where she was responsible for global and United States marketing, alliance management, and early development strategy. Prior to Otsuka, Behshad held positions with increasing responsibility at SmithKline Beecham and Bristol-Myers Squibb. Throughout her 27-year career, Behshad has driven the success of blockbuster products such as Glucophage, Plavix, and Abilify, and has contributed to several strategic alliances and acquisitions, including the landmark 2011 agreement between Otsuka and Lundbeck involving 5 CNS products. Behshad holds a BS degree in Neuroscience from the University of Rochester.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Board responsibilities include: CleanSlate Addiction Treatment Centers (Board Observer).<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Venture Partner\",\"80\":\"<p>Behshad has more than 25 years of experience leading pharmaceutical development and commercialization in the United States and globally.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:44:31', '2016-07-11 20:44:31', 'e2bb1de2-8a1b-454c-89b0-5e087fac046a'),
 ('169', '114', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Mikael Dolsten, MD, Ph.D.\",\"slug\":\"mikael-dolsten\",\"postDate\":1468269973,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":\"\",\"56\":\"<p>Mikael Dolsten, M.D., Ph.D. became the Chairman of Apple Tree Partner\\u2019s Translational Advisory Board in 2016. Mikael is currently the President of Pfizer Worldwide Research and Development (WRD) and Executive Vice President of Pfizer Inc. Dr. Dolsten is also a member of the Pfizer Executive Leadership Team and co-chairs the company\\u2019s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities.<\\/p>\\r\\n\\r\\n<p>Prior to joining Pfizer in 2009, Dr. Dolsten was President of Wyeth Research responsible for global research and development activities. Before joining Wyeth, he served as Executive Vice President for Worldwide Research at Boehringer Ingelheim. His earlier career as a research leader included VP leadership positions with AstraZeneca, Pharmacia and Upjohn. Mikael has also served as a Private Equity partner at Orbimed, the world\\u2019s largest healthcare focused investment company. In addition, he gained leadership experience from five large-scale M&A transactions.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Mikael is a governor of the New York Academy of Sciences, a member of the board of Karyopharm Therapeutics Inc., a member of the Biomedical Advisory Council of The Pharmaceutical Research and Manufacturers of America (PhRMA), co-lead for the industry-NIH Accelerating Medicine Partnership (AMP) Executive Committee and serves on the PhRMA Foundation Board of Directors. He has been a board member of a Swedish Business School for Innovation and Chamber of Commerce. Dr. Dolsten is a named inventor on several patents and has published approximately 150 articles in international journals, with particular contributions in areas such as molecular cell biology, immunology and oncology.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Dr. Dolsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund, Sweden.<\\/p>\",\"57\":\"\",\"110\":\"\",\"109\":\"Chairman, Translational Advisory Board\",\"80\":\"<p>Mikael is currently the President of Pfizer Worldwide Research and Development (WRD) and Executive Vice President of Pfizer Inc.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:46:13', '2016-07-11 20:46:13', '2d06ad98-4053-4469-b06e-e42a57fdfd4c'),
 ('170', '116', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Amir Abolfathi\",\"slug\":\"amir-abolfathi\",\"postDate\":1468270057,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"92\"],\"56\":\"<p>Amir has over 26 years of operating experience in the healthcare industry focused on developing and commercializing cardiovascular devices, dental products, hearing prosthetics, and genomic diagnostics & analytics. Amir was the inventor and founder of Sonitus Medical in 2006, a novel non-surgical hearing prosthetic designed for treatment of unilateral deafness, and Sonitus Technologies in 2010, which is currently developing the first truly covert two-way communication device.<\\/p>\\r\\n\\r\\n<p>Prior to Sonitus, Amir served for six years as an Officer, Executive Vice President of R&D at Align Technology Inc. (NASDAQ: ALGN), creators of a unique, invisible orthodontic product called Invisalign. Previously, Amir was the first member of the senior management team at Embolic Protection Inc., where he was a consulting VP of Operations. EPI was successfully acquired by Boston Scientific in 2001.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>In early 1995, Amir co-founded EndoTex Interventional Systems, developers of minimally invasive solutions for treatment of carotid artery disease, which was also acquired by Boston Scientific in 2006. Amir has also held various management and engineering positions at Pfizer, Guidant, and Baxter-Edwards. He has over 100+ issued patents. Cleveland Clinic Foundation and Popular Science recognized one of his inventions as Top 10 Inventions of the Year in 2010.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Amir currently sits on the Board of Directors of Sonitus Technologies and Rodo Medical. He is also a business adviser to Guardant Health. He was previously on the Board of Directors of NextBio, acquired by Illumina in 2013, and an adviser to On-Pharma, acquired by Valeant Pharmaceutical in 2014.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Amir received a MS in Engineering Management from University of Southern California and BS in Biomedical Engineering from University of California, San Diego. He is a member of the University of California, San Diego Jacobs School Council of Advisers.<\\/p>\",\"57\":\"\",\"110\":[\"97\"],\"109\":\"Entrepreneur-in-Residence, Ear, Nose & Throat\",\"80\":\"<p>Amir has over 26 years of operating experience in the healthcare industry focused on developing and commercializing cardiovascular devices, dental products, hearing prosthetics, and genomic diagnostics & analytics.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:47:37', '2016-07-11 20:47:37', '4b077895-e365-41cf-be3d-f0a1a4d8a6e0'),
 ('171', '123', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Andreas Loew, Ph.D.\",\"slug\":\"andreas-loew\",\"postDate\":1468270575,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Andreas Loew is an Entrepreneur-in-Residence focused on creating novel biotherapeutics to combat cancer and auto-immune disease. Andreas has over fifteen years of experience in the biopharmaceutical industry, most recently as the global head of new technologies in the biologics center at the Novartis Institutes for Biomedical Research (NIBR). At NIBR, Andreas established a group to lead drug discovery efforts in multiple disease indications across a large spectrum of biotherapeutics including multi-specific antibodies, therapeutic proteins and chimeric antigen receptors (CARs). Prior to joining Novartis, Andreas provided structure-based drug design support at Abbott both for small molecules and anti-body based therapies including HUMIRA\\u00ae.<\\/p>\\r\\n\\r\\n<p>Andreas earned his master degrees in Chemistry at the University of Kaiserslautern, Germany and a PhD degree in Biochemistry at the University of Bayreuth, Germany. He conducted post-doctoral research in protein biochemistry and x-ray structural biology in Yee-Kin Ho\\u2019s laboratory at the University of Illinois, Chicago, at Steven Sprang\\u2019s laboratory at the University of Texas, Medical Center, Dallas and in Tom Blundell\\u2019s laboratory at Birkbeck College, London, UK.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Entrepreneur-in-Residence, Biotherapeutics\",\"80\":\"<p>Andreas Loew is an Entrepreneur-in-Residence focused on creating novel biotherapeutics to combat cancer and auto-immune disease.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:56:15', '2016-07-11 20:56:15', 'f420d96b-fe88-4e37-a392-e7c3ab748d75'),
 ('172', '125', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Chris Cain, Ph.D.\",\"slug\":\"chris-cain\",\"postDate\":1468270718,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Chris joined Apple Tree Partners in 2016 as an Associate focused on therapeutics. Prior to joining Apple Tree Partners, Chris was an Associate at RA Capital Management, LLC, a crossover fund invested in healthcare and the life sciences. Previously, Chris was a writer and editor at BioCentury Publications and the Science-Business eXchange (SciBX), a translational science journal co-published with Nature Publishing Group, where he evaluated the clinical and commercial potential of novel molecular targets and drug platforms emerging from academic labs. Prior to BioCentury, Chris was a researcher at the University of California, San Francisco, where his work focused on understanding the transcriptional regulation and evolution of morphological change in fungi including the pathogen Candida albicans.<\\/p>\\r\\n\\r\\n<p>Chris holds a B.A. in Biology from the University of California, Santa Barbara, College of Creative Studies. He earned his Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco, where he was awarded a Genentech Graduate Fellowship.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Associate\",\"80\":\"<p>Chris joined Apple Tree Partners in 2016 as an Associate focused on therapeutics.<\\/p>\",\"104\":\"\"}}', '2016-07-11 20:58:38', '2016-07-11 20:58:38', 'c9f42fb3-d1b2-41a0-814a-89e0660f8f71'),
 ('173', '126', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Jernej Godec, Ph.D.\",\"slug\":\"jernej-godec-ph-d\",\"postDate\":1468270805,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Jernej joined Apple Tree Partners in 2016 as an Associate focused on therapeutics. His work focuses on the development of breakthrough companies with transformative therapies. Prior to joining Apple Tree Partners, he completed his doctorate in Immunology at Harvard University. He was jointly mentored by Arlene Sharpe at Harvard Medical School and Nicholas Haining at the Dana-Farber Cancer Institute, where he studied how co-inhibitory receptors and transcriptional programs orchestrate differentiation of cytotoxic T lymphocytes. He published his work in top peer-reviewed journals, including&nbsp;<em>Cell<\\/em>,&nbsp;<em>Immunity<\\/em>, and<em>Nature Immunology<\\/em>. While at Harvard, he was also on the leadership board of the Harvard Biotechnology Club.<\\/p>\\r\\n\\r\\n<p>While in graduate school, Jernej co-founded Mifcor, a biotechnology company focused on developing new therapies for ischemic disease. As the co-founder and CSO, he successfully helped raise funding and lead the scientific strategy for preclinical drug development. Concurrently, he completed the Flagship VentureLabs fellows program and during the last year of his doctorate continued working with Flagship Ventures. As a consultant, he assisted in developing innovative concepts with accompanying intellectual property, marketable products, and founding strategy for new companies.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Jernej received his B.A. with honors in Molecular and Cell Biology at the University of California at Berkeley where his research focused on innate immunity and bacterial pathogenesis. During his time at Cal, he was an All-American student-athlete in swimming and competed in two Olympic Games for his home country of Slovenia.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Associate\",\"80\":\"<p>Jernej\'s&nbsp;work focuses on the development of breakthrough companies with transformative therapies.<\\/p>\",\"104\":\"\"}}', '2016-07-11 21:00:05', '2016-07-11 21:00:05', 'b1470be3-05ea-408a-823d-4df31b15f77b'),
 ('174', '127', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Stephanie Papes\",\"slug\":\"stephanie-papes\",\"postDate\":1468270884,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"89\"],\"56\":\"<p>Stephanie joined Apple Tree Partners in 2014 as an Associate focused on healthcare services and IT investments. Prior to joining Apple Tree Partners, Stephanie was as an Investment Banking Analyst in the Financial Sponsors Group of Wells Fargo Securities in San Francisco, CA and New York, NY. In this role, she was responsible for supporting the leveraged finance origination process for private equity transactions. Stephanie previously worked within Duke University Health System, where she assisted in the initial implementation stages of a $500 million EHR rollout and on a pilot program for an innovative bundled payment model, among other projects. She also worked in Washington, DC during the passing of the Affordable Care Act, where she served health systems in government funding requests and health policy consulting.<\\/p>\\r\\n\\r\\n<p>Stephanie graduated from Duke University with highest distinction in studies of Public Policy, Economics and Biology. She was a Civic Engagement Scholar, Dean\\u2019s Research Fellow, South Asian Studies Fellow and Sanford School of Public Policy Grant Recipient. Stephanie\'s Honors thesis focused on provider financial incentives in rural India, and she continues to conduct international nonprofit work in Delhi and West Bengal.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Board responsibilities include: CleanSlate (Board Observer), TripleCare (Board Observer), QualDerm (Board Observer), Cure Forward (Director).<\\/p>\",\"57\":\"\",\"110\":[\"96\"],\"109\":\"Associate\",\"80\":\"<p>Stephanie joined Apple Tree Partners in 2014 as an Associate focused on healthcare services and IT investments.<\\/p>\",\"104\":\"\"}}', '2016-07-11 21:01:24', '2016-07-11 21:01:24', '06189635-bcc0-4586-8355-ef1ac9894cac'),
 ('175', '128', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Joshua Sherman\",\"slug\":\"joshua-sherman\",\"postDate\":1468270981,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"92\"],\"56\":\"<p>Josh joined Apple Tree Partners in 2014 as an Associate focused on the Life Science, Pharmaceutical and Medical Device industries. He has a strong interest in the healthcare space and benefits greatly from his background in both science and finance.<\\/p>\\r\\n\\r\\n<p>Prior to joining Apple Tree Partners, Josh was an Analyst in the Healthcare Investment Banking Group at Barclays where he developed broad industry knowledge and M&A experience. He was also formerly an Analyst at Morgan Stanley in the Financial Institutions Group where he focused on transactions in the Insurance and Asset Management space.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Josh graduated from The University of Pennsylvania in 2012 earning dual-degrees as a member of the Vagelos Life Sciences & Management Program. He holds a B.S. in Economics (Concentration in Finance) from The Wharton School and a B.A. in Biology from The College of Arts and Sciences.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Josh grew up in New York City, is fluent in French, and enjoys travel and tennis.<\\/p>\",\"57\":\"\",\"110\":[\"97\"],\"109\":\"Associate\",\"80\":\"<p>Josh joined Apple Tree Partners in 2014 as an Associate focused on the Life Science, Pharmaceutical and Medical Device industries.<\\/p>\",\"104\":\"\"}}', '2016-07-11 21:03:01', '2016-07-11 21:03:01', 'a8dd5801-a178-4cff-b6c9-c8803de66733'),
 ('176', '12', '9', '1', 'en_us', '19', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"88\"],\"38\":\"<p>We start companies, or invest in existing companies, with commitments as high as $250 million; in this sense, we scale to the buy-out or growth equity level. But we take the long view, both as a matter of principle and for value creation. An ATP company may choose to sell in an M&A transaction, but only if the price is right, or may access the public markets, but only if advantageous to do so. This means our managers can build with confidence, knowing that we are funding them to grow and develop their businesses.<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Management\",\"teamImage\":[\"89\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"57\",\"55\",\"53\"]}},\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":[\"95\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":[\"92\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":[\"89\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\"]}}}}}', '2016-07-11 21:04:51', '2016-07-11 21:04:51', '84292dcb-22d4-4ee3-a294-726f299debe6'),
 ('179', '12', '9', '1', 'en_us', '20', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"88\"],\"38\":\"<p>We start companies, or invest in existing companies, with commitments as high as $250 million; in this sense, we scale to the buy-out or growth equity level. But we take the long view, both as a matter of principle and for value creation. An ATP company may choose to sell in an M&A transaction, but only if the price is right, or may access the public markets, but only if advantageous to do so. This means our managers can build with confidence, knowing that we are funding them to grow and develop their businesses.<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":[\"95\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"105\",\"106\",\"125\",\"126\",\"108\",\"109\",\"123\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":[\"92\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\",\"53\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":[\"89\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"55\"]}},\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Finance & Administration\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"57\",\"55\",\"53\"]}}}}}', '2016-07-11 21:09:49', '2016-07-11 21:09:49', '31574eea-cdbb-4619-8662-4a742c22da98'),
 ('190', '12', '9', '1', 'en_us', '21', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"88\"],\"38\":\"<p>We start companies, or invest in existing companies, with commitments as high as $250 million; in this sense, we scale to the buy-out or growth equity level. But we take the long view, both as a matter of principle and for value creation. An ATP company may choose to sell in an M&A transaction, but only if the price is right, or may access the public markets, but only if advantageous to do so. This means our managers can build with confidence, knowing that we are funding them to grow and develop their businesses.<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":[\"95\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"105\",\"106\",\"125\",\"126\",\"108\",\"109\",\"123\",\"113\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":[\"92\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"55\",\"57\",\"107\",\"128\",\"116\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":[\"89\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"53\",\"102\",\"127\"]}},\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Finance & Administration\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"99\"]}}}}}', '2016-07-11 21:23:47', '2016-07-11 21:23:47', 'f4a619a3-447f-4f6f-8ddb-b50a9b108e3e'),
 ('192', '141', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Kristin Howell\",\"slug\":\"kristin-howell\",\"postDate\":1468272267,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":\"\",\"56\":\"\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Fund Accountant\",\"80\":\"\",\"104\":\"\"}}', '2016-07-11 21:24:27', '2016-07-11 21:24:27', '84e41344-7566-42fc-ae8a-4228c26c443c'),
 ('193', '142', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Maja Nowak\",\"slug\":\"maja-nowak\",\"postDate\":1468272288,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":\"\",\"56\":\"\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Accounting Manager\",\"80\":\"\",\"104\":\"\"}}', '2016-07-11 21:24:48', '2016-07-11 21:24:48', '5a769924-c5f4-40f3-9a64-eccca88a1188'),
 ('194', '143', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Shivranie Singh\",\"slug\":\"shivranie-singh\",\"postDate\":1468272307,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":\"\",\"56\":\"\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Accounts Payable\",\"80\":\"\",\"104\":\"\"}}', '2016-07-11 21:25:07', '2016-07-11 21:25:07', 'caf7bcdc-e6d0-46c8-a273-aa91d2b6cbac'),
 ('196', '144', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Steph Lazarus\",\"slug\":\"steph-lazarus\",\"postDate\":1468272328,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":\"\",\"56\":\"\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Senior Executive Assistant\",\"80\":\"\",\"104\":\"\"}}', '2016-07-11 21:25:28', '2016-07-11 21:25:28', '02fd3955-52e3-4e82-9214-ca5f8b490fc0'),
 ('197', '145', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Lisa Cagney\",\"slug\":\"lisa-cagney\",\"postDate\":1468272355,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":\"\",\"56\":\"\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Executive Assistant (Therapeutics)\",\"80\":\"\",\"104\":\"\"}}', '2016-07-11 21:25:55', '2016-07-11 21:25:55', '628dd745-cf8e-4f43-9797-28556d249080'),
 ('198', '146', '12', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Salam Farhat\",\"slug\":\"salam-farhat\",\"postDate\":1468272371,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":\"\",\"56\":\"\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Executive Assistant (Medical Devices and Healthcare Services)\",\"80\":\"\",\"104\":\"\"}}', '2016-07-11 21:26:11', '2016-07-11 21:26:11', 'e04a8dca-d55d-463c-aa6f-85af6aff82de'),
 ('201', '12', '9', '1', 'en_us', '22', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"88\"],\"38\":\"<p>We start companies, or invest in existing companies, with commitments as high as $250 million; in this sense, we scale to the buy-out or growth equity level. But we take the long view, both as a matter of principle and for value creation. An ATP company may choose to sell in an M&A transaction, but only if the price is right, or may access the public markets, but only if advantageous to do so. This means our managers can build with confidence, knowing that we are funding them to grow and develop their businesses.<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":[\"95\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"105\",\"106\",\"125\",\"126\",\"108\",\"109\",\"123\",\"113\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":[\"92\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"55\",\"57\",\"107\",\"128\",\"116\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":[\"89\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"53\",\"102\",\"127\"]}},\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Finance & Administration\",\"teamImage\":\"\",\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"99\",\"141\",\"142\",\"143\",\"144\",\"145\",\"146\"]}}}}}', '2016-07-11 21:27:02', '2016-07-11 21:27:02', 'c5a8bcee-5802-48e5-9865-3049ba5d29aa'),
 ('208', '27', '13', '1', 'en_us', '8', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Aileron Therapeutics\",\"slug\":\"aileron-therapeutics\",\"postDate\":1465920840,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. ALRN-6924, in Phase 1, is a p53 re-activator for the treatment of cancer, the only p53 molecule in development that targets both MDM2 and MDMX.<\\/p>\",\"62\":{\"28\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.aileronrx.com\\/\",\"linkedin\":\"linkedin\"}}},\"130\":[\"95\"],\"66\":\"\",\"81\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide&nbsp;drug platform.<\\/p>\",\"103\":[\"70\"]}}', '2016-07-11 21:54:56', '2016-07-11 21:54:56', 'e4644df3-3fd0-4ec6-bfe5-f7d677446b0c'),
 ('210', '27', '13', '1', 'en_us', '9', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Aileron Therapeutics\",\"slug\":\"aileron-therapeutics\",\"postDate\":1465920840,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. ALRN-6924, in Phase 1, is a p53 re-activator for the treatment of cancer, the only p53 molecule in development that targets both MDM2 and MDMX.<\\/p>\",\"62\":{\"28\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.aileronrx.com\\/\",\"linkedin\":\"linkedin\"}}},\"130\":[\"95\"],\"66\":\"\",\"81\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide&nbsp;drug platform.<\\/p>\",\"103\":[\"70\"]}}', '2016-07-11 21:55:22', '2016-07-11 21:55:22', '92c2a13b-ad52-4673-8ec0-bb8a8b53b63b'),
 ('211', '200', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Braeburn Pharmaceuticals\",\"slug\":\"braeburn-pharmaceuticals\",\"postDate\":1468274207,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Braeburn Pharmaceuticals is developing a portfolio of long-acting therapeutic treatment options for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Long-acting implantable and injectable therapies can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. The current portfolio includes: Probuphine\\u00ae, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia.<\\/p>\",\"62\":\"\",\"130\":[\"95\"],\"66\":\"\",\"81\":\"<p>Braeburn Pharmaceuticals is developing a portfolio of long-acting therapeutic treatment options for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia.<\\/p>\",\"103\":\"\"}}', '2016-07-11 21:56:47', '2016-07-11 21:56:47', 'd9e756f2-bc9e-4cad-8437-4d64bb3cf705'),
 ('212', '200', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Braeburn Pharmaceuticals\",\"slug\":\"braeburn-pharmaceuticals\",\"postDate\":1468274160,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Braeburn Pharmaceuticals is developing a portfolio of long-acting therapeutic treatment options for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Long-acting implantable and injectable therapies can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. The current portfolio includes: Probuphine\\u00ae, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia.<\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"https:\\/\\/braeburnpharmaceuticals.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"95\"],\"66\":\"\",\"81\":\"<p>Braeburn Pharmaceuticals is developing a portfolio of long-acting therapeutic treatment options for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia.<\\/p>\",\"103\":\"\"}}', '2016-07-11 21:57:13', '2016-07-11 21:57:13', 'ef74f773-8938-44d7-8737-e8e16f96a171'),
 ('213', '204', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"CleanSlate Addiction Treatment Centers\",\"slug\":\"cleanslate-addiction-treatment-centers\",\"postDate\":1468274320,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania. CleanSlate provides medication-assisted treatment and related therapies using the highest quality, evidence-based practices for patients who have addiction and associated disorders.<\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/cleanslatecenters.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"89\"],\"66\":[\"203\"],\"81\":\"<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania.&nbsp;<\\/p>\",\"103\":\"\"}}', '2016-07-11 21:58:40', '2016-07-11 21:58:40', 'c1e34187-1e96-42e8-adef-cb66f5b9a175'),
 ('214', '27', '13', '1', 'en_us', '10', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Aileron Therapeutics\",\"slug\":\"aileron-therapeutics\",\"postDate\":1465920840,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. ALRN-6924, in Phase 1, is a p53 re-activator for the treatment of cancer, the only p53 molecule in development that targets both MDM2 and MDMX.<\\/p>\",\"62\":{\"28\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.aileronrx.com\\/\",\"linkedin\":\"linkedin\"}}},\"130\":[\"95\"],\"66\":[\"218\"],\"81\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide&nbsp;drug platform.<\\/p>\",\"103\":[\"70\"]}}', '2016-07-11 22:01:17', '2016-07-11 22:01:17', '12534a78-7b07-4668-b5ce-b21e65fd8b42'),
 ('215', '200', '13', '1', 'en_us', '3', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Braeburn Pharmaceuticals\",\"slug\":\"braeburn-pharmaceuticals\",\"postDate\":1468274160,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Braeburn Pharmaceuticals is developing a portfolio of long-acting therapeutic treatment options for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Long-acting implantable and injectable therapies can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. The current portfolio includes: Probuphine\\u00ae, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia.<\\/p>\",\"62\":{\"201\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"https:\\/\\/braeburnpharmaceuticals.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"95\"],\"66\":[\"221\"],\"81\":\"<p>Braeburn Pharmaceuticals is developing a portfolio of long-acting therapeutic treatment options for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia.<\\/p>\",\"103\":\"\"}}', '2016-07-11 22:01:26', '2016-07-11 22:01:26', '28e5835f-9bdf-40d3-a243-3722bac4ecab'),
 ('216', '204', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"CleanSlate Addiction Treatment Centers\",\"slug\":\"cleanslate-addiction-treatment-centers\",\"postDate\":1468274280,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania. CleanSlate provides medication-assisted treatment and related therapies using the highest quality, evidence-based practices for patients who have addiction and associated disorders.<\\/p>\",\"62\":{\"205\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/cleanslatecenters.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"89\"],\"66\":[\"203\"],\"81\":\"<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania.&nbsp;<\\/p>\",\"103\":\"\"}}', '2016-07-11 22:02:16', '2016-07-11 22:02:16', '74510be1-214a-48ef-8cad-1b68cc891df7'),
 ('218', '229', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"http:\\/\\/www.appletreepartners.com\\/portfolio\\/detail\\/coelacanth-acquired-by-lexicon-genetics\",\"slug\":\"http-www-appletreepartners-com-portfolio-detail-coelacanth-acquired-by-lexicon-genetics\",\"postDate\":1468274603,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \\\"click\\\" chemistry.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Lexicon Genetics July 2001<\\/em><\\/p>\",\"62\":\"\",\"130\":\"\",\"66\":[\"215\"],\"81\":\"<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \\\"click\\\" chemistry.<\\/p>\",\"103\":\"\"}}', '2016-07-11 22:03:23', '2016-07-11 22:03:23', '85cc645c-0f31-4f0b-8241-b726310189bf'),
 ('220', '229', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Coelacanth Chemical Corporation\",\"slug\":\"http-www-appletreepartners-com-portfolio-detail-coelacanth-acquired-by-lexicon-genetics\",\"postDate\":1468274580,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \\\"click\\\" chemistry.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Lexicon Genetics July 2001<\\/em><\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.lexicon-genetics.com\\/\",\"linkedin\":\"\"}}},\"130\":\"\",\"66\":[\"215\"],\"81\":\"<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \\\"click\\\" chemistry.<\\/p>\",\"103\":\"\"}}', '2016-07-11 22:03:47', '2016-07-11 22:03:47', '7fb711f4-2686-4f56-b005-6bcf5cbfc7ee'),
 ('227', '239', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Corvidia\",\"slug\":\"corvidia\",\"postDate\":1468275699,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company has identified mechanistically-driven responder populations in a variety of cardio-metabolic and cardio-renal disorders.<\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/corvidiatx.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"95\"],\"66\":[\"209\"],\"81\":\"<p>Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies.<\\/p>\",\"103\":\"\"}}', '2016-07-11 22:21:39', '2016-07-11 22:21:39', '0a83f224-7544-49d2-a47a-1b60e9aee5eb'),
 ('230', '13', '10', '1', 'en_us', '9', '', '{\"typeId\":\"10\",\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1466010801,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"19\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseImage\":[\"95\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\",\"200\",\"239\"]}},\"20\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseImage\":[\"92\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\"]}},\"21\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseImage\":[\"89\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"204\"]}},\"22\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Legacy Investments\",\"expertiseImage\":[\"90\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"229\"]}}}}}', '2016-07-11 22:28:17', '2016-07-11 22:28:17', '047f0c07-097f-4193-ba39-f98a4aad1c81'),
 ('231', '242', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Gala Therapeutics\",\"slug\":\"gala-therapeutics\",\"postDate\":1468276159,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Gala Therapeutics is an early stage medical device company developing a novel catheter based approach to treating pulmonary disease including chronic bronchitis, COPD, and asthma.<\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.galatherapeutics.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"92\"],\"66\":[\"222\"],\"81\":\"<p>Gala Therapeutics is an early stage medical device company developing a novel catheter based approach to treating pulmonary disease including chronic bronchitis, COPD, and asthma.<\\/p>\",\"103\":\"\"}}', '2016-07-11 22:29:19', '2016-07-11 22:29:19', 'c0a5dbb0-1baf-42fc-a4d0-eac8e4db55ec'),
 ('232', '13', '10', '1', 'en_us', '10', '', '{\"typeId\":\"10\",\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1466010801,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"19\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseImage\":[\"95\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"27\",\"200\",\"239\"]}},\"20\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseImage\":[\"92\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"242\"]}},\"21\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseImage\":[\"89\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"204\"]}},\"22\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Legacy Investments\",\"expertiseImage\":[\"90\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"company\":[\"229\"]}}}}}', '2016-07-11 22:30:41', '2016-07-11 22:30:41', '60261d44-cd73-4a96-bc80-03e5fd1672ab'),
 ('233', '244', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Cure Forward\",\"slug\":\"cure-forward\",\"postDate\":1468276510,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Cure Forward connects cancer patients with clinical trial administrators working to reduce trial recruitment times and increase participation. Cure Forward\\u2019s online portal, in addition to providing access to clinical trials, can also help patients retrieve molecular diagnostic test results ordered by physicians, access educational information, connect with other patients, and investigate treatment options.<\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"https:\\/\\/www.cureforward.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"89\"],\"66\":[\"225\"],\"81\":\"<p>Cure Forward connects cancer patients with clinical trial administrators working to reduce trial recruitment times and increase participation.<\\/p>\",\"103\":\"\"}}', '2016-07-11 22:35:11', '2016-07-11 22:35:11', '72ce7686-18d5-4391-8407-87b108efcb42'),
 ('234', '246', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Cyrano Sciences\",\"slug\":\"cyrano-sciences\",\"postDate\":1468276571,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>An electronic nose for homeland defense applications.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Smiths Detection March 2004<\\/em><\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.smithsdetection.com\\/\",\"linkedin\":\"\"}}},\"130\":\"\",\"66\":[\"212\"],\"81\":\"<p>An electronic nose for homeland defense applications.<\\/p><p><em>Acquired by Smiths Detection March 2004<\\/em><br><\\/p>\",\"103\":\"\"}}', '2016-07-11 22:36:11', '2016-07-11 22:36:11', '5288dfae-2868-46d6-9059-d299d8f3a440'),
 ('235', '248', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Gloucester Pharmaceuticals\",\"slug\":\"gloucester-pharmaceuticals\",\"postDate\":1468276668,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Creators of ISTODAX\\u00ae (romidepsin) for T-cell lymphoma and other malignancies.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Celgene January 2010<\\/em><\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.celgene.com\\/\",\"linkedin\":\"\"}}},\"130\":\"\",\"66\":[\"214\"],\"81\":\"<p>Creators of ISTODAX\\u00ae (romidepsin) for T-cell lymphoma and other malignancies.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Celgene January 2010<\\/em><\\/p>\",\"103\":\"\"}}', '2016-07-11 22:37:48', '2016-07-11 22:37:48', '57c0bb70-1e32-4ba9-8211-05e5bd9b295f'),
 ('236', '250', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"HeartWare International\",\"slug\":\"heartware-international\",\"postDate\":1468276809,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"\",\"62\":\"\",\"130\":\"\",\"66\":\"\",\"81\":\"\",\"103\":\"\"}}', '2016-07-11 22:40:09', '2016-07-11 22:40:09', '07d17c94-d53d-4d12-82f1-6ed324c76884'),
 ('240', '239', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Corvidia\",\"slug\":\"corvidia\",\"postDate\":1468275660,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company has identified mechanistically-driven responder populations in a variety of cardio-metabolic and cardio-renal disorders.<\\/p>\",\"62\":{\"240\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/corvidiatx.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"95\"],\"66\":[\"265\"],\"81\":\"<p>Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies.<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:39:31', '2016-07-11 23:39:31', 'f09983f5-4e6b-480d-8b2c-44ec148daaa8'),
 ('241', '248', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Gloucester Pharmaceuticals\",\"slug\":\"gloucester-pharmaceuticals\",\"postDate\":1468276620,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Creators of ISTODAX\\u00ae (romidepsin) for T-cell lymphoma and other malignancies.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Celgene January 2010<\\/em><\\/p>\",\"62\":{\"249\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.celgene.com\\/\",\"linkedin\":\"\"}}},\"130\":\"\",\"66\":[\"264\"],\"81\":\"<p>Creators of ISTODAX\\u00ae (romidepsin) for T-cell lymphoma and other malignancies.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Celgene January 2010<\\/em><\\/p>\",\"103\":\"\"}}', '2016-07-11 23:39:51', '2016-07-11 23:39:51', '42c30c0f-e8d5-4e4e-979b-f8a6d53c82b2'),
 ('243', '250', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"HeartWare International\",\"slug\":\"heartware-international\",\"postDate\":1468276800,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>HeartWare (HTWR)develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.<\\/p>\\r\\n\\r\\n<p><em>IPO January 2005 ASX; listed on NASDAQ September 2013<\\/em><\\/p>\\r\\n\\r\\n\",\"62\":\"\",\"130\":\"\",\"66\":[\"263\"],\"81\":\"<p>HeartWare (HTWR)develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:40:43', '2016-07-11 23:40:43', '8b8a2ce4-574b-42ff-961d-8773b860e065'),
 ('244', '250', '13', '1', 'en_us', '3', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"HeartWare International\",\"slug\":\"heartware-international\",\"postDate\":1468276800,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>HeartWare (HTWR)develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.<\\/p>\\r\\n\\r\\n<p><em>IPO January 2005 ASX; listed on NASDAQ September 2013<\\/em><\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.heartware.com\\/\",\"linkedin\":\"\"}}},\"130\":\"\",\"66\":[\"263\"],\"81\":\"<p>HeartWare (HTWR)develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:41:01', '2016-07-11 23:41:01', 'b8fd9785-080d-40fe-b469-1caaa93fa8a4');
INSERT INTO `craft_entryversions` (`id`, `entryId`, `sectionId`, `creatorId`, `locale`, `num`, `notes`, `data`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('245', '27', '13', '1', 'en_us', '11', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Aileron Therapeutics\",\"slug\":\"aileron-therapeutics\",\"postDate\":1465920840,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. ALRN-6924, in Phase 1, is a p53 re-activator for the treatment of cancer, the only p53 molecule in development that targets both MDM2 and MDMX.<\\/p>\",\"62\":{\"28\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.aileronrx.com\\/\",\"linkedin\":\"linkedin\"}}},\"130\":[\"95\"],\"66\":[\"269\"],\"81\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide&nbsp;drug platform.<\\/p>\",\"103\":[\"70\"]}}', '2016-07-11 23:42:10', '2016-07-11 23:42:10', 'f9f9e2e9-26cc-4234-b7ed-f84281d67e29'),
 ('246', '200', '13', '1', 'en_us', '4', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Braeburn Pharmaceuticals\",\"slug\":\"braeburn-pharmaceuticals\",\"postDate\":1468274160,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Braeburn Pharmaceuticals is developing a portfolio of long-acting therapeutic treatment options for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Long-acting implantable and injectable therapies can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. The current portfolio includes: Probuphine\\u00ae, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia.<\\/p>\",\"62\":{\"201\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"https:\\/\\/braeburnpharmaceuticals.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"95\"],\"66\":[\"270\"],\"81\":\"<p>Braeburn Pharmaceuticals is developing a portfolio of long-acting therapeutic treatment options for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia.<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:42:43', '2016-07-11 23:42:43', '842a6b08-6d42-4ccb-bff1-a23da30d603a'),
 ('247', '204', '13', '1', 'en_us', '3', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"CleanSlate Addiction Treatment Centers\",\"slug\":\"cleanslate-addiction-treatment-centers\",\"postDate\":1468274280,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania. CleanSlate provides medication-assisted treatment and related therapies using the highest quality, evidence-based practices for patients who have addiction and associated disorders.<\\/p>\",\"62\":{\"205\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/cleanslatecenters.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"89\"],\"66\":[\"271\"],\"81\":\"<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania.&nbsp;<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:43:10', '2016-07-11 23:43:10', '350cd625-d441-4c5c-b908-f6b68cf7a899'),
 ('248', '242', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Gala Therapeutics\",\"slug\":\"gala-therapeutics\",\"postDate\":1468276140,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Gala Therapeutics is an early stage medical device company developing a novel catheter based approach to treating pulmonary disease including chronic bronchitis, COPD, and asthma.<\\/p>\",\"62\":{\"243\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.galatherapeutics.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"92\"],\"66\":[\"272\"],\"81\":\"<p>Gala Therapeutics is an early stage medical device company developing a novel catheter based approach to treating pulmonary disease including chronic bronchitis, COPD, and asthma.<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:44:30', '2016-07-11 23:44:30', '1ce8cebd-71ff-4909-aab6-b7004808f9ba'),
 ('249', '244', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Cure Forward\",\"slug\":\"cure-forward\",\"postDate\":1468276500,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Cure Forward connects cancer patients with clinical trial administrators working to reduce trial recruitment times and increase participation. Cure Forward\\u2019s online portal, in addition to providing access to clinical trials, can also help patients retrieve molecular diagnostic test results ordered by physicians, access educational information, connect with other patients, and investigate treatment options.<\\/p>\",\"62\":{\"245\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"https:\\/\\/www.cureforward.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"89\"],\"66\":[\"273\"],\"81\":\"<p>Cure Forward connects cancer patients with clinical trial administrators working to reduce trial recruitment times and increase participation.<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:44:59', '2016-07-11 23:44:59', '26764592-ab04-4e7b-bede-110bc7a5975c'),
 ('250', '246', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Cyrano Sciences\",\"slug\":\"cyrano-sciences\",\"postDate\":1468276560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>An electronic nose for homeland defense applications.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Smiths Detection March 2004<\\/em><\\/p>\",\"62\":{\"247\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.smithsdetection.com\\/\",\"linkedin\":\"\"}}},\"130\":\"\",\"66\":[\"274\"],\"81\":\"<p>An electronic nose for homeland defense applications.<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:46:16', '2016-07-11 23:46:16', '59acbd8d-3d21-4a00-aed2-0ea1f1d42dd8'),
 ('251', '248', '13', '1', 'en_us', '3', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Gloucester Pharmaceuticals\",\"slug\":\"gloucester-pharmaceuticals\",\"postDate\":1468276620,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Creators of ISTODAX\\u00ae (romidepsin) for T-cell lymphoma and other malignancies.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Celgene January 2010<\\/em><\\/p>\",\"62\":{\"249\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.celgene.com\\/\",\"linkedin\":\"\"}}},\"130\":\"\",\"66\":[\"264\"],\"81\":\"<p>Creators of ISTODAX\\u00ae (romidepsin) for T-cell lymphoma and other malignancies.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Celgene January 2010<\\/em><\\/p>\",\"103\":\"\"}}', '2016-07-11 23:46:23', '2016-07-11 23:46:23', '93f9509c-e763-4111-9cf2-1322a941d4b1'),
 ('252', '250', '13', '1', 'en_us', '4', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"HeartWare International\",\"slug\":\"heartware-international\",\"postDate\":1468276800,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>HeartWare (HTWR)develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.<\\/p>\\r\\n\\r\\n<p><em>IPO January 2005 ASX; listed on NASDAQ September 2013<\\/em><\\/p>\",\"62\":{\"268\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.heartware.com\\/\",\"linkedin\":\"\"}}},\"130\":\"\",\"66\":[\"263\"],\"81\":\"<p>HeartWare (HTWR)develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:46:27', '2016-07-11 23:46:27', 'af2df7c6-0697-4e62-9fd9-761ff9a35d76'),
 ('253', '275', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"QualDerm Partners\",\"slug\":\"qualderm-partners\",\"postDate\":1468280840,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>QualDerm Partners provides strategic leadership and practice management services through partnerships with highly qualified dermatologists throughout the Southeastern US. The company alleviates practice administrative burdens, empowering providers to focus solely on delivering exceptional patient care.<\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/qualderm.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"89\"],\"66\":[\"262\"],\"81\":\"<p>QualDerm Partners provides strategic leadership and practice management services through partnerships with highly qualified dermatologists throughout the Southeastern US.&nbsp;<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:47:20', '2016-07-11 23:47:20', 'de848e2b-6942-4558-ba25-cc5a4f4471b7'),
 ('254', '275', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"QualDerm Partners\",\"slug\":\"qualderm-partners\",\"postDate\":1468280820,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>QualDerm Partners provides strategic leadership and practice management services through partnerships with highly qualified dermatologists throughout the Southeastern US. The company alleviates practice administrative burdens, empowering providers to focus solely on delivering exceptional patient care.<\\/p>\",\"62\":{\"276\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/qualderm.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/6471786?trk=tyah&trkInfo=clickedVertical%3Acompany%2Cidx%3A2-1-4%2CtarId%3A1435163699111%2Ctas%3Aqualderm%20partners\"}}},\"130\":[\"89\"],\"66\":[\"262\"],\"81\":\"<p>QualDerm Partners provides strategic leadership and practice management services through partnerships with highly qualified dermatologists throughout the Southeastern US.&nbsp;<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:48:06', '2016-07-11 23:48:06', '496ef39d-daf4-422e-952b-71a49db51f41'),
 ('255', '250', '13', '1', 'en_us', '5', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"HeartWare International\",\"slug\":\"heartware-international\",\"postDate\":1468276800,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>HeartWare (HTWR)develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.<\\/p>\\r\\n\\r\\n<p><em>IPO January 2005 ASX; listed on NASDAQ September 2013<\\/em><\\/p>\",\"62\":{\"268\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.heartware.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/heartware-inc\"}}},\"130\":\"\",\"66\":[\"263\"],\"81\":\"<p>HeartWare (HTWR)develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:49:49', '2016-07-11 23:49:49', '9f9eabb9-21b7-436a-bcef-295a64bfbbfa'),
 ('256', '244', '13', '1', 'en_us', '3', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Cure Forward\",\"slug\":\"cure-forward\",\"postDate\":1468276500,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Cure Forward connects cancer patients with clinical trial administrators working to reduce trial recruitment times and increase participation. Cure Forward\\u2019s online portal, in addition to providing access to clinical trials, can also help patients retrieve molecular diagnostic test results ordered by physicians, access educational information, connect with other patients, and investigate treatment options.<\\/p>\",\"62\":{\"245\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"https:\\/\\/www.cureforward.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/cureforward\"}}},\"130\":[\"89\"],\"66\":[\"273\"],\"81\":\"<p>Cure Forward connects cancer patients with clinical trial administrators working to reduce trial recruitment times and increase participation.<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:51:04', '2016-07-11 23:51:04', '598ebc86-9278-4c18-be9b-2f520a24f868'),
 ('257', '239', '13', '1', 'en_us', '3', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Corvidia\",\"slug\":\"corvidia\",\"postDate\":1468275660,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company has identified mechanistically-driven responder populations in a variety of cardio-metabolic and cardio-renal disorders.<\\/p>\",\"62\":{\"240\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/corvidiatx.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"95\"],\"66\":[\"265\"],\"81\":\"<p>Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies.<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:52:18', '2016-07-11 23:52:18', '6cbebf90-9924-40aa-b4c3-2ed0837feca2'),
 ('258', '239', '13', '1', 'en_us', '4', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Corvidia\",\"slug\":\"corvidia\",\"postDate\":1468275660,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company has identified mechanistically-driven responder populations in a variety of cardio-metabolic and cardio-renal disorders.<\\/p>\",\"62\":{\"240\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/corvidiatx.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/corvidia-therapeutics\"}}},\"130\":[\"95\"],\"66\":[\"265\"],\"81\":\"<p>Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies.<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:52:24', '2016-07-11 23:52:24', 'c60237f9-018a-4c59-bdbf-fd39945a3d3b'),
 ('259', '229', '13', '1', 'en_us', '3', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Coelacanth Chemical Corporation\",\"slug\":\"http-www-appletreepartners-com-portfolio-detail-coelacanth-acquired-by-lexicon-genetics\",\"postDate\":1468274580,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \\\"click\\\" chemistry.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Lexicon Genetics July 2001<\\/em><\\/p>\",\"62\":{\"230\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.lexicon-genetics.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/coelacanth-chemical-corp\"}}},\"130\":\"\",\"66\":\"\",\"81\":\"<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \\\"click\\\" chemistry.<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:52:56', '2016-07-11 23:52:56', 'b2f9277f-aa27-45eb-84c5-a567679a88ba'),
 ('260', '204', '13', '1', 'en_us', '4', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"CleanSlate Addiction Treatment Centers\",\"slug\":\"cleanslate-addiction-treatment-centers\",\"postDate\":1468274280,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania. CleanSlate provides medication-assisted treatment and related therapies using the highest quality, evidence-based practices for patients who have addiction and associated disorders.<\\/p>\",\"62\":{\"205\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/cleanslatecenters.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/cleanslate-centers\"}}},\"130\":[\"89\"],\"66\":[\"271\"],\"81\":\"<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania.&nbsp;<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:53:25', '2016-07-11 23:53:25', '6ea34490-e9c9-4c59-b193-82ed9a478478'),
 ('261', '204', '13', '1', 'en_us', '5', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"CleanSlate Addiction Treatment Centers\",\"slug\":\"cleanslate-addiction-treatment-centers\",\"postDate\":1468274280,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania. CleanSlate provides medication-assisted treatment and related therapies using the highest quality, evidence-based practices for patients who have addiction and associated disorders.<\\/p>\",\"62\":{\"205\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/cleanslatecenters.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/cleanslate-centers\"}}},\"130\":[\"89\"],\"66\":[\"277\"],\"81\":\"<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania.&nbsp;<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:54:54', '2016-07-11 23:54:54', '95591704-9872-4eac-8db4-487343985c7d'),
 ('262', '204', '13', '1', 'en_us', '6', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"CleanSlate Addiction Treatment Centers\",\"slug\":\"cleanslate-addiction-treatment-centers\",\"postDate\":1468274280,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania. CleanSlate provides medication-assisted treatment and related therapies using the highest quality, evidence-based practices for patients who have addiction and associated disorders.<\\/p>\",\"62\":{\"205\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/cleanslatecenters.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/cleanslate-centers\"}}},\"130\":[\"89\"],\"66\":[\"277\"],\"81\":\"<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania.&nbsp;<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:55:13', '2016-07-11 23:55:13', 'c2458e92-fccc-4c2a-8ff6-f29aa7bd520b'),
 ('263', '200', '13', '1', 'en_us', '5', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Braeburn Pharmaceuticals\",\"slug\":\"braeburn-pharmaceuticals\",\"postDate\":1468274160,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Braeburn Pharmaceuticals is developing a portfolio of long-acting therapeutic treatment options for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Long-acting implantable and injectable therapies can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. The current portfolio includes: Probuphine\\u00ae, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia.<\\/p>\",\"62\":{\"201\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"https:\\/\\/braeburnpharmaceuticals.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/braeburn-pharmaceuticals\"}}},\"130\":[\"95\"],\"66\":[\"270\"],\"81\":\"<p>Braeburn Pharmaceuticals is developing a portfolio of long-acting therapeutic treatment options for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia.<\\/p>\",\"103\":\"\"}}', '2016-07-11 23:56:46', '2016-07-11 23:56:46', '68aa90fd-a0ab-4db1-815c-cef0b0540887'),
 ('265', '27', '13', '1', 'en_us', '12', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Aileron Therapeutics\",\"slug\":\"aileron-therapeutics\",\"postDate\":1465920840,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. ALRN-6924, in Phase 1, is a p53 re-activator for the treatment of cancer, the only p53 molecule in development that targets both MDM2 and MDMX.<\\/p>\",\"62\":{\"28\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.aileronrx.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/aileron-therapeutics\"}}},\"130\":[\"95\"],\"66\":[\"269\"],\"81\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide&nbsp;drug platform.<\\/p>\",\"103\":[\"70\"]}}', '2016-07-11 23:59:03', '2016-07-11 23:59:03', '4f20e062-b884-4bb2-ba54-0d58981d489d'),
 ('266', '239', '13', '1', 'en_us', '5', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Corvidia\",\"slug\":\"corvidia\",\"postDate\":1468275660,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company has identified mechanistically-driven responder populations in a variety of cardio-metabolic and cardio-renal disorders.<\\/p>\",\"62\":{\"240\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/corvidiatx.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/corvidia-therapeutics\"}}},\"130\":[\"95\"],\"66\":[\"265\"],\"81\":\"<p>Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies.<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:03:45', '2016-07-12 00:03:45', '9d3f9bda-461c-414a-8730-f1fe748df59c'),
 ('267', '244', '13', '1', 'en_us', '4', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Cure Forward\",\"slug\":\"cure-forward\",\"postDate\":1468276500,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Cure Forward connects cancer patients with clinical trial administrators working to reduce trial recruitment times and increase participation. Cure Forward\\u2019s online portal, in addition to providing access to clinical trials, can also help patients retrieve molecular diagnostic test results ordered by physicians, access educational information, connect with other patients, and investigate treatment options.<\\/p>\",\"62\":{\"245\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"https:\\/\\/www.cureforward.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/cureforward\"}}},\"130\":[\"89\"],\"66\":[\"273\"],\"81\":\"<p>Cure Forward connects cancer patients with clinical trial administrators working to reduce trial recruitment times and increase participation.<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:03:51', '2016-07-12 00:03:51', '321ffe3c-4fa9-4755-aa09-4d259cac21b7'),
 ('268', '246', '13', '1', 'en_us', '3', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Cyrano Sciences\",\"slug\":\"cyrano-sciences\",\"postDate\":1468276560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>An electronic nose for homeland defense applications.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Smiths Detection March 2004<\\/em><\\/p>\",\"62\":{\"247\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.smithsdetection.com\\/\",\"linkedin\":\"\"}}},\"130\":\"\",\"66\":[\"274\"],\"81\":\"<p>An electronic nose for homeland defense applications.<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:04:00', '2016-07-12 00:04:00', 'eef7cebc-e8b2-4428-a0ef-2cc18cad49d9'),
 ('269', '275', '13', '1', 'en_us', '3', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"QualDerm Partners\",\"slug\":\"qualderm-partners\",\"postDate\":1468280820,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>QualDerm Partners provides strategic leadership and practice management services through partnerships with highly qualified dermatologists throughout the Southeastern US. The company alleviates practice administrative burdens, empowering providers to focus solely on delivering exceptional patient care.<\\/p>\",\"62\":{\"276\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/qualderm.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/6471786?trk=tyah&trkInfo=clickedVertical%3Acompany%2Cidx%3A2-1-4%2CtarId%3A1435163699111%2Ctas%3Aqualderm%20partners\"}}},\"130\":[\"89\"],\"66\":[\"262\"],\"81\":\"<p>QualDerm Partners provides strategic leadership and practice management services through partnerships with highly qualified dermatologists throughout the Southeastern US.&nbsp;<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:04:44', '2016-07-12 00:04:44', 'f5d3476f-38fd-434b-90a6-b868d6a391b8'),
 ('270', '281', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"SGX Pharmaceuticals\",\"slug\":\"sgx-pharmaceuticals\",\"postDate\":1468282053,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>A biotechnology company focused on discovery and development of small molecule therapeutics generated by its proprietary Fragments of Active Structures (FAST) medicinal chemistry platform.<\\/p>\\r\\n\\r\\n<p><em>IPO February 2006 (acquired by Eli Lilly July 2008)<\\/em><\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"https:\\/\\/www.lilly.com\\/home.aspx\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/sgx-pharmaceuticals\"}}},\"130\":\"\",\"66\":[\"261\"],\"81\":\"<p>A biotechnology company focused on discovery and development of small molecule therapeutics generated by its proprietary Fragments of Active Structures (FAST) medicinal chemistry platform.<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:07:33', '2016-07-12 00:07:33', '694de663-d11c-43ac-a953-5047f6d6bfee'),
 ('271', '284', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Syntimmune\",\"slug\":\"syntimmune\",\"postDate\":1468282172,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Syntimmune is developing novel antibody therapies for inflammatory diseases and severe toxicities. Syntimmune\\u2019s lead program, SYNT-001, specifically blocks FcRn-IgG interaction, resulting in the rapid clearance of pathogenic IgG important in a variety of antibody-mediated diseases.<\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/syntimmune.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"95\"],\"66\":[\"283\"],\"81\":\"<p>Syntimmune is developing novel antibody therapies for inflammatory diseases and severe toxicities.<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:09:32', '2016-07-12 00:09:32', '89bfe325-6f0f-4650-b5d7-31c78683b108'),
 ('272', '287', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Tendyne\",\"slug\":\"tendyne\",\"postDate\":1468282528,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Tendyne is focused on the development and commercialization of minimally invasive therapies for the treatment of mitral regurgitation. Tendyne\\u2019s first product is a percutaneous transcatheter mitral valve prosthesis.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Abbott August 2015<\\/em><\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.tendyne.com\\/\",\"linkedin\":\"\"}}},\"130\":\"\",\"66\":[\"286\"],\"81\":\"<p>Tendyne is focused on the development and commercialization of minimally invasive therapies for the treatment of mitral regurgitation.&nbsp;<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:15:28', '2016-07-12 00:15:28', '0299006a-ad48-4eb5-8533-a1dccf15208b'),
 ('273', '290', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Tokai Pharmaceuticals\",\"slug\":\"tokai-pharmaceuticals\",\"postDate\":1468282643,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Tokai (TKAI) is developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. The company is conducting a pivotal clinical trial of its lead drug candidate, galeterone, in patients with metastatic castration-resistant prostate cancer (mCRPC) whose tumors express the AR-V7 splice variant, which is a truncated form of the androgen receptor associated with non-responsiveness to commonly-used oral therapies for mCRPC. This trial is the first precision medicine based pivotal clinical trial in prostate cancer.<\\/p>\\r\\n\\r\\n\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/tokaipharmaceuticals.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/tokai-pharmaceuticals-inc-\"}}},\"130\":[\"95\"],\"66\":[\"289\"],\"81\":\"<p>Tokai (TKAI) is developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases.<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:17:23', '2016-07-12 00:17:23', '99b881e8-21f4-421d-a800-98ced32e7326'),
 ('274', '293', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"TripleCare\",\"slug\":\"triplecare\",\"postDate\":1468282799,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>TripleCare provides acute hospital-level care to patients residing in skilled nursing facilities (\\u201cSNFs\\u201d) using state-of-the-art telemedicine technology. The company expands patient access to care after hours and on weekends by providing physicians, equipment, and software to SNFs, with the goal of treating patients in place. The company presently operates across over thirty-five facilities in six states.<\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/triple.care\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/esnf\\/\"}}},\"130\":[\"89\"],\"66\":[\"292\"],\"81\":\"<p>TripleCare provides acute hospital-level care to patients residing in skilled nursing facilities (\\u201cSNFs\\u201d) using state-of-the-art telemedicine technology.<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:19:59', '2016-07-12 00:19:59', 'c7ab9385-45d8-4731-9896-e56718195d19'),
 ('275', '296', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Tusker Medical\",\"slug\":\"tusker-medical\",\"postDate\":1468282981,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Tusker Medical is an early stage medical device company developing innovative ear, nose and throat treatments. Tusker is currently developing a suite of pediatric-focused technologies designed to enable placement of tubes within the comfort of an office environment, eliminating the need for general anesthetics.<\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.tuskermed.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/tusker-medical-inc.\"}}},\"130\":[\"92\"],\"66\":[\"295\"],\"81\":\"<p>Tusker Medical is an early stage medical device company developing innovative ear, nose and throat treatments.<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:23:01', '2016-07-12 00:23:01', 'f33ce21b-48a0-4b85-963c-1ec7f9b8b701'),
 ('276', '298', '13', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"VytronUS\",\"slug\":\"vytronus\",\"postDate\":1468283076,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>VytronUS is a clinical stage company redefining ablation by using a next generation ultrasound based robotic catheter to treat complex cardiac arrhythmias including atrial fibrillation. The company has developed an endocardial ablation platform based on Low-Intensity Collimated Ultrasound (LICU&trade;). LICU is capable of quickly producing high-resolution maps of cardiac anatomy and allows for non-contact energy delivery to create durable continuous linear lesions. VytronUS will help simplify the procedure and improve efficacy by leading to more predictable outcomes.<\\/p>\",\"62\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.vytronus.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"92\"],\"66\":[\"259\"],\"81\":\"<p>VytronUS is a clinical stage company redefining ablation by using a next generation ultrasound based robotic catheter to treat complex cardiac arrhythmias including atrial fibrillation.<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:24:36', '2016-07-12 00:24:36', 'f81a2533-1443-49ea-b15d-8452f9250b50'),
 ('277', '287', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Tendyne\",\"slug\":\"tendyne\",\"postDate\":1468282500,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Tendyne is focused on the development and commercialization of minimally invasive therapies for the treatment of mitral regurgitation. Tendyne\\u2019s first product is a percutaneous transcatheter mitral valve prosthesis.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Abbott August 2015<\\/em><\\/p>\",\"62\":{\"288\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.tendyne.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"90\"],\"66\":[\"286\"],\"81\":\"<p>Tendyne is focused on the development and commercialization of minimally invasive therapies for the treatment of mitral regurgitation.&nbsp;<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:25:23', '2016-07-12 00:25:23', '6662794f-3947-423a-8e64-0c0214e41dcc'),
 ('278', '281', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"SGX Pharmaceuticals\",\"slug\":\"sgx-pharmaceuticals\",\"postDate\":1468282020,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>A biotechnology company focused on discovery and development of small molecule therapeutics generated by its proprietary Fragments of Active Structures (FAST) medicinal chemistry platform.<\\/p>\\r\\n\\r\\n<p><em>IPO February 2006 (acquired by Eli Lilly July 2008)<\\/em><\\/p>\",\"62\":{\"282\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"https:\\/\\/www.lilly.com\\/home.aspx\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/sgx-pharmaceuticals\"}}},\"130\":[\"90\"],\"66\":[\"261\"],\"81\":\"<p>A biotechnology company focused on discovery and development of small molecule therapeutics generated by its proprietary Fragments of Active Structures (FAST) medicinal chemistry platform.<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:25:41', '2016-07-12 00:25:41', 'd9491853-3264-4281-bf62-6dbf8ee6fc2e'),
 ('279', '250', '13', '1', 'en_us', '6', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"HeartWare International\",\"slug\":\"heartware-international\",\"postDate\":1468276800,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>HeartWare (HTWR)develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.<\\/p>\\r\\n\\r\\n<p><em>IPO January 2005 ASX; listed on NASDAQ September 2013<\\/em><\\/p>\",\"62\":{\"268\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.heartware.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/heartware-inc\"}}},\"130\":[\"90\"],\"66\":[\"263\"],\"81\":\"<p>HeartWare (HTWR)develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:26:09', '2016-07-12 00:26:09', '6d6de7b0-2861-449e-a803-5e8bad5912dc'),
 ('280', '248', '13', '1', 'en_us', '4', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Gloucester Pharmaceuticals\",\"slug\":\"gloucester-pharmaceuticals\",\"postDate\":1468276620,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Creators of ISTODAX\\u00ae (romidepsin) for T-cell lymphoma and other malignancies.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Celgene January 2010<\\/em><\\/p>\",\"62\":{\"249\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.celgene.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"90\"],\"66\":[\"264\"],\"81\":\"<p>Creators of ISTODAX\\u00ae (romidepsin) for T-cell lymphoma and other malignancies.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Celgene January 2010<\\/em><\\/p>\",\"103\":\"\"}}', '2016-07-12 00:26:24', '2016-07-12 00:26:24', 'c65bf544-e91d-4bbc-8692-5812c0494b37'),
 ('281', '246', '13', '1', 'en_us', '4', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Cyrano Sciences\",\"slug\":\"cyrano-sciences\",\"postDate\":1468276560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>An electronic nose for homeland defense applications.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Smiths Detection March 2004<\\/em><\\/p>\",\"62\":{\"247\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.smithsdetection.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"90\"],\"66\":[\"274\"],\"81\":\"<p>An electronic nose for homeland defense applications.<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:26:42', '2016-07-12 00:26:42', 'ded056c5-8988-4138-8ceb-b43973b3a861'),
 ('282', '229', '13', '1', 'en_us', '4', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Coelacanth Chemical Corporation\",\"slug\":\"http-www-appletreepartners-com-portfolio-detail-coelacanth-acquired-by-lexicon-genetics\",\"postDate\":1468274580,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \\\"click\\\" chemistry.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Lexicon Genetics July 2001<\\/em><\\/p>\",\"62\":{\"230\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.lexicon-genetics.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/coelacanth-chemical-corp\"}}},\"130\":[\"90\"],\"66\":\"\",\"81\":\"<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \\\"click\\\" chemistry.<\\/p>\",\"103\":\"\"}}', '2016-07-12 00:27:09', '2016-07-12 00:27:09', '7786d736-fe41-4e7f-8016-da3f62d258b2'),
 ('283', '146', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Salam Farhat\",\"slug\":\"salam-farhat\",\"postDate\":1468272360,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Executive Assistant (Medical Devices and Healthcare Services)\",\"80\":\"\",\"104\":\"\"}}', '2016-07-12 00:28:03', '2016-07-12 00:28:03', '09b6d4ab-b736-4707-a580-1f1f2caa2ccc'),
 ('284', '145', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Lisa Cagney\",\"slug\":\"lisa-cagney\",\"postDate\":1468272300,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Executive Assistant (Therapeutics)\",\"80\":\"\",\"104\":\"\"}}', '2016-07-12 00:28:13', '2016-07-12 00:28:13', 'de9a3d79-b230-445b-ba0b-c0bf6b7dd95e'),
 ('285', '143', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Shivranie Singh\",\"slug\":\"shivranie-singh\",\"postDate\":1468272300,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Accounts Payable\",\"80\":\"\",\"104\":\"\"}}', '2016-07-12 00:28:23', '2016-07-12 00:28:23', 'a0282cab-9080-4ffb-8894-62ffefafb132'),
 ('286', '145', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Lisa Cagney\",\"slug\":\"lisa-cagney\",\"postDate\":1468272300,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Executive Assistant (Therapeutics)\",\"80\":\"\",\"104\":\"\"}}', '2016-07-12 00:28:30', '2016-07-12 00:28:30', '71009c8d-43a5-4597-ab8e-f4164553d323'),
 ('287', '142', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Maja Nowak\",\"slug\":\"maja-nowak\",\"postDate\":1468272240,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Accounting Manager\",\"80\":\"\",\"104\":\"\"}}', '2016-07-12 00:28:38', '2016-07-12 00:28:38', '43346ef7-4714-4744-b613-58705227da39'),
 ('288', '142', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Maja Nowak\",\"slug\":\"maja-nowak\",\"postDate\":1468272240,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Accounting Manager\",\"80\":\"\",\"104\":\"\"}}', '2016-07-12 00:28:47', '2016-07-12 00:28:47', 'b395b47c-6194-43e8-9b7c-9b9ed33d79a4'),
 ('289', '128', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Joshua Sherman\",\"slug\":\"joshua-sherman\",\"postDate\":1468270980,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"92\"],\"56\":\"<p>Josh joined Apple Tree Partners in 2014 as an Associate focused on the Life Science, Pharmaceutical and Medical Device industries. He has a strong interest in the healthcare space and benefits greatly from his background in both science and finance.<\\/p>\\r\\n\\r\\n<p>Prior to joining Apple Tree Partners, Josh was an Analyst in the Healthcare Investment Banking Group at Barclays where he developed broad industry knowledge and M&A experience. He was also formerly an Analyst at Morgan Stanley in the Financial Institutions Group where he focused on transactions in the Insurance and Asset Management space.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Josh graduated from The University of Pennsylvania in 2012 earning dual-degrees as a member of the Vagelos Life Sciences & Management Program. He holds a B.S. in Economics (Concentration in Finance) from The Wharton School and a B.A. in Biology from The College of Arts and Sciences.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Josh grew up in New York City, is fluent in French, and enjoys travel and tennis.<\\/p>\",\"57\":\"\",\"110\":[\"97\"],\"109\":\"Associate\",\"80\":\"<p>Josh joined Apple Tree Partners in 2014 as an Associate focused on the Life Science, Pharmaceutical and Medical Device industries.<\\/p>\",\"104\":\"\"}}', '2016-07-12 00:28:51', '2016-07-12 00:28:51', '12baedf9-3a76-4e72-a8c2-5e25101f1329'),
 ('290', '99', '12', '1', 'en_us', '4', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Lauren Farrell\",\"slug\":\"lauren-farrell\",\"postDate\":1468263900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"<p>Lauren has over 20 years accounting and finance experience including roles in public accounting, financial management and reporting, and strategic financial consulting across multiple industries. Prior to joining Apple Tree Partners, Lauren was Vice President and Chief Accounting Officer at HeartWare International, Inc. (NASDAQ:HTWR) from 2006 to 2013, where she led the Company\\u2019s financial management and reporting activities. From 2005 to 2006, Lauren was Chief Financial Officer at Ambient Corporation. From January 2001 to July 2004, Lauren served as Vice President at Bingham Strategic Advisors providing M&A advisory services.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Lauren is a Certified Public Accountant and holds a Bachelors of Science in Accounting and a Masters of Business Administration from Bentley University.<\\/p>\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Chief Financial Officer\",\"80\":\"<p>Lauren has over 20 years accounting and finance experience including roles in public accounting, financial management and reporting, and strategic financial consulting across multiple industries.<\\/p>\",\"104\":\"\"}}', '2016-07-12 00:29:02', '2016-07-12 00:29:02', '2702fcbc-d898-4d5a-a04b-f6a61a12dc88'),
 ('291', '12', '9', '1', 'en_us', '23', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"88\"],\"38\":\"<p>We start companies, or invest in existing companies, with commitments as high as $250 million; in this sense, we scale to the buy-out or growth equity level. But we take the long view, both as a matter of principle and for value creation. An ATP company may choose to sell in an M&A transaction, but only if the price is right, or may access the public markets, but only if advantageous to do so. This means our managers can build with confidence, knowing that we are funding them to grow and develop their businesses.<\\/p>\",\"37\":\"About Apple Tree Partners\",\"47\":{\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":[\"95\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"105\",\"106\",\"125\",\"126\",\"108\",\"109\",\"123\",\"113\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":[\"92\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"55\",\"57\",\"107\",\"128\",\"116\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":[\"89\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"53\",\"102\",\"127\"]}},\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Finance & Administration\",\"teamImage\":[\"90\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"99\",\"141\",\"142\",\"143\",\"144\",\"145\",\"146\"]}}}}}', '2016-07-12 00:29:29', '2016-07-12 00:29:29', 'a2daadc2-cb72-4a56-a154-15f951033ccd'),
 ('292', '75', '15', '1', 'en_us', '6', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Press\",\"slug\":\"press\",\"postDate\":1467840682,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"132\":[\"94\"],\"113\":{\"76\":{\"type\":\"pressInfo\",\"enabled\":\"1\",\"fields\":{\"pressHeader\":\"Press\",\"pressDescription\":\"Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam.\",\"pressLink\":\"<p>Didn\\u2019t find what you were looking for? <em>Get in touch.<\\/em><\\/p>\"}},\"77\":{\"type\":\"brandAssets\",\"enabled\":\"1\",\"fields\":{\"brandAssetsHeader\":\"Brand Assets\",\"logoOptions\":\"\"}},\"78\":{\"type\":\"pressTeam\",\"enabled\":\"1\",\"fields\":{\"pressTeamHeader\":\"Headshots and Bios\",\"headshotBioNames\":\"\",\"headshotAndBio\":\"\"}},\"79\":{\"type\":\"pressNews\",\"enabled\":\"1\",\"fields\":{\"pressNewsHeader\":\"Recent News\"}}}}}', '2016-07-12 00:29:45', '2016-07-12 00:29:45', 'ee2427b0-29d2-490e-8524-ca7ac565c624'),
 ('293', '13', '10', '1', 'en_us', '11', '', '{\"typeId\":\"10\",\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1466010801,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"19\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseImage\":[\"95\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"companyImage\":\"\"}},\"20\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseImage\":[\"92\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"companyImage\":\"\"}},\"21\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseImage\":[\"89\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"companyImage\":\"\"}},\"22\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Legacy Investments\",\"expertiseImage\":[\"90\"],\"expertiseDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.&nbsp;<\\/p>\",\"companyImage\":\"\"}}}}}', '2016-07-12 00:33:57', '2016-07-12 00:33:57', 'a97cba77-cc1a-4276-952c-db98c072e2b9'),
 ('294', '10', '7', '1', 'en_us', '9', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Contact\",\"slug\":\"contact\",\"postDate\":1465917860,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"70\":{\"41\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"New York City\",\"cityImage\":\"\",\"address\":\"230 Park Avenue, Suite 2800\\r\\nNew York, New York 10169\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}},\"42\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Cambridge \",\"cityImage\":\"\",\"address\":\"300 Technology Square, Suite 803G\\r\\nCambridge, MA 02139\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}},\"43\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Los Altos\",\"cityImage\":\"\",\"address\":\"4970 El Camino Real, Suite 220\\r\\nLos Altos, CA 94022\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}}}}}', '2016-07-12 00:37:30', '2016-07-12 00:37:30', '27fda951-b689-422b-a95e-c7fae352eb2b'),
 ('295', '10', '7', '1', 'en_us', '10', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Contact\",\"slug\":\"contact\",\"postDate\":1465917860,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"70\":{\"41\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"New York City\",\"cityImage\":\"\",\"address\":\"230 Park Avenue, Suite 2800\\r\\nNew York, New York 10169\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}},\"42\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Cambridge \",\"cityImage\":\"\",\"address\":\"300 Technology Square, Suite 803G\\r\\nCambridge, MA 02139\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}},\"43\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Los Altos\",\"cityImage\":\"\",\"address\":\"4970 El Camino Real, Suite 220\\r\\nLos Altos, CA 94022\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}}}}}', '2016-07-12 00:37:51', '2016-07-12 00:37:51', '8e625af0-e69d-409b-b216-b7613faaac53'),
 ('296', '9', '6', '1', 'en_us', '31', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use <em>long term investment philosophy<\\/em> to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\",\"trajectoryBody\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.67\",\"trajectoryDescription\":\"$1.5 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"\"}}}}}', '2016-07-12 03:23:39', '2016-07-12 03:23:39', '93b7a5f9-8e21-405e-9882-0597d7a20853'),
 ('297', '9', '6', '1', 'en_us', '32', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use <em>long term investment philosophy<\\/em> to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"35\",\"trajectoryDescription\":\"\",\"trajectoryBody\":\"\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.67B\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"\"}}}}}', '2016-07-12 03:24:47', '2016-07-12 03:24:47', '98502458-a693-4ea7-bdf3-c4d9dbae6827'),
 ('298', '9', '6', '1', 'en_us', '33', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use <em>long term investment philosophy<\\/em> to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million to start or incest in new companies\",\"trajectoryBody\":\"We scale to the buy-out or growth equity level but we take the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"\"}}}}}', '2016-07-12 03:30:55', '2016-07-12 03:30:55', '969319f4-ac26-4e0b-ac7d-e06aebb65f29'),
 ('299', '9', '6', '1', 'en_us', '34', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use <em>long term investment philosophy<\\/em> to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"\"}}}}}', '2016-07-12 03:35:29', '2016-07-12 03:35:29', '5db58972-6f1c-4010-abcf-3b79d64a6691'),
 ('300', '9', '6', '1', 'en_us', '35', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use <em>long term investment philosophy<\\/em> to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}}}}', '2016-07-12 03:40:41', '2016-07-12 03:40:41', 'a92cbd7c-5caa-4761-b4f3-f6a4cf5bc720'),
 ('301', '9', '6', '1', 'en_us', '36', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use <em>long term investment philosophy<\\/em> to build long term companies ipsum adi dolor sit ametia siti adipicing tectuer.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}}}}', '2016-07-12 03:41:43', '2016-07-12 03:41:43', '839acdb8-cebe-4bbc-89b1-533c2b096982'),
 ('302', '9', '6', '1', 'en_us', '37', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies across therapeutics, medtech and healthcare services through meaningful partnerships and deep expertise.<\\/p><p><br><\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}}}}', '2016-07-12 03:43:53', '2016-07-12 03:43:53', '16c5b001-c988-4d06-aac7-5063a896403f'),
 ('303', '9', '6', '1', 'en_us', '38', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies across therapeutics, medtech and healthcare services through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}}}}', '2016-07-12 03:44:16', '2016-07-12 03:44:16', '29163492-f705-4f48-b6a9-7b31f4357f97'),
 ('304', '9', '6', '1', 'en_us', '39', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}}}}', '2016-07-12 03:44:43', '2016-07-12 03:44:43', '99d9546b-3be3-4037-80e2-c95bc82fc8ed'),
 ('305', '9', '6', '1', 'en_us', '40', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1>FDA approves first buprenorphine implant from&nbsp;<a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;for treatment of opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical#entry:296\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}}}}', '2016-07-12 04:00:01', '2016-07-12 04:00:01', '12172cca-3dc2-49ff-981b-a8a56da60710'),
 ('306', '9', '6', '1', 'en_us', '41', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical#entry:296:url\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a> is developing  the first opiod addiction treatment.<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}}}}', '2016-07-12 04:01:55', '2016-07-12 04:01:55', '0409efc0-8e5d-41b4-88c2-e9c9774ccd5a'),
 ('307', '9', '6', '1', 'en_us', '42', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical#entry:296:url\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/cure-forward#entry:244\\\">Cure Forward<\\/a>\\u2019s unique Clinical Trial Exchange&nbsp;platform empowers patients to govern their own care plans.&nbsp;<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}}}}', '2016-07-12 04:07:29', '2016-07-12 04:07:29', '140d9907-f4b8-459b-8310-64e5e96169b6'),
 ('308', '9', '6', '1', 'en_us', '43', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"<p>A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.<\\/p>\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical#entry:296:url\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/cure-forward#entry:244:url\\\">Cure Forward<\\/a>\\u2019s unique Clinical Trial Exchange&nbsp;platform empowers patients to govern their own care plans.&nbsp;<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}}}}', '2016-07-12 04:08:32', '2016-07-12 04:08:32', '0d373cf7-ab81-4eb9-9554-e8a9053ec10c'),
 ('309', '66', '14', '1', 'en_us', '7', '', '{\"typeId\":\"14\",\"authorId\":null,\"title\":\"Legal\",\"slug\":\"legal\",\"postDate\":1467043290,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"128\":[\"91\"],\"86\":{\"67\":{\"type\":\"legalHeader\",\"enabled\":\"1\",\"fields\":{\"legalHeader\":\"Legal\",\"position\":\"full\"}},\"68\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Terms of Use\",\"legalCopy\":\"Thank you for your interest in our Website at www.appletreepartners.com.  Your use of this Website, including the content, materials and information available on or through this Website (together, the \\\"Materials\\\"), is governed by these Terms of Use (these \\\"Terms\\\"). By using this Website, you acknowledge that you have read and agree to these Terms.\",\"position\":\"left\"}},\"new1\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Who We Are\",\"legalCopy\":\"This Website is maintained and operated by Apple Tree Venture Management, LLC, which provides administrative and other services to various Apple Tree entities.  In accordance with industry custom, this Website occasionally uses terminology that may be interpreted to suggest that our firm is actually a single entity. However, there is no such single entity and all of the entities that comprise our firm have their own separate legal existence.\",\"position\":\"left\"}},\"new2\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Materials\",\"legalCopy\":\"ALL MATERIALS ARE PROVIDED \\\"AS IS,\\\" MAY NOT BE RELIED UPON FOR ANY PURPOSE, AND ARE NOT SUBJECT TO EXPRESS OR IMPLIED WARRANTIES OF ANY KIND. In particular, we make no representations or warranties with regard to the Materials\' accuracy, completeness, non-infringement or fitness for a particular purpose. You should be aware that a significant portion of the Materials include or consist of information that has been provided by third parties and has not been validated or verified by us. In connection with our investment activities, we often become subject to a variety of confidentiality obligations to funds, investors, portfolio companies and other third parties. Any statements we make may be affected by those confidentiality obligations, with the result that we may be prohibited from making full disclosures. Without limitation on the effect of other warnings and disclaimers set forth in these Terms, you should interpret any statements we make (on this Website or otherwise) in that context. Please ensure that your own computer security is comprehensive and up to date. We accept no responsibility for viruses, malware or other malicious or damaging software contained in the Materials or otherwise.\",\"position\":\"left\"}},\"new3\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Third-Party Sites\",\"legalCopy\":\"We accept no responsibility for third-party sites available through this Website, via hyperlink or otherwise. You are encouraged to review the terms of use applicable to those sites. Any access to, or use of, a third-party site is solely at your own risk.\",\"position\":\"left\"}},\"new4\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"No Offer, Solicitation or Advice\",\"legalCopy\":\"Nothing on this Website is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by an Apple Tree Partners entity in writing, neither this Website nor any of the Materials make any effort to present a comprehensive or balanced description of Apple Tree Partners or its investment activities.\",\"position\":\"left\"}},\"new5\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Restrictions on Use; No License\",\"legalCopy\":\"We reserve all rights with respect to the design and content of this Website. In particular, you must not misappropriate the design or content of this Website and you must not alter or deface such design or content in any way. Nothing on this Website grants any license with respect to such design or content, except that you may download and use Materials solely for your own personal information.\",\"position\":\"left\"}},\"new6\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Ownership of Trademarks, Etc.\",\"legalCopy\":\"All text, photos, graphics, logos, content and other Materials on this Website are protected by United States and foreign copyright, trademark and other applicable laws. In particular, all trademarks, trade names and logos displayed on this Website are proprietary to Apple Tree Partners, its affiliates or their respective owners, and this Website grants no license to them. Apple Tree Partners and our tree logo are among our trademarks in the United States and\\/or other countries.\",\"position\":\"left\"}},\"new7\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Submitting a Business Plan\",\"legalCopy\":\" or Other Confidential Information. Due to the large number of business plan ideas and related materials that we review, and the similarity of many such plans and materials, we cannot accept responsibility for protecting against misuse or disclosure any confidential or proprietary information or other materials in the absence of our express written agreement to do so. Any plans, information and other materials you submit in connection with this Website may be used or disclosed by us for any purpose and in any manner, as we determine in our sole discretion. Please consider this carefully before sending us any information or other materials that you deem confidential or proprietary.\",\"position\":\"left\"}},\"new8\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Privacy Policy\",\"legalCopy\":\"We reserve the right to track visitors to, and usage of, this Website through \\\"cookies\\\" and similar techniques and to use any resulting information as we determine in our sole discretion.\",\"position\":\"left\"}},\"new9\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Limitation of Liability\",\"legalCopy\":\"Except as specifically agreed by an Apple Tree Partners entity in writing, NO APPLE TREE PARTNERS INDIVIDUAL OR ENTITY SHALL HAVE ANY LIABILITY BASED UPON YOUR USE OF, OR RELIANCE UPON, THIS WEBSITE OR THE MATERIALS. Some jurisdictions limit our ability to disclaim liability. With regard to those jurisdictions, our liability shall be limited to the greatest extent permitted by applicable law.\",\"position\":\"left\"}},\"new10\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Modification of these Terms\",\"legalCopy\":\"We reserve the right to modify these Terms at any time. Please check these Terms periodically for changes. Your continued use of this Website after the posting of changes constitutes your binding acceptance of such changes.\",\"position\":\"left\"}},\"new11\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"General Information\",\"legalCopy\":\"This Website is operated and controlled by Apple Tree Venture Management, LLC in the United States of America. If it is illegal or prohibited in your country of origin to access or use this Website, then you should not do so. Those who choose to access this Website outside the United States of America access it on their own initiative and are responsible for compliance with all local laws and regulations. These Terms, and any disputes relating to these Terms or your use of this Website or the Materials, shall be governed in all respects by the laws of the State of New York, without regard to conflicts of laws principles. Except as otherwise agreed in writing by the applicable Apple Tree Partners entities, any disputes relating to these Terms shall be resolved exclusively in the state or federal courts located in New York, New York. These Terms set forth the entire agreement between you and us with respect to the subject matter hereof and supersede all prior agreements relating to such subject matter. All Apple Tree Partners individuals and entities are intended third-party beneficiaries of these Terms. Our rights under these Terms may be waived by us only in writing. These Terms are binding on you as well as your successors and permitted assigns. In the event any provision of these Terms is determined to be invalid or unenforceable, such provision shall be deemed severed from the remainder of these Terms and replaced with a valid and enforceable provision as similar in intent as reasonably possible to the provision so severed, and shall not cause the invalidity or unenforceability of the remainder of these Terms.\",\"position\":\"left\"}},\"69\":{\"type\":\"legalLink\",\"enabled\":\"1\",\"fields\":{\"linkCopy\":\"Do you have a question? Contact us.\",\"linkPosition\":\"left\"}}}}}', '2016-07-12 04:16:32', '2016-07-12 04:16:32', 'a6cfc70a-9b60-4836-833b-d10a7c4faf8a'),
 ('310', '12', '9', '1', 'en_us', '24', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"88\"],\"38\":\"Founded in 1999, we are a venture capital firm that invests in and starts new therapeutic, medtech, and healthcare service companies. With a history of well-known successes, we closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\",\"37\":\"About Apple Tree Partners (ATP)\",\"47\":{\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":[\"95\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"105\",\"106\",\"125\",\"126\",\"108\",\"109\",\"123\",\"113\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":[\"92\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"55\",\"57\",\"107\",\"128\",\"116\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":[\"89\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"53\",\"102\",\"127\"]}},\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Finance & Administration\",\"teamImage\":[\"90\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"99\",\"141\",\"142\",\"143\",\"144\",\"145\",\"146\"]}}}}}', '2016-07-12 04:35:20', '2016-07-12 04:35:20', 'deed5ec8-8a92-4bae-86f4-9378048d0d11'),
 ('311', '12', '9', '1', 'en_us', '25', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"88\"],\"38\":\"Founded in 1999, we are a venture capital firm that invests in and starts new therapeutic, medtech, and healthcare service companies. With a history of well-known successes in long-term investment strategies, our managers can build with confidence, knowing that we are funding them to grow and develop their businesses.\",\"37\":\"About Apple Tree Partners (ATP)\",\"47\":{\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":[\"95\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"105\",\"106\",\"125\",\"126\",\"108\",\"109\",\"123\",\"113\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":[\"92\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"55\",\"57\",\"107\",\"128\",\"116\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":[\"89\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"53\",\"102\",\"127\"]}},\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Finance & Administration\",\"teamImage\":[\"90\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"99\",\"141\",\"142\",\"143\",\"144\",\"145\",\"146\"]}}}}}', '2016-07-12 04:37:41', '2016-07-12 04:37:41', '80ee0515-2ec4-455a-819c-432b16563e5f'),
 ('312', '29', '12', '1', 'en_us', '25', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"104\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"100\"],\"109\":\"Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio compani\",\"104\":\"\"}}', '2016-07-12 04:40:21', '2016-07-12 04:40:21', '4af0d95b-127f-4891-a375-b5907948d061'),
 ('313', '312', '8', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"High-Tech Healthcare Helps Eliminate Unnecessary Hospital Visits\",\"slug\":\"high-tech-healthcare-helps-eliminate-unnecessary-hospital-visits\",\"postDate\":1468298730,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"new3\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>A high-tech version of healthcare is becoming more and more popular. It\'s called TeleMedicine. And in many cases, it helps keep people out of the hospital. Right now, there\'s a big push to cut the rate of people who are re-admitted to the hospital. It not only saves money, but it also lowers the risk for infection and other complication. Plus, it helps keep patients more comfortable.<\\/p>\\r\\n\\r\\n<p>Sue and Charlie Lake just celebrated their 60th wedding anniversary. They both live at Meadowood Senior Living. Because 91-year-old Mr. Lake has health problems, he stays at the skilled nursing facility. They demonstrated their new TripleCare Telemedicine system for us. On nights, weekends or holidays when there isn\'t a doctor in person at the center, there\'s one available through cyberspace. With nurses help, a doctor can do a thorough examination. The camera can zoom in to look for swelling, lesions or discoloration. The stethoscope is also connected. What nurses hear, the doctor hears at the same time.<\\/p><p><br><br>\\\"It\'s like Skype except that you have all the dimensions, you have all the senses that the physician can hone in on,\\\" said Sally-Ann Heckert Bikin, attorney and Director of Nursing at Meadowood. Mrs. Lake tells Action News she was skeptical about the new technology at first.<\\/p><p><br><br>\\\"I say I don\'t think it\'s going to work. You are going to lose the face to face,\\\" she said. But when her husband got sick on a Sunday night, with the help of TripleCare they were able to diagnose and treat him in his room as opposed to being transported by ambulance to the hospital.<\\/p><p><br><br>\\\"I went from saying it\'s not going to work to telling everyone this is such a great thing,\\\" said Sue.<\\/p><p><br><br>\\\"So far, we\'ve had 16 calls and out of 16, 13 we were able to treat here in the patient\'s room,\\\" said Lynn Plepis, Clinical Informatics at Meadowood. Mr Lake was one of those 13.<\\/p><p><br><br>TripleCare is also set up to keep up the information private and secure.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Many other centers are using similar technology.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>View the&nbsp;<a href=\\\"http:\\/\\/6abc.com\\/health\\/high-tech-healthcare-helps-eliminate-unnecessary-hospital-visits\\/1416091\\/\\\" target=\\\"_blank\\\">original news clip<\\/a> including the video.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"7\\/6\\/2016\"},\"36\":[\"311\"]}}', '2016-07-12 04:45:30', '2016-07-12 04:45:30', '337bb158-e837-4542-b2df-2e48fc7bebca'),
 ('314', '314', '8', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Cure Forward Announces First Trial Recruitment Collaboration That Will Expand Patient Access to Innovative Treatments\",\"slug\":\"cure-forward-announces-first-trial-recruitment-collaboration-that-will-expand-patient-access-to-innovative-treatments\",\"postDate\":1468298842,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"new1\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Cure Forward, an online precision medicine platform for cancer patients and their care teams, and Novartis Pharmaceuticals Corporation today announced that Cure Forward\\u2019s unique Clinical Trial Exchange will support Novartis in identifying potential patients for all of its current oncology trials.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>The collaboration further validates Cure Forward\\u2019s approach for real-time patient sourcing in clinical trials. By utilizing its patent pending Clinical Trial Exchange, Cure Forward facilitates connections between patients and drug development companies, based on mutual criteria and preferences, comparable to popular online dating platforms.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>There is a significant efficiency gap in the clinical trial process today, placing undue burden on patients and caregivers to navigate the vast, complex landscape of medical research options \\u2013 often at stages in which their time is most valuable. Drug developers are concurrently developing investigational treatments, but often struggle to find the right patients to receive these investigational treatments.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Cure Forward\\u2019s platform empowers patients to govern their own care plans, providing accurate, easily accessible information to help drive individual choices.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>\\u201cToday\\u2019s patient is active in his or her care, accessing data to make important treatment decisions,\\u201d said Martin Naley, Founder and Chief Strategy Officer, Cure Forward. \\u201cCure Forward makes clinical trial enrollment easier and more accessible. Novartis\\u2019 bold approach of activating searches for oncology trials on our platform will help patients find possible investigational treatments for their care.\\u201d<span><\\/span><\\/p>\",\"position\":\"left\"}},\"new2\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Cure Forward\"}},\"new3\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Cure Forward bridges the gap between patients and precision medicine, beginning in cancer. Cure Forward provides a simple-to-use platform that allows patients to obtain their genomic data and use it to identify treatment options including clinical trials, solving critical business needs for diagnostic laboratories, health care providers and clinical trial recruiters. Cure Forward is based in Cambridge, Massachusetts and was incubated and launched by Apple Tree Partners, New York City. The company\\u2019s platform is in beta release at&nbsp;<a href=\\\"http:\\/\\/cts.businesswire.com\\/ct\\/CT?id=smartlink&url=http%3A%2F%2Fwww.cureforward.com%2F&esheet=51370740&newsitemid=20160628005534&lan=en-US&anchor=www.cureforward.com&index=2&md5=24eaf06114eb049ec8095911016dcfef\\\" target=\\\"_blank\\\">www.cureforward.com<\\/a>.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"6\\/28\\/2016\"},\"36\":\"\"}}', '2016-07-12 04:47:22', '2016-07-12 04:47:22', '303f84f3-3be1-4c58-aca5-c5bb95c3f38c'),
 ('315', '319', '8', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Medtronic to Expand Heart Failure Portfolio with Acquisition of HeartWare International\",\"slug\":\"medtronic-to-expand-heart-failure-portfolio-with-acquisition-of-heartware-international\",\"postDate\":1468299011,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"new1\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Medtronic plc (NYSE: MDT), the global leader in medical technology, and HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies for the treatment of advanced heart failure, today announced that the companies have entered into a definitive merger agreement under which Medtronic will acquire HeartWare in a transaction valued at approximately $1.1 billion. Under the terms of the agreement, Medtronic will commence a tender offer for all outstanding shares of HeartWare common stock for $58.00 per share, in cash. The boards of directors of both Medtronic and HeartWare have unanimously approved the transaction. The acquisition is expected to close during Medtronic\'s second fiscal quarter ending Oct. 28, 2016, subject to the satisfaction of customary closing conditions.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Medtronic\'s acquisition of HeartWare will expand Medtronic\'s portfolio of diagnostic tools, therapies and services for patients suffering from heart failure, aligning with Medtronic\'s Mission of alleviating pain, restoring health and extending life, and is in line with the Company\'s strategy to surround the physician with innovative products while focusing on patients and disease states.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>HeartWare\'s flagship product, the HVAD \\u00ae System, features the world\'s smallest full-support ventricular assist device (VAD) and is designed to reduce surgical invasiveness, improve patient recovery times and enhance patient outcomes. In addition, HeartWare has multiple technologies in development designed to offer progressively less-invasive mechanical circulatory support options for patients with end-stage heart failure. Medtronic estimates that the global VAD market is approximately $800 million currently and worldwide is expected to grow in the mid-to-high single digits for CY16-17, and accelerate to high-single\\/low-double digits beyond CY17.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>\\\"The addition of HeartWare\'s innovative portfolio adds to our expanding portfolio of diagnostics, therapeutics and services that address heart failure patients,\\\" said Mike Coyle, executive vice president and president of the Cardiac and Vascular Group at Medtronic. \\\"The team at HeartWare has established excellent relationships with its hospital customers and built a strong position and reputation in the marketplace. This transaction, once closed, will be a further, important step toward Medtronic offering a complete suite of solutions to address patient needs across the heart failure care continuum.\\\"<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>\\\"Medtronic is the worldwide leader in cardiovascular device technologies. Its expansive expertise in the development of implantable systems and battery technologies, patient monitoring, manufacturing, global regulatory policy and commercialization should help accelerate the development and introduction of our innovative pipeline products, and will expand access to our therapies and offerings to the sizeable heart failure population,\\\" said Doug Godshall, president and chief executive officer, HeartWare. \\\"Combining the unique capabilities of the HeartWare team, which has been entirely focused on mechanical support technologies, with the broad strength of the Medtronic organization provides a unique opportunity to enhance growth in the mechanical circulatory support market. All of our stakeholders, including customers, employees, shareholders, and most importantly, patients, will benefit meaningfully from this complementary combination.\\\"<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Heart failure, also known as congestive heart failure, is a condition or a collection of symptoms in which the heart isn\'t pumping enough blood to meet the body\'s needs. Heart failure usually develops slowly after an injury to the heart. Some injuries may include a heart attack, too much strain on the heart due to years of untreated high blood pressure, or a diseased heart valve, among others. Heart failure remains a leading cause of hospitalization and death in the United States, and its prevalence continues to increase, affecting more than five million people in the U.S. alone. The cost of heart failure is high. Healthcare expenditures in the U.S. on heart failure are estimated to be approximately $39 billion per year, making it one of the largest expenses to the healthcare system. With the aging of the population, Medtronic estimates that the number of patients with heart failure could exceed eight million by 2030.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>\\\"HeartWare\'s HVAD System enhances the portfolio of our Cardiac & Vascular Group, a team with a proven track record of executing and a demonstrated ability to scale early stage concepts into large, sustainable end markets,\\\" said Omar Ishrak, chairman and chief executive officer of Medtronic. \\\"In addition, from a financial perspective, we are pleased to reach an agreement that meets our acquisition criteria of adding minimal to no net EPS dilution in the near-term, while at the same time creating strong, long-term expected returns for our shareholders.\\\"<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>This acquisition supports Medtronic\'s therapy innovation strategic priority. In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>This transaction is expected to meet Medtronic\'s long-term financial metrics for acquisitions. Medtronic does not intend to modify its fiscal year 2017 revenue outlook or earnings per share (EPS) guidance as a result of this transaction, although it is expected to provide increased confidence in the company\'s ability to deliver on its FY17 revenue growth outlook. In addition, Medtronic expects minimal to no net EPS dilution from this transaction for the first two years as the company intends to offset the expected dilutive impact. The acquisition is expected to be earnings accretive in year three. Medtronic intends to report results from the acquired HeartWare business as part of its Cardiac Rhythm & Heart Failure division within the Cardiac & Vascular Group.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Medtronic\'s financial advisor for the transaction is J.P. Morgan Securities LLC, with Ropes & Gray LLP acting as legal advisor. HeartWare\'s financial advisor is Perella Weinberg Partners LP, with Shearman & Sterling LLP acting as legal advisor<\\/p>\",\"position\":\"left\"}},\"new2\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About HeartWare International\"}},\"new3\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>HeartWare International Inc. (<a href=\\\"http:\\/\\/www.heartware.com\\/\\\" target=\\\"_blank\\\">www.HeartWare.com<\\/a>) develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients around the world suffering from advanced heart failure. Dedicated to developing new, minimally invasive technologies to revolutionize the treatment of patients with end-stage heart failure, HeartWare has multiple technologies in development to offer progressively less-invasive mechanical circulatory support options. HeartWare\'s corporate headquarters are located in Framingham, Massachusetts, and the company has technology, operations, manufacturing and distribution centers in Miami Lakes, Florida; Arden Hills, Minnesota; and Hannover, Germany.<\\/p>\",\"position\":\"left\"}},\"new4\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Medtronic\"}},\"new5\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Medtronic plc (<a href=\\\"http:\\/\\/www.medtronic.com\\/\\\" target=\\\"_blank\\\">www.medtronic.com<\\/a>), headquartered in Dublin, Ireland, is among the world\'s largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"6\\/27\\/2016\"},\"36\":[\"318\"]}}', '2016-07-12 04:50:11', '2016-07-12 04:50:11', '2cb2fba2-c3ef-44df-8210-820a184c30a4'),
 ('316', '14', '8', '1', 'en_us', '8', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"cleanslate\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"131\":\"\",\"20\":{\"date\":\"6\\/13\\/2016\"},\"36\":[\"65\"]}}', '2016-07-12 04:50:29', '2016-07-12 04:50:29', 'b3a9ea20-3b86-442f-a2f1-dfcfc3aadfa6'),
 ('317', '314', '8', '1', 'en_us', '2', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Cure Forward Announces First Trial Recruitment Collaboration That Will Expand Patient Access to Innovative Treatments\",\"slug\":\"cure-forward-announces-first-trial-recruitment-collaboration-that-will-expand-patient-access-to-innovative-treatments\",\"postDate\":1468298820,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"315\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Cure Forward, an online precision medicine platform for cancer patients and their care teams, and Novartis Pharmaceuticals Corporation today announced that Cure Forward\\u2019s unique Clinical Trial Exchange will support Novartis in identifying potential patients for all of its current oncology trials.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n<p>The collaboration further validates Cure Forward\\u2019s approach for real-time patient sourcing in clinical trials. By utilizing its patent pending Clinical Trial Exchange, Cure Forward facilitates connections between patients and drug development companies, based on mutual criteria and preferences, comparable to popular online dating platforms.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>There is a significant efficiency gap in the clinical trial process today, placing undue burden on patients and caregivers to navigate the vast, complex landscape of medical research options \\u2013 often at stages in which their time is most valuable. Drug developers are concurrently developing investigational treatments, but often struggle to find the right patients to receive these investigational treatments.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Cure Forward\\u2019s platform empowers patients to govern their own care plans, providing accurate, easily accessible information to help drive individual choices.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cToday\\u2019s patient is active in his or her care, accessing data to make important treatment decisions,\\u201d said Martin Naley, Founder and Chief Strategy Officer, Cure Forward. \\u201cCure Forward makes clinical trial enrollment easier and more accessible. Novartis\\u2019 bold approach of activating searches for oncology trials on our platform will help patients find possible investigational treatments for their care.\\u201d<\\/p>\",\"position\":\"left\"}},\"316\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Cure Forward\"}},\"317\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Cure Forward bridges the gap between patients and precision medicine, beginning in cancer. Cure Forward provides a simple-to-use platform that allows patients to obtain their genomic data and use it to identify treatment options including clinical trials, solving critical business needs for diagnostic laboratories, health care providers and clinical trial recruiters. Cure Forward is based in Cambridge, Massachusetts and was incubated and launched by Apple Tree Partners, New York City. The company\\u2019s platform is in beta release at&nbsp;<a href=\\\"http:\\/\\/cts.businesswire.com\\/ct\\/CT?id=smartlink&url=http%3A%2F%2Fwww.cureforward.com%2F&esheet=51370740&newsitemid=20160628005534&lan=en-US&anchor=www.cureforward.com&index=2&md5=24eaf06114eb049ec8095911016dcfef\\\" target=\\\"_blank\\\">www.cureforward.com<\\/a>.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"6\\/28\\/2016\"},\"36\":[\"325\"]}}', '2016-07-12 04:50:46', '2016-07-12 04:50:46', 'a3f553bd-622d-4d88-bac5-9e267c5374fd'),
 ('318', '327', '8', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"FDA approves first buprenorphine implant for treatment of opioid dependence\",\"slug\":\"fda-approves-first-buprenorphine-implant-for-treatment-of-opioid-dependence\",\"postDate\":1468299157,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"new1\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.<\\/p>\\r\\n\\r\\n<p>Until today, buprenorphine for the treatment of opioid dependence was only approved as a pill or a film placed under the tongue or on the inside of a person\\u2019s cheek until it dissolved. While effective, a pill or film may be lost, forgotten or stolen. However, as an implant, Probuphine provides a new treatment option for people in recovery who may value the unique benefits of a six-month implant compared to other forms of buprenorphine, such as the possibility of improved patient convenience from not needing to take medication on a daily basis. An independent FDA advisory committee supported the approval of Probuphine in a meeting held earlier this year.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>\\\"Opioid abuse and addiction have taken a devastating toll on American families. We must do everything we can to make new, innovative treatment options available that can help patients regain control over their lives,\\u201d said FDA Commissioner Robert M. Califf, M.D. \\u201cToday\\u2019s approval provides the first-ever implantable option to support patients\\u2019 efforts to maintain treatment as part of their overall recovery program.\\u201d<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Expanding the use and availability of medication-assisted treatment (MAT) options like buprenorphine is an important component of&nbsp;<a href=\\\"http:\\/\\/www.fda.gov\\/NewsEvents\\/Newsroom\\/FactSheets\\/ucm484714.htm\\\">the FDA\\u2019s opioid action plan<\\/a>&nbsp;and one of&nbsp;<a href=\\\"http:\\/\\/www.hhs.gov\\/about\\/news\\/2015\\/03\\/26\\/hhs-takes-strong-steps-to-address-opioid-drug-related-overdose-death-and-dependence.html\\\">three top priorities<\\/a>&nbsp;for the U.S. Department of Health and Human Services\\u2019 Opioid Initiative aimed at reducing prescription opioid and heroin related overdose, death and dependence.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Opioid dependence is the diagnostic term used for the more common concept, \\u201caddiction,\\u201d in the Probuphine clinical trials. Addiction is defined as a cluster of behavioral, cognitive and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use, persisting in drug use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, as well as the possibility of the development of tolerance or development of physical dependence. Physical dependence is not the same as addiction. Newer diagnostic terminology uses the term \\u201copioid use disorder,\\u201d which includes both milder forms of problematic opioid use as well as addiction.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>MAT is a comprehensive approach that combines approved medications (currently, methadone, buprenorphine or naltrexone) with counseling and other behavioral therapies to treat patients with opioid use disorder. Regular adherence to MAT with buprenorphine reduces opioid withdrawal symptoms and the desire to use, without causing the cycle of highs and lows associated with opioid misuse or abuse. At sufficient doses, it also decreases the pleasurable effects of other opioids, making continued opioid abuse less attractive. According to the Substance Abuse and Mental Health Services Administration, patients receiving MAT for their opioid use disorder cut their risk of death from all causes in half.<\\/p>\\r\\n\\r\\n<p><br><\\/p><p>\\u201cScientific evidence suggests that maintenance treatment with these medications in the context of behavioral treatment and recovery support are more effective in the treatment of opioid use disorder than short-term detoxification programs aimed at abstinence,\\u201d said Nora Volkow, M.D., director of the National Institute on Drug Abuse at the National Institutes of Health. \\u201cThis product will expand the treatment alternatives available to people suffering from an opioid use disorder.\\u201d<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Probuphine should be used as part of a complete treatment program that includes counseling and psychosocial support. Probuphine consists of four, one-inch-long rods that are implanted under the skin on the inside of the upper arm and provide treatment for six months. Administering Probuphine requires specific training because it must be surgically inserted and removed. Only a health care provider who has completed the training and become certified through a restricted program called the Probuphine Risk Evaluation and Mitigation Strategy (REMS) program should insert and remove the implants. If further treatment is needed, new implants may be inserted in the opposite arm for one additional course of treatment. The FDA is requiring postmarketing studies to establish the safety and feasibility of placing the Probuphine implants for additional courses of treatment.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>The safety and efficacy of Probuphine were demonstrated in a randomized clinical trial of adults who met the clinical criteria for opioid dependence and were considered stable after prior buprenorphine treatment. A response to MAT was measured by urine screening and self-reporting of illicit opioid use during the six month treatment period. Sixty-three percent of Probuphine-treated patients had no evidence of illicit opioid use throughout the six months of treatment \\u2013 similar to the 64 percent of those who responded to sublingual (under the tongue) buprenorphine alone.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>The most common side effects from treatment with Probuphine include implant-site pain, itching, and redness, as well as headache, depression, constipation, nausea, vomiting, back pain, toothache and oropharyngeal pain. The safety and efficacy of Probuphine have not been established in children or adolescents less than 16 years of age. Clinical studies of Probuphine did not include participants over the age of 65.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Probuphine has a boxed warning that provides important safety information for health care professionals, including a warning that insertion and removal of Probuphine are associated with the risk of implant migration, protrusion, expulsion and nerve damage resulting from the procedure. Probuphine must be prescribed and dispensed according to the Probuphine REMS program because of the risks of surgical complications and because of the risks of accidental overdose, misuse and abuse if an implant comes out or protrudes from the skin. As part of this program, Probuphine can only be prescribed and dispensed by health care providers who are certified with the REMS program and have completed live training, among other requirements.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Probuphine implants contain a significant amount of drug that can potentially be expelled or removed, resulting in the potential for accidental exposure or intentional misuse and abuse if the implant comes out of the skin. Patients should be seen during the first week after insertion and a visit schedule of no less than once-monthly is recommended for continued counseling and psychosocial support.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Probuphine is marketed by San Francisco-based Titan Pharmaceuticals Inc. and Braeburn Pharmaceuticals based in Princeton, New Jersey.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation\\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"5\\/26\\/2016\"},\"36\":[\"326\"]}}', '2016-07-12 04:52:37', '2016-07-12 04:52:37', 'b505f9b0-011f-4822-97d9-4729fe649c57'),
 ('319', '329', '8', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Dermatology Services Company QualDerm Unveils $31.8M Growth Investment\",\"slug\":\"dermatology-services-company-qualderm-unveils-31-8m-growth-investment\",\"postDate\":1468299312,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"new1\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>QualDerm Partners LLC (\\u201cQDP\\u201d), a dermatology services company, announced today it has raised $31.8 million in growth equity funding from Apple Tree Partners (\\u201cATP\\u201d) and Cressey & Company (\\u201cCressey\\u201d). The financing will enable QualDerm to strengthen its comprehensive physician support services and accelerate expansion through partnerships with leading dermatology practices.<\\/p>\\r\\n\\r\\n<p>Headquartered in Brentwood, TN, QualDerm provides physician support services through partnerships with best-in-class dermatology practices in the southeastern U.S. The company provides leadership, growth resources, and management services to skin surgeons, pediatric, and general dermatologists and mid-level providers to alleviate the burden of the day-to-day administrative demands of running a business.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p><em>\\u201cOur investment in QDP aligns with ATP\\u2019s commitment to partner with exceptional management teams and build leading healthcare companies,\\\" said Diane Daych, Partner of Apple Tree Partners, who joined QualDerm\\u2019s Board of Directors. \\\"With extensive experience building and operating multi-site provider businesses and deep knowledge in effective practice management strategy, ATP looks forward to supporting QDP\\u2019s growth.\\u201d<\\/em><\\/p>\\r\\n\\r\\n<p><em>\\u201cCressey & Company is excited to have additional resources from ATP to support the continued professional success and clinical excellence of our existing partnership with QDP,\\u201d said David Schuppan, Cressey Partner and QDP Board member.<\\/em><\\/p>\\r\\n\\r\\n<p>Under the leadership of Bill Southwick, CEO, QualDerm partners with physicians to create high functioning teams through shared culture, shared services, and shared decision making. QualDerm is dedicated to expanding patient access to high quality care in secondary markets as well as other underserved areas, where the nationwide dearth of dermatologists is particularly problematic.<em>&nbsp;\\u201cWe are pleased to partner with our investors, who bring significant experience building healthcare companies and adding operational value. This investment will facilitate QDP\\u2019s mission to provide management, growth, and strategic services that enable high quality dermatology care while preserving physician autonomy in true partnership fashion,\\u201d&nbsp;<\\/em>said Southwick.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>The company\\u2019s practice affiliates include The Skin Surgery Center, a full-service, multi-site specialty group based in North Carolina, led by distinguished physicians, Drs. Barry Leshin and John Albertini.&nbsp;<em>\\u201cAs the platform practice for QDP, we have been truly gratified by the sophistication and expertise of our management team and anticipate that ATP\\u2019s investment in both capital and strategic vision will synergize with Cressey in a way that adds tremendous value as we expand our mission to provide high quality dermatologic care to the region and beyond.\\u201d<\\/em><\\/p>\",\"position\":\"left\"}},\"new2\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Apple Tree Partners\"}},\"new3\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Apple Tree Partners (ATP) is a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, ATP closed its current capital pool of $1.5 billion in 2012 and is actively funding healthcare innovation. ATP starts companies, or invests in existing companies, with commitments as high as $250 million. The firm is headquartered in New York City, with satellite offices in Princeton, NJ, Cambridge, MA, and Los Altos, CA.<\\/p>\\r\\n\\r\\n<p>For more information, please visit:&nbsp;<a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\">www.appletreepartners.com<\\/a><\\/p>\",\"position\":\"left\"}},\"new4\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Cressey & Company\"}},\"new5\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Based in Chicago, IL and Nashville, TN, Cressey & Company is a private investment firm focused on building leading healthcare provider, service and information technology businesses. With a history spanning nearly 35 years, the Cressey & Company team is one of the most experienced and successful in the healthcare private equity field.<\\/p>\\r\\n\\r\\n<p>More information about Cressey & Company is available at&nbsp;<a href=\\\"http:\\/\\/www.cresseyco.com\\/\\\" target=\\\"_blank\\\">www.cresseyco.com<\\/a>.<\\/p>\",\"position\":\"left\"}},\"new6\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About QualDerm\"}},\"new7\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Based in Brentwood, TN, QualDerm Partners provides strategic leadership and practice management services for dermatologists and skin care professionals. The company strives to be the partner of choice for premier, patient-centric dermatology practices throughout the southeast.<\\/p>\\r\\n\\r\\n<p>For more information, please visit&nbsp;<a href=\\\"http:\\/\\/www.qualderm.com\\/\\\" target=\\\"_blank\\\">www.qualderm.com<\\/a><\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"4\\/20\\/2016\"},\"36\":\"\"}}', '2016-07-12 04:55:12', '2016-07-12 04:55:12', 'a662a2b7-b157-4827-abf2-1d911de3a816'),
 ('320', '338', '8', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Syntimmune Secures Second Tranche of $26 Million Series A Financing\",\"slug\":\"syntimmune-secures-second-tranche-of-26-million-series-a-financing\",\"postDate\":1468299411,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"new1\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Syntimmune, Inc., a development-stage company advancing novel treatments for IgG-mediated autoimmune diseases based on leading expertise in FcRn biology, today announced that it has made important progress by achieving preclinical proof of concept and completing preclinical safety testing, triggering a second, $10 million tranche of the Company\\u2019s committed $26 million Series A financing. The Series A financing is co-led by Apple Tree Partners and Baxalta Ventures, the corporate venture capital arm of Baxalta Incorporated, with participation by the Partners Innovation Fund and additional investors. Funds from this tranche of the Series A round will be used to complete the anticipated Phase 1a clinical trial in healthy volunteers of Syntimmune\\u2019s lead candidate, SYNT001. The Company intends to submit an IND application to the Food and Drug Administration for SYNT001 in mid-2016 to authorize initiation of the Phase 1a study later this year. SYNT001 is a biologic that blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases.<\\/p>\\r\\n\\r\\n<p>\\u201cThe closing of the second tranche in the Series A affirms the progress Syntimmune has achieved and reflects the importance of targeting FcRn as a breakthrough modality for treating IgG-mediated autoimmune diseases,\\u201d said Laurence Blumberg, M.D., Founder and COO of Syntimmune. \\u201cSince our founding just over two years ago, Syntimmune has made rapid progress in advancing its pipeline of candidates and progressing its lead program, SYNT001, through IND-enabling studies and toward the clinic. SYNT001 is showing a promising preclinical safety profile and robust activity in unique in vivo preclinical models, which we plan to present at appropriate peer-reviewed forums.\\u201d<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>\\u201cThe opportunity for SYNT001 is substantial,\\u201d stated David de Graaf, Ph.D., Venture Partner at Apple Tree Partners. \\u201cWe are extremely happy with the progress the team has made on the lead molecule, which has the potential to address a large number of autoimmune indications.\\u201d<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>\\u201cFcRn is a central mediator of IgG-related immunity and part of an important pathway that enables abnormal IgG responses in a large number of clinical settings, including autoimmune disease,\\u201d commented Richard Blumberg, M.D., Scientific Founder of Syntimmune and Division Chief of Gastroenterology, Hepatology and Endoscopy at Brigham and Women\\u2019s Hospital, as well as co-Director of the Harvard Digestive Diseases Center and Director of the Brigham Research Institute. \\u201cWhile FcRn is a highly validated target and has attracted substantial industry interest, there are no commercially available therapies designed to block IgG-FcRn interactions, which underlie diseases that affect multiple organ systems and for which there are continuing substantial medical needs, such as inflammatory bowel disease, lupus erythematosus, dermatomyositis and others. I am thrilled with the progress of Syntimmune and look forward to the advancement of the clinical program for SYNT001.\\u201d<\\/p>\",\"position\":\"left\"}},\"new2\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Syntimmune\"}},\"new3\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Founded in 2013, Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-mediated autoimmune diseases and represents a central common pathway that enables abnormal IgG responses. Syntimmune\\u2019s lead candidate, SYNT001, is a biologic progressing through IND-enabling studies that specifically blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases. Syntimmune has two additional, earlier-stage therapeutic programs, targeting other unique aspects of FcRn biology. The Syntimmune team has world-class experience in the field of FcRn biology and has successfully pioneered and advanced biologics targeting FcRn, including approved therapies currently on the market. Since its founding, the Company has received a total of $28 million in funding commitments from leading life sciences investors, including Apple Tree Partners, Baxalta Ventures, and Partners Innovation Fund. For more information on Syntimmune, please visit the Company\\u2019s website at<a href=\\\"http:\\/\\/cts.businesswire.com\\/ct\\/CT?id=smartlink&url=http%3A%2F%2Fwww.syntimmune.com&esheet=51304447&newsitemid=20160322005211&lan=en-US&anchor=www.syntimmune.com&index=1&md5=62fb1a7393f2201155ab419b9a8b964d\\\" target=\\\"_blank\\\">www.syntimmune.com<\\/a>.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"3\\/22\\/2016\"},\"36\":[\"337\"]}}', '2016-07-12 04:56:51', '2016-07-12 04:56:51', '20d651ba-dfcb-4e14-97fa-0297266f760e'),
 ('321', '342', '8', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain\",\"slug\":\"braeburn-and-camurus-announce-initiation-of-a-phase-2-study-in-opioid-dependent-patients-with-moderate-to-severe-chronic-pain\",\"postDate\":1468299573,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"new1\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Braeburn Pharmaceuticals and Camurus announced today that the first patients have been dosed with CAM2038, weekly and monthly subcutaneous buprenorphine injections, in a pharmacokinetic study of opioid dependent patients with chronic pain.<\\/p>\\r\\n\\r\\n<p>The primary objective of this Phase 2 study is to assess the steady state pharmacokinetics of buprenorphine after repeated doses in opioid dependent patients with chronic pain, including effects of injection into different subcutaneous sites. This study will also explore the effect of CAM2038 on chronic pain, along with evaluation of safety and tolerability.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>\\\"This marks the fourth clinical study that has been started in the last five months for CAM2038, including two Phase 3 trials in opioid dependence. The ability to use CAM2038 in multiple injection sites would allow physicians the flexibility to personalize treatments,\\\" said Behshad Sheldon, President and CEO, Braeburn Pharmaceuticals. \\\"Our goal is to provide a suite of best-in-class long-acting treatment options tailored to the individual needs of patients suffering from opioid dependence and chronic pain.\\\"<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>\\\"Patients that suffer from chronic pain and are also opioid dependent are a difficult population to treat,\\\" said the principal investigator Dr. Greg Sullivan, medical director at Parkway Medical Center in Birmingham, Alabama. \\\"By using a long acting buprenorphine injectable, these patients would no longer be required to take medication multiple times per day. Buprenorphine also guards against hyperanalgesia and opiate tolerance, both of which are problems with conventional opiates.\\\"<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>\\\"CAM2038 has the potential to offer effective and safe around-the-clock pain relief, without risks of abuse and diversion. The pharmacological properties of buprenorphine together with long-acting release from the FluidCrystal formulation could also decrease risks of respiratory depression and overdose mortality associated with current opioid pain treatments,\\\" said Fredrik Tiberg, President and CEO, Camurus.<\\/p>\",\"position\":\"left\"}},\"new2\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Braeburn Pharmaceuticals\"}},\"new3\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Braeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience. In September 2015 the Food and Drug Administration (FDA) accepted for review Braeburn\'s New Drug Application for its lead candidate, Probuphine, a six-month buprenorphine implant for treatment of opioid dependence. The Agency has set May 27, 2016 as the target date for action.<\\/p>\\r\\n\\r\\n<p>Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. Braeburn\'s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Candidates include: Probuphine\\u00ae, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia. More information on Braeburn, can be found at&nbsp;<a href=\\\"https:\\/\\/braeburnpharmaceuticals.com\\/\\\" target=\\\"_blank\\\">https:\\/\\/braeburnpharmaceuticals.com\\/<\\/a>.<\\/p>\",\"position\":\"left\"}},\"new4\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CAM2038\"}},\"new5\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>The investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid addiction and pain are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance. The CAM2038 products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion, abuse, misuse, and accidental exposure. The CAM2038 products have been evaluated in three Phase 1\\/2 clinical trials, which evaluated the safety and tolerability as well as pharmacokinetic and pharmacodynamics properties of the products in a total of 176 individuals (opioid-dependent patients and healthy volunteers under naltrexone blockage). The CAM2038 products are also being developed for treatment of chronic pain, combining the effective analgesic properties of buprenorphine with the long acting release provided by the FluidCrystal\\u00ae injection depot.<\\/p>\",\"position\":\"left\"}},\"new6\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Camurus\"}},\"new7\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal\\u00ae drug delivery technologies and an extensive R&D expertise. Camurus\' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company\'s share is listed on Nasdaq Stockholm under the ticker \\\"CAMX\\\". For more information, visit&nbsp;<a href=\\\"http:\\/\\/www.camurus.com\\/\\\" target=\\\"_blank\\\">www.camurus.com<\\/a>.<\\/p>\",\"position\":\"left\"}}},\"131\":\"\",\"20\":{\"date\":\"2\\/22\\/2016\"},\"36\":[\"326\"]}}', '2016-07-12 04:59:33', '2016-07-12 04:59:33', '7b4c3e85-1e6d-4ecb-8f77-439e1a65cea7'),
 ('322', '351', '8', '1', 'en_us', '1', '', '{\"typeId\":null,\"authorId\":\"1\",\"title\":\"Corvidia Therapeutics Raises $26M in a Series A Financing, Led by Sofinnova Partners and Apple Tree Partners\",\"slug\":\"corvidia-therapeutics-raises-26m-in-a-series-a-financing-led-by-sofinnova-partners-and-apple-tree-partners\",\"postDate\":1468299716,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"new1\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple Tree Partners.<\\/p>\\r\\n\\r\\n<p>Concurrent with the financing, Corvidia has licensed a clinical stage compound from AstraZeneca to develop and commercialize as its lead therapeutic (COR-001). Funds from the Series A financing will be used to progress COR-001 into Phase I\\/II clinical trials during 2016, as well as to advance the company\'s preclinical pipeline.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Corvidia was co-founded by serial entrepreneur and Chief Executive Officer, Michael Davidson, M.D. Dr. Davidson, a recognized expert in the field of cardiology, previously served as Chief Medical Officer of Sofinnova-backed Omthera Pharmaceuticals, and was instrumental in the successful acquisition of that company by AstraZeneca in 2013 for $443 million. Joining Dr. Davidson at Corvidia are Co-founders Rahul Kakkar M.D. and Matt Devalaraja, Ph.D., both of whom previously worked in AstraZeneca\'s Emerging Innovations Unit, where they developed the science behind genome-guided cardiovascular therapies. Ram Aiyar Ph.D., MBA, an Entrepreneur-in-Residence at the National Institutes of Health and BioHealth Innovation, completes Corvidia\'s founding team.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Commenting on today\'s news, Dr. Davidson stated,&nbsp;<em>\\\"Our ability to complete this significant Series A financing with such high-quality investors is a testament to the promise of our technology and expertise of our management team, positioning Corvidia as a leader in the field of precision medicine as applied to cardiovascular diseases. With these funds, we aim to drive each of our assets through clinical trials and validate our precision medicine approach.\\\"<\\/em><\\/p>\\r\\n\\r\\n<p>Graziano Seghezzi, Partner at Sofinnova Partners, and Corvidia\'s board member commented,&nbsp;<em>\\\"Given Omthera\'s success, we were strongly in favor of teaming up once again with Dr. Davidson. The seed funding that Sofinnova Partners provided allowed for Corvidia\'s inception, for the pipeline crafting and for the eventual structuring of the Series A. We are pleased to continue to support Corvidia and this latest financing represents a major step for the future advancement of novel, cardiovascular therapeutics.\\\"<\\/em><\\/p>\\r\\n\\r\\n<p>Seth Harrison, M.D., Managing Partner of Apple Tree Partners, noted, \\\"<em>In&nbsp;<\\/em><em>our years of start-up investing we have not seen a better team than the group that Michael Davidson has assembled from AstraZeneca and the NIH. We are thrilled to be able to support Corvidia with our capital resources and company building experience, and look forward to working with Sofinnova Partners, AstraZeneca, and management to create the first great precision cardiovascular medicine company.<\\/em>\\\"<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>COR-001, a monoclonal antibody initially developed by MedImmune, AstraZeneca\'s global biologics research and development arm, was previously in a Phase 1 study for a different indication. It was repurposed by AstraZeneca\'s Emerging Innovations Unit, Scientific Partnering and Alliances (SP&A), prior to licensing to Corvidia.&nbsp;<em>\\\"This is another example of the strong entrepreneurial culture within AstraZeneca, where we push the boundaries of science to explore new therapeutic uses for our compounds. We will continue to divest or out-license assets where we believe it will help accelerate the development of new medicines.\\\"&nbsp;<\\/em>said Kumar Srinivasan, Vice President, SP&A, Innovative Medicines Unit, AstraZeneca.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>In conjunction with the financing, Seth Harrison and Adrien Lemoine, Executive Director, Corporate Development for AstraZeneca, will join Graziano Seghezzi and Michael Davidson on Corvidia\'s Board of Directors.<\\/p>\",\"position\":\"left\"}},\"new2\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Sofinnova Partners\"}},\"new3\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs, and has backed nearly 500 companies over more than 40 years, creating market leaders around the globe. Today, Sofinnova Partners has over \\u20ac1.5 billion under management. For more information, please visit:<a href=\\\"http:\\/\\/www.sofinnova.fr\\/\\\" target=\\\"_blank\\\">www.sofinnova.fr<\\/a><\\/p>\",\"position\":\"left\"}},\"new4\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Corvidia Therapeutics\"}},\"new5\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Based in Boston, MA, Corvidia is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company\'s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia\'s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. For more information, please visit:<a href=\\\"http:\\/\\/www.corvidiatx.com\\/\\\" target=\\\"_blank\\\">www.corvidiatx.com<\\/a><\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"2\\/17\\/2016\"},\"36\":[\"350\"]}}', '2016-07-12 05:01:56', '2016-07-12 05:01:56', '6de38198-0374-4a08-a603-835a6675b6b8'),
 ('323', '9', '6', '1', 'en_us', '44', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical#entry:296:url\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/cure-forward#entry:244:url\\\">Cure Forward<\\/a>\\u2019s unique Clinical Trial Exchange&nbsp;platform empowers patients to govern their own care plans.&nbsp;<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}}}}', '2016-07-12 14:36:38', '2016-07-12 14:36:38', 'ce49cadd-5041-4915-8400-377a3822a8ac'),
 ('324', '13', '10', '1', 'en_us', '12', '', '{\"typeId\":\"10\",\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1466010801,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"19\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseImage\":[\"95\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"298\",\"242\",\"244\",\"239\"]}},\"20\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseImage\":[\"92\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"296\",\"27\",\"287\"]}},\"21\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseImage\":[\"89\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":\"\"}},\"22\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Legacy Investments\",\"expertiseImage\":[\"90\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":\"\"}}}}}', '2016-07-12 23:28:32', '2016-07-12 23:28:32', '777364be-6fa4-4bf5-83e0-35fb66b507b0'),
 ('325', '29', '12', '1', 'en_us', '26', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"104\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"298\",\"248\",\"204\",\"27\"],\"109\":\"Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio compani\",\"104\":\"\"}}', '2016-07-13 00:28:05', '2016-07-13 00:28:05', '20b92a1f-f6ce-4e3b-852e-9f6a12482acb'),
 ('326', '29', '12', '1', 'en_us', '27', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"104\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"298\",\"248\",\"204\",\"27\"],\"109\":\"Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio compani\",\"104\":\"\"}}', '2016-07-13 00:29:04', '2016-07-13 00:29:04', '4bfa22ee-37e3-461f-aead-9c762843d70f'),
 ('327', '29', '12', '1', 'en_us', '28', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"104\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"70\"],\"109\":\"Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio compani\",\"104\":[\"298\",\"293\",\"284\",\"27\"]}}', '2016-07-13 00:36:48', '2016-07-13 00:36:48', 'bbbc73a3-86ee-485a-b0b0-aff171d2f51d'),
 ('328', '9', '6', '1', 'en_us', '45', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"new1\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Areas of Expertise\"}},\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical#entry:296:url\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/cure-forward#entry:244:url\\\">Cure Forward<\\/a>\\u2019s unique Clinical Trial Exchange&nbsp;platform empowers patients to govern their own care plans.&nbsp;<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}}}}', '2016-07-13 00:53:43', '2016-07-13 00:53:43', '919fbcd9-2da2-4130-b583-69c07aee84ff'),
 ('329', '9', '6', '1', 'en_us', '46', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"357\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Areas of Expertise\"}},\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"new1\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Partnerships\"}},\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical#entry:296:url\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/cure-forward#entry:244:url\\\">Cure Forward<\\/a>\\u2019s unique Clinical Trial Exchange&nbsp;platform empowers patients to govern their own care plans.&nbsp;<\\/h1>\"}}},\"9\":{\"new1\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Charting a Trajectory\"}},\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}}}}', '2016-07-13 00:54:24', '2016-07-13 00:54:24', 'd0f686b3-e8ca-45b5-ab72-1a6cab5d95a8'),
 ('330', '9', '6', '1', 'en_us', '47', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"357\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Areas of Expertise\"}},\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"358\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Partnerships\"}},\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical#entry:296:url\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/cure-forward#entry:244:url\\\">Cure Forward<\\/a>\\u2019s unique Clinical Trial Exchange&nbsp;platform empowers patients to govern their own care plans.&nbsp;<\\/h1>\"}},\"new1\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<p>Test partnership<\\/p>\"}}},\"9\":{\"359\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Charting a Trajectory\"}},\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}}}}', '2016-07-13 14:57:40', '2016-07-13 14:57:40', '384ada52-ee01-4c91-8897-cac7d71fba8a'),
 ('331', '9', '6', '1', 'en_us', '48', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"357\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Areas of Expertise\"}},\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"82\":{\"358\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Partnerships\"}},\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical#entry:296:url\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/cure-forward#entry:244:url\\\">Cure Forward<\\/a>\\u2019s unique Clinical Trial Exchange&nbsp;platform empowers patients to govern their own care plans.&nbsp;<\\/h1>\"}}},\"9\":{\"359\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Charting a Trajectory\"}},\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}}}}', '2016-07-13 14:58:26', '2016-07-13 14:58:26', '3402cc50-4426-4ab1-b9f7-1e2b3730c14e'),
 ('332', '9', '6', '1', 'en_us', '49', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"357\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Areas of Expertise\"}},\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"141\":\"Partnerships\",\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical#entry:296:url\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/cure-forward#entry:244:url\\\">Cure Forward<\\/a>\\u2019s unique Clinical Trial Exchange&nbsp;platform empowers patients to govern their own care plans.&nbsp;<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}},\"140\":\"Trajectories\"}}', '2016-07-13 15:03:02', '2016-07-13 15:03:02', '523e01e9-c8f4-4c08-ad1a-ce73e651877b'),
 ('333', '9', '6', '1', 'en_us', '50', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"357\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Areas of Expertise\"}},\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"141\":\"Partnerships\",\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/aileron-therapeutics#entry:27:url\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical#entry:296:url\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/cure-forward#entry:244:url\\\">Cure Forward<\\/a>\\u2019s unique Clinical Trial Exchange&nbsp;platform empowers patients to govern their own care plans.&nbsp;<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}},\"140\":\"Charting a trajectory\"}}', '2016-07-13 15:19:55', '2016-07-13 15:19:55', 'a9bdf6d7-c88b-4961-9061-2bc828b5c2ec'),
 ('334', '298', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"VytronUS\",\"slug\":\"vytronus\",\"postDate\":1468283040,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>VytronUS is a clinical stage company redefining ablation by using a next generation ultrasound based robotic catheter to treat complex cardiac arrhythmias including atrial fibrillation. The company has developed an endocardial ablation platform based on Low-Intensity Collimated Ultrasound (LICU&trade;). LICU is capable of quickly producing high-resolution maps of cardiac anatomy and allows for non-contact energy delivery to create durable continuous linear lesions. VytronUS will help simplify the procedure and improve efficacy by leading to more predictable outcomes.<\\/p>\",\"62\":{\"299\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.vytronus.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"92\"],\"66\":[\"372\"],\"81\":\"<p>VytronUS is a clinical stage company redefining ablation by using a next generation ultrasound based robotic catheter to treat complex cardiac arrhythmias including atrial fibrillation.<\\/p>\",\"103\":[\"97\"]}}', '2016-07-13 16:27:51', '2016-07-13 16:27:51', '0f3d790e-9b9e-4b19-bd05-917ab4d3e3ad'),
 ('335', '296', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Tusker Medical\",\"slug\":\"tusker-medical\",\"postDate\":1468282980,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Tusker Medical is an early stage medical device company developing innovative ear, nose and throat treatments. Tusker is currently developing a suite of pediatric-focused technologies designed to enable placement of tubes within the comfort of an office environment, eliminating the need for general anesthetics.<\\/p>\",\"62\":{\"297\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.tuskermed.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/tusker-medical-inc.\"}}},\"130\":[\"92\"],\"66\":[\"375\"],\"81\":\"<p>Tusker Medical is an early stage medical device company developing innovative ear, nose and throat treatments.<\\/p>\",\"103\":[\"97\"]}}', '2016-07-13 16:28:22', '2016-07-13 16:28:22', 'f1338056-aa7c-42c2-b581-92465ac69fcd'),
 ('336', '293', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"TripleCare\",\"slug\":\"triplecare\",\"postDate\":1468282740,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>TripleCare provides acute hospital-level care to patients residing in skilled nursing facilities (\\u201cSNFs\\u201d) using state-of-the-art telemedicine technology. The company expands patient access to care after hours and on weekends by providing physicians, equipment, and software to SNFs, with the goal of treating patients in place. The company presently operates across over thirty-five facilities in six states.<\\/p>\",\"62\":{\"294\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/triple.care\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/esnf\\/\"}}},\"130\":[\"89\"],\"66\":[\"363\"],\"81\":\"<p>TripleCare provides acute hospital-level care to patients residing in skilled nursing facilities (\\u201cSNFs\\u201d) using state-of-the-art telemedicine technology.<\\/p>\",\"103\":[\"96\"]}}', '2016-07-13 16:28:42', '2016-07-13 16:28:42', 'c8e78baa-d60e-48b3-8380-25082b81e362'),
 ('337', '290', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Tokai Pharmaceuticals\",\"slug\":\"tokai-pharmaceuticals\",\"postDate\":1468282620,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Tokai (TKAI) is developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. The company is conducting a pivotal clinical trial of its lead drug candidate, galeterone, in patients with metastatic castration-resistant prostate cancer (mCRPC) whose tumors express the AR-V7 splice variant, which is a truncated form of the androgen receptor associated with non-responsiveness to commonly-used oral therapies for mCRPC. This trial is the first precision medicine based pivotal clinical trial in prostate cancer.<\\/p>\",\"62\":{\"291\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/tokaipharmaceuticals.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/tokai-pharmaceuticals-inc-\"}}},\"130\":[\"95\"],\"66\":[\"365\"],\"81\":\"<p>Tokai (TKAI) is developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases.<\\/p>\",\"103\":[\"376\"]}}', '2016-07-13 16:29:12', '2016-07-13 16:29:12', '0a2ab300-c2d4-4bb3-95ce-2f5b13d46734'),
 ('338', '287', '13', '1', 'en_us', '3', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Tendyne\",\"slug\":\"tendyne\",\"postDate\":1468282500,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Tendyne is focused on the development and commercialization of minimally invasive therapies for the treatment of mitral regurgitation. Tendyne\\u2019s first product is a percutaneous transcatheter mitral valve prosthesis.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Abbott August 2015<\\/em><\\/p>\",\"62\":{\"288\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.tendyne.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"90\"],\"66\":[\"371\"],\"81\":\"<p>Tendyne is focused on the development and commercialization of minimally invasive therapies for the treatment of mitral regurgitation.&nbsp;<\\/p>\",\"103\":[\"376\"]}}', '2016-07-13 16:29:30', '2016-07-13 16:29:30', '939b36ac-7fa9-404a-8e5e-44420c1eb05d'),
 ('339', '284', '13', '1', 'en_us', '2', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Syntimmune\",\"slug\":\"syntimmune\",\"postDate\":1468282140,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Syntimmune is developing novel antibody therapies for inflammatory diseases and severe toxicities. Syntimmune\\u2019s lead program, SYNT-001, specifically blocks FcRn-IgG interaction, resulting in the rapid clearance of pathogenic IgG important in a variety of antibody-mediated diseases.<\\/p>\",\"62\":{\"285\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/syntimmune.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"95\"],\"66\":[\"362\"],\"81\":\"<p>Syntimmune is developing novel antibody therapies for inflammatory diseases and severe toxicities.<\\/p>\",\"103\":[\"100\"]}}', '2016-07-13 16:29:54', '2016-07-13 16:29:54', 'fc4825c2-3e91-4586-9b97-53e89a45f5aa'),
 ('340', '281', '13', '1', 'en_us', '3', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"SGX Pharmaceuticals\",\"slug\":\"sgx-pharmaceuticals\",\"postDate\":1468282020,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>A biotechnology company focused on discovery and development of small molecule therapeutics generated by its proprietary Fragments of Active Structures (FAST) medicinal chemistry platform.<\\/p>\\r\\n\\r\\n<p><em>IPO February 2006 (acquired by Eli Lilly July 2008)<\\/em><\\/p>\",\"62\":{\"282\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"https:\\/\\/www.lilly.com\\/home.aspx\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/sgx-pharmaceuticals\"}}},\"130\":[\"90\"],\"66\":[\"370\"],\"81\":\"<p>A biotechnology company focused on discovery and development of small molecule therapeutics generated by its proprietary Fragments of Active Structures (FAST) medicinal chemistry platform.<\\/p>\",\"103\":[\"376\"]}}', '2016-07-13 16:30:20', '2016-07-13 16:30:20', '9d0a40aa-62be-4edb-ade1-20816d8f01d8'),
 ('341', '275', '13', '1', 'en_us', '4', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"QualDerm Partners\",\"slug\":\"qualderm-partners\",\"postDate\":1468280820,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>QualDerm Partners provides strategic leadership and practice management services through partnerships with highly qualified dermatologists throughout the Southeastern US. The company alleviates practice administrative burdens, empowering providers to focus solely on delivering exceptional patient care.<\\/p>\",\"62\":{\"276\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/qualderm.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/6471786?trk=tyah&trkInfo=clickedVertical%3Acompany%2Cidx%3A2-1-4%2CtarId%3A1435163699111%2Ctas%3Aqualderm%20partners\"}}},\"130\":[\"89\"],\"66\":[\"374\"],\"81\":\"<p>QualDerm Partners provides strategic leadership and practice management services through partnerships with highly qualified dermatologists throughout the Southeastern US.&nbsp;<\\/p>\",\"103\":[\"96\"]}}', '2016-07-13 16:30:36', '2016-07-13 16:30:36', 'e28edb29-8782-490a-947d-c8771fb2fb03'),
 ('342', '250', '13', '1', 'en_us', '7', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"HeartWare International\",\"slug\":\"heartware-international\",\"postDate\":1468276800,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>HeartWare (HTWR)develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.<\\/p>\\r\\n\\r\\n<p><em>IPO January 2005 ASX; listed on NASDAQ September 2013<\\/em><\\/p>\",\"62\":{\"268\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.heartware.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/heartware-inc\"}}},\"130\":[\"90\"],\"66\":[\"369\"],\"81\":\"<p>HeartWare (HTWR)develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.<\\/p>\",\"103\":[\"376\"]}}', '2016-07-13 16:30:57', '2016-07-13 16:30:57', '21a2afa7-b0c4-432a-8d8a-7b945f4d4905'),
 ('343', '248', '13', '1', 'en_us', '5', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Gloucester Pharmaceuticals\",\"slug\":\"gloucester-pharmaceuticals\",\"postDate\":1468276620,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Creators of ISTODAX\\u00ae (romidepsin) for T-cell lymphoma and other malignancies.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Celgene January 2010<\\/em><\\/p>\",\"62\":{\"249\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.celgene.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"90\"],\"66\":[\"367\"],\"81\":\"<p>Creators of ISTODAX\\u00ae (romidepsin) for T-cell lymphoma and other malignancies.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Celgene January 2010<\\/em><\\/p>\",\"103\":[\"376\"]}}', '2016-07-13 16:31:14', '2016-07-13 16:31:14', '390ea507-80cb-4aee-8c72-aa55b0d5b593'),
 ('344', '246', '13', '1', 'en_us', '5', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Cyrano Sciences\",\"slug\":\"cyrano-sciences\",\"postDate\":1468276560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>An electronic nose for homeland defense applications.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Smiths Detection March 2004<\\/em><\\/p>\",\"62\":{\"247\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.smithsdetection.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"90\"],\"66\":\"\",\"81\":\"<p>An electronic nose for homeland defense applications.<\\/p>\",\"103\":[\"376\"]}}', '2016-07-13 16:31:34', '2016-07-13 16:31:34', 'd07b6080-8a36-4e58-94a9-11f6fee8fc3e'),
 ('345', '244', '13', '1', 'en_us', '5', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Cure Forward\",\"slug\":\"cure-forward\",\"postDate\":1468276500,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Cure Forward connects cancer patients with clinical trial administrators working to reduce trial recruitment times and increase participation. Cure Forward\\u2019s online portal, in addition to providing access to clinical trials, can also help patients retrieve molecular diagnostic test results ordered by physicians, access educational information, connect with other patients, and investigate treatment options.<\\/p>\",\"62\":{\"245\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"https:\\/\\/www.cureforward.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/cureforward\"}}},\"130\":[\"89\"],\"66\":[\"373\"],\"81\":\"<p>Cure Forward connects cancer patients with clinical trial administrators working to reduce trial recruitment times and increase participation.<\\/p>\",\"103\":[\"96\"]}}', '2016-07-13 16:31:59', '2016-07-13 16:31:59', 'ca8390c9-1dde-413c-9bfd-9271b7cb9658');
INSERT INTO `craft_entryversions` (`id`, `entryId`, `sectionId`, `creatorId`, `locale`, `num`, `notes`, `data`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('346', '242', '13', '1', 'en_us', '3', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Gala Therapeutics\",\"slug\":\"gala-therapeutics\",\"postDate\":1468276140,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Gala Therapeutics is an early stage medical device company developing a novel catheter based approach to treating pulmonary disease including chronic bronchitis, COPD, and asthma.<\\/p>\",\"62\":{\"243\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.galatherapeutics.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"92\"],\"66\":\"\",\"81\":\"<p>Gala Therapeutics is an early stage medical device company developing a novel catheter based approach to treating pulmonary disease including chronic bronchitis, COPD, and asthma.<\\/p>\",\"103\":[\"97\"]}}', '2016-07-13 16:32:13', '2016-07-13 16:32:13', '451e8a44-7629-4702-b22e-97864575abc7'),
 ('347', '239', '13', '1', 'en_us', '6', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Corvidia\",\"slug\":\"corvidia\",\"postDate\":1468275660,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company has identified mechanistically-driven responder populations in a variety of cardio-metabolic and cardio-renal disorders.<\\/p>\",\"62\":{\"240\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/corvidiatx.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/corvidia-therapeutics\"}}},\"130\":[\"95\"],\"66\":[\"368\"],\"81\":\"<p>Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies.<\\/p>\",\"103\":[\"100\"]}}', '2016-07-13 16:32:34', '2016-07-13 16:32:34', 'ed539505-a248-4f62-995c-49c8d3144a34'),
 ('348', '229', '13', '1', 'en_us', '5', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Coelacanth Chemical Corporation\",\"slug\":\"http-www-appletreepartners-com-portfolio-detail-coelacanth-acquired-by-lexicon-genetics\",\"postDate\":1468274580,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \\\"click\\\" chemistry.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Lexicon Genetics July 2001<\\/em><\\/p>\",\"62\":{\"230\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.lexicon-genetics.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/coelacanth-chemical-corp\"}}},\"130\":[\"90\"],\"66\":\"\",\"81\":\"<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \\\"click\\\" chemistry.<\\/p>\",\"103\":[\"376\"]}}', '2016-07-13 16:32:52', '2016-07-13 16:32:52', 'bb37d5e8-448f-442c-9ec7-ac46db3be556'),
 ('349', '204', '13', '1', 'en_us', '7', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"CleanSlate Addiction Treatment Centers\",\"slug\":\"cleanslate-addiction-treatment-centers\",\"postDate\":1468274280,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania. CleanSlate provides medication-assisted treatment and related therapies using the highest quality, evidence-based practices for patients who have addiction and associated disorders.<\\/p>\",\"62\":{\"205\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/cleanslatecenters.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/cleanslate-centers\"}}},\"130\":[\"89\"],\"66\":[\"366\"],\"81\":\"<p>CleanSlate is an outpatient addiction treatment company with a rapidly expanding multi-site network, currently comprised of twelve physician-led centers located in both Massachusetts and Pennsylvania.&nbsp;<\\/p>\",\"103\":[\"96\"]}}', '2016-07-13 16:33:16', '2016-07-13 16:33:16', '96b63fb3-f902-42c5-bb09-6fc2fbd9cafe'),
 ('350', '200', '13', '1', 'en_us', '6', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Braeburn Pharmaceuticals\",\"slug\":\"braeburn-pharmaceuticals\",\"postDate\":1468274160,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Braeburn Pharmaceuticals is developing a portfolio of long-acting therapeutic treatment options for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Long-acting implantable and injectable therapies can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. The current portfolio includes: Probuphine\\u00ae, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia.<\\/p>\",\"62\":{\"201\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"https:\\/\\/braeburnpharmaceuticals.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/braeburn-pharmaceuticals\"}}},\"130\":[\"95\"],\"66\":[\"361\"],\"81\":\"<p>Braeburn Pharmaceuticals is developing a portfolio of long-acting therapeutic treatment options for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia.<\\/p>\",\"103\":[\"100\"]}}', '2016-07-13 16:33:35', '2016-07-13 16:33:35', '5350ff5f-ce62-41d1-b946-f5f1aedff479'),
 ('351', '27', '13', '1', 'en_us', '13', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Aileron Therapeutics\",\"slug\":\"aileron-therapeutics\",\"postDate\":1465920840,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. ALRN-6924, in Phase 1, is a p53 re-activator for the treatment of cancer, the only p53 molecule in development that targets both MDM2 and MDMX.<\\/p>\",\"62\":{\"28\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.aileronrx.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/aileron-therapeutics\"}}},\"130\":[\"95\"],\"66\":[\"364\"],\"81\":\"<p>Aileron Therapeutics is developing first-in-class therapeutics based on its proprietary stapled peptide&nbsp;drug platform.<\\/p>\",\"103\":[\"70\"]}}', '2016-07-13 16:33:56', '2016-07-13 16:33:56', '9aff7a6d-9f1d-44aa-92c3-f8f97d8f4b70'),
 ('352', '29', '12', '1', 'en_us', '29', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"104\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"seth@test.com\",\"linkedin\":\"linkedin.com\",\"phone\":\"555-555-5555\"}}},\"110\":[\"70\"],\"109\":\"Managing Partner\",\"80\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio compani\",\"104\":[\"298\",\"293\",\"284\",\"27\"]}}', '2016-07-13 16:35:58', '2016-07-13 16:35:58', '87fd21a7-d4fb-42a0-aefb-8a741889b639'),
 ('353', '13', '10', '1', 'en_us', '13', '', '{\"typeId\":\"10\",\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1466010801,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"19\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseImage\":[\"95\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"27\",\"200\",\"239\",\"284\"]}},\"20\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseImage\":[\"92\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"242\",\"296\",\"287\",\"298\"]}},\"21\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseImage\":[\"89\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"204\",\"244\",\"275\",\"293\"]}},\"22\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Legacy Investments\",\"expertiseImage\":[\"90\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"229\",\"246\",\"248\",\"250\",\"281\",\"290\"]}}}}}', '2016-07-13 16:38:01', '2016-07-13 16:38:01', 'bc5308b5-2dcb-4c32-93fc-e0029e2be958'),
 ('354', '287', '13', '1', 'en_us', '4', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Tendyne\",\"slug\":\"tendyne\",\"postDate\":1468282500,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Tendyne is focused on the development and commercialization of minimally invasive therapies for the treatment of mitral regurgitation. Tendyne\\u2019s first product is a percutaneous transcatheter mitral valve prosthesis.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Abbott August 2015<\\/em><\\/p>\",\"62\":{\"288\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.tendyne.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"90\"],\"66\":[\"371\"],\"81\":\"<p>Exited<\\/p><p>Tendyne is focused on the development and commercialization of minimally invasive therapies for the treatment of mitral regurgitation.&nbsp;<\\/p>\",\"103\":[\"100\"]}}', '2016-07-13 16:38:45', '2016-07-13 16:38:45', 'cb5a22f5-8ee0-4c6a-ac18-24e7be5da8c1'),
 ('355', '9', '6', '1', 'en_us', '51', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"357\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Areas of Expertise\"}},\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"141\":\"Partnerships\",\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/braeburn-pharmaceuticals\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/cure-forward\\\">Cure Forward<\\/a>\\u2019s unique Clinical Trial Exchange&nbsp;platform empowers patients to govern their own care plans.&nbsp;<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}},\"140\":\"Charting a trajectory\"}}', '2016-07-13 16:40:57', '2016-07-13 16:40:57', '507ff7f6-6565-47e6-abfe-bd7389989966'),
 ('356', '29', '12', '1', 'en_us', '30', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"104\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"100\"],\"109\":\"Managing Partner\",\"80\":\"Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991.\",\"104\":[\"239\",\"244\",\"284\"]}}', '2016-07-13 16:47:03', '2016-07-13 16:47:03', '8fad6275-e515-4823-a796-e0189aee5caf'),
 ('357', '105', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Sam Hall, Ph.D.\",\"slug\":\"sam-hall\",\"postDate\":1468264320,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Sam Hall has experience in the life sciences across roles as a private equity investor, investment banker and basic scientist. Prior to joining Apple Tree in 2013, he was a researcher at the University of Cambridge in the UK, where his work focused on novel therapeutic strategies for autoimmune diseases. Previously, Sam was a member of the investment team at Symphony Capital, a private equity firm dedicated to investments in biopharmaceutical development. Prior to Symphony, he served as a member of the healthcare investment banking team at Citigroup, where he advised leading biotechnology, medical device and healthcare services businesses on numerous completed strategic and debt and equity financing engagements.<\\/p>\\r\\n\\r\\n<p><br><\\/p><p>Sam holds an A.B. in Molecular Biology from Princeton University and completed his M.Phil. and Ph.D. research at the University of Cambridge, where he was a Taylor Research Scholar and was awarded an NSF Graduate Research Fellowship for his work.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Board responsibilities include: Syntimmune (Director), Stoke Therapeutics (Director).<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Principal\",\"80\":\"Sam Hall has experience in the life sciences across roles as a private equity investor, investment banker and basic scientist.\",\"104\":[\"284\"]}}', '2016-07-13 16:54:50', '2016-07-13 16:54:50', '20d5d550-2445-42cd-87ff-052d0f3ab936'),
 ('358', '106', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Aaron Kantoff\",\"slug\":\"aaron-kantoff\",\"postDate\":1468264380,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Aaron has significant early and late-stage biotech experience, serving financial analysis and restructuring. Prior to joining Apple Tree in 2011, Aaron was a partner at Recess Global, LLC, an investment company, focused on funding startups. Prior to starting Recess Global, LLC, Aaron was a member of the investment banking team at Rothschild Inc., in the Restructuring Group. Selected transactions that he worked on at Rothschild, Inc. include: advising the U.S Treasury on restructuring of Chrysler Group, LLC; assisting Milacron Inc. with the Section 363 sale of assets; working with Delphi Automotive on its in-court Chapter 11 bankruptcy; developing the Penton Media \\\"Pre-packaged\\\" Chapter 11 filing. In addition to his role with Apple Tree, Aaron has also served as Executive Director of Business Development & Corporate Strategy of Braeburn Pharmaceuticals.<\\/p>\\r\\n\\r\\n<p><br><\\/p><p>Aaron holds a Bachelor of Science in Finance and International Business from the New York University Stern School of Business.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Board responsibilities include: Cure Forward (Director), Corvidia (Board Observer), and Syntimmune (Board Observer).<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Principal\",\"80\":\"Aaron has significant early and late-stage biotech experience, serving financial analysis and restructuring.\",\"104\":[\"244\",\"239\",\"284\"]}}', '2016-07-13 16:56:01', '2016-07-13 16:56:01', '67c64437-ef95-4e18-ba4e-f08359348a43'),
 ('359', '125', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Chris Cain, Ph.D.\",\"slug\":\"chris-cain\",\"postDate\":1468270680,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Chris joined Apple Tree Partners in 2016 as an Associate focused on therapeutics. Prior to joining Apple Tree Partners, Chris was an Associate at RA Capital Management, LLC, a crossover fund invested in healthcare and the life sciences. Previously, Chris was a writer and editor at BioCentury Publications and the Science-Business eXchange (SciBX), a translational science journal co-published with Nature Publishing Group, where he evaluated the clinical and commercial potential of novel molecular targets and drug platforms emerging from academic labs. Prior to BioCentury, Chris was a researcher at the University of California, San Francisco, where his work focused on understanding the transcriptional regulation and evolution of morphological change in fungi including the pathogen Candida albicans.<\\/p>\\r\\n\\r\\n<p><br><\\/p><p>Chris holds a B.A. in Biology from the University of California, Santa Barbara, College of Creative Studies. He earned his Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco, where he was awarded a Genentech Graduate Fellowship.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Associate\",\"80\":\"Chris joined Apple Tree Partners in 2016 as an Associate focused on therapeutics.\",\"104\":\"\"}}', '2016-07-13 16:56:41', '2016-07-13 16:56:41', 'c47afcc6-8a59-4c9c-9ff6-c53e017ac128'),
 ('360', '13', '10', '1', 'en_us', '14', '', '{\"typeId\":\"10\",\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1466010801,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"19\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseImage\":[\"95\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"27\",\"200\",\"239\",\"284\"],\"expertiseLink\":\"Meet the Therapeutics team\"}},\"20\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseImage\":[\"92\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"242\",\"296\",\"287\",\"298\"],\"expertiseLink\":\"\"}},\"21\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseImage\":[\"89\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"204\",\"244\",\"275\",\"293\"],\"expertiseLink\":\"\"}},\"22\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Legacy Investments\",\"expertiseImage\":[\"90\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"229\",\"246\",\"248\",\"250\",\"281\",\"290\"],\"expertiseLink\":\"\"}}}}}', '2016-07-13 16:57:28', '2016-07-13 16:57:28', 'fcd54d0b-70d3-43b4-b5ff-37848f820148'),
 ('361', '13', '10', '1', 'en_us', '15', '', '{\"typeId\":\"10\",\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1466010801,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"19\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseImage\":[\"95\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"27\",\"200\",\"239\",\"284\"],\"expertiseLink\":\"Meet the Therapeutics team\"}},\"20\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseImage\":[\"92\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"242\",\"296\",\"287\",\"298\"],\"expertiseLink\":\"Meet the Medical Devices team\"}},\"21\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseImage\":[\"89\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"204\",\"244\",\"275\",\"293\"],\"expertiseLink\":\"Meet the Healthcare Services team\"}},\"22\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Legacy Investments\",\"expertiseImage\":[\"90\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"229\",\"246\",\"248\",\"250\",\"281\",\"290\"],\"expertiseLink\":\"\"}}}}}', '2016-07-13 16:58:10', '2016-07-13 16:58:10', 'b1db041e-e457-433f-8461-21db463de307'),
 ('362', '29', '12', '1', 'en_us', '31', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Managing Partner\",\"80\":\"Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991.\",\"104\":[\"239\",\"244\",\"284\"]}}', '2016-07-13 17:08:28', '2016-07-13 17:08:28', 'afcae1e2-9d53-447e-8f53-45185766e751'),
 ('363', '29', '12', '1', 'en_us', '32', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":{\"new1\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"email\":\"\",\"linkedin\":\"\",\"phone\":\"\"}}},\"110\":[\"100\"],\"109\":\"Managing Partner\",\"80\":\"Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991.\",\"104\":[\"239\",\"244\",\"284\"]}}', '2016-07-13 17:08:38', '2016-07-13 17:08:38', 'd3ee3baa-b02a-4bdc-a56e-af0153955eb1'),
 ('364', '246', '13', '1', 'en_us', '6', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Cyrano Sciences\",\"slug\":\"cyrano-sciences\",\"postDate\":1468276560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>An electronic nose for homeland defense applications.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Smiths Detection March 2004<\\/em><\\/p>\",\"62\":{\"247\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.smithsdetection.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"90\"],\"66\":[\"382\"],\"81\":\"<p>An electronic nose for homeland defense applications.<\\/p>\",\"103\":[\"376\"]}}', '2016-07-13 17:18:26', '2016-07-13 17:18:26', '3aeee72b-0edd-411f-89c7-4d070c02fb63'),
 ('365', '229', '13', '1', 'en_us', '6', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Coelacanth Chemical Corporation\",\"slug\":\"http-www-appletreepartners-com-portfolio-detail-coelacanth-acquired-by-lexicon-genetics\",\"postDate\":1468274580,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \\\"click\\\" chemistry.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Lexicon Genetics July 2001<\\/em><\\/p>\",\"62\":{\"230\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.lexicon-genetics.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/coelacanth-chemical-corp\"}}},\"130\":[\"90\"],\"66\":[\"381\"],\"81\":\"<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \\\"click\\\" chemistry.<\\/p>\",\"103\":[\"376\"]}}', '2016-07-13 17:18:48', '2016-07-13 17:18:48', '67198963-9aeb-4e89-968e-63bd4ef28cb2'),
 ('366', '242', '13', '1', 'en_us', '4', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Gala Therapeutics\",\"slug\":\"gala-therapeutics\",\"postDate\":1468276140,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Gala Therapeutics is an early stage medical device company developing a novel catheter based approach to treating pulmonary disease including chronic bronchitis, COPD, and asthma.<\\/p>\",\"62\":{\"243\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.galatherapeutics.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"92\"],\"66\":[\"381\"],\"81\":\"<p>Gala Therapeutics is an early stage medical device company developing a novel catheter based approach to treating pulmonary disease including chronic bronchitis, COPD, and asthma.<\\/p>\",\"103\":[\"97\"]}}', '2016-07-13 17:19:52', '2016-07-13 17:19:52', '01196be3-34dd-4ddd-9d7d-47f033f0cd2d'),
 ('367', '126', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Jernej Godec, Ph.D.\",\"slug\":\"jernej-godec-ph-d\",\"postDate\":1468270800,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Jernej joined Apple Tree Partners in 2016 as an Associate focused on therapeutics. His work focuses on the development of breakthrough companies with transformative therapies. Prior to joining Apple Tree Partners, he completed his doctorate in Immunology at Harvard University. He was jointly mentored by Arlene Sharpe at Harvard Medical School and Nicholas Haining at the Dana-Farber Cancer Institute, where he studied how co-inhibitory receptors and transcriptional programs orchestrate differentiation of cytotoxic T lymphocytes. He published his work in top peer-reviewed journals, including&nbsp;<em>Cell<\\/em>,&nbsp;<em>Immunity<\\/em>, and<em>Nature Immunology<\\/em>. While at Harvard, he was also on the leadership board of the Harvard Biotechnology Club.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>While in graduate school, Jernej co-founded Mifcor, a biotechnology company focused on developing new therapies for ischemic disease. As the co-founder and CSO, he successfully helped raise funding and lead the scientific strategy for preclinical drug development. Concurrently, he completed the Flagship VentureLabs fellows program and during the last year of his doctorate continued working with Flagship Ventures. As a consultant, he assisted in developing innovative concepts with accompanying intellectual property, marketable products, and founding strategy for new companies.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Jernej received his B.A. with honors in Molecular and Cell Biology at the University of California at Berkeley where his research focused on innate immunity and bacterial pathogenesis. During his time at Cal, he was an All-American student-athlete in swimming and competed in two Olympic Games for his home country of Slovenia.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Associate\",\"80\":\"<p>Jernej\'s\\u00a0work focuses on the development of breakthrough companies with transformative therapies.<\\/p>\",\"104\":\"\"}}', '2016-07-13 17:22:31', '2016-07-13 17:22:31', '03b28ca9-9728-4488-819d-336d35fb5028'),
 ('368', '126', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Jernej Godec, Ph.D.\",\"slug\":\"jernej-godec-ph-d\",\"postDate\":1468270800,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Jernej joined Apple Tree Partners in 2016 as an Associate focused on therapeutics. His work focuses on the development of breakthrough companies with transformative therapies. Prior to joining Apple Tree Partners, he completed his doctorate in Immunology at Harvard University. He was jointly mentored by Arlene Sharpe at Harvard Medical School and Nicholas Haining at the Dana-Farber Cancer Institute, where he studied how co-inhibitory receptors and transcriptional programs orchestrate differentiation of cytotoxic T lymphocytes. He published his work in top peer-reviewed journals, including&nbsp;<em>Cell<\\/em>,&nbsp;<em>Immunity<\\/em>, and<em>Nature Immunology<\\/em>. While at Harvard, he was also on the leadership board of the Harvard Biotechnology Club.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n<p>While in graduate school, Jernej co-founded Mifcor, a biotechnology company focused on developing new therapies for ischemic disease. As the co-founder and CSO, he successfully helped raise funding and lead the scientific strategy for preclinical drug development. Concurrently, he completed the Flagship VentureLabs fellows program and during the last year of his doctorate continued working with Flagship Ventures. As a consultant, he assisted in developing innovative concepts with accompanying intellectual property, marketable products, and founding strategy for new companies.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Jernej received his B.A. with honors in Molecular and Cell Biology at the University of California at Berkeley where his research focused on innate immunity and bacterial pathogenesis. During his time at Cal, he was an All-American student-athlete in swimming and competed in two Olympic Games for his home country of Slovenia.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Associate\",\"80\":\"Jernej\'s\\u00a0work focuses on the development of breakthrough companies with transformative therapies.\",\"104\":\"\"}}', '2016-07-13 17:23:31', '2016-07-13 17:23:31', 'eec805b9-45cf-4562-8eb3-4a67c3ee19d4'),
 ('369', '108', '12', '1', 'en_us', '4', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Keting Chu, MD, Ph.D.\",\"slug\":\"keting-chu\",\"postDate\":1468264500,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Keting Chu joined Apple Tree Partners in 2016 as a Venture Partner. Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture philanthropy.<\\/p>\\r\\n\\r\\n<p>Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS). There she was responsible for venture philanthropy, also known as the Therapy Acceleration program. At LLS, Keting led the investment of Celator, Stemline, Constellation, Affimed, arGen-X, Kite Pharma, Kiadis, OncoPepe, Valor and a number of projects within academic institutions. Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc. Prior to co-founding DigitAB, Keting was the Co-Founder and CEO of BioCubed Corporation, Vice President of Biology and Head of R&D at Five Prime Therapeutics during its founding stage and the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical and clinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Keting received her MD in Sun Yat-sen Medical University specialized in infectious diseases in China, Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF). She also conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Venture Partner\",\"80\":\"Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development.\",\"104\":\"\"}}', '2016-07-13 17:24:47', '2016-07-13 17:24:47', 'af0186b3-4604-4b87-8507-d061dda2a318'),
 ('370', '108', '12', '1', 'en_us', '5', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Keting Chu, MD, Ph.D.\",\"slug\":\"keting-chu\",\"postDate\":1468264500,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Keting Chu joined Apple Tree Partners in 2016 as a Venture Partner. Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture philanthropy.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS). There she was responsible for venture philanthropy, also known as the Therapy Acceleration program. At LLS, Keting led the investment of Celator, Stemline, Constellation, Affimed, arGen-X, Kite Pharma, Kiadis, OncoPepe, Valor and a number of projects within academic institutions. Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc. Prior to co-founding DigitAB, Keting was the Co-Founder and CEO of BioCubed Corporation, Vice President of Biology and Head of R&D at Five Prime Therapeutics during its founding stage and the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical and clinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Keting received her MD in Sun Yat-sen Medical University specialized in infectious diseases in China, Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF). She also conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Venture Partner\",\"80\":\"Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development.\",\"104\":\"\"}}', '2016-07-13 17:25:02', '2016-07-13 17:25:02', 'd9606b7d-d53b-4ecf-b1cc-c88e73091a92'),
 ('371', '109', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Paul DaSilva-Jardine, Ph.D.\",\"slug\":\"paul-dasilva-jardine\",\"postDate\":1468269000,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Paul DaSilva-Jardine joined Apple Tree Partners in 2016 as a Venture Partner. Paul has over 25 years of drug discovery and development experience in the Cardiovascular, Metabolic and Endocrine diseases space. Prior to joining Apple Tree, Paul spent over 25 years at Pfizer Research and Development where he participated in the discovery and development of over fifty drug candidates including the first, lasofoxifene, a SERM which received authorization from European Medicines Agency. Paul held various leadership positions at Pfizer R&D including Vice President, Head of CVMED Chemistry, and Vice President in the CVMED Research Unit which was responsible for drug development from Idea to Phase 2 Proof of Concept.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Paul earned his PhD and completed post-doctoral studies in Synthetic Organic Chemistry with Professor Corey at Harvard University.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Venture Partner\",\"80\":\"Paul has over 25 years of drug discovery and development experience in the Cardiovascular, Metabolic and Endocrine diseases space.\",\"104\":\"\"}}', '2016-07-13 17:26:39', '2016-07-13 17:26:39', '03308262-dbf3-48c2-8b60-3607ee5d63fb'),
 ('372', '123', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Andreas Loew, Ph.D.\",\"slug\":\"andreas-loew\",\"postDate\":1468270560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Andreas Loew is an Entrepreneur-in-Residence focused on creating novel biotherapeutics to combat cancer and auto-immune disease. Andreas has over fifteen years of experience in the biopharmaceutical industry, most recently as the global head of new technologies in the biologics center at the Novartis Institutes for Biomedical Research (NIBR). At NIBR, Andreas established a group to lead drug discovery efforts in multiple disease indications across a large spectrum of biotherapeutics including multi-specific antibodies, therapeutic proteins and chimeric antigen receptors (CARs). Prior to joining Novartis, Andreas provided structure-based drug design support at Abbott both for small molecules and anti-body based therapies including HUMIRA\\u00ae.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Andreas earned his master degrees in Chemistry at the University of Kaiserslautern, Germany and a PhD degree in Biochemistry at the University of Bayreuth, Germany. He conducted post-doctoral research in protein biochemistry and x-ray structural biology in Yee-Kin Ho\\u2019s laboratory at the University of Illinois, Chicago, at Steven Sprang\\u2019s laboratory at the University of Texas, Medical Center, Dallas and in Tom Blundell\\u2019s laboratory at Birkbeck College, London, UK.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Entrepreneur-in-Residence, Biotherapeutics\",\"80\":\"Andreas Loew is an Entrepreneur-in-Residence focused on creating novel biotherapeutics to combat cancer and auto-immune disease.\",\"104\":\"\"}}', '2016-07-13 17:27:41', '2016-07-13 17:27:41', 'e6c68a96-4dae-4332-a673-d5335629bc20'),
 ('373', '113', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Behshad Sheldon\",\"slug\":\"behshad-sheldon\",\"postDate\":1468269840,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Behshad has more than 25 years of experience leading pharmaceutical development and commercialization in the United States and globally. She currently also serves as the President and Chief Executive Officer of Braeburn Pharmaceuticals, a portfolio company of Apple Tree Partners. Prior to joining Braeburn, Behshad spent 10 years at Otsuka Pharmaceuticals, having co-founded the Otsuka Princeton office in 2002. Ms. Sheldon last served as a member of the board of directors of the Otsuka R&D organization, contributing to the oversight of 18 pre-approval programs for 13 products in CNS, cardio-renal, pain, dermatology, and oncology. Simultaneously, she served as senior vice president, patient & branding strategy in the commercial organization, where she was responsible for global and United States marketing, alliance management, and early development strategy. Prior to Otsuka, Behshad held positions with increasing responsibility at SmithKline Beecham and Bristol-Myers Squibb. Throughout her 27-year career, Behshad has driven the success of blockbuster products such as Glucophage, Plavix, and Abilify, and has contributed to several strategic alliances and acquisitions, including the landmark 2011 agreement between Otsuka and Lundbeck involving 5 CNS products. Behshad holds a BS degree in Neuroscience from the University of Rochester.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n<p>Board responsibilities include: CleanSlate Addiction Treatment Centers (Board Observer).<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Venture Partner\",\"80\":\"Behshad has more than 25 years of experience leading pharmaceutical development and commercialization in the United States and globally.\",\"104\":[\"204\"]}}', '2016-07-13 17:28:32', '2016-07-13 17:28:32', '61d22787-3a57-476e-bd3f-deae9a9069af'),
 ('374', '29', '12', '1', 'en_us', '33', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Seth L. Harrison, MD\",\"slug\":\"seth-l-harrison\",\"postDate\":1465920900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"<p>Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He serves currently as Executive Chairman of Braeburn Pharmaceuticals, Chairman of Tokai Pharmaceuticals, and Deputy Chairman of Heartware International, all companies he founded. He founded and chaired Aileron Therapeutics since its inception until 2013 and remains an active board member. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York.&nbsp;<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>From 2002 to 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation\\/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Additional board responsibilities include: ASOthera Pharmaceuticals, Corvidia, Cure Forward, and Syntimmune.<br><\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Managing Partner\",\"80\":\"Seth Harrison is the managing partner of Apple Tree Partners. He has invested in life sciences since 1991.\",\"104\":[\"239\",\"244\",\"284\"]}}', '2016-07-13 17:29:25', '2016-07-13 17:29:25', '70c4d93b-a8b2-4d2d-805f-fcf2d4d8e41d'),
 ('375', '55', '12', '1', 'en_us', '7', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Sami Hamad\\u00e9\",\"slug\":\"sami-hamad\\u00e9\",\"postDate\":1466183520,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"92\"],\"56\":\"<p>With over 20 years of operating and investing experience across a broad spectrum of therapeutic areas, Sami is a prominent figure in the medical technology sector and will be leading Apple Tree\\u2019s efforts in this area. His interests include therapeutic devices, sensors and healthcare IT solutions.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Prior to joining Apple Tree Partners, Sami was a Partner at Aberdare Ventures where he oversaw the sale of Ablation Frontiers to Medtronic and participated in a number of key investments including NxThera Inc., Nevro and Sonitus.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In prior years, Sami was Vice President at the Guidant Corporation and head of the Compass Group, where he was responsible for Guidant\\u2019s venture capital, business development and M&A activities. Successful investments included Cardionet Inc (Nasdaq: BEAT), Evalve (Acquired by ABT), Cryovascular (Acquired by BSX), Remon medical (Acquired by BSX) Cardiomems (Acquired by St. Jude Medical) and Spiration Inc (Acquired by Olympus).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Earlier in his career, Sami played a critical operating role at Advanced Cardiovascular Systems (ACS), the pioneering company in the then emerging field of interventional cardiology which subsequently became a central part of Guidant\\u2019s multi-billion dollar leadership position in the stent market.\\u2028 He was also a senior executive in Guidant\\u2019s peripheral business. Sami has been a regular guest lecturer at the Stanford Business School and Biodesign programs. He is also an inventor and recipient of the prestigious Boss Kettering Award for innovation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Sami holds a Bachelor\\u2019s Degree in Engineering from the American University of Beirut, a Masters Degree in Engineering from the University of Michigan, Ann Arbor and an MBA from the Stanford Graduate School of Business.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Board responsibilities include: Gala Therapeutics, VytronUS.<\\/p>\",\"57\":\"\",\"110\":[\"97\"],\"109\":\"Partner\",\"80\":\"With over 20 years of operating and investing experience across a broad spectrum of therapeutic areas, Sami leads ATP\'s medical technology investments.\",\"104\":[\"242\",\"298\"]}}', '2016-07-13 17:30:51', '2016-07-13 17:30:51', '56443b66-3d1f-453c-9b3a-7b86eb443c78'),
 ('376', '57', '12', '1', 'en_us', '8', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"David J. McIntyre\",\"slug\":\"david-j-mcintyre\",\"postDate\":1466183580,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"92\"],\"56\":\"<p>David has over 20 years of experience as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries, including medical devices. With professional qualifications in finance and law, David has held senior financial, legal and operational roles.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>More recently, David was Executive Vice President, Chief Financial Officer of HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) from 2005 through 2011, and assumed the additional responsibilities of Chief Operating Officer during HeartWare\\u2019s global commercialization phase for the period from 2008 through 2011.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Prior to HeartWare, David practiced as a senior attorney in private practice specializing in corporate, mergers and acquisitions and equity capital markets with Baker & McKenzie and KPMG as well as holding various senior financial roles in multi-national companies including Coal & Allied Limited, a publicly traded subsidiary of the Rio Tinto Group of companies.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>David holds a Bachelor of Economics (Accounting) from the University of Sydney (Australia), a Bachelor of Law from the University of Technology, Sydney (Australia) and a Masters of Business Administration (Fuqua Scholar) from Duke University. He is also a Certified Practicing Accountant (CPA) and is admitted as a Legal Practitioner of the Supreme Court of New South Wales (in Australia).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Board responsibilities include: VytronUS, QualDerm, Tusker Medical, Braeburn Pharmaceuticals, Gala Therapeutics and previously Tendyne (acquired by Abbott).<\\/p>\",\"57\":\"\",\"110\":[\"97\"],\"109\":\"Partner\",\"80\":\"David has over 20 years of experience as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries, including medical devices.\",\"104\":[\"298\",\"275\",\"296\",\"200\",\"242\",\"287\"]}}', '2016-07-13 17:33:12', '2016-07-13 17:33:12', '051e735d-3140-4937-a4c6-45831e9099d3'),
 ('377', '107', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Jonathan Waldstreicher, MD\",\"slug\":\"jonathan-waldstreicher-md\",\"postDate\":1468264500,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"92\"],\"56\":\"<p>Jonathan Waldstreicher joined Apple Tree in 2013 to invest in medical devices. After incubating an interventional pulmonary technology for two years, Jon founded Gala Therapeutics in Silicon Valley and assumed the CEO role to further its development.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Prior to joining Apple Tree, Jon was a Director, Global Surgery R&D, at Johnson & Johnson where he initiated and led an investment strategy and R&D development program in a new growth platform technology area. He started at Johnson & Johnson as an Associate Director in the Corporate Office of Science & Technology where he executed numerous seed grants to startup companies and participated in technical diligence of venture capital investments. Before medical school, Jon worked in Equity Research at Bear Stearns.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Jon received a B.A. from Brandeis University in Economics and an M.D. and M.B.A. from Tufts University School of Medicine where he was awarded the Norman Stearns award for highest achievement and overall excellence within the dual degree program. Between his third and fourth year of medical school, Jon worked as a fellow at the Corporate Office of Science & Technology at J&J. He completed a General Surgery Internship at Tufts Medical Center in Boston.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Board responsibilities include: Gala Therapeutics, VytronUS (Board Observer).<\\/p>\",\"57\":\"\",\"110\":[\"97\"],\"109\":\"Principal\",\"80\":\"Jonathan Waldstreicher joined Apple Tree in 2013 to invest in medical devices.\",\"104\":[\"242\",\"298\"]}}', '2016-07-13 17:36:08', '2016-07-13 17:36:08', '5c6d2ad2-b78a-4684-adf7-5349c1581dbc'),
 ('378', '128', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Joshua Sherman\",\"slug\":\"joshua-sherman\",\"postDate\":1468270980,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"92\"],\"56\":\"<p>Josh joined Apple Tree Partners in 2014 as an Associate focused on the Life Science, Pharmaceutical and Medical Device industries. He has a strong interest in the healthcare space and benefits greatly from his background in both science and finance.<\\/p>\\r\\n\\r\\n<p><br><\\/p><p>Prior to joining Apple Tree Partners, Josh was an Analyst in the Healthcare Investment Banking Group at Barclays where he developed broad industry knowledge and M&A experience. He was also formerly an Analyst at Morgan Stanley in the Financial Institutions Group where he focused on transactions in the Insurance and Asset Management space.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Josh graduated from The University of Pennsylvania in 2012 earning dual-degrees as a member of the Vagelos Life Sciences & Management Program. He holds a B.S. in Economics (Concentration in Finance) from The Wharton School and a B.A. in Biology from The College of Arts and Sciences.&nbsp;Josh grew up in New York City, is fluent in French, and enjoys travel and tennis.<\\/p>\",\"57\":\"\",\"110\":[\"97\"],\"109\":\"Associate\",\"80\":\"Josh joined Apple Tree Partners in 2014 as an Associate focused on the Life Science, Pharmaceutical and Medical Device industries.\",\"104\":\"\"}}', '2016-07-13 17:37:59', '2016-07-13 17:37:59', 'df3887fd-a296-44d7-853a-23e107850ba5'),
 ('379', '9', '6', '1', 'en_us', '52', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"357\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Areas of Expertise\"}},\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"141\":\"Partnerships\",\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/braeburn-pharmaceuticals\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/cure-forward\\\">Cure Forward<\\/a>\\u2019s unique Clinical Trial Exchange&nbsp;platform empowers patients to govern their own care plans.&nbsp;<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"$1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}},\"140\":\"Charting a trajectory\"}}', '2016-07-13 17:42:24', '2016-07-13 17:42:24', 'e4676bc6-1e1a-4192-a6a7-8f324968c690'),
 ('380', '116', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Amir Abolfathi\",\"slug\":\"amir-abolfathi\",\"postDate\":1468270020,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"92\"],\"56\":\"<p>Amir has over 26 years of operating experience in the healthcare industry focused on developing and commercializing cardiovascular devices, dental products, hearing prosthetics, and genomic diagnostics & analytics. Amir was the inventor and founder of Sonitus Medical in 2006, a novel non-surgical hearing prosthetic designed for treatment of unilateral deafness, and Sonitus Technologies in 2010, which is currently developing the first truly covert two-way communication device.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Prior to Sonitus, Amir served for six years as an Officer, Executive Vice President of R&D at Align Technology Inc. (NASDAQ: ALGN), creators of a unique, invisible orthodontic product called Invisalign. Previously, Amir was the first member of the senior management team at Embolic Protection Inc., where he was a consulting VP of Operations. EPI was successfully acquired by Boston Scientific in 2001.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>In early 1995, Amir co-founded EndoTex Interventional Systems, developers of minimally invasive solutions for treatment of carotid artery disease, which was also acquired by Boston Scientific in 2006. Amir has also held various management and engineering positions at Pfizer, Guidant, and Baxter-Edwards. He has over 100+ issued patents. Cleveland Clinic Foundation and Popular Science recognized one of his inventions as Top 10 Inventions of the Year in 2010.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Amir currently sits on the Board of Directors of Sonitus Technologies and Rodo Medical. He is also a business adviser to Guardant Health. He was previously on the Board of Directors of NextBio, acquired by Illumina in 2013, and an adviser to On-Pharma, acquired by Valeant Pharmaceutical in 2014.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Amir received a MS in Engineering Management from University of Southern California and BS in Biomedical Engineering from University of California, San Diego. He is a member of the University of California, San Diego Jacobs School Council of Advisers.<\\/p>\",\"57\":\"\",\"110\":[\"97\"],\"109\":\"Entrepreneur-in-Residence, Ear, Nose & Throat\",\"80\":\"Amir has over 26 years of operating experience in the healthcare industry focused on developing and commercializing medical devices. \",\"104\":\"\"}}', '2016-07-13 17:44:33', '2016-07-13 17:44:33', 'd00f05df-8540-4329-a001-546e0971d050'),
 ('381', '53', '12', '1', 'en_us', '8', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Diane M. Daych\",\"slug\":\"diane-m-daych\",\"postDate\":1466183520,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"89\"],\"56\":\"<p>Diane has over 25 years of investing, advisory and operating experience, with over 20 years focused on the healthcare services industry. She joined Apple Tree Partners in 2013 to lead their healthcare services investing. From 2010 to 2012, she was a Managing Director and Co-Head, Private Equity of the Marwood Group. Additionally, since 2000, Diane has been a partner and principal at CCP Equity Partners (\\u201cCCP\\u201d) and its predecessor firm, Conning Capital Partners, where she invested in growth companies that offer specialized solutions for the financing, management and delivery of health care in industries such as managed care, disease and care management, outpatient services, information technology and healthcare-related ancillary and outsourcing services. Prior to joining CCP in 2000, she held a senior development role at Mariner Health, a post acute care company, where she worked with operating management to develop the strategies and structures for physician practice management acquisitions and joint ventures. Prior to Mariner, Diane held senior operating roles at Medical Care America (MCA), one of the largest operators of free standing ambulatory surgery centers at that time.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Diane currently sits on the Board of directors of TripleCare, CleanSlate Addiction Treatment Centers, QualDerm Partners, Prism Education Group, the Tuck School\\u2019s MBA Advisory Board and The Healthcare Private Equity Association (HCPEA). She was previously on the Board of directors of Cogent Healthcare, Relay Health, Zoologic and an observer for Evolution Benefits and Vantage Oncology. She also previously sat on the Board of directors of the Women\\u2019s Association of Venture and Equity (WAVE), and she is a past president of the Hartford Chapter of the Connecticut Venture Group and sat on its statewide Board for several years. She received an MBA from the Tuck School at Dartmouth College and a BA in Economics from Lehigh University.<\\/p>\",\"57\":\"\",\"110\":[\"96\"],\"109\":\"Partner\",\"80\":\"Diane has over 25 years of investing, advisory and operating experience, with over 20 years focused on the healthcare services industry.\",\"104\":[\"293\",\"204\",\"275\"]}}', '2016-07-13 17:46:39', '2016-07-13 17:46:39', 'e4769d18-4bea-439c-806c-6ff247b8282a'),
 ('382', '102', '12', '1', 'en_us', '4', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Julie Gionfriddo\",\"slug\":\"julie-gionfriddo\",\"postDate\":1468264020,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"89\"],\"56\":\"<p>Julie Gionfriddo joined Apple Tree Partners in 2014 and has spent nearly 18 years prior focused on private equity. Prior to joining Apple Tree, Julie was a vice president within the private equity secondary group at Landmark Partners, where she was involved in transaction origination, underwriting, and negotiation of private equity investments, as well as investor relations and marketing.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Julie serves on the board of directors for the Women\\u2019s Association of Venture and Equity. Julie also serves on the Board of Fellows and the Women\\u2019s Leadership Council for Trinity College. She received her BA and MA in Economics from Trinity College.<\\/p>\",\"57\":\"\",\"110\":[\"96\"],\"109\":\"Principal\",\"80\":\"Julie Gionfriddo joined Apple Tree Partners in 2014 and has spent nearly 18 years prior focused on private equity.\",\"104\":\"\"}}', '2016-07-13 17:47:35', '2016-07-13 17:47:35', 'ae867ddd-e61d-45ed-8a91-8a1f078a0f1f'),
 ('383', '127', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Stephanie Papes\",\"slug\":\"stephanie-papes\",\"postDate\":1468270860,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"89\"],\"56\":\"<p>Stephanie joined Apple Tree Partners in 2014 as an Associate focused on healthcare services and IT investments. Prior to joining Apple Tree Partners, Stephanie was as an Investment Banking Analyst in the Financial Sponsors Group of Wells Fargo Securities in San Francisco, CA and New York, NY. In this role, she was responsible for supporting the leveraged finance origination process for private equity transactions. Stephanie previously worked within Duke University Health System, where she assisted in the initial implementation stages of a $500 million EHR rollout and on a pilot program for an innovative bundled payment model, among other projects. She also worked in Washington, DC during the passing of the Affordable Care Act, where she served health systems in government funding requests and health policy consulting.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Stephanie graduated from Duke University with highest distinction in studies of Public Policy, Economics and Biology. She was a Civic Engagement Scholar, Dean\\u2019s Research Fellow, South Asian Studies Fellow and Sanford School of Public Policy Grant Recipient. Stephanie\'s Honors thesis focused on provider financial incentives in rural India, and she continues to conduct international nonprofit work in Delhi and West Bengal.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Board responsibilities include: CleanSlate (Board Observer), TripleCare (Board Observer), QualDerm (Board Observer), Cure Forward (Director).<\\/p>\",\"57\":\"\",\"110\":[\"96\"],\"109\":\"Associate\",\"80\":\"Stephanie joined Apple Tree Partners in 2014 as an Associate focused on healthcare services and IT investments.\",\"104\":[\"204\",\"293\",\"275\",\"244\"]}}', '2016-07-13 17:48:41', '2016-07-13 17:48:41', '08909698-c268-441a-b987-ce68222cf1aa'),
 ('384', '99', '12', '1', 'en_us', '5', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Lauren Farrell\",\"slug\":\"lauren-farrell\",\"postDate\":1468263900,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"90\"],\"56\":\"<p>Lauren has over 20 years accounting and finance experience including roles in public accounting, financial management and reporting, and strategic financial consulting across multiple industries. Prior to joining Apple Tree Partners, Lauren was Vice President and Chief Accounting Officer at HeartWare International, Inc. (NASDAQ:HTWR) from 2006 to 2013, where she led the Company\\u2019s financial management and reporting activities. From 2005 to 2006, Lauren was Chief Financial Officer at Ambient Corporation. From January 2001 to July 2004, Lauren served as Vice President at Bingham Strategic Advisors providing M&A advisory services.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Lauren is a Certified Public Accountant and holds a Bachelors of Science in Accounting and a Masters of Business Administration from Bentley University.<\\/p>\",\"57\":\"\",\"110\":[\"101\"],\"109\":\"Chief Financial Officer\",\"80\":\"Lauren has over 20 years accounting and finance experience including roles in public accounting, financial management and reporting, and strategic financial consulting across multiple industries.\",\"104\":\"\"}}', '2016-07-13 17:50:10', '2016-07-13 17:50:10', '5a931e62-e931-4e1e-8da7-ec33ffdabb43'),
 ('385', '10', '7', '1', 'en_us', '11', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Contact\",\"slug\":\"contact\",\"postDate\":1465917860,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"70\":{\"41\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"New York City\",\"cityImage\":\"\",\"address\":\"230 Park Avenue, Suite 2800\\r\\nNew York, New York 10169\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}},\"42\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Cambridge \",\"cityImage\":\"\",\"address\":\"300 Technology Square, Suite 803G\\r\\nCambridge, MA 02139\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"42.363437\",\"locationLongitude\":\"-71.091471\"}},\"43\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Los Altos\",\"cityImage\":\"\",\"address\":\"4970 El Camino Real, Suite 220\\r\\nLos Altos, CA 94022\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"37.397596\",\"locationLongitude\":\"-122.106320\"}}}}}', '2016-07-13 18:17:37', '2016-07-13 18:17:37', '61ff5f5b-db23-4f18-a440-d1947d9ff0e7'),
 ('386', '351', '8', '1', 'en_us', '2', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Corvidia Therapeutics Raises $26M in a Series A Financing, Led by Sofinnova Partners and Apple Tree Partners\",\"slug\":\"corvidia-therapeutics-raises-26m-in-a-series-a-financing-led-by-sofinnova-partners-and-apple-tree-partners\",\"postDate\":1468299660,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"352\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple Tree Partners.<\\/p>\\r\\n\\r\\n<p>Concurrent with the financing, Corvidia has licensed a clinical stage compound from AstraZeneca to develop and commercialize as its lead therapeutic (COR-001). Funds from the Series A financing will be used to progress COR-001 into Phase I\\/II clinical trials during 2016, as well as to advance the company\'s preclinical pipeline.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Corvidia was co-founded by serial entrepreneur and Chief Executive Officer, Michael Davidson, M.D. Dr. Davidson, a recognized expert in the field of cardiology, previously served as Chief Medical Officer of Sofinnova-backed Omthera Pharmaceuticals, and was instrumental in the successful acquisition of that company by AstraZeneca in 2013 for $443 million. Joining Dr. Davidson at Corvidia are Co-founders Rahul Kakkar M.D. and Matt Devalaraja, Ph.D., both of whom previously worked in AstraZeneca\'s Emerging Innovations Unit, where they developed the science behind genome-guided cardiovascular therapies. Ram Aiyar Ph.D., MBA, an Entrepreneur-in-Residence at the National Institutes of Health and BioHealth Innovation, completes Corvidia\'s founding team.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Commenting on today\'s news, Dr. Davidson stated,&nbsp;<em>\\\"Our ability to complete this significant Series A financing with such high-quality investors is a testament to the promise of our technology and expertise of our management team, positioning Corvidia as a leader in the field of precision medicine as applied to cardiovascular diseases. With these funds, we aim to drive each of our assets through clinical trials and validate our precision medicine approach.\\\"<\\/em><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Graziano Seghezzi, Partner at Sofinnova Partners, and Corvidia\'s board member commented,&nbsp;<em>\\\"Given Omthera\'s success, we were strongly in favor of teaming up once again with Dr. Davidson. The seed funding that Sofinnova Partners provided allowed for Corvidia\'s inception, for the pipeline crafting and for the eventual structuring of the Series A. We are pleased to continue to support Corvidia and this latest financing represents a major step for the future advancement of novel, cardiovascular therapeutics.\\\"<\\/em><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Seth Harrison, M.D., Managing Partner of Apple Tree Partners, noted, \\\"<em>In&nbsp;<\\/em><em>our years of start-up investing we have not seen a better team than the group that Michael Davidson has assembled from AstraZeneca and the NIH. We are thrilled to be able to support Corvidia with our capital resources and company building experience, and look forward to working with Sofinnova Partners, AstraZeneca, and management to create the first great precision cardiovascular medicine company.<\\/em>\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>COR-001, a monoclonal antibody initially developed by MedImmune, AstraZeneca\'s global biologics research and development arm, was previously in a Phase 1 study for a different indication. It was repurposed by AstraZeneca\'s Emerging Innovations Unit, Scientific Partnering and Alliances (SP&A), prior to licensing to Corvidia.&nbsp;<em>\\\"This is another example of the strong entrepreneurial culture within AstraZeneca, where we push the boundaries of science to explore new therapeutic uses for our compounds. We will continue to divest or out-license assets where we believe it will help accelerate the development of new medicines.\\\"&nbsp;<\\/em>said Kumar Srinivasan, Vice President, SP&A, Innovative Medicines Unit, AstraZeneca.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>In conjunction with the financing, Seth Harrison and Adrien Lemoine, Executive Director, Corporate Development for AstraZeneca, will join Graziano Seghezzi and Michael Davidson on Corvidia\'s Board of Directors.<\\/p>\",\"position\":\"left\"}},\"353\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Sofinnova Partners\"}},\"354\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs, and has backed nearly 500 companies over more than 40 years, creating market leaders around the globe. Today, Sofinnova Partners has over \\u20ac1.5 billion under management. For more information, please visit:<a href=\\\"http:\\/\\/www.sofinnova.fr\\/\\\" target=\\\"_blank\\\">www.sofinnova.fr<\\/a><\\/p>\",\"position\":\"left\"}},\"355\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Corvidia Therapeutics\"}},\"356\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Based in Boston, MA, Corvidia is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company\'s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia\'s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. For more information, please visit:<a href=\\\"http:\\/\\/www.corvidiatx.com\\/\\\" target=\\\"_blank\\\">www.corvidiatx.com<\\/a><\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"2\\/17\\/2016\"},\"36\":[\"350\"]}}', '2016-07-13 18:33:47', '2016-07-13 18:33:47', '5e37e5f2-0b1b-4370-b135-55051e19db7b'),
 ('387', '342', '8', '1', 'en_us', '2', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain\",\"slug\":\"braeburn-and-camurus-announce-initiation-of-a-phase-2-study-in-opioid-dependent-patients-with-moderate-to-severe-chronic-pain\",\"postDate\":1468299540,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"343\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Braeburn Pharmaceuticals and Camurus announced today that the first patients have been dosed with CAM2038, weekly and monthly subcutaneous buprenorphine injections, in a pharmacokinetic study of opioid dependent patients with chronic pain.<\\/p>\\r\\n\\r\\n<p>The primary objective of this Phase 2 study is to assess the steady state pharmacokinetics of buprenorphine after repeated doses in opioid dependent patients with chronic pain, including effects of injection into different subcutaneous sites. This study will also explore the effect of CAM2038 on chronic pain, along with evaluation of safety and tolerability.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"This marks the fourth clinical study that has been started in the last five months for CAM2038, including two Phase 3 trials in opioid dependence. The ability to use CAM2038 in multiple injection sites would allow physicians the flexibility to personalize treatments,\\\" said Behshad Sheldon, President and CEO, Braeburn Pharmaceuticals. \\\"Our goal is to provide a suite of best-in-class long-acting treatment options tailored to the individual needs of patients suffering from opioid dependence and chronic pain.\\\"<\\/p>\\r\\n\\r\\n<p>\\\"Patients that suffer from chronic pain and are also opioid dependent are a difficult population to treat,\\\" said the principal investigator Dr. Greg Sullivan, medical director at Parkway Medical Center in Birmingham, Alabama. \\\"By using a long acting buprenorphine injectable, these patients would no longer be required to take medication multiple times per day. Buprenorphine also guards against hyperanalgesia and opiate tolerance, both of which are problems with conventional opiates.\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"CAM2038 has the potential to offer effective and safe around-the-clock pain relief, without risks of abuse and diversion. The pharmacological properties of buprenorphine together with long-acting release from the FluidCrystal formulation could also decrease risks of respiratory depression and overdose mortality associated with current opioid pain treatments,\\\" said Fredrik Tiberg, President and CEO, Camurus.<\\/p>\",\"position\":\"left\"}},\"344\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Braeburn Pharmaceuticals\"}},\"345\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Braeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience. In September 2015 the Food and Drug Administration (FDA) accepted for review Braeburn\'s New Drug Application for its lead candidate, Probuphine, a six-month buprenorphine implant for treatment of opioid dependence. The Agency has set May 27, 2016 as the target date for action.<\\/p>\\r\\n\\r\\n<p>Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. Braeburn\'s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Candidates include: Probuphine\\u00ae, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia. More information on Braeburn, can be found at&nbsp;<a href=\\\"https:\\/\\/braeburnpharmaceuticals.com\\/\\\" target=\\\"_blank\\\">https:\\/\\/braeburnpharmaceuticals.com\\/<\\/a>.<\\/p>\",\"position\":\"left\"}},\"346\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CAM2038\"}},\"347\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>The investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid addiction and pain are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance. The CAM2038 products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion, abuse, misuse, and accidental exposure. The CAM2038 products have been evaluated in three Phase 1\\/2 clinical trials, which evaluated the safety and tolerability as well as pharmacokinetic and pharmacodynamics properties of the products in a total of 176 individuals (opioid-dependent patients and healthy volunteers under naltrexone blockage). The CAM2038 products are also being developed for treatment of chronic pain, combining the effective analgesic properties of buprenorphine with the long acting release provided by the FluidCrystal\\u00ae injection depot.<\\/p>\",\"position\":\"left\"}},\"348\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Camurus\"}},\"349\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal\\u00ae drug delivery technologies and an extensive R&D expertise. Camurus\' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company\'s share is listed on Nasdaq Stockholm under the ticker \\\"CAMX\\\". For more information, visit&nbsp;<a href=\\\"http:\\/\\/www.camurus.com\\/\\\" target=\\\"_blank\\\">www.camurus.com<\\/a>.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"2\\/22\\/2016\"},\"36\":[\"326\"]}}', '2016-07-13 18:36:02', '2016-07-13 18:36:02', 'faae3dec-36c5-46c4-8604-bd8a9917c893'),
 ('388', '338', '8', '1', 'en_us', '2', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Syntimmune Secures Second Tranche of $26 Million Series A Financing\",\"slug\":\"syntimmune-secures-second-tranche-of-26-million-series-a-financing\",\"postDate\":1468299360,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"339\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Syntimmune, Inc., a development-stage company advancing novel treatments for IgG-mediated autoimmune diseases based on leading expertise in FcRn biology, today announced that it has made important progress by achieving preclinical proof of concept and completing preclinical safety testing, triggering a second, $10 million tranche of the Company\\u2019s committed $26 million Series A financing. The Series A financing is co-led by Apple Tree Partners and Baxalta Ventures, the corporate venture capital arm of Baxalta Incorporated, with participation by the Partners Innovation Fund and additional investors. Funds from this tranche of the Series A round will be used to complete the anticipated Phase 1a clinical trial in healthy volunteers of Syntimmune\\u2019s lead candidate, SYNT001. The Company intends to submit an IND application to the Food and Drug Administration for SYNT001 in mid-2016 to authorize initiation of the Phase 1a study later this year. SYNT001 is a biologic that blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases.<\\/p>\\r\\n\\r\\n<p>\\u201cThe closing of the second tranche in the Series A affirms the progress Syntimmune has achieved and reflects the importance of targeting FcRn as a breakthrough modality for treating IgG-mediated autoimmune diseases,\\u201d said Laurence Blumberg, M.D., Founder and COO of Syntimmune. \\u201cSince our founding just over two years ago, Syntimmune has made rapid progress in advancing its pipeline of candidates and progressing its lead program, SYNT001, through IND-enabling studies and toward the clinic. SYNT001 is showing a promising preclinical safety profile and robust activity in unique in vivo preclinical models, which we plan to present at appropriate peer-reviewed forums.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cThe opportunity for SYNT001 is substantial,\\u201d stated David de Graaf, Ph.D., Venture Partner at Apple Tree Partners. \\u201cWe are extremely happy with the progress the team has made on the lead molecule, which has the potential to address a large number of autoimmune indications.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cFcRn is a central mediator of IgG-related immunity and part of an important pathway that enables abnormal IgG responses in a large number of clinical settings, including autoimmune disease,\\u201d commented Richard Blumberg, M.D., Scientific Founder of Syntimmune and Division Chief of Gastroenterology, Hepatology and Endoscopy at Brigham and Women\\u2019s Hospital, as well as co-Director of the Harvard Digestive Diseases Center and Director of the Brigham Research Institute. \\u201cWhile FcRn is a highly validated target and has attracted substantial industry interest, there are no commercially available therapies designed to block IgG-FcRn interactions, which underlie diseases that affect multiple organ systems and for which there are continuing substantial medical needs, such as inflammatory bowel disease, lupus erythematosus, dermatomyositis and others. I am thrilled with the progress of Syntimmune and look forward to the advancement of the clinical program for SYNT001.\\u201d<\\/p>\",\"position\":\"left\"}},\"340\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Syntimmune\"}},\"341\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Founded in 2013, Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-mediated autoimmune diseases and represents a central common pathway that enables abnormal IgG responses. Syntimmune\\u2019s lead candidate, SYNT001, is a biologic progressing through IND-enabling studies that specifically blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases. Syntimmune has two additional, earlier-stage therapeutic programs, targeting other unique aspects of FcRn biology. The Syntimmune team has world-class experience in the field of FcRn biology and has successfully pioneered and advanced biologics targeting FcRn, including approved therapies currently on the market. Since its founding, the Company has received a total of $28 million in funding commitments from leading life sciences investors, including Apple Tree Partners, Baxalta Ventures, and Partners Innovation Fund. For more information on Syntimmune, please visit the Company\\u2019s website at<a href=\\\"http:\\/\\/cts.businesswire.com\\/ct\\/CT?id=smartlink&url=http%3A%2F%2Fwww.syntimmune.com&esheet=51304447&newsitemid=20160322005211&lan=en-US&anchor=www.syntimmune.com&index=1&md5=62fb1a7393f2201155ab419b9a8b964d\\\" target=\\\"_blank\\\">www.syntimmune.com<\\/a>.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"3\\/22\\/2016\"},\"36\":[\"337\"]}}', '2016-07-13 18:37:36', '2016-07-13 18:37:36', '5ab2e960-0d65-4b24-b21e-60b6d462bd7f'),
 ('389', '329', '8', '1', 'en_us', '2', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Dermatology Services Company QualDerm Unveils $31.8M Growth Investment\",\"slug\":\"dermatology-services-company-qualderm-unveils-31-8m-growth-investment\",\"postDate\":1468299300,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"330\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>QualDerm Partners LLC (\\u201cQDP\\u201d), a dermatology services company, announced today it has raised $31.8 million in growth equity funding from Apple Tree Partners (\\u201cATP\\u201d) and Cressey & Company (\\u201cCressey\\u201d). The financing will enable QualDerm to strengthen its comprehensive physician support services and accelerate expansion through partnerships with leading dermatology practices.<\\/p>\\r\\n\\r\\n<p>Headquartered in Brentwood, TN, QualDerm provides physician support services through partnerships with best-in-class dermatology practices in the southeastern U.S. The company provides leadership, growth resources, and management services to skin surgeons, pediatric, and general dermatologists and mid-level providers to alleviate the burden of the day-to-day administrative demands of running a business.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><em>\\u201cOur investment in QDP aligns with ATP\\u2019s commitment to partner with exceptional management teams and build leading healthcare companies,\\\" said Diane Daych, Partner of Apple Tree Partners, who joined QualDerm\\u2019s Board of Directors. \\\"With extensive experience building and operating multi-site provider businesses and deep knowledge in effective practice management strategy, ATP looks forward to supporting QDP\\u2019s growth.\\u201d<\\/em><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><em>\\u201cCressey & Company is excited to have additional resources from ATP to support the continued professional success and clinical excellence of our existing partnership with QDP,\\u201d said David Schuppan, Cressey Partner and QDP Board member.<\\/em><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Under the leadership of Bill Southwick, CEO, QualDerm partners with physicians to create high functioning teams through shared culture, shared services, and shared decision making. QualDerm is dedicated to expanding patient access to high quality care in secondary markets as well as other underserved areas, where the nationwide dearth of dermatologists is particularly problematic.<em>&nbsp;\\u201cWe are pleased to partner with our investors, who bring significant experience building healthcare companies and adding operational value. This investment will facilitate QDP\\u2019s mission to provide management, growth, and strategic services that enable high quality dermatology care while preserving physician autonomy in true partnership fashion,\\u201d&nbsp;<\\/em>said Southwick.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>The company\\u2019s practice affiliates include The Skin Surgery Center, a full-service, multi-site specialty group based in North Carolina, led by distinguished physicians, Drs. Barry Leshin and John Albertini.&nbsp;<em>\\u201cAs the platform practice for QDP, we have been truly gratified by the sophistication and expertise of our management team and anticipate that ATP\\u2019s investment in both capital and strategic vision will synergize with Cressey in a way that adds tremendous value as we expand our mission to provide high quality dermatologic care to the region and beyond.\\u201d<\\/em><\\/p>\",\"position\":\"left\"}},\"331\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Apple Tree Partners\"}},\"332\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Apple Tree Partners (ATP) is a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, ATP closed its current capital pool of $1.5 billion in 2012 and is actively funding healthcare innovation. ATP starts companies, or invests in existing companies, with commitments as high as $250 million. The firm is headquartered in New York City, with satellite offices in Princeton, NJ, Cambridge, MA, and Los Altos, CA.<\\/p>\\r\\n\\r\\n<p>For more information, please visit:&nbsp;<a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\">www.appletreepartners.com<\\/a><\\/p>\",\"position\":\"left\"}},\"333\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Cressey & Company\"}},\"334\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Based in Chicago, IL and Nashville, TN, Cressey & Company is a private investment firm focused on building leading healthcare provider, service and information technology businesses. With a history spanning nearly 35 years, the Cressey & Company team is one of the most experienced and successful in the healthcare private equity field.<\\/p>\\r\\n\\r\\n<p>More information about Cressey & Company is available at&nbsp;<a href=\\\"http:\\/\\/www.cresseyco.com\\/\\\" target=\\\"_blank\\\">www.cresseyco.com<\\/a>.<\\/p>\",\"position\":\"left\"}},\"335\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About QualDerm\"}},\"336\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Based in Brentwood, TN, QualDerm Partners provides strategic leadership and practice management services for dermatologists and skin care professionals. The company strives to be the partner of choice for premier, patient-centric dermatology practices throughout the southeast.<\\/p>\\r\\n\\r\\n<p>For more information, please visit&nbsp;<a href=\\\"http:\\/\\/www.qualderm.com\\/\\\" target=\\\"_blank\\\">www.qualderm.com<\\/a><\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"4\\/20\\/2016\"},\"36\":\"\"}}', '2016-07-13 18:37:54', '2016-07-13 18:37:54', '313b62e0-76a4-49c3-8d08-11f51d95ee52'),
 ('390', '327', '8', '1', 'en_us', '2', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"FDA approves first buprenorphine implant for treatment of opioid dependence\",\"slug\":\"fda-approves-first-buprenorphine-implant-for-treatment-of-opioid-dependence\",\"postDate\":1468299120,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"328\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.<\\/p>\\r\\n\\r\\n<p>Until today, buprenorphine for the treatment of opioid dependence was only approved as a pill or a film placed under the tongue or on the inside of a person\\u2019s cheek until it dissolved. While effective, a pill or film may be lost, forgotten or stolen. However, as an implant, Probuphine provides a new treatment option for people in recovery who may value the unique benefits of a six-month implant compared to other forms of buprenorphine, such as the possibility of improved patient convenience from not needing to take medication on a daily basis. An independent FDA advisory committee supported the approval of Probuphine in a meeting held earlier this year.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"Opioid abuse and addiction have taken a devastating toll on American families. We must do everything we can to make new, innovative treatment options available that can help patients regain control over their lives,\\u201d said FDA Commissioner Robert M. Califf, M.D. \\u201cToday\\u2019s approval provides the first-ever implantable option to support patients\\u2019 efforts to maintain treatment as part of their overall recovery program.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Expanding the use and availability of medication-assisted treatment (MAT) options like buprenorphine is an important component of&nbsp;<a href=\\\"http:\\/\\/www.fda.gov\\/NewsEvents\\/Newsroom\\/FactSheets\\/ucm484714.htm\\\">the FDA\\u2019s opioid action plan<\\/a>&nbsp;and one of&nbsp;<a href=\\\"http:\\/\\/www.hhs.gov\\/about\\/news\\/2015\\/03\\/26\\/hhs-takes-strong-steps-to-address-opioid-drug-related-overdose-death-and-dependence.html\\\">three top priorities<\\/a>&nbsp;for the U.S. Department of Health and Human Services\\u2019 Opioid Initiative aimed at reducing prescription opioid and heroin related overdose, death and dependence.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Opioid dependence is the diagnostic term used for the more common concept, \\u201caddiction,\\u201d in the Probuphine clinical trials. Addiction is defined as a cluster of behavioral, cognitive and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use, persisting in drug use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, as well as the possibility of the development of tolerance or development of physical dependence. Physical dependence is not the same as addiction. Newer diagnostic terminology uses the term \\u201copioid use disorder,\\u201d which includes both milder forms of problematic opioid use as well as addiction.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>MAT is a comprehensive approach that combines approved medications (currently, methadone, buprenorphine or naltrexone) with counseling and other behavioral therapies to treat patients with opioid use disorder. Regular adherence to MAT with buprenorphine reduces opioid withdrawal symptoms and the desire to use, without causing the cycle of highs and lows associated with opioid misuse or abuse. At sufficient doses, it also decreases the pleasurable effects of other opioids, making continued opioid abuse less attractive. According to the Substance Abuse and Mental Health Services Administration, patients receiving MAT for their opioid use disorder cut their risk of death from all causes in half.<\\/p>\\r\\n\\r\\n<p>\\u201cScientific evidence suggests that maintenance treatment with these medications in the context of behavioral treatment and recovery support are more effective in the treatment of opioid use disorder than short-term detoxification programs aimed at abstinence,\\u201d said Nora Volkow, M.D., director of the National Institute on Drug Abuse at the National Institutes of Health. \\u201cThis product will expand the treatment alternatives available to people suffering from an opioid use disorder.\\u201d<\\/p>\\r\\n\\r\\n<p>Probuphine should be used as part of a complete treatment program that includes counseling and psychosocial support. Probuphine consists of four, one-inch-long rods that are implanted under the skin on the inside of the upper arm and provide treatment for six months. Administering Probuphine requires specific training because it must be surgically inserted and removed. Only a health care provider who has completed the training and become certified through a restricted program called the Probuphine Risk Evaluation and Mitigation Strategy (REMS) program should insert and remove the implants. If further treatment is needed, new implants may be inserted in the opposite arm for one additional course of treatment. The FDA is requiring postmarketing studies to establish the safety and feasibility of placing the Probuphine implants for additional courses of treatment.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>The safety and efficacy of Probuphine were demonstrated in a randomized clinical trial of adults who met the clinical criteria for opioid dependence and were considered stable after prior buprenorphine treatment. A response to MAT was measured by urine screening and self-reporting of illicit opioid use during the six month treatment period. Sixty-three percent of Probuphine-treated patients had no evidence of illicit opioid use throughout the six months of treatment \\u2013 similar to the 64 percent of those who responded to sublingual (under the tongue) buprenorphine alone.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>The most common side effects from treatment with Probuphine include implant-site pain, itching, and redness, as well as headache, depression, constipation, nausea, vomiting, back pain, toothache and oropharyngeal pain. The safety and efficacy of Probuphine have not been established in children or adolescents less than 16 years of age. Clinical studies of Probuphine did not include participants over the age of 65.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Probuphine has a boxed warning that provides important safety information for health care professionals, including a warning that insertion and removal of Probuphine are associated with the risk of implant migration, protrusion, expulsion and nerve damage resulting from the procedure. Probuphine must be prescribed and dispensed according to the Probuphine REMS program because of the risks of surgical complications and because of the risks of accidental overdose, misuse and abuse if an implant comes out or protrudes from the skin. As part of this program, Probuphine can only be prescribed and dispensed by health care providers who are certified with the REMS program and have completed live training, among other requirements.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Probuphine implants contain a significant amount of drug that can potentially be expelled or removed, resulting in the potential for accidental exposure or intentional misuse and abuse if the implant comes out of the skin. Patients should be seen during the first week after insertion and a visit schedule of no less than once-monthly is recommended for continued counseling and psychosocial support.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Probuphine is marketed by San Francisco-based Titan Pharmaceuticals Inc. and Braeburn Pharmaceuticals based in Princeton, New Jersey.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation\\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"5\\/26\\/2016\"},\"36\":[\"326\"]}}', '2016-07-13 18:38:16', '2016-07-13 18:38:16', '95b44ea2-a4af-4139-846c-53a3ab622c20'),
 ('391', '319', '8', '1', 'en_us', '2', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Medtronic to Expand Heart Failure Portfolio with Acquisition of HeartWare International\",\"slug\":\"medtronic-to-expand-heart-failure-portfolio-with-acquisition-of-heartware-international\",\"postDate\":1468299000,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"320\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Medtronic plc (NYSE: MDT), the global leader in medical technology, and HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies for the treatment of advanced heart failure, today announced that the companies have entered into a definitive merger agreement under which Medtronic will acquire HeartWare in a transaction valued at approximately $1.1 billion. Under the terms of the agreement, Medtronic will commence a tender offer for all outstanding shares of HeartWare common stock for $58.00 per share, in cash. The boards of directors of both Medtronic and HeartWare have unanimously approved the transaction. The acquisition is expected to close during Medtronic\'s second fiscal quarter ending Oct. 28, 2016, subject to the satisfaction of customary closing conditions.<\\/p>\\r\\n\\r\\n<p>Medtronic\'s acquisition of HeartWare will expand Medtronic\'s portfolio of diagnostic tools, therapies and services for patients suffering from heart failure, aligning with Medtronic\'s Mission of alleviating pain, restoring health and extending life, and is in line with the Company\'s strategy to surround the physician with innovative products while focusing on patients and disease states.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>HeartWare\'s flagship product, the HVAD \\u00ae System, features the world\'s smallest full-support ventricular assist device (VAD) and is designed to reduce surgical invasiveness, improve patient recovery times and enhance patient outcomes. In addition, HeartWare has multiple technologies in development designed to offer progressively less-invasive mechanical circulatory support options for patients with end-stage heart failure. Medtronic estimates that the global VAD market is approximately $800 million currently and worldwide is expected to grow in the mid-to-high single digits for CY16-17, and accelerate to high-single\\/low-double digits beyond CY17.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"The addition of HeartWare\'s innovative portfolio adds to our expanding portfolio of diagnostics, therapeutics and services that address heart failure patients,\\\" said Mike Coyle, executive vice president and president of the Cardiac and Vascular Group at Medtronic. \\\"The team at HeartWare has established excellent relationships with its hospital customers and built a strong position and reputation in the marketplace. This transaction, once closed, will be a further, important step toward Medtronic offering a complete suite of solutions to address patient needs across the heart failure care continuum.\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"Medtronic is the worldwide leader in cardiovascular device technologies. Its expansive expertise in the development of implantable systems and battery technologies, patient monitoring, manufacturing, global regulatory policy and commercialization should help accelerate the development and introduction of our innovative pipeline products, and will expand access to our therapies and offerings to the sizeable heart failure population,\\\" said Doug Godshall, president and chief executive officer, HeartWare. \\\"Combining the unique capabilities of the HeartWare team, which has been entirely focused on mechanical support technologies, with the broad strength of the Medtronic organization provides a unique opportunity to enhance growth in the mechanical circulatory support market. All of our stakeholders, including customers, employees, shareholders, and most importantly, patients, will benefit meaningfully from this complementary combination.\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Heart failure, also known as congestive heart failure, is a condition or a collection of symptoms in which the heart isn\'t pumping enough blood to meet the body\'s needs. Heart failure usually develops slowly after an injury to the heart. Some injuries may include a heart attack, too much strain on the heart due to years of untreated high blood pressure, or a diseased heart valve, among others. Heart failure remains a leading cause of hospitalization and death in the United States, and its prevalence continues to increase, affecting more than five million people in the U.S. alone. The cost of heart failure is high. Healthcare expenditures in the U.S. on heart failure are estimated to be approximately $39 billion per year, making it one of the largest expenses to the healthcare system. With the aging of the population, Medtronic estimates that the number of patients with heart failure could exceed eight million by 2030.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"HeartWare\'s HVAD System enhances the portfolio of our Cardiac & Vascular Group, a team with a proven track record of executing and a demonstrated ability to scale early stage concepts into large, sustainable end markets,\\\" said Omar Ishrak, chairman and chief executive officer of Medtronic. \\\"In addition, from a financial perspective, we are pleased to reach an agreement that meets our acquisition criteria of adding minimal to no net EPS dilution in the near-term, while at the same time creating strong, long-term expected returns for our shareholders.\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>This acquisition supports Medtronic\'s therapy innovation strategic priority. In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>This transaction is expected to meet Medtronic\'s long-term financial metrics for acquisitions. Medtronic does not intend to modify its fiscal year 2017 revenue outlook or earnings per share (EPS) guidance as a result of this transaction, although it is expected to provide increased confidence in the company\'s ability to deliver on its FY17 revenue growth outlook. In addition, Medtronic expects minimal to no net EPS dilution from this transaction for the first two years as the company intends to offset the expected dilutive impact. The acquisition is expected to be earnings accretive in year three. Medtronic intends to report results from the acquired HeartWare business as part of its Cardiac Rhythm & Heart Failure division within the Cardiac & Vascular Group.<\\/p>\\r\\n\\r\\n<p>Medtronic\'s financial advisor for the transaction is J.P. Morgan Securities LLC, with Ropes & Gray LLP acting as legal advisor. HeartWare\'s financial advisor is Perella Weinberg Partners LP, with Shearman & Sterling LLP acting as legal advisor<br><\\/p>\",\"position\":\"left\"}},\"321\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About HeartWare International\"}},\"322\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>HeartWare International Inc. (<a href=\\\"http:\\/\\/www.heartware.com\\/\\\" target=\\\"_blank\\\">www.HeartWare.com<\\/a>) develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients around the world suffering from advanced heart failure. Dedicated to developing new, minimally invasive technologies to revolutionize the treatment of patients with end-stage heart failure, HeartWare has multiple technologies in development to offer progressively less-invasive mechanical circulatory support options. HeartWare\'s corporate headquarters are located in Framingham, Massachusetts, and the company has technology, operations, manufacturing and distribution centers in Miami Lakes, Florida; Arden Hills, Minnesota; and Hannover, Germany.<\\/p>\",\"position\":\"left\"}},\"323\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Medtronic\"}},\"324\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Medtronic plc (<a href=\\\"http:\\/\\/www.medtronic.com\\/\\\" target=\\\"_blank\\\">www.medtronic.com<\\/a>), headquartered in Dublin, Ireland, is among the world\'s largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"6\\/27\\/2016\"},\"36\":[\"318\"]}}', '2016-07-13 18:38:37', '2016-07-13 18:38:37', 'e70082d1-b29f-45a0-bf21-743befcfa95a'),
 ('392', '314', '8', '1', 'en_us', '3', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Cure Forward Announces First Trial Recruitment Collaboration That Will Expand Patient Access to Innovative Treatments\",\"slug\":\"cure-forward-announces-first-trial-recruitment-collaboration-that-will-expand-patient-access-to-innovative-treatments\",\"postDate\":1468298820,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"315\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Cure Forward, an online precision medicine platform for cancer patients and their care teams, and Novartis Pharmaceuticals Corporation today announced that Cure Forward\\u2019s unique Clinical Trial Exchange will support Novartis in identifying potential patients for all of its current oncology trials.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>The collaboration further validates Cure Forward\\u2019s approach for real-time patient sourcing in clinical trials. By utilizing its patent pending Clinical Trial Exchange, Cure Forward facilitates connections between patients and drug development companies, based on mutual criteria and preferences, comparable to popular online dating platforms.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>There is a significant efficiency gap in the clinical trial process today, placing undue burden on patients and caregivers to navigate the vast, complex landscape of medical research options \\u2013 often at stages in which their time is most valuable. Drug developers are concurrently developing investigational treatments, but often struggle to find the right patients to receive these investigational treatments.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Cure Forward\\u2019s platform empowers patients to govern their own care plans, providing accurate, easily accessible information to help drive individual choices.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cToday\\u2019s patient is active in his or her care, accessing data to make important treatment decisions,\\u201d said Martin Naley, Founder and Chief Strategy Officer, Cure Forward. \\u201cCure Forward makes clinical trial enrollment easier and more accessible. Novartis\\u2019 bold approach of activating searches for oncology trials on our platform will help patients find possible investigational treatments for their care.\\u201d<\\/p>\",\"position\":\"left\"}},\"316\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Cure Forward\"}},\"317\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Cure Forward bridges the gap between patients and precision medicine, beginning in cancer. Cure Forward provides a simple-to-use platform that allows patients to obtain their genomic data and use it to identify treatment options including clinical trials, solving critical business needs for diagnostic laboratories, health care providers and clinical trial recruiters. Cure Forward is based in Cambridge, Massachusetts and was incubated and launched by Apple Tree Partners, New York City. The company\\u2019s platform is in beta release at&nbsp;<a href=\\\"http:\\/\\/cts.businesswire.com\\/ct\\/CT?id=smartlink&url=http%3A%2F%2Fwww.cureforward.com%2F&esheet=51370740&newsitemid=20160628005534&lan=en-US&anchor=www.cureforward.com&index=2&md5=24eaf06114eb049ec8095911016dcfef\\\" target=\\\"_blank\\\">www.cureforward.com<\\/a>.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"6\\/28\\/2016\"},\"36\":[\"325\"]}}', '2016-07-13 18:38:50', '2016-07-13 18:38:50', '9739155c-6b92-4efa-8de9-da9a8435de67'),
 ('393', '312', '8', '1', 'en_us', '2', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"High-Tech Healthcare Helps Eliminate Unnecessary Hospital Visits\",\"slug\":\"high-tech-healthcare-helps-eliminate-unnecessary-hospital-visits\",\"postDate\":1468298700,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"313\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>A high-tech version of healthcare is becoming more and more popular. It\'s called TeleMedicine. And in many cases, it helps keep people out of the hospital. Right now, there\'s a big push to cut the rate of people who are re-admitted to the hospital. It not only saves money, but it also lowers the risk for infection and other complication. Plus, it helps keep patients more comfortable.<\\/p>\\r\\n\\r\\n<p>Sue and Charlie Lake just celebrated their 60th wedding anniversary. They both live at Meadowood Senior Living. Because 91-year-old Mr. Lake has health problems, he stays at the skilled nursing facility. They demonstrated their new TripleCare Telemedicine system for us. On nights, weekends or holidays when there isn\'t a doctor in person at the center, there\'s one available through cyberspace. With nurses help, a doctor can do a thorough examination. The camera can zoom in to look for swelling, lesions or discoloration. The stethoscope is also connected. What nurses hear, the doctor hears at the same time.<\\/p><p>\\\"It\'s like Skype except that you have all the dimensions, you have all the senses that the physician can hone in on,\\\" said Sally-Ann Heckert Bikin, attorney and Director of Nursing at Meadowood. Mrs. Lake tells Action News she was skeptical about the new technology at first.<\\/p><p>\\\"I say I don\'t think it\'s going to work. You are going to lose the face to face,\\\" she said. But when her husband got sick on a Sunday night, with the help of TripleCare they were able to diagnose and treat him in his room as opposed to being transported by ambulance to the hospital.<\\/p><p>\\\"I went from saying it\'s not going to work to telling everyone this is such a great thing,\\\" said Sue.<\\/p><p>\\\"So far, we\'ve had 16 calls and out of 16, 13 we were able to treat here in the patient\'s room,\\\" said Lynn Plepis, Clinical Informatics at Meadowood. Mr Lake was one of those 13.<\\/p><p>TripleCare is also set up to keep up the information private and secure.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Many other centers are using similar technology.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>View the&nbsp;<a href=\\\"http:\\/\\/6abc.com\\/health\\/high-tech-healthcare-helps-eliminate-unnecessary-hospital-visits\\/1416091\\/\\\" target=\\\"_blank\\\">original news clip<\\/a> including the video.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"7\\/6\\/2016\"},\"36\":[\"311\"]}}', '2016-07-13 18:39:13', '2016-07-13 18:39:13', '31452516-e7bb-40d2-a450-677e57749f4e'),
 ('394', '312', '8', '1', 'en_us', '3', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"High-Tech Healthcare Helps Eliminate Unnecessary Hospital Visits\",\"slug\":\"high-tech-healthcare-helps-eliminate-unnecessary-hospital-visits\",\"postDate\":1468298700,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"313\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>A high-tech version of healthcare is becoming more and more popular. It\'s called TeleMedicine. And in many cases, it helps keep people out of the hospital. Right now, there\'s a big push to cut the rate of people who are re-admitted to the hospital. It not only saves money, but it also lowers the risk for infection and other complication. Plus, it helps keep patients more comfortable.<\\/p>\\r\\n\\r\\n<p>Sue and Charlie Lake just celebrated their 60th wedding anniversary. They both live at Meadowood Senior Living. Because 91-year-old Mr. Lake has health problems, he stays at the skilled nursing facility. They demonstrated their new TripleCare Telemedicine system for us. On nights, weekends or holidays when there isn\'t a doctor in person at the center, there\'s one available through cyberspace. With nurses help, a doctor can do a thorough examination. The camera can zoom in to look for swelling, lesions or discoloration. The stethoscope is also connected. What nurses hear, the doctor hears at the same time.<\\/p>\\r\\n\\r\\n<p>\\\"It\'s like Skype except that you have all the dimensions, you have all the senses that the physician can hone in on,\\\" said Sally-Ann Heckert Bikin, attorney and Director of Nursing at Meadowood. Mrs. Lake tells Action News she was skeptical about the new technology at first.<\\/p>\\r\\n\\r\\n<p>\\\"I say I don\'t think it\'s going to work. You are going to lose the face to face,\\\" she said. But when her husband got sick on a Sunday night, with the help of TripleCare they were able to diagnose and treat him in his room as opposed to being transported by ambulance to the hospital.<\\/p>\\r\\n\\r\\n<p>\\\"I went from saying it\'s not going to work to telling everyone this is such a great thing,\\\" said Sue.<\\/p>\\r\\n\\r\\n<p>\\\"So far, we\'ve had 16 calls and out of 16, 13 we were able to treat here in the patient\'s room,\\\" said Lynn Plepis, Clinical Informatics at Meadowood. Mr Lake was one of those 13.<\\/p>\\r\\n\\r\\n<p>TripleCare is also set up to keep up the information private and secure.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Many other centers are using similar technology.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>View the&nbsp;<a href=\\\"http:\\/\\/6abc.com\\/health\\/high-tech-healthcare-helps-eliminate-unnecessary-hospital-visits\\/1416091\\/\\\" target=\\\"_blank\\\">original news clip<\\/a> including the video.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"7\\/6\\/2016\"},\"36\":[\"311\"]}}', '2016-07-13 18:39:21', '2016-07-13 18:39:21', '064ae909-19ca-4f24-883b-a8db27fc64aa'),
 ('395', '52', '8', '1', 'en_us', '7', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Mass.-based addiction treatment center expands nationally as opioid epidemic rages on\",\"slug\":\"mass-based-addiction-treatment-center-expands-nationally-as-opioid-epidemic-rages-on\",\"postDate\":1466109060,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"59\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"Two more opiate and alcohol treatment centers will be popping up in Massachusetts, as Northampton-based CleanSlate Centers looks to expand in the Bay State and nationally.\"}},\"60\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"90\"],\"20\":{\"date\":\"6\\/15\\/2016\"},\"36\":[\"65\"]}}', '2016-07-13 18:39:27', '2016-07-13 18:39:27', '32f6a6bb-ce68-4006-bb47-0861fc76372b'),
 ('396', '52', '8', '1', 'en_us', '8', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Mass.-based addiction treatment center expands nationally as opioid epidemic rages on\",\"slug\":\"mass-based-addiction-treatment-center-expands-nationally-as-opioid-epidemic-rages-on\",\"postDate\":1466109060,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"59\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"Two more opiate and alcohol treatment centers will be popping up in Massachusetts, as Northampton-based CleanSlate Centers looks to expand in the Bay State and nationally.\"}},\"60\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"90\"],\"20\":{\"date\":\"6\\/15\\/2016\"},\"36\":[\"65\"]}}', '2016-07-13 18:39:34', '2016-07-13 18:39:34', '51e16c14-1b70-4dd3-bdec-c939ed9d8b32'),
 ('397', '14', '8', '1', 'en_us', '9', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"cleanslate\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"131\":\"\",\"20\":{\"date\":\"6\\/13\\/2016\"},\"36\":[\"65\"]}}', '2016-07-13 18:39:42', '2016-07-13 18:39:42', '3d7ba137-729b-4025-8040-9466218cba5b'),
 ('398', '9', '6', '1', 'en_us', '53', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"357\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Areas of Expertise\"}},\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"141\":\"Partnerships\",\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/braeburn-pharmaceuticals\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/cure-forward\\\">Cure Forward<\\/a>\\u2019s unique Clinical Trial Exchange&nbsp;platform empowers patients to govern their own care plans.&nbsp;<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}},\"140\":\"Charting a trajectory\"}}', '2016-07-13 18:40:00', '2016-07-13 18:40:00', '1d8fdb79-275c-4561-b246-59c386b0f6af'),
 ('399', '114', '12', '1', 'en_us', '2', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Mikael Dolsten, MD, Ph.D.\",\"slug\":\"mikael-dolsten\",\"postDate\":1468269960,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":\"\",\"56\":\"<p>Mikael Dolsten, M.D., Ph.D. became the Chairman of Apple Tree Partner\\u2019s Translational Advisory Board in 2016. Mikael is currently the President of Pfizer Worldwide Research and Development (WRD) and Executive Vice President of Pfizer Inc. Dr. Dolsten is also a member of the Pfizer Executive Leadership Team and co-chairs the company\\u2019s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities.<\\/p>\\r\\n\\r\\n<p>Prior to joining Pfizer in 2009, Dr. Dolsten was President of Wyeth Research responsible for global research and development activities. Before joining Wyeth, he served as Executive Vice President for Worldwide Research at Boehringer Ingelheim. His earlier career as a research leader included VP leadership positions with AstraZeneca, Pharmacia and Upjohn. Mikael has also served as a Private Equity partner at Orbimed, the world\\u2019s largest healthcare focused investment company. In addition, he gained leadership experience from five large-scale M&A transactions.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Mikael is a governor of the New York Academy of Sciences, a member of the board of Karyopharm Therapeutics Inc., a member of the Biomedical Advisory Council of The Pharmaceutical Research and Manufacturers of America (PhRMA), co-lead for the industry-NIH Accelerating Medicine Partnership (AMP) Executive Committee and serves on the PhRMA Foundation Board of Directors. He has been a board member of a Swedish Business School for Innovation and Chamber of Commerce. Dr. Dolsten is a named inventor on several patents and has published approximately 150 articles in international journals, with particular contributions in areas such as molecular cell biology, immunology and oncology.<\\/p>\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Dr. Dolsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund, Sweden.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Chairman, Translational Advisory Board\",\"80\":\"<p>Mikael is currently the President of Pfizer Worldwide Research and Development (WRD) and Executive Vice President of Pfizer Inc.<\\/p>\",\"104\":\"\"}}', '2016-07-13 19:57:12', '2016-07-13 19:57:12', '2de238b7-ea13-4589-a10d-bf1da4520590'),
 ('400', '114', '12', '1', 'en_us', '3', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Mikael Dolsten, MD, Ph.D.\",\"slug\":\"mikael-dolsten\",\"postDate\":1468269960,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Mikael Dolsten, M.D., Ph.D. became the Chairman of Apple Tree Partner\\u2019s Translational Advisory Board in 2016. Mikael is currently the President of Pfizer Worldwide Research and Development (WRD) and Executive Vice President of Pfizer Inc. Dr. Dolsten is also a member of the Pfizer Executive Leadership Team and co-chairs the company\\u2019s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities.<\\/p>\\r\\n\\r\\n<p>Prior to joining Pfizer in 2009, Dr. Dolsten was President of Wyeth Research responsible for global research and development activities. Before joining Wyeth, he served as Executive Vice President for Worldwide Research at Boehringer Ingelheim. His earlier career as a research leader included VP leadership positions with AstraZeneca, Pharmacia and Upjohn. Mikael has also served as a Private Equity partner at Orbimed, the world\\u2019s largest healthcare focused investment company. In addition, he gained leadership experience from five large-scale M&A transactions.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Mikael is a governor of the New York Academy of Sciences, a member of the board of Karyopharm Therapeutics Inc., a member of the Biomedical Advisory Council of The Pharmaceutical Research and Manufacturers of America (PhRMA), co-lead for the industry-NIH Accelerating Medicine Partnership (AMP) Executive Committee and serves on the PhRMA Foundation Board of Directors. He has been a board member of a Swedish Business School for Innovation and Chamber of Commerce. Dr. Dolsten is a named inventor on several patents and has published approximately 150 articles in international journals, with particular contributions in areas such as molecular cell biology, immunology and oncology.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Dr. Dolsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund, Sweden.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Chairman, Translational Advisory Board\",\"80\":\"<p>Mikael is currently the President of Pfizer Worldwide Research and Development (WRD) and Executive Vice President of Pfizer Inc.<\\/p>\",\"104\":\"\"}}', '2016-07-13 19:57:38', '2016-07-13 19:57:38', '0a49b573-d425-4f2c-8a3c-0f1fcaccaf3c'),
 ('401', '12', '9', '1', 'en_us', '26', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"88\"],\"38\":\"Founded in 1999, we are a venture capital firm that invests in and starts new therapeutic, medtech, and healthcare service companies. With a history of well-known successes in long-term investment strategies, our managers can build with confidence, knowing that we are funding them to grow and develop their businesses.\",\"37\":\"About Apple Tree Partners (ATP)\",\"47\":{\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamImage\":[\"95\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"105\",\"106\",\"125\",\"126\",\"108\",\"109\",\"123\",\"113\",\"114\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamImage\":[\"92\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"55\",\"57\",\"107\",\"128\",\"116\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamImage\":[\"89\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"53\",\"102\",\"127\"]}},\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Finance & Administration\",\"teamImage\":[\"90\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"99\",\"141\",\"142\",\"143\",\"144\",\"145\",\"146\"]}}}}}', '2016-07-13 19:58:07', '2016-07-13 19:58:07', '396a9163-e93c-4434-8fa1-eba88abb5ad4'),
 ('402', '9', '6', '1', 'en_us', '54', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"357\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Areas of Expertise\"}},\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"141\":\"Partnerships\",\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/braeburn-pharmaceuticals\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/cure-forward\\\">Cure Forward\'s<\\/a>&nbsp;unique Clinical Trial Exchange&nbsp;platform empowers patients to govern their own care plans.&nbsp;<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}},\"140\":\"Charting a trajectory\"}}', '2016-07-13 20:01:19', '2016-07-13 20:01:19', 'e4d1e694-0ce0-4dbc-88cb-e01d92d8ecbb'),
 ('403', '114', '12', '1', 'en_us', '4', '', '{\"typeId\":\"12\",\"authorId\":\"1\",\"title\":\"Mikael Dolsten, MD, Ph.D.\",\"slug\":\"mikael-dolsten\",\"postDate\":1468269960,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"129\":[\"95\"],\"56\":\"<p>Mikael Dolsten, M.D., Ph.D. became the Chairman of Apple Tree Partner\\u2019s Translational Advisory Board in 2016. Mikael is currently the President of Pfizer Worldwide Research and Development (WRD) and Executive Vice President of Pfizer Inc. Dr. Dolsten is also a member of the Pfizer Executive Leadership Team and co-chairs the company\\u2019s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p>Prior to joining Pfizer in 2009, Dr. Dolsten was President of Wyeth Research responsible for global research and development activities. Before joining Wyeth, he served as Executive Vice President for Worldwide Research at Boehringer Ingelheim. His earlier career as a research leader included VP leadership positions with AstraZeneca, Pharmacia and Upjohn. Mikael has also served as a Private Equity partner at Orbimed, the world\\u2019s largest healthcare focused investment company. In addition, he gained leadership experience from five large-scale M&A transactions.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Mikael is a governor of the New York Academy of Sciences, a member of the board of Karyopharm Therapeutics Inc., a member of the Biomedical Advisory Council of The Pharmaceutical Research and Manufacturers of America (PhRMA), co-lead for the industry-NIH Accelerating Medicine Partnership (AMP) Executive Committee and serves on the PhRMA Foundation Board of Directors. He has been a board member of a Swedish Business School for Innovation and Chamber of Commerce. Dr. Dolsten is a named inventor on several patents and has published approximately 150 articles in international journals, with particular contributions in areas such as molecular cell biology, immunology and oncology.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><br><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Dr. Dolsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund, Sweden.<\\/p>\",\"57\":\"\",\"110\":[\"100\"],\"109\":\"Chairman, Translational Advisory Board\",\"80\":\"Mikael is currently the President of Pfizer Worldwide Research and Development (WRD) and Executive Vice President of Pfizer Inc.\",\"104\":\"\"}}', '2016-07-13 20:16:47', '2016-07-13 20:16:47', '69f2f2ce-c71c-4bb6-bf46-fe96c836e2d9'),
 ('404', '351', '8', '1', 'en_us', '3', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Corvidia Therapeutics Raises $26M in a Series A Financing, Led by Sofinnova Partners and Apple Tree Partners\",\"slug\":\"corvidia-therapeutics-raises-26m-in-a-series-a-financing-led-by-sofinnova-partners-and-apple-tree-partners\",\"postDate\":1468299660,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"352\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple Tree Partners.<\\/p>\\r\\n\\r\\n<p>Concurrent with the financing, Corvidia has licensed a clinical stage compound from AstraZeneca to develop and commercialize as its lead therapeutic (COR-001). Funds from the Series A financing will be used to progress COR-001 into Phase I\\/II clinical trials during 2016, as well as to advance the company\'s preclinical pipeline.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Corvidia was co-founded by serial entrepreneur and Chief Executive Officer, Michael Davidson, M.D. Dr. Davidson, a recognized expert in the field of cardiology, previously served as Chief Medical Officer of Sofinnova-backed Omthera Pharmaceuticals, and was instrumental in the successful acquisition of that company by AstraZeneca in 2013 for $443 million. Joining Dr. Davidson at Corvidia are Co-founders Rahul Kakkar M.D. and Matt Devalaraja, Ph.D., both of whom previously worked in AstraZeneca\'s Emerging Innovations Unit, where they developed the science behind genome-guided cardiovascular therapies. Ram Aiyar Ph.D., MBA, an Entrepreneur-in-Residence at the National Institutes of Health and BioHealth Innovation, completes Corvidia\'s founding team.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Commenting on today\'s news, Dr. Davidson stated,&nbsp;<em>\\\"Our ability to complete this significant Series A financing with such high-quality investors is a testament to the promise of our technology and expertise of our management team, positioning Corvidia as a leader in the field of precision medicine as applied to cardiovascular diseases. With these funds, we aim to drive each of our assets through clinical trials and validate our precision medicine approach.\\\"<\\/em><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Graziano Seghezzi, Partner at Sofinnova Partners, and Corvidia\'s board member commented,&nbsp;<em>\\\"Given Omthera\'s success, we were strongly in favor of teaming up once again with Dr. Davidson. The seed funding that Sofinnova Partners provided allowed for Corvidia\'s inception, for the pipeline crafting and for the eventual structuring of the Series A. We are pleased to continue to support Corvidia and this latest financing represents a major step for the future advancement of novel, cardiovascular therapeutics.\\\"<\\/em><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Seth Harrison, M.D., Managing Partner of Apple Tree Partners, noted, \\\"<em>In&nbsp;<\\/em><em>our years of start-up investing we have not seen a better team than the group that Michael Davidson has assembled from AstraZeneca and the NIH. We are thrilled to be able to support Corvidia with our capital resources and company building experience, and look forward to working with Sofinnova Partners, AstraZeneca, and management to create the first great precision cardiovascular medicine company.<\\/em>\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>COR-001, a monoclonal antibody initially developed by MedImmune, AstraZeneca\'s global biologics research and development arm, was previously in a Phase 1 study for a different indication. It was repurposed by AstraZeneca\'s Emerging Innovations Unit, Scientific Partnering and Alliances (SP&A), prior to licensing to Corvidia.&nbsp;<em>\\\"This is another example of the strong entrepreneurial culture within AstraZeneca, where we push the boundaries of science to explore new therapeutic uses for our compounds. We will continue to divest or out-license assets where we believe it will help accelerate the development of new medicines.\\\"&nbsp;<\\/em>said Kumar Srinivasan, Vice President, SP&A, Innovative Medicines Unit, AstraZeneca.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In conjunction with the financing, Seth Harrison and Adrien Lemoine, Executive Director, Corporate Development for AstraZeneca, will join Graziano Seghezzi and Michael Davidson on Corvidia\'s Board of Directors.<\\/p>\",\"position\":\"left\"}},\"353\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Sofinnova Partners\"}},\"354\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs, and has backed nearly 500 companies over more than 40 years, creating market leaders around the globe. Today, Sofinnova Partners has over \\u20ac1.5 billion under management. For more information, please visit:<a href=\\\"http:\\/\\/www.sofinnova.fr\\/\\\" target=\\\"_blank\\\">www.sofinnova.fr<\\/a><\\/p>\",\"position\":\"left\"}},\"355\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Corvidia Therapeutics\"}},\"356\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Based in Boston, MA, Corvidia is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company\'s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia\'s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. For more information, please visit:<a href=\\\"http:\\/\\/www.corvidiatx.com\\/\\\" target=\\\"_blank\\\">www.corvidiatx.com<\\/a><\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"2\\/17\\/2016\"},\"36\":[\"350\"]}}', '2016-07-13 21:06:06', '2016-07-13 21:06:06', '7846d820-c8a4-4617-a59e-7d885ee0a7db'),
 ('405', '296', '13', '1', 'en_us', '3', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Tusker Medical\",\"slug\":\"tusker-medical\",\"postDate\":1468282980,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Tusker Medical is an early stage medical device company developing innovative ear, nose and throat treatments. Tusker is currently developing a suite of pediatric-focused technologies designed to enable placement of tubes within the comfort of an office environment, eliminating the need for general anesthetics.<\\/p>\",\"62\":{\"297\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.tuskermed.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/tusker-medical-inc.\"}}},\"130\":[\"92\"],\"66\":[\"375\"],\"81\":\"<p>Tusker Medical is an early stage medical device company developing innovative ear, nose and throat treatments.<\\/p>\",\"103\":[\"97\"]}}', '2016-07-13 21:07:29', '2016-07-13 21:07:29', '42bf54b2-a9dc-4380-b1c3-7956b11f566c'),
 ('406', '296', '13', '1', 'en_us', '4', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Tusker Medical\",\"slug\":\"tusker-medical\",\"postDate\":1468282980,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Tusker Medical is an early stage medical device company developing innovative ear, nose and throat treatments. Tusker is currently developing a suite of pediatric-focused technologies designed to enable placement of tubes within the comfort of an office environment, eliminating the need for general anesthetics.<\\/p>\",\"62\":{\"297\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.tuskermed.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/tusker-medical-inc.\"}}},\"130\":[\"92\"],\"66\":[\"375\"],\"81\":\"<p>Tusker Medical is an early stage medical device company developing innovative ear, nose and throat treatments.<\\/p>\",\"103\":[\"97\"]}}', '2016-07-13 21:07:42', '2016-07-13 21:07:42', '3cc5bcdf-37f8-4b1d-b289-d7732069a9b0'),
 ('407', '296', '13', '1', 'en_us', '5', '', '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Tusker Medical\",\"slug\":\"tusker-medical\",\"postDate\":1468282980,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"61\":\"<p>Tusker Medical is an early stage medical device company developing innovative ear, nose and throat treatments. Tusker is currently developing a suite of pediatric-focused technologies designed to enable placement of tubes within the comfort of an office environment, eliminating the need for general anesthetics.<\\/p>\",\"62\":{\"297\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.tuskermed.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/tusker-medical-inc.\"}}},\"130\":[\"92\"],\"66\":[\"375\"],\"81\":\"<p>Tusker Medical is an early stage medical device company developing innovative ear, nose and throat treatments.<\\/p>\",\"103\":[\"97\"]}}', '2016-07-13 21:08:08', '2016-07-13 21:08:08', '2dd5745e-8093-4ace-9966-09a337fcfd47'),
 ('408', '9', '6', '1', 'en_us', '55', '', '{\"typeId\":\"6\",\"authorId\":null,\"title\":\"Home\",\"slug\":\"home\",\"postDate\":1465917935,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"5\":{\"357\":{\"type\":\"sectionTitle\",\"enabled\":\"1\",\"fields\":{\"header\":\"Areas of Expertise\"}},\"36\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Therapeutics\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key\\u00a0successes.\\u00a0It\\u00a0should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"37\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Medical Devices\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}},\"38\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"areaTitle\":\"Healthcare Services\",\"areaDescription\":\"A little blurb goes here explaining our mission in this vertical and key successes. It should\\u00a0describe\\u00a0why ATP is a leader in this field and what innovation we\'ve pioneered.\"}}},\"4\":\"<p>We use a <em>long term investment philosophy<\\/em> to build&nbsp;sustainable healthcare companies through meaningful partnerships and deep expertise.<\\/p>\",\"69\":[\"14\",\"52\"],\"3\":[\"87\"],\"141\":\"Partnerships\",\"82\":{\"62\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/braeburn-pharmaceuticals\\\">Braeburn Pharmaceuticals<\\/a>&nbsp;is helping to change the conversation about&nbsp;opioid dependence.&nbsp;<\\/h1>\"}},\"63\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/tusker-medical\\\">Tusker Medical<\\/a>&nbsp;is developing a suite of pediatric-focused technologies designed to avoid&nbsp;general anesthetics.<\\/h1>\"}},\"64\":{\"type\":\"partnership\",\"enabled\":\"1\",\"fields\":{\"partnershipInfo\":\"<h1><a href=\\\"http:\\/\\/atp.sdny.in\\/portfolio\\/cure-forward\\\">Cure Forward\'s<\\/a>&nbsp;unique Clinical Trial Exchange&nbsp;platform empowers patients to govern their own care plans.&nbsp;<\\/h1>\"}}},\"9\":{\"39\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"250\",\"trajectoryDescription\":\"Commitments as high as $250 million \",\"trajectoryBody\":\"We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.\"}},\"74\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"1.67\",\"trajectoryDescription\":\"$1.67 billion dedicated to building healthcare businesses\",\"trajectoryBody\":\"We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.\"}},\"40\":{\"type\":\"trajectory\",\"enabled\":\"1\",\"fields\":{\"trajectoryTitle\":\"16\",\"trajectoryDescription\":\"16 portfolio companies\",\"trajectoryBody\":\"We start companies, or invest in existing companies, that bring products to patients. \"}}},\"140\":\"Charting a trajectory\"}}', '2016-07-13 21:11:57', '2016-07-13 21:11:57', '2ef34832-dbe8-409d-ac87-f4139172e980'),
 ('409', '229', '13', '1', 'en_us', '7', NULL, '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Coelacanth Chemical Corporation\",\"slug\":\"http-www-appletreepartners-com-portfolio-detail-coelacanth-acquired-by-lexicon-genetics\",\"postDate\":1468274580,\"expiryDate\":null,\"enabled\":\"1\",\"parentId\":null,\"fields\":{\"61\":\"<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \\\"click\\\" chemistry.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Lexicon Genetics July 2001<\\/em><\\/p>\",\"62\":{\"230\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.lexicon-genetics.com\\/\",\"linkedin\":\"https:\\/\\/www.linkedin.com\\/company\\/coelacanth-chemical-corp\"}}},\"130\":[\"90\"],\"66\":[\"380\"],\"81\":\"<p>Combinatorial chemistry building blocks based upon Nobel-prize winning K. Barry Sharpless\' \\\"click\\\" chemistry.<\\/p>\",\"103\":[\"376\"]}}', '2016-07-13 21:14:28', '2016-07-13 21:14:28', 'f79dc0a3-ab7f-49c4-8b6d-eff6e75dd025'),
 ('410', '13', '10', '1', 'en_us', '16', '', '{\"typeId\":\"10\",\"authorId\":null,\"title\":\"Portfolio\",\"slug\":\"portfolio\",\"postDate\":1466010801,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"50\":{\"19\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Therapeutics\",\"expertiseImage\":[\"95\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"27\",\"200\",\"239\",\"284\"],\"expertiseLink\":\"Meet the Therapeutics team\"}},\"20\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Medical Devices\",\"expertiseImage\":[\"92\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"242\",\"296\",\"287\",\"298\"],\"expertiseLink\":\"Meet the Medical Devices team\"}},\"21\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Healthcare Services\",\"expertiseImage\":[\"89\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"204\",\"244\",\"275\",\"293\"],\"expertiseLink\":\"Meet the Healthcare Services team\"}},\"22\":{\"type\":\"areaOfExpertise\",\"enabled\":\"1\",\"fields\":{\"expertiseTitle\":\"Legacy Investments\",\"expertiseImage\":[\"90\"],\"expertiseDescription\":\"Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.\",\"company\":[\"229\",\"246\",\"248\",\"250\",\"281\",\"290\"],\"expertiseLink\":\"\"}}}}}', '2016-07-13 21:16:21', '2016-07-13 21:16:21', 'fc8d3658-eb60-4da8-9f6c-07393139c839'),
 ('411', '246', '13', '1', 'en_us', '7', NULL, '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Cyrano Sciences\",\"slug\":\"cyrano-sciences\",\"postDate\":1468276560,\"expiryDate\":null,\"enabled\":\"1\",\"parentId\":null,\"fields\":{\"61\":\"<p>An electronic nose for homeland defense applications.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Smiths Detection March 2004<\\/em><\\/p>\",\"62\":{\"247\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.smithsdetection.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"90\"],\"66\":[\"382\"],\"81\":\"<p>An electronic nose for homeland defense applications.<\\/p><p><em>Acquired by Smiths Detection March 2004<\\/em><br><\\/p>\",\"103\":[\"376\"]}}', '2016-07-13 21:17:20', '2016-07-13 21:17:20', 'ef7e5515-e679-4c72-ad09-c3f89a1db9db'),
 ('412', '246', '13', '1', 'en_us', '8', NULL, '{\"typeId\":\"13\",\"authorId\":\"1\",\"title\":\"Cyrano Sciences\",\"slug\":\"cyrano-sciences\",\"postDate\":1468276560,\"expiryDate\":null,\"enabled\":\"1\",\"parentId\":null,\"fields\":{\"61\":\"<p>An electronic nose for homeland defense applications.<\\/p>\\r\\n\\r\\n<p><em>Acquired by Smiths Detection March 2004<\\/em><\\/p>\",\"62\":{\"247\":{\"type\":\"contactMethods\",\"enabled\":\"1\",\"fields\":{\"companyWebsite\":\"http:\\/\\/www.smithsdetection.com\\/\",\"linkedin\":\"\"}}},\"130\":[\"90\"],\"66\":[\"382\"],\"81\":\"<p>An electronic nose for homeland defense applications.<\\/p><p><br><\\/p>\\r\\n\\r\\n<p><em>Acquired by Smiths Detection March 2004<\\/em><br><\\/p>\",\"103\":[\"376\"]}}', '2016-07-13 21:17:31', '2016-07-13 21:17:31', '500bd22c-bc53-4f26-9799-1c9dd153a9a2'),
 ('413', '10', '7', '1', 'en_us', '12', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Contact\",\"slug\":\"contact\",\"postDate\":1465917860,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"70\":{\"41\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"New York City\",\"cityImage\":\"\",\"address\":\"230 Park Avenue, Suite 2800\\r\\nNew York, New York 10169\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"40.7543\",\"locationLongitude\":\"-73.97618\"}},\"42\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Cambridge \",\"cityImage\":\"\",\"address\":\"300 Technology Square, Suite 803G\\r\\nCambridge, MA 02139\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"42.36344\",\"locationLongitude\":\"-71.09147\"}},\"43\":{\"type\":\"location\",\"enabled\":\"1\",\"fields\":{\"cityName\":\"Los Altos\",\"cityImage\":\"\",\"address\":\"4970 El Camino Real, Suite 220\\r\\nLos Altos, CA 94022\",\"telephone\":\"212.476.9900\",\"fax\":\"212.999.0000\",\"contactLine\":\"Do you have a revolutionary innovation?\",\"email\":\"info@appletreepartners.com\",\"emailCopy\":\"Let\'s talk.\",\"locationLatitude\":\"37.3976\",\"locationLongitude\":\"-122.10632\"}}}}}', '2016-07-13 21:20:34', '2016-07-13 21:20:34', '91671e91-e68d-482c-b7fd-323530286065'),
 ('414', '14', '8', '1', 'en_us', '10', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"cleanslate\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"131\":\"\",\"20\":{\"date\":\"6\\/13\\/2015\"},\"36\":[\"65\"]}}', '2016-07-13 21:48:12', '2016-07-13 21:48:12', 'bda6a01f-5e3a-4b6b-a0d6-dc04c14bf8b9'),
 ('415', '14', '8', '1', 'en_us', '11', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"cleanslate\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"131\":\"\",\"20\":{\"date\":\"6\\/13\\/2015\"},\"36\":[\"65\"]}}', '2016-07-13 21:48:52', '2016-07-13 21:48:52', 'd2febfdf-105d-439b-a41f-74226e7b6dc9'),
 ('416', '14', '8', '1', 'en_us', '12', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"cleanslate\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"131\":\"\",\"20\":{\"date\":\"6\\/13\\/2015\"},\"36\":[\"65\"]}}', '2016-07-13 21:49:45', '2016-07-13 21:49:45', 'e0235462-4438-4ef6-b5cc-9fcc085aa7ab'),
 ('417', '351', '8', '1', 'en_us', '4', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Corvidia Therapeutics Raises $26M in a Series A Financing, Led by Sofinnova Partners and Apple Tree Partners\",\"slug\":\"corvidia-therapeutics-raises-26m-in-a-series-a-financing-led-by-sofinnova-partners-and-apple-tree-partners\",\"postDate\":1468299660,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"352\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple Tree Partners.<\\/p>\\r\\n\\r\\n<p>Concurrent with the financing, Corvidia has licensed a clinical stage compound from AstraZeneca to develop and commercialize as its lead therapeutic (COR-001). Funds from the Series A financing will be used to progress COR-001 into Phase I\\/II clinical trials during 2016, as well as to advance the company\'s preclinical pipeline.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Corvidia was co-founded by serial entrepreneur and Chief Executive Officer, Michael Davidson, M.D. Dr. Davidson, a recognized expert in the field of cardiology, previously served as Chief Medical Officer of Sofinnova-backed Omthera Pharmaceuticals, and was instrumental in the successful acquisition of that company by AstraZeneca in 2013 for $443 million. Joining Dr. Davidson at Corvidia are Co-founders Rahul Kakkar M.D. and Matt Devalaraja, Ph.D., both of whom previously worked in AstraZeneca\'s Emerging Innovations Unit, where they developed the science behind genome-guided cardiovascular therapies. Ram Aiyar Ph.D., MBA, an Entrepreneur-in-Residence at the National Institutes of Health and BioHealth Innovation, completes Corvidia\'s founding team.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Commenting on today\'s news, Dr. Davidson stated,&nbsp;<em>\\\"Our ability to complete this significant Series A financing with such high-quality investors is a testament to the promise of our technology and expertise of our management team, positioning Corvidia as a leader in the field of precision medicine as applied to cardiovascular diseases. With these funds, we aim to drive each of our assets through clinical trials and validate our precision medicine approach.\\\"<\\/em><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Graziano Seghezzi, Partner at Sofinnova Partners, and Corvidia\'s board member commented,&nbsp;<em>\\\"Given Omthera\'s success, we were strongly in favor of teaming up once again with Dr. Davidson. The seed funding that Sofinnova Partners provided allowed for Corvidia\'s inception, for the pipeline crafting and for the eventual structuring of the Series A. We are pleased to continue to support Corvidia and this latest financing represents a major step for the future advancement of novel, cardiovascular therapeutics.\\\"<\\/em><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Seth Harrison, M.D., Managing Partner of Apple Tree Partners, noted, \\\"<em>In&nbsp;<\\/em><em>our years of start-up investing we have not seen a better team than the group that Michael Davidson has assembled from AstraZeneca and the NIH. We are thrilled to be able to support Corvidia with our capital resources and company building experience, and look forward to working with Sofinnova Partners, AstraZeneca, and management to create the first great precision cardiovascular medicine company.<\\/em>\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>COR-001, a monoclonal antibody initially developed by MedImmune, AstraZeneca\'s global biologics research and development arm, was previously in a Phase 1 study for a different indication. It was repurposed by AstraZeneca\'s Emerging Innovations Unit, Scientific Partnering and Alliances (SP&A), prior to licensing to Corvidia.&nbsp;<em>\\\"This is another example of the strong entrepreneurial culture within AstraZeneca, where we push the boundaries of science to explore new therapeutic uses for our compounds. We will continue to divest or out-license assets where we believe it will help accelerate the development of new medicines.\\\"&nbsp;<\\/em>said Kumar Srinivasan, Vice President, SP&A, Innovative Medicines Unit, AstraZeneca.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In conjunction with the financing, Seth Harrison and Adrien Lemoine, Executive Director, Corporate Development for AstraZeneca, will join Graziano Seghezzi and Michael Davidson on Corvidia\'s Board of Directors.<\\/p>\",\"position\":\"left\"}},\"353\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Sofinnova Partners\"}},\"354\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs, and has backed nearly 500 companies over more than 40 years, creating market leaders around the globe. Today, Sofinnova Partners has over \\u20ac1.5 billion under management. For more information, please visit:<a href=\\\"http:\\/\\/www.sofinnova.fr\\/\\\" target=\\\"_blank\\\">www.sofinnova.fr<\\/a><\\/p>\",\"position\":\"left\"}},\"355\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Corvidia Therapeutics\"}},\"356\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Based in Boston, MA, Corvidia is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company\'s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia\'s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. For more information, please visit:<a href=\\\"http:\\/\\/www.corvidiatx.com\\/\\\" target=\\\"_blank\\\">www.corvidiatx.com<\\/a><\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"2\\/17\\/2016\"},\"36\":[\"383\"]}}', '2016-07-13 21:52:59', '2016-07-13 21:52:59', '995850a9-de79-49b4-b639-01dc57791557'),
 ('418', '342', '8', '1', 'en_us', '3', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain\",\"slug\":\"braeburn-and-camurus-announce-initiation-of-a-phase-2-study-in-opioid-dependent-patients-with-moderate-to-severe-chronic-pain\",\"postDate\":1468299540,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"343\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Braeburn Pharmaceuticals and Camurus announced today that the first patients have been dosed with CAM2038, weekly and monthly subcutaneous buprenorphine injections, in a pharmacokinetic study of opioid dependent patients with chronic pain.<\\/p>\\r\\n\\r\\n<p>The primary objective of this Phase 2 study is to assess the steady state pharmacokinetics of buprenorphine after repeated doses in opioid dependent patients with chronic pain, including effects of injection into different subcutaneous sites. This study will also explore the effect of CAM2038 on chronic pain, along with evaluation of safety and tolerability.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"This marks the fourth clinical study that has been started in the last five months for CAM2038, including two Phase 3 trials in opioid dependence. The ability to use CAM2038 in multiple injection sites would allow physicians the flexibility to personalize treatments,\\\" said Behshad Sheldon, President and CEO, Braeburn Pharmaceuticals. \\\"Our goal is to provide a suite of best-in-class long-acting treatment options tailored to the individual needs of patients suffering from opioid dependence and chronic pain.\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"Patients that suffer from chronic pain and are also opioid dependent are a difficult population to treat,\\\" said the principal investigator Dr. Greg Sullivan, medical director at Parkway Medical Center in Birmingham, Alabama. \\\"By using a long acting buprenorphine injectable, these patients would no longer be required to take medication multiple times per day. Buprenorphine also guards against hyperanalgesia and opiate tolerance, both of which are problems with conventional opiates.\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"CAM2038 has the potential to offer effective and safe around-the-clock pain relief, without risks of abuse and diversion. The pharmacological properties of buprenorphine together with long-acting release from the FluidCrystal formulation could also decrease risks of respiratory depression and overdose mortality associated with current opioid pain treatments,\\\" said Fredrik Tiberg, President and CEO, Camurus.<\\/p>\",\"position\":\"left\"}},\"344\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Braeburn Pharmaceuticals\"}},\"345\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Braeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience. In September 2015 the Food and Drug Administration (FDA) accepted for review Braeburn\'s New Drug Application for its lead candidate, Probuphine, a six-month buprenorphine implant for treatment of opioid dependence. The Agency has set May 27, 2016 as the target date for action.<\\/p>\\r\\n\\r\\n<p>Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. Braeburn\'s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Candidates include: Probuphine\\u00ae, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia. More information on Braeburn, can be found at&nbsp;<a href=\\\"https:\\/\\/braeburnpharmaceuticals.com\\/\\\" target=\\\"_blank\\\">https:\\/\\/braeburnpharmaceuticals.com\\/<\\/a>.<\\/p>\",\"position\":\"left\"}},\"346\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CAM2038\"}},\"347\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>The investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid addiction and pain are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance. The CAM2038 products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion, abuse, misuse, and accidental exposure. The CAM2038 products have been evaluated in three Phase 1\\/2 clinical trials, which evaluated the safety and tolerability as well as pharmacokinetic and pharmacodynamics properties of the products in a total of 176 individuals (opioid-dependent patients and healthy volunteers under naltrexone blockage). The CAM2038 products are also being developed for treatment of chronic pain, combining the effective analgesic properties of buprenorphine with the long acting release provided by the FluidCrystal\\u00ae injection depot.<\\/p>\",\"position\":\"left\"}},\"348\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Camurus\"}},\"349\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal\\u00ae drug delivery technologies and an extensive R&D expertise. Camurus\' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company\'s share is listed on Nasdaq Stockholm under the ticker \\\"CAMX\\\". For more information, visit&nbsp;<a href=\\\"http:\\/\\/www.camurus.com\\/\\\" target=\\\"_blank\\\">www.camurus.com<\\/a>.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"2\\/22\\/2016\"},\"36\":[\"384\"]}}', '2016-07-13 21:53:10', '2016-07-13 21:53:10', 'd588ce40-039a-43a9-b005-f0eb1c50588d'),
 ('419', '338', '8', '1', 'en_us', '3', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Syntimmune Secures Second Tranche of $26 Million Series A Financing\",\"slug\":\"syntimmune-secures-second-tranche-of-26-million-series-a-financing\",\"postDate\":1468299360,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"339\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Syntimmune, Inc., a development-stage company advancing novel treatments for IgG-mediated autoimmune diseases based on leading expertise in FcRn biology, today announced that it has made important progress by achieving preclinical proof of concept and completing preclinical safety testing, triggering a second, $10 million tranche of the Company\\u2019s committed $26 million Series A financing. The Series A financing is co-led by Apple Tree Partners and Baxalta Ventures, the corporate venture capital arm of Baxalta Incorporated, with participation by the Partners Innovation Fund and additional investors. Funds from this tranche of the Series A round will be used to complete the anticipated Phase 1a clinical trial in healthy volunteers of Syntimmune\\u2019s lead candidate, SYNT001. The Company intends to submit an IND application to the Food and Drug Administration for SYNT001 in mid-2016 to authorize initiation of the Phase 1a study later this year. SYNT001 is a biologic that blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases.<\\/p>\\r\\n\\r\\n<p>\\u201cThe closing of the second tranche in the Series A affirms the progress Syntimmune has achieved and reflects the importance of targeting FcRn as a breakthrough modality for treating IgG-mediated autoimmune diseases,\\u201d said Laurence Blumberg, M.D., Founder and COO of Syntimmune. \\u201cSince our founding just over two years ago, Syntimmune has made rapid progress in advancing its pipeline of candidates and progressing its lead program, SYNT001, through IND-enabling studies and toward the clinic. SYNT001 is showing a promising preclinical safety profile and robust activity in unique in vivo preclinical models, which we plan to present at appropriate peer-reviewed forums.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cThe opportunity for SYNT001 is substantial,\\u201d stated David de Graaf, Ph.D., Venture Partner at Apple Tree Partners. \\u201cWe are extremely happy with the progress the team has made on the lead molecule, which has the potential to address a large number of autoimmune indications.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cFcRn is a central mediator of IgG-related immunity and part of an important pathway that enables abnormal IgG responses in a large number of clinical settings, including autoimmune disease,\\u201d commented Richard Blumberg, M.D., Scientific Founder of Syntimmune and Division Chief of Gastroenterology, Hepatology and Endoscopy at Brigham and Women\\u2019s Hospital, as well as co-Director of the Harvard Digestive Diseases Center and Director of the Brigham Research Institute. \\u201cWhile FcRn is a highly validated target and has attracted substantial industry interest, there are no commercially available therapies designed to block IgG-FcRn interactions, which underlie diseases that affect multiple organ systems and for which there are continuing substantial medical needs, such as inflammatory bowel disease, lupus erythematosus, dermatomyositis and others. I am thrilled with the progress of Syntimmune and look forward to the advancement of the clinical program for SYNT001.\\u201d<\\/p>\",\"position\":\"left\"}},\"340\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Syntimmune\"}},\"341\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Founded in 2013, Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-mediated autoimmune diseases and represents a central common pathway that enables abnormal IgG responses. Syntimmune\\u2019s lead candidate, SYNT001, is a biologic progressing through IND-enabling studies that specifically blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases. Syntimmune has two additional, earlier-stage therapeutic programs, targeting other unique aspects of FcRn biology. The Syntimmune team has world-class experience in the field of FcRn biology and has successfully pioneered and advanced biologics targeting FcRn, including approved therapies currently on the market. Since its founding, the Company has received a total of $28 million in funding commitments from leading life sciences investors, including Apple Tree Partners, Baxalta Ventures, and Partners Innovation Fund. For more information on Syntimmune, please visit the Company\\u2019s website at<a href=\\\"http:\\/\\/cts.businesswire.com\\/ct\\/CT?id=smartlink&url=http%3A%2F%2Fwww.syntimmune.com&esheet=51304447&newsitemid=20160322005211&lan=en-US&anchor=www.syntimmune.com&index=1&md5=62fb1a7393f2201155ab419b9a8b964d\\\" target=\\\"_blank\\\">www.syntimmune.com<\\/a>.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"3\\/22\\/2016\"},\"36\":[\"385\"]}}', '2016-07-13 21:53:20', '2016-07-13 21:53:20', '02dd1184-4911-480f-a3d3-85407d9dc601'),
 ('420', '14', '8', '1', 'en_us', '13', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"cleanslate\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"131\":\"\",\"20\":{\"date\":\"6\\/13\\/2015\"},\"36\":\"\"}}', '2016-07-13 21:53:41', '2016-07-13 21:53:41', '44621dcd-6b80-4427-a669-63a0ee5b4704'),
 ('421', '14', '8', '1', 'en_us', '14', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"cleanslate\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"131\":\"\",\"20\":{\"date\":\"6\\/13\\/2015\"},\"36\":[\"386\"]}}', '2016-07-13 21:53:46', '2016-07-13 21:53:46', '47e0b6c3-a7e1-45bc-89d7-abc6ef3170d7'),
 ('422', '14', '8', '1', 'en_us', '15', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"cleanslate\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"131\":\"\",\"20\":{\"date\":\"6\\/13\\/2016\"},\"36\":[\"386\"]}}', '2016-07-13 23:27:54', '2016-07-13 23:27:54', 'dd11c806-5471-4575-b95e-4fa6de250aaa'),
 ('423', '12', '9', '1', 'en_us', '27', '', '{\"typeId\":\"9\",\"authorId\":null,\"title\":\"Team\",\"slug\":\"team\",\"postDate\":1466010771,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"39\":[\"88\"],\"38\":\"Founded in 1999, we are a venture capital firm that invests in and starts new therapeutic, medtech, and healthcare service companies. With a history of well-known successes in long-term investment strategies, our managers can build with confidence, knowing that we are funding them to grow and develop their businesses.\",\"37\":\"About Apple Tree Partners (ATP)\",\"47\":{\"24\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Therapeutics\",\"teamLink\":\"See the Therapeutics portfolio\",\"teamImage\":[\"95\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"29\",\"105\",\"106\",\"125\",\"126\",\"108\",\"109\",\"123\",\"113\",\"114\"]}},\"25\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Medical Devices\",\"teamLink\":\"See the Medical Devices portfolio\",\"teamImage\":[\"92\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"55\",\"57\",\"107\",\"128\",\"116\"]}},\"26\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Healthcare Services\",\"teamLink\":\"See the Healthcare Services portfolio\",\"teamImage\":[\"89\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"53\",\"102\",\"127\"]}},\"23\":{\"type\":\"teamName\",\"enabled\":\"1\",\"fields\":{\"teamName\":\"Finance & Administration\",\"teamLink\":\"\",\"teamImage\":[\"90\"],\"teamDescription\":\"<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.<\\/p>\",\"teamMember\":[\"99\",\"141\",\"142\",\"143\",\"144\",\"145\",\"146\"]}}}}}', '2016-07-14 16:36:40', '2016-07-14 16:36:40', 'c62275e5-7711-4095-8b7f-3a58b471ff71'),
 ('424', '66', '14', '1', 'en_us', '8', '', '{\"typeId\":\"14\",\"authorId\":null,\"title\":\"Legal\",\"slug\":\"legal\",\"postDate\":1467043290,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"128\":[\"387\"],\"86\":{\"67\":{\"type\":\"legalHeader\",\"enabled\":\"1\",\"fields\":{\"legalHeader\":\"Legal\",\"position\":\"full\"}},\"68\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Terms of Use\",\"legalCopy\":\"Thank you for your interest in our Website at www.appletreepartners.com.  Your use of this Website, including the content, materials and information available on or through this Website (together, the \\\"Materials\\\"), is governed by these Terms of Use (these \\\"Terms\\\"). By using this Website, you acknowledge that you have read and agree to these Terms.\",\"position\":\"left\"}},\"300\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Who We Are\",\"legalCopy\":\"This Website is maintained and operated by Apple Tree Venture Management, LLC, which provides administrative and other services to various Apple Tree entities.  In accordance with industry custom, this Website occasionally uses terminology that may be interpreted to suggest that our firm is actually a single entity. However, there is no such single entity and all of the entities that comprise our firm have their own separate legal existence.\",\"position\":\"left\"}},\"301\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Materials\",\"legalCopy\":\"ALL MATERIALS ARE PROVIDED \\\"AS IS,\\\" MAY NOT BE RELIED UPON FOR ANY PURPOSE, AND ARE NOT SUBJECT TO EXPRESS OR IMPLIED WARRANTIES OF ANY KIND. In particular, we make no representations or warranties with regard to the Materials\' accuracy, completeness, non-infringement or fitness for a particular purpose. You should be aware that a significant portion of the Materials include or consist of information that has been provided by third parties and has not been validated or verified by us. In connection with our investment activities, we often become subject to a variety of confidentiality obligations to funds, investors, portfolio companies and other third parties. Any statements we make may be affected by those confidentiality obligations, with the result that we may be prohibited from making full disclosures. Without limitation on the effect of other warnings and disclaimers set forth in these Terms, you should interpret any statements we make (on this Website or otherwise) in that context. Please ensure that your own computer security is comprehensive and up to date. We accept no responsibility for viruses, malware or other malicious or damaging software contained in the Materials or otherwise.\",\"position\":\"left\"}},\"302\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Third-Party Sites\",\"legalCopy\":\"We accept no responsibility for third-party sites available through this Website, via hyperlink or otherwise. You are encouraged to review the terms of use applicable to those sites. Any access to, or use of, a third-party site is solely at your own risk.\",\"position\":\"left\"}},\"303\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"No Offer, Solicitation or Advice\",\"legalCopy\":\"Nothing on this Website is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by an Apple Tree Partners entity in writing, neither this Website nor any of the Materials make any effort to present a comprehensive or balanced description of Apple Tree Partners or its investment activities.\",\"position\":\"left\"}},\"304\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Restrictions on Use; No License\",\"legalCopy\":\"We reserve all rights with respect to the design and content of this Website. In particular, you must not misappropriate the design or content of this Website and you must not alter or deface such design or content in any way. Nothing on this Website grants any license with respect to such design or content, except that you may download and use Materials solely for your own personal information.\",\"position\":\"left\"}},\"305\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Ownership of Trademarks, Etc.\",\"legalCopy\":\"All text, photos, graphics, logos, content and other Materials on this Website are protected by United States and foreign copyright, trademark and other applicable laws. In particular, all trademarks, trade names and logos displayed on this Website are proprietary to Apple Tree Partners, its affiliates or their respective owners, and this Website grants no license to them. Apple Tree Partners and our tree logo are among our trademarks in the United States and\\/or other countries.\",\"position\":\"left\"}},\"306\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Submitting a Business Plan\",\"legalCopy\":\" or Other Confidential Information. Due to the large number of business plan ideas and related materials that we review, and the similarity of many such plans and materials, we cannot accept responsibility for protecting against misuse or disclosure any confidential or proprietary information or other materials in the absence of our express written agreement to do so. Any plans, information and other materials you submit in connection with this Website may be used or disclosed by us for any purpose and in any manner, as we determine in our sole discretion. Please consider this carefully before sending us any information or other materials that you deem confidential or proprietary.\",\"position\":\"left\"}},\"307\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Privacy Policy\",\"legalCopy\":\"We reserve the right to track visitors to, and usage of, this Website through \\\"cookies\\\" and similar techniques and to use any resulting information as we determine in our sole discretion.\",\"position\":\"left\"}},\"308\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Limitation of Liability\",\"legalCopy\":\"Except as specifically agreed by an Apple Tree Partners entity in writing, NO APPLE TREE PARTNERS INDIVIDUAL OR ENTITY SHALL HAVE ANY LIABILITY BASED UPON YOUR USE OF, OR RELIANCE UPON, THIS WEBSITE OR THE MATERIALS. Some jurisdictions limit our ability to disclaim liability. With regard to those jurisdictions, our liability shall be limited to the greatest extent permitted by applicable law.\",\"position\":\"left\"}},\"309\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"Modification of these Terms\",\"legalCopy\":\"We reserve the right to modify these Terms at any time. Please check these Terms periodically for changes. Your continued use of this Website after the posting of changes constitutes your binding acceptance of such changes.\",\"position\":\"left\"}},\"310\":{\"type\":\"legalBody\",\"enabled\":\"1\",\"fields\":{\"subheader\":\"General Information\",\"legalCopy\":\"This Website is operated and controlled by Apple Tree Venture Management, LLC in the United States of America. If it is illegal or prohibited in your country of origin to access or use this Website, then you should not do so. Those who choose to access this Website outside the United States of America access it on their own initiative and are responsible for compliance with all local laws and regulations. These Terms, and any disputes relating to these Terms or your use of this Website or the Materials, shall be governed in all respects by the laws of the State of New York, without regard to conflicts of laws principles. Except as otherwise agreed in writing by the applicable Apple Tree Partners entities, any disputes relating to these Terms shall be resolved exclusively in the state or federal courts located in New York, New York. These Terms set forth the entire agreement between you and us with respect to the subject matter hereof and supersede all prior agreements relating to such subject matter. All Apple Tree Partners individuals and entities are intended third-party beneficiaries of these Terms. Our rights under these Terms may be waived by us only in writing. These Terms are binding on you as well as your successors and permitted assigns. In the event any provision of these Terms is determined to be invalid or unenforceable, such provision shall be deemed severed from the remainder of these Terms and replaced with a valid and enforceable provision as similar in intent as reasonably possible to the provision so severed, and shall not cause the invalidity or unenforceability of the remainder of these Terms.\",\"position\":\"left\"}},\"69\":{\"type\":\"legalLink\",\"enabled\":\"1\",\"fields\":{\"linkCopy\":\"Do you have a question? Contact us.\",\"linkPosition\":\"left\"}}}}}', '2016-07-14 19:37:10', '2016-07-14 19:37:10', '93f40316-303d-4701-8d38-d986817c8422'),
 ('425', '75', '15', '1', 'en_us', '7', '', '{\"typeId\":null,\"authorId\":null,\"title\":\"Press\",\"slug\":\"press\",\"postDate\":1467840682,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"132\":[\"94\"],\"113\":{\"76\":{\"type\":\"pressInfo\",\"enabled\":\"1\",\"fields\":{\"pressHeader\":\"Press\",\"pressDescription\":\"Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam.\",\"pressLink\":\"<p>Didn\\u2019t find what you were looking for? <em>Get in touch.<\\/em><\\/p>\"}},\"77\":{\"type\":\"brandAssets\",\"enabled\":\"1\",\"fields\":{\"brandAssetsHeader\":\"Brand Assets\",\"logoOptions\":\"\"}},\"78\":{\"type\":\"pressTeam\",\"enabled\":\"1\",\"fields\":{\"pressTeamHeader\":\"Headshots and Bios\",\"headshotBioNames\":\"\",\"headshotAndBio\":\"\"}},\"79\":{\"type\":\"pressNews\",\"enabled\":\"1\",\"fields\":{\"pressNewsHeader\":\"Recent News\",\"pressNewsLink\":\"<p>More Press Releases on our <em>News Page<\\/em><\\/p>\"}}}}}', '2016-07-14 20:30:23', '2016-07-14 20:30:23', '5c5c76c5-295e-405c-958e-dea47ea54354'),
 ('426', '351', '8', '1', 'en_us', '5', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Corvidia Therapeutics Raises $26M in a Series A Financing, Led by Sofinnova Partners and Apple Tree Partners\",\"slug\":\"corvidia-therapeutics-raises-26m-in-a-series-a-financing-led-by-sofinnova-partners-and-apple-tree-partners\",\"postDate\":1468299660,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"352\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple Tree Partners.<\\/p>\\r\\n\\r\\n<p>Concurrent with the financing, Corvidia has licensed a clinical stage compound from AstraZeneca to develop and commercialize as its lead therapeutic (COR-001). Funds from the Series A financing will be used to progress COR-001 into Phase I\\/II clinical trials during 2016, as well as to advance the company\'s preclinical pipeline.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Corvidia was co-founded by serial entrepreneur and Chief Executive Officer, Michael Davidson, M.D. Dr. Davidson, a recognized expert in the field of cardiology, previously served as Chief Medical Officer of Sofinnova-backed Omthera Pharmaceuticals, and was instrumental in the successful acquisition of that company by AstraZeneca in 2013 for $443 million. Joining Dr. Davidson at Corvidia are Co-founders Rahul Kakkar M.D. and Matt Devalaraja, Ph.D., both of whom previously worked in AstraZeneca\'s Emerging Innovations Unit, where they developed the science behind genome-guided cardiovascular therapies. Ram Aiyar Ph.D., MBA, an Entrepreneur-in-Residence at the National Institutes of Health and BioHealth Innovation, completes Corvidia\'s founding team.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Commenting on today\'s news, Dr. Davidson stated,&nbsp;<em>\\\"Our ability to complete this significant Series A financing with such high-quality investors is a testament to the promise of our technology and expertise of our management team, positioning Corvidia as a leader in the field of precision medicine as applied to cardiovascular diseases. With these funds, we aim to drive each of our assets through clinical trials and validate our precision medicine approach.\\\"<\\/em><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Graziano Seghezzi, Partner at Sofinnova Partners, and Corvidia\'s board member commented,&nbsp;<em>\\\"Given Omthera\'s success, we were strongly in favor of teaming up once again with Dr. Davidson. The seed funding that Sofinnova Partners provided allowed for Corvidia\'s inception, for the pipeline crafting and for the eventual structuring of the Series A. We are pleased to continue to support Corvidia and this latest financing represents a major step for the future advancement of novel, cardiovascular therapeutics.\\\"<\\/em><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Seth Harrison, M.D., Managing Partner of Apple Tree Partners, noted, \\\"<em>In&nbsp;<\\/em><em>our years of start-up investing we have not seen a better team than the group that Michael Davidson has assembled from AstraZeneca and the NIH. We are thrilled to be able to support Corvidia with our capital resources and company building experience, and look forward to working with Sofinnova Partners, AstraZeneca, and management to create the first great precision cardiovascular medicine company.<\\/em>\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>COR-001, a monoclonal antibody initially developed by MedImmune, AstraZeneca\'s global biologics research and development arm, was previously in a Phase 1 study for a different indication. It was repurposed by AstraZeneca\'s Emerging Innovations Unit, Scientific Partnering and Alliances (SP&A), prior to licensing to Corvidia.&nbsp;<em>\\\"This is another example of the strong entrepreneurial culture within AstraZeneca, where we push the boundaries of science to explore new therapeutic uses for our compounds. We will continue to divest or out-license assets where we believe it will help accelerate the development of new medicines.\\\"&nbsp;<\\/em>said Kumar Srinivasan, Vice President, SP&A, Innovative Medicines Unit, AstraZeneca.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In conjunction with the financing, Seth Harrison and Adrien Lemoine, Executive Director, Corporate Development for AstraZeneca, will join Graziano Seghezzi and Michael Davidson on Corvidia\'s Board of Directors.<\\/p>\",\"position\":\"left\"}},\"353\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Sofinnova Partners\"}},\"354\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs, and has backed nearly 500 companies over more than 40 years, creating market leaders around the globe. Today, Sofinnova Partners has over \\u20ac1.5 billion under management. For more information, please visit:<a href=\\\"http:\\/\\/www.sofinnova.fr\\/\\\" target=\\\"_blank\\\">www.sofinnova.fr<\\/a><\\/p>\",\"position\":\"left\"}},\"355\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Corvidia Therapeutics\"}},\"356\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Based in Boston, MA, Corvidia is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company\'s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia\'s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. For more information, please visit:<a href=\\\"http:\\/\\/www.corvidiatx.com\\/\\\" target=\\\"_blank\\\">www.corvidiatx.com<\\/a><\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"2\\/17\\/2016\"},\"36\":[\"383\"],\"146\":\"Corvidia Therapeutics Raises $26M in a Series A Financing, Led by Sofinnova Partners and Apple Tree Partners\"}}', '2016-07-15 16:24:52', '2016-07-15 16:24:52', '2f056bfe-847f-4abd-bda2-3fa851b86f10'),
 ('427', '342', '8', '1', 'en_us', '4', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain\",\"slug\":\"braeburn-and-camurus-announce-initiation-of-a-phase-2-study-in-opioid-dependent-patients-with-moderate-to-severe-chronic-pain\",\"postDate\":1468299540,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"343\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Braeburn Pharmaceuticals and Camurus announced today that the first patients have been dosed with CAM2038, weekly and monthly subcutaneous buprenorphine injections, in a pharmacokinetic study of opioid dependent patients with chronic pain.<\\/p>\\r\\n\\r\\n<p>The primary objective of this Phase 2 study is to assess the steady state pharmacokinetics of buprenorphine after repeated doses in opioid dependent patients with chronic pain, including effects of injection into different subcutaneous sites. This study will also explore the effect of CAM2038 on chronic pain, along with evaluation of safety and tolerability.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"This marks the fourth clinical study that has been started in the last five months for CAM2038, including two Phase 3 trials in opioid dependence. The ability to use CAM2038 in multiple injection sites would allow physicians the flexibility to personalize treatments,\\\" said Behshad Sheldon, President and CEO, Braeburn Pharmaceuticals. \\\"Our goal is to provide a suite of best-in-class long-acting treatment options tailored to the individual needs of patients suffering from opioid dependence and chronic pain.\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"Patients that suffer from chronic pain and are also opioid dependent are a difficult population to treat,\\\" said the principal investigator Dr. Greg Sullivan, medical director at Parkway Medical Center in Birmingham, Alabama. \\\"By using a long acting buprenorphine injectable, these patients would no longer be required to take medication multiple times per day. Buprenorphine also guards against hyperanalgesia and opiate tolerance, both of which are problems with conventional opiates.\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"CAM2038 has the potential to offer effective and safe around-the-clock pain relief, without risks of abuse and diversion. The pharmacological properties of buprenorphine together with long-acting release from the FluidCrystal formulation could also decrease risks of respiratory depression and overdose mortality associated with current opioid pain treatments,\\\" said Fredrik Tiberg, President and CEO, Camurus.<\\/p>\",\"position\":\"left\"}},\"344\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Braeburn Pharmaceuticals\"}},\"345\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Braeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience. In September 2015 the Food and Drug Administration (FDA) accepted for review Braeburn\'s New Drug Application for its lead candidate, Probuphine, a six-month buprenorphine implant for treatment of opioid dependence. The Agency has set May 27, 2016 as the target date for action.<\\/p>\\r\\n\\r\\n<p>Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. Braeburn\'s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Candidates include: Probuphine\\u00ae, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia. More information on Braeburn, can be found at&nbsp;<a href=\\\"https:\\/\\/braeburnpharmaceuticals.com\\/\\\" target=\\\"_blank\\\">https:\\/\\/braeburnpharmaceuticals.com\\/<\\/a>.<\\/p>\",\"position\":\"left\"}},\"346\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CAM2038\"}},\"347\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>The investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid addiction and pain are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance. The CAM2038 products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion, abuse, misuse, and accidental exposure. The CAM2038 products have been evaluated in three Phase 1\\/2 clinical trials, which evaluated the safety and tolerability as well as pharmacokinetic and pharmacodynamics properties of the products in a total of 176 individuals (opioid-dependent patients and healthy volunteers under naltrexone blockage). The CAM2038 products are also being developed for treatment of chronic pain, combining the effective analgesic properties of buprenorphine with the long acting release provided by the FluidCrystal\\u00ae injection depot.<\\/p>\",\"position\":\"left\"}},\"348\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Camurus\"}},\"349\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal\\u00ae drug delivery technologies and an extensive R&D expertise. Camurus\' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company\'s share is listed on Nasdaq Stockholm under the ticker \\\"CAMX\\\". For more information, visit&nbsp;<a href=\\\"http:\\/\\/www.camurus.com\\/\\\" target=\\\"_blank\\\">www.camurus.com<\\/a>.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"2\\/22\\/2016\"},\"36\":[\"384\"],\"146\":\"Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Chronic Pain\"}}', '2016-07-15 16:25:20', '2016-07-15 16:25:20', '2b8b3350-ca2e-406d-8f3f-62fd4ec6e83c'),
 ('428', '338', '8', '1', 'en_us', '4', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Syntimmune Secures Second Tranche of $26 Million Series A Financing\",\"slug\":\"syntimmune-secures-second-tranche-of-26-million-series-a-financing\",\"postDate\":1468299360,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"339\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Syntimmune, Inc., a development-stage company advancing novel treatments for IgG-mediated autoimmune diseases based on leading expertise in FcRn biology, today announced that it has made important progress by achieving preclinical proof of concept and completing preclinical safety testing, triggering a second, $10 million tranche of the Company\\u2019s committed $26 million Series A financing. The Series A financing is co-led by Apple Tree Partners and Baxalta Ventures, the corporate venture capital arm of Baxalta Incorporated, with participation by the Partners Innovation Fund and additional investors. Funds from this tranche of the Series A round will be used to complete the anticipated Phase 1a clinical trial in healthy volunteers of Syntimmune\\u2019s lead candidate, SYNT001. The Company intends to submit an IND application to the Food and Drug Administration for SYNT001 in mid-2016 to authorize initiation of the Phase 1a study later this year. SYNT001 is a biologic that blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases.<\\/p>\\r\\n\\r\\n<p>\\u201cThe closing of the second tranche in the Series A affirms the progress Syntimmune has achieved and reflects the importance of targeting FcRn as a breakthrough modality for treating IgG-mediated autoimmune diseases,\\u201d said Laurence Blumberg, M.D., Founder and COO of Syntimmune. \\u201cSince our founding just over two years ago, Syntimmune has made rapid progress in advancing its pipeline of candidates and progressing its lead program, SYNT001, through IND-enabling studies and toward the clinic. SYNT001 is showing a promising preclinical safety profile and robust activity in unique in vivo preclinical models, which we plan to present at appropriate peer-reviewed forums.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cThe opportunity for SYNT001 is substantial,\\u201d stated David de Graaf, Ph.D., Venture Partner at Apple Tree Partners. \\u201cWe are extremely happy with the progress the team has made on the lead molecule, which has the potential to address a large number of autoimmune indications.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cFcRn is a central mediator of IgG-related immunity and part of an important pathway that enables abnormal IgG responses in a large number of clinical settings, including autoimmune disease,\\u201d commented Richard Blumberg, M.D., Scientific Founder of Syntimmune and Division Chief of Gastroenterology, Hepatology and Endoscopy at Brigham and Women\\u2019s Hospital, as well as co-Director of the Harvard Digestive Diseases Center and Director of the Brigham Research Institute. \\u201cWhile FcRn is a highly validated target and has attracted substantial industry interest, there are no commercially available therapies designed to block IgG-FcRn interactions, which underlie diseases that affect multiple organ systems and for which there are continuing substantial medical needs, such as inflammatory bowel disease, lupus erythematosus, dermatomyositis and others. I am thrilled with the progress of Syntimmune and look forward to the advancement of the clinical program for SYNT001.\\u201d<\\/p>\",\"position\":\"left\"}},\"340\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Syntimmune\"}},\"341\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Founded in 2013, Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-mediated autoimmune diseases and represents a central common pathway that enables abnormal IgG responses. Syntimmune\\u2019s lead candidate, SYNT001, is a biologic progressing through IND-enabling studies that specifically blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases. Syntimmune has two additional, earlier-stage therapeutic programs, targeting other unique aspects of FcRn biology. The Syntimmune team has world-class experience in the field of FcRn biology and has successfully pioneered and advanced biologics targeting FcRn, including approved therapies currently on the market. Since its founding, the Company has received a total of $28 million in funding commitments from leading life sciences investors, including Apple Tree Partners, Baxalta Ventures, and Partners Innovation Fund. For more information on Syntimmune, please visit the Company\\u2019s website at<a href=\\\"http:\\/\\/cts.businesswire.com\\/ct\\/CT?id=smartlink&url=http%3A%2F%2Fwww.syntimmune.com&esheet=51304447&newsitemid=20160322005211&lan=en-US&anchor=www.syntimmune.com&index=1&md5=62fb1a7393f2201155ab419b9a8b964d\\\" target=\\\"_blank\\\">www.syntimmune.com<\\/a>.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"3\\/22\\/2016\"},\"36\":[\"385\"],\"146\":\"Syntimmune Secures Second Tranche of $26 Million Series A Financing\"}}', '2016-07-15 16:25:27', '2016-07-15 16:25:27', 'ac161848-e3eb-4968-a398-b4c3056c9524'),
 ('429', '338', '8', '1', 'en_us', '5', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Syntimmune Secures Second Tranche of $26 Million Series A Financing\",\"slug\":\"syntimmune-secures-second-tranche-of-26-million-series-a-financing\",\"postDate\":1468299360,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"339\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Syntimmune, Inc., a development-stage company advancing novel treatments for IgG-mediated autoimmune diseases based on leading expertise in FcRn biology, today announced that it has made important progress by achieving preclinical proof of concept and completing preclinical safety testing, triggering a second, $10 million tranche of the Company\\u2019s committed $26 million Series A financing. The Series A financing is co-led by Apple Tree Partners and Baxalta Ventures, the corporate venture capital arm of Baxalta Incorporated, with participation by the Partners Innovation Fund and additional investors. Funds from this tranche of the Series A round will be used to complete the anticipated Phase 1a clinical trial in healthy volunteers of Syntimmune\\u2019s lead candidate, SYNT001. The Company intends to submit an IND application to the Food and Drug Administration for SYNT001 in mid-2016 to authorize initiation of the Phase 1a study later this year. SYNT001 is a biologic that blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases.<\\/p>\\r\\n\\r\\n<p>\\u201cThe closing of the second tranche in the Series A affirms the progress Syntimmune has achieved and reflects the importance of targeting FcRn as a breakthrough modality for treating IgG-mediated autoimmune diseases,\\u201d said Laurence Blumberg, M.D., Founder and COO of Syntimmune. \\u201cSince our founding just over two years ago, Syntimmune has made rapid progress in advancing its pipeline of candidates and progressing its lead program, SYNT001, through IND-enabling studies and toward the clinic. SYNT001 is showing a promising preclinical safety profile and robust activity in unique in vivo preclinical models, which we plan to present at appropriate peer-reviewed forums.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cThe opportunity for SYNT001 is substantial,\\u201d stated David de Graaf, Ph.D., Venture Partner at Apple Tree Partners. \\u201cWe are extremely happy with the progress the team has made on the lead molecule, which has the potential to address a large number of autoimmune indications.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cFcRn is a central mediator of IgG-related immunity and part of an important pathway that enables abnormal IgG responses in a large number of clinical settings, including autoimmune disease,\\u201d commented Richard Blumberg, M.D., Scientific Founder of Syntimmune and Division Chief of Gastroenterology, Hepatology and Endoscopy at Brigham and Women\\u2019s Hospital, as well as co-Director of the Harvard Digestive Diseases Center and Director of the Brigham Research Institute. \\u201cWhile FcRn is a highly validated target and has attracted substantial industry interest, there are no commercially available therapies designed to block IgG-FcRn interactions, which underlie diseases that affect multiple organ systems and for which there are continuing substantial medical needs, such as inflammatory bowel disease, lupus erythematosus, dermatomyositis and others. I am thrilled with the progress of Syntimmune and look forward to the advancement of the clinical program for SYNT001.\\u201d<\\/p>\",\"position\":\"left\"}},\"340\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Syntimmune\"}},\"341\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Founded in 2013, Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-mediated autoimmune diseases and represents a central common pathway that enables abnormal IgG responses. Syntimmune\\u2019s lead candidate, SYNT001, is a biologic progressing through IND-enabling studies that specifically blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases. Syntimmune has two additional, earlier-stage therapeutic programs, targeting other unique aspects of FcRn biology. The Syntimmune team has world-class experience in the field of FcRn biology and has successfully pioneered and advanced biologics targeting FcRn, including approved therapies currently on the market. Since its founding, the Company has received a total of $28 million in funding commitments from leading life sciences investors, including Apple Tree Partners, Baxalta Ventures, and Partners Innovation Fund. For more information on Syntimmune, please visit the Company\\u2019s website at<a href=\\\"http:\\/\\/cts.businesswire.com\\/ct\\/CT?id=smartlink&url=http%3A%2F%2Fwww.syntimmune.com&esheet=51304447&newsitemid=20160322005211&lan=en-US&anchor=www.syntimmune.com&index=1&md5=62fb1a7393f2201155ab419b9a8b964d\\\" target=\\\"_blank\\\">www.syntimmune.com<\\/a>.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"3\\/22\\/2016\"},\"36\":[\"385\"],\"146\":\"Syntimmune Secures Second Tranche of $26 Million Series A Financing\"}}', '2016-07-15 16:25:30', '2016-07-15 16:25:30', '1320b318-20f0-4ed4-80a1-e854074d589b'),
 ('430', '329', '8', '1', 'en_us', '3', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Dermatology Services Company QualDerm Unveils $31.8M Growth Investment\",\"slug\":\"dermatology-services-company-qualderm-unveils-31-8m-growth-investment\",\"postDate\":1468299300,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"330\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>QualDerm Partners LLC (\\u201cQDP\\u201d), a dermatology services company, announced today it has raised $31.8 million in growth equity funding from Apple Tree Partners (\\u201cATP\\u201d) and Cressey & Company (\\u201cCressey\\u201d). The financing will enable QualDerm to strengthen its comprehensive physician support services and accelerate expansion through partnerships with leading dermatology practices.<\\/p>\\r\\n\\r\\n<p>Headquartered in Brentwood, TN, QualDerm provides physician support services through partnerships with best-in-class dermatology practices in the southeastern U.S. The company provides leadership, growth resources, and management services to skin surgeons, pediatric, and general dermatologists and mid-level providers to alleviate the burden of the day-to-day administrative demands of running a business.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><em>\\u201cOur investment in QDP aligns with ATP\\u2019s commitment to partner with exceptional management teams and build leading healthcare companies,\\\" said Diane Daych, Partner of Apple Tree Partners, who joined QualDerm\\u2019s Board of Directors. \\\"With extensive experience building and operating multi-site provider businesses and deep knowledge in effective practice management strategy, ATP looks forward to supporting QDP\\u2019s growth.\\u201d<\\/em><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p><em>\\u201cCressey & Company is excited to have additional resources from ATP to support the continued professional success and clinical excellence of our existing partnership with QDP,\\u201d said David Schuppan, Cressey Partner and QDP Board member.<\\/em><\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Under the leadership of Bill Southwick, CEO, QualDerm partners with physicians to create high functioning teams through shared culture, shared services, and shared decision making. QualDerm is dedicated to expanding patient access to high quality care in secondary markets as well as other underserved areas, where the nationwide dearth of dermatologists is particularly problematic.<em>&nbsp;\\u201cWe are pleased to partner with our investors, who bring significant experience building healthcare companies and adding operational value. This investment will facilitate QDP\\u2019s mission to provide management, growth, and strategic services that enable high quality dermatology care while preserving physician autonomy in true partnership fashion,\\u201d&nbsp;<\\/em>said Southwick.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The company\\u2019s practice affiliates include The Skin Surgery Center, a full-service, multi-site specialty group based in North Carolina, led by distinguished physicians, Drs. Barry Leshin and John Albertini.&nbsp;<em>\\u201cAs the platform practice for QDP, we have been truly gratified by the sophistication and expertise of our management team and anticipate that ATP\\u2019s investment in both capital and strategic vision will synergize with Cressey in a way that adds tremendous value as we expand our mission to provide high quality dermatologic care to the region and beyond.\\u201d<\\/em><\\/p>\",\"position\":\"left\"}},\"331\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Apple Tree Partners\"}},\"332\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Apple Tree Partners (ATP) is a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, ATP closed its current capital pool of $1.5 billion in 2012 and is actively funding healthcare innovation. ATP starts companies, or invests in existing companies, with commitments as high as $250 million. The firm is headquartered in New York City, with satellite offices in Princeton, NJ, Cambridge, MA, and Los Altos, CA.<\\/p>\\r\\n\\r\\n<p>For more information, please visit:&nbsp;<a href=\\\"http:\\/\\/www.appletreepartners.com\\/\\\">www.appletreepartners.com<\\/a><\\/p>\",\"position\":\"left\"}},\"333\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Cressey & Company\"}},\"334\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Based in Chicago, IL and Nashville, TN, Cressey & Company is a private investment firm focused on building leading healthcare provider, service and information technology businesses. With a history spanning nearly 35 years, the Cressey & Company team is one of the most experienced and successful in the healthcare private equity field.<\\/p>\\r\\n\\r\\n<p>More information about Cressey & Company is available at&nbsp;<a href=\\\"http:\\/\\/www.cresseyco.com\\/\\\" target=\\\"_blank\\\">www.cresseyco.com<\\/a>.<\\/p>\",\"position\":\"left\"}},\"335\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About QualDerm\"}},\"336\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Based in Brentwood, TN, QualDerm Partners provides strategic leadership and practice management services for dermatologists and skin care professionals. The company strives to be the partner of choice for premier, patient-centric dermatology practices throughout the southeast.<\\/p>\\r\\n\\r\\n<p>For more information, please visit&nbsp;<a href=\\\"http:\\/\\/www.qualderm.com\\/\\\" target=\\\"_blank\\\">www.qualderm.com<\\/a><\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"4\\/20\\/2016\"},\"36\":\"\",\"146\":\"Dermatology Services Company QualDerm Unveils $31.8M Growth Investment\"}}', '2016-07-15 16:25:37', '2016-07-15 16:25:37', 'a212f194-aba6-4f12-83f6-e68f67e2390c'),
 ('431', '327', '8', '1', 'en_us', '3', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"FDA approves first buprenorphine implant for treatment of opioid dependence\",\"slug\":\"fda-approves-first-buprenorphine-implant-for-treatment-of-opioid-dependence\",\"postDate\":1468299120,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"328\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.<\\/p>\\r\\n\\r\\n<p>Until today, buprenorphine for the treatment of opioid dependence was only approved as a pill or a film placed under the tongue or on the inside of a person\\u2019s cheek until it dissolved. While effective, a pill or film may be lost, forgotten or stolen. However, as an implant, Probuphine provides a new treatment option for people in recovery who may value the unique benefits of a six-month implant compared to other forms of buprenorphine, such as the possibility of improved patient convenience from not needing to take medication on a daily basis. An independent FDA advisory committee supported the approval of Probuphine in a meeting held earlier this year.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"Opioid abuse and addiction have taken a devastating toll on American families. We must do everything we can to make new, innovative treatment options available that can help patients regain control over their lives,\\u201d said FDA Commissioner Robert M. Califf, M.D. \\u201cToday\\u2019s approval provides the first-ever implantable option to support patients\\u2019 efforts to maintain treatment as part of their overall recovery program.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Expanding the use and availability of medication-assisted treatment (MAT) options like buprenorphine is an important component of&nbsp;<a href=\\\"http:\\/\\/www.fda.gov\\/NewsEvents\\/Newsroom\\/FactSheets\\/ucm484714.htm\\\">the FDA\\u2019s opioid action plan<\\/a>&nbsp;and one of&nbsp;<a href=\\\"http:\\/\\/www.hhs.gov\\/about\\/news\\/2015\\/03\\/26\\/hhs-takes-strong-steps-to-address-opioid-drug-related-overdose-death-and-dependence.html\\\">three top priorities<\\/a>&nbsp;for the U.S. Department of Health and Human Services\\u2019 Opioid Initiative aimed at reducing prescription opioid and heroin related overdose, death and dependence.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Opioid dependence is the diagnostic term used for the more common concept, \\u201caddiction,\\u201d in the Probuphine clinical trials. Addiction is defined as a cluster of behavioral, cognitive and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use, persisting in drug use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, as well as the possibility of the development of tolerance or development of physical dependence. Physical dependence is not the same as addiction. Newer diagnostic terminology uses the term \\u201copioid use disorder,\\u201d which includes both milder forms of problematic opioid use as well as addiction.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>MAT is a comprehensive approach that combines approved medications (currently, methadone, buprenorphine or naltrexone) with counseling and other behavioral therapies to treat patients with opioid use disorder. Regular adherence to MAT with buprenorphine reduces opioid withdrawal symptoms and the desire to use, without causing the cycle of highs and lows associated with opioid misuse or abuse. At sufficient doses, it also decreases the pleasurable effects of other opioids, making continued opioid abuse less attractive. According to the Substance Abuse and Mental Health Services Administration, patients receiving MAT for their opioid use disorder cut their risk of death from all causes in half.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cScientific evidence suggests that maintenance treatment with these medications in the context of behavioral treatment and recovery support are more effective in the treatment of opioid use disorder than short-term detoxification programs aimed at abstinence,\\u201d said Nora Volkow, M.D., director of the National Institute on Drug Abuse at the National Institutes of Health. \\u201cThis product will expand the treatment alternatives available to people suffering from an opioid use disorder.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Probuphine should be used as part of a complete treatment program that includes counseling and psychosocial support. Probuphine consists of four, one-inch-long rods that are implanted under the skin on the inside of the upper arm and provide treatment for six months. Administering Probuphine requires specific training because it must be surgically inserted and removed. Only a health care provider who has completed the training and become certified through a restricted program called the Probuphine Risk Evaluation and Mitigation Strategy (REMS) program should insert and remove the implants. If further treatment is needed, new implants may be inserted in the opposite arm for one additional course of treatment. The FDA is requiring postmarketing studies to establish the safety and feasibility of placing the Probuphine implants for additional courses of treatment.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The safety and efficacy of Probuphine were demonstrated in a randomized clinical trial of adults who met the clinical criteria for opioid dependence and were considered stable after prior buprenorphine treatment. A response to MAT was measured by urine screening and self-reporting of illicit opioid use during the six month treatment period. Sixty-three percent of Probuphine-treated patients had no evidence of illicit opioid use throughout the six months of treatment \\u2013 similar to the 64 percent of those who responded to sublingual (under the tongue) buprenorphine alone.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The most common side effects from treatment with Probuphine include implant-site pain, itching, and redness, as well as headache, depression, constipation, nausea, vomiting, back pain, toothache and oropharyngeal pain. The safety and efficacy of Probuphine have not been established in children or adolescents less than 16 years of age. Clinical studies of Probuphine did not include participants over the age of 65.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Probuphine has a boxed warning that provides important safety information for health care professionals, including a warning that insertion and removal of Probuphine are associated with the risk of implant migration, protrusion, expulsion and nerve damage resulting from the procedure. Probuphine must be prescribed and dispensed according to the Probuphine REMS program because of the risks of surgical complications and because of the risks of accidental overdose, misuse and abuse if an implant comes out or protrudes from the skin. As part of this program, Probuphine can only be prescribed and dispensed by health care providers who are certified with the REMS program and have completed live training, among other requirements.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Probuphine implants contain a significant amount of drug that can potentially be expelled or removed, resulting in the potential for accidental exposure or intentional misuse and abuse if the implant comes out of the skin. Patients should be seen during the first week after insertion and a visit schedule of no less than once-monthly is recommended for continued counseling and psychosocial support.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Probuphine is marketed by San Francisco-based Titan Pharmaceuticals Inc. and Braeburn Pharmaceuticals based in Princeton, New Jersey.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation\\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"5\\/26\\/2016\"},\"36\":\"\",\"146\":\"FDA approves first buprenorphine implant for treatment of opioid dependence\"}}', '2016-07-15 16:25:44', '2016-07-15 16:25:44', '91b3d004-a8f7-4dfa-901e-0837f1b38dfb'),
 ('432', '319', '8', '1', 'en_us', '3', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Medtronic to Expand Heart Failure Portfolio with Acquisition of HeartWare International\",\"slug\":\"medtronic-to-expand-heart-failure-portfolio-with-acquisition-of-heartware-international\",\"postDate\":1468299000,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"320\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Medtronic plc (NYSE: MDT), the global leader in medical technology, and HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies for the treatment of advanced heart failure, today announced that the companies have entered into a definitive merger agreement under which Medtronic will acquire HeartWare in a transaction valued at approximately $1.1 billion. Under the terms of the agreement, Medtronic will commence a tender offer for all outstanding shares of HeartWare common stock for $58.00 per share, in cash. The boards of directors of both Medtronic and HeartWare have unanimously approved the transaction. The acquisition is expected to close during Medtronic\'s second fiscal quarter ending Oct. 28, 2016, subject to the satisfaction of customary closing conditions.<\\/p>\\r\\n\\r\\n<p>Medtronic\'s acquisition of HeartWare will expand Medtronic\'s portfolio of diagnostic tools, therapies and services for patients suffering from heart failure, aligning with Medtronic\'s Mission of alleviating pain, restoring health and extending life, and is in line with the Company\'s strategy to surround the physician with innovative products while focusing on patients and disease states.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>HeartWare\'s flagship product, the HVAD \\u00ae System, features the world\'s smallest full-support ventricular assist device (VAD) and is designed to reduce surgical invasiveness, improve patient recovery times and enhance patient outcomes. In addition, HeartWare has multiple technologies in development designed to offer progressively less-invasive mechanical circulatory support options for patients with end-stage heart failure. Medtronic estimates that the global VAD market is approximately $800 million currently and worldwide is expected to grow in the mid-to-high single digits for CY16-17, and accelerate to high-single\\/low-double digits beyond CY17.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"The addition of HeartWare\'s innovative portfolio adds to our expanding portfolio of diagnostics, therapeutics and services that address heart failure patients,\\\" said Mike Coyle, executive vice president and president of the Cardiac and Vascular Group at Medtronic. \\\"The team at HeartWare has established excellent relationships with its hospital customers and built a strong position and reputation in the marketplace. This transaction, once closed, will be a further, important step toward Medtronic offering a complete suite of solutions to address patient needs across the heart failure care continuum.\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"Medtronic is the worldwide leader in cardiovascular device technologies. Its expansive expertise in the development of implantable systems and battery technologies, patient monitoring, manufacturing, global regulatory policy and commercialization should help accelerate the development and introduction of our innovative pipeline products, and will expand access to our therapies and offerings to the sizeable heart failure population,\\\" said Doug Godshall, president and chief executive officer, HeartWare. \\\"Combining the unique capabilities of the HeartWare team, which has been entirely focused on mechanical support technologies, with the broad strength of the Medtronic organization provides a unique opportunity to enhance growth in the mechanical circulatory support market. All of our stakeholders, including customers, employees, shareholders, and most importantly, patients, will benefit meaningfully from this complementary combination.\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Heart failure, also known as congestive heart failure, is a condition or a collection of symptoms in which the heart isn\'t pumping enough blood to meet the body\'s needs. Heart failure usually develops slowly after an injury to the heart. Some injuries may include a heart attack, too much strain on the heart due to years of untreated high blood pressure, or a diseased heart valve, among others. Heart failure remains a leading cause of hospitalization and death in the United States, and its prevalence continues to increase, affecting more than five million people in the U.S. alone. The cost of heart failure is high. Healthcare expenditures in the U.S. on heart failure are estimated to be approximately $39 billion per year, making it one of the largest expenses to the healthcare system. With the aging of the population, Medtronic estimates that the number of patients with heart failure could exceed eight million by 2030.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"HeartWare\'s HVAD System enhances the portfolio of our Cardiac & Vascular Group, a team with a proven track record of executing and a demonstrated ability to scale early stage concepts into large, sustainable end markets,\\\" said Omar Ishrak, chairman and chief executive officer of Medtronic. \\\"In addition, from a financial perspective, we are pleased to reach an agreement that meets our acquisition criteria of adding minimal to no net EPS dilution in the near-term, while at the same time creating strong, long-term expected returns for our shareholders.\\\"<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>This acquisition supports Medtronic\'s therapy innovation strategic priority. In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>This transaction is expected to meet Medtronic\'s long-term financial metrics for acquisitions. Medtronic does not intend to modify its fiscal year 2017 revenue outlook or earnings per share (EPS) guidance as a result of this transaction, although it is expected to provide increased confidence in the company\'s ability to deliver on its FY17 revenue growth outlook. In addition, Medtronic expects minimal to no net EPS dilution from this transaction for the first two years as the company intends to offset the expected dilutive impact. The acquisition is expected to be earnings accretive in year three. Medtronic intends to report results from the acquired HeartWare business as part of its Cardiac Rhythm & Heart Failure division within the Cardiac & Vascular Group.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>Medtronic\'s financial advisor for the transaction is J.P. Morgan Securities LLC, with Ropes & Gray LLP acting as legal advisor. HeartWare\'s financial advisor is Perella Weinberg Partners LP, with Shearman & Sterling LLP acting as legal advisor<br><\\/p>\",\"position\":\"left\"}},\"321\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About HeartWare International\"}},\"322\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>HeartWare International Inc. (<a href=\\\"http:\\/\\/www.heartware.com\\/\\\" target=\\\"_blank\\\">www.HeartWare.com<\\/a>) develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients around the world suffering from advanced heart failure. Dedicated to developing new, minimally invasive technologies to revolutionize the treatment of patients with end-stage heart failure, HeartWare has multiple technologies in development to offer progressively less-invasive mechanical circulatory support options. HeartWare\'s corporate headquarters are located in Framingham, Massachusetts, and the company has technology, operations, manufacturing and distribution centers in Miami Lakes, Florida; Arden Hills, Minnesota; and Hannover, Germany.<\\/p>\",\"position\":\"left\"}},\"323\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Medtronic\"}},\"324\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Medtronic plc (<a href=\\\"http:\\/\\/www.medtronic.com\\/\\\" target=\\\"_blank\\\">www.medtronic.com<\\/a>), headquartered in Dublin, Ireland, is among the world\'s largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"6\\/27\\/2016\"},\"36\":\"\",\"146\":\"Medtronic to Expand Heart Failure Portfolio with Acquisition of HeartWare International\"}}', '2016-07-15 16:25:52', '2016-07-15 16:25:52', 'fb36d914-4b00-4b9b-8e25-030a1d1653c2'),
 ('433', '314', '8', '1', 'en_us', '4', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Cure Forward Announces First Trial Recruitment Collaboration That Will Expand Patient Access to Innovative Treatments\",\"slug\":\"cure-forward-announces-first-trial-recruitment-collaboration-that-will-expand-patient-access-to-innovative-treatments\",\"postDate\":1468298820,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"315\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Cure Forward, an online precision medicine platform for cancer patients and their care teams, and Novartis Pharmaceuticals Corporation today announced that Cure Forward\\u2019s unique Clinical Trial Exchange will support Novartis in identifying potential patients for all of its current oncology trials.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>The collaboration further validates Cure Forward\\u2019s approach for real-time patient sourcing in clinical trials. By utilizing its patent pending Clinical Trial Exchange, Cure Forward facilitates connections between patients and drug development companies, based on mutual criteria and preferences, comparable to popular online dating platforms.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>There is a significant efficiency gap in the clinical trial process today, placing undue burden on patients and caregivers to navigate the vast, complex landscape of medical research options \\u2013 often at stages in which their time is most valuable. Drug developers are concurrently developing investigational treatments, but often struggle to find the right patients to receive these investigational treatments.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Cure Forward\\u2019s platform empowers patients to govern their own care plans, providing accurate, easily accessible information to help drive individual choices.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cToday\\u2019s patient is active in his or her care, accessing data to make important treatment decisions,\\u201d said Martin Naley, Founder and Chief Strategy Officer, Cure Forward. \\u201cCure Forward makes clinical trial enrollment easier and more accessible. Novartis\\u2019 bold approach of activating searches for oncology trials on our platform will help patients find possible investigational treatments for their care.\\u201d<\\/p>\",\"position\":\"left\"}},\"316\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Cure Forward\"}},\"317\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Cure Forward bridges the gap between patients and precision medicine, beginning in cancer. Cure Forward provides a simple-to-use platform that allows patients to obtain their genomic data and use it to identify treatment options including clinical trials, solving critical business needs for diagnostic laboratories, health care providers and clinical trial recruiters. Cure Forward is based in Cambridge, Massachusetts and was incubated and launched by Apple Tree Partners, New York City. The company\\u2019s platform is in beta release at&nbsp;<a href=\\\"http:\\/\\/cts.businesswire.com\\/ct\\/CT?id=smartlink&url=http%3A%2F%2Fwww.cureforward.com%2F&esheet=51370740&newsitemid=20160628005534&lan=en-US&anchor=www.cureforward.com&index=2&md5=24eaf06114eb049ec8095911016dcfef\\\" target=\\\"_blank\\\">www.cureforward.com<\\/a>.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"6\\/28\\/2016\"},\"36\":\"\",\"146\":\"Cure Forward Announces First Trial Recruitment Collaboration That expands Patient Access to Innovative Treatments\"}}', '2016-07-15 16:26:41', '2016-07-15 16:26:41', '9e4927b0-c2bb-4267-b787-96ff0ad509c6'),
 ('434', '314', '8', '1', 'en_us', '5', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Cure Forward Announces First Trial Recruitment Collaboration That Will Expand Patient Access to Innovative Treatments\",\"slug\":\"cure-forward-announces-first-trial-recruitment-collaboration-that-will-expand-patient-access-to-innovative-treatments\",\"postDate\":1468298820,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"315\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Cure Forward, an online precision medicine platform for cancer patients and their care teams, and Novartis Pharmaceuticals Corporation today announced that Cure Forward\\u2019s unique Clinical Trial Exchange will support Novartis in identifying potential patients for all of its current oncology trials.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>The collaboration further validates Cure Forward\\u2019s approach for real-time patient sourcing in clinical trials. By utilizing its patent pending Clinical Trial Exchange, Cure Forward facilitates connections between patients and drug development companies, based on mutual criteria and preferences, comparable to popular online dating platforms.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>There is a significant efficiency gap in the clinical trial process today, placing undue burden on patients and caregivers to navigate the vast, complex landscape of medical research options \\u2013 often at stages in which their time is most valuable. Drug developers are concurrently developing investigational treatments, but often struggle to find the right patients to receive these investigational treatments.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Cure Forward\\u2019s platform empowers patients to govern their own care plans, providing accurate, easily accessible information to help drive individual choices.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cToday\\u2019s patient is active in his or her care, accessing data to make important treatment decisions,\\u201d said Martin Naley, Founder and Chief Strategy Officer, Cure Forward. \\u201cCure Forward makes clinical trial enrollment easier and more accessible. Novartis\\u2019 bold approach of activating searches for oncology trials on our platform will help patients find possible investigational treatments for their care.\\u201d<\\/p>\",\"position\":\"left\"}},\"316\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About Cure Forward\"}},\"317\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>Cure Forward bridges the gap between patients and precision medicine, beginning in cancer. Cure Forward provides a simple-to-use platform that allows patients to obtain their genomic data and use it to identify treatment options including clinical trials, solving critical business needs for diagnostic laboratories, health care providers and clinical trial recruiters. Cure Forward is based in Cambridge, Massachusetts and was incubated and launched by Apple Tree Partners, New York City. The company\\u2019s platform is in beta release at&nbsp;<a href=\\\"http:\\/\\/cts.businesswire.com\\/ct\\/CT?id=smartlink&url=http%3A%2F%2Fwww.cureforward.com%2F&esheet=51370740&newsitemid=20160628005534&lan=en-US&anchor=www.cureforward.com&index=2&md5=24eaf06114eb049ec8095911016dcfef\\\" target=\\\"_blank\\\">www.cureforward.com<\\/a>.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"6\\/28\\/2016\"},\"36\":\"\",\"146\":\"Cure Forward Announces First Trial Recruitment Collaboration That expands Patient Access to Innovative Treatments\"}}', '2016-07-15 16:26:47', '2016-07-15 16:26:47', '7d50b54a-bf1d-46e1-9969-f1154fcf7150'),
 ('435', '312', '8', '1', 'en_us', '4', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"High-Tech Healthcare Helps Eliminate Unnecessary Hospital Visits\",\"slug\":\"high-tech-healthcare-helps-eliminate-unnecessary-hospital-visits\",\"postDate\":1468298700,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"313\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>A high-tech version of healthcare is becoming more and more popular. It\'s called TeleMedicine. And in many cases, it helps keep people out of the hospital. Right now, there\'s a big push to cut the rate of people who are re-admitted to the hospital. It not only saves money, but it also lowers the risk for infection and other complication. Plus, it helps keep patients more comfortable.<\\/p>\\r\\n\\r\\n<p>Sue and Charlie Lake just celebrated their 60th wedding anniversary. They both live at Meadowood Senior Living. Because 91-year-old Mr. Lake has health problems, he stays at the skilled nursing facility. They demonstrated their new TripleCare Telemedicine system for us. On nights, weekends or holidays when there isn\'t a doctor in person at the center, there\'s one available through cyberspace. With nurses help, a doctor can do a thorough examination. The camera can zoom in to look for swelling, lesions or discoloration. The stethoscope is also connected. What nurses hear, the doctor hears at the same time.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"It\'s like Skype except that you have all the dimensions, you have all the senses that the physician can hone in on,\\\" said Sally-Ann Heckert Bikin, attorney and Director of Nursing at Meadowood. Mrs. Lake tells Action News she was skeptical about the new technology at first.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"I say I don\'t think it\'s going to work. You are going to lose the face to face,\\\" she said. But when her husband got sick on a Sunday night, with the help of TripleCare they were able to diagnose and treat him in his room as opposed to being transported by ambulance to the hospital.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"I went from saying it\'s not going to work to telling everyone this is such a great thing,\\\" said Sue.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>\\\"So far, we\'ve had 16 calls and out of 16, 13 we were able to treat here in the patient\'s room,\\\" said Lynn Plepis, Clinical Informatics at Meadowood. Mr Lake was one of those 13.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n<p>TripleCare is also set up to keep up the information private and secure.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>Many other centers are using similar technology.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>View the&nbsp;<a href=\\\"http:\\/\\/6abc.com\\/health\\/high-tech-healthcare-helps-eliminate-unnecessary-hospital-visits\\/1416091\\/\\\" target=\\\"_blank\\\">original news clip<\\/a> including the video.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"93\"],\"20\":{\"date\":\"7\\/6\\/2016\"},\"36\":\"\",\"146\":\"High-Tech Healthcare Helps Eliminate Unnecessary Hospital Visits\"}}', '2016-07-15 16:26:54', '2016-07-15 16:26:54', '9716a550-5b3c-45dd-8659-cc599fc2e830'),
 ('436', '52', '8', '1', 'en_us', '9', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"Mass.-based addiction treatment center expands nationally as opioid epidemic rages on\",\"slug\":\"mass-based-addiction-treatment-center-expands-nationally-as-opioid-epidemic-rages-on\",\"postDate\":1466109060,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"59\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"Two more opiate and alcohol treatment centers will be popping up in Massachusetts, as Northampton-based CleanSlate Centers looks to expand in the Bay State and nationally.\"}},\"60\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\",\"position\":\"left\"}}},\"131\":[\"90\"],\"20\":{\"date\":\"6\\/15\\/2016\"},\"36\":\"\",\"146\":\"Mass.-based addiction treatment center expands nationally as opioid epidemic rages on\"}}', '2016-07-15 16:27:02', '2016-07-15 16:27:02', '28d7667a-cbed-45bd-99f0-7293478c3e97'),
 ('437', '14', '8', '1', 'en_us', '16', '', '{\"typeId\":\"8\",\"authorId\":\"1\",\"title\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\",\"slug\":\"cleanslate\",\"postDate\":1465918560,\"expiryDate\":null,\"enabled\":1,\"parentId\":null,\"fields\":{\"22\":{\"15\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}},\"16\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate\\u2019s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.<\\/p>\\r\\n\\r\\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cI am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,\\u201d Mr. Marotta said. \\u201cI am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.\\u201d<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate\\u2019s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate\\u2019s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>\\u201cCleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,\\u201d Dr. Wilson said. \\u201cThese changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.\\u201d<\\/p>\",\"position\":\"left\"}},\"17\":{\"type\":\"newSection\",\"enabled\":\"1\",\"fields\":{\"sectionHeading\":\"About CleanSlate Centers\"}},\"18\":{\"type\":\"text\",\"enabled\":\"1\",\"fields\":{\"text\":\"<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.<\\/p>\\r\\n\\r\\n<p>CleanSlate\\u2019s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate\\u2019s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).<\\/p>\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n\\r\\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.<\\/p>\",\"position\":\"left\"}}},\"131\":\"\",\"20\":{\"date\":\"6\\/13\\/2016\"},\"36\":[\"386\"],\"146\":\"CleanSlate Centers names Gregory C. Marotta President & CEO\"}}', '2016-07-15 16:27:09', '2016-07-15 16:27:09', '2e426874-00dd-4fc6-b707-1affce86b03d');



DROP TABLE IF EXISTS `craft_fieldgroups`;


--
-- Schema for table `craft_fieldgroups`
--
CREATE TABLE `craft_fieldgroups` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_fieldgroups_name_unq_idx` (`name`)
) ENGINE=InnoDB AUTO_INCREMENT=17 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_fieldgroups`
--

INSERT INTO `craft_fieldgroups` (`id`, `name`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('2', 'Home', '2016-06-10 18:53:51', '2016-06-10 18:53:51', '4bd50a44-dc59-41ca-9b0e-fc635561c7a7'),
 ('5', 'Footer', '2016-06-13 15:34:13', '2016-06-15 20:22:44', 'bd08e773-6e51-4bb8-a051-c7ea4c0308f4'),
 ('6', 'Contact', '2016-06-13 15:34:22', '2016-06-13 15:34:22', '7a6c8c84-7ade-4709-a5b9-d38ff42b00b9'),
 ('7', 'Team', '2016-06-13 15:34:28', '2016-06-13 15:34:28', '3f650b07-cb7a-4526-921a-0e15dfc05b57'),
 ('8', 'Portfolio', '2016-06-13 15:34:33', '2016-06-13 15:34:33', '8234112d-22a4-44d5-a6b0-5ee8e852ff10'),
 ('9', 'News', '2016-06-13 15:34:36', '2016-06-13 15:34:36', 'dc92e5e9-9ee3-4ed5-9506-2388fdccc6dc'),
 ('10', 'Team Member', '2016-06-14 15:57:48', '2016-06-14 15:57:48', '9e253181-299b-4c64-ab25-3b80a0a6beb0'),
 ('11', 'Company', '2016-06-14 16:08:45', '2016-06-14 16:08:45', 'f72c9426-c538-4683-95c5-2a7aee97c0f6'),
 ('12', 'Legal', '2016-06-27 16:02:16', '2016-06-27 16:02:16', 'f614763f-1bc1-4531-a6ec-2f49b039a27a'),
 ('13', 'Press', '2016-07-06 21:32:55', '2016-07-06 21:32:55', 'e8840ba8-921b-4412-8edc-61cb18de6522'),
 ('14', 'Global Header', '2016-07-11 16:26:17', '2016-07-11 16:26:17', 'a9ebee23-8d41-49f4-9d87-53f76cc2f940'),
 ('15', 'Homepage Logo', '2016-07-13 17:09:30', '2016-07-13 17:09:30', 'ca061214-f860-45fb-aab6-86b226ddfb34'),
 ('16', 'Header Background', '2016-07-15 17:07:16', '2016-07-15 17:07:16', 'f4a79d94-46ff-4077-95c4-7d97e50afef5');



DROP TABLE IF EXISTS `craft_fieldlayoutfields`;


--
-- Schema for table `craft_fieldlayoutfields`
--
CREATE TABLE `craft_fieldlayoutfields` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `layoutId` int(11) NOT NULL,
  `tabId` int(11) NOT NULL,
  `fieldId` int(11) NOT NULL,
  `required` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `sortOrder` smallint(6) unsigned DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_fieldlayoutfields_layoutId_fieldId_unq_idx` (`layoutId`,`fieldId`),
  KEY `craft_fieldlayoutfields_sortOrder_idx` (`sortOrder`),
  KEY `craft_fieldlayoutfields_tabId_fk` (`tabId`),
  KEY `craft_fieldlayoutfields_fieldId_fk` (`fieldId`)
) ENGINE=InnoDB AUTO_INCREMENT=591 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_fieldlayoutfields`
--

INSERT INTO `craft_fieldlayoutfields` (`id`, `layoutId`, `tabId`, `fieldId`, `required`, `sortOrder`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('87', '49', '31', '50', '0', '1', '2016-06-14 15:47:44', '2016-06-14 15:47:44', 'bb4f1f11-6a97-4dc3-9b77-25be8975a727'),
 ('130', '62', '47', '37', '0', '1', '2016-06-14 16:05:47', '2016-06-14 16:05:47', 'ec111f9c-cd4a-44bc-8c9e-d010bc383b6d'),
 ('131', '62', '47', '38', '0', '2', '2016-06-14 16:05:47', '2016-06-14 16:05:47', 'f2c63548-f4fb-4e6b-bdfb-1a4d8167bf59'),
 ('132', '62', '47', '39', '0', '3', '2016-06-14 16:05:47', '2016-06-14 16:05:47', '642e496a-9f21-4eee-aea5-53ca6f7b314b'),
 ('133', '62', '48', '47', '0', '1', '2016-06-14 16:05:47', '2016-06-14 16:05:47', '8ad674c5-58f6-412b-b788-6e0dc6f02f73'),
 ('181', '93', '64', '70', '0', '1', '2016-06-15 19:29:46', '2016-06-15 19:29:46', '4f95c73d-5a8d-4000-b0df-b74599cb15bb'),
 ('186', '96', '67', '78', '0', '1', '2016-06-15 20:22:25', '2016-06-15 20:22:25', '5aef4bde-7e11-4ae8-99c9-0d62311ebb11'),
 ('187', '96', '67', '79', '0', '2', '2016-06-15 20:22:25', '2016-06-15 20:22:25', 'fa82c5ab-8eab-4827-a21f-e7715dcfe5d1'),
 ('275', '136', '101', '63', '0', '1', '2016-06-27 21:51:18', '2016-06-27 21:51:18', '361e60b7-899c-418b-8631-6cdcdc0e8554'),
 ('276', '136', '101', '64', '0', '2', '2016-06-27 21:51:18', '2016-06-27 21:51:18', '23512b13-86d3-4c54-82b7-9e048ee37d72'),
 ('334', '154', '115', '58', '0', '1', '2016-07-05 19:10:28', '2016-07-05 19:10:28', '8cd8dc3c-3739-4339-bd6f-3988616fc8a7'),
 ('335', '154', '115', '59', '0', '2', '2016-07-05 19:10:28', '2016-07-05 19:10:28', 'defcbd3d-e02d-41eb-8a4b-5be199fe0a71'),
 ('336', '154', '115', '100', '0', '3', '2016-07-05 19:10:28', '2016-07-05 19:10:28', '9f61a90c-cf5a-4a63-9bb3-a094463a6a95'),
 ('343', '157', '117', '71', '0', '1', '2016-07-06 19:13:45', '2016-07-06 19:13:45', 'a6aa9654-18a1-4955-9233-aa2b241bacae'),
 ('344', '157', '117', '101', '0', '2', '2016-07-06 19:13:45', '2016-07-06 19:13:45', 'a24792e3-f075-4c8d-9179-9fa0dae78e26'),
 ('345', '157', '117', '72', '0', '3', '2016-07-06 19:13:45', '2016-07-06 19:13:45', '0c66d70d-9fa3-43a0-9faf-885dbe46fcf7'),
 ('346', '157', '117', '73', '0', '4', '2016-07-06 19:13:45', '2016-07-06 19:13:45', '67fc92c8-438f-406f-bfc5-0b7b589f51d6'),
 ('347', '157', '117', '74', '0', '5', '2016-07-06 19:13:45', '2016-07-06 19:13:45', '257b9e39-729b-4a93-b98a-92b81a8992af'),
 ('348', '157', '117', '75', '0', '6', '2016-07-06 19:13:45', '2016-07-06 19:13:45', '80342768-5d7c-4e6d-b1f4-26803754d18d'),
 ('349', '157', '117', '76', '0', '7', '2016-07-06 19:13:45', '2016-07-06 19:13:45', '5df9c55f-06f9-4b24-a389-9d64b2a433a3'),
 ('350', '157', '117', '102', '0', '8', '2016-07-06 19:13:45', '2016-07-06 19:13:45', 'e23e059d-d205-4a3c-bce1-4b37e21a6551'),
 ('351', '157', '117', '111', '1', '9', '2016-07-06 19:13:45', '2016-07-06 19:13:45', '44cba142-ef89-426f-802a-4877f997b416'),
 ('352', '157', '117', '112', '1', '10', '2016-07-06 19:13:45', '2016-07-06 19:13:45', '3d5af517-e959-4429-89e2-aa641441de62'),
 ('450', '221', '158', '128', '0', '1', '2016-07-11 19:18:59', '2016-07-11 19:18:59', 'e120aeef-0e31-45c4-9a77-8e270c6e6b41'),
 ('451', '221', '158', '86', '0', '2', '2016-07-11 19:18:59', '2016-07-11 19:18:59', 'a310c58f-e5bf-4303-85c0-d1b4bc52e7bf'),
 ('452', '222', '159', '129', '0', '1', '2016-07-11 19:21:06', '2016-07-11 19:21:06', 'a456a2ba-368d-453b-a44c-f48c8db55d65'),
 ('453', '222', '159', '110', '0', '2', '2016-07-11 19:21:06', '2016-07-11 19:21:06', '211f2071-9587-4c3c-985b-ec2bef95f98c'),
 ('454', '222', '159', '109', '0', '3', '2016-07-11 19:21:06', '2016-07-11 19:21:06', 'bb968130-5986-48c5-a8eb-54105b6a6f92'),
 ('455', '222', '159', '80', '0', '4', '2016-07-11 19:21:06', '2016-07-11 19:21:06', '3c5cc9ee-1240-4ad9-9021-1edee43830c9'),
 ('456', '222', '159', '56', '0', '5', '2016-07-11 19:21:06', '2016-07-11 19:21:06', '1f7899a3-e363-435e-9640-680aef60b273'),
 ('457', '222', '159', '57', '0', '6', '2016-07-11 19:21:06', '2016-07-11 19:21:06', '4201a423-478c-4ff4-8883-89c871b76b08'),
 ('458', '222', '159', '104', '0', '7', '2016-07-11 19:21:06', '2016-07-11 19:21:06', '29109646-69af-4eb6-94a4-20a3f76e2dc6'),
 ('459', '223', '160', '66', '0', '1', '2016-07-11 19:26:30', '2016-07-11 19:26:30', 'eb1d777a-a7a5-4679-b43c-1d050fa06c7b'),
 ('460', '223', '160', '130', '0', '2', '2016-07-11 19:26:30', '2016-07-11 19:26:30', '6e790b45-6163-4849-9e31-33c96617215d'),
 ('461', '223', '160', '81', '0', '3', '2016-07-11 19:26:30', '2016-07-11 19:26:30', '59f38685-ad21-4091-b96d-73228017bc36'),
 ('462', '223', '160', '61', '0', '4', '2016-07-11 19:26:30', '2016-07-11 19:26:30', '0cb747b4-0d42-4387-bdbf-acfb9cc862f5'),
 ('463', '223', '160', '62', '0', '5', '2016-07-11 19:26:30', '2016-07-11 19:26:30', 'd43272a2-0e53-4768-aa99-ccb641489f8f'),
 ('464', '223', '160', '103', '0', '6', '2016-07-11 19:26:30', '2016-07-11 19:26:30', 'f9ebc80c-4283-4174-bd34-617c2004d12f'),
 ('469', '225', '162', '132', '0', '1', '2016-07-11 19:33:14', '2016-07-11 19:33:14', 'fc71d02a-1713-4221-ba60-e08227538f0e'),
 ('470', '225', '162', '113', '0', '2', '2016-07-11 19:33:14', '2016-07-11 19:33:14', '33a2c7b1-57f3-41be-85d7-747218052f5a'),
 ('478', '232', '166', '23', '0', '1', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '78869aa6-cb6d-423e-a9d8-54f1aff37390'),
 ('479', '233', '167', '24', '0', '1', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '3ee4e8bb-08eb-42aa-a526-8fe3c71fb7b9'),
 ('480', '234', '168', '25', '0', '1', '2016-07-12 01:05:12', '2016-07-12 01:05:12', 'c5894056-cc10-4796-adf6-b5dd673a3f00'),
 ('481', '234', '168', '26', '0', '2', '2016-07-12 01:05:12', '2016-07-12 01:05:12', 'b4bbe07f-9961-45c7-9478-7bbb499c3fb7'),
 ('482', '235', '169', '27', '0', '1', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '03cc7d43-e931-49b2-8326-d569ed4cdb21'),
 ('483', '235', '169', '28', '0', '2', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '6b1303b1-6e1a-4fc7-9880-1d2e5c180a60'),
 ('484', '236', '170', '29', '0', '1', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '53ddc923-dce6-4185-a5de-002a9c5a7874'),
 ('485', '236', '170', '30', '0', '2', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '016d7dd6-2ccd-4c7c-962d-135bb940bb3c'),
 ('486', '236', '170', '31', '0', '3', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '24ad2b49-6b91-4f60-8c47-5bf4ecf3226d'),
 ('487', '237', '171', '32', '0', '1', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '8a9c1e6e-005c-469b-a17e-058e3e54310e'),
 ('488', '238', '172', '33', '0', '1', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '9c2af5e3-bd09-4ba3-8a67-4f75c61804c8'),
 ('489', '238', '172', '34', '0', '2', '2016-07-12 01:05:12', '2016-07-12 01:05:12', 'd6da2542-3e7e-41dc-b5a1-70d2b9b575dd'),
 ('490', '238', '172', '35', '0', '3', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '5e66a78f-8690-4617-8b16-87467132db80'),
 ('528', '254', '188', '137', '0', '1', '2016-07-13 00:53:25', '2016-07-13 00:53:25', 'f18002f6-b33f-4747-82da-6aed68f86c1f'),
 ('529', '255', '189', '6', '1', '1', '2016-07-13 00:53:25', '2016-07-13 00:53:25', 'a4a3eb3a-df94-41a5-b2a5-43b6e2a371de'),
 ('530', '255', '189', '7', '0', '2', '2016-07-13 00:53:25', '2016-07-13 00:53:25', '57592f8e-6429-4b9c-bcba-a2220031e21c'),
 ('531', '256', '190', '87', '1', '1', '2016-07-13 01:10:54', '2016-07-13 01:10:54', 'e7a41973-ec19-4234-865f-2ed971badf2d'),
 ('532', '256', '190', '93', '0', '2', '2016-07-13 01:10:54', '2016-07-13 01:10:54', '946f3d2b-9681-4508-9069-2947ecc1f555'),
 ('533', '257', '191', '94', '0', '1', '2016-07-13 01:10:54', '2016-07-13 01:10:54', 'da329b00-6a4e-4aeb-8ea5-f81c1074e85e'),
 ('534', '257', '191', '95', '0', '2', '2016-07-13 01:10:54', '2016-07-13 01:10:54', '39f38578-35e7-428a-a26f-f6ddd13e59b6'),
 ('535', '257', '191', '96', '0', '3', '2016-07-13 01:10:54', '2016-07-13 01:10:54', '3142dfaa-cf16-4246-9495-329967184d3b'),
 ('536', '258', '192', '97', '0', '1', '2016-07-13 01:10:54', '2016-07-13 01:10:54', 'd0a5865e-fe0e-4753-b1ac-522179a1df4f'),
 ('537', '258', '192', '98', '0', '2', '2016-07-13 01:10:54', '2016-07-13 01:10:54', 'eeeb2f20-4b02-480a-9a60-703923c7014b'),
 ('538', '259', '193', '106', '0', '1', '2016-07-13 01:12:46', '2016-07-13 01:12:46', '44ba012b-ae08-4f54-a7e7-fea03ef51d4c'),
 ('539', '259', '193', '77', '0', '2', '2016-07-13 01:12:46', '2016-07-13 01:12:46', 'c30bbdae-3a89-4a48-907c-f72c547e43c9'),
 ('540', '259', '193', '105', '0', '3', '2016-07-13 01:12:46', '2016-07-13 01:12:46', '8645cd1f-7434-4206-b3f7-08c73c73cbc1'),
 ('541', '259', '193', '70', '0', '4', '2016-07-13 01:12:46', '2016-07-13 01:12:46', 'd8ea16a5-cc08-4338-9dd2-58885d6a800c'),
 ('542', '260', '194', '83', '0', '1', '2016-07-13 15:00:20', '2016-07-13 15:00:20', '6b7bab96-7fa1-4a0b-9712-344b899f33c4'),
 ('543', '261', '195', '10', '0', '1', '2016-07-13 15:00:45', '2016-07-13 15:00:45', 'aaff9633-60cc-4b24-890c-86dcb8af9fea'),
 ('544', '261', '195', '11', '0', '2', '2016-07-13 15:00:45', '2016-07-13 15:00:45', '323099ab-1ff5-4a21-a0c7-5bacc8dfcbd0'),
 ('545', '261', '195', '107', '0', '3', '2016-07-13 15:00:45', '2016-07-13 15:00:45', 'e1c7ddcc-6ff1-424c-8ada-e7b410b7b9a7'),
 ('546', '262', '196', '3', '0', '1', '2016-07-13 15:02:39', '2016-07-13 15:02:39', '9c8f5b0b-5e43-458d-b224-b499ec2d42c7'),
 ('547', '262', '196', '4', '0', '2', '2016-07-13 15:02:39', '2016-07-13 15:02:39', '4316d588-531f-490b-927b-a367c2635b09'),
 ('548', '262', '196', '5', '0', '3', '2016-07-13 15:02:39', '2016-07-13 15:02:39', '674c3191-7faa-46fa-8246-dc7efd7182f3'),
 ('549', '262', '196', '141', '0', '4', '2016-07-13 15:02:39', '2016-07-13 15:02:39', 'b5f51426-bf97-4798-9674-574a11136523'),
 ('550', '262', '196', '82', '0', '5', '2016-07-13 15:02:39', '2016-07-13 15:02:39', '7dcdc956-b4a6-46ad-bf4d-6345d48efb4f'),
 ('551', '262', '196', '140', '0', '6', '2016-07-13 15:02:39', '2016-07-13 15:02:39', 'ae23c33a-6c84-46b1-a3bc-208c90fbe84e'),
 ('552', '262', '196', '9', '0', '7', '2016-07-13 15:02:39', '2016-07-13 15:02:39', '3fb0e514-c9ed-4f7a-9072-ed4b0254522c'),
 ('553', '262', '196', '69', '0', '8', '2016-07-13 15:02:39', '2016-07-13 15:02:39', '73f3b607-3750-435a-9679-456d909326da'),
 ('554', '263', '197', '51', '0', '1', '2016-07-13 16:41:42', '2016-07-13 16:41:42', '686316ef-4209-4b74-a1fc-e9f69b24cf58'),
 ('555', '263', '197', '125', '0', '2', '2016-07-13 16:41:42', '2016-07-13 16:41:42', '1196e7ae-1060-4495-80d3-6e600a5db6d3'),
 ('556', '263', '197', '52', '0', '3', '2016-07-13 16:41:42', '2016-07-13 16:41:42', 'b4a4266e-11e7-493f-9f94-17a4f084e164'),
 ('557', '263', '197', '53', '0', '4', '2016-07-13 16:41:42', '2016-07-13 16:41:42', '1dd23fab-7911-4bd7-bd3b-eea0ad94ecb0'),
 ('558', '263', '197', '142', '0', '5', '2016-07-13 16:41:42', '2016-07-13 16:41:42', '84647f79-8bcc-4d29-af98-73dbd17628b5'),
 ('559', '265', '198', '143', '0', '1', '2016-07-13 17:10:10', '2016-07-13 17:10:10', 'cc4a4840-2d69-454d-836a-57b57384f39e'),
 ('565', '273', '200', '48', '0', '1', '2016-07-14 16:36:07', '2016-07-14 16:36:07', '19c2c7d7-4ac5-4961-b245-7bda2b7fe91f'),
 ('566', '273', '200', '144', '0', '2', '2016-07-14 16:36:07', '2016-07-14 16:36:07', '4b7b423d-be0c-44b6-805c-6a96c4cade64'),
 ('567', '273', '200', '124', '0', '3', '2016-07-14 16:36:07', '2016-07-14 16:36:07', '6361b2fb-e16b-44d4-b0f4-af59282e0bcc'),
 ('568', '273', '200', '49', '0', '4', '2016-07-14 16:36:07', '2016-07-14 16:36:07', 'a196aaef-09b1-4868-9bdf-194d505265e5'),
 ('569', '273', '200', '54', '0', '5', '2016-07-14 16:36:07', '2016-07-14 16:36:07', '87c980b3-d84d-4f26-9fdf-3bf48479b5f2'),
 ('570', '274', '201', '119', '0', '1', '2016-07-14 20:29:42', '2016-07-14 20:29:42', '54018fb1-a235-4671-ac28-ec72092f0c66'),
 ('571', '274', '201', '114', '0', '2', '2016-07-14 20:29:42', '2016-07-14 20:29:42', '2446ebc3-b61e-4ffe-804f-c5347584c9e9'),
 ('572', '274', '201', '115', '0', '3', '2016-07-14 20:29:42', '2016-07-14 20:29:42', '877ad3c9-667d-483e-a664-50e8ab9ebb2c'),
 ('573', '275', '202', '120', '0', '1', '2016-07-14 20:29:42', '2016-07-14 20:29:42', '51a77274-2a85-4be5-9111-aefca824dae0'),
 ('574', '275', '202', '116', '0', '2', '2016-07-14 20:29:42', '2016-07-14 20:29:42', '440e0979-5dcf-4894-aef1-b0f3da83f3f7'),
 ('575', '276', '203', '121', '0', '1', '2016-07-14 20:29:42', '2016-07-14 20:29:42', '695f36cc-f8d1-4555-b50e-facc27392aea'),
 ('576', '276', '203', '117', '0', '2', '2016-07-14 20:29:42', '2016-07-14 20:29:42', 'e040fe3d-effe-44f9-bb43-30e571cc5f4c'),
 ('577', '276', '203', '123', '0', '3', '2016-07-14 20:29:42', '2016-07-14 20:29:42', 'e5b2eb13-055d-485d-b5fd-bf84090cb54d'),
 ('578', '277', '204', '122', '0', '1', '2016-07-14 20:29:42', '2016-07-14 20:29:42', 'b9cf9be7-ca30-464b-bb8b-4b994f5214be'),
 ('579', '277', '204', '145', '0', '2', '2016-07-14 20:29:42', '2016-07-14 20:29:42', '02f6d906-20fc-4be8-92ac-bc3dc16431aa');
INSERT INTO `craft_fieldlayoutfields` (`id`, `layoutId`, `tabId`, `fieldId`, `required`, `sortOrder`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('580', '278', '205', '131', '0', '1', '2016-07-15 16:24:40', '2016-07-15 16:24:40', '0e63fce4-1a62-4fee-99ef-afed42ad4130'),
 ('581', '278', '205', '20', '0', '2', '2016-07-15 16:24:40', '2016-07-15 16:24:40', 'f43dcbfb-b17f-45f9-a672-8cfc2030c587'),
 ('582', '278', '205', '146', '0', '3', '2016-07-15 16:24:40', '2016-07-15 16:24:40', 'dcdcfeeb-08fa-4cac-b411-3bc70b5113da'),
 ('583', '278', '205', '22', '0', '4', '2016-07-15 16:24:40', '2016-07-15 16:24:40', 'd07ab68c-09a7-4354-a22b-b8bcbabcf507'),
 ('584', '278', '205', '36', '0', '5', '2016-07-15 16:24:40', '2016-07-15 16:24:40', '565ac95b-cdfb-42c5-873f-66623154d32f'),
 ('589', '281', '208', '147', '0', '1', '2016-07-15 17:08:03', '2016-07-15 17:08:03', 'e1bae2c0-d3f2-44ec-8b0b-9685cec70a8c'),
 ('590', '282', '209', '126', '0', '1', '2016-07-15 17:08:20', '2016-07-15 17:08:20', 'e1f88981-768e-4a9f-8545-589af71ee40f');



DROP TABLE IF EXISTS `craft_fieldlayouts`;


--
-- Schema for table `craft_fieldlayouts`
--
CREATE TABLE `craft_fieldlayouts` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `type` varchar(150) COLLATE utf8_unicode_ci NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  KEY `craft_fieldlayouts_type_idx` (`type`)
) ENGINE=InnoDB AUTO_INCREMENT=283 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_fieldlayouts`
--

INSERT INTO `craft_fieldlayouts` (`id`, `type`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('49', 'Entry', '2016-06-14 15:47:44', '2016-06-14 15:47:44', '6fb94ea1-3ec8-46ad-b5a3-1a6313ffd705'),
 ('62', 'Entry', '2016-06-14 16:05:47', '2016-06-14 16:05:47', 'e189f971-9f1f-4ae2-94b7-8eabb1e7372d'),
 ('84', 'Asset', '2016-06-14 20:15:55', '2016-06-14 20:15:55', '2a02cfb7-ca85-4a91-96b9-611b6f1c4c34'),
 ('85', 'Asset', '2016-06-14 20:16:18', '2016-06-14 20:16:18', '472f5f41-3bb9-4e73-b5c6-dc624aff1d35'),
 ('93', 'Entry', '2016-06-15 19:29:46', '2016-06-15 19:29:46', '72261007-fa81-4f13-b7c3-15f6c3e48a82'),
 ('96', 'MatrixBlock', '2016-06-15 20:22:25', '2016-06-15 20:22:25', '2d4177f5-0e4a-4bc6-8743-cce0fd256816'),
 ('108', 'Tag', '2016-06-23 18:57:25', '2016-06-23 18:57:25', '215ea167-9123-4c62-bd20-03a3dfa22f7a'),
 ('136', 'MatrixBlock', '2016-06-27 21:51:18', '2016-06-27 21:51:18', 'd2a7e533-49e1-4ea1-ab9f-6be1374472a2'),
 ('141', 'Tag', '2016-06-28 15:57:34', '2016-06-28 15:57:34', 'f0c7bece-9f94-4bc2-a9db-caed6153907e'),
 ('144', 'Tag', '2016-06-28 16:24:59', '2016-06-28 16:24:59', '8b6a37da-9478-4b2e-be62-80975994b4f6'),
 ('154', 'MatrixBlock', '2016-07-05 19:10:28', '2016-07-05 19:10:28', 'cbba713c-7f64-47e1-ace9-12e610a93d50'),
 ('157', 'MatrixBlock', '2016-07-06 19:13:45', '2016-07-06 19:13:45', 'd7b1c872-b56b-4989-8422-f9904683b6bd'),
 ('221', 'Entry', '2016-07-11 19:18:59', '2016-07-11 19:18:59', '6037430c-8e4d-4668-8db2-457b32f4eb67'),
 ('222', 'Entry', '2016-07-11 19:21:06', '2016-07-11 19:21:06', '0a1643ad-e407-4561-b8c6-ca6755937089'),
 ('223', 'Entry', '2016-07-11 19:26:30', '2016-07-11 19:26:30', '8b02ed73-e6b4-4d8c-9821-2367f78bfd5d'),
 ('225', 'Entry', '2016-07-11 19:33:14', '2016-07-11 19:33:14', '4eea2437-f75d-4b2f-864f-fa32b3b58036'),
 ('229', 'Asset', '2016-07-11 21:57:34', '2016-07-11 21:57:34', '943ee72d-1ad6-4892-b87d-f2c8acfffe27'),
 ('232', 'MatrixBlock', '2016-07-12 01:05:12', '2016-07-12 01:05:12', 'd06325dc-be0b-4b0a-a29c-08fef8131017'),
 ('233', 'MatrixBlock', '2016-07-12 01:05:12', '2016-07-12 01:05:12', 'd9bd1fc4-d272-4412-bb6b-2ca5caeb5cf2'),
 ('234', 'MatrixBlock', '2016-07-12 01:05:12', '2016-07-12 01:05:12', 'de00b81f-2bdf-4f83-b001-cca69d73fce2'),
 ('235', 'MatrixBlock', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '85584783-9d97-4e67-9b8e-b5df29206eb7'),
 ('236', 'MatrixBlock', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '67d4f882-549a-4c37-adc8-a008e5e6a653'),
 ('237', 'MatrixBlock', '2016-07-12 01:05:12', '2016-07-12 01:05:12', 'b2953a09-5fc6-4a26-81df-e3731f6cbdc1'),
 ('238', 'MatrixBlock', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '09909ef1-01fc-4ef9-bf44-82afab97859d'),
 ('254', 'MatrixBlock', '2016-07-13 00:53:25', '2016-07-13 00:53:25', 'bfa6e08e-4f9e-4649-b0d5-2c4c4878953b'),
 ('255', 'MatrixBlock', '2016-07-13 00:53:25', '2016-07-13 00:53:25', 'e0427ece-b93e-4b0a-8832-af4bdf2bcdf5'),
 ('256', 'MatrixBlock', '2016-07-13 01:10:54', '2016-07-13 01:10:54', '56968a14-c060-47d7-8e52-afc9ec98d0c4'),
 ('257', 'MatrixBlock', '2016-07-13 01:10:54', '2016-07-13 01:10:54', '15e3bc0b-47e8-4717-af54-15d9e3cb243f'),
 ('258', 'MatrixBlock', '2016-07-13 01:10:54', '2016-07-13 01:10:54', 'b4ff9efd-4769-42cf-95b4-45c9a41e2b30'),
 ('259', 'GlobalSet', '2016-07-13 01:12:46', '2016-07-13 01:12:46', '58bdcfec-b252-4235-9638-cb98b7d4e6b9'),
 ('260', 'MatrixBlock', '2016-07-13 15:00:20', '2016-07-13 15:00:20', '17435646-5e74-478e-9a11-b3b947a8d65f'),
 ('261', 'MatrixBlock', '2016-07-13 15:00:45', '2016-07-13 15:00:45', 'e3adbfd9-1511-4449-aec9-b57f8f767e85'),
 ('262', 'Entry', '2016-07-13 15:02:39', '2016-07-13 15:02:39', 'd6a93d06-5f3a-40e2-bb9f-3c4a2fb3cfc3'),
 ('263', 'MatrixBlock', '2016-07-13 16:41:42', '2016-07-13 16:41:42', '177c1c77-ceb2-4710-a434-e47eac81c70d'),
 ('265', 'GlobalSet', '2016-07-13 17:10:10', '2016-07-13 17:10:10', 'f3ed5d0f-9721-4d40-8757-00e59ed2064f'),
 ('270', 'Asset', '2016-07-13 18:59:45', '2016-07-13 18:59:45', '7dbe363d-62a0-4d42-a788-5e1bcac3402e'),
 ('271', 'Tag', '2016-07-13 21:51:33', '2016-07-13 21:51:33', '63b36a1f-0940-46cc-accb-265d9abd135a'),
 ('273', 'MatrixBlock', '2016-07-14 16:36:07', '2016-07-14 16:36:07', 'e6be170a-dc0d-4de4-9118-30ce74b46e35'),
 ('274', 'MatrixBlock', '2016-07-14 20:29:42', '2016-07-14 20:29:42', 'ee971651-4db2-44d3-a781-65eb30a90880'),
 ('275', 'MatrixBlock', '2016-07-14 20:29:42', '2016-07-14 20:29:42', 'c27bc0b7-1931-4fbb-b6bc-5c3cff2560cd'),
 ('276', 'MatrixBlock', '2016-07-14 20:29:42', '2016-07-14 20:29:42', '6162f78a-8263-4f1c-b0a6-208a633047a7'),
 ('277', 'MatrixBlock', '2016-07-14 20:29:42', '2016-07-14 20:29:42', '024f3a85-b14e-42d4-9dce-38e00fd0dd65'),
 ('278', 'Entry', '2016-07-15 16:24:40', '2016-07-15 16:24:40', '9e6e46bb-40f8-4cd4-9ee2-31792fececad'),
 ('281', 'GlobalSet', '2016-07-15 17:08:03', '2016-07-15 17:08:03', '1946d99d-d7dc-4e2c-acd9-98be99a762a8'),
 ('282', 'GlobalSet', '2016-07-15 17:08:20', '2016-07-15 17:08:20', '924a2101-46ea-4520-b820-c48ba3db44d1');



DROP TABLE IF EXISTS `craft_fieldlayouttabs`;


--
-- Schema for table `craft_fieldlayouttabs`
--
CREATE TABLE `craft_fieldlayouttabs` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `layoutId` int(11) NOT NULL,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `sortOrder` smallint(6) unsigned DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  KEY `craft_fieldlayouttabs_sortOrder_idx` (`sortOrder`),
  KEY `craft_fieldlayouttabs_layoutId_fk` (`layoutId`)
) ENGINE=InnoDB AUTO_INCREMENT=210 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_fieldlayouttabs`
--

INSERT INTO `craft_fieldlayouttabs` (`id`, `layoutId`, `name`, `sortOrder`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('31', '49', 'Content', '1', '2016-06-14 15:47:44', '2016-06-14 15:47:44', '1be2232c-a38a-4919-9d5c-c74610f226cd'),
 ('47', '62', 'About Section', '1', '2016-06-14 16:05:47', '2016-06-14 16:05:47', 'ea1443f7-8536-4174-9a75-d25ea2e9a810'),
 ('48', '62', 'Teams', '2', '2016-06-14 16:05:47', '2016-06-14 16:05:47', '41a65277-49a6-41e3-80ad-a9e844ea73ff'),
 ('64', '93', 'Contact', '1', '2016-06-15 19:29:46', '2016-06-15 19:29:46', '2d6de30c-7b94-49a8-b3b9-895a527a2a11'),
 ('67', '96', 'Content', '1', '2016-06-15 20:22:25', '2016-06-15 20:22:25', '6de8b347-acfb-4bca-99e5-5cf81d5d22a7'),
 ('101', '136', 'Content', '1', '2016-06-27 21:51:18', '2016-06-27 21:51:18', '86c1610f-876b-4fc1-b2ca-281c6fb0659e'),
 ('115', '154', 'Content', '1', '2016-07-05 19:10:28', '2016-07-05 19:10:28', '771e62ee-b4f3-4c05-b5bb-019c2a563239'),
 ('117', '157', 'Content', '1', '2016-07-06 19:13:45', '2016-07-06 19:13:45', '08c9b84e-1331-42b5-8aa4-7f2609a8df6e'),
 ('158', '221', 'Content', '1', '2016-07-11 19:18:59', '2016-07-11 19:18:59', '60f03dec-05bd-4986-bb57-c90fdaaecaf9'),
 ('159', '222', 'Team Member', '1', '2016-07-11 19:21:06', '2016-07-11 19:21:06', '93be5837-2a92-4e59-8115-7671e9078c61'),
 ('160', '223', 'Company', '1', '2016-07-11 19:26:30', '2016-07-11 19:26:30', '837ba1dd-57a7-482a-815f-aa23b1296b8c'),
 ('162', '225', 'Press', '1', '2016-07-11 19:33:14', '2016-07-11 19:33:14', '06274265-13fc-408a-8f5f-779c9cf45f9b'),
 ('166', '232', 'Content', '1', '2016-07-12 01:05:12', '2016-07-12 01:05:12', 'b586e26a-d95d-468f-a968-a3644425c52e'),
 ('167', '233', 'Content', '1', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '71cfb9eb-d67b-4d3f-8f99-b0be721a2fdd'),
 ('168', '234', 'Content', '1', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '4b08e248-0f75-41d9-b620-484af82d3c20'),
 ('169', '235', 'Content', '1', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '707c0fab-bfcf-491c-a35c-56cb5e200907'),
 ('170', '236', 'Content', '1', '2016-07-12 01:05:12', '2016-07-12 01:05:12', 'e6baac6f-d3d2-4b8b-b4ed-271db68cb4fc'),
 ('171', '237', 'Content', '1', '2016-07-12 01:05:12', '2016-07-12 01:05:12', 'f2b99562-dd4e-48b1-9744-189645095aa2'),
 ('172', '238', 'Content', '1', '2016-07-12 01:05:12', '2016-07-12 01:05:12', '4af852b8-0c0e-43b9-a8ed-147d83e080ee'),
 ('188', '254', 'Content', '1', '2016-07-13 00:53:25', '2016-07-13 00:53:25', 'b37db896-7c4c-4868-9c5c-a2a30c33a606'),
 ('189', '255', 'Content', '1', '2016-07-13 00:53:25', '2016-07-13 00:53:25', '34f34ed6-f393-4815-9399-a0fcdbd408eb'),
 ('190', '256', 'Content', '1', '2016-07-13 01:10:54', '2016-07-13 01:10:54', '5b2a7131-2d63-45ca-8fd2-49394ebfe2e4'),
 ('191', '257', 'Content', '1', '2016-07-13 01:10:54', '2016-07-13 01:10:54', '4eca8bb0-87bf-4aa2-9900-26e8cc968fc3'),
 ('192', '258', 'Content', '1', '2016-07-13 01:10:54', '2016-07-13 01:10:54', '29de9b5f-cac4-4e1b-9c55-431aa3e7bd0e'),
 ('193', '259', 'Content', '1', '2016-07-13 01:12:46', '2016-07-13 01:12:46', '861ff82d-9398-42fb-a770-35e92c81850e'),
 ('194', '260', 'Content', '1', '2016-07-13 15:00:20', '2016-07-13 15:00:20', '17b54488-37cc-4541-9045-7bee5c6478a9'),
 ('195', '261', 'Content', '1', '2016-07-13 15:00:45', '2016-07-13 15:00:45', '100658cf-9be7-47c5-a62e-381d18188c62'),
 ('196', '262', 'Content', '1', '2016-07-13 15:02:39', '2016-07-13 15:02:39', '439f4ee3-d768-46e9-a487-2facf48d0679'),
 ('197', '263', 'Content', '1', '2016-07-13 16:41:42', '2016-07-13 16:41:42', '2a9ccf11-b11d-4893-a3f4-e0ae65adc3e8'),
 ('198', '265', 'Content', '1', '2016-07-13 17:10:10', '2016-07-13 17:10:10', '554f945b-17da-4eb7-8bb1-65164bfa6dc3'),
 ('200', '273', 'Content', '1', '2016-07-14 16:36:07', '2016-07-14 16:36:07', 'd9e816a5-44cf-4aee-bc72-2e7b5ebc0978'),
 ('201', '274', 'Content', '1', '2016-07-14 20:29:42', '2016-07-14 20:29:42', '312efeac-cfc6-44c2-8e32-05525ffa21a1'),
 ('202', '275', 'Content', '1', '2016-07-14 20:29:42', '2016-07-14 20:29:42', '65dff4d5-1ef7-44cf-abe6-cc65df14772c'),
 ('203', '276', 'Content', '1', '2016-07-14 20:29:42', '2016-07-14 20:29:42', '19543166-ddfb-4010-85ac-986b21a7a35d'),
 ('204', '277', 'Content', '1', '2016-07-14 20:29:42', '2016-07-14 20:29:42', 'dcb90d23-ed23-4a0b-8f9b-897d113dd788'),
 ('205', '278', 'Content', '1', '2016-07-15 16:24:40', '2016-07-15 16:24:40', '361ebd19-512f-442f-b7c3-632393f58a2f'),
 ('208', '281', 'Content', '1', '2016-07-15 17:08:03', '2016-07-15 17:08:03', '67e6387d-1392-4d7b-8c04-2bd7816094bb'),
 ('209', '282', 'Content', '1', '2016-07-15 17:08:20', '2016-07-15 17:08:20', '6973c0c3-41ea-464f-b3b0-8528c2acb5b4');



DROP TABLE IF EXISTS `craft_fields`;


--
-- Schema for table `craft_fields`
--
CREATE TABLE `craft_fields` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `groupId` int(11) DEFAULT NULL,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `handle` varchar(58) COLLATE utf8_unicode_ci NOT NULL,
  `context` varchar(255) COLLATE utf8_unicode_ci NOT NULL DEFAULT 'global',
  `instructions` text COLLATE utf8_unicode_ci,
  `translatable` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `type` varchar(150) COLLATE utf8_unicode_ci NOT NULL,
  `settings` text COLLATE utf8_unicode_ci,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_fields_handle_context_unq_idx` (`handle`,`context`),
  KEY `craft_fields_context_idx` (`context`),
  KEY `craft_fields_groupId_fk` (`groupId`)
) ENGINE=InnoDB AUTO_INCREMENT=148 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_fields`
--

INSERT INTO `craft_fields` (`id`, `groupId`, `name`, `handle`, `context`, `instructions`, `translatable`, `type`, `settings`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('3', '2', 'Hero Image', 'heroImage', 'global', 'The image should be at least 1450×916 for best results.', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"1\",\"viewMode\":\"large\",\"selectionLabel\":\"\"}', '2016-06-13 15:50:59', '2016-07-13 17:04:06', '288c7590-b2cc-4cff-8354-4282c30fbe64'),
 ('4', '2', 'Blurb', 'blurb', 'global', 'Write a heading of max 255 characters', '0', 'RichText', '{\"configFile\":\"\",\"availableAssetSources\":\"*\",\"availableTransforms\":\"*\",\"cleanupHtml\":\"1\",\"purifyHtml\":\"\",\"columnType\":\"text\"}', '2016-06-13 15:55:03', '2016-07-06 14:37:27', '5a3eae8f-681a-4c30-bdf1-303e0fa500d8'),
 ('5', '2', 'Areas of Expertise', 'areasOfExpertise', 'global', '', '0', 'Matrix', '{\"maxBlocks\":\"4\"}', '2016-06-13 16:04:48', '2016-07-13 00:53:25', '7702c9b5-5e2b-4294-958e-935c098c8851'),
 ('6', NULL, 'Area Title', 'areaTitle', 'matrixBlockType:1', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 16:04:48', '2016-07-13 00:53:25', '45d07d28-65cd-42cc-b6c7-82420cd7df25'),
 ('7', NULL, 'Area Description', 'areaDescription', 'matrixBlockType:1', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"260\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 16:04:48', '2016-07-13 00:53:25', 'e54c2716-5576-4d14-95a7-c1746cf42b74'),
 ('9', '2', 'Trajectories', 'trajectories', 'global', '', '0', 'Matrix', '{\"maxBlocks\":null}', '2016-06-13 16:14:34', '2016-07-13 15:00:45', 'b794a44e-1804-4798-a0e2-ab9e836beb91'),
 ('10', NULL, 'Trajectory Title', 'trajectoryTitle', 'matrixBlockType:2', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 16:14:34', '2016-07-13 15:00:45', 'd98bfcc1-fbbc-49c6-ba01-5a1e868c88c8'),
 ('11', NULL, 'Trajectory Description', 'trajectoryDescription', 'matrixBlockType:2', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 16:14:34', '2016-07-13 15:00:45', 'c570b1bc-6085-4a97-af7b-90977e05341a'),
 ('20', '9', 'Published Date', 'publishedDate', 'global', '', '0', 'Date', '{\"minuteIncrement\":\"30\",\"showDate\":1,\"showTime\":0}', '2016-06-13 18:45:49', '2016-06-13 18:45:49', '883201c8-6483-455b-98af-e31f07be7eff'),
 ('22', '9', 'Article Body', 'articleBody', 'global', '', '0', 'Matrix', '{\"maxBlocks\":null}', '2016-06-13 19:19:49', '2016-07-12 01:05:12', 'a586d4aa-5c2e-4f55-aaa1-625b14645422'),
 ('23', NULL, 'Section Heading', 'sectionHeading', 'matrixBlockType:4', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"255\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 19:19:49', '2016-07-12 01:05:12', '2992d641-0308-453a-9872-fb01b792e272'),
 ('24', NULL, 'Heading', 'heading', 'matrixBlockType:5', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"100\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 19:19:49', '2016-07-12 01:05:12', 'cb9197db-6c56-4122-a012-742c1bd03945'),
 ('25', NULL, 'Text', 'text', 'matrixBlockType:6', '', '0', 'RichText', '{\"configFile\":\"\",\"availableAssetSources\":\"*\",\"availableTransforms\":\"*\",\"cleanupHtml\":\"1\",\"purifyHtml\":\"\",\"columnType\":\"text\"}', '2016-06-13 19:19:49', '2016-07-12 01:05:12', '33491664-fa85-4ed3-a313-1d91eef61b5d'),
 ('26', NULL, 'Position', 'position', 'matrixBlockType:6', '', '0', 'PositionSelect', '{\"options\":[\"left\",\"center\",\"right\",\"full\"]}', '2016-06-13 19:19:49', '2016-07-12 01:05:12', 'b9396743-9aaf-442e-a394-ecff239f1ea9'),
 ('27', NULL, 'Quote', 'quote', 'matrixBlockType:7', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 19:19:49', '2016-07-12 01:05:12', 'f65a404e-9ecc-4eb9-b5c7-c3277a40548b'),
 ('28', NULL, 'Position', 'position', 'matrixBlockType:7', '', '0', 'PositionSelect', '{\"options\":[\"left\",\"center\",\"right\"]}', '2016-06-13 19:19:49', '2016-07-12 01:05:12', 'a3d85709-1db5-4b04-99c8-99508b815526'),
 ('29', NULL, 'Image', 'image', 'matrixBlockType:8', '', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"\",\"limit\":\"\",\"viewMode\":\"list\",\"selectionLabel\":\"\"}', '2016-06-13 19:19:49', '2016-07-12 01:05:12', 'a9f958a7-a6f0-42e9-8a1a-7939ce718172'),
 ('30', NULL, 'Caption', 'caption', 'matrixBlockType:8', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 19:19:49', '2016-07-12 01:05:12', '87aa39a8-b7c3-48c7-b89d-154a7b077af6'),
 ('31', NULL, 'Position', 'position', 'matrixBlockType:8', '', '0', 'PositionSelect', '{\"options\":[\"left\",\"center\",\"right\",\"full\"]}', '2016-06-13 19:19:49', '2016-07-12 01:05:12', '34b5efff-cc38-482b-b5f4-d58c3d27a976'),
 ('32', NULL, 'Images ', 'images', 'matrixBlockType:9', '', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"\",\"limit\":\"\",\"viewMode\":\"list\",\"selectionLabel\":\"\"}', '2016-06-13 19:19:49', '2016-07-12 01:05:12', '4a8812d5-254d-43fb-9d64-ced4b2e591d5'),
 ('33', NULL, 'Quote', 'quote', 'matrixBlockType:10', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 19:19:49', '2016-07-12 01:05:12', '34ea5113-75a8-46c6-baf0-10934452d7b0'),
 ('34', NULL, 'Attribution', 'attribution', 'matrixBlockType:10', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 19:19:49', '2016-07-12 01:05:12', '937a08a4-b23b-40f4-a2bb-17381fd1a139'),
 ('35', NULL, 'Position', 'position', 'matrixBlockType:10', '', '0', 'PositionSelect', '{\"options\":[\"left\",\"right\"]}', '2016-06-13 19:19:49', '2016-07-12 01:05:12', 'd4ba19fe-a7b8-45b6-8127-7639fd073dea'),
 ('36', '9', 'Tags', 'tags', 'global', 'This will tell the news filter which company to assign this article to', '0', 'Tags', '{\"source\":\"taggroup:6\",\"selectionLabel\":\"\"}', '2016-06-13 19:39:44', '2016-07-13 21:52:24', 'a834b8af-554d-442c-bf68-d5e0e34752a5'),
 ('37', '7', 'About Title', 'aboutTitle', 'global', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"255\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 19:53:35', '2016-06-13 19:53:41', 'bf5ac6e7-862c-41a2-838a-3c20687d786d'),
 ('38', '7', 'About Text', 'aboutText', 'global', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"350\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 19:54:00', '2016-07-12 01:06:35', 'a414b8ca-700e-43ec-a1ce-31b367bb727b'),
 ('39', '7', 'About Image', 'aboutImage', 'global', '', '0', 'Assets', '{\"useSingleFolder\":\"\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"\",\"limit\":\"\",\"viewMode\":\"list\",\"selectionLabel\":\"\"}', '2016-06-13 19:54:10', '2016-06-13 19:54:10', '19924059-1bea-4eb8-9a05-dbad5a2bfc27'),
 ('47', '7', 'Teams', 'teams', 'global', '', '0', 'Matrix', '{\"maxBlocks\":null}', '2016-06-13 20:28:48', '2016-07-14 16:36:07', '5eba20d4-ac10-4db3-beef-35a21aa0e121'),
 ('48', NULL, 'Team Name', 'teamName', 'matrixBlockType:12', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 20:28:48', '2016-07-14 16:36:07', '656a9c2e-8658-40ef-aa4d-8505287c1484'),
 ('49', NULL, 'Info', 'teamDescription', 'matrixBlockType:12', '', '0', 'RichText', '{\"configFile\":\"\",\"availableAssetSources\":\"*\",\"availableTransforms\":\"*\",\"cleanupHtml\":\"1\",\"purifyHtml\":\"\",\"columnType\":\"text\"}', '2016-06-13 20:28:48', '2016-07-14 16:36:07', 'cf4317c1-2e7e-4e91-9171-5e5ab51da9bf'),
 ('50', '8', 'Expertise Section', 'expertiseSection', 'global', '', '0', 'Matrix', '{\"maxBlocks\":null}', '2016-06-13 21:39:05', '2016-07-13 16:41:42', 'b2832a6d-9b6f-4635-9f81-0a478d147eea'),
 ('51', NULL, 'Expertise Title', 'expertiseTitle', 'matrixBlockType:13', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 21:39:05', '2016-07-13 16:41:42', '9f60389a-2143-4150-94e3-f1016f238616'),
 ('52', NULL, 'Expertise Description', 'expertiseDescription', 'matrixBlockType:13', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"500\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-13 21:39:05', '2016-07-13 16:41:42', '6fa24474-cb27-47f6-b80a-0fd083d2ce60'),
 ('53', NULL, 'Company Image', 'company', 'matrixBlockType:13', '', '0', 'Entries', '{\"sources\":[\"section:13\"],\"limit\":\"\",\"selectionLabel\":\"\"}', '2016-06-13 21:39:05', '2016-07-13 16:41:42', '493c680f-a0b9-47e4-8d27-4e85657b7895'),
 ('54', NULL, 'Team Member Name', 'teamMember', 'matrixBlockType:12', '', '0', 'Entries', '{\"sources\":[\"section:12\"],\"limit\":\"\",\"selectionLabel\":\"Team Member\"}', '2016-06-14 15:56:51', '2016-07-14 16:36:07', '96ceac43-1d55-43df-8520-567559040c2f'),
 ('56', '10', 'Team Member Bio', 'teamMemberBio', 'global', '', '0', 'RichText', '{\"configFile\":\"\",\"availableAssetSources\":\"\",\"availableTransforms\":\"\",\"cleanupHtml\":\"1\",\"purifyHtml\":\"1\",\"columnType\":\"text\"}', '2016-06-14 15:58:46', '2016-06-14 15:58:46', 'cff0b2c5-b8d0-473a-a8ad-4caee14162b5'),
 ('57', '10', 'Team Member Contact Methods', 'teamMemberContactMethods', 'global', '', '0', 'Matrix', '{\"maxBlocks\":\"1\"}', '2016-06-14 16:00:09', '2016-07-05 19:10:28', 'a8b7dd27-00bf-4a89-92ac-536ead9cc3be'),
 ('58', NULL, 'Email', 'email', 'matrixBlockType:14', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-14 16:00:09', '2016-07-05 19:10:28', 'cbac9e89-095b-4914-a889-9cdc7f248825'),
 ('59', NULL, 'Linkedin', 'linkedin', 'matrixBlockType:14', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-14 16:00:09', '2016-07-05 19:10:28', '81b306bd-70f7-415b-9e60-6acafe771243'),
 ('61', '11', 'Company Bio', 'companyBio', 'global', '', '0', 'RichText', '{\"configFile\":\"\",\"availableAssetSources\":\"\",\"availableTransforms\":\"\",\"cleanupHtml\":\"1\",\"purifyHtml\":\"1\",\"columnType\":\"text\"}', '2016-06-14 16:09:17', '2016-06-14 16:09:17', '9d28ba06-9ec1-44a7-8a4f-eb1b01683606'),
 ('62', '11', 'Company Contact Methods', 'companyContactMethods', 'global', '', '0', 'Matrix', '{\"maxBlocks\":null}', '2016-06-14 16:10:17', '2016-06-27 21:51:18', '128b9672-8216-4c3f-b54e-09087a60cf53'),
 ('63', NULL, 'Company Website', 'companyWebsite', 'matrixBlockType:15', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-14 16:10:17', '2016-06-27 21:51:18', '09c313f6-55e7-4339-ae86-e1b4eb0441d3'),
 ('64', NULL, 'Linkedin', 'linkedin', 'matrixBlockType:15', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-14 16:10:29', '2016-06-27 21:51:18', 'cb45e229-1265-4120-95cd-d4467df9451b'),
 ('66', '11', 'Company Logo', 'companyLogo', 'global', '', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":[\"folder:2\"],\"defaultUploadLocationSource\":\"2\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"\",\"limit\":\"1\",\"viewMode\":\"list\",\"selectionLabel\":\"\"}', '2016-06-14 16:12:00', '2016-07-12 21:48:04', '162c8688-fbaf-4622-b7a0-99917366ec66'),
 ('69', '2', 'FeaturedNewsItems', 'featurednewsitems', 'global', '', '0', 'Entries', '{\"sources\":[\"section:8\"],\"limit\":\"2\",\"selectionLabel\":\"Featured News Item\"}', '2016-06-15 19:15:03', '2016-06-16 20:35:39', 'b5f0a0d6-464d-4984-932c-799bfae30b24'),
 ('70', '6', 'Locations', 'locations', 'global', '', '0', 'Matrix', '{\"maxBlocks\":null}', '2016-06-15 19:29:13', '2016-07-06 19:13:44', '2b71a757-cb5f-4f5f-aede-f0295996b76f'),
 ('71', NULL, 'City Name', 'cityName', 'matrixBlockType:16', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-15 19:29:13', '2016-07-06 19:13:44', '99252682-46b9-4361-8bff-dc988b49b025'),
 ('72', NULL, 'Address', 'address', 'matrixBlockType:16', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"1\",\"initialRows\":\"4\"}', '2016-06-15 19:29:13', '2016-07-06 19:13:44', 'ac81c6df-0f2f-4d4b-8e12-6bc61819737e'),
 ('73', NULL, 'Telephone', 'telephone', 'matrixBlockType:16', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-15 19:29:13', '2016-07-06 19:13:44', 'a28e0cd6-e925-421a-b89e-eae3e8bed991'),
 ('74', NULL, 'Fax', 'fax', 'matrixBlockType:16', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-15 19:29:13', '2016-07-06 19:13:44', 'a5abbe99-8942-4ceb-8136-5458431dd153'),
 ('75', NULL, 'Contact Line', 'contactLine', 'matrixBlockType:16', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-15 19:29:13', '2016-07-06 19:13:44', 'ced636a5-6d7e-4ee1-8a68-78353152bff9'),
 ('76', NULL, 'Email', 'email', 'matrixBlockType:16', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-15 19:29:13', '2016-07-06 19:13:44', '48b5caae-148e-4e1b-b53d-6e84a94a2e44'),
 ('77', '5', 'Footer Link', 'footerLink', 'global', '', '0', 'Matrix', '{\"maxBlocks\":null}', '2016-06-15 20:22:25', '2016-06-15 20:22:25', '16c6f04e-d0ee-4a21-bf03-e0a5f1e21b88'),
 ('78', NULL, 'Display Link', 'displayLink', 'matrixBlockType:17', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-15 20:22:25', '2016-06-15 20:22:25', '641730dd-21c5-4b4f-be9a-9f407399d6dc'),
 ('79', NULL, 'Hyperlink', 'hyperlink', 'matrixBlockType:17', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-15 20:22:25', '2016-06-15 20:22:25', '39882c4b-70af-48bf-9d7b-3ba70061b45e'),
 ('80', '10', 'Team Member Short Description', 'teamMemberShortDescription', 'global', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"200\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-21 19:49:30', '2016-07-12 01:06:22', '7ba3d69e-13c1-47e8-bf53-0c41c23722e1'),
 ('81', '11', 'Company Short Description', 'companyShortDescription', 'global', '', '0', 'RichText', '{\"configFile\":\"\",\"availableAssetSources\":\"\",\"availableTransforms\":\"\",\"cleanupHtml\":\"1\",\"purifyHtml\":\"1\",\"columnType\":\"text\"}', '2016-06-21 19:49:49', '2016-06-21 19:49:49', '8c289527-40fb-4f1d-88da-953b8dedb8a8'),
 ('82', '2', 'Partnerships', 'partnerships', 'global', '', '0', 'Matrix', '{\"maxBlocks\":null}', '2016-06-22 14:37:27', '2016-07-13 15:00:20', '62c27cac-a0b8-4c27-bd59-2ee8d7879b0b'),
 ('83', NULL, 'Partnership Info', 'partnershipInfo', 'matrixBlockType:18', '', '0', 'RichText', '{\"configFile\":\"\",\"availableAssetSources\":\"*\",\"availableTransforms\":\"*\",\"cleanupHtml\":\"1\",\"purifyHtml\":\"1\",\"columnType\":\"text\"}', '2016-06-22 14:37:27', '2016-07-13 15:00:20', '9bde038c-c670-4ae4-92bb-2562216ecbb0'),
 ('86', '12', 'Legal Copy', 'legalCopy', 'global', 'Copy for legal page', '0', 'Matrix', '{\"maxBlocks\":null}', '2016-06-27 16:03:56', '2016-07-13 01:10:54', 'f5d0a3ff-cc6a-4324-ae82-b836a15ff55f'),
 ('87', NULL, 'Legal Header', 'legalHeader', 'matrixBlockType:19', 'Top level header for legal page', '0', 'PlainText', '{\"placeholder\":\"Legal\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-27 16:08:00', '2016-07-13 01:10:54', 'fc0e168a-25be-47f5-a008-06a36ad57c8b'),
 ('93', NULL, 'Position', 'position', 'matrixBlockType:19', '', '0', 'PositionSelect', '{\"options\":[\"left\",\"center\",\"right\",\"full\"]}', '2016-06-27 16:27:09', '2016-07-13 01:10:54', 'aa1d8c7b-7feb-4ed8-80d3-96b3fb4801d2'),
 ('94', NULL, 'Subheader', 'subheader', 'matrixBlockType:22', '', '0', 'PlainText', '{\"placeholder\":\"Lorem Ipsum\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-27 16:55:41', '2016-07-13 01:10:54', '0ef4f105-2db3-44a6-a412-5f1e0d7b1ee3'),
 ('95', NULL, 'Legal Copy', 'legalCopy', 'matrixBlockType:22', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-27 16:55:41', '2016-07-13 01:10:54', '28e05a1f-930b-4261-85d4-13260eae454f'),
 ('96', NULL, 'Position', 'position', 'matrixBlockType:22', '', '0', 'PositionSelect', '{\"options\":[\"left\",\"center\",\"right\",\"full\"]}', '2016-06-27 16:55:41', '2016-07-13 01:10:54', 'b5dbf1c4-35f0-421d-b304-069f84410678'),
 ('97', NULL, 'Link Copy', 'linkCopy', 'matrixBlockType:23', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-27 16:55:41', '2016-07-13 01:10:54', '97add91e-6062-46c8-bf6a-d9e5b67a6922'),
 ('98', NULL, 'Link Position', 'linkPosition', 'matrixBlockType:23', '', '0', 'PositionSelect', '{\"options\":[\"left\",\"center\",\"right\",\"full\"]}', '2016-06-27 16:55:41', '2016-07-13 01:10:54', '8a708bdd-a93a-49c9-97ec-f45df4e4e964'),
 ('100', NULL, 'Phone', 'phone', 'matrixBlockType:14', '', '0', 'PlainText', '{\"placeholder\":\"(123) 456-7890\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-27 21:54:08', '2016-07-05 19:10:28', 'bb0d071f-6f62-456a-a1b9-0ca4d8fb7d95'),
 ('101', NULL, 'City Image', 'cityImage', 'matrixBlockType:16', '', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"3\",\"viewMode\":\"large\",\"selectionLabel\":\"\"}', '2016-06-27 22:05:13', '2016-07-06 19:13:44', '42bafe5b-758e-4390-a40f-2c4d65860385'),
 ('102', NULL, 'Email Copy', 'emailCopy', 'matrixBlockType:16', 'Copy for email link', '0', 'PlainText', '{\"placeholder\":\"Let\'s talk\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-27 22:09:47', '2016-07-06 19:13:44', '1d8a95ca-b4f4-4bb1-acec-f12780f3c2ab'),
 ('103', '11', 'Company Tags', 'companyTags', 'global', 'Focus area of company', '0', 'Tags', '{\"source\":\"taggroup:4\",\"selectionLabel\":\"\"}', '2016-06-28 15:56:41', '2016-06-28 15:57:50', '9b0b549e-796d-4440-96e7-06e846f46e53'),
 ('104', '10', 'Team Tags', 'teamTags', 'global', 'Board responsibility tags', '0', 'Entries', '{\"sources\":[\"section:13\"],\"limit\":\"\",\"selectionLabel\":\"\"}', '2016-06-28 16:25:51', '2016-07-13 00:35:55', 'f09131c7-534e-49bd-a5e6-bdd0262cc6de'),
 ('105', '5', 'Footer Image', 'footerImage', 'global', 'Texture for left hand side of footer', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"1\",\"viewMode\":\"large\",\"selectionLabel\":\"\"}', '2016-06-29 21:41:56', '2016-06-29 21:41:56', '9cef73ff-abc9-43b0-978b-5b673658bd13'),
 ('106', '5', 'Footer Copy', 'footerCopy', 'global', 'Copy for left hand side of footer', '0', 'RichText', '{\"configFile\":\"\",\"availableAssetSources\":\"*\",\"availableTransforms\":\"*\",\"cleanupHtml\":\"1\",\"purifyHtml\":\"\",\"columnType\":\"text\"}', '2016-06-29 21:51:10', '2016-06-29 21:52:11', '36d8a885-2adf-4b85-b903-20edb2071aa6'),
 ('107', NULL, 'Trajectory Body', 'trajectoryBody', 'matrixBlockType:2', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"200\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-06-29 22:36:33', '2016-07-13 15:00:45', '3fa862a0-d178-4ee3-b5e2-b4e277978c96'),
 ('109', '10', 'Team Member Position', 'teamMemberPosition', 'global', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-07-01 20:00:34', '2016-07-01 20:00:34', '83d807fc-0c29-4f77-abb3-f00e76149d02'),
 ('110', '10', 'Team Member Expertise', 'teamMemberExpertise', 'global', '', '0', 'Tags', '{\"source\":\"taggroup:4\",\"selectionLabel\":\"\"}', '2016-07-05 21:14:01', '2016-07-13 00:36:22', '6ae084c5-eefc-49ca-bfd6-3c3b5960074c'),
 ('111', NULL, 'Location Latitude', 'locationLatitude', 'matrixBlockType:16', 'Latitude used for marker on Google Maps', '0', 'Number', '{\"min\":\"-180\",\"max\":\"180\",\"decimals\":\"5\"}', '2016-07-06 19:13:45', '2016-07-06 19:13:45', 'ac0173c0-0e64-41cb-ad0f-79f231e70aee'),
 ('112', NULL, 'Location Longitude', 'locationLongitude', 'matrixBlockType:16', 'Longitude used for marker on Google Maps', '0', 'Number', '{\"min\":\"-180\",\"max\":\"180\",\"decimals\":\"5\"}', '2016-07-06 19:13:45', '2016-07-06 19:13:45', '685b3bb5-0f7c-4fa5-a1f2-97d690811ec1'),
 ('113', '13', 'Press Materials', 'pressMaterials', 'global', '', '0', 'Matrix', '{\"maxBlocks\":null}', '2016-07-06 21:40:26', '2016-07-14 20:29:42', '96cd69e6-9030-4460-8c60-aeb88ef835bf'),
 ('114', NULL, 'Press Description', 'pressDescription', 'matrixBlockType:24', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-07-06 21:40:27', '2016-07-14 20:29:42', '6b22e9f5-3ce9-45f4-80d7-c4e29b059f7d'),
 ('115', NULL, 'Press Link', 'pressLink', 'matrixBlockType:24', '', '0', 'RichText', '{\"configFile\":\"\",\"availableAssetSources\":\"*\",\"availableTransforms\":\"*\",\"cleanupHtml\":\"1\",\"purifyHtml\":\"\",\"columnType\":\"text\"}', '2016-07-06 21:40:27', '2016-07-14 20:29:42', 'ccf4de49-28ab-40e9-b171-0fcad325e894'),
 ('116', NULL, 'Logo Options', 'logoOptions', 'matrixBlockType:25', '', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":[\"folder:2\"],\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"2\",\"viewMode\":\"large\",\"selectionLabel\":\"\"}', '2016-07-06 21:40:27', '2016-07-14 20:29:42', '4713a660-22b5-4d77-a8ee-66ab9e1733cb'),
 ('117', NULL, 'Headshot Bio Names', 'headshotBioNames', 'matrixBlockType:26', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"50\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-07-06 21:40:27', '2016-07-14 20:29:42', 'e61a1e59-700e-45dc-bee3-588bcfb48333'),
 ('119', NULL, 'Press Header', 'pressHeader', 'matrixBlockType:24', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-07-06 21:47:22', '2016-07-14 20:29:42', '55fd8196-9c04-4af4-93f6-89f42b56bd36'),
 ('120', NULL, 'Brand Assets Header', 'brandAssetsHeader', 'matrixBlockType:25', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-07-06 21:47:45', '2016-07-14 20:29:42', '474a0cce-39be-46c1-83ad-670e19ac9b3d'),
 ('121', NULL, 'Press Team Header', 'pressTeamHeader', 'matrixBlockType:26', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-07-06 21:48:02', '2016-07-14 20:29:42', '73a60589-fcca-4f96-8c06-2fd3e6ace286'),
 ('122', NULL, 'Press News Header', 'pressNewsHeader', 'matrixBlockType:27', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-07-06 21:49:29', '2016-07-14 20:29:42', '445b7b1e-cc6c-44f8-a6a3-52d28c9a817e'),
 ('123', NULL, 'Headshot and Bio', 'headshotAndBio', 'matrixBlockType:26', 'A zip file of the user bio pdf and headshot', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"compressed\"],\"limit\":\"\",\"viewMode\":\"list\",\"selectionLabel\":\"\"}', '2016-07-06 21:56:18', '2016-07-14 20:29:42', 'a8ae7dfe-8049-4d18-9021-cd5f11d841e7'),
 ('124', NULL, 'Team Image', 'teamImage', 'matrixBlockType:12', 'Background asset for team header', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"..\\/assets\\/images\\/site\\/\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"1\",\"viewMode\":\"large\",\"selectionLabel\":\"\"}', '2016-07-11 15:13:21', '2016-07-14 16:36:07', '1b08092a-2ea2-4ce1-abb3-df9fc41d936e'),
 ('125', NULL, 'Expertise Image', 'expertiseImage', 'matrixBlockType:13', 'Background header image for expertise sections', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"1\",\"viewMode\":\"list\",\"selectionLabel\":\"\"}', '2016-07-11 16:21:04', '2016-07-13 16:41:42', '36817b39-ecf8-41de-a39e-f77b4e79dad5'),
 ('126', '14', 'Global Header Image', 'globalHeaderImage', 'global', '', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"1\",\"viewMode\":\"large\",\"selectionLabel\":\"\"}', '2016-07-11 16:26:45', '2016-07-13 17:09:16', 'bcebafe7-4123-4dd9-a5ae-742da6f7e0b2'),
 ('128', '12', 'Header Image', 'headerImage', 'global', 'Header image for legal page', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"1\",\"viewMode\":\"large\",\"selectionLabel\":\"\"}', '2016-07-11 19:18:42', '2016-07-11 19:18:42', '1364f955-0244-4dd1-a60e-625f31fb3785'),
 ('129', '10', 'Member Header Image', 'memberHeaderImage', 'global', '', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"1\",\"viewMode\":\"large\",\"selectionLabel\":\"\"}', '2016-07-11 19:20:43', '2016-07-11 19:20:43', '3bf00f8f-1aae-42d7-a97b-d42d380da284'),
 ('130', '11', 'Company Header Image', 'companyHeaderImage', 'global', '', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"1\",\"viewMode\":\"large\",\"selectionLabel\":\"\"}', '2016-07-11 19:26:17', '2016-07-11 19:26:17', '28b37f54-ff03-486d-8d78-9cd536eb94eb'),
 ('131', '9', 'News Header Image', 'newsHeaderImage', 'global', '', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"1\",\"viewMode\":\"list\",\"selectionLabel\":\"\"}', '2016-07-11 19:27:28', '2016-07-11 19:27:28', 'ce0d69f3-524f-482d-a77c-99b33e85a617'),
 ('132', '13', 'Press Header Image', 'pressHeaderImage', 'global', '', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"1\",\"viewMode\":\"list\",\"selectionLabel\":\"\"}', '2016-07-11 19:33:02', '2016-07-11 19:33:02', '9b3b518b-862f-4bae-bbf9-e0aa8094d9f3'),
 ('133', '11', 'Header Logo', 'headerLogo', 'global', '', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"1\",\"viewMode\":\"large\",\"selectionLabel\":\"\"}', '2016-07-11 20:41:44', '2016-07-11 20:41:44', '23b26299-2e00-4e34-9708-3b69f081c65e'),
 ('137', NULL, 'Header', 'header', 'matrixBlockType:29', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"50\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-07-13 00:51:52', '2016-07-13 00:53:25', '927b7fac-df9f-44f7-83a7-edb19b845df2'),
 ('140', '2', 'Trajectory Section Title', 'trajectorySectionTitle', 'global', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"255\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-07-13 15:01:46', '2016-07-13 15:01:46', 'd13fe5b4-0001-45dd-b78f-bf21f5a06820');
INSERT INTO `craft_fields` (`id`, `groupId`, `name`, `handle`, `context`, `instructions`, `translatable`, `type`, `settings`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('141', '2', 'Partnership Section Title', 'partnershipSectionTitle', 'global', '', '0', 'PlainText', '{\"placeholder\":\"\",\"maxLength\":\"255\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-07-13 15:02:08', '2016-07-13 15:02:08', '725ef90d-b0b2-4834-b7b7-61ebe24e67cd'),
 ('142', NULL, 'Expertise Link', 'expertiseLink', 'matrixBlockType:13', 'Link out to the expertise team', '0', 'PlainText', '{\"placeholder\":\"Meet the team\",\"maxLength\":\"50\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-07-13 16:41:42', '2016-07-13 16:41:42', '9c5c80e6-6a43-4068-be10-cac043517a54'),
 ('143', '15', 'Homepage Logo Image', 'homepageLogoImage', 'global', '', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"1\",\"viewMode\":\"list\",\"selectionLabel\":\"\"}', '2016-07-13 17:09:57', '2016-07-13 17:09:57', 'ef7aef47-2d5c-4591-b2df-a2bec4d3932e'),
 ('144', NULL, 'Team Link', 'teamLink', 'matrixBlockType:12', 'Link copy that will appear under portfolio description', '0', 'PlainText', '{\"placeholder\":\"See the portfolio\",\"maxLength\":\"50\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-07-14 16:33:59', '2016-07-14 16:36:07', 'bc253155-d7dc-4eb6-994a-78411f286fc5'),
 ('145', NULL, 'Press News Link', 'pressNewsLink', 'matrixBlockType:27', 'Link to news page copy', '0', 'RichText', '{\"configFile\":\"\",\"availableAssetSources\":\"\",\"availableTransforms\":\"\",\"cleanupHtml\":\"1\",\"purifyHtml\":\"\",\"columnType\":\"text\"}', '2016-07-14 20:29:42', '2016-07-14 20:29:42', 'ff1b0b61-2e59-4377-acc7-62932e75f444'),
 ('146', '9', 'Twitter Short Description', 'twitterShortDescription', 'global', 'Add a Twitter description that is shorter than 115 characters', '0', 'PlainText', '{\"placeholder\":\"Short description (max 115 characters)\",\"maxLength\":\"115\",\"multiline\":\"\",\"initialRows\":\"4\"}', '2016-07-15 16:24:11', '2016-07-15 16:24:11', 'a3c3d9a9-c33d-4b66-9952-65c62e90ee74'),
 ('147', '16', 'Header Background', 'headerBackground', 'global', 'Background image for the header on mobile', '0', 'Assets', '{\"useSingleFolder\":\"\",\"sources\":\"*\",\"defaultUploadLocationSource\":\"1\",\"defaultUploadLocationSubpath\":\"\",\"singleUploadLocationSource\":\"1\",\"singleUploadLocationSubpath\":\"\",\"restrictFiles\":\"1\",\"allowedKinds\":[\"image\"],\"limit\":\"1\",\"viewMode\":\"list\",\"selectionLabel\":\"\"}', '2016-07-15 17:01:33', '2016-07-15 17:07:28', '10017404-04b7-4936-b97d-18e5cf3f319d');



DROP TABLE IF EXISTS `craft_globalsets`;


--
-- Schema for table `craft_globalsets`
--
CREATE TABLE `craft_globalsets` (
  `id` int(11) NOT NULL,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `handle` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `fieldLayoutId` int(10) DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_globalsets_name_unq_idx` (`name`),
  UNIQUE KEY `craft_globalsets_handle_unq_idx` (`handle`),
  KEY `craft_globalsets_fieldLayoutId_fk` (`fieldLayoutId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_globalsets`
--

INSERT INTO `craft_globalsets` (`id`, `name`, `handle`, `fieldLayoutId`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('4', 'Footer', 'footer', '259', '2016-06-10 18:12:53', '2016-07-13 01:12:46', '59f4a423-8399-46ec-88c6-3849613f83c8'),
 ('111', 'Header Logo', 'headerLogo', '282', '2016-07-11 20:41:13', '2016-07-15 17:08:20', 'ddc870cb-17e9-45de-868d-b4b95bdd1e24'),
 ('379', 'Homepage Logo', 'homepageLogo', '265', '2016-07-13 17:09:06', '2016-07-13 17:10:10', '6bedfcdb-5cff-47e0-9655-247c1c1dbf0c'),
 ('389', 'Header Background', 'headerBackground', '281', '2016-07-15 17:08:03', '2016-07-15 17:08:03', 'a12af75a-6388-43a4-93d9-a68c183fbc7d');



DROP TABLE IF EXISTS `craft_info`;


--
-- Schema for table `craft_info`
--
CREATE TABLE `craft_info` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `version` varchar(15) COLLATE utf8_unicode_ci NOT NULL,
  `build` int(11) unsigned NOT NULL,
  `schemaVersion` varchar(15) COLLATE utf8_unicode_ci NOT NULL,
  `releaseDate` datetime NOT NULL,
  `edition` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `siteName` varchar(100) COLLATE utf8_unicode_ci NOT NULL,
  `siteUrl` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `timezone` varchar(30) COLLATE utf8_unicode_ci DEFAULT NULL,
  `on` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `maintenance` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `track` varchar(40) COLLATE utf8_unicode_ci NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=2 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_info`
--

INSERT INTO `craft_info` (`id`, `version`, `build`, `schemaVersion`, `releaseDate`, `edition`, `siteName`, `siteUrl`, `timezone`, `on`, `maintenance`, `track`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '2.6', '2791', '2.6.5', '2016-06-07 21:19:08', '1', 'Apple Tree Partners', 'http://atp.local', 'America/New_York', '1', '0', 'stable', '2016-06-10 14:33:28', '2016-07-14 14:27:01', '6c96c8bd-6510-42ea-87ad-a508964f13d4');



DROP TABLE IF EXISTS `craft_locales`;


--
-- Schema for table `craft_locales`
--
CREATE TABLE `craft_locales` (
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `sortOrder` smallint(6) unsigned DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`locale`),
  KEY `craft_locales_sortOrder_idx` (`sortOrder`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_locales`
--

INSERT INTO `craft_locales` (`locale`, `sortOrder`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('en_us', '1', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '38738a26-7f0e-4bcd-a665-0e934e11cfc1');



DROP TABLE IF EXISTS `craft_matrixblocks`;


--
-- Schema for table `craft_matrixblocks`
--
CREATE TABLE `craft_matrixblocks` (
  `id` int(11) NOT NULL,
  `ownerId` int(11) NOT NULL,
  `fieldId` int(11) NOT NULL,
  `typeId` int(11) DEFAULT NULL,
  `sortOrder` smallint(6) unsigned DEFAULT NULL,
  `ownerLocale` char(12) COLLATE utf8_unicode_ci DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  KEY `craft_matrixblocks_ownerId_idx` (`ownerId`),
  KEY `craft_matrixblocks_fieldId_idx` (`fieldId`),
  KEY `craft_matrixblocks_typeId_idx` (`typeId`),
  KEY `craft_matrixblocks_sortOrder_idx` (`sortOrder`),
  KEY `craft_matrixblocks_ownerLocale_fk` (`ownerLocale`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_matrixblocks`
--

INSERT INTO `craft_matrixblocks` (`id`, `ownerId`, `fieldId`, `typeId`, `sortOrder`, `ownerLocale`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('15', '14', '22', '4', '1', NULL, '2016-06-14 15:37:22', '2016-07-15 16:27:09', 'a7025c82-a230-432a-99ab-bb9846d855ce'),
 ('16', '14', '22', '6', '2', NULL, '2016-06-14 15:37:22', '2016-07-15 16:27:09', '1cbba464-3bc3-42a4-8bb1-989755706203'),
 ('17', '14', '22', '4', '3', NULL, '2016-06-14 15:37:22', '2016-07-15 16:27:09', 'd32d480e-3b31-468a-b9a2-3e209db37324'),
 ('18', '14', '22', '6', '4', NULL, '2016-06-14 15:37:22', '2016-07-15 16:27:09', 'd9e9083d-7aa3-4966-9303-267521a0b652'),
 ('19', '13', '50', '13', '1', NULL, '2016-06-14 15:52:39', '2016-07-13 21:16:21', '536d5e9c-819c-4e82-a1a7-c8793e9ad561'),
 ('20', '13', '50', '13', '2', NULL, '2016-06-14 15:52:39', '2016-07-13 21:16:21', '2e9b380a-2fae-4440-b3f6-85f762656c17'),
 ('21', '13', '50', '13', '3', NULL, '2016-06-14 15:52:39', '2016-07-13 21:16:21', '30e9d424-9bf0-4133-8a5c-8be34afe6015'),
 ('22', '13', '50', '13', '4', NULL, '2016-06-14 15:52:39', '2016-07-13 21:16:21', '88c35694-c626-4b56-b23c-67210038eeec'),
 ('23', '12', '47', '12', '4', NULL, '2016-06-14 16:06:35', '2016-07-14 16:36:40', 'bf26c3f1-58d1-407f-a392-8aada0a66c20'),
 ('24', '12', '47', '12', '1', NULL, '2016-06-14 16:06:35', '2016-07-14 16:36:40', 'c1af253c-d765-4604-9093-5b0a38dd2271'),
 ('25', '12', '47', '12', '2', NULL, '2016-06-14 16:06:35', '2016-07-14 16:36:40', '6622ac70-df94-47d6-a115-b4ce06cbdb50'),
 ('26', '12', '47', '12', '3', NULL, '2016-06-14 16:06:35', '2016-07-14 16:36:40', 'a393727f-c781-46a3-b68c-6534617554bb'),
 ('28', '27', '62', '15', '1', NULL, '2016-06-14 16:14:38', '2016-07-13 16:33:56', '49018dd1-2877-488c-9694-d563378b877d'),
 ('36', '9', '5', '1', '2', NULL, '2016-06-15 18:44:39', '2016-07-13 21:11:57', '0ed8024e-f23d-436d-a3f5-972a0abf8099'),
 ('37', '9', '5', '1', '3', NULL, '2016-06-15 19:06:53', '2016-07-13 21:11:57', '76a9053b-7436-4468-b0ce-3147ca172439'),
 ('38', '9', '5', '1', '4', NULL, '2016-06-15 19:06:53', '2016-07-13 21:11:57', '55fbfaa4-babf-49e6-90c6-2b465d4e33cb'),
 ('39', '9', '9', '2', '1', NULL, '2016-06-15 19:06:53', '2016-07-13 21:11:57', '07db3b69-fffa-49e6-96e8-2f528f6c14e5'),
 ('40', '9', '9', '2', '3', NULL, '2016-06-15 19:06:53', '2016-07-13 21:11:57', '07be989c-5f1a-4ebf-bc90-2840a78ef35a'),
 ('41', '10', '70', '16', '1', NULL, '2016-06-15 19:36:44', '2016-07-13 21:20:34', '74fb52a8-c454-40d8-8486-f888d44d7657'),
 ('42', '10', '70', '16', '2', NULL, '2016-06-15 20:03:58', '2016-07-13 21:20:34', 'd8781b2c-d287-4707-be3a-291e7b36a5aa'),
 ('43', '10', '70', '16', '3', NULL, '2016-06-15 20:03:58', '2016-07-13 21:20:34', '4cf8ac2e-9082-4e27-84c6-d2988e31285e'),
 ('44', '4', '77', '17', '1', NULL, '2016-06-15 20:23:24', '2016-07-13 18:21:00', 'e5dcf516-4924-409b-8e9b-d873af242741'),
 ('46', '4', '77', '17', '2', NULL, '2016-06-15 20:24:14', '2016-07-13 18:21:00', '0e282e3c-3ffa-4c5d-b6cb-001b8c0f4929'),
 ('47', '4', '77', '17', '3', NULL, '2016-06-15 20:24:14', '2016-07-13 18:21:00', '1fc39bd5-720f-4544-b4cf-1256668b6be8'),
 ('48', '4', '70', '16', '1', NULL, '2016-06-15 20:30:16', '2016-07-13 18:21:00', '82a62212-5ced-4981-a1dd-00d62453fd4a'),
 ('49', '4', '70', '16', '2', NULL, '2016-06-15 20:30:16', '2016-07-13 18:21:00', 'e593493e-ed40-4313-aed5-bf01c8d5908c'),
 ('50', '4', '70', '16', '3', NULL, '2016-06-15 20:30:16', '2016-07-13 18:21:00', '71255f80-454d-4f45-a4c9-18bc9ce95c2c'),
 ('59', '52', '22', '4', '1', NULL, '2016-06-20 19:49:21', '2016-07-15 16:27:02', '51a3acf7-bd3b-4999-ac07-fd171829c45a'),
 ('60', '52', '22', '6', '2', NULL, '2016-06-20 19:49:21', '2016-07-15 16:27:02', 'd6c7047a-4c49-4233-8b8b-1a5773bddf54'),
 ('62', '9', '82', '18', '1', NULL, '2016-06-22 14:39:26', '2016-07-13 21:11:57', 'bf04f108-c16f-4c87-96d2-c6d381fc16f0'),
 ('63', '9', '82', '18', '2', NULL, '2016-06-22 14:39:26', '2016-07-13 21:11:57', 'b2b3cddb-8089-42ab-adba-8df9900e337e'),
 ('64', '9', '82', '18', '3', NULL, '2016-06-22 14:39:26', '2016-07-13 21:11:57', '8babd3fd-79cb-4701-b9ca-eec4fdd277b1'),
 ('67', '66', '86', '19', '1', NULL, '2016-06-27 16:58:18', '2016-07-14 19:37:10', '55f13c75-0551-4180-bed2-d66216fea4e6'),
 ('68', '66', '86', '22', '2', NULL, '2016-06-27 16:58:18', '2016-07-14 19:37:10', '811c2e03-8f3e-4823-885c-fbc2fdab6a76'),
 ('69', '66', '86', '23', '14', NULL, '2016-06-27 16:58:18', '2016-07-14 19:37:10', '06f951cb-ba75-4f2c-a4a2-83e41bfbfa45'),
 ('74', '9', '9', '2', '2', NULL, '2016-06-28 20:56:54', '2016-07-13 21:11:57', '3a5cbd95-19a1-4a27-a306-a44c1142b654'),
 ('76', '75', '113', '24', '1', NULL, '2016-07-06 21:49:07', '2016-07-14 20:30:23', '5e2f7109-976d-409a-9587-83f68c3b56ec'),
 ('77', '75', '113', '25', '2', NULL, '2016-07-06 21:49:07', '2016-07-14 20:30:23', 'dd78796d-a357-4fb5-ba3a-ef0d99e277f1'),
 ('78', '75', '113', '26', '3', NULL, '2016-07-06 21:49:08', '2016-07-14 20:30:23', 'beaa277a-4c2c-4cd0-89d4-9e63cd759824'),
 ('79', '75', '113', '27', '4', NULL, '2016-07-06 22:06:29', '2016-07-14 20:30:23', '7f183abd-1102-4ca0-a1bf-8e2eb8e4248b'),
 ('201', '200', '62', '15', '1', NULL, '2016-07-11 21:57:13', '2016-07-13 16:33:35', 'f5b77b43-80e7-4818-a061-be087c837c75'),
 ('205', '204', '62', '15', '1', NULL, '2016-07-11 21:58:40', '2016-07-13 16:33:16', '8500ef74-f016-485d-9920-58dae1130c5d'),
 ('230', '229', '62', '15', '1', NULL, '2016-07-11 22:03:47', '2016-07-13 21:14:28', '8f419f02-7f41-40a6-9cb3-d71c1cb13c56'),
 ('240', '239', '62', '15', '1', NULL, '2016-07-11 22:21:39', '2016-07-13 16:32:34', 'c885a76c-5de7-40c5-9baa-91e3778c91bc'),
 ('243', '242', '62', '15', '1', NULL, '2016-07-11 22:29:19', '2016-07-13 17:19:52', '38b4e71b-0d4d-4fbd-9076-68c39d6b7b6b'),
 ('245', '244', '62', '15', '1', NULL, '2016-07-11 22:35:11', '2016-07-13 16:31:59', '2f89bb09-837a-4cf9-ad25-012e313e2467'),
 ('247', '246', '62', '15', '1', NULL, '2016-07-11 22:36:11', '2016-07-13 21:17:31', '1a485e2a-f586-499f-bf19-14d4b79d9462'),
 ('249', '248', '62', '15', '1', NULL, '2016-07-11 22:37:48', '2016-07-13 16:31:14', 'fae43fb1-d112-4993-a102-6481f2a9e13d'),
 ('268', '250', '62', '15', '1', NULL, '2016-07-11 23:41:01', '2016-07-13 16:30:57', '9cab33ce-8edd-420d-9e46-a0271a7d9051'),
 ('276', '275', '62', '15', '1', NULL, '2016-07-11 23:47:20', '2016-07-13 16:30:36', 'db8673df-a96e-4656-8770-6115ce47685f'),
 ('282', '281', '62', '15', '1', NULL, '2016-07-12 00:07:33', '2016-07-13 16:30:20', '61d17c93-0061-491b-bebf-2e14f8e7134b'),
 ('285', '284', '62', '15', '1', NULL, '2016-07-12 00:09:32', '2016-07-13 16:29:54', '48d12136-606c-41cd-aefb-e770393a5b3c'),
 ('288', '287', '62', '15', '1', NULL, '2016-07-12 00:15:28', '2016-07-13 16:38:44', '3f3fd613-5d75-43a6-b8ff-09d05dceeb93'),
 ('291', '290', '62', '15', '1', NULL, '2016-07-12 00:17:23', '2016-07-13 16:29:12', '9a0aa0cb-7a31-488e-bc87-1cc036743fc3'),
 ('294', '293', '62', '15', '1', NULL, '2016-07-12 00:19:59', '2016-07-13 16:28:42', 'fe63fb12-3c77-42bf-aca5-d69995b61cc4'),
 ('297', '296', '62', '15', '1', NULL, '2016-07-12 00:23:01', '2016-07-13 21:08:08', '96ee7d4b-6c32-4aad-8a03-cad6b594faf3'),
 ('299', '298', '62', '15', '1', NULL, '2016-07-12 00:24:36', '2016-07-13 16:27:51', '7ceef2ef-e2f8-4884-9f53-38a03fff35ca'),
 ('300', '66', '86', '22', '3', NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', '2b602c55-360b-47b5-a28f-dd4fabefe8ba'),
 ('301', '66', '86', '22', '4', NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', '97c33a96-1d6f-4573-89ae-e2e703bde33f'),
 ('302', '66', '86', '22', '5', NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', '6ccdb556-9d01-4633-8ea5-7a095be7d1ad'),
 ('303', '66', '86', '22', '6', NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'd0407e67-9238-4e85-8207-d9e2fbefdafa'),
 ('304', '66', '86', '22', '7', NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'a3261bbd-a3f0-442c-8129-7575bfbf9329'),
 ('305', '66', '86', '22', '8', NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'e524fe4a-ba4f-4158-a981-e50343b5af65'),
 ('306', '66', '86', '22', '9', NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'd2630098-8c09-497f-8582-7168409f3be7'),
 ('307', '66', '86', '22', '10', NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', '0b470505-dd4a-4337-88c4-a8a8b1c3f0b4'),
 ('308', '66', '86', '22', '11', NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'f5a4c2e5-26ab-40b0-a145-eb8a65a2d8b9'),
 ('309', '66', '86', '22', '12', NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', '364bd948-c950-41da-9930-8c205b4231d3'),
 ('310', '66', '86', '22', '13', NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', '1cbb8317-4214-41a5-8127-eb2fd5afef33'),
 ('313', '312', '22', '6', '1', NULL, '2016-07-12 04:45:30', '2016-07-15 16:26:54', '73816f78-ea53-47e3-80e1-1a802d58bb5c'),
 ('315', '314', '22', '6', '1', NULL, '2016-07-12 04:47:22', '2016-07-15 16:26:47', '44770017-dbed-4ddb-8ca8-460e5e6dbeb8'),
 ('316', '314', '22', '4', '2', NULL, '2016-07-12 04:47:22', '2016-07-15 16:26:47', '8d044cd9-bc0d-46f4-bb12-8c4f8e401596'),
 ('317', '314', '22', '6', '3', NULL, '2016-07-12 04:47:22', '2016-07-15 16:26:47', 'a1fab10f-b2c0-498b-b5e8-d11d60f28ae4'),
 ('320', '319', '22', '6', '1', NULL, '2016-07-12 04:50:11', '2016-07-15 16:25:52', '7b0cbd12-e9f2-419e-a8a9-6618a2eb2de0'),
 ('321', '319', '22', '4', '2', NULL, '2016-07-12 04:50:11', '2016-07-15 16:25:52', '5964a030-a322-45f7-b774-e0f9ab2d209f'),
 ('322', '319', '22', '6', '3', NULL, '2016-07-12 04:50:11', '2016-07-15 16:25:52', '67fd1616-159e-445a-ad31-5a8671f8430a'),
 ('323', '319', '22', '4', '4', NULL, '2016-07-12 04:50:11', '2016-07-15 16:25:52', 'd2d2ea10-4740-4d77-bee7-8a1782cee27c'),
 ('324', '319', '22', '6', '5', NULL, '2016-07-12 04:50:11', '2016-07-15 16:25:52', '38727aee-8838-4e8a-9668-dc0032264f95'),
 ('328', '327', '22', '6', '1', NULL, '2016-07-12 04:52:37', '2016-07-15 16:25:44', 'dcbe77b4-ed51-4979-bf59-8ec66b7e7133'),
 ('330', '329', '22', '6', '1', NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', '8ec044d0-92d9-47de-9a28-73f69bacbc8d'),
 ('331', '329', '22', '4', '2', NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', 'c978250c-8851-4b72-b1a8-12f39a60586b'),
 ('332', '329', '22', '6', '3', NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', '5e8df8b9-31f7-4fc9-a880-01a314f4863f'),
 ('333', '329', '22', '4', '4', NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', '0b9dfe00-b1d9-495f-8c94-8516e8a1d386'),
 ('334', '329', '22', '6', '5', NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', 'f2b9c0f3-67d0-4d47-b8bf-c947421a2b4c'),
 ('335', '329', '22', '4', '6', NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', '067ca437-d96b-4133-9df8-61ba038058f6'),
 ('336', '329', '22', '6', '7', NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', '4990c5ae-0e7d-4569-a7fd-902d26e00a19'),
 ('339', '338', '22', '6', '1', NULL, '2016-07-12 04:56:51', '2016-07-15 16:25:30', '1b5856f2-4ad6-4fc8-b639-0eee76446464'),
 ('340', '338', '22', '4', '2', NULL, '2016-07-12 04:56:51', '2016-07-15 16:25:30', 'f6beb752-2b34-413b-9d36-fa19b2209108'),
 ('341', '338', '22', '6', '3', NULL, '2016-07-12 04:56:51', '2016-07-15 16:25:30', '3f825091-cc9f-4939-93b3-72ca4949d9a3'),
 ('343', '342', '22', '6', '1', NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'fcb52df8-04b6-464f-b8b0-eac8c2d776e4'),
 ('344', '342', '22', '4', '2', NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', '616d0efc-a781-472c-ad7e-6b19929106cd'),
 ('345', '342', '22', '6', '3', NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'da6cfd6a-dc09-40dd-86b4-e5f831d811c6'),
 ('346', '342', '22', '4', '4', NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'dba0e98b-30ec-49bd-a2ef-f8dfe24697b7'),
 ('347', '342', '22', '6', '5', NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'fe7ad05d-fe6a-41c6-b0ae-bc065b6699e9'),
 ('348', '342', '22', '4', '6', NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'f95774fe-5217-4b76-b9f7-7351059eec99'),
 ('349', '342', '22', '6', '7', NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'e2216db8-4c32-463f-af5d-808a68c5fcc9'),
 ('352', '351', '22', '6', '1', NULL, '2016-07-12 05:01:56', '2016-07-15 16:24:52', '95769617-d6f5-4b8a-9d8f-948df3b9fdcd'),
 ('353', '351', '22', '4', '2', NULL, '2016-07-12 05:01:56', '2016-07-15 16:24:52', '40b66c80-6371-4346-85bd-746baebf0881'),
 ('354', '351', '22', '6', '3', NULL, '2016-07-12 05:01:56', '2016-07-15 16:24:52', '9c4efae1-8d18-43a2-83a8-8750f5815539'),
 ('355', '351', '22', '4', '4', NULL, '2016-07-12 05:01:56', '2016-07-15 16:24:52', 'a60b2526-086c-44c8-a8e4-42406e8ee38d'),
 ('356', '351', '22', '6', '5', NULL, '2016-07-12 05:01:56', '2016-07-15 16:24:52', 'aa893321-94a1-44ef-b10b-ee1e566b0667');
INSERT INTO `craft_matrixblocks` (`id`, `ownerId`, `fieldId`, `typeId`, `sortOrder`, `ownerLocale`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('357', '9', '5', '29', '1', NULL, '2016-07-13 00:53:43', '2016-07-13 21:11:57', 'cdabe1dc-6df5-4c4c-8c84-256e14e9d886');



DROP TABLE IF EXISTS `craft_matrixblocktypes`;


--
-- Schema for table `craft_matrixblocktypes`
--
CREATE TABLE `craft_matrixblocktypes` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `fieldId` int(11) NOT NULL,
  `fieldLayoutId` int(11) DEFAULT NULL,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `handle` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `sortOrder` smallint(6) unsigned DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_matrixblocktypes_name_fieldId_unq_idx` (`name`,`fieldId`),
  UNIQUE KEY `craft_matrixblocktypes_handle_fieldId_unq_idx` (`handle`,`fieldId`),
  KEY `craft_matrixblocktypes_fieldId_fk` (`fieldId`),
  KEY `craft_matrixblocktypes_fieldLayoutId_fk` (`fieldLayoutId`)
) ENGINE=InnoDB AUTO_INCREMENT=30 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_matrixblocktypes`
--

INSERT INTO `craft_matrixblocktypes` (`id`, `fieldId`, `fieldLayoutId`, `name`, `handle`, `sortOrder`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '5', '255', 'Area of Expertise', 'areaOfExpertise', '2', '2016-06-13 16:04:48', '2016-07-13 00:53:25', '97bfa615-8ffc-4b84-b4f9-ceba5b99d3c6'),
 ('2', '9', '261', 'Trajectory', 'trajectory', '1', '2016-06-13 16:14:34', '2016-07-13 15:00:45', '1d13a389-6ab9-4ac9-a3cf-98e1164875bf'),
 ('4', '22', '232', 'New Section', 'newSection', '1', '2016-06-13 19:19:49', '2016-07-12 01:05:12', '0b7ba1de-0f44-47ca-9319-613d1faab278'),
 ('5', '22', '233', 'Heading', 'heading', '2', '2016-06-13 19:19:49', '2016-07-12 01:05:12', '92b12917-cc88-46c7-986f-9aa0591686c9'),
 ('6', '22', '234', 'Text', 'text', '3', '2016-06-13 19:19:49', '2016-07-12 01:05:12', '61aaeb8d-a114-4a6d-9605-ad916b708e70'),
 ('7', '22', '235', 'Pull Quote', 'pullQuote', '4', '2016-06-13 19:19:49', '2016-07-12 01:05:12', '7ea734cb-00cf-44f4-af7d-22b3b0e64d2f'),
 ('8', '22', '236', 'Image', 'image', '5', '2016-06-13 19:19:49', '2016-07-12 01:05:12', '29b4c5eb-0cb4-4ec7-aaec-fee760b930a7'),
 ('9', '22', '237', 'Gallery', 'gallery', '6', '2016-06-13 19:19:49', '2016-07-12 01:05:12', '79980700-09e7-4810-a668-c9a1e3765572'),
 ('10', '22', '238', 'Quote', 'quote', '7', '2016-06-13 19:19:49', '2016-07-12 01:05:12', '782a478f-56d9-4cc9-a2a4-f45759f097a3'),
 ('12', '47', '273', 'Team', 'teamName', '1', '2016-06-13 20:28:48', '2016-07-14 16:36:07', '3d12cf86-3e7f-4818-93a7-78bda25ea332'),
 ('13', '50', '263', 'Area of Expertise', 'areaOfExpertise', '1', '2016-06-13 21:39:05', '2016-07-13 16:41:42', '689dadc6-329d-4085-98f7-58b670fe3baa'),
 ('14', '57', '154', 'Contact Methods', 'contactMethods', '1', '2016-06-14 16:00:09', '2016-07-05 19:10:28', 'cc01eaed-13b6-4c25-96fd-935741d13f66'),
 ('15', '62', '136', 'Contact Methods', 'contactMethods', '1', '2016-06-14 16:10:17', '2016-06-27 21:51:18', '0e04b21f-f517-478f-ba7c-5fc96735f5fc'),
 ('16', '70', '157', 'Locations', 'location', '1', '2016-06-15 19:29:13', '2016-07-06 19:13:45', '0995de11-26dc-4af3-984d-8bdfe7029348'),
 ('17', '77', '96', 'link', 'link', '1', '2016-06-15 20:22:25', '2016-06-15 20:22:25', '5ee2c5a6-41ad-41bc-8930-af66a3530171'),
 ('18', '82', '260', 'Partnership', 'partnership', '1', '2016-06-22 14:37:27', '2016-07-13 15:00:20', 'c43616de-2391-4cef-bef7-099c2567be87'),
 ('19', '86', '256', 'Legal Header', 'legalHeader', '1', '2016-06-27 16:08:00', '2016-07-13 01:10:54', 'a89aefc7-e6a6-4602-8a2f-7733ebcfeb2f'),
 ('22', '86', '257', 'Legal Body', 'legalBody', '2', '2016-06-27 16:55:41', '2016-07-13 01:10:54', '50a4ba03-03cb-423b-8bd8-766eaa4e634b'),
 ('23', '86', '258', 'Legal Link', 'legalLink', '3', '2016-06-27 16:55:41', '2016-07-13 01:10:54', '8cb1513a-a699-4ac0-aa4b-4b330ea76a80'),
 ('24', '113', '274', 'Press Info', 'pressInfo', '1', '2016-07-06 21:40:27', '2016-07-14 20:29:42', 'c6d8f0d7-c5fc-4376-b2ae-b66301feac4e'),
 ('25', '113', '275', 'Brand Assets', 'brandAssets', '2', '2016-07-06 21:40:27', '2016-07-14 20:29:42', '899a51f4-7fe9-44cd-ae3d-82287a7d8648'),
 ('26', '113', '276', 'Press Team', 'pressTeam', '3', '2016-07-06 21:40:27', '2016-07-14 20:29:42', '5ef0eb3b-ab43-4925-97ac-4e1ccc673c78'),
 ('27', '113', '277', 'Press News', 'pressNews', '4', '2016-07-06 21:49:28', '2016-07-14 20:29:42', '4e9b2647-3f88-455e-9bff-95e3dcfb0c8d'),
 ('29', '5', '254', 'Section Title', 'sectionTitle', '1', '2016-07-13 00:51:52', '2016-07-13 00:53:25', '60d694ed-c158-46ed-a3ab-df833398a55c');



DROP TABLE IF EXISTS `craft_matrixcontent_areasofexpertise`;


--
-- Schema for table `craft_matrixcontent_areasofexpertise`
--
CREATE TABLE `craft_matrixcontent_areasofexpertise` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `elementId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `field_areaOfExpertise_areaTitle` text COLLATE utf8_unicode_ci,
  `field_areaOfExpertise_areaDescription` text COLLATE utf8_unicode_ci,
  `field_sectionTitle_header` varchar(50) COLLATE utf8_unicode_ci DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_matrixcontent_areasofexpertise_elementId_locale_unq_idx` (`elementId`,`locale`),
  KEY `craft_matrixcontent_areasofexpertise_locale_fk` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=5 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_matrixcontent_areasofexpertise`
--

INSERT INTO `craft_matrixcontent_areasofexpertise` (`id`, `elementId`, `locale`, `field_areaOfExpertise_areaTitle`, `field_areaOfExpertise_areaDescription`, `field_sectionTitle_header`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '36', 'en_us', 'Therapeutics', 'A little blurb goes here explaining our mission in this vertical and key successes. It should describe why ATP is a leader in this field and what innovation we\'ve pioneered.', NULL, '2016-06-15 18:44:39', '2016-07-13 21:11:57', '7b067b25-4f2b-4492-a3c5-e280f3ca5a16'),
 ('2', '37', 'en_us', 'Medical Devices', 'A little blurb goes here explaining our mission in this vertical and key successes. It should describe why ATP is a leader in this field and what innovation we\'ve pioneered.', NULL, '2016-06-15 19:06:53', '2016-07-13 21:11:57', '2de6f0d4-7a4b-47c2-8214-257d44a8ae0d'),
 ('3', '38', 'en_us', 'Healthcare Services', 'A little blurb goes here explaining our mission in this vertical and key successes. It should describe why ATP is a leader in this field and what innovation we\'ve pioneered.', NULL, '2016-06-15 19:06:53', '2016-07-13 21:11:57', 'a0c029de-18f6-461f-a9f5-6089cb4af89a'),
 ('4', '357', 'en_us', NULL, NULL, 'Areas of Expertise', '2016-07-13 00:53:43', '2016-07-13 21:11:57', '7c72ba6d-7eda-4092-87b5-c5ffcc48a0fc');



DROP TABLE IF EXISTS `craft_matrixcontent_articlebody`;


--
-- Schema for table `craft_matrixcontent_articlebody`
--
CREATE TABLE `craft_matrixcontent_articlebody` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `elementId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `field_newSection_sectionHeading` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `field_heading_heading` varchar(100) COLLATE utf8_unicode_ci DEFAULT NULL,
  `field_text_text` text COLLATE utf8_unicode_ci,
  `field_text_position` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `field_pullQuote_quote` text COLLATE utf8_unicode_ci,
  `field_pullQuote_position` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `field_image_caption` text COLLATE utf8_unicode_ci,
  `field_image_position` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `field_quote_quote` text COLLATE utf8_unicode_ci,
  `field_quote_attribution` text COLLATE utf8_unicode_ci,
  `field_quote_position` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_matrixcontent_articlebody_elementId_locale_unq_idx` (`elementId`,`locale`),
  KEY `craft_matrixcontent_articlebody_locale_fk` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=53 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_matrixcontent_articlebody`
--

INSERT INTO `craft_matrixcontent_articlebody` (`id`, `elementId`, `locale`, `field_newSection_sectionHeading`, `field_heading_heading`, `field_text_text`, `field_text_position`, `field_pullQuote_quote`, `field_pullQuote_position`, `field_image_caption`, `field_image_position`, `field_quote_quote`, `field_quote_attribution`, `field_quote_position`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '15', 'en_us', 'CleanSlate Centers names Gregory C. Marotta President & CEO', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-14 15:37:22', '2016-07-15 16:27:09', 'b4658242-a273-425f-be80-26b2c786f808'),
 ('2', '16', 'en_us', NULL, NULL, '<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate’s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.</p>\r\n\r\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>“I am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,” Mr. Marotta said. “I am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.”</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate’s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate’s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>“CleanSlate has been remarkably successful over the past six years thanks to our dedicated physicians, other clinical professionals and support team, and this is just the beginning,” Dr. Wilson said. “These changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve.”</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-14 15:37:22', '2016-07-15 16:27:09', 'd481ec03-1ca2-4317-93e8-f53daae21495'),
 ('3', '17', 'en_us', 'About CleanSlate Centers', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-14 15:37:22', '2016-07-15 16:27:09', '56326fb7-f621-4f25-b13b-8a8e14f64cbf'),
 ('4', '18', 'en_us', NULL, NULL, '<p>CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices.</p>\r\n\r\n<p>CleanSlate’s proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate’s treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA).</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>In 2014 CleanSlate partnered with Apple Tree Partners, a healthcare focused venture capital fund, to help expand efforts geographically and increase access to care in under-served communities with demonstrated need.</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-14 15:37:22', '2016-07-15 16:27:09', '8797ae68-fae4-4c0f-862d-d6673b8cb2f7'),
 ('5', '59', 'en_us', 'Two more opiate and alcohol treatment centers will be popping up in Massachusetts, as Northampton-based CleanSlate Centers looks to expand in the Bay State and nationally.', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-20 19:49:21', '2016-07-15 16:27:02', '291cdfec-bf5c-4f31-9311-4a175fcf3adc'),
 ('6', '60', 'en_us', NULL, NULL, '<p>CleanSlate Centers announced today that Gregory C. Marotta has been promoted to President and CEO, from his role as Chief Operating Officer that he has held since joining the organization more than a year ago. Mr. Marotta also joined CleanSlate’s Board of Directors. Amanda Wilson, MD, the founder of CleanSlate, remains Chairwoman of the Board and will continue as President and CEO of the CleanSlate Research and Education Foundation. The leadership changes are the culmination of a year-long succession plan established by the CleanSlate Board of Directors and Dr. Wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation.</p>\r\n\r\n<p>Mr. Marotta will be responsible for the overall strategic and daily operational leadership of CleanSlate, with all areas of the organization reporting to him. The Board of Directors chose Mr. Marotta to lead the company because of his knowledge of every aspect of CleanSlate and his expansive business and operational expertise. He has helped build and deploy direct-to-patient provider organizations on a large- scale basis, including leading a network of over 230 healthcare facilities across 20 states for U.S. Healthworks, and in his work as head of outpatient services for Kessler Institute for Rehabilitation.</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>“I am honored by the confidence Dr. Wilson and our Board of Directors have placed in me to lead the CleanSlate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country,” Mr. Marotta said. “I am looking forward to continuing to work closely with everyone in the CleanSlate family, Dr. Wilson and other members of the Board as we move to fulfill our mission of making effective, quality treatment available to everyone facing addition.”</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>The changes will provide Dr. Wilson the ability to singularly focus her energy on mission critical efforts for CleanSlate that are driven by the dynamic addiction treatment landscape. She will dedicate her time, expertise and knowledge to leading CleanSlate’s Board, driving change at the national level regarding the addiction epidemic and will continue CleanSlate’s commitment to thought leadership and making a measurable difference in the lives of the people served by the company.</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-06-20 19:49:21', '2016-07-15 16:27:02', '29e3b0f2-b703-47e6-b8f0-6da136b726f8'),
 ('21', '313', 'en_us', NULL, NULL, '<p>A high-tech version of healthcare is becoming more and more popular. It\'s called TeleMedicine. And in many cases, it helps keep people out of the hospital. Right now, there\'s a big push to cut the rate of people who are re-admitted to the hospital. It not only saves money, but it also lowers the risk for infection and other complication. Plus, it helps keep patients more comfortable.</p>\r\n\r\n<p>Sue and Charlie Lake just celebrated their 60th wedding anniversary. They both live at Meadowood Senior Living. Because 91-year-old Mr. Lake has health problems, he stays at the skilled nursing facility. They demonstrated their new TripleCare Telemedicine system for us. On nights, weekends or holidays when there isn\'t a doctor in person at the center, there\'s one available through cyberspace. With nurses help, a doctor can do a thorough examination. The camera can zoom in to look for swelling, lesions or discoloration. The stethoscope is also connected. What nurses hear, the doctor hears at the same time.</p>\r\n\r\n\r\n\r\n<p>\"It\'s like Skype except that you have all the dimensions, you have all the senses that the physician can hone in on,\" said Sally-Ann Heckert Bikin, attorney and Director of Nursing at Meadowood. Mrs. Lake tells Action News she was skeptical about the new technology at first.</p>\r\n\r\n\r\n\r\n<p>\"I say I don\'t think it\'s going to work. You are going to lose the face to face,\" she said. But when her husband got sick on a Sunday night, with the help of TripleCare they were able to diagnose and treat him in his room as opposed to being transported by ambulance to the hospital.</p>\r\n\r\n\r\n\r\n<p>\"I went from saying it\'s not going to work to telling everyone this is such a great thing,\" said Sue.</p>\r\n\r\n\r\n\r\n<p>\"So far, we\'ve had 16 calls and out of 16, 13 we were able to treat here in the patient\'s room,\" said Lynn Plepis, Clinical Informatics at Meadowood. Mr Lake was one of those 13.</p>\r\n\r\n\r\n\r\n<p>TripleCare is also set up to keep up the information private and secure.</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>Many other centers are using similar technology.</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>View the&nbsp;<a href=\"http://6abc.com/health/high-tech-healthcare-helps-eliminate-unnecessary-hospital-visits/1416091/\" target=\"_blank\">original news clip</a> including the video.</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:45:30', '2016-07-15 16:26:54', 'b151288e-5fc5-47a2-9e9f-0e74121ec76f'),
 ('22', '315', 'en_us', NULL, NULL, '<p>Cure Forward, an online precision medicine platform for cancer patients and their care teams, and Novartis Pharmaceuticals Corporation today announced that Cure Forward’s unique Clinical Trial Exchange will support Novartis in identifying potential patients for all of its current oncology trials.</p>\r\n\r\n\r\n\r\n<p>The collaboration further validates Cure Forward’s approach for real-time patient sourcing in clinical trials. By utilizing its patent pending Clinical Trial Exchange, Cure Forward facilitates connections between patients and drug development companies, based on mutual criteria and preferences, comparable to popular online dating platforms.</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>There is a significant efficiency gap in the clinical trial process today, placing undue burden on patients and caregivers to navigate the vast, complex landscape of medical research options – often at stages in which their time is most valuable. Drug developers are concurrently developing investigational treatments, but often struggle to find the right patients to receive these investigational treatments.</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>Cure Forward’s platform empowers patients to govern their own care plans, providing accurate, easily accessible information to help drive individual choices.</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>“Today’s patient is active in his or her care, accessing data to make important treatment decisions,” said Martin Naley, Founder and Chief Strategy Officer, Cure Forward. “Cure Forward makes clinical trial enrollment easier and more accessible. Novartis’ bold approach of activating searches for oncology trials on our platform will help patients find possible investigational treatments for their care.”</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:47:22', '2016-07-15 16:26:47', '13f35934-cff3-47d9-bc0f-9a96c0cc7ea1'),
 ('23', '316', 'en_us', 'About Cure Forward', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:47:22', '2016-07-15 16:26:47', '94775a09-c33a-4289-acb4-639785b5b0b8'),
 ('24', '317', 'en_us', NULL, NULL, '<p>Cure Forward bridges the gap between patients and precision medicine, beginning in cancer. Cure Forward provides a simple-to-use platform that allows patients to obtain their genomic data and use it to identify treatment options including clinical trials, solving critical business needs for diagnostic laboratories, health care providers and clinical trial recruiters. Cure Forward is based in Cambridge, Massachusetts and was incubated and launched by Apple Tree Partners, New York City. The company’s platform is in beta release at&nbsp;<a href=\"http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cureforward.com%2F&esheet=51370740&newsitemid=20160628005534&lan=en-US&anchor=www.cureforward.com&index=2&md5=24eaf06114eb049ec8095911016dcfef\" target=\"_blank\">www.cureforward.com</a>.</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:47:22', '2016-07-15 16:26:47', 'b52bca8e-b976-4714-8f26-56da5ad65cea'),
 ('25', '320', 'en_us', NULL, NULL, '<p>Medtronic plc (NYSE: MDT), the global leader in medical technology, and HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies for the treatment of advanced heart failure, today announced that the companies have entered into a definitive merger agreement under which Medtronic will acquire HeartWare in a transaction valued at approximately $1.1 billion. Under the terms of the agreement, Medtronic will commence a tender offer for all outstanding shares of HeartWare common stock for $58.00 per share, in cash. The boards of directors of both Medtronic and HeartWare have unanimously approved the transaction. The acquisition is expected to close during Medtronic\'s second fiscal quarter ending Oct. 28, 2016, subject to the satisfaction of customary closing conditions.</p>\r\n\r\n<p>Medtronic\'s acquisition of HeartWare will expand Medtronic\'s portfolio of diagnostic tools, therapies and services for patients suffering from heart failure, aligning with Medtronic\'s Mission of alleviating pain, restoring health and extending life, and is in line with the Company\'s strategy to surround the physician with innovative products while focusing on patients and disease states.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>HeartWare\'s flagship product, the HVAD ® System, features the world\'s smallest full-support ventricular assist device (VAD) and is designed to reduce surgical invasiveness, improve patient recovery times and enhance patient outcomes. In addition, HeartWare has multiple technologies in development designed to offer progressively less-invasive mechanical circulatory support options for patients with end-stage heart failure. Medtronic estimates that the global VAD market is approximately $800 million currently and worldwide is expected to grow in the mid-to-high single digits for CY16-17, and accelerate to high-single/low-double digits beyond CY17.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>\"The addition of HeartWare\'s innovative portfolio adds to our expanding portfolio of diagnostics, therapeutics and services that address heart failure patients,\" said Mike Coyle, executive vice president and president of the Cardiac and Vascular Group at Medtronic. \"The team at HeartWare has established excellent relationships with its hospital customers and built a strong position and reputation in the marketplace. This transaction, once closed, will be a further, important step toward Medtronic offering a complete suite of solutions to address patient needs across the heart failure care continuum.\"</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>\"Medtronic is the worldwide leader in cardiovascular device technologies. Its expansive expertise in the development of implantable systems and battery technologies, patient monitoring, manufacturing, global regulatory policy and commercialization should help accelerate the development and introduction of our innovative pipeline products, and will expand access to our therapies and offerings to the sizeable heart failure population,\" said Doug Godshall, president and chief executive officer, HeartWare. \"Combining the unique capabilities of the HeartWare team, which has been entirely focused on mechanical support technologies, with the broad strength of the Medtronic organization provides a unique opportunity to enhance growth in the mechanical circulatory support market. All of our stakeholders, including customers, employees, shareholders, and most importantly, patients, will benefit meaningfully from this complementary combination.\"</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>Heart failure, also known as congestive heart failure, is a condition or a collection of symptoms in which the heart isn\'t pumping enough blood to meet the body\'s needs. Heart failure usually develops slowly after an injury to the heart. Some injuries may include a heart attack, too much strain on the heart due to years of untreated high blood pressure, or a diseased heart valve, among others. Heart failure remains a leading cause of hospitalization and death in the United States, and its prevalence continues to increase, affecting more than five million people in the U.S. alone. The cost of heart failure is high. Healthcare expenditures in the U.S. on heart failure are estimated to be approximately $39 billion per year, making it one of the largest expenses to the healthcare system. With the aging of the population, Medtronic estimates that the number of patients with heart failure could exceed eight million by 2030.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>\"HeartWare\'s HVAD System enhances the portfolio of our Cardiac & Vascular Group, a team with a proven track record of executing and a demonstrated ability to scale early stage concepts into large, sustainable end markets,\" said Omar Ishrak, chairman and chief executive officer of Medtronic. \"In addition, from a financial perspective, we are pleased to reach an agreement that meets our acquisition criteria of adding minimal to no net EPS dilution in the near-term, while at the same time creating strong, long-term expected returns for our shareholders.\"</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>This acquisition supports Medtronic\'s therapy innovation strategic priority. In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>This transaction is expected to meet Medtronic\'s long-term financial metrics for acquisitions. Medtronic does not intend to modify its fiscal year 2017 revenue outlook or earnings per share (EPS) guidance as a result of this transaction, although it is expected to provide increased confidence in the company\'s ability to deliver on its FY17 revenue growth outlook. In addition, Medtronic expects minimal to no net EPS dilution from this transaction for the first two years as the company intends to offset the expected dilutive impact. The acquisition is expected to be earnings accretive in year three. Medtronic intends to report results from the acquired HeartWare business as part of its Cardiac Rhythm & Heart Failure division within the Cardiac & Vascular Group.</p>\r\n\r\n\r\n\r\n<p>Medtronic\'s financial advisor for the transaction is J.P. Morgan Securities LLC, with Ropes & Gray LLP acting as legal advisor. HeartWare\'s financial advisor is Perella Weinberg Partners LP, with Shearman & Sterling LLP acting as legal advisor<br></p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:50:11', '2016-07-15 16:25:52', 'e60552b8-fd9d-499f-ba0b-26ba33a4c5fd'),
 ('26', '321', 'en_us', 'About HeartWare International', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:50:11', '2016-07-15 16:25:52', '5414c5d5-5aeb-4929-befa-a945806be399'),
 ('27', '322', 'en_us', NULL, NULL, '<p>HeartWare International Inc. (<a href=\"http://www.heartware.com/\" target=\"_blank\">www.HeartWare.com</a>) develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients around the world suffering from advanced heart failure. Dedicated to developing new, minimally invasive technologies to revolutionize the treatment of patients with end-stage heart failure, HeartWare has multiple technologies in development to offer progressively less-invasive mechanical circulatory support options. HeartWare\'s corporate headquarters are located in Framingham, Massachusetts, and the company has technology, operations, manufacturing and distribution centers in Miami Lakes, Florida; Arden Hills, Minnesota; and Hannover, Germany.</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:50:11', '2016-07-15 16:25:52', '2c51dd6b-68d9-44af-b734-694d3ca4dc42'),
 ('28', '323', 'en_us', 'About Medtronic', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:50:11', '2016-07-15 16:25:52', 'efa0fb1d-e423-42ed-ae7e-e28775661a51'),
 ('29', '324', 'en_us', NULL, NULL, '<p>Medtronic plc (<a href=\"http://www.medtronic.com/\" target=\"_blank\">www.medtronic.com</a>), headquartered in Dublin, Ireland, is among the world\'s largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:50:11', '2016-07-15 16:25:52', 'cb43f7de-5198-43dd-8f7e-70d805713859'),
 ('30', '328', 'en_us', NULL, NULL, '<p>The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.</p>\r\n\r\n<p>Until today, buprenorphine for the treatment of opioid dependence was only approved as a pill or a film placed under the tongue or on the inside of a person’s cheek until it dissolved. While effective, a pill or film may be lost, forgotten or stolen. However, as an implant, Probuphine provides a new treatment option for people in recovery who may value the unique benefits of a six-month implant compared to other forms of buprenorphine, such as the possibility of improved patient convenience from not needing to take medication on a daily basis. An independent FDA advisory committee supported the approval of Probuphine in a meeting held earlier this year.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>\"Opioid abuse and addiction have taken a devastating toll on American families. We must do everything we can to make new, innovative treatment options available that can help patients regain control over their lives,” said FDA Commissioner Robert M. Califf, M.D. “Today’s approval provides the first-ever implantable option to support patients’ efforts to maintain treatment as part of their overall recovery program.”</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>Expanding the use and availability of medication-assisted treatment (MAT) options like buprenorphine is an important component of&nbsp;<a href=\"http://www.fda.gov/NewsEvents/Newsroom/FactSheets/ucm484714.htm\">the FDA’s opioid action plan</a>&nbsp;and one of&nbsp;<a href=\"http://www.hhs.gov/about/news/2015/03/26/hhs-takes-strong-steps-to-address-opioid-drug-related-overdose-death-and-dependence.html\">three top priorities</a>&nbsp;for the U.S. Department of Health and Human Services’ Opioid Initiative aimed at reducing prescription opioid and heroin related overdose, death and dependence.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>Opioid dependence is the diagnostic term used for the more common concept, “addiction,” in the Probuphine clinical trials. Addiction is defined as a cluster of behavioral, cognitive and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use, persisting in drug use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, as well as the possibility of the development of tolerance or development of physical dependence. Physical dependence is not the same as addiction. Newer diagnostic terminology uses the term “opioid use disorder,” which includes both milder forms of problematic opioid use as well as addiction.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>MAT is a comprehensive approach that combines approved medications (currently, methadone, buprenorphine or naltrexone) with counseling and other behavioral therapies to treat patients with opioid use disorder. Regular adherence to MAT with buprenorphine reduces opioid withdrawal symptoms and the desire to use, without causing the cycle of highs and lows associated with opioid misuse or abuse. At sufficient doses, it also decreases the pleasurable effects of other opioids, making continued opioid abuse less attractive. According to the Substance Abuse and Mental Health Services Administration, patients receiving MAT for their opioid use disorder cut their risk of death from all causes in half.</p>\r\n\r\n\r\n\r\n<p>“Scientific evidence suggests that maintenance treatment with these medications in the context of behavioral treatment and recovery support are more effective in the treatment of opioid use disorder than short-term detoxification programs aimed at abstinence,” said Nora Volkow, M.D., director of the National Institute on Drug Abuse at the National Institutes of Health. “This product will expand the treatment alternatives available to people suffering from an opioid use disorder.”</p>\r\n\r\n\r\n\r\n<p>Probuphine should be used as part of a complete treatment program that includes counseling and psychosocial support. Probuphine consists of four, one-inch-long rods that are implanted under the skin on the inside of the upper arm and provide treatment for six months. Administering Probuphine requires specific training because it must be surgically inserted and removed. Only a health care provider who has completed the training and become certified through a restricted program called the Probuphine Risk Evaluation and Mitigation Strategy (REMS) program should insert and remove the implants. If further treatment is needed, new implants may be inserted in the opposite arm for one additional course of treatment. The FDA is requiring postmarketing studies to establish the safety and feasibility of placing the Probuphine implants for additional courses of treatment.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>The safety and efficacy of Probuphine were demonstrated in a randomized clinical trial of adults who met the clinical criteria for opioid dependence and were considered stable after prior buprenorphine treatment. A response to MAT was measured by urine screening and self-reporting of illicit opioid use during the six month treatment period. Sixty-three percent of Probuphine-treated patients had no evidence of illicit opioid use throughout the six months of treatment – similar to the 64 percent of those who responded to sublingual (under the tongue) buprenorphine alone.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>The most common side effects from treatment with Probuphine include implant-site pain, itching, and redness, as well as headache, depression, constipation, nausea, vomiting, back pain, toothache and oropharyngeal pain. The safety and efficacy of Probuphine have not been established in children or adolescents less than 16 years of age. Clinical studies of Probuphine did not include participants over the age of 65.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>Probuphine has a boxed warning that provides important safety information for health care professionals, including a warning that insertion and removal of Probuphine are associated with the risk of implant migration, protrusion, expulsion and nerve damage resulting from the procedure. Probuphine must be prescribed and dispensed according to the Probuphine REMS program because of the risks of surgical complications and because of the risks of accidental overdose, misuse and abuse if an implant comes out or protrudes from the skin. As part of this program, Probuphine can only be prescribed and dispensed by health care providers who are certified with the REMS program and have completed live training, among other requirements.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>Probuphine implants contain a significant amount of drug that can potentially be expelled or removed, resulting in the potential for accidental exposure or intentional misuse and abuse if the implant comes out of the skin. Patients should be seen during the first week after insertion and a visit schedule of no less than once-monthly is recommended for continued counseling and psychosocial support.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>Probuphine is marketed by San Francisco-based Titan Pharmaceuticals Inc. and Braeburn Pharmaceuticals based in Princeton, New Jersey.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:52:37', '2016-07-15 16:25:44', 'e34f4a6c-c70b-4407-9118-33294e92ac58'),
 ('31', '330', 'en_us', NULL, NULL, '<p>QualDerm Partners LLC (“QDP”), a dermatology services company, announced today it has raised $31.8 million in growth equity funding from Apple Tree Partners (“ATP”) and Cressey & Company (“Cressey”). The financing will enable QualDerm to strengthen its comprehensive physician support services and accelerate expansion through partnerships with leading dermatology practices.</p>\r\n\r\n<p>Headquartered in Brentwood, TN, QualDerm provides physician support services through partnerships with best-in-class dermatology practices in the southeastern U.S. The company provides leadership, growth resources, and management services to skin surgeons, pediatric, and general dermatologists and mid-level providers to alleviate the burden of the day-to-day administrative demands of running a business.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p><em>“Our investment in QDP aligns with ATP’s commitment to partner with exceptional management teams and build leading healthcare companies,\" said Diane Daych, Partner of Apple Tree Partners, who joined QualDerm’s Board of Directors. \"With extensive experience building and operating multi-site provider businesses and deep knowledge in effective practice management strategy, ATP looks forward to supporting QDP’s growth.”</em></p>\r\n\r\n\r\n\r\n\r\n\r\n<p><em>“Cressey & Company is excited to have additional resources from ATP to support the continued professional success and clinical excellence of our existing partnership with QDP,” said David Schuppan, Cressey Partner and QDP Board member.</em></p>\r\n\r\n\r\n\r\n\r\n\r\n<p>Under the leadership of Bill Southwick, CEO, QualDerm partners with physicians to create high functioning teams through shared culture, shared services, and shared decision making. QualDerm is dedicated to expanding patient access to high quality care in secondary markets as well as other underserved areas, where the nationwide dearth of dermatologists is particularly problematic.<em>&nbsp;“We are pleased to partner with our investors, who bring significant experience building healthcare companies and adding operational value. This investment will facilitate QDP’s mission to provide management, growth, and strategic services that enable high quality dermatology care while preserving physician autonomy in true partnership fashion,”&nbsp;</em>said Southwick.</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>The company’s practice affiliates include The Skin Surgery Center, a full-service, multi-site specialty group based in North Carolina, led by distinguished physicians, Drs. Barry Leshin and John Albertini.&nbsp;<em>“As the platform practice for QDP, we have been truly gratified by the sophistication and expertise of our management team and anticipate that ATP’s investment in both capital and strategic vision will synergize with Cressey in a way that adds tremendous value as we expand our mission to provide high quality dermatologic care to the region and beyond.”</em></p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', '8aeecf89-db76-4925-895e-092178f73a49'),
 ('32', '331', 'en_us', 'About Apple Tree Partners', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', '63a7c32d-671d-47dc-aaf3-d5b2cf56c824'),
 ('33', '332', 'en_us', NULL, NULL, '<p>Apple Tree Partners (ATP) is a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded in 1999, with a history of well-known successes, ATP closed its current capital pool of $1.5 billion in 2012 and is actively funding healthcare innovation. ATP starts companies, or invests in existing companies, with commitments as high as $250 million. The firm is headquartered in New York City, with satellite offices in Princeton, NJ, Cambridge, MA, and Los Altos, CA.</p>\r\n\r\n<p>For more information, please visit:&nbsp;<a href=\"http://www.appletreepartners.com/\">www.appletreepartners.com</a></p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', 'f7075bc2-70e9-42f9-9617-2f18db93c299'),
 ('34', '333', 'en_us', 'About Cressey & Company', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', 'a8c43eee-a254-4d11-bc2e-1997f9119136'),
 ('35', '334', 'en_us', NULL, NULL, '<p>Based in Chicago, IL and Nashville, TN, Cressey & Company is a private investment firm focused on building leading healthcare provider, service and information technology businesses. With a history spanning nearly 35 years, the Cressey & Company team is one of the most experienced and successful in the healthcare private equity field.</p>\r\n\r\n<p>More information about Cressey & Company is available at&nbsp;<a href=\"http://www.cresseyco.com/\" target=\"_blank\">www.cresseyco.com</a>.</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', '92bbca75-c8fd-4413-af36-bd9ad2815f9f'),
 ('36', '335', 'en_us', 'About QualDerm', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', 'bbdbeb0d-e8f6-4e5b-960c-866dfc319cdc'),
 ('37', '336', 'en_us', NULL, NULL, '<p>Based in Brentwood, TN, QualDerm Partners provides strategic leadership and practice management services for dermatologists and skin care professionals. The company strives to be the partner of choice for premier, patient-centric dermatology practices throughout the southeast.</p>\r\n\r\n<p>For more information, please visit&nbsp;<a href=\"http://www.qualderm.com/\" target=\"_blank\">www.qualderm.com</a></p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:55:12', '2016-07-15 16:25:37', '1b649244-482e-443e-b221-7ccf0e5cbb68'),
 ('38', '339', 'en_us', NULL, NULL, '<p>Syntimmune, Inc., a development-stage company advancing novel treatments for IgG-mediated autoimmune diseases based on leading expertise in FcRn biology, today announced that it has made important progress by achieving preclinical proof of concept and completing preclinical safety testing, triggering a second, $10 million tranche of the Company’s committed $26 million Series A financing. The Series A financing is co-led by Apple Tree Partners and Baxalta Ventures, the corporate venture capital arm of Baxalta Incorporated, with participation by the Partners Innovation Fund and additional investors. Funds from this tranche of the Series A round will be used to complete the anticipated Phase 1a clinical trial in healthy volunteers of Syntimmune’s lead candidate, SYNT001. The Company intends to submit an IND application to the Food and Drug Administration for SYNT001 in mid-2016 to authorize initiation of the Phase 1a study later this year. SYNT001 is a biologic that blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases.</p>\r\n\r\n<p>“The closing of the second tranche in the Series A affirms the progress Syntimmune has achieved and reflects the importance of targeting FcRn as a breakthrough modality for treating IgG-mediated autoimmune diseases,” said Laurence Blumberg, M.D., Founder and COO of Syntimmune. “Since our founding just over two years ago, Syntimmune has made rapid progress in advancing its pipeline of candidates and progressing its lead program, SYNT001, through IND-enabling studies and toward the clinic. SYNT001 is showing a promising preclinical safety profile and robust activity in unique in vivo preclinical models, which we plan to present at appropriate peer-reviewed forums.”</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>“The opportunity for SYNT001 is substantial,” stated David de Graaf, Ph.D., Venture Partner at Apple Tree Partners. “We are extremely happy with the progress the team has made on the lead molecule, which has the potential to address a large number of autoimmune indications.”</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>“FcRn is a central mediator of IgG-related immunity and part of an important pathway that enables abnormal IgG responses in a large number of clinical settings, including autoimmune disease,” commented Richard Blumberg, M.D., Scientific Founder of Syntimmune and Division Chief of Gastroenterology, Hepatology and Endoscopy at Brigham and Women’s Hospital, as well as co-Director of the Harvard Digestive Diseases Center and Director of the Brigham Research Institute. “While FcRn is a highly validated target and has attracted substantial industry interest, there are no commercially available therapies designed to block IgG-FcRn interactions, which underlie diseases that affect multiple organ systems and for which there are continuing substantial medical needs, such as inflammatory bowel disease, lupus erythematosus, dermatomyositis and others. I am thrilled with the progress of Syntimmune and look forward to the advancement of the clinical program for SYNT001.”</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:56:51', '2016-07-15 16:25:30', '4b9a8c1a-f63b-463d-8654-e1c8781aab06'),
 ('39', '340', 'en_us', 'About Syntimmune', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:56:51', '2016-07-15 16:25:30', 'f8e9e72c-34a8-48f7-8f4b-0a9accf24bed'),
 ('40', '341', 'en_us', NULL, NULL, '<p>Founded in 2013, Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-mediated autoimmune diseases and represents a central common pathway that enables abnormal IgG responses. Syntimmune’s lead candidate, SYNT001, is a biologic progressing through IND-enabling studies that specifically blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases. Syntimmune has two additional, earlier-stage therapeutic programs, targeting other unique aspects of FcRn biology. The Syntimmune team has world-class experience in the field of FcRn biology and has successfully pioneered and advanced biologics targeting FcRn, including approved therapies currently on the market. Since its founding, the Company has received a total of $28 million in funding commitments from leading life sciences investors, including Apple Tree Partners, Baxalta Ventures, and Partners Innovation Fund. For more information on Syntimmune, please visit the Company’s website at<a href=\"http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.syntimmune.com&esheet=51304447&newsitemid=20160322005211&lan=en-US&anchor=www.syntimmune.com&index=1&md5=62fb1a7393f2201155ab419b9a8b964d\" target=\"_blank\">www.syntimmune.com</a>.</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:56:51', '2016-07-15 16:25:30', '5536c56b-78d7-4195-9f65-97dc6036a246'),
 ('41', '343', 'en_us', NULL, NULL, '<p>Braeburn Pharmaceuticals and Camurus announced today that the first patients have been dosed with CAM2038, weekly and monthly subcutaneous buprenorphine injections, in a pharmacokinetic study of opioid dependent patients with chronic pain.</p>\r\n\r\n<p>The primary objective of this Phase 2 study is to assess the steady state pharmacokinetics of buprenorphine after repeated doses in opioid dependent patients with chronic pain, including effects of injection into different subcutaneous sites. This study will also explore the effect of CAM2038 on chronic pain, along with evaluation of safety and tolerability.</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>\"This marks the fourth clinical study that has been started in the last five months for CAM2038, including two Phase 3 trials in opioid dependence. The ability to use CAM2038 in multiple injection sites would allow physicians the flexibility to personalize treatments,\" said Behshad Sheldon, President and CEO, Braeburn Pharmaceuticals. \"Our goal is to provide a suite of best-in-class long-acting treatment options tailored to the individual needs of patients suffering from opioid dependence and chronic pain.\"</p>\r\n\r\n\r\n\r\n\r\n\r\n<p>\"Patients that suffer from chronic pain and are also opioid dependent are a difficult population to treat,\" said the principal investigator Dr. Greg Sullivan, medical director at Parkway Medical Center in Birmingham, Alabama. \"By using a long acting buprenorphine injectable, these patients would no longer be required to take medication multiple times per day. Buprenorphine also guards against hyperanalgesia and opiate tolerance, both of which are problems with conventional opiates.\"</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>\"CAM2038 has the potential to offer effective and safe around-the-clock pain relief, without risks of abuse and diversion. The pharmacological properties of buprenorphine together with long-acting release from the FluidCrystal formulation could also decrease risks of respiratory depression and overdose mortality associated with current opioid pain treatments,\" said Fredrik Tiberg, President and CEO, Camurus.</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'c42679c4-f7ed-401f-bd48-281cfc16264b'),
 ('42', '344', 'en_us', 'About Braeburn Pharmaceuticals', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', '3fb6581d-6327-4136-81a2-21751511bf5e'),
 ('43', '345', 'en_us', NULL, NULL, '<p>Braeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience. In September 2015 the Food and Drug Administration (FDA) accepted for review Braeburn\'s New Drug Application for its lead candidate, Probuphine, a six-month buprenorphine implant for treatment of opioid dependence. The Agency has set May 27, 2016 as the target date for action.</p>\r\n\r\n<p>Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. Braeburn\'s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Candidates include: Probuphine®, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia. More information on Braeburn, can be found at&nbsp;<a href=\"https://braeburnpharmaceuticals.com/\" target=\"_blank\">https://braeburnpharmaceuticals.com/</a>.</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', '68eaf842-4f7c-485d-99dc-fcb4e6ad49a7'),
 ('44', '346', 'en_us', 'About CAM2038', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', 'e2aed7c2-e9a4-4268-b462-3423f3b344ec'),
 ('45', '347', 'en_us', NULL, NULL, '<p>The investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid addiction and pain are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance. The CAM2038 products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion, abuse, misuse, and accidental exposure. The CAM2038 products have been evaluated in three Phase 1/2 clinical trials, which evaluated the safety and tolerability as well as pharmacokinetic and pharmacodynamics properties of the products in a total of 176 individuals (opioid-dependent patients and healthy volunteers under naltrexone blockage). The CAM2038 products are also being developed for treatment of chronic pain, combining the effective analgesic properties of buprenorphine with the long acting release provided by the FluidCrystal® injection depot.</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', '0f739eb3-e8b5-4404-8fd0-d3860d15fa6d'),
 ('46', '348', 'en_us', 'About Camurus', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', '10f7afa0-c628-4767-8180-d2f45d9f668b'),
 ('47', '349', 'en_us', NULL, NULL, '<p>Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus\' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company\'s share is listed on Nasdaq Stockholm under the ticker \"CAMX\". For more information, visit&nbsp;<a href=\"http://www.camurus.com/\" target=\"_blank\">www.camurus.com</a>.</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 04:59:33', '2016-07-15 16:25:20', '105dedfa-2caa-4f39-931c-bed923ad8fed'),
 ('48', '352', 'en_us', NULL, NULL, '<p>Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple Tree Partners.</p>\r\n\r\n<p>Concurrent with the financing, Corvidia has licensed a clinical stage compound from AstraZeneca to develop and commercialize as its lead therapeutic (COR-001). Funds from the Series A financing will be used to progress COR-001 into Phase I/II clinical trials during 2016, as well as to advance the company\'s preclinical pipeline.</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>Corvidia was co-founded by serial entrepreneur and Chief Executive Officer, Michael Davidson, M.D. Dr. Davidson, a recognized expert in the field of cardiology, previously served as Chief Medical Officer of Sofinnova-backed Omthera Pharmaceuticals, and was instrumental in the successful acquisition of that company by AstraZeneca in 2013 for $443 million. Joining Dr. Davidson at Corvidia are Co-founders Rahul Kakkar M.D. and Matt Devalaraja, Ph.D., both of whom previously worked in AstraZeneca\'s Emerging Innovations Unit, where they developed the science behind genome-guided cardiovascular therapies. Ram Aiyar Ph.D., MBA, an Entrepreneur-in-Residence at the National Institutes of Health and BioHealth Innovation, completes Corvidia\'s founding team.</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>Commenting on today\'s news, Dr. Davidson stated,&nbsp;<em>\"Our ability to complete this significant Series A financing with such high-quality investors is a testament to the promise of our technology and expertise of our management team, positioning Corvidia as a leader in the field of precision medicine as applied to cardiovascular diseases. With these funds, we aim to drive each of our assets through clinical trials and validate our precision medicine approach.\"</em></p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>Graziano Seghezzi, Partner at Sofinnova Partners, and Corvidia\'s board member commented,&nbsp;<em>\"Given Omthera\'s success, we were strongly in favor of teaming up once again with Dr. Davidson. The seed funding that Sofinnova Partners provided allowed for Corvidia\'s inception, for the pipeline crafting and for the eventual structuring of the Series A. We are pleased to continue to support Corvidia and this latest financing represents a major step for the future advancement of novel, cardiovascular therapeutics.\"</em></p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>Seth Harrison, M.D., Managing Partner of Apple Tree Partners, noted, \"<em>In&nbsp;</em><em>our years of start-up investing we have not seen a better team than the group that Michael Davidson has assembled from AstraZeneca and the NIH. We are thrilled to be able to support Corvidia with our capital resources and company building experience, and look forward to working with Sofinnova Partners, AstraZeneca, and management to create the first great precision cardiovascular medicine company.</em>\"</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>COR-001, a monoclonal antibody initially developed by MedImmune, AstraZeneca\'s global biologics research and development arm, was previously in a Phase 1 study for a different indication. It was repurposed by AstraZeneca\'s Emerging Innovations Unit, Scientific Partnering and Alliances (SP&A), prior to licensing to Corvidia.&nbsp;<em>\"This is another example of the strong entrepreneurial culture within AstraZeneca, where we push the boundaries of science to explore new therapeutic uses for our compounds. We will continue to divest or out-license assets where we believe it will help accelerate the development of new medicines.\"&nbsp;</em>said Kumar Srinivasan, Vice President, SP&A, Innovative Medicines Unit, AstraZeneca.</p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n<p>In conjunction with the financing, Seth Harrison and Adrien Lemoine, Executive Director, Corporate Development for AstraZeneca, will join Graziano Seghezzi and Michael Davidson on Corvidia\'s Board of Directors.</p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 05:01:56', '2016-07-15 16:24:52', 'f807c9ed-9a00-4eef-aa39-4b829ac2533e'),
 ('49', '353', 'en_us', 'About Sofinnova Partners', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 05:01:56', '2016-07-15 16:24:52', 'a36e2cc4-d184-4571-b9fe-c6c64969e141'),
 ('50', '354', 'en_us', NULL, NULL, '<p>Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs, and has backed nearly 500 companies over more than 40 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.5 billion under management. For more information, please visit:<a href=\"http://www.sofinnova.fr/\" target=\"_blank\">www.sofinnova.fr</a></p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 05:01:56', '2016-07-15 16:24:52', '7733995b-dae3-4e8b-99a7-0776b22e6cc5'),
 ('51', '355', 'en_us', 'About Corvidia Therapeutics', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 05:01:56', '2016-07-15 16:24:52', '491bf61c-7afc-41f9-a54f-c5e1f97e641b'),
 ('52', '356', 'en_us', NULL, NULL, '<p>Based in Boston, MA, Corvidia is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company\'s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia\'s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. For more information, please visit:<a href=\"http://www.corvidiatx.com/\" target=\"_blank\">www.corvidiatx.com</a></p>', 'left', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2016-07-12 05:01:56', '2016-07-15 16:24:52', '485e6695-5571-45c8-b849-6c88f9befc21');



DROP TABLE IF EXISTS `craft_matrixcontent_companycontactmethods`;


--
-- Schema for table `craft_matrixcontent_companycontactmethods`
--
CREATE TABLE `craft_matrixcontent_companycontactmethods` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `elementId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `field_contactMethods_companyWebsite` text COLLATE utf8_unicode_ci,
  `field_contactMethods_linkedin` text COLLATE utf8_unicode_ci,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_matrixcontent_companycontactmethod_elementId_locale_unq_id` (`elementId`,`locale`),
  KEY `craft_matrixcontent_companycontactmethods_locale_fk` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=19 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_matrixcontent_companycontactmethods`
--

INSERT INTO `craft_matrixcontent_companycontactmethods` (`id`, `elementId`, `locale`, `field_contactMethods_companyWebsite`, `field_contactMethods_linkedin`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '28', 'en_us', 'http://www.aileronrx.com/', 'https://www.linkedin.com/company/aileron-therapeutics', '2016-06-14 16:14:38', '2016-07-13 16:33:56', 'a0538b81-37e5-4eb2-9e85-e4410f791d5f'),
 ('2', '201', 'en_us', 'https://braeburnpharmaceuticals.com/', 'https://www.linkedin.com/company/braeburn-pharmaceuticals', '2016-07-11 21:57:13', '2016-07-13 16:33:35', '59471328-5d14-44c1-becc-596bad4b0171'),
 ('3', '205', 'en_us', 'http://cleanslatecenters.com/', 'https://www.linkedin.com/company/cleanslate-centers', '2016-07-11 21:58:40', '2016-07-13 16:33:16', '17bc24d8-12b9-4aeb-a2be-529c3f4cf8eb'),
 ('4', '230', 'en_us', 'http://www.lexicon-genetics.com/', 'https://www.linkedin.com/company/coelacanth-chemical-corp', '2016-07-11 22:03:47', '2016-07-13 21:14:28', '1c575c7e-a92f-4878-9ced-e15828d219e0'),
 ('5', '240', 'en_us', 'http://corvidiatx.com/', 'https://www.linkedin.com/company/corvidia-therapeutics', '2016-07-11 22:21:39', '2016-07-13 16:32:34', '9f9245ed-c9ed-45f0-9d09-b91a944a8952'),
 ('6', '243', 'en_us', 'http://www.galatherapeutics.com/', '', '2016-07-11 22:29:19', '2016-07-13 17:19:52', '1233331e-28b1-4456-8314-f31ba928cabc'),
 ('7', '245', 'en_us', 'https://www.cureforward.com/', 'https://www.linkedin.com/company/cureforward', '2016-07-11 22:35:11', '2016-07-13 16:31:59', '632f1ccf-95b7-4c9d-b7a5-77cff69a8d4b'),
 ('8', '247', 'en_us', 'http://www.smithsdetection.com/', '', '2016-07-11 22:36:11', '2016-07-13 21:17:31', 'b2b8974f-28a1-4089-88e3-c9ade8e5d4cc'),
 ('9', '249', 'en_us', 'http://www.celgene.com/', '', '2016-07-11 22:37:48', '2016-07-13 16:31:14', 'd8e4a91c-9476-4aa8-b42d-b79aab34a86a'),
 ('10', '268', 'en_us', 'http://www.heartware.com/', 'https://www.linkedin.com/company/heartware-inc', '2016-07-11 23:41:01', '2016-07-13 16:30:57', 'bd34ef17-b835-4882-b22d-58dbfb99e664'),
 ('11', '276', 'en_us', 'http://qualderm.com/', 'https://www.linkedin.com/company/6471786?trk=tyah&trkInfo=clickedVertical%3Acompany%2Cidx%3A2-1-4%2CtarId%3A1435163699111%2Ctas%3Aqualderm%20partners', '2016-07-11 23:47:20', '2016-07-13 16:30:36', '07f1ea71-7f9b-423b-b20d-b7f6c76140f0'),
 ('12', '282', 'en_us', 'https://www.lilly.com/home.aspx', 'https://www.linkedin.com/company/sgx-pharmaceuticals', '2016-07-12 00:07:33', '2016-07-13 16:30:20', 'd7084971-6d87-4ad2-929c-5d5f1d065eee'),
 ('13', '285', 'en_us', 'http://syntimmune.com/', '', '2016-07-12 00:09:32', '2016-07-13 16:29:54', 'c2f41f72-eec4-43e0-aa3a-3a7e43e7cb28'),
 ('14', '288', 'en_us', 'http://www.tendyne.com/', '', '2016-07-12 00:15:28', '2016-07-13 16:38:44', '213948fc-ac8c-4ec4-a81b-b2f1e92df1a2'),
 ('15', '291', 'en_us', 'http://tokaipharmaceuticals.com/', 'https://www.linkedin.com/company/tokai-pharmaceuticals-inc-', '2016-07-12 00:17:23', '2016-07-13 16:29:12', '6ceca450-4c23-47cb-bfa9-d83029f326fb'),
 ('16', '294', 'en_us', 'http://triple.care/', 'https://www.linkedin.com/company/esnf/', '2016-07-12 00:19:59', '2016-07-13 16:28:41', '0bc58822-be2f-4d78-b669-2003ed0c1b1e'),
 ('17', '297', 'en_us', 'http://www.tuskermed.com/', 'https://www.linkedin.com/company/tusker-medical-inc.', '2016-07-12 00:23:01', '2016-07-13 21:08:08', '0aaca6c9-b606-40a5-a39e-d84dbc5893bc'),
 ('18', '299', 'en_us', 'http://www.vytronus.com/', '', '2016-07-12 00:24:36', '2016-07-13 16:27:51', '73e4b93c-ee13-4000-8c9c-a35ab39a37c4');



DROP TABLE IF EXISTS `craft_matrixcontent_expertisesection`;


--
-- Schema for table `craft_matrixcontent_expertisesection`
--
CREATE TABLE `craft_matrixcontent_expertisesection` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `elementId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `field_areaOfExpertise_expertiseTitle` text COLLATE utf8_unicode_ci,
  `field_areaOfExpertise_expertiseDescription` text COLLATE utf8_unicode_ci,
  `field_areaOfExpertise_expertiseLink` varchar(50) COLLATE utf8_unicode_ci DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_matrixcontent_expertisesection_elementId_locale_unq_idx` (`elementId`,`locale`),
  KEY `craft_matrixcontent_expertisesection_locale_fk` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=6 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_matrixcontent_expertisesection`
--

INSERT INTO `craft_matrixcontent_expertisesection` (`id`, `elementId`, `locale`, `field_areaOfExpertise_expertiseTitle`, `field_areaOfExpertise_expertiseDescription`, `field_areaOfExpertise_expertiseLink`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('2', '19', 'en_us', 'Therapeutics', 'Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.', 'Meet the Therapeutics team', '2016-06-14 15:52:39', '2016-07-13 21:16:21', '52b1bb35-7452-4781-8e63-22074292cdb2'),
 ('3', '20', 'en_us', 'Medical Devices', 'Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.', 'Meet the Medical Devices team', '2016-06-14 15:52:39', '2016-07-13 21:16:21', '3bdb5f81-e197-476e-8870-bb2a280a52d7'),
 ('4', '21', 'en_us', 'Healthcare Services', 'Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.', 'Meet the Healthcare Services team', '2016-06-14 15:52:39', '2016-07-13 21:16:21', 'cce971ef-4478-4790-8010-40c108076563'),
 ('5', '22', 'en_us', 'Legacy Investments', 'Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.', '', '2016-06-14 15:52:39', '2016-07-13 21:16:21', '60ca0858-f0a7-4338-99c2-1bb8399e2f32');



DROP TABLE IF EXISTS `craft_matrixcontent_footerlink`;


--
-- Schema for table `craft_matrixcontent_footerlink`
--
CREATE TABLE `craft_matrixcontent_footerlink` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `elementId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `field_link_displayLink` text COLLATE utf8_unicode_ci,
  `field_link_hyperlink` text COLLATE utf8_unicode_ci,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_matrixcontent_footerlink_elementId_locale_unq_idx` (`elementId`,`locale`),
  KEY `craft_matrixcontent_footerlink_locale_fk` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=5 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_matrixcontent_footerlink`
--

INSERT INTO `craft_matrixcontent_footerlink` (`id`, `elementId`, `locale`, `field_link_displayLink`, `field_link_hyperlink`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '44', 'en_us', 'Press', '/press', '2016-06-15 20:23:24', '2016-07-13 18:21:00', '0b9f4042-2c1d-49da-b591-43811292ecb9'),
 ('3', '46', 'en_us', 'Legal', '/legal', '2016-06-15 20:24:14', '2016-07-13 18:21:00', '54f4b702-1c06-45b2-aadf-37d53a831d76'),
 ('4', '47', 'en_us', 'Linkedin', 'https://www.linkedin.com/company/apple-tree-partners', '2016-06-15 20:24:14', '2016-07-13 18:21:00', '4fc9c0bc-8c1c-4fcd-a753-c5ba84b6cd99');



DROP TABLE IF EXISTS `craft_matrixcontent_legalcopy`;


--
-- Schema for table `craft_matrixcontent_legalcopy`
--
CREATE TABLE `craft_matrixcontent_legalcopy` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `elementId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `field_legalHeader_legalHeader` text COLLATE utf8_unicode_ci,
  `field_legalHeader_position` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `field_legalBody_subheader` text COLLATE utf8_unicode_ci,
  `field_legalBody_legalCopy` text COLLATE utf8_unicode_ci,
  `field_legalBody_position` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `field_legalLink_linkCopy` text COLLATE utf8_unicode_ci,
  `field_legalLink_linkPosition` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_matrixcontent_legalcopy_elementId_locale_unq_idx` (`elementId`,`locale`),
  KEY `craft_matrixcontent_legalcopy_locale_fk` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=16 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_matrixcontent_legalcopy`
--

INSERT INTO `craft_matrixcontent_legalcopy` (`id`, `elementId`, `locale`, `field_legalHeader_legalHeader`, `field_legalHeader_position`, `field_legalBody_subheader`, `field_legalBody_legalCopy`, `field_legalBody_position`, `field_legalLink_linkCopy`, `field_legalLink_linkPosition`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '67', 'en_us', 'Legal', 'full', NULL, NULL, NULL, NULL, NULL, '2016-06-27 16:58:18', '2016-07-14 19:37:10', 'c0eb68fc-b627-45af-94c5-7155f0faded1'),
 ('2', '68', 'en_us', NULL, NULL, 'Terms of Use', 'Thank you for your interest in our Website at www.appletreepartners.com.  Your use of this Website, including the content, materials and information available on or through this Website (together, the \"Materials\"), is governed by these Terms of Use (these \"Terms\"). By using this Website, you acknowledge that you have read and agree to these Terms.', 'left', NULL, NULL, '2016-06-27 16:58:18', '2016-07-14 19:37:10', '104fb6e9-52ff-4067-93d1-cd39b91eaa31'),
 ('3', '69', 'en_us', NULL, NULL, NULL, NULL, NULL, 'Do you have a question? Contact us.', 'left', '2016-06-27 16:58:18', '2016-07-14 19:37:10', 'd5d9695f-87d9-4d97-84b5-b37df57d0a9f'),
 ('5', '300', 'en_us', NULL, NULL, 'Who We Are', 'This Website is maintained and operated by Apple Tree Venture Management, LLC, which provides administrative and other services to various Apple Tree entities.  In accordance with industry custom, this Website occasionally uses terminology that may be interpreted to suggest that our firm is actually a single entity. However, there is no such single entity and all of the entities that comprise our firm have their own separate legal existence.', 'left', NULL, NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', '3c0d779f-e8b5-484f-af27-cd6f40e68494'),
 ('6', '301', 'en_us', NULL, NULL, 'Materials', 'ALL MATERIALS ARE PROVIDED \"AS IS,\" MAY NOT BE RELIED UPON FOR ANY PURPOSE, AND ARE NOT SUBJECT TO EXPRESS OR IMPLIED WARRANTIES OF ANY KIND. In particular, we make no representations or warranties with regard to the Materials\' accuracy, completeness, non-infringement or fitness for a particular purpose. You should be aware that a significant portion of the Materials include or consist of information that has been provided by third parties and has not been validated or verified by us. In connection with our investment activities, we often become subject to a variety of confidentiality obligations to funds, investors, portfolio companies and other third parties. Any statements we make may be affected by those confidentiality obligations, with the result that we may be prohibited from making full disclosures. Without limitation on the effect of other warnings and disclaimers set forth in these Terms, you should interpret any statements we make (on this Website or otherwise) in that context. Please ensure that your own computer security is comprehensive and up to date. We accept no responsibility for viruses, malware or other malicious or damaging software contained in the Materials or otherwise.', 'left', NULL, NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', '9ee72767-7c96-49f5-9455-5c28c7a1469c'),
 ('7', '302', 'en_us', NULL, NULL, 'Third-Party Sites', 'We accept no responsibility for third-party sites available through this Website, via hyperlink or otherwise. You are encouraged to review the terms of use applicable to those sites. Any access to, or use of, a third-party site is solely at your own risk.', 'left', NULL, NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'c826c4e2-3a36-40dc-a3af-51665b1d8747'),
 ('8', '303', 'en_us', NULL, NULL, 'No Offer, Solicitation or Advice', 'Nothing on this Website is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by an Apple Tree Partners entity in writing, neither this Website nor any of the Materials make any effort to present a comprehensive or balanced description of Apple Tree Partners or its investment activities.', 'left', NULL, NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'dfcd7817-9450-405c-b8ea-295d77c1fc25'),
 ('9', '304', 'en_us', NULL, NULL, 'Restrictions on Use; No License', 'We reserve all rights with respect to the design and content of this Website. In particular, you must not misappropriate the design or content of this Website and you must not alter or deface such design or content in any way. Nothing on this Website grants any license with respect to such design or content, except that you may download and use Materials solely for your own personal information.', 'left', NULL, NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', '9e5c6630-21d6-4cf9-a2a9-27cd93f15bfb'),
 ('10', '305', 'en_us', NULL, NULL, 'Ownership of Trademarks, Etc.', 'All text, photos, graphics, logos, content and other Materials on this Website are protected by United States and foreign copyright, trademark and other applicable laws. In particular, all trademarks, trade names and logos displayed on this Website are proprietary to Apple Tree Partners, its affiliates or their respective owners, and this Website grants no license to them. Apple Tree Partners and our tree logo are among our trademarks in the United States and/or other countries.', 'left', NULL, NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'b663166b-32c8-45b4-b00e-6dd37cfed1e1'),
 ('11', '306', 'en_us', NULL, NULL, 'Submitting a Business Plan', ' or Other Confidential Information. Due to the large number of business plan ideas and related materials that we review, and the similarity of many such plans and materials, we cannot accept responsibility for protecting against misuse or disclosure any confidential or proprietary information or other materials in the absence of our express written agreement to do so. Any plans, information and other materials you submit in connection with this Website may be used or disclosed by us for any purpose and in any manner, as we determine in our sole discretion. Please consider this carefully before sending us any information or other materials that you deem confidential or proprietary.', 'left', NULL, NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', '0aa9b490-12b2-4cfc-92e2-657ce424e02b'),
 ('12', '307', 'en_us', NULL, NULL, 'Privacy Policy', 'We reserve the right to track visitors to, and usage of, this Website through \"cookies\" and similar techniques and to use any resulting information as we determine in our sole discretion.', 'left', NULL, NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'dd848fd6-9cb8-4f23-beed-340deb7263dc'),
 ('13', '308', 'en_us', NULL, NULL, 'Limitation of Liability', 'Except as specifically agreed by an Apple Tree Partners entity in writing, NO APPLE TREE PARTNERS INDIVIDUAL OR ENTITY SHALL HAVE ANY LIABILITY BASED UPON YOUR USE OF, OR RELIANCE UPON, THIS WEBSITE OR THE MATERIALS. Some jurisdictions limit our ability to disclaim liability. With regard to those jurisdictions, our liability shall be limited to the greatest extent permitted by applicable law.', 'left', NULL, NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', '0b12c811-6182-4fc4-b0c5-69a576d0a4fd'),
 ('14', '309', 'en_us', NULL, NULL, 'Modification of these Terms', 'We reserve the right to modify these Terms at any time. Please check these Terms periodically for changes. Your continued use of this Website after the posting of changes constitutes your binding acceptance of such changes.', 'left', NULL, NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', 'fe446d4f-d212-4bac-935c-bcffbf4f8b40'),
 ('15', '310', 'en_us', NULL, NULL, 'General Information', 'This Website is operated and controlled by Apple Tree Venture Management, LLC in the United States of America. If it is illegal or prohibited in your country of origin to access or use this Website, then you should not do so. Those who choose to access this Website outside the United States of America access it on their own initiative and are responsible for compliance with all local laws and regulations. These Terms, and any disputes relating to these Terms or your use of this Website or the Materials, shall be governed in all respects by the laws of the State of New York, without regard to conflicts of laws principles. Except as otherwise agreed in writing by the applicable Apple Tree Partners entities, any disputes relating to these Terms shall be resolved exclusively in the state or federal courts located in New York, New York. These Terms set forth the entire agreement between you and us with respect to the subject matter hereof and supersede all prior agreements relating to such subject matter. All Apple Tree Partners individuals and entities are intended third-party beneficiaries of these Terms. Our rights under these Terms may be waived by us only in writing. These Terms are binding on you as well as your successors and permitted assigns. In the event any provision of these Terms is determined to be invalid or unenforceable, such provision shall be deemed severed from the remainder of these Terms and replaced with a valid and enforceable provision as similar in intent as reasonably possible to the provision so severed, and shall not cause the invalidity or unenforceability of the remainder of these Terms.', 'left', NULL, NULL, '2016-07-12 04:16:32', '2016-07-14 19:37:10', '04ee2431-cab5-411d-92b6-8b05ba210d57');



DROP TABLE IF EXISTS `craft_matrixcontent_locations`;


--
-- Schema for table `craft_matrixcontent_locations`
--
CREATE TABLE `craft_matrixcontent_locations` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `elementId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `field_location_cityName` text COLLATE utf8_unicode_ci,
  `field_location_address` text COLLATE utf8_unicode_ci,
  `field_location_telephone` text COLLATE utf8_unicode_ci,
  `field_location_fax` text COLLATE utf8_unicode_ci,
  `field_location_contactLine` text COLLATE utf8_unicode_ci,
  `field_location_email` text COLLATE utf8_unicode_ci,
  `field_location_emailCopy` text COLLATE utf8_unicode_ci,
  `field_location_locationLatitude` decimal(8,5) DEFAULT '0.00000',
  `field_location_locationLongitude` decimal(8,5) DEFAULT '0.00000',
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_matrixcontent_locations_elementId_locale_unq_idx` (`elementId`,`locale`),
  KEY `craft_matrixcontent_locations_locale_fk` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=7 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_matrixcontent_locations`
--

INSERT INTO `craft_matrixcontent_locations` (`id`, `elementId`, `locale`, `field_location_cityName`, `field_location_address`, `field_location_telephone`, `field_location_fax`, `field_location_contactLine`, `field_location_email`, `field_location_emailCopy`, `field_location_locationLatitude`, `field_location_locationLongitude`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '41', 'en_us', 'New York City', '230 Park Avenue, Suite 2800\r\nNew York, New York 10169', '212.476.9900', '212.999.0000', 'Do you have a revolutionary innovation?', 'info@appletreepartners.com', 'Let\'s talk.', '40.75430', '-73.97618', '2016-06-15 19:36:44', '2016-07-13 21:20:34', 'e9953b4a-54ed-45a9-b8b2-1f67370b07f7'),
 ('2', '42', 'en_us', 'Cambridge ', '300 Technology Square, Suite 803G\r\nCambridge, MA 02139', '212.476.9900', '212.999.0000', 'Do you have a revolutionary innovation?', 'info@appletreepartners.com', 'Let\'s talk.', '42.36344', '-71.09147', '2016-06-15 20:03:58', '2016-07-13 21:20:34', 'e9c39c22-dae1-41fb-ae14-07995d71516e'),
 ('3', '43', 'en_us', 'Los Altos', '4970 El Camino Real, Suite 220\r\nLos Altos, CA 94022', '212.476.9900', '212.999.0000', 'Do you have a revolutionary innovation?', 'info@appletreepartners.com', 'Let\'s talk.', '37.39760', '-122.10632', '2016-06-15 20:03:58', '2016-07-13 21:20:34', '444fb097-2516-479d-9dc5-f76d7f8516b9'),
 ('4', '48', 'en_us', 'New York', '230 Park Avenue, Suite 2800\r\nNew York, New York 10169', '212.476.9900', '212.999.0000', 'Do you have a revolutionary innovation?', 'info@appletreepartners.com', '', '0.00000', '0.00000', '2016-06-15 20:30:16', '2016-07-13 18:21:00', '85506e20-3c34-4d13-91b6-d2aa86933e9c'),
 ('5', '49', 'en_us', 'Cambridge', '300 Technology Square, Suite 803G\r\nCambridge, MA 02139', '212.476.9900', '212.999.0000', 'Do you have a revolutionary innovation?', 'info@appletreepartners.com', '', '0.00000', '0.00000', '2016-06-15 20:30:16', '2016-07-13 18:21:00', 'f5cb73e1-54be-4544-9213-9d9aee416902'),
 ('6', '50', 'en_us', 'Los Altos', '4970 El Camino Real, Suite 220\r\nLos Altos, CA 94022', '212.476.9900', '212.999.0000', 'Do you have a revolutionary innovation?', 'info@appletreepartners.com', '', '0.00000', '0.00000', '2016-06-15 20:30:16', '2016-07-13 18:21:00', '77194d1f-3b5f-495b-a0b4-07bbfaa7a2f5');



DROP TABLE IF EXISTS `craft_matrixcontent_partnerships`;


--
-- Schema for table `craft_matrixcontent_partnerships`
--
CREATE TABLE `craft_matrixcontent_partnerships` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `elementId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `field_partnership_partnershipInfo` text COLLATE utf8_unicode_ci,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_matrixcontent_partnerships_elementId_locale_unq_idx` (`elementId`,`locale`),
  KEY `craft_matrixcontent_partnerships_locale_fk` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=4 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_matrixcontent_partnerships`
--

INSERT INTO `craft_matrixcontent_partnerships` (`id`, `elementId`, `locale`, `field_partnership_partnershipInfo`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '62', 'en_us', '<h1><a href=\"http://atp.sdny.in/portfolio/braeburn-pharmaceuticals\">Braeburn Pharmaceuticals</a> is helping to change the conversation about opioid dependence. </h1>', '2016-06-22 14:39:26', '2016-07-13 21:11:57', 'b078a9f0-20e7-4126-a359-90526afc929a'),
 ('2', '63', 'en_us', '<h1><a href=\"http://atp.sdny.in/portfolio/tusker-medical\">Tusker Medical</a> is developing a suite of pediatric-focused technologies designed to avoid general anesthetics.</h1>', '2016-06-22 14:39:26', '2016-07-13 21:11:57', 'a1eb3aca-cae9-4172-b4ab-495b5d860028'),
 ('3', '64', 'en_us', '<h1><a href=\"http://atp.sdny.in/portfolio/cure-forward\">Cure Forward\'s</a> unique Clinical Trial Exchange platform empowers patients to govern their own care plans. </h1>', '2016-06-22 14:39:26', '2016-07-13 21:11:57', '2e187a54-5fc6-4737-91b2-10bb6ad5f89d');



DROP TABLE IF EXISTS `craft_matrixcontent_pressmaterials`;


--
-- Schema for table `craft_matrixcontent_pressmaterials`
--
CREATE TABLE `craft_matrixcontent_pressmaterials` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `elementId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `field_pressInfo_pressDescription` text COLLATE utf8_unicode_ci,
  `field_pressInfo_pressLink` text COLLATE utf8_unicode_ci,
  `field_pressTeam_headshotBioNames` varchar(50) COLLATE utf8_unicode_ci DEFAULT NULL,
  `field_pressInfo_pressHeader` text COLLATE utf8_unicode_ci,
  `field_brandAssets_brandAssetsHeader` text COLLATE utf8_unicode_ci,
  `field_pressTeam_pressTeamHeader` text COLLATE utf8_unicode_ci,
  `field_pressNews_pressNewsHeader` text COLLATE utf8_unicode_ci,
  `field_pressNews_pressNewsLink` text COLLATE utf8_unicode_ci,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_matrixcontent_pressmaterials_elementId_locale_unq_idx` (`elementId`,`locale`),
  KEY `craft_matrixcontent_pressmaterials_locale_fk` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=5 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_matrixcontent_pressmaterials`
--

INSERT INTO `craft_matrixcontent_pressmaterials` (`id`, `elementId`, `locale`, `field_pressInfo_pressDescription`, `field_pressInfo_pressLink`, `field_pressTeam_headshotBioNames`, `field_pressInfo_pressHeader`, `field_brandAssets_brandAssetsHeader`, `field_pressTeam_pressTeamHeader`, `field_pressNews_pressNewsHeader`, `field_pressNews_pressNewsLink`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '76', 'en_us', 'Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam.', '<p>Didn’t find what you were looking for? <em>Get in touch.</em></p>', NULL, 'Press', NULL, NULL, NULL, NULL, '2016-07-06 21:49:07', '2016-07-14 20:30:23', 'e4971c58-b23c-4cdf-b71a-73754e34c524'),
 ('2', '77', 'en_us', NULL, NULL, NULL, NULL, 'Brand Assets', NULL, NULL, NULL, '2016-07-06 21:49:07', '2016-07-14 20:30:23', 'd29ecb3b-fae2-408b-8233-e63d70483060'),
 ('3', '78', 'en_us', NULL, NULL, '', NULL, NULL, 'Headshots and Bios', NULL, NULL, '2016-07-06 21:49:07', '2016-07-14 20:30:23', '6d71b0c5-ebf5-4263-b3ce-9d32d44b88a8'),
 ('4', '79', 'en_us', NULL, NULL, NULL, NULL, NULL, NULL, 'Recent News', '<p>More Press Releases on our <em>News Page</em></p>', '2016-07-06 22:06:29', '2016-07-14 20:30:23', 'a775192c-06cd-474d-b1e9-79af1e3cd8ba');



DROP TABLE IF EXISTS `craft_matrixcontent_teammembercontactmethods`;


--
-- Schema for table `craft_matrixcontent_teammembercontactmethods`
--
CREATE TABLE `craft_matrixcontent_teammembercontactmethods` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `elementId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `field_contactMethods_email` text COLLATE utf8_unicode_ci,
  `field_contactMethods_linkedin` text COLLATE utf8_unicode_ci,
  `field_contactMethods_phone` text COLLATE utf8_unicode_ci,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_matrixconten_teammembercontactmetho_elementI_locale_unq_id` (`elementId`,`locale`),
  KEY `craft_matrixcontent_teammembercontactmethods_locale_fk` (`locale`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_matrixcontent_teams`;


--
-- Schema for table `craft_matrixcontent_teams`
--
CREATE TABLE `craft_matrixcontent_teams` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `elementId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `field_teamName_teamName` text COLLATE utf8_unicode_ci,
  `field_teamName_teamDescription` text COLLATE utf8_unicode_ci,
  `field_teamName_teamLink` varchar(50) COLLATE utf8_unicode_ci DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_matrixcontent_teams_elementId_locale_unq_idx` (`elementId`,`locale`),
  KEY `craft_matrixcontent_teams_locale_idx` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=5 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_matrixcontent_teams`
--

INSERT INTO `craft_matrixcontent_teams` (`id`, `elementId`, `locale`, `field_teamName_teamName`, `field_teamName_teamDescription`, `field_teamName_teamLink`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '23', 'en_us', 'Finance & Administration', '<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.</p>', '', '2016-06-14 16:06:35', '2016-07-14 16:36:40', '801ed017-4c2e-4703-86a7-3b0ee5a34533'),
 ('2', '24', 'en_us', 'Therapeutics', '<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.</p>', 'See the Therapeutics portfolio', '2016-06-14 16:06:35', '2016-07-14 16:36:40', '0c1337be-f6dd-4229-a597-b84216c2cb62'),
 ('3', '25', 'en_us', 'Medical Devices', '<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.</p>', 'See the Medical Devices portfolio', '2016-06-14 16:06:35', '2016-07-14 16:36:40', 'd7aa6c47-19fb-4dca-b4d3-ac1523ae1112'),
 ('4', '26', 'en_us', 'Healthcare Services', '<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et nunc nec ex egestas mollis at vel orci. Cras eu volutpat libero. Aenean blandit porttitor ex, nec aliquam elit consequat ac. Vivamus at nibh sit amet enim ornare lacinia. In vitae dui id risus elementum euismod a et augue. Sed sit amet finibus tellus, ut tincidunt tellus. Nam cursus arcu eu tortor dapibus cursus. Cras a turpis sed diam tempor ornare id quis est. Quisque arcu est, pulvinar ac leo ac, hendrerit sodales sapien.</p>', 'See the Healthcare Services portfolio', '2016-06-14 16:06:35', '2016-07-14 16:36:40', 'da5d24fa-2b33-4b2c-802c-c568596c4fa7');



DROP TABLE IF EXISTS `craft_matrixcontent_trajectories`;


--
-- Schema for table `craft_matrixcontent_trajectories`
--
CREATE TABLE `craft_matrixcontent_trajectories` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `elementId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `field_trajectory_trajectoryTitle` text COLLATE utf8_unicode_ci,
  `field_trajectory_trajectoryDescription` text COLLATE utf8_unicode_ci,
  `field_trajectory_trajectoryBody` varchar(200) COLLATE utf8_unicode_ci DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_matrixcontent_trajectories_elementId_locale_unq_idx` (`elementId`,`locale`),
  KEY `craft_matrixcontent_trajectories_locale_fk` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=4 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_matrixcontent_trajectories`
--

INSERT INTO `craft_matrixcontent_trajectories` (`id`, `elementId`, `locale`, `field_trajectory_trajectoryTitle`, `field_trajectory_trajectoryDescription`, `field_trajectory_trajectoryBody`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '39', 'en_us', '250', 'Commitments as high as $250 million ', 'We scale to the buy-out or growth equity level by taking the long view, both as a matter of principle and for value creation.', '2016-06-15 19:06:53', '2016-07-13 21:11:57', 'a6065efb-3072-4264-a957-db1cca31edfa'),
 ('2', '40', 'en_us', '16', '16 portfolio companies', 'We start companies, or invest in existing companies, that bring products to patients. ', '2016-06-15 19:06:53', '2016-07-13 21:11:57', '864d0003-2e89-4f0b-95af-9b3f84127666'),
 ('3', '74', 'en_us', '1.67', '$1.67 billion dedicated to building healthcare businesses', 'We closed our current capital pool of $1.5 billion in 2012 and are actively funding healthcare innovation.', '2016-06-28 20:56:54', '2016-07-13 21:11:57', '723b474b-4db5-4543-86d7-235dba6c5778');



DROP TABLE IF EXISTS `craft_migrations`;


--
-- Schema for table `craft_migrations`
--
CREATE TABLE `craft_migrations` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `pluginId` int(11) DEFAULT NULL,
  `version` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `applyTime` datetime NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_migrations_version_unq_idx` (`version`),
  KEY `craft_migrations_pluginId_fk` (`pluginId`)
) ENGINE=InnoDB AUTO_INCREMENT=34 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_migrations`
--

INSERT INTO `craft_migrations` (`id`, `pluginId`, `version`, `applyTime`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', NULL, 'm000000_000000_base', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '459a8c76-b7aa-45ee-af4d-e47791a9aca1'),
 ('2', NULL, 'm140730_000001_add_filename_and_format_to_transformindex', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', 'fabb778f-901c-41fe-880c-3563e171e5c3'),
 ('3', NULL, 'm140815_000001_add_format_to_transforms', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '6f2e6ac2-ceee-4490-b736-940b91e97aae'),
 ('4', NULL, 'm140822_000001_allow_more_than_128_items_per_field', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', 'c188971d-07a5-42a9-928b-e8eff377b0e7'),
 ('5', NULL, 'm140829_000001_single_title_formats', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', 'b3fb10e4-0af6-41c4-b147-0ead22a1825e'),
 ('6', NULL, 'm140831_000001_extended_cache_keys', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', 'ee8f9424-767c-4ce4-b57d-5a68651e90cb'),
 ('7', NULL, 'm140922_000001_delete_orphaned_matrix_blocks', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', 'd7528285-b4c9-4f2f-b293-7a5db408a3bb'),
 ('8', NULL, 'm141008_000001_elements_index_tune', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '9d858fb9-55ca-4781-8256-45b6be152f22'),
 ('9', NULL, 'm141009_000001_assets_source_handle', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', 'd15822b1-1cf7-494f-8b25-3b25bd45a0e0'),
 ('10', NULL, 'm141024_000001_field_layout_tabs', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', 'f35dfa51-ef67-4fb0-a3d1-1171e0ae0eda'),
 ('11', NULL, 'm141030_000000_plugin_schema_versions', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', 'a4e8f460-6766-492e-8078-e95c50f7c53d'),
 ('12', NULL, 'm141030_000001_drop_structure_move_permission', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', 'c9c1d913-a81d-4fff-9041-40adedd35574'),
 ('13', NULL, 'm141103_000001_tag_titles', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '0aa2af4a-2bf7-415c-bd8a-eba7e8d9d1c9'),
 ('14', NULL, 'm141109_000001_user_status_shuffle', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '24543a29-921c-4402-8ee5-a77380da48fe'),
 ('15', NULL, 'm141126_000001_user_week_start_day', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '5e3a178f-0d53-4830-8d95-9000a3601638'),
 ('16', NULL, 'm150210_000001_adjust_user_photo_size', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '786b6862-d639-4502-81cb-a40322e80882'),
 ('17', NULL, 'm150724_000001_adjust_quality_settings', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '0c33d4cf-fbf5-406e-97a3-967ea43f9d9a'),
 ('18', NULL, 'm150827_000000_element_index_settings', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '9978bf52-3f89-4474-b403-206f7a0356b7'),
 ('19', NULL, 'm150918_000001_add_colspan_to_widgets', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '21c06d23-8308-4c19-a58e-7b79bdf60107'),
 ('20', NULL, 'm151007_000000_clear_asset_caches', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', 'f8550d82-0ac0-4504-a7c6-6d79b40ab568'),
 ('21', NULL, 'm151109_000000_text_url_formats', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '4382b116-6319-4d6d-a1a5-dd78922da998'),
 ('22', NULL, 'm151110_000000_move_logo', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '6462e80f-f440-4332-9cba-fac3395112a8'),
 ('23', NULL, 'm151117_000000_adjust_image_widthheight', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '0fe2869e-e4a7-405c-bc5b-791c5a5422a5'),
 ('24', NULL, 'm151127_000000_clear_license_key_status', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '8c969eb8-beb7-4d46-8b1e-0767470cd932'),
 ('25', NULL, 'm151127_000000_plugin_license_keys', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '91845c74-b428-41ac-85a6-a7f802f18897'),
 ('26', NULL, 'm151130_000000_update_pt_widget_feeds', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', 'dae9a309-e6ed-4d8a-a75b-16100d870eeb'),
 ('27', NULL, 'm160114_000000_asset_sources_public_url_default_true', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '4dcde6ac-6027-4797-9fb3-92634140c801'),
 ('28', NULL, 'm160223_000000_sortorder_to_smallint', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '509b9005-a4b8-4708-a41a-6dde85856877'),
 ('29', NULL, 'm160229_000000_set_default_entry_statuses', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '8589565e-1d84-4911-a486-285c6fda20bd'),
 ('30', NULL, 'm160304_000000_client_permissions', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', 'c5c5132c-0578-426e-ade4-53b4a0e26655'),
 ('31', NULL, 'm160322_000000_asset_filesize', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '5d5adfb0-36dd-42b2-a46e-891969834788'),
 ('32', NULL, 'm160503_000000_orphaned_fieldlayouts', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', 'dad3938a-255e-4e3a-a6a8-671783eaa55d'),
 ('33', NULL, 'm160510_000000_tasksettings', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '2016-06-10 14:33:28', '7f0ab305-88f2-41fa-9f38-11bddd3a99fc');



DROP TABLE IF EXISTS `craft_plugins`;


--
-- Schema for table `craft_plugins`
--
CREATE TABLE `craft_plugins` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `class` varchar(150) COLLATE utf8_unicode_ci NOT NULL,
  `version` varchar(15) COLLATE utf8_unicode_ci NOT NULL,
  `schemaVersion` varchar(15) COLLATE utf8_unicode_ci DEFAULT NULL,
  `licenseKey` char(24) COLLATE utf8_unicode_ci DEFAULT NULL,
  `licenseKeyStatus` enum('valid','invalid','mismatched','unknown') COLLATE utf8_unicode_ci NOT NULL DEFAULT 'unknown',
  `enabled` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `settings` text COLLATE utf8_unicode_ci,
  `installDate` datetime NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=3 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_plugins`
--

INSERT INTO `craft_plugins` (`id`, `class`, `version`, `schemaVersion`, `licenseKey`, `licenseKeyStatus`, `enabled`, `settings`, `installDate`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('2', 'Shortener', '1.1', NULL, NULL, 'unknown', '1', '{\"token\":\"fdb458380d37e3f9872dbd6cb981c098c492581e\",\"cacheTime\":\"604800\",\"domain\":\"bit.ly\",\"customDomain\":\"\"}', '2016-07-15 16:34:34', '2016-07-15 16:34:34', '2016-07-15 16:40:07', '79097dda-7631-486b-97d8-832ca8f3293c');



DROP TABLE IF EXISTS `craft_rackspaceaccess`;


--
-- Schema for table `craft_rackspaceaccess`
--
CREATE TABLE `craft_rackspaceaccess` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `connectionKey` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `token` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `storageUrl` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `cdnUrl` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_rackspaceaccess_connectionKey_unq_idx` (`connectionKey`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_relations`;


--
-- Schema for table `craft_relations`
--
CREATE TABLE `craft_relations` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `fieldId` int(11) NOT NULL,
  `sourceId` int(11) NOT NULL,
  `sourceLocale` char(12) COLLATE utf8_unicode_ci DEFAULT NULL,
  `targetId` int(11) NOT NULL,
  `sortOrder` smallint(6) DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_relations_fieldId_sourceId_sourceLocale_targetId_unq_idx` (`fieldId`,`sourceId`,`sourceLocale`,`targetId`),
  KEY `craft_relations_sourceId_fk` (`sourceId`),
  KEY `craft_relations_sourceLocale_fk` (`sourceLocale`),
  KEY `craft_relations_targetId_fk` (`targetId`)
) ENGINE=InnoDB AUTO_INCREMENT=1290 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_relations`
--

INSERT INTO `craft_relations` (`id`, `fieldId`, `sourceId`, `sourceLocale`, `targetId`, `sortOrder`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('503', '110', '141', NULL, '101', '1', '2016-07-11 21:24:27', '2016-07-11 21:24:27', 'f6b9bbe5-de04-4a07-a159-85a102f9a9f2'),
 ('506', '110', '144', NULL, '101', '1', '2016-07-11 21:25:28', '2016-07-11 21:25:28', '14e2b96e-cf8f-4c24-9e83-aea522f09d72'),
 ('680', '129', '146', NULL, '90', '1', '2016-07-12 00:28:03', '2016-07-12 00:28:03', '86b2b19c-0117-4100-8551-763b6cf264fd'),
 ('681', '110', '146', NULL, '101', '1', '2016-07-12 00:28:03', '2016-07-12 00:28:03', '133addac-7095-468d-993d-d7750fb59810'),
 ('684', '129', '143', NULL, '90', '1', '2016-07-12 00:28:23', '2016-07-12 00:28:23', 'abec2e27-5b63-4109-8a86-6a6a09b4d985'),
 ('685', '110', '143', NULL, '101', '1', '2016-07-12 00:28:23', '2016-07-12 00:28:23', '8203c826-fa61-43c9-822d-f76b5d013d4d'),
 ('686', '129', '145', NULL, '90', '1', '2016-07-12 00:28:30', '2016-07-12 00:28:30', '1f7e057c-95f2-4e45-a3b9-557424098f10'),
 ('687', '110', '145', NULL, '101', '1', '2016-07-12 00:28:30', '2016-07-12 00:28:30', 'de078a2b-6cb9-4f79-b940-6a30cb22f69c'),
 ('690', '129', '142', NULL, '90', '1', '2016-07-12 00:28:47', '2016-07-12 00:28:47', '507e00a0-a090-43b3-9759-b8b3c04f80ab'),
 ('691', '110', '142', NULL, '101', '1', '2016-07-12 00:28:47', '2016-07-12 00:28:47', 'd19225e5-9a52-49ef-b0b8-160e228ca5da'),
 ('895', '66', '298', NULL, '372', '1', '2016-07-13 16:27:51', '2016-07-13 16:27:51', '65ab5b77-c6d7-4f1c-9412-255f81504498'),
 ('896', '130', '298', NULL, '92', '1', '2016-07-13 16:27:51', '2016-07-13 16:27:51', '5ccd17ce-9166-4e09-93c8-ca185688307a'),
 ('897', '103', '298', NULL, '97', '1', '2016-07-13 16:27:51', '2016-07-13 16:27:51', '03881e49-a3ca-4221-8606-4581f0683fe2'),
 ('901', '66', '293', NULL, '363', '1', '2016-07-13 16:28:41', '2016-07-13 16:28:41', '1abd1848-338b-4f9d-82fa-5fcd0571fd11'),
 ('902', '130', '293', NULL, '89', '1', '2016-07-13 16:28:41', '2016-07-13 16:28:41', '6ba6b38e-5d2e-4a44-9565-0cc509b2d203'),
 ('903', '103', '293', NULL, '96', '1', '2016-07-13 16:28:42', '2016-07-13 16:28:42', '20845d6d-6a38-4e77-8ef3-098296afc1e8'),
 ('904', '66', '290', NULL, '365', '1', '2016-07-13 16:29:12', '2016-07-13 16:29:12', '1fe599c3-4a16-4115-9b14-dcf7fad00713'),
 ('905', '130', '290', NULL, '95', '1', '2016-07-13 16:29:12', '2016-07-13 16:29:12', 'b1562fdd-99ef-463d-93b1-21ba68a6de3f'),
 ('906', '103', '290', NULL, '376', '1', '2016-07-13 16:29:12', '2016-07-13 16:29:12', 'a3ab86d8-5246-45e7-8772-78a6a9b2e147'),
 ('910', '66', '284', NULL, '362', '1', '2016-07-13 16:29:54', '2016-07-13 16:29:54', '77e54574-3279-4d65-a8a0-b6c20d3a42a4'),
 ('911', '130', '284', NULL, '95', '1', '2016-07-13 16:29:54', '2016-07-13 16:29:54', 'f9dbee44-cb10-46c2-914b-0fe0b89005b1'),
 ('912', '103', '284', NULL, '100', '1', '2016-07-13 16:29:54', '2016-07-13 16:29:54', 'f7cf87da-2c3d-4003-a503-4e8d1aef831a'),
 ('913', '66', '281', NULL, '370', '1', '2016-07-13 16:30:20', '2016-07-13 16:30:20', 'c34c819c-f814-47a7-8b21-b986ffeec161'),
 ('914', '130', '281', NULL, '90', '1', '2016-07-13 16:30:20', '2016-07-13 16:30:20', '6af17f37-0ba2-4965-9b15-728b23e81d61'),
 ('915', '103', '281', NULL, '376', '1', '2016-07-13 16:30:20', '2016-07-13 16:30:20', '5d20d485-e6ec-49f1-b55a-11f3a7d5d585'),
 ('916', '66', '275', NULL, '374', '1', '2016-07-13 16:30:36', '2016-07-13 16:30:36', 'a9554b99-2813-4c1a-ab77-667262ded51c'),
 ('917', '130', '275', NULL, '89', '1', '2016-07-13 16:30:36', '2016-07-13 16:30:36', '3c99b750-8f73-4ce9-a713-436ab2c84ebe'),
 ('918', '103', '275', NULL, '96', '1', '2016-07-13 16:30:36', '2016-07-13 16:30:36', '299b0f96-e618-4947-84cd-a40c60a2c91b'),
 ('919', '66', '250', NULL, '369', '1', '2016-07-13 16:30:57', '2016-07-13 16:30:57', '5e7977ad-68a1-4192-b57b-85db5e5e10f5'),
 ('920', '130', '250', NULL, '90', '1', '2016-07-13 16:30:57', '2016-07-13 16:30:57', '9b7d2a3e-d2d2-4d53-9d4a-e8a3b040c9b8'),
 ('921', '103', '250', NULL, '376', '1', '2016-07-13 16:30:57', '2016-07-13 16:30:57', '084a835d-f060-4151-8923-526e6d79076e'),
 ('922', '66', '248', NULL, '367', '1', '2016-07-13 16:31:14', '2016-07-13 16:31:14', '69ceed2d-4ff2-4bcd-bebe-bb5e92fc387b'),
 ('923', '130', '248', NULL, '90', '1', '2016-07-13 16:31:14', '2016-07-13 16:31:14', 'f0e7eb7a-eaad-42ea-829b-2c6d83461aa8'),
 ('924', '103', '248', NULL, '376', '1', '2016-07-13 16:31:14', '2016-07-13 16:31:14', '2f4c4c54-8ea3-4309-a87c-6827124ded89'),
 ('927', '66', '244', NULL, '373', '1', '2016-07-13 16:31:59', '2016-07-13 16:31:59', '7af00116-5de0-446f-ad06-48d1979cf325'),
 ('928', '130', '244', NULL, '89', '1', '2016-07-13 16:31:59', '2016-07-13 16:31:59', 'ebb06bc5-e536-40bd-9e0a-e39f5c19faa4'),
 ('929', '103', '244', NULL, '96', '1', '2016-07-13 16:31:59', '2016-07-13 16:31:59', 'd3e6ceed-8f2c-4e32-9212-15c12a236d61'),
 ('933', '130', '239', NULL, '95', '1', '2016-07-13 16:32:34', '2016-07-13 16:32:34', '83e7a17e-e942-40ce-952c-3f007af4e6b9'),
 ('934', '103', '239', NULL, '100', '1', '2016-07-13 16:32:34', '2016-07-13 16:32:34', '51a29370-66cb-4368-b4f6-1eb05363cef0'),
 ('937', '66', '204', NULL, '366', '1', '2016-07-13 16:33:16', '2016-07-13 16:33:16', '5c61c90b-d43c-405f-84ca-785e68a5d5fc'),
 ('938', '130', '204', NULL, '89', '1', '2016-07-13 16:33:16', '2016-07-13 16:33:16', '12190ea1-6a23-4103-8045-3e8b8bfc177c'),
 ('939', '103', '204', NULL, '96', '1', '2016-07-13 16:33:16', '2016-07-13 16:33:16', 'b8614a8f-d823-4c80-9932-503c3cc26308'),
 ('940', '66', '200', NULL, '361', '1', '2016-07-13 16:33:35', '2016-07-13 16:33:35', '8055d0b1-ffa5-4c4c-9cd1-672c949005e8'),
 ('941', '130', '200', NULL, '95', '1', '2016-07-13 16:33:35', '2016-07-13 16:33:35', '9b906c08-18f0-43d4-ba76-ff508fc3d91f'),
 ('942', '103', '200', NULL, '100', '1', '2016-07-13 16:33:35', '2016-07-13 16:33:35', '4e37e0c5-6c6c-442b-b165-45ba4b1eb55f'),
 ('943', '66', '27', NULL, '364', '1', '2016-07-13 16:33:56', '2016-07-13 16:33:56', '2664e585-80fc-4811-acc5-322904fb889b'),
 ('944', '130', '27', NULL, '95', '1', '2016-07-13 16:33:56', '2016-07-13 16:33:56', 'ba07731d-8e59-4778-9ad1-d11bbea14d9f'),
 ('945', '103', '27', NULL, '70', '1', '2016-07-13 16:33:56', '2016-07-13 16:33:56', '3ad05a26-f6a6-4323-8aa0-18ad72e9e771'),
 ('974', '66', '287', NULL, '371', '1', '2016-07-13 16:38:44', '2016-07-13 16:38:44', '66332bae-a4b3-4da6-855f-41e01513e9fc'),
 ('975', '130', '287', NULL, '90', '1', '2016-07-13 16:38:44', '2016-07-13 16:38:44', 'f62941cc-49ca-4189-b66a-52c6ddaa47e7'),
 ('976', '103', '287', NULL, '100', '1', '2016-07-13 16:38:44', '2016-07-13 16:38:44', '89d56097-c8ba-4326-b17f-a62a585b4d2c'),
 ('985', '129', '105', NULL, '95', '1', '2016-07-13 16:54:50', '2016-07-13 16:54:50', 'eaeedc54-5f61-4c6d-b05b-4a209b5627d1'),
 ('986', '110', '105', NULL, '100', '1', '2016-07-13 16:54:50', '2016-07-13 16:54:50', '9f9e6f0d-281c-43de-bce3-e8c219f1933b'),
 ('987', '104', '105', NULL, '284', '1', '2016-07-13 16:54:50', '2016-07-13 16:54:50', '7c85f139-8949-4fba-a66f-426de7530351'),
 ('988', '129', '106', NULL, '95', '1', '2016-07-13 16:56:01', '2016-07-13 16:56:01', '8cc21604-d32a-47ce-a4bb-c2fd8c463e16'),
 ('989', '110', '106', NULL, '100', '1', '2016-07-13 16:56:01', '2016-07-13 16:56:01', '28d8800b-d7a1-4640-81fb-a8a0e1df93fb'),
 ('990', '104', '106', NULL, '244', '1', '2016-07-13 16:56:01', '2016-07-13 16:56:01', 'a69e73fe-d5e2-4e92-a328-a6ac5c8e22dc'),
 ('991', '104', '106', NULL, '239', '2', '2016-07-13 16:56:01', '2016-07-13 16:56:01', 'd33112d3-cd80-4473-9eaa-5c2f7c589fed'),
 ('992', '104', '106', NULL, '284', '3', '2016-07-13 16:56:01', '2016-07-13 16:56:01', '455ee5b3-a281-40bb-9340-42d68d8fa48e'),
 ('993', '129', '125', NULL, '95', '1', '2016-07-13 16:56:41', '2016-07-13 16:56:41', '20ab32b4-aec1-486f-945d-2ac22662cd7d'),
 ('994', '110', '125', NULL, '100', '1', '2016-07-13 16:56:41', '2016-07-13 16:56:41', '707c2c76-413e-4670-92a4-991f287d2fca'),
 ('1051', '143', '379', NULL, '377', '1', '2016-07-13 17:10:34', '2016-07-13 17:10:34', '578fab71-1428-4c03-b035-9e5b4a849165'),
 ('1058', '66', '242', NULL, '381', '1', '2016-07-13 17:19:52', '2016-07-13 17:19:52', '59a2749e-70f8-4c9e-8175-243d4d468ab7'),
 ('1059', '130', '242', NULL, '92', '1', '2016-07-13 17:19:52', '2016-07-13 17:19:52', 'fa361ac4-df5c-447e-8c1f-61627b2de9ea'),
 ('1060', '103', '242', NULL, '97', '1', '2016-07-13 17:19:52', '2016-07-13 17:19:52', '3712c885-d007-4b1e-828c-9d53d1188b69'),
 ('1063', '129', '126', NULL, '95', '1', '2016-07-13 17:23:31', '2016-07-13 17:23:31', '8901c851-de5b-4c7e-b0aa-60ab1c3fd595'),
 ('1064', '110', '126', NULL, '100', '1', '2016-07-13 17:23:31', '2016-07-13 17:23:31', '10243a54-8e66-43a5-8220-737df41ed198'),
 ('1067', '129', '108', NULL, '95', '1', '2016-07-13 17:25:02', '2016-07-13 17:25:02', '4819a49b-3899-43fc-a2e3-67b29981a0dd'),
 ('1068', '110', '108', NULL, '100', '1', '2016-07-13 17:25:02', '2016-07-13 17:25:02', '272f6a5d-7a4b-4769-934d-0924faeb72ff'),
 ('1069', '129', '109', NULL, '95', '1', '2016-07-13 17:26:39', '2016-07-13 17:26:39', '0532d182-20e6-4882-a2cd-e78966d121d1'),
 ('1070', '110', '109', NULL, '100', '1', '2016-07-13 17:26:39', '2016-07-13 17:26:39', 'c7223ca2-5ea2-4bf3-bbab-6c4ad1327376'),
 ('1071', '129', '123', NULL, '95', '1', '2016-07-13 17:27:41', '2016-07-13 17:27:41', '488a4987-cf2e-48b1-a77b-35983381e6cf'),
 ('1072', '110', '123', NULL, '100', '1', '2016-07-13 17:27:41', '2016-07-13 17:27:41', '9150fc9a-c856-4737-8111-c4d7d6df9ed6'),
 ('1073', '129', '113', NULL, '95', '1', '2016-07-13 17:28:32', '2016-07-13 17:28:32', '581e0fe9-2e3e-48a7-9ae6-8155269003af'),
 ('1074', '110', '113', NULL, '100', '1', '2016-07-13 17:28:32', '2016-07-13 17:28:32', 'd6350ea4-2301-4f08-8e8a-241fc56698e3'),
 ('1075', '104', '113', NULL, '204', '1', '2016-07-13 17:28:32', '2016-07-13 17:28:32', 'b113dc74-0e3d-4442-8ff4-3caccfdde716'),
 ('1076', '129', '29', NULL, '90', '1', '2016-07-13 17:29:25', '2016-07-13 17:29:25', 'cf2c5fd2-d192-43c7-af32-66bf38461a5f'),
 ('1077', '110', '29', NULL, '100', '1', '2016-07-13 17:29:25', '2016-07-13 17:29:25', '7f0a054b-37ea-4431-8eb0-a4edb6504fd7'),
 ('1078', '104', '29', NULL, '239', '1', '2016-07-13 17:29:25', '2016-07-13 17:29:25', '30a08d73-492d-4b51-88d3-1a61d9de7404'),
 ('1079', '104', '29', NULL, '244', '2', '2016-07-13 17:29:25', '2016-07-13 17:29:25', 'e47eebfd-be5f-4f86-81c4-1bf669660a67'),
 ('1080', '104', '29', NULL, '284', '3', '2016-07-13 17:29:25', '2016-07-13 17:29:25', 'f56007a3-de1b-4255-bf8f-f76d5c8c86b7'),
 ('1081', '129', '55', NULL, '92', '1', '2016-07-13 17:30:51', '2016-07-13 17:30:51', 'a1810faf-c91e-48e8-bb49-340c620a699b'),
 ('1082', '110', '55', NULL, '97', '1', '2016-07-13 17:30:51', '2016-07-13 17:30:51', 'e851fbe7-c9ba-4b0f-99ef-286b5519ee0f'),
 ('1083', '104', '55', NULL, '242', '1', '2016-07-13 17:30:51', '2016-07-13 17:30:51', '9d3c7ffe-890a-4c04-b3c1-8b2e9897e69a'),
 ('1084', '104', '55', NULL, '298', '2', '2016-07-13 17:30:51', '2016-07-13 17:30:51', '233438f4-a7a7-47a5-9af1-fb9359a84169'),
 ('1085', '129', '57', NULL, '92', '1', '2016-07-13 17:33:12', '2016-07-13 17:33:12', 'ccd73d51-19a6-4fe6-a6e2-21e349a1d637'),
 ('1086', '110', '57', NULL, '97', '1', '2016-07-13 17:33:12', '2016-07-13 17:33:12', '67dbaffd-4975-405d-9b42-4fd35b91e9b5'),
 ('1087', '104', '57', NULL, '298', '1', '2016-07-13 17:33:12', '2016-07-13 17:33:12', '93b40f09-4cb9-4ee4-8bc9-2847eddd0fbb'),
 ('1088', '104', '57', NULL, '275', '2', '2016-07-13 17:33:12', '2016-07-13 17:33:12', '3645dc0e-a021-4bbb-81bd-4b3b0ee0ce8a'),
 ('1089', '104', '57', NULL, '296', '3', '2016-07-13 17:33:12', '2016-07-13 17:33:12', '352cb59c-bcab-4115-a3a4-56b7932e8654'),
 ('1090', '104', '57', NULL, '200', '4', '2016-07-13 17:33:12', '2016-07-13 17:33:12', '97b2db12-3b37-42f4-8558-bafca7870667'),
 ('1091', '104', '57', NULL, '242', '5', '2016-07-13 17:33:12', '2016-07-13 17:33:12', '994c9a2b-c8cc-4ca4-9ae0-31c19744552d'),
 ('1092', '104', '57', NULL, '287', '6', '2016-07-13 17:33:12', '2016-07-13 17:33:12', '5af291b1-332c-4db4-81d3-bcc7a2176213'),
 ('1093', '129', '107', NULL, '92', '1', '2016-07-13 17:36:08', '2016-07-13 17:36:08', '8207e082-3758-433a-807e-681577b10816'),
 ('1094', '110', '107', NULL, '97', '1', '2016-07-13 17:36:08', '2016-07-13 17:36:08', '3479a887-7aaa-4e81-bfb9-e59fdaf8842f'),
 ('1095', '104', '107', NULL, '242', '1', '2016-07-13 17:36:08', '2016-07-13 17:36:08', '43054a05-3cbe-478b-9d2e-8b57fb9408ad'),
 ('1096', '104', '107', NULL, '298', '2', '2016-07-13 17:36:08', '2016-07-13 17:36:08', '5ed67311-bd82-4c81-853c-f2b6313070e3'),
 ('1097', '129', '128', NULL, '92', '1', '2016-07-13 17:37:59', '2016-07-13 17:37:59', '47c19be2-fce3-478c-bd2e-5e55b2e3664a'),
 ('1098', '110', '128', NULL, '97', '1', '2016-07-13 17:37:59', '2016-07-13 17:37:59', '7d04755d-9a37-42cc-8b5e-bd31fbaffed1'),
 ('1102', '129', '116', NULL, '92', '1', '2016-07-13 17:44:33', '2016-07-13 17:44:33', 'f49c354c-c255-4a85-8fb0-7ae0fb8214f9');
INSERT INTO `craft_relations` (`id`, `fieldId`, `sourceId`, `sourceLocale`, `targetId`, `sortOrder`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1103', '110', '116', NULL, '97', '1', '2016-07-13 17:44:33', '2016-07-13 17:44:33', '63bb622b-9419-43d9-ad75-4fbcffc7ef53'),
 ('1104', '129', '53', NULL, '89', '1', '2016-07-13 17:46:39', '2016-07-13 17:46:39', '234ec709-bca3-4dcb-8348-124bd5fffd31'),
 ('1105', '110', '53', NULL, '96', '1', '2016-07-13 17:46:39', '2016-07-13 17:46:39', '49b444af-2682-43cf-bdad-525a4260f4ce'),
 ('1106', '104', '53', NULL, '293', '1', '2016-07-13 17:46:39', '2016-07-13 17:46:39', '21f907a7-5ab9-4a9d-ae5f-d736c4cec130'),
 ('1107', '104', '53', NULL, '204', '2', '2016-07-13 17:46:39', '2016-07-13 17:46:39', '591b2564-a733-452f-a5e1-78359db72f24'),
 ('1108', '104', '53', NULL, '275', '3', '2016-07-13 17:46:39', '2016-07-13 17:46:39', '89c98387-d54c-4c3d-b7c8-2d69e965dad7'),
 ('1109', '129', '102', NULL, '89', '1', '2016-07-13 17:47:35', '2016-07-13 17:47:35', 'f174b21f-a681-47b0-9eb9-c4da452357ea'),
 ('1110', '110', '102', NULL, '96', '1', '2016-07-13 17:47:35', '2016-07-13 17:47:35', '72574694-f19d-4fa9-992b-6bbbe4371b27'),
 ('1111', '129', '127', NULL, '89', '1', '2016-07-13 17:48:41', '2016-07-13 17:48:41', 'd2830159-4a0d-4e2d-9299-733bd84787fc'),
 ('1112', '110', '127', NULL, '96', '1', '2016-07-13 17:48:41', '2016-07-13 17:48:41', '7a36c6b9-8d28-40fd-b0b8-549fde37ad83'),
 ('1113', '104', '127', NULL, '204', '1', '2016-07-13 17:48:41', '2016-07-13 17:48:41', 'c24686e1-e3b4-4d26-8d24-f817edc1c1ea'),
 ('1114', '104', '127', NULL, '293', '2', '2016-07-13 17:48:41', '2016-07-13 17:48:41', '4245f15d-08a6-4ad5-b326-7d0a8231f0c6'),
 ('1115', '104', '127', NULL, '275', '3', '2016-07-13 17:48:41', '2016-07-13 17:48:41', '22065b3b-c745-4566-b68b-bdefbb280d5b'),
 ('1116', '104', '127', NULL, '244', '4', '2016-07-13 17:48:41', '2016-07-13 17:48:41', '9b3c8a40-2179-4a37-9624-f3ed00637b81'),
 ('1117', '129', '99', NULL, '90', '1', '2016-07-13 17:50:10', '2016-07-13 17:50:10', 'd49f1082-631c-46d4-9b29-36752ca1d8f8'),
 ('1118', '110', '99', NULL, '101', '1', '2016-07-13 17:50:10', '2016-07-13 17:50:10', '005dc587-fd57-44cd-b458-8917659c931b'),
 ('1119', '105', '4', NULL, '136', '1', '2016-07-13 18:21:00', '2016-07-13 18:21:00', 'b38dcfef-d75c-4e93-bf66-6e46b7b7edda'),
 ('1181', '129', '114', NULL, '95', '1', '2016-07-13 20:16:47', '2016-07-13 20:16:47', 'c018c1ef-0aa4-43eb-a913-50347ff37d10'),
 ('1182', '110', '114', NULL, '100', '1', '2016-07-13 20:16:47', '2016-07-13 20:16:47', 'b8117451-4bc5-41ec-8caa-7dc4587700d6'),
 ('1191', '66', '296', NULL, '375', '1', '2016-07-13 21:08:08', '2016-07-13 21:08:08', 'f3e313e6-78a6-444e-9ad3-feeb656503fa'),
 ('1192', '130', '296', NULL, '92', '1', '2016-07-13 21:08:08', '2016-07-13 21:08:08', '9b450a83-c8fb-49da-aefe-6274a698b4e1'),
 ('1193', '103', '296', NULL, '97', '1', '2016-07-13 21:08:08', '2016-07-13 21:08:08', '1e6aed5f-1d27-4303-864f-df72bf73e102'),
 ('1194', '3', '9', NULL, '87', '1', '2016-07-13 21:11:57', '2016-07-13 21:11:57', '764e7d2d-796e-471c-9b2a-0528b69da6f3'),
 ('1195', '69', '9', NULL, '14', '1', '2016-07-13 21:11:57', '2016-07-13 21:11:57', 'a2343d47-3bf4-4024-a74b-f20ee3d87048'),
 ('1196', '69', '9', NULL, '52', '2', '2016-07-13 21:11:57', '2016-07-13 21:11:57', '854a7cdf-22f9-49e0-b1a2-d619de699ade'),
 ('1197', '66', '229', NULL, '380', '1', '2016-07-13 21:14:28', '2016-07-13 21:14:28', '83081c11-6d23-43ef-8319-0d07ea180669'),
 ('1198', '130', '229', NULL, '90', '1', '2016-07-13 21:14:28', '2016-07-13 21:14:28', 'c4ceadff-d784-4903-acb9-631a4538ca8d'),
 ('1199', '103', '229', NULL, '376', '1', '2016-07-13 21:14:28', '2016-07-13 21:14:28', '50f22b72-5d08-4116-9d21-12e64df1bac0'),
 ('1200', '125', '19', NULL, '95', '1', '2016-07-13 21:16:21', '2016-07-13 21:16:21', 'cb954fb5-8851-4991-a6c3-4f643fb9b1af'),
 ('1201', '53', '19', NULL, '27', '1', '2016-07-13 21:16:21', '2016-07-13 21:16:21', 'dbe70e5b-6d11-4981-a335-1f3a9ca5813e'),
 ('1202', '53', '19', NULL, '200', '2', '2016-07-13 21:16:21', '2016-07-13 21:16:21', 'd9aeb2df-7260-41bd-b633-a033739bfc84'),
 ('1203', '53', '19', NULL, '239', '3', '2016-07-13 21:16:21', '2016-07-13 21:16:21', 'f6eae980-41a9-4169-b790-664bd4580776'),
 ('1204', '53', '19', NULL, '284', '4', '2016-07-13 21:16:21', '2016-07-13 21:16:21', '4c05cabc-4a7e-4195-a0ce-823d59a20f1f'),
 ('1205', '125', '20', NULL, '92', '1', '2016-07-13 21:16:21', '2016-07-13 21:16:21', '0b8ed5fc-ade8-4ce6-8691-588242ec2e0f'),
 ('1206', '53', '20', NULL, '242', '1', '2016-07-13 21:16:21', '2016-07-13 21:16:21', '407367a9-e7dc-4ab5-9bea-7720d6e937cb'),
 ('1207', '53', '20', NULL, '296', '2', '2016-07-13 21:16:21', '2016-07-13 21:16:21', '3da8bf4d-d563-465c-a8d4-e65750a8cdc7'),
 ('1208', '53', '20', NULL, '287', '3', '2016-07-13 21:16:21', '2016-07-13 21:16:21', '22f9f0e1-bd5b-4f92-9723-8c10aac57ae3'),
 ('1209', '53', '20', NULL, '298', '4', '2016-07-13 21:16:21', '2016-07-13 21:16:21', '0e57d7a9-9e67-4183-9c04-42c31b5592e4'),
 ('1210', '125', '21', NULL, '89', '1', '2016-07-13 21:16:21', '2016-07-13 21:16:21', '97e2dff9-7f9f-4802-ab25-ca20a36178c2'),
 ('1211', '53', '21', NULL, '204', '1', '2016-07-13 21:16:21', '2016-07-13 21:16:21', '2c9b152e-e097-4596-b7f0-43cbce051f34'),
 ('1212', '53', '21', NULL, '244', '2', '2016-07-13 21:16:21', '2016-07-13 21:16:21', 'ae96699b-5a4d-46d6-aa91-1b442f02b4fa'),
 ('1213', '53', '21', NULL, '275', '3', '2016-07-13 21:16:21', '2016-07-13 21:16:21', '07eaa18d-b4e1-49be-8e44-bfffaff6a84c'),
 ('1214', '53', '21', NULL, '293', '4', '2016-07-13 21:16:21', '2016-07-13 21:16:21', '30ad8c2f-206e-42f4-9564-2c545bf08a5f'),
 ('1215', '125', '22', NULL, '90', '1', '2016-07-13 21:16:21', '2016-07-13 21:16:21', '3d2871fb-673c-481a-aa2f-0ceeddf0867c'),
 ('1216', '53', '22', NULL, '229', '1', '2016-07-13 21:16:21', '2016-07-13 21:16:21', 'a19df397-045c-40ee-aab0-5c786473bab8'),
 ('1217', '53', '22', NULL, '246', '2', '2016-07-13 21:16:21', '2016-07-13 21:16:21', '2ef967ae-e297-41fd-b67f-2518704509ce'),
 ('1218', '53', '22', NULL, '248', '3', '2016-07-13 21:16:21', '2016-07-13 21:16:21', 'b0aec988-feb6-48e0-b7cc-72d7afe72fbb'),
 ('1219', '53', '22', NULL, '250', '4', '2016-07-13 21:16:21', '2016-07-13 21:16:21', '72ca4252-19dd-49d7-b97e-b97ac1d67b89'),
 ('1220', '53', '22', NULL, '281', '5', '2016-07-13 21:16:21', '2016-07-13 21:16:21', '9e3c0c4b-e0e0-4840-9a88-7dd5a97e96cb'),
 ('1221', '53', '22', NULL, '290', '6', '2016-07-13 21:16:21', '2016-07-13 21:16:21', 'f50a1e94-5318-46e2-8c78-45ea28848133'),
 ('1225', '66', '246', NULL, '382', '1', '2016-07-13 21:17:31', '2016-07-13 21:17:31', '07fad09a-9247-44c4-a48a-9ce9da97e77b'),
 ('1226', '130', '246', NULL, '90', '1', '2016-07-13 21:17:31', '2016-07-13 21:17:31', '29c73a85-4303-4de7-99ec-adb1a7c2025f'),
 ('1227', '103', '246', NULL, '376', '1', '2016-07-13 21:17:31', '2016-07-13 21:17:31', '7f626fa0-dc60-4799-9888-5748f1d9c2e8'),
 ('1239', '39', '12', NULL, '88', '1', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '4186fe99-bda5-409c-be2e-7aa9a3bd6ab0'),
 ('1240', '124', '24', NULL, '95', '1', '2016-07-14 16:36:40', '2016-07-14 16:36:40', 'c181ae4c-1254-4271-908a-dc0f95cb48d4'),
 ('1241', '54', '24', NULL, '29', '1', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '7be1d29e-7bed-43bd-96a3-83d53c35f855'),
 ('1242', '54', '24', NULL, '105', '2', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '6a92ee51-6b70-44f0-b10e-da38427b4916'),
 ('1243', '54', '24', NULL, '106', '3', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '71dd6dd5-f724-40ec-9c53-937790125ac9'),
 ('1244', '54', '24', NULL, '125', '4', '2016-07-14 16:36:40', '2016-07-14 16:36:40', 'b1746f3b-3e46-4de4-8452-1d1f8a06a4ed'),
 ('1245', '54', '24', NULL, '126', '5', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '71a243ef-c398-40d8-b4f1-c98722f731bd'),
 ('1246', '54', '24', NULL, '108', '6', '2016-07-14 16:36:40', '2016-07-14 16:36:40', 'e2436203-4938-4e33-af0a-20e94793bc55'),
 ('1247', '54', '24', NULL, '109', '7', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '7d70c63d-8766-4327-82a6-6d96905a4951'),
 ('1248', '54', '24', NULL, '123', '8', '2016-07-14 16:36:40', '2016-07-14 16:36:40', 'de0bb52b-4bfc-47ec-8fe9-6a9a5e36b4b8'),
 ('1249', '54', '24', NULL, '113', '9', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '17f480e0-9223-4b57-9480-a08e878da2cf'),
 ('1250', '54', '24', NULL, '114', '10', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '09f0dc82-bff1-467e-bef2-411f209018c8'),
 ('1251', '124', '25', NULL, '92', '1', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '7a290296-90ac-428d-8044-372aee7fac48'),
 ('1252', '54', '25', NULL, '55', '1', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '5e30d7aa-ef68-4e21-88dd-4d35748f5747'),
 ('1253', '54', '25', NULL, '57', '2', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '5d72013a-5bac-4161-81dc-f646054c74ef'),
 ('1254', '54', '25', NULL, '107', '3', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '3eab107f-795f-4014-9e26-4a6af86b998d'),
 ('1255', '54', '25', NULL, '128', '4', '2016-07-14 16:36:40', '2016-07-14 16:36:40', 'e2c9d10c-1622-4c19-af8f-c48d2e2f5ab9'),
 ('1256', '54', '25', NULL, '116', '5', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '3c1b9c41-fe7a-411b-b59f-540cd4b83c3a'),
 ('1257', '124', '26', NULL, '89', '1', '2016-07-14 16:36:40', '2016-07-14 16:36:40', 'dc6623e6-46d3-4c6d-8c93-840edbc19738'),
 ('1258', '54', '26', NULL, '53', '1', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '9fdf51aa-1cf1-484d-884b-947085b633e5'),
 ('1259', '54', '26', NULL, '102', '2', '2016-07-14 16:36:40', '2016-07-14 16:36:40', 'e0f8ec1b-cf5c-4ff4-b045-282e0c4e604e'),
 ('1260', '54', '26', NULL, '127', '3', '2016-07-14 16:36:40', '2016-07-14 16:36:40', 'db31be29-57b9-49ca-9308-1abe3ae842c5'),
 ('1261', '124', '23', NULL, '90', '1', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '2e666ba7-bcc2-40d0-9d90-59d7bbea03ff'),
 ('1262', '54', '23', NULL, '99', '1', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '2564d828-b09e-4232-aa32-b7680352f64e'),
 ('1263', '54', '23', NULL, '141', '2', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '049140fb-1738-4cc7-8ce3-d2307e7c3e91'),
 ('1264', '54', '23', NULL, '142', '3', '2016-07-14 16:36:40', '2016-07-14 16:36:40', 'e83db58c-5b8f-4f59-82a9-3f656bc22784'),
 ('1265', '54', '23', NULL, '143', '4', '2016-07-14 16:36:40', '2016-07-14 16:36:40', 'f3a3cf3f-0f44-4750-8628-95c3859ac37c'),
 ('1266', '54', '23', NULL, '144', '5', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '27e4afd8-b8b2-4378-8059-09aa88c20b69'),
 ('1267', '54', '23', NULL, '145', '6', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '4987c118-75a4-45f2-9718-8edeac9962c1'),
 ('1268', '54', '23', NULL, '146', '7', '2016-07-14 16:36:40', '2016-07-14 16:36:40', '3d49ab7f-f8f2-4a19-8771-e54edbfcd9df'),
 ('1269', '128', '66', NULL, '387', '1', '2016-07-14 19:37:10', '2016-07-14 19:37:10', '8515c481-6c6b-422f-b8cd-0e379a515521'),
 ('1270', '132', '75', NULL, '94', '1', '2016-07-14 20:30:23', '2016-07-14 20:30:23', 'ce15d784-691d-4214-bccf-264ffd5e6135'),
 ('1271', '131', '351', NULL, '93', '1', '2016-07-15 16:24:52', '2016-07-15 16:24:52', '16650b9d-1e74-4894-9a7f-fe6f4a14cffc'),
 ('1272', '36', '351', NULL, '383', '1', '2016-07-15 16:24:52', '2016-07-15 16:24:52', '1b25655b-b72c-4385-988e-5eabe6a09f84'),
 ('1273', '131', '342', NULL, '93', '1', '2016-07-15 16:25:20', '2016-07-15 16:25:20', '4da181c0-b0ed-4702-ac56-a3c442dc3ce0'),
 ('1274', '36', '342', NULL, '384', '1', '2016-07-15 16:25:20', '2016-07-15 16:25:20', '10bc9e28-3555-4cc4-9265-fb587c32608d'),
 ('1277', '131', '338', NULL, '93', '1', '2016-07-15 16:25:30', '2016-07-15 16:25:30', 'ce95f058-60b6-4490-9555-8d3f90c85996'),
 ('1278', '36', '338', NULL, '385', '1', '2016-07-15 16:25:30', '2016-07-15 16:25:30', '0a35d474-5b68-490c-a789-7016b4f2a2de'),
 ('1279', '131', '329', NULL, '93', '1', '2016-07-15 16:25:37', '2016-07-15 16:25:37', '461af075-8b4d-4462-ac01-48b5dcad0f11'),
 ('1280', '131', '327', NULL, '93', '1', '2016-07-15 16:25:44', '2016-07-15 16:25:44', '713f78ab-a740-4727-a8a5-5abafb1f1ce5'),
 ('1281', '131', '319', NULL, '93', '1', '2016-07-15 16:25:52', '2016-07-15 16:25:52', 'a1f28b3f-0b7b-4c7e-966e-b2eed899c4d7'),
 ('1283', '131', '314', NULL, '93', '1', '2016-07-15 16:26:47', '2016-07-15 16:26:47', '6b86c715-43f9-4179-8a9e-db6928fac364'),
 ('1284', '131', '312', NULL, '93', '1', '2016-07-15 16:26:54', '2016-07-15 16:26:54', '1b693a19-aed1-4b64-97f6-39cc41baf313'),
 ('1285', '131', '52', NULL, '90', '1', '2016-07-15 16:27:02', '2016-07-15 16:27:02', '1c957753-e1e7-4163-981f-1cbda9524274'),
 ('1286', '36', '14', NULL, '386', '1', '2016-07-15 16:27:09', '2016-07-15 16:27:09', 'd2bb5b40-e652-4820-9a3a-18bee5383669'),
 ('1287', '126', '111', NULL, '112', '1', '2016-07-15 17:02:14', '2016-07-15 17:02:14', 'baaa7a5f-327e-48e3-9194-ff9267a4d558'),
 ('1288', '147', '111', NULL, '388', '1', '2016-07-15 17:02:14', '2016-07-15 17:02:14', 'c3e61aef-dab1-4089-956f-30e7f68f4c69');
INSERT INTO `craft_relations` (`id`, `fieldId`, `sourceId`, `sourceLocale`, `targetId`, `sortOrder`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1289', '147', '389', NULL, '388', '1', '2016-07-15 17:08:27', '2016-07-15 17:08:27', '723020ac-d817-45d9-9fa6-58dc0bb9bfd9');



DROP TABLE IF EXISTS `craft_routes`;


--
-- Schema for table `craft_routes`
--
CREATE TABLE `craft_routes` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `locale` char(12) COLLATE utf8_unicode_ci DEFAULT NULL,
  `urlParts` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `urlPattern` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `template` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `sortOrder` smallint(6) unsigned DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_routes_urlPattern_unq_idx` (`urlPattern`),
  KEY `craft_routes_locale_idx` (`locale`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_searchindex`;


--
-- Schema for table `craft_searchindex`
--
CREATE TABLE `craft_searchindex` (
  `elementId` int(11) NOT NULL,
  `attribute` varchar(25) COLLATE utf8_unicode_ci NOT NULL,
  `fieldId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `keywords` text COLLATE utf8_unicode_ci NOT NULL,
  PRIMARY KEY (`elementId`,`attribute`,`fieldId`,`locale`),
  FULLTEXT KEY `craft_searchindex_keywords_idx` (`keywords`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_searchindex`
--

INSERT INTO `craft_searchindex` (`elementId`, `attribute`, `fieldId`, `locale`, `keywords`) VALUES
 ('1', 'username', '0', 'en_us', ' atp_admin '),
 ('1', 'firstname', '0', 'en_us', ''),
 ('1', 'lastname', '0', 'en_us', ''),
 ('1', 'fullname', '0', 'en_us', ''),
 ('1', 'email', '0', 'en_us', ' jamesl stinkdigital com '),
 ('1', 'slug', '0', 'en_us', ''),
 ('9', 'title', '0', 'en_us', ' home '),
 ('10', 'slug', '0', 'en_us', ' contact '),
 ('10', 'title', '0', 'en_us', ' contact '),
 ('14', 'field', '21', 'en_us', ' cleanslate centers announced today that gregory c marotta has been promoted to president and ceo from his role as chief operating officer that he has held since joining the organization more than a year ago mr marotta also joined cleanslate s board of directors amanda wilson md the founder of cleanslate remains chairwoman of the board and will continue as president and ceo of the cleanslate research and education foundation '),
 ('12', 'slug', '0', 'en_us', ' team '),
 ('12', 'title', '0', 'en_us', ' team '),
 ('13', 'slug', '0', 'en_us', ' portfolio '),
 ('13', 'title', '0', 'en_us', ' portfolio '),
 ('9', 'slug', '0', 'en_us', ' home '),
 ('4', 'field', '18', 'en_us', ''),
 ('14', 'field', '20', 'en_us', ' 2016 06 13 '),
 ('14', 'field', '22', 'en_us', ' cleanslate centers names gregory c marotta president ceo left cleanslate centers announced today that gregory c marotta has been promoted to president and ceo from his role as chief operating officer that he has held since joining the organization more than a year ago mr marotta also joined cleanslate s board of directors amanda wilson md the founder of cleanslate remains chairwoman of the board and will continue as president and ceo of the cleanslate research and education foundation the leadership changes are the culmination of a year long succession plan established by the cleanslate board of directors and dr wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation mr marotta will be responsible for the overall strategic and daily operational leadership of cleanslate with all areas of the organization reporting to him the board of directors chose mr marotta to lead the company because of his knowledge of every aspect of cleanslate and his expansive business and operational expertise he has helped build and deploy direct to patient provider organizations on a large scale basis including leading a network of over 230 healthcare facilities across 20 states for u s healthworks and in his work as head of outpatient services for kessler institute for rehabilitation i am honored by the confidence dr wilson and our board of directors have placed in me to lead the cleanslate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country mr marotta said i am looking forward to continuing to work closely with everyone in the cleanslate family dr wilson and other members of the board as we move to fulfill our mission of making effective quality treatment available to everyone facing addition the changes will provide dr wilson the ability to singularly focus her energy on mission critical efforts for cleanslate that are driven by the dynamic addiction treatment landscape she will dedicate her time expertise and knowledge to leading cleanslate s board driving change at the national level regarding the addiction epidemic and will continue cleanslate s commitment to thought leadership and making a measurable difference in the lives of the people served by the company cleanslate has been remarkably successful over the past six years thanks to our dedicated physicians other clinical professionals and support team and this is just the beginning dr wilson said these changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve about cleanslate centers left cleanslate centers was founded in 2009 in response to the growing opioid epidemic facing the country a multi state network of physician led outpatient addiction treatment centers cleanslate provides medication assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality evidence based practices cleanslate s proven model of individualized care gives patients the tools and support they need to achieve long term success in recognition of their innovation and effectiveness cleanslate s treatment programs received the inaugural 2012 science and service award for office based opioid treatment by the federal substance abuse and mental health service administration samhsa in 2014 cleanslate partnered with apple tree partners a healthcare focused venture capital fund to help expand efforts geographically and increase access to care in under served communities with demonstrated need '),
 ('4', 'field', '17', 'en_us', ''),
 ('4', 'field', '12', 'en_us', ''),
 ('4', 'slug', '0', 'en_us', ''),
 ('4', 'field', '16', 'en_us', ''),
 ('14', 'field', '19', 'en_us', ' cleanslate centers names gregory c marotta president ceo '),
 ('4', 'field', '13', 'en_us', ''),
 ('14', 'field', '36', 'en_us', ' cleanslate '),
 ('14', 'slug', '0', 'en_us', ' cleanslate '),
 ('14', 'title', '0', 'en_us', ' cleanslate centers names gregory c marotta president ceo '),
 ('15', 'field', '23', 'en_us', ' cleanslate centers names gregory c marotta president ceo '),
 ('15', 'slug', '0', 'en_us', ''),
 ('16', 'field', '25', 'en_us', ' cleanslate centers announced today that gregory c marotta has been promoted to president and ceo from his role as chief operating officer that he has held since joining the organization more than a year ago mr marotta also joined cleanslate s board of directors amanda wilson md the founder of cleanslate remains chairwoman of the board and will continue as president and ceo of the cleanslate research and education foundation the leadership changes are the culmination of a year long succession plan established by the cleanslate board of directors and dr wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation mr marotta will be responsible for the overall strategic and daily operational leadership of cleanslate with all areas of the organization reporting to him the board of directors chose mr marotta to lead the company because of his knowledge of every aspect of cleanslate and his expansive business and operational expertise he has helped build and deploy direct to patient provider organizations on a large scale basis including leading a network of over 230 healthcare facilities across 20 states for u s healthworks and in his work as head of outpatient services for kessler institute for rehabilitation i am honored by the confidence dr wilson and our board of directors have placed in me to lead the cleanslate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country mr marotta said i am looking forward to continuing to work closely with everyone in the cleanslate family dr wilson and other members of the board as we move to fulfill our mission of making effective quality treatment available to everyone facing addition the changes will provide dr wilson the ability to singularly focus her energy on mission critical efforts for cleanslate that are driven by the dynamic addiction treatment landscape she will dedicate her time expertise and knowledge to leading cleanslate s board driving change at the national level regarding the addiction epidemic and will continue cleanslate s commitment to thought leadership and making a measurable difference in the lives of the people served by the company cleanslate has been remarkably successful over the past six years thanks to our dedicated physicians other clinical professionals and support team and this is just the beginning dr wilson said these changes are part of a strategic effort to invest in our current clinics and staff and continue to expand access to our superior treatment approach so that more patients in need can receive the care they deserve '),
 ('16', 'field', '26', 'en_us', ' left '),
 ('16', 'slug', '0', 'en_us', ''),
 ('17', 'field', '23', 'en_us', ' about cleanslate centers '),
 ('17', 'slug', '0', 'en_us', ''),
 ('18', 'field', '25', 'en_us', ' cleanslate centers was founded in 2009 in response to the growing opioid epidemic facing the country a multi state network of physician led outpatient addiction treatment centers cleanslate provides medication assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality evidence based practices cleanslate s proven model of individualized care gives patients the tools and support they need to achieve long term success in recognition of their innovation and effectiveness cleanslate s treatment programs received the inaugural 2012 science and service award for office based opioid treatment by the federal substance abuse and mental health service administration samhsa in 2014 cleanslate partnered with apple tree partners a healthcare focused venture capital fund to help expand efforts geographically and increase access to care in under served communities with demonstrated need '),
 ('18', 'field', '26', 'en_us', ' left '),
 ('18', 'slug', '0', 'en_us', ''),
 ('13', 'field', '50', 'en_us', ' aileron therapeutics braeburn pharmaceuticals corvidia syntimmune lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien header section therapeutics meet the therapeutics team therapeutics gala therapeutics tusker medical tendyne vytronus lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien header section medical devices meet the medical devices team medical devices cleanslate addiction treatment centers cure forward qualderm partners triplecare lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien header section healthcare services meet the healthcare services team healthcare services coelacanth chemical corporation cyrano sciences gloucester pharmaceuticals heartware international sgx pharmaceuticals tokai pharmaceuticals lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien header section legacy companies legacy investments '),
 ('19', 'field', '51', 'en_us', ' therapeutics '),
 ('19', 'field', '52', 'en_us', ' lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien '),
 ('19', 'field', '53', 'en_us', ' aileron therapeutics braeburn pharmaceuticals corvidia syntimmune '),
 ('19', 'slug', '0', 'en_us', ''),
 ('20', 'field', '51', 'en_us', ' medical devices '),
 ('20', 'field', '52', 'en_us', ' lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien '),
 ('20', 'field', '53', 'en_us', ' gala therapeutics tusker medical tendyne vytronus '),
 ('20', 'slug', '0', 'en_us', ''),
 ('21', 'field', '51', 'en_us', ' healthcare services '),
 ('21', 'field', '52', 'en_us', ' lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien '),
 ('21', 'field', '53', 'en_us', ' cleanslate addiction treatment centers cure forward qualderm partners triplecare '),
 ('21', 'slug', '0', 'en_us', ''),
 ('22', 'field', '51', 'en_us', ' legacy investments '),
 ('22', 'field', '52', 'en_us', ' lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien '),
 ('22', 'field', '53', 'en_us', ' coelacanth chemical corporation cyrano sciences gloucester pharmaceuticals heartware international sgx pharmaceuticals tokai pharmaceuticals '),
 ('22', 'slug', '0', 'en_us', ''),
 ('12', 'field', '39', 'en_us', ' cover about '),
 ('12', 'field', '38', 'en_us', ' founded in 1999 we are a venture capital firm that invests in and starts new therapeutic medtech and healthcare service companies with a history of well known successes in long term investment strategies our managers can build with confidence knowing that we are funding them to grow and develop their businesses '),
 ('29', 'field', '110', 'en_us', ' therapeutics '),
 ('12', 'field', '37', 'en_us', ' about apple tree partners atp '),
 ('12', 'field', '47', 'en_us', ' lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien header section therapeutics see the therapeutics portfolio seth l harrison md sam hall ph d aaron kantoff chris cain ph d jernej godec ph d keting chu md ph d paul dasilva jardine ph d andreas loew ph d behshad sheldon mikael dolsten md ph d therapeutics lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien header section medical devices see the medical devices portfolio sami hamade david j mcintyre jonathan waldstreicher md joshua sherman amir abolfathi medical devices lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien header section healthcare services see the healthcare services portfolio diane m daych julie gionfriddo stephanie papes healthcare services lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien header section legacy companies lauren farrell kristin howell maja nowak shivranie singh steph lazarus lisa cagney salam farhat finance administration '),
 ('41', 'field', '111', 'en_us', ' 40 7543 '),
 ('23', 'field', '48', 'en_us', ' finance administration '),
 ('23', 'field', '49', 'en_us', ' lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien '),
 ('23', 'field', '54', 'en_us', ' lauren farrell kristin howell maja nowak shivranie singh steph lazarus lisa cagney salam farhat '),
 ('250', 'title', '0', 'en_us', ' heartware international '),
 ('23', 'slug', '0', 'en_us', ''),
 ('24', 'field', '48', 'en_us', ' therapeutics '),
 ('24', 'field', '49', 'en_us', ' lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien '),
 ('24', 'field', '54', 'en_us', ' seth l harrison md sam hall ph d aaron kantoff chris cain ph d jernej godec ph d keting chu md ph d paul dasilva jardine ph d andreas loew ph d behshad sheldon mikael dolsten md ph d '),
 ('24', 'slug', '0', 'en_us', ''),
 ('25', 'field', '48', 'en_us', ' medical devices '),
 ('25', 'field', '49', 'en_us', ' lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien '),
 ('25', 'field', '54', 'en_us', ' sami hamade david j mcintyre jonathan waldstreicher md joshua sherman amir abolfathi '),
 ('25', 'slug', '0', 'en_us', ''),
 ('26', 'field', '48', 'en_us', ' healthcare services '),
 ('26', 'field', '49', 'en_us', ' lorem ipsum dolor sit amet consectetur adipiscing elit aliquam et nunc nec ex egestas mollis at vel orci cras eu volutpat libero aenean blandit porttitor ex nec aliquam elit consequat ac vivamus at nibh sit amet enim ornare lacinia in vitae dui id risus elementum euismod a et augue sed sit amet finibus tellus ut tincidunt tellus nam cursus arcu eu tortor dapibus cursus cras a turpis sed diam tempor ornare id quis est quisque arcu est pulvinar ac leo ac hendrerit sodales sapien '),
 ('26', 'field', '54', 'en_us', ' diane m daych julie gionfriddo stephanie papes '),
 ('26', 'slug', '0', 'en_us', ''),
 ('27', 'field', '66', 'en_us', ' aileron logo 4 c '),
 ('27', 'field', '60', 'en_us', ' aileron therapeutics '),
 ('27', 'field', '61', 'en_us', ' aileron therapeutics is developing first in class therapeutics based on its proprietary stapled peptide drug platform alrn 6924 in phase 1 is a p53 re activator for the treatment of cancer the only p53 molecule in development that targets both mdm2 and mdmx '),
 ('27', 'field', '62', 'en_us', ' http www aileronrx com https www linkedin com company aileron therapeutics '),
 ('27', 'slug', '0', 'en_us', ' aileron therapeutics '),
 ('27', 'title', '0', 'en_us', ' aileron therapeutics '),
 ('28', 'field', '63', 'en_us', ' http www aileronrx com '),
 ('28', 'field', '64', 'en_us', ' https www linkedin com company aileron therapeutics '),
 ('28', 'field', '65', 'en_us', ' http aileronrx com contact php '),
 ('28', 'slug', '0', 'en_us', ''),
 ('29', 'field', '56', 'en_us', ' seth harrison is the managing partner of apple tree partners he has invested in life sciences since 1991 seth has served as founding investor acting ceo or chairman of numerous portfolio companies he serves currently as executive chairman of braeburn pharmaceuticals chairman of tokai pharmaceuticals and deputy chairman of heartware international all companies he founded he founded and chaired aileron therapeutics since its inception until 2013 and remains an active board member prior to founding atp seth was a general partner at oak investment partners and earlier was a venture partner at sevin rosen funds his prior investments include arqule coelacanth cyrano sciences gloucester pharmaceuticals informed access sgx pharmaceuticals ultracision and viropharma seth received an a b from princeton university an md and mba both from columbia university and completed a surgery internship at the presbyterian hospital in the city of new york from 2002 to 2010 he served on the board of the international partnership for microbicides a rockefeller foundation gates foundation sponsored public private partnership engaged in the development of anti hiv microbicides additional board responsibilities include asothera pharmaceuticals corvidia cure forward and syntimmune '),
 ('57', 'field', '110', 'en_us', ' medical devices '),
 ('29', 'field', '57', 'en_us', ''),
 ('29', 'field', '55', 'en_us', ''),
 ('29', 'slug', '0', 'en_us', ' seth l harrison '),
 ('29', 'title', '0', 'en_us', ' seth l harrison md '),
 ('31', 'filename', '0', 'en_us', ' texture_1 png '),
 ('31', 'extension', '0', 'en_us', ' png '),
 ('31', 'kind', '0', 'en_us', ' image '),
 ('31', 'slug', '0', 'en_us', ' texture 1 '),
 ('31', 'title', '0', 'en_us', ' texture 1 '),
 ('34', 'filename', '0', 'en_us', ' texture_1 png '),
 ('34', 'extension', '0', 'en_us', ' png ');
INSERT INTO `craft_searchindex` (`elementId`, `attribute`, `fieldId`, `locale`, `keywords`) VALUES
 ('34', 'kind', '0', 'en_us', ' image '),
 ('34', 'slug', '0', 'en_us', ' texture 1 '),
 ('34', 'title', '0', 'en_us', ' texture 1 '),
 ('204', 'field', '130', 'en_us', ' header section healthcare services '),
 ('204', 'field', '66', 'en_us', ' clean slate transparent '),
 ('9', 'field', '3', 'en_us', ' cover homepage '),
 ('9', 'field', '4', 'en_us', ' we use a long term investment philosophy to build sustainable healthcare companies through meaningful partnerships and deep expertise '),
 ('74', 'field', '10', 'en_us', ' 1 67 '),
 ('74', 'field', '11', 'en_us', ' $1 67 billion dedicated to building healthcare businesses '),
 ('9', 'field', '5', 'en_us', ' areas of expertise a little blurb goes here explaining our mission in this vertical and key successes it should describe why atp is a leader in this field and what innovation we ve pioneered therapeutics a little blurb goes here explaining our mission in this vertical and key successes it should describe why atp is a leader in this field and what innovation we ve pioneered medical devices a little blurb goes here explaining our mission in this vertical and key successes it should describe why atp is a leader in this field and what innovation we ve pioneered healthcare services '),
 ('9', 'field', '9', 'en_us', ' we scale to the buy out or growth equity level by taking the long view both as a matter of principle and for value creation commitments as high as $250 million 250 we closed our current capital pool of $1 5 billion in 2012 and are actively funding healthcare innovation $1 67 billion dedicated to building healthcare businesses 1 67 we start companies or invest in existing companies that bring products to patients 16 portfolio companies 16 '),
 ('36', 'field', '6', 'en_us', ' therapeutics '),
 ('36', 'field', '7', 'en_us', ' a little blurb goes here explaining our mission in this vertical and key successes it should describe why atp is a leader in this field and what innovation we ve pioneered '),
 ('36', 'slug', '0', 'en_us', ''),
 ('37', 'field', '6', 'en_us', ' medical devices '),
 ('37', 'field', '7', 'en_us', ' a little blurb goes here explaining our mission in this vertical and key successes it should describe why atp is a leader in this field and what innovation we ve pioneered '),
 ('37', 'slug', '0', 'en_us', ''),
 ('38', 'field', '6', 'en_us', ' healthcare services '),
 ('38', 'field', '7', 'en_us', ' a little blurb goes here explaining our mission in this vertical and key successes it should describe why atp is a leader in this field and what innovation we ve pioneered '),
 ('38', 'slug', '0', 'en_us', ''),
 ('39', 'field', '10', 'en_us', ' 250 '),
 ('39', 'field', '11', 'en_us', ' commitments as high as $250 million '),
 ('39', 'slug', '0', 'en_us', ''),
 ('40', 'field', '10', 'en_us', ' 16 '),
 ('40', 'field', '11', 'en_us', ' 16 portfolio companies '),
 ('40', 'slug', '0', 'en_us', ''),
 ('9', 'field', '69', 'en_us', ' cleanslate centers names gregory c marotta president ceo mass based addiction treatment center expands nationally as opioid epidemic rages on '),
 ('4', 'field', '70', 'en_us', ' 230 park avenue suite 2800 new york new york 10169 new york do you have a revolutionary innovation info appletreepartners com 212 999 0000 0 0 212 476 9900 300 technology square suite 803g cambridge ma 02139 cambridge do you have a revolutionary innovation info appletreepartners com 212 999 0000 0 0 212 476 9900 4970 el camino real suite 220 los altos ca 94022 los altos do you have a revolutionary innovation info appletreepartners com 212 999 0000 0 0 212 476 9900 '),
 ('10', 'field', '70', 'en_us', ' 230 park avenue suite 2800 new york new york 10169 new york city do you have a revolutionary innovation info appletreepartners com let s talk 212 999 0000 40 7543 73 97618 212 476 9900 300 technology square suite 803g cambridge ma 02139 cambridge do you have a revolutionary innovation info appletreepartners com let s talk 212 999 0000 42 36344 71 09147 212 476 9900 4970 el camino real suite 220 los altos ca 94022 los altos do you have a revolutionary innovation info appletreepartners com let s talk 212 999 0000 37 3976 122 10632 212 476 9900 '),
 ('41', 'field', '71', 'en_us', ' new york city '),
 ('41', 'field', '72', 'en_us', ' 230 park avenue suite 2800 new york new york 10169 '),
 ('41', 'field', '73', 'en_us', ' 212 476 9900 '),
 ('41', 'field', '74', 'en_us', ' 212 999 0000 '),
 ('41', 'field', '75', 'en_us', ' do you have a revolutionary innovation '),
 ('41', 'field', '76', 'en_us', ' info appletreepartners com '),
 ('41', 'slug', '0', 'en_us', ''),
 ('42', 'field', '71', 'en_us', ' cambridge '),
 ('42', 'field', '72', 'en_us', ' 300 technology square suite 803g cambridge ma 02139 '),
 ('42', 'field', '73', 'en_us', ' 212 476 9900 '),
 ('42', 'field', '74', 'en_us', ' 212 999 0000 '),
 ('42', 'field', '75', 'en_us', ' do you have a revolutionary innovation '),
 ('42', 'field', '76', 'en_us', ' info appletreepartners com '),
 ('42', 'slug', '0', 'en_us', ''),
 ('43', 'field', '71', 'en_us', ' los altos '),
 ('43', 'field', '72', 'en_us', ' 4970 el camino real suite 220 los altos ca 94022 '),
 ('43', 'field', '73', 'en_us', ' 212 476 9900 '),
 ('43', 'field', '74', 'en_us', ' 212 999 0000 '),
 ('43', 'field', '75', 'en_us', ' do you have a revolutionary innovation '),
 ('43', 'field', '76', 'en_us', ' info appletreepartners com '),
 ('43', 'slug', '0', 'en_us', ''),
 ('4', 'field', '77', 'en_us', ' press press legal legal linkedin https www linkedin com company apple tree partners '),
 ('44', 'field', '78', 'en_us', ' press '),
 ('44', 'field', '79', 'en_us', ' press '),
 ('44', 'slug', '0', 'en_us', ''),
 ('4', 'field', '106', 'en_us', ' do you have a revolutionary innovation let s talk '),
 ('4', 'field', '105', 'en_us', ' footer '),
 ('46', 'field', '78', 'en_us', ' legal '),
 ('46', 'field', '79', 'en_us', ' legal '),
 ('46', 'slug', '0', 'en_us', ''),
 ('47', 'field', '78', 'en_us', ' linkedin '),
 ('47', 'field', '79', 'en_us', ' https www linkedin com company apple tree partners '),
 ('47', 'slug', '0', 'en_us', ''),
 ('48', 'field', '71', 'en_us', ' new york '),
 ('48', 'field', '72', 'en_us', ' 230 park avenue suite 2800 new york new york 10169 '),
 ('48', 'field', '73', 'en_us', ' 212 476 9900 '),
 ('48', 'field', '74', 'en_us', ' 212 999 0000 '),
 ('48', 'field', '75', 'en_us', ' do you have a revolutionary innovation '),
 ('48', 'field', '76', 'en_us', ' info appletreepartners com '),
 ('48', 'slug', '0', 'en_us', ''),
 ('49', 'field', '71', 'en_us', ' cambridge '),
 ('49', 'field', '72', 'en_us', ' 300 technology square suite 803g cambridge ma 02139 '),
 ('49', 'field', '73', 'en_us', ' 212 476 9900 '),
 ('49', 'field', '74', 'en_us', ' 212 999 0000 '),
 ('49', 'field', '75', 'en_us', ' do you have a revolutionary innovation '),
 ('49', 'field', '76', 'en_us', ' info appletreepartners com '),
 ('49', 'slug', '0', 'en_us', ''),
 ('50', 'field', '71', 'en_us', ' los altos '),
 ('50', 'field', '72', 'en_us', ' 4970 el camino real suite 220 los altos ca 94022 '),
 ('50', 'field', '73', 'en_us', ' 212 476 9900 '),
 ('50', 'field', '74', 'en_us', ' 212 999 0000 '),
 ('50', 'field', '75', 'en_us', ' do you have a revolutionary innovation '),
 ('50', 'field', '76', 'en_us', ' info appletreepartners com '),
 ('50', 'slug', '0', 'en_us', ''),
 ('51', 'filename', '0', 'en_us', ' marble jpg '),
 ('51', 'extension', '0', 'en_us', ' jpg '),
 ('51', 'kind', '0', 'en_us', ' image '),
 ('51', 'slug', '0', 'en_us', ''),
 ('51', 'title', '0', 'en_us', ' marble '),
 ('52', 'field', '21', 'en_us', ' two more opiate and alcohol treatment centers will be popping up in massachusetts as northampton based cleanslate centers looks to expand in the bay state and nationally '),
 ('52', 'field', '20', 'en_us', ' 2016 06 15 '),
 ('52', 'field', '22', 'en_us', ' two more opiate and alcohol treatment centers will be popping up in massachusetts as northampton based cleanslate centers looks to expand in the bay state and nationally left cleanslate centers announced today that gregory c marotta has been promoted to president and ceo from his role as chief operating officer that he has held since joining the organization more than a year ago mr marotta also joined cleanslate s board of directors amanda wilson md the founder of cleanslate remains chairwoman of the board and will continue as president and ceo of the cleanslate research and education foundation the leadership changes are the culmination of a year long succession plan established by the cleanslate board of directors and dr wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation mr marotta will be responsible for the overall strategic and daily operational leadership of cleanslate with all areas of the organization reporting to him the board of directors chose mr marotta to lead the company because of his knowledge of every aspect of cleanslate and his expansive business and operational expertise he has helped build and deploy direct to patient provider organizations on a large scale basis including leading a network of over 230 healthcare facilities across 20 states for u s healthworks and in his work as head of outpatient services for kessler institute for rehabilitation i am honored by the confidence dr wilson and our board of directors have placed in me to lead the cleanslate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country mr marotta said i am looking forward to continuing to work closely with everyone in the cleanslate family dr wilson and other members of the board as we move to fulfill our mission of making effective quality treatment available to everyone facing addition the changes will provide dr wilson the ability to singularly focus her energy on mission critical efforts for cleanslate that are driven by the dynamic addiction treatment landscape she will dedicate her time expertise and knowledge to leading cleanslate s board driving change at the national level regarding the addiction epidemic and will continue cleanslate s commitment to thought leadership and making a measurable difference in the lives of the people served by the company '),
 ('52', 'field', '68', 'en_us', ' 1 '),
 ('52', 'field', '36', 'en_us', ''),
 ('52', 'slug', '0', 'en_us', ' mass based addiction treatment center expands nationally as opioid epidemic rages on '),
 ('52', 'title', '0', 'en_us', ' mass based addiction treatment center expands nationally as opioid epidemic rages on '),
 ('29', 'field', '67', 'en_us', ''),
 ('53', 'field', '67', 'en_us', ''),
 ('53', 'field', '56', 'en_us', ' diane has over 25 years of investing advisory and operating experience with over 20 years focused on the healthcare services industry she joined apple tree partners in 2013 to lead their healthcare services investing from 2010 to 2012 she was a managing director and co head private equity of the marwood group additionally since 2000 diane has been a partner and principal at ccp equity partners ccp and its predecessor firm conning capital partners where she invested in growth companies that offer specialized solutions for the financing management and delivery of health care in industries such as managed care disease and care management outpatient services information technology and healthcare related ancillary and outsourcing services prior to joining ccp in 2000 she held a senior development role at mariner health a post acute care company where she worked with operating management to develop the strategies and structures for physician practice management acquisitions and joint ventures prior to mariner diane held senior operating roles at medical care america mca one of the largest operators of free standing ambulatory surgery centers at that time diane currently sits on the board of directors of triplecare cleanslate addiction treatment centers qualderm partners prism education group the tuck school s mba advisory board and the healthcare private equity association hcpea she was previously on the board of directors of cogent healthcare relay health zoologic and an observer for evolution benefits and vantage oncology she also previously sat on the board of directors of the women s association of venture and equity wave and she is a past president of the hartford chapter of the connecticut venture group and sat on its statewide board for several years she received an mba from the tuck school at dartmouth college and a ba in economics from lehigh university '),
 ('53', 'field', '57', 'en_us', ''),
 ('53', 'slug', '0', 'en_us', ' diane m daych ');
INSERT INTO `craft_searchindex` (`elementId`, `attribute`, `fieldId`, `locale`, `keywords`) VALUES
 ('53', 'title', '0', 'en_us', ' diane m daych '),
 ('55', 'field', '67', 'en_us', ''),
 ('55', 'field', '56', 'en_us', ' with over 20 years of operating and investing experience across a broad spectrum of therapeutic areas sami is a prominent figure in the medical technology sector and will be leading apple tree s efforts in this area his interests include therapeutic devices sensors and healthcare it solutions prior to joining apple tree partners sami was a partner at aberdare ventures where he oversaw the sale of ablation frontiers to medtronic and participated in a number of key investments including nxthera inc nevro and sonitus in prior years sami was vice president at the guidant corporation and head of the compass group where he was responsible for guidant s venture capital business development and ma activities successful investments included cardionet inc nasdaq beat evalve acquired by abt cryovascular acquired by bsx remon medical acquired by bsx cardiomems acquired by st jude medical and spiration inc acquired by olympus earlier in his career sami played a critical operating role at advanced cardiovascular systems acs the pioneering company in the then emerging field of interventional cardiology which subsequently became a central part of guidant s multi billion dollar leadership position in the stent market he was also a senior executive in guidant s peripheral business sami has been a regular guest lecturer at the stanford business school and biodesign programs he is also an inventor and recipient of the prestigious boss kettering award for innovation sami holds a bachelor s degree in engineering from the american university of beirut a masters degree in engineering from the university of michigan ann arbor and an mba from the stanford graduate school of business board responsibilities include gala therapeutics vytronus '),
 ('55', 'field', '57', 'en_us', ''),
 ('55', 'slug', '0', 'en_us', ' sami hamade '),
 ('55', 'title', '0', 'en_us', ' sami hamade '),
 ('57', 'field', '67', 'en_us', ''),
 ('57', 'field', '56', 'en_us', ' david has over 20 years of experience as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries including medical devices with professional qualifications in finance and law david has held senior financial legal and operational roles more recently david was executive vice president chief financial officer of heartware international inc nasdaq htwr asx hin from 2005 through 2011 and assumed the additional responsibilities of chief operating officer during heartware s global commercialization phase for the period from 2008 through 2011 prior to heartware david practiced as a senior attorney in private practice specializing in corporate mergers and acquisitions and equity capital markets with baker mckenzie and kpmg as well as holding various senior financial roles in multi national companies including coal allied limited a publicly traded subsidiary of the rio tinto group of companies david holds a bachelor of economics accounting from the university of sydney australia a bachelor of law from the university of technology sydney australia and a masters of business administration fuqua scholar from duke university he is also a certified practicing accountant cpa and is admitted as a legal practitioner of the supreme court of new south wales in australia board responsibilities include vytronus qualderm tusker medical braeburn pharmaceuticals gala therapeutics and previously tendyne acquired by abbott '),
 ('57', 'field', '57', 'en_us', ''),
 ('57', 'slug', '0', 'en_us', ' david j mcintyre '),
 ('57', 'title', '0', 'en_us', ' david j mcintyre '),
 ('59', 'field', '23', 'en_us', ' two more opiate and alcohol treatment centers will be popping up in massachusetts as northampton based cleanslate centers looks to expand in the bay state and nationally '),
 ('59', 'slug', '0', 'en_us', ''),
 ('60', 'field', '25', 'en_us', ' cleanslate centers announced today that gregory c marotta has been promoted to president and ceo from his role as chief operating officer that he has held since joining the organization more than a year ago mr marotta also joined cleanslate s board of directors amanda wilson md the founder of cleanslate remains chairwoman of the board and will continue as president and ceo of the cleanslate research and education foundation the leadership changes are the culmination of a year long succession plan established by the cleanslate board of directors and dr wilson to align the organization to provide expanded access to treatment to help address the opioid addiction crisis sweeping the nation mr marotta will be responsible for the overall strategic and daily operational leadership of cleanslate with all areas of the organization reporting to him the board of directors chose mr marotta to lead the company because of his knowledge of every aspect of cleanslate and his expansive business and operational expertise he has helped build and deploy direct to patient provider organizations on a large scale basis including leading a network of over 230 healthcare facilities across 20 states for u s healthworks and in his work as head of outpatient services for kessler institute for rehabilitation i am honored by the confidence dr wilson and our board of directors have placed in me to lead the cleanslate team as we work to provide treatment solutions for patients at our current facilities and at the new centers we will be opening across the country mr marotta said i am looking forward to continuing to work closely with everyone in the cleanslate family dr wilson and other members of the board as we move to fulfill our mission of making effective quality treatment available to everyone facing addition the changes will provide dr wilson the ability to singularly focus her energy on mission critical efforts for cleanslate that are driven by the dynamic addiction treatment landscape she will dedicate her time expertise and knowledge to leading cleanslate s board driving change at the national level regarding the addiction epidemic and will continue cleanslate s commitment to thought leadership and making a measurable difference in the lives of the people served by the company '),
 ('60', 'field', '26', 'en_us', ' left '),
 ('60', 'slug', '0', 'en_us', ''),
 ('61', 'name', '0', 'en_us', ' company '),
 ('61', 'slug', '0', 'en_us', ''),
 ('61', 'title', '0', 'en_us', ' company '),
 ('14', 'field', '68', 'en_us', ' 0 '),
 ('27', 'field', '81', 'en_us', ' aileron therapeutics is developing first in class therapeutics based on its proprietary stapled peptide drug platform '),
 ('57', 'field', '80', 'en_us', ' david has over 20 years of experience as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries including medical devices '),
 ('29', 'field', '80', 'en_us', ' seth harrison is the managing partner of apple tree partners he has invested in life sciences since 1991 '),
 ('19', 'field', '142', 'en_us', ' meet the therapeutics team '),
 ('41', 'field', '112', 'en_us', ' 73 97618 '),
 ('9', 'field', '82', 'en_us', ' braeburn pharmaceuticals is helping to change the conversation about opioid dependence tusker medical is developing a suite of pediatric focused technologies designed to avoid general anesthetics cure forward s unique clinical trial exchange platform empowers patients to govern their own care plans '),
 ('74', 'field', '107', 'en_us', ' we closed our current capital pool of $1 5 billion in 2012 and are actively funding healthcare innovation '),
 ('40', 'field', '107', 'en_us', ' we start companies or invest in existing companies that bring products to patients '),
 ('29', 'field', '109', 'en_us', ' managing partner '),
 ('55', 'field', '109', 'en_us', ' partner '),
 ('55', 'field', '104', 'en_us', ' gala therapeutics vytronus '),
 ('53', 'field', '109', 'en_us', ' partner '),
 ('53', 'field', '80', 'en_us', ' diane has over 25 years of investing advisory and operating experience with over 20 years focused on the healthcare services industry '),
 ('53', 'field', '104', 'en_us', ' triplecare cleanslate addiction treatment centers qualderm partners '),
 ('57', 'field', '109', 'en_us', ' partner '),
 ('62', 'field', '83', 'en_us', ' braeburn pharmaceuticals is helping to change the conversation about opioid dependence '),
 ('39', 'field', '107', 'en_us', ' we scale to the buy out or growth equity level by taking the long view both as a matter of principle and for value creation '),
 ('62', 'slug', '0', 'en_us', ''),
 ('63', 'field', '83', 'en_us', ' tusker medical is developing a suite of pediatric focused technologies designed to avoid general anesthetics '),
 ('49', 'field', '101', 'en_us', ''),
 ('49', 'field', '102', 'en_us', ''),
 ('50', 'field', '101', 'en_us', ''),
 ('50', 'field', '102', 'en_us', ''),
 ('63', 'slug', '0', 'en_us', ''),
 ('64', 'field', '83', 'en_us', ' cure forward s unique clinical trial exchange platform empowers patients to govern their own care plans '),
 ('48', 'field', '101', 'en_us', ''),
 ('48', 'field', '102', 'en_us', ''),
 ('64', 'slug', '0', 'en_us', ''),
 ('65', 'name', '0', 'en_us', ' cleanslate centers '),
 ('65', 'slug', '0', 'en_us', ''),
 ('65', 'title', '0', 'en_us', ' cleanslate centers '),
 ('66', 'slug', '0', 'en_us', ' legal '),
 ('386', 'name', '0', 'en_us', ' cleanslate '),
 ('66', 'title', '0', 'en_us', ' legal '),
 ('66', 'field', '86', 'en_us', ' legal full thank you for your interest in our website at www appletreepartners com your use of this website including the content materials and information available on or through this website together the materials is governed by these terms of use these terms by using this website you acknowledge that you have read and agree to these terms left terms of use this website is maintained and operated by apple tree venture management llc which provides administrative and other services to various apple tree entities in accordance with industry custom this website occasionally uses terminology that may be interpreted to suggest that our firm is actually a single entity however there is no such single entity and all of the entities that comprise our firm have their own separate legal existence left who we are all materials are provided as is may not be relied upon for any purpose and are not subject to express or implied warranties of any kind in particular we make no representations or warranties with regard to the materials accuracy completeness non infringement or fitness for a particular purpose you should be aware that a significant portion of the materials include or consist of information that has been provided by third parties and has not been validated or verified by us in connection with our investment activities we often become subject to a variety of confidentiality obligations to funds investors portfolio companies and other third parties any statements we make may be affected by those confidentiality obligations with the result that we may be prohibited from making full disclosures without limitation on the effect of other warnings and disclaimers set forth in these terms you should interpret any statements we make on this website or otherwise in that context please ensure that your own computer security is comprehensive and up to date we accept no responsibility for viruses malware or other malicious or damaging software contained in the materials or otherwise left materials we accept no responsibility for third party sites available through this website via hyperlink or otherwise you are encouraged to review the terms of use applicable to those sites any access to or use of a third party site is solely at your own risk left third party sites nothing on this website is intended to constitute i an offer or solicitation of an offer to purchase or sell any security other asset or service ii investment advice or an offer to provide such advice or iii a basis for making any investment decision except as expressly stated by an apple tree partners entity in writing neither this website nor any of the materials make any effort to present a comprehensive or balanced description of apple tree partners or its investment activities left no offer solicitation or advice we reserve all rights with respect to the design and content of this website in particular you must not misappropriate the design or content of this website and you must not alter or deface such design or content in any way nothing on this website grants any license with respect to such design or content except that you may download and use materials solely for your own personal information left restrictions on use no license all text photos graphics logos content and other materials on this website are protected by united states and foreign copyright trademark and other applicable laws in particular all trademarks trade names and logos displayed on this website are proprietary to apple tree partners its affiliates or their respective owners and this website grants no license to them apple tree partners and our tree logo are among our trademarks in the united states and or other countries left ownership of trademarks etc or other confidential information due to the large number of business plan ideas and related materials that we review and the similarity of many such plans and materials we cannot accept responsibility for protecting against misuse or disclosure any confidential or proprietary information or other materials in the absence of our express written agreement to do so any plans information and other materials you submit in connection with this website may be used or disclosed by us for any purpose and in any manner as we determine in our sole discretion please consider this carefully before sending us any information or other materials that you deem confidential or proprietary left submitting a business plan we reserve the right to track visitors to and usage of this website through cookies and similar techniques and to use any resulting information as we determine in our sole discretion left privacy policy except as specifically agreed by an apple tree partners entity in writing no apple tree partners individual or entity shall have any liability based upon your use of or reliance upon this website or the materials some jurisdictions limit our ability to disclaim liability with regard to those jurisdictions our liability shall be limited to the greatest extent permitted by applicable law left limitation of liability we reserve the right to modify these terms at any time please check these terms periodically for changes your continued use of this website after the posting of changes constitutes your binding acceptance of such changes left modification of these terms this website is operated and controlled by apple tree venture management llc in the united states of america if it is illegal or prohibited in your country of origin to access or use this website then you should not do so those who choose to access this website outside the united states of america access it on their own initiative and are responsible for compliance with all local laws and regulations these terms and any disputes relating to these terms or your use of this website or the materials shall be governed in all respects by the laws of the state of new york without regard to conflicts of laws principles except as otherwise agreed in writing by the applicable apple tree partners entities any disputes relating to these terms shall be resolved exclusively in the state or federal courts located in new york new york these terms set forth the entire agreement between you and us with respect to the subject matter hereof and supersede all prior agreements relating to such subject matter all apple tree partners individuals and entities are intended third party beneficiaries of these terms our rights under these terms may be waived by us only in writing these terms are binding on you as well as your successors and permitted assigns in the event any provision of these terms is determined to be invalid or unenforceable such provision shall be deemed severed from the remainder of these terms and replaced with a valid and enforceable provision as similar in intent as reasonably possible to the provision so severed and shall not cause the invalidity or unenforceability of the remainder of these terms left general information do you have a question contact us left '),
 ('67', 'field', '87', 'en_us', ' legal '),
 ('67', 'field', '93', 'en_us', ' full '),
 ('67', 'slug', '0', 'en_us', ''),
 ('68', 'field', '94', 'en_us', ' terms of use '),
 ('68', 'field', '95', 'en_us', ' thank you for your interest in our website at www appletreepartners com your use of this website including the content materials and information available on or through this website together the materials is governed by these terms of use these terms by using this website you acknowledge that you have read and agree to these terms '),
 ('300', 'field', '94', 'en_us', ' who we are '),
 ('300', 'field', '95', 'en_us', ' this website is maintained and operated by apple tree venture management llc which provides administrative and other services to various apple tree entities in accordance with industry custom this website occasionally uses terminology that may be interpreted to suggest that our firm is actually a single entity however there is no such single entity and all of the entities that comprise our firm have their own separate legal existence '),
 ('68', 'field', '96', 'en_us', ' left '),
 ('68', 'slug', '0', 'en_us', ''),
 ('69', 'field', '97', 'en_us', ' do you have a question contact us '),
 ('69', 'field', '98', 'en_us', ' left '),
 ('69', 'slug', '0', 'en_us', ''),
 ('9', 'field', '99', 'en_us', ' texture 1 '),
 ('99', 'field', '110', 'en_us', ' finance administration '),
 ('55', 'field', '80', 'en_us', ' with over 20 years of operating and investing experience across a broad spectrum of therapeutic areas sami leads atp s medical technology investments '),
 ('41', 'field', '101', 'en_us', ''),
 ('41', 'field', '102', 'en_us', ' let s talk '),
 ('42', 'field', '101', 'en_us', ''),
 ('42', 'field', '102', 'en_us', ' let s talk '),
 ('43', 'field', '101', 'en_us', ''),
 ('43', 'field', '102', 'en_us', ' let s talk '),
 ('70', 'name', '0', 'en_us', ' therapuetics '),
 ('70', 'slug', '0', 'en_us', ''),
 ('70', 'title', '0', 'en_us', ' therapuetics '),
 ('27', 'field', '103', 'en_us', ' therapuetics '),
 ('71', 'name', '0', 'en_us', ' company name '),
 ('71', 'slug', '0', 'en_us', ''),
 ('71', 'title', '0', 'en_us', ' company name '),
 ('72', 'name', '0', 'en_us', ' company '),
 ('72', 'slug', '0', 'en_us', ''),
 ('72', 'title', '0', 'en_us', ' company '),
 ('29', 'field', '104', 'en_us', ' corvidia cure forward syntimmune '),
 ('29', 'field', '129', 'en_us', ' header section legacy companies '),
 ('73', 'name', '0', 'en_us', ' company name 2 '),
 ('73', 'slug', '0', 'en_us', ''),
 ('73', 'title', '0', 'en_us', ' company name 2 '),
 ('96', 'name', '0', 'en_us', ' healthcare services '),
 ('74', 'slug', '0', 'en_us', ''),
 ('57', 'field', '104', 'en_us', ' vytronus qualderm partners tusker medical braeburn pharmaceuticals gala therapeutics tendyne '),
 ('42', 'field', '111', 'en_us', ' 42 36344 '),
 ('42', 'field', '112', 'en_us', ' 71 09147 '),
 ('43', 'field', '111', 'en_us', ' 37 3976 '),
 ('43', 'field', '112', 'en_us', ' 122 10632 '),
 ('75', 'slug', '0', 'en_us', ' press '),
 ('75', 'title', '0', 'en_us', ' press ');
INSERT INTO `craft_searchindex` (`elementId`, `attribute`, `fieldId`, `locale`, `keywords`) VALUES
 ('75', 'field', '113', 'en_us', ' nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt neque porro quisquam est qui dolorem ipsum quia dolor sit amet consectetur adipisci velit sed quia non numquam press didn t find what you were looking for get in touch brand assets headshots and bios recent news more press releases on our news page '),
 ('76', 'field', '119', 'en_us', ' press '),
 ('76', 'field', '114', 'en_us', ' nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt neque porro quisquam est qui dolorem ipsum quia dolor sit amet consectetur adipisci velit sed quia non numquam '),
 ('76', 'field', '115', 'en_us', ' didn t find what you were looking for get in touch '),
 ('76', 'slug', '0', 'en_us', ''),
 ('77', 'field', '120', 'en_us', ' brand assets '),
 ('77', 'field', '116', 'en_us', ''),
 ('77', 'slug', '0', 'en_us', ''),
 ('78', 'field', '121', 'en_us', ' headshots and bios '),
 ('78', 'field', '117', 'en_us', ''),
 ('78', 'field', '118', 'en_us', ''),
 ('78', 'slug', '0', 'en_us', ''),
 ('78', 'field', '123', 'en_us', ''),
 ('79', 'field', '122', 'en_us', ' recent news '),
 ('79', 'slug', '0', 'en_us', ''),
 ('80', 'filename', '0', 'en_us', ' texture_2_160707_220422 jpg '),
 ('80', 'extension', '0', 'en_us', ' jpg '),
 ('80', 'kind', '0', 'en_us', ' image '),
 ('80', 'slug', '0', 'en_us', ''),
 ('80', 'title', '0', 'en_us', ' texture 2 '),
 ('375', 'slug', '0', 'en_us', ''),
 ('375', 'title', '0', 'en_us', ' tusker transparent '),
 ('83', 'filename', '0', 'en_us', ' stock photo light micrograph of white adipose tissue adipocytes fat cells contain a large lipid droplet the 267094196 jpg '),
 ('83', 'extension', '0', 'en_us', ' jpg '),
 ('83', 'kind', '0', 'en_us', ' image '),
 ('83', 'slug', '0', 'en_us', ''),
 ('83', 'title', '0', 'en_us', ' stock photo light micrograph of white adipose tissue adipocytes fat cells contain a large lipid droplet the 267094196 '),
 ('23', 'field', '124', 'en_us', ' header section legacy companies '),
 ('24', 'field', '124', 'en_us', ' header section therapeutics '),
 ('25', 'field', '124', 'en_us', ' header section medical devices '),
 ('26', 'field', '124', 'en_us', ' header section healthcare services '),
 ('229', 'field', '103', 'en_us', ' legacy investment '),
 ('229', 'field', '130', 'en_us', ' header section legacy companies '),
 ('228', 'name', '0', 'en_us', ' testing '),
 ('228', 'slug', '0', 'en_us', ''),
 ('228', 'title', '0', 'en_us', ' testing '),
 ('229', 'field', '66', 'en_us', ' coelacanth chemical corporation '),
 ('19', 'field', '125', 'en_us', ' header section therapeutics '),
 ('20', 'field', '125', 'en_us', ' header section medical devices '),
 ('21', 'field', '125', 'en_us', ' header section healthcare services '),
 ('22', 'field', '125', 'en_us', ' header section legacy companies '),
 ('102', 'field', '110', 'en_us', ' healthcare services '),
 ('87', 'filename', '0', 'en_us', ' cover_homepage jpg '),
 ('87', 'extension', '0', 'en_us', ' jpg '),
 ('87', 'kind', '0', 'en_us', ' image '),
 ('87', 'slug', '0', 'en_us', ''),
 ('87', 'title', '0', 'en_us', ' cover homepage '),
 ('88', 'filename', '0', 'en_us', ' cover about jpg '),
 ('88', 'extension', '0', 'en_us', ' jpg '),
 ('88', 'kind', '0', 'en_us', ' image '),
 ('88', 'slug', '0', 'en_us', ''),
 ('88', 'title', '0', 'en_us', ' cover about '),
 ('89', 'filename', '0', 'en_us', ' header_section healthcare_services jpg '),
 ('89', 'extension', '0', 'en_us', ' jpg '),
 ('89', 'kind', '0', 'en_us', ' image '),
 ('89', 'slug', '0', 'en_us', ''),
 ('89', 'title', '0', 'en_us', ' header section healthcare services '),
 ('90', 'filename', '0', 'en_us', ' header_section legacy_companies jpg '),
 ('90', 'extension', '0', 'en_us', ' jpg '),
 ('90', 'kind', '0', 'en_us', ' image '),
 ('90', 'slug', '0', 'en_us', ''),
 ('90', 'title', '0', 'en_us', ' header section legacy companies '),
 ('387', 'extension', '0', 'en_us', ' jpg '),
 ('387', 'kind', '0', 'en_us', ' image '),
 ('387', 'filename', '0', 'en_us', ' header_section legal 1 jpg '),
 ('92', 'filename', '0', 'en_us', ' header_section medical_devices jpg '),
 ('92', 'extension', '0', 'en_us', ' jpg '),
 ('92', 'kind', '0', 'en_us', ' image '),
 ('92', 'slug', '0', 'en_us', ''),
 ('92', 'title', '0', 'en_us', ' header section medical devices '),
 ('93', 'filename', '0', 'en_us', ' header_section news jpg '),
 ('93', 'extension', '0', 'en_us', ' jpg '),
 ('93', 'kind', '0', 'en_us', ' image '),
 ('93', 'slug', '0', 'en_us', ''),
 ('93', 'title', '0', 'en_us', ' header section news '),
 ('94', 'filename', '0', 'en_us', ' header_section press jpg '),
 ('94', 'extension', '0', 'en_us', ' jpg '),
 ('94', 'kind', '0', 'en_us', ' image '),
 ('94', 'slug', '0', 'en_us', ''),
 ('94', 'title', '0', 'en_us', ' header section press '),
 ('95', 'filename', '0', 'en_us', ' header_section therapeutics jpg '),
 ('95', 'extension', '0', 'en_us', ' jpg '),
 ('95', 'kind', '0', 'en_us', ' image '),
 ('95', 'slug', '0', 'en_us', ''),
 ('95', 'title', '0', 'en_us', ' header section therapeutics '),
 ('96', 'slug', '0', 'en_us', ''),
 ('96', 'title', '0', 'en_us', ' healthcare services '),
 ('53', 'field', '110', 'en_us', ' healthcare services '),
 ('97', 'name', '0', 'en_us', ' medical devices '),
 ('97', 'slug', '0', 'en_us', ''),
 ('97', 'title', '0', 'en_us', ' medical devices '),
 ('98', 'name', '0', 'en_us', ' medtech '),
 ('98', 'slug', '0', 'en_us', ''),
 ('98', 'title', '0', 'en_us', ' medtech '),
 ('55', 'field', '110', 'en_us', ' medical devices '),
 ('99', 'field', '109', 'en_us', ' chief financial officer '),
 ('99', 'field', '80', 'en_us', ' lauren has over 20 years accounting and finance experience including roles in public accounting financial management and reporting and strategic financial consulting across multiple industries '),
 ('99', 'field', '56', 'en_us', ' lauren has over 20 years accounting and finance experience including roles in public accounting financial management and reporting and strategic financial consulting across multiple industries prior to joining apple tree partners lauren was vice president and chief accounting officer at heartware international inc nasdaq htwr from 2006 to 2013 where she led the company s financial management and reporting activities from 2005 to 2006 lauren was chief financial officer at ambient corporation from january 2001 to july 2004 lauren served as vice president at bingham strategic advisors providing ma advisory services lauren is a certified public accountant and holds a bachelors of science in accounting and a masters of business administration from bentley university '),
 ('99', 'field', '57', 'en_us', ''),
 ('99', 'field', '104', 'en_us', '');
INSERT INTO `craft_searchindex` (`elementId`, `attribute`, `fieldId`, `locale`, `keywords`) VALUES
 ('99', 'slug', '0', 'en_us', ' lauren farrell '),
 ('99', 'title', '0', 'en_us', ' lauren farrell '),
 ('100', 'name', '0', 'en_us', ' therapeutics '),
 ('100', 'slug', '0', 'en_us', ''),
 ('100', 'title', '0', 'en_us', ' therapeutics '),
 ('101', 'name', '0', 'en_us', ' finance administration '),
 ('101', 'slug', '0', 'en_us', ''),
 ('101', 'title', '0', 'en_us', ' finance administration '),
 ('102', 'field', '109', 'en_us', ' principal '),
 ('102', 'field', '80', 'en_us', ' julie gionfriddo joined apple tree partners in 2014 and has spent nearly 18 years prior focused on private equity '),
 ('102', 'field', '56', 'en_us', ' julie gionfriddo joined apple tree partners in 2014 and has spent nearly 18 years prior focused on private equity prior to joining apple tree julie was a vice president within the private equity secondary group at landmark partners where she was involved in transaction origination underwriting and negotiation of private equity investments as well as investor relations and marketing julie serves on the board of directors for the women s association of venture and equity julie also serves on the board of fellows and the women s leadership council for trinity college she received her ba and ma in economics from trinity college '),
 ('102', 'field', '57', 'en_us', ''),
 ('102', 'field', '104', 'en_us', ''),
 ('102', 'slug', '0', 'en_us', ' julie gionfriddo '),
 ('102', 'title', '0', 'en_us', ' julie gionfriddo '),
 ('66', 'field', '128', 'en_us', ' header section legal 1 '),
 ('105', 'field', '110', 'en_us', ' therapeutics '),
 ('105', 'field', '109', 'en_us', ' principal '),
 ('105', 'field', '80', 'en_us', ' sam hall has experience in the life sciences across roles as a private equity investor investment banker and basic scientist '),
 ('105', 'field', '56', 'en_us', ' sam hall has experience in the life sciences across roles as a private equity investor investment banker and basic scientist prior to joining apple tree in 2013 he was a researcher at the university of cambridge in the uk where his work focused on novel therapeutic strategies for autoimmune diseases previously sam was a member of the investment team at symphony capital a private equity firm dedicated to investments in biopharmaceutical development prior to symphony he served as a member of the healthcare investment banking team at citigroup where he advised leading biotechnology medical device and healthcare services businesses on numerous completed strategic and debt and equity financing engagements sam holds an a b in molecular biology from princeton university and completed his m phil and ph d research at the university of cambridge where he was a taylor research scholar and was awarded an nsf graduate research fellowship for his work board responsibilities include syntimmune director stoke therapeutics director '),
 ('105', 'field', '57', 'en_us', ''),
 ('105', 'field', '104', 'en_us', ' syntimmune '),
 ('105', 'slug', '0', 'en_us', ' sam hall '),
 ('105', 'title', '0', 'en_us', ' sam hall ph d '),
 ('106', 'field', '110', 'en_us', ' therapeutics '),
 ('106', 'field', '109', 'en_us', ' principal '),
 ('106', 'field', '80', 'en_us', ' aaron has significant early and late stage biotech experience serving financial analysis and restructuring '),
 ('106', 'field', '56', 'en_us', ' aaron has significant early and late stage biotech experience serving financial analysis and restructuring prior to joining apple tree in 2011 aaron was a partner at recess global llc an investment company focused on funding startups prior to starting recess global llc aaron was a member of the investment banking team at rothschild inc in the restructuring group selected transactions that he worked on at rothschild inc include advising the u s treasury on restructuring of chrysler group llc assisting milacron inc with the section 363 sale of assets working with delphi automotive on its in court chapter 11 bankruptcy developing the penton media pre packaged chapter 11 filing in addition to his role with apple tree aaron has also served as executive director of business development corporate strategy of braeburn pharmaceuticals aaron holds a bachelor of science in finance and international business from the new york university stern school of business board responsibilities include cure forward director corvidia board observer and syntimmune board observer '),
 ('106', 'field', '57', 'en_us', ''),
 ('106', 'field', '104', 'en_us', ' cure forward corvidia syntimmune '),
 ('106', 'slug', '0', 'en_us', ' aaron kantoff '),
 ('106', 'title', '0', 'en_us', ' aaron kantoff '),
 ('107', 'field', '110', 'en_us', ' medical devices '),
 ('107', 'field', '109', 'en_us', ' principal '),
 ('107', 'field', '80', 'en_us', ' jonathan waldstreicher joined apple tree in 2013 to invest in medical devices '),
 ('107', 'field', '56', 'en_us', ' jonathan waldstreicher joined apple tree in 2013 to invest in medical devices after incubating an interventional pulmonary technology for two years jon founded gala therapeutics in silicon valley and assumed the ceo role to further its development prior to joining apple tree jon was a director global surgery rd at johnson johnson where he initiated and led an investment strategy and rd development program in a new growth platform technology area he started at johnson johnson as an associate director in the corporate office of science technology where he executed numerous seed grants to startup companies and participated in technical diligence of venture capital investments before medical school jon worked in equity research at bear stearns jon received a b a from brandeis university in economics and an m d and m b a from tufts university school of medicine where he was awarded the norman stearns award for highest achievement and overall excellence within the dual degree program between his third and fourth year of medical school jon worked as a fellow at the corporate office of science technology at jj he completed a general surgery internship at tufts medical center in boston board responsibilities include gala therapeutics vytronus board observer '),
 ('107', 'field', '57', 'en_us', ''),
 ('107', 'field', '104', 'en_us', ' gala therapeutics vytronus '),
 ('107', 'slug', '0', 'en_us', ' jonathan waldstreicher md '),
 ('107', 'title', '0', 'en_us', ' jonathan waldstreicher md '),
 ('108', 'field', '110', 'en_us', ' therapeutics '),
 ('108', 'field', '109', 'en_us', ' venture partner '),
 ('108', 'field', '80', 'en_us', ' keting is a scientist entrepreneur and life science venture investor with a broad range of experiences in therapeutic development '),
 ('108', 'field', '56', 'en_us', ' keting chu joined apple tree partners in 2016 as a venture partner keting is a scientist entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture philanthropy before joining apple tree partners keting spent five years as vp research tap at the leukemia and lymphoma society lls there she was responsible for venture philanthropy also known as the therapy acceleration program at lls keting led the investment of celator stemline constellation affimed argen x kite pharma kiadis oncopepe valor and a number of projects within academic institutions prior to lls keting was the ceo of mission therapeutics and the co founder president and ceo of digitab inc prior to co founding digitab keting was the co founder and ceo of biocubed corporation vice president of biology and head of rd at five prime therapeutics during its founding stage and the head of immunotherapy and antibody therapeutics division at chiron corporation where she engaged in preclinical and clinical developments of protein dna based and small molecule therapeutics for cancer and inflammatory diseases keting received her md in sun yat sen medical university specialized in infectious diseases in china ph d in microbiology and immunology at university of california at san francisco ucsf she also conducted her postdoctoral training at cardiovascular research institute at ucsf '),
 ('108', 'field', '57', 'en_us', ''),
 ('108', 'field', '104', 'en_us', ''),
 ('108', 'slug', '0', 'en_us', ' keting chu '),
 ('108', 'title', '0', 'en_us', ' keting chu md ph d '),
 ('27', 'field', '130', 'en_us', ' header section therapeutics '),
 ('52', 'field', '131', 'en_us', ' header section legacy companies '),
 ('75', 'field', '132', 'en_us', ' header section press '),
 ('109', 'field', '129', 'en_us', ' header section therapeutics '),
 ('109', 'field', '110', 'en_us', ' therapeutics '),
 ('109', 'field', '109', 'en_us', ' venture partner '),
 ('109', 'field', '80', 'en_us', ' paul has over 25 years of drug discovery and development experience in the cardiovascular metabolic and endocrine diseases space '),
 ('109', 'field', '56', 'en_us', ' paul dasilva jardine joined apple tree partners in 2016 as a venture partner paul has over 25 years of drug discovery and development experience in the cardiovascular metabolic and endocrine diseases space prior to joining apple tree paul spent over 25 years at pfizer research and development where he participated in the discovery and development of over fifty drug candidates including the first lasofoxifene a serm which received authorization from european medicines agency paul held various leadership positions at pfizer rd including vice president head of cvmed chemistry and vice president in the cvmed research unit which was responsible for drug development from idea to phase 2 proof of concept paul earned his phd and completed post doctoral studies in synthetic organic chemistry with professor corey at harvard university '),
 ('109', 'field', '57', 'en_us', ''),
 ('109', 'field', '104', 'en_us', ''),
 ('109', 'slug', '0', 'en_us', ' paul dasilva jardine '),
 ('109', 'title', '0', 'en_us', ' paul dasilva jardine ph d '),
 ('110', 'field', '129', 'en_us', ''),
 ('110', 'field', '110', 'en_us', ''),
 ('110', 'field', '109', 'en_us', ' venture partner '),
 ('110', 'field', '80', 'en_us', ' david is a scientist and entrepreneur with broad experience ranging from operational leadership to the development of new companies '),
 ('110', 'field', '56', 'en_us', ' david de graaf joined apple tree partners in 2015 as a venture partner david is a scientist and entrepreneur with broad experience ranging from operational leadership to the development of new companies most recently david was entrepreneur in residence for flagship ventures and executive chairman of selventa a flagship portfolio company which he restarted and rebranded as ceo david brought selventa to revenue stage and financial independence with a line of services and products in the personalized medicine space before selventa david held roles of increasing responsibility at astrazeneca pfizer and boehringer ingleheim with a focus on the early portfolio in a variety of therapeutic areas he brought pathway biology to astrazeneca building functions for pathway analysis in the uk and the us he headed systems biology at pfizer with a focus on biotherapeutics and predictive toxicology and at boehringer ingelheim as vice president of biotherapeutics and integrative biology he built a new biotherapeutics capability which brought a handful of candidates to the clinic in auto immune diseases and oncology david s academic career initially brought him to the whitehead mit center for functional genomics as one of the founding scientists to work with prof eric lander after his postdoctoral work at the weizmann institute in israel david also serves on a variety of boards ranging from the swiss institute of bioinformatics to chugai pharmabody david holds a phd in mammalian genetics from the university of illinois at chicago and a masters in evolutionary genetics form the university of utrecht '),
 ('110', 'field', '57', 'en_us', ''),
 ('110', 'field', '104', 'en_us', ''),
 ('110', 'slug', '0', 'en_us', ' david de graaf '),
 ('110', 'title', '0', 'en_us', ' david de graaf ph d '),
 ('55', 'field', '129', 'en_us', ' header section medical devices '),
 ('53', 'field', '129', 'en_us', ' header section healthcare services '),
 ('57', 'field', '129', 'en_us', ' header section medical devices '),
 ('99', 'field', '129', 'en_us', ' header section legacy companies '),
 ('102', 'field', '129', 'en_us', ' header section healthcare services '),
 ('105', 'field', '129', 'en_us', ' header section therapeutics '),
 ('106', 'field', '129', 'en_us', ' header section therapeutics '),
 ('108', 'field', '129', 'en_us', ' header section therapeutics '),
 ('107', 'field', '129', 'en_us', ' header section medical devices '),
 ('111', 'slug', '0', 'en_us', ''),
 ('111', 'field', '126', 'en_us', ' icon atp logo '),
 ('112', 'filename', '0', 'en_us', ' icon_atp_logo svg '),
 ('112', 'extension', '0', 'en_us', ' svg '),
 ('112', 'kind', '0', 'en_us', ' image '),
 ('112', 'slug', '0', 'en_us', ''),
 ('112', 'title', '0', 'en_us', ' icon atp logo '),
 ('113', 'field', '129', 'en_us', ' header section therapeutics '),
 ('113', 'field', '110', 'en_us', ' therapeutics '),
 ('113', 'field', '109', 'en_us', ' venture partner '),
 ('113', 'field', '80', 'en_us', ' behshad has more than 25 years of experience leading pharmaceutical development and commercialization in the united states and globally '),
 ('113', 'field', '56', 'en_us', ' behshad has more than 25 years of experience leading pharmaceutical development and commercialization in the united states and globally she currently also serves as the president and chief executive officer of braeburn pharmaceuticals a portfolio company of apple tree partners prior to joining braeburn behshad spent 10 years at otsuka pharmaceuticals having co founded the otsuka princeton office in 2002 ms sheldon last served as a member of the board of directors of the otsuka rd organization contributing to the oversight of 18 pre approval programs for 13 products in cns cardio renal pain dermatology and oncology simultaneously she served as senior vice president patient branding strategy in the commercial organization where she was responsible for global and united states marketing alliance management and early development strategy prior to otsuka behshad held positions with increasing responsibility at smithkline beecham and bristol myers squibb throughout her 27 year career behshad has driven the success of blockbuster products such as glucophage plavix and abilify and has contributed to several strategic alliances and acquisitions including the landmark 2011 agreement between otsuka and lundbeck involving 5 cns products behshad holds a bs degree in neuroscience from the university of rochester board responsibilities include cleanslate addiction treatment centers board observer '),
 ('113', 'field', '57', 'en_us', ''),
 ('113', 'field', '104', 'en_us', ' cleanslate addiction treatment centers '),
 ('113', 'slug', '0', 'en_us', ' behshad sheldon '),
 ('113', 'title', '0', 'en_us', ' behshad sheldon '),
 ('114', 'field', '129', 'en_us', ' header section therapeutics '),
 ('114', 'field', '110', 'en_us', ' therapeutics '),
 ('114', 'field', '109', 'en_us', ' chairman translational advisory board '),
 ('114', 'field', '80', 'en_us', ' mikael is currently the president of pfizer worldwide research and development wrd and executive vice president of pfizer inc '),
 ('114', 'field', '56', 'en_us', ' mikael dolsten m d ph d became the chairman of apple tree partner s translational advisory board in 2016 mikael is currently the president of pfizer worldwide research and development wrd and executive vice president of pfizer inc dr dolsten is also a member of the pfizer executive leadership team and co chairs the company s portfolio strategy and investment committee which governs major pipeline investments and strategic end to end rd priorities prior to joining pfizer in 2009 dr dolsten was president of wyeth research responsible for global research and development activities before joining wyeth he served as executive vice president for worldwide research at boehringer ingelheim his earlier career as a research leader included vp leadership positions with astrazeneca pharmacia and upjohn mikael has also served as a private equity partner at orbimed the world s largest healthcare focused investment company in addition he gained leadership experience from five large scale ma transactions mikael is a governor of the new york academy of sciences a member of the board of karyopharm therapeutics inc a member of the biomedical advisory council of the pharmaceutical research and manufacturers of america phrma co lead for the industry nih accelerating medicine partnership amp executive committee and serves on the phrma foundation board of directors he has been a board member of a swedish business school for innovation and chamber of commerce dr dolsten is a named inventor on several patents and has published approximately 150 articles in international journals with particular contributions in areas such as molecular cell biology immunology and oncology dr dolsten earned his ph d in tumor immunology and m d from the university of lund in sweden he studied virology and cell biology at the weizmann institute in israel and has been appointed as adjunct professor in immunology at the medical faculty in lund sweden '),
 ('114', 'field', '57', 'en_us', '');
INSERT INTO `craft_searchindex` (`elementId`, `attribute`, `fieldId`, `locale`, `keywords`) VALUES
 ('114', 'field', '104', 'en_us', ''),
 ('114', 'slug', '0', 'en_us', ' mikael dolsten '),
 ('114', 'title', '0', 'en_us', ' mikael dolsten md ph d '),
 ('229', 'field', '61', 'en_us', ' combinatorial chemistry building blocks based upon nobel prize winning k barry sharpless click chemistry acquired by lexicon genetics july 2001 '),
 ('116', 'field', '129', 'en_us', ' header section medical devices '),
 ('116', 'field', '110', 'en_us', ' medical devices '),
 ('116', 'field', '109', 'en_us', ' entrepreneur in residence ear nose throat '),
 ('116', 'field', '80', 'en_us', ' amir has over 26 years of operating experience in the healthcare industry focused on developing and commercializing medical devices '),
 ('116', 'field', '56', 'en_us', ' amir has over 26 years of operating experience in the healthcare industry focused on developing and commercializing cardiovascular devices dental products hearing prosthetics and genomic diagnostics analytics amir was the inventor and founder of sonitus medical in 2006 a novel non surgical hearing prosthetic designed for treatment of unilateral deafness and sonitus technologies in 2010 which is currently developing the first truly covert two way communication device prior to sonitus amir served for six years as an officer executive vice president of rd at align technology inc nasdaq algn creators of a unique invisible orthodontic product called invisalign previously amir was the first member of the senior management team at embolic protection inc where he was a consulting vp of operations epi was successfully acquired by boston scientific in 2001 in early 1995 amir co founded endotex interventional systems developers of minimally invasive solutions for treatment of carotid artery disease which was also acquired by boston scientific in 2006 amir has also held various management and engineering positions at pfizer guidant and baxter edwards he has over 100 issued patents cleveland clinic foundation and popular science recognized one of his inventions as top 10 inventions of the year in 2010 amir currently sits on the board of directors of sonitus technologies and rodo medical he is also a business adviser to guardant health he was previously on the board of directors of nextbio acquired by illumina in 2013 and an adviser to on pharma acquired by valeant pharmaceutical in 2014 amir received a ms in engineering management from university of southern california and bs in biomedical engineering from university of california san diego he is a member of the university of california san diego jacobs school council of advisers '),
 ('116', 'field', '57', 'en_us', ''),
 ('116', 'field', '104', 'en_us', ''),
 ('116', 'slug', '0', 'en_us', ' amir abolfathi '),
 ('116', 'title', '0', 'en_us', ' amir abolfathi '),
 ('117', 'name', '0', 'en_us', ' bubble gum '),
 ('117', 'slug', '0', 'en_us', ''),
 ('117', 'title', '0', 'en_us', ' bubble gum '),
 ('118', 'name', '0', 'en_us', ' swimming '),
 ('118', 'slug', '0', 'en_us', ''),
 ('118', 'title', '0', 'en_us', ' swimming '),
 ('119', 'name', '0', 'en_us', ' $% '),
 ('119', 'slug', '0', 'en_us', ''),
 ('119', 'title', '0', 'en_us', ' $% '),
 ('120', 'name', '0', 'en_us', ' 123456789 '),
 ('120', 'slug', '0', 'en_us', ''),
 ('120', 'title', '0', 'en_us', ' 123456789 '),
 ('121', 'name', '0', 'en_us', ' abcdefghijklmnopqrstuvwxyz '),
 ('121', 'slug', '0', 'en_us', ''),
 ('121', 'title', '0', 'en_us', ' abcdefghijklmnopqrstuvwxyz '),
 ('122', 'name', '0', 'en_us', ' new tag '),
 ('122', 'slug', '0', 'en_us', ''),
 ('122', 'title', '0', 'en_us', ' new tag '),
 ('123', 'field', '129', 'en_us', ' header section therapeutics '),
 ('123', 'field', '110', 'en_us', ' therapeutics '),
 ('123', 'field', '109', 'en_us', ' entrepreneur in residence biotherapeutics '),
 ('123', 'field', '80', 'en_us', ' andreas loew is an entrepreneur in residence focused on creating novel biotherapeutics to combat cancer and auto immune disease '),
 ('123', 'field', '56', 'en_us', ' andreas loew is an entrepreneur in residence focused on creating novel biotherapeutics to combat cancer and auto immune disease andreas has over fifteen years of experience in the biopharmaceutical industry most recently as the global head of new technologies in the biologics center at the novartis institutes for biomedical research nibr at nibr andreas established a group to lead drug discovery efforts in multiple disease indications across a large spectrum of biotherapeutics including multi specific antibodies therapeutic proteins and chimeric antigen receptors cars prior to joining novartis andreas provided structure based drug design support at abbott both for small molecules and anti body based therapies including humira andreas earned his master degrees in chemistry at the university of kaiserslautern germany and a phd degree in biochemistry at the university of bayreuth germany he conducted post doctoral research in protein biochemistry and x ray structural biology in yee kin ho s laboratory at the university of illinois chicago at steven sprang s laboratory at the university of texas medical center dallas and in tom blundell s laboratory at birkbeck college london uk '),
 ('123', 'field', '57', 'en_us', ''),
 ('123', 'field', '104', 'en_us', ''),
 ('123', 'slug', '0', 'en_us', ' andreas loew '),
 ('123', 'title', '0', 'en_us', ' andreas loew ph d '),
 ('124', 'name', '0', 'en_us', ' new tag '),
 ('124', 'slug', '0', 'en_us', ''),
 ('124', 'title', '0', 'en_us', ' new tag '),
 ('125', 'field', '129', 'en_us', ' header section therapeutics '),
 ('125', 'field', '110', 'en_us', ' therapeutics '),
 ('125', 'field', '109', 'en_us', ' associate '),
 ('125', 'field', '80', 'en_us', ' chris joined apple tree partners in 2016 as an associate focused on therapeutics '),
 ('125', 'field', '56', 'en_us', ' chris joined apple tree partners in 2016 as an associate focused on therapeutics prior to joining apple tree partners chris was an associate at ra capital management llc a crossover fund invested in healthcare and the life sciences previously chris was a writer and editor at biocentury publications and the science business exchange scibx a translational science journal co published with nature publishing group where he evaluated the clinical and commercial potential of novel molecular targets and drug platforms emerging from academic labs prior to biocentury chris was a researcher at the university of california san francisco where his work focused on understanding the transcriptional regulation and evolution of morphological change in fungi including the pathogen candida albicans chris holds a b a in biology from the university of california santa barbara college of creative studies he earned his ph d in biochemistry and molecular biology from the university of california san francisco where he was awarded a genentech graduate fellowship '),
 ('125', 'field', '57', 'en_us', ''),
 ('125', 'field', '104', 'en_us', ''),
 ('125', 'slug', '0', 'en_us', ' chris cain '),
 ('125', 'title', '0', 'en_us', ' chris cain ph d '),
 ('126', 'field', '129', 'en_us', ' header section therapeutics '),
 ('126', 'field', '110', 'en_us', ' therapeutics '),
 ('126', 'field', '109', 'en_us', ' associate '),
 ('126', 'field', '80', 'en_us', ' jernej s work focuses on the development of breakthrough companies with transformative therapies '),
 ('126', 'field', '56', 'en_us', ' jernej joined apple tree partners in 2016 as an associate focused on therapeutics his work focuses on the development of breakthrough companies with transformative therapies prior to joining apple tree partners he completed his doctorate in immunology at harvard university he was jointly mentored by arlene sharpe at harvard medical school and nicholas haining at the dana farber cancer institute where he studied how co inhibitory receptors and transcriptional programs orchestrate differentiation of cytotoxic t lymphocytes he published his work in top peer reviewed journals including cell immunity andnature immunology while at harvard he was also on the leadership board of the harvard biotechnology club while in graduate school jernej co founded mifcor a biotechnology company focused on developing new therapies for ischemic disease as the co founder and cso he successfully helped raise funding and lead the scientific strategy for preclinical drug development concurrently he completed the flagship venturelabs fellows program and during the last year of his doctorate continued working with flagship ventures as a consultant he assisted in developing innovative concepts with accompanying intellectual property marketable products and founding strategy for new companies jernej received his b a with honors in molecular and cell biology at the university of california at berkeley where his research focused on innate immunity and bacterial pathogenesis during his time at cal he was an all american student athlete in swimming and competed in two olympic games for his home country of slovenia '),
 ('126', 'field', '57', 'en_us', ''),
 ('126', 'field', '104', 'en_us', ''),
 ('126', 'slug', '0', 'en_us', ' jernej godec ph d '),
 ('126', 'title', '0', 'en_us', ' jernej godec ph d '),
 ('127', 'field', '129', 'en_us', ' header section healthcare services '),
 ('127', 'field', '110', 'en_us', ' healthcare services '),
 ('127', 'field', '109', 'en_us', ' associate '),
 ('127', 'field', '80', 'en_us', ' stephanie joined apple tree partners in 2014 as an associate focused on healthcare services and it investments '),
 ('127', 'field', '56', 'en_us', ' stephanie joined apple tree partners in 2014 as an associate focused on healthcare services and it investments prior to joining apple tree partners stephanie was as an investment banking analyst in the financial sponsors group of wells fargo securities in san francisco ca and new york ny in this role she was responsible for supporting the leveraged finance origination process for private equity transactions stephanie previously worked within duke university health system where she assisted in the initial implementation stages of a $500 million ehr rollout and on a pilot program for an innovative bundled payment model among other projects she also worked in washington dc during the passing of the affordable care act where she served health systems in government funding requests and health policy consulting stephanie graduated from duke university with highest distinction in studies of public policy economics and biology she was a civic engagement scholar dean s research fellow south asian studies fellow and sanford school of public policy grant recipient stephanie s honors thesis focused on provider financial incentives in rural india and she continues to conduct international nonprofit work in delhi and west bengal board responsibilities include cleanslate board observer triplecare board observer qualderm board observer cure forward director '),
 ('127', 'field', '57', 'en_us', ''),
 ('127', 'field', '104', 'en_us', ' cleanslate addiction treatment centers triplecare qualderm partners cure forward '),
 ('127', 'slug', '0', 'en_us', ' stephanie papes '),
 ('127', 'title', '0', 'en_us', ' stephanie papes '),
 ('128', 'field', '129', 'en_us', ' header section medical devices '),
 ('128', 'field', '110', 'en_us', ' medical devices '),
 ('128', 'field', '109', 'en_us', ' associate '),
 ('128', 'field', '80', 'en_us', ' josh joined apple tree partners in 2014 as an associate focused on the life science pharmaceutical and medical device industries '),
 ('128', 'field', '56', 'en_us', ' josh joined apple tree partners in 2014 as an associate focused on the life science pharmaceutical and medical device industries he has a strong interest in the healthcare space and benefits greatly from his background in both science and finance prior to joining apple tree partners josh was an analyst in the healthcare investment banking group at barclays where he developed broad industry knowledge and ma experience he was also formerly an analyst at morgan stanley in the financial institutions group where he focused on transactions in the insurance and asset management space josh graduated from the university of pennsylvania in 2012 earning dual degrees as a member of the vagelos life sciences management program he holds a b s in economics concentration in finance from the wharton school and a b a in biology from the college of arts and sciences josh grew up in new york city is fluent in french and enjoys travel and tennis '),
 ('128', 'field', '57', 'en_us', ''),
 ('128', 'field', '104', 'en_us', ''),
 ('128', 'slug', '0', 'en_us', ' joshua sherman '),
 ('128', 'title', '0', 'en_us', ' joshua sherman '),
 ('129', 'name', '0', 'en_us', ' test '),
 ('129', 'slug', '0', 'en_us', ''),
 ('129', 'title', '0', 'en_us', ' test '),
 ('311', 'name', '0', 'en_us', ' triplecare '),
 ('311', 'slug', '0', 'en_us', ''),
 ('311', 'title', '0', 'en_us', ' triplecare '),
 ('312', 'field', '131', 'en_us', ' header section news '),
 ('367', 'title', '0', 'en_us', ' gloucestor transparent '),
 ('136', 'title', '0', 'en_us', ' footer '),
 ('48', 'field', '111', 'en_us', ' 0 '),
 ('48', 'field', '112', 'en_us', ' 0 '),
 ('369', 'filename', '0', 'en_us', ' heartware_transparent png '),
 ('268', 'field', '63', 'en_us', ' http www heartware com '),
 ('268', 'field', '64', 'en_us', ' https www linkedin com company heartware inc '),
 ('268', 'slug', '0', 'en_us', ''),
 ('136', 'filename', '0', 'en_us', ' footer jpg '),
 ('136', 'extension', '0', 'en_us', ' jpg '),
 ('136', 'kind', '0', 'en_us', ' image '),
 ('136', 'slug', '0', 'en_us', ' footer '),
 ('50', 'field', '111', 'en_us', ' 0 '),
 ('50', 'field', '112', 'en_us', ' 0 ');
INSERT INTO `craft_searchindex` (`elementId`, `attribute`, `fieldId`, `locale`, `keywords`) VALUES
 ('243', 'field', '63', 'en_us', ' http www galatherapeutics com '),
 ('242', 'title', '0', 'en_us', ' gala therapeutics '),
 ('242', 'field', '81', 'en_us', ' gala therapeutics is an early stage medical device company developing a novel catheter based approach to treating pulmonary disease including chronic bronchitis copd and asthma '),
 ('242', 'field', '61', 'en_us', ' gala therapeutics is an early stage medical device company developing a novel catheter based approach to treating pulmonary disease including chronic bronchitis copd and asthma '),
 ('242', 'field', '66', 'en_us', ' gala logo '),
 ('242', 'field', '130', 'en_us', ' header section medical devices '),
 ('250', 'field', '66', 'en_us', ' heart ware transparent '),
 ('250', 'field', '130', 'en_us', ' header section legacy companies '),
 ('250', 'field', '81', 'en_us', ' heartware htwr develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure '),
 ('250', 'field', '61', 'en_us', ' heartware htwr develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure ipo january 2005 asx listed on nasdaq september 2013 '),
 ('250', 'field', '62', 'en_us', ' http www heartware com https www linkedin com company heartware inc '),
 ('250', 'field', '103', 'en_us', ' legacy investment '),
 ('250', 'slug', '0', 'en_us', ' heartware international '),
 ('141', 'field', '129', 'en_us', ''),
 ('141', 'field', '110', 'en_us', ' finance administration '),
 ('141', 'field', '109', 'en_us', ' fund accountant '),
 ('49', 'field', '112', 'en_us', ' 0 '),
 ('49', 'field', '111', 'en_us', ' 0 '),
 ('141', 'field', '80', 'en_us', ''),
 ('141', 'field', '56', 'en_us', ''),
 ('141', 'field', '57', 'en_us', ''),
 ('141', 'field', '104', 'en_us', ''),
 ('141', 'slug', '0', 'en_us', ' kristin howell '),
 ('141', 'title', '0', 'en_us', ' kristin howell '),
 ('142', 'field', '129', 'en_us', ' header section legacy companies '),
 ('142', 'field', '110', 'en_us', ' finance administration '),
 ('142', 'field', '109', 'en_us', ' accounting manager '),
 ('142', 'field', '80', 'en_us', ''),
 ('142', 'field', '56', 'en_us', ''),
 ('142', 'field', '57', 'en_us', ''),
 ('142', 'field', '104', 'en_us', ''),
 ('142', 'slug', '0', 'en_us', ' maja nowak '),
 ('142', 'title', '0', 'en_us', ' maja nowak '),
 ('143', 'field', '129', 'en_us', ' header section legacy companies '),
 ('143', 'field', '110', 'en_us', ' finance administration '),
 ('143', 'field', '109', 'en_us', ' accounts payable '),
 ('143', 'field', '80', 'en_us', ''),
 ('143', 'field', '56', 'en_us', ''),
 ('143', 'field', '57', 'en_us', ''),
 ('143', 'field', '104', 'en_us', ''),
 ('143', 'slug', '0', 'en_us', ' shivranie singh '),
 ('143', 'title', '0', 'en_us', ' shivranie singh '),
 ('144', 'field', '129', 'en_us', ''),
 ('144', 'field', '110', 'en_us', ' finance administration '),
 ('144', 'field', '109', 'en_us', ' senior executive assistant '),
 ('144', 'field', '80', 'en_us', ''),
 ('144', 'field', '56', 'en_us', ''),
 ('144', 'field', '57', 'en_us', ''),
 ('144', 'field', '104', 'en_us', ''),
 ('144', 'slug', '0', 'en_us', ' steph lazarus '),
 ('144', 'title', '0', 'en_us', ' steph lazarus '),
 ('145', 'field', '129', 'en_us', ' header section legacy companies '),
 ('145', 'field', '110', 'en_us', ' finance administration '),
 ('145', 'field', '109', 'en_us', ' executive assistant therapeutics '),
 ('145', 'field', '80', 'en_us', ''),
 ('145', 'field', '56', 'en_us', ''),
 ('145', 'field', '57', 'en_us', ''),
 ('145', 'field', '104', 'en_us', ''),
 ('145', 'slug', '0', 'en_us', ' lisa cagney '),
 ('145', 'title', '0', 'en_us', ' lisa cagney '),
 ('146', 'field', '129', 'en_us', ' header section legacy companies '),
 ('146', 'field', '110', 'en_us', ' finance administration '),
 ('146', 'field', '109', 'en_us', ' executive assistant medical devices and healthcare services '),
 ('146', 'field', '80', 'en_us', ''),
 ('146', 'field', '56', 'en_us', ''),
 ('146', 'field', '57', 'en_us', ''),
 ('146', 'field', '104', 'en_us', ''),
 ('146', 'slug', '0', 'en_us', ' salam farhat '),
 ('146', 'title', '0', 'en_us', ' salam farhat '),
 ('275', 'field', '130', 'en_us', ' header section healthcare services '),
 ('275', 'field', '66', 'en_us', ' qualderm transparent '),
 ('369', 'extension', '0', 'en_us', ' png '),
 ('255', 'name', '0', 'en_us', ' new tag '),
 ('255', 'slug', '0', 'en_us', ''),
 ('255', 'title', '0', 'en_us', ' new tag '),
 ('256', 'name', '0', 'en_us', ' thisisreallyreallyreallyreallyreallyreallyreallylongandkajs dlfkja sldfjk aslkjf laskjdf lasjdf laskjflkasjdf lkjasdf lkasdf klasdjf lkasjdf klasjdf kasf kasjf kldsfj aslkdfj aklfj aslkjf sadlkfj '),
 ('256', 'slug', '0', 'en_us', ''),
 ('256', 'title', '0', 'en_us', ' thisisreallyreallyreallyreallyreallyreallyreallylongandkajs dlfkja sldfjk aslkjf laskjdf lasjdf laskjflkasjdf lkjasdf lkasdf klasdjf lkasjdf klasjdf kasf kasjf kldsfj aslkdfj aklfj aslkjf sadlkfj '),
 ('257', 'name', '0', 'en_us', ' will this appear on the top of the page '),
 ('257', 'slug', '0', 'en_us', ''),
 ('257', 'title', '0', 'en_us', ' will this appear on the top of the page '),
 ('266', 'title', '0', 'en_us', ' where do you belong '),
 ('275', 'field', '81', 'en_us', ' qualderm partners provides strategic leadership and practice management services through partnerships with highly qualified dermatologists throughout the southeastern us '),
 ('266', 'slug', '0', 'en_us', ''),
 ('266', 'name', '0', 'en_us', ' where do you belong '),
 ('375', 'filename', '0', 'en_us', ' tusker_transparent png '),
 ('375', 'extension', '0', 'en_us', ' png '),
 ('374', 'title', '0', 'en_us', ' qualderm transparent '),
 ('374', 'slug', '0', 'en_us', ''),
 ('374', 'kind', '0', 'en_us', ' image '),
 ('374', 'extension', '0', 'en_us', ' png '),
 ('374', 'filename', '0', 'en_us', ' qualderm_transparent png '),
 ('373', 'title', '0', 'en_us', ' cure forward transparent '),
 ('373', 'kind', '0', 'en_us', ' image '),
 ('373', 'slug', '0', 'en_us', ''),
 ('373', 'extension', '0', 'en_us', ' png '),
 ('373', 'filename', '0', 'en_us', ' cureforward_transparent png '),
 ('372', 'slug', '0', 'en_us', ''),
 ('372', 'title', '0', 'en_us', ' vytronus transparent '),
 ('372', 'kind', '0', 'en_us', ' image ');
INSERT INTO `craft_searchindex` (`elementId`, `attribute`, `fieldId`, `locale`, `keywords`) VALUES
 ('372', 'extension', '0', 'en_us', ' png '),
 ('371', 'title', '0', 'en_us', ' tendyne transparent '),
 ('372', 'filename', '0', 'en_us', ' vytronus_transparent png '),
 ('371', 'slug', '0', 'en_us', ''),
 ('371', 'kind', '0', 'en_us', ' image '),
 ('371', 'extension', '0', 'en_us', ' png '),
 ('370', 'title', '0', 'en_us', ' sgx transparent '),
 ('371', 'filename', '0', 'en_us', ' tendyne_transparent png '),
 ('370', 'slug', '0', 'en_us', ''),
 ('370', 'kind', '0', 'en_us', ' image '),
 ('370', 'extension', '0', 'en_us', ' png '),
 ('229', 'field', '62', 'en_us', ' http www lexicon genetics com https www linkedin com company coelacanth chemical corp '),
 ('229', 'field', '81', 'en_us', ' combinatorial chemistry building blocks based upon nobel prize winning k barry sharpless click chemistry '),
 ('351', 'field', '146', 'en_us', ' corvidia therapeutics raises $26m in a series a financing led by sofinnova partners and apple tree partners '),
 ('367', 'slug', '0', 'en_us', ''),
 ('367', 'kind', '0', 'en_us', ' image '),
 ('367', 'extension', '0', 'en_us', ' png '),
 ('281', 'field', '61', 'en_us', ' a biotechnology company focused on discovery and development of small molecule therapeutics generated by its proprietary fragments of active structures fast medicinal chemistry platform ipo february 2006 acquired by eli lilly july 2008 '),
 ('367', 'filename', '0', 'en_us', ' gloucestor_transparent png '),
 ('366', 'title', '0', 'en_us', ' clean slate transparent '),
 ('366', 'slug', '0', 'en_us', ''),
 ('366', 'kind', '0', 'en_us', ' image '),
 ('366', 'filename', '0', 'en_us', ' cleanslate_transparent png '),
 ('366', 'extension', '0', 'en_us', ' png '),
 ('365', 'title', '0', 'en_us', ' tokai pharmaceuticals logo pms '),
 ('365', 'slug', '0', 'en_us', ''),
 ('365', 'extension', '0', 'en_us', ' png '),
 ('365', 'kind', '0', 'en_us', ' image '),
 ('365', 'filename', '0', 'en_us', ' tokai_pharmaceuticals_logo_pms png '),
 ('364', 'title', '0', 'en_us', ' aileron logo 4 c '),
 ('275', 'field', '61', 'en_us', ' qualderm partners provides strategic leadership and practice management services through partnerships with highly qualified dermatologists throughout the southeastern us the company alleviates practice administrative burdens empowering providers to focus solely on delivering exceptional patient care '),
 ('232', 'name', '0', 'en_us', ' lorem ipsum dolor sit amet consectetuer adipiscing elit aenean commodo ligula eget dolor aenean massa cum sociis natoque penatibus et magnis dis parturient montes nascetur ridiculus mus donec quam felis ultricies nec pellentesque eu pretium quis '),
 ('200', 'field', '66', 'en_us', ' braeburn transparent '),
 ('200', 'field', '130', 'en_us', ' header section therapeutics '),
 ('200', 'field', '81', 'en_us', ' braeburn pharmaceuticals is developing a portfolio of long acting therapeutic treatment options for serious neurological and psychiatric disorders including opioid addiction pain and schizophrenia '),
 ('200', 'field', '61', 'en_us', ' braeburn pharmaceuticals is developing a portfolio of long acting therapeutic treatment options for serious neurological and psychiatric disorders including opioid addiction pain and schizophrenia long acting implantable and injectable therapies can be essential to improving patient outcomes and facilitating recovery in these conditions which are often complicated by stigma and present significant public health challenges the current portfolio includes probuphine a six month buprenorphine implant for treatment of opioid addiction cam2038 weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain a risperidone six month implant for treatment of schizophrenia and a novel molecule ati 9242 for treatment of schizophrenia '),
 ('200', 'field', '62', 'en_us', ' https braeburnpharmaceuticals com https www linkedin com company braeburn pharmaceuticals '),
 ('200', 'field', '103', 'en_us', ' therapeutics '),
 ('200', 'slug', '0', 'en_us', ' braeburn pharmaceuticals '),
 ('200', 'title', '0', 'en_us', ' braeburn pharmaceuticals '),
 ('201', 'field', '63', 'en_us', ' https braeburnpharmaceuticals com '),
 ('201', 'field', '64', 'en_us', ' https www linkedin com company braeburn pharmaceuticals '),
 ('201', 'slug', '0', 'en_us', ''),
 ('202', 'filename', '0', 'en_us', ' icon_atp_logo svg '),
 ('202', 'extension', '0', 'en_us', ' svg '),
 ('202', 'kind', '0', 'en_us', ' image '),
 ('202', 'slug', '0', 'en_us', ''),
 ('202', 'title', '0', 'en_us', ' icon atp logo '),
 ('204', 'field', '81', 'en_us', ' cleanslate is an outpatient addiction treatment company with a rapidly expanding multi site network currently comprised of twelve physician led centers located in both massachusetts and pennsylvania '),
 ('204', 'field', '61', 'en_us', ' cleanslate is an outpatient addiction treatment company with a rapidly expanding multi site network currently comprised of twelve physician led centers located in both massachusetts and pennsylvania cleanslate provides medication assisted treatment and related therapies using the highest quality evidence based practices for patients who have addiction and associated disorders '),
 ('204', 'field', '62', 'en_us', ' http cleanslatecenters com https www linkedin com company cleanslate centers '),
 ('204', 'field', '103', 'en_us', ' healthcare services '),
 ('204', 'slug', '0', 'en_us', ' cleanslate addiction treatment centers '),
 ('204', 'title', '0', 'en_us', ' cleanslate addiction treatment centers '),
 ('205', 'field', '63', 'en_us', ' http cleanslatecenters com '),
 ('205', 'field', '64', 'en_us', ' https www linkedin com company cleanslate centers '),
 ('205', 'slug', '0', 'en_us', ''),
 ('369', 'title', '0', 'en_us', ' heart ware transparent '),
 ('370', 'filename', '0', 'en_us', ' sgx_transparent png '),
 ('369', 'slug', '0', 'en_us', ''),
 ('369', 'kind', '0', 'en_us', ' image '),
 ('227', 'name', '0', 'en_us', ' testing '),
 ('227', 'slug', '0', 'en_us', ''),
 ('227', 'title', '0', 'en_us', ' testing '),
 ('229', 'slug', '0', 'en_us', ' http www appletreepartners com portfolio detail coelacanth acquired by lexicon genetics '),
 ('229', 'title', '0', 'en_us', ' coelacanth chemical corporation '),
 ('230', 'field', '63', 'en_us', ' http www lexicon genetics com '),
 ('230', 'field', '64', 'en_us', ' https www linkedin com company coelacanth chemical corp '),
 ('230', 'slug', '0', 'en_us', ''),
 ('232', 'title', '0', 'en_us', ' lorem ipsum dolor sit amet consectetuer adipiscing elit aenean commodo ligula eget dolor aenean massa cum sociis natoque penatibus et magnis dis parturient montes nascetur ridiculus mus donec quam felis ultricies nec pellentesque eu pretium quis '),
 ('232', 'slug', '0', 'en_us', ''),
 ('242', 'field', '62', 'en_us', ' http www galatherapeutics com '),
 ('242', 'field', '103', 'en_us', ' medical devices '),
 ('242', 'slug', '0', 'en_us', ' gala therapeutics '),
 ('233', 'name', '0', 'en_us', ' new tag '),
 ('233', 'slug', '0', 'en_us', ''),
 ('233', 'title', '0', 'en_us', ' new tag '),
 ('244', 'field', '61', 'en_us', ' cure forward connects cancer patients with clinical trial administrators working to reduce trial recruitment times and increase participation cure forward s online portal in addition to providing access to clinical trials can also help patients retrieve molecular diagnostic test results ordered by physicians access educational information connect with other patients and investigate treatment options '),
 ('244', 'field', '81', 'en_us', ' cure forward connects cancer patients with clinical trial administrators working to reduce trial recruitment times and increase participation '),
 ('244', 'field', '66', 'en_us', ' cure forward transparent '),
 ('243', 'field', '64', 'en_us', ''),
 ('245', 'field', '63', 'en_us', ' https www cureforward com '),
 ('244', 'title', '0', 'en_us', ' cure forward '),
 ('244', 'field', '62', 'en_us', ' https www cureforward com https www linkedin com company cureforward '),
 ('244', 'field', '103', 'en_us', ' healthcare services '),
 ('244', 'slug', '0', 'en_us', ' cure forward '),
 ('238', 'name', '0', 'en_us', ' new tag '),
 ('238', 'slug', '0', 'en_us', ''),
 ('238', 'title', '0', 'en_us', ' new tag '),
 ('239', 'field', '66', 'en_us', ' corvidia transparent '),
 ('239', 'field', '130', 'en_us', ' header section therapeutics '),
 ('239', 'field', '81', 'en_us', ' corvidia therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies '),
 ('239', 'field', '61', 'en_us', ' corvidia therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies leveraging functional genomics the company has identified mechanistically driven responder populations in a variety of cardio metabolic and cardio renal disorders '),
 ('239', 'field', '62', 'en_us', ' http corvidiatx com https www linkedin com company corvidia therapeutics '),
 ('239', 'field', '103', 'en_us', ' therapeutics '),
 ('239', 'slug', '0', 'en_us', ' corvidia '),
 ('239', 'title', '0', 'en_us', ' corvidia '),
 ('240', 'field', '63', 'en_us', ' http corvidiatx com '),
 ('240', 'field', '64', 'en_us', ' https www linkedin com company corvidia therapeutics '),
 ('240', 'slug', '0', 'en_us', '');
INSERT INTO `craft_searchindex` (`elementId`, `attribute`, `fieldId`, `locale`, `keywords`) VALUES
 ('244', 'field', '130', 'en_us', ' header section healthcare services '),
 ('243', 'slug', '0', 'en_us', ''),
 ('245', 'field', '64', 'en_us', ' https www linkedin com company cureforward '),
 ('245', 'slug', '0', 'en_us', ''),
 ('246', 'field', '66', 'en_us', ' cyrano '),
 ('246', 'field', '130', 'en_us', ' header section legacy companies '),
 ('246', 'field', '81', 'en_us', ' an electronic nose for homeland defense applications acquired by smiths detection march 2004 '),
 ('246', 'field', '61', 'en_us', ' an electronic nose for homeland defense applications acquired by smiths detection march 2004 '),
 ('246', 'field', '62', 'en_us', ' http www smithsdetection com '),
 ('246', 'field', '103', 'en_us', ' legacy investment '),
 ('246', 'slug', '0', 'en_us', ' cyrano sciences '),
 ('246', 'title', '0', 'en_us', ' cyrano sciences '),
 ('247', 'field', '63', 'en_us', ' http www smithsdetection com '),
 ('247', 'field', '64', 'en_us', ''),
 ('247', 'slug', '0', 'en_us', ''),
 ('248', 'field', '66', 'en_us', ' gloucestor transparent '),
 ('248', 'field', '130', 'en_us', ' header section legacy companies '),
 ('248', 'field', '81', 'en_us', ' creators of istodax romidepsin for t cell lymphoma and other malignancies acquired by celgene january 2010 '),
 ('248', 'field', '61', 'en_us', ' creators of istodax romidepsin for t cell lymphoma and other malignancies acquired by celgene january 2010 '),
 ('248', 'field', '62', 'en_us', ' http www celgene com '),
 ('248', 'field', '103', 'en_us', ' legacy investment '),
 ('248', 'slug', '0', 'en_us', ' gloucester pharmaceuticals '),
 ('248', 'title', '0', 'en_us', ' gloucester pharmaceuticals '),
 ('249', 'field', '63', 'en_us', ' http www celgene com '),
 ('249', 'field', '64', 'en_us', ''),
 ('249', 'slug', '0', 'en_us', ''),
 ('275', 'field', '62', 'en_us', ' http qualderm com https www linkedin com company 6471786 trk=tyah trkinfo=clickedvertical%3acompany%2cidx%3a2 1 4%2ctarid%3a1435163699111%2ctas%3aqualderm%20partners '),
 ('275', 'field', '103', 'en_us', ' healthcare services '),
 ('275', 'slug', '0', 'en_us', ' qualderm partners '),
 ('275', 'title', '0', 'en_us', ' qualderm partners '),
 ('276', 'field', '63', 'en_us', ' http qualderm com '),
 ('276', 'field', '64', 'en_us', ' https www linkedin com company 6471786 trk=tyah trkinfo=clickedvertical%3acompany%2cidx%3a2 1 4%2ctarid%3a1435163699111%2ctas%3aqualderm%20partners '),
 ('276', 'slug', '0', 'en_us', ''),
 ('364', 'kind', '0', 'en_us', ' image '),
 ('364', 'slug', '0', 'en_us', ''),
 ('364', 'extension', '0', 'en_us', ' png '),
 ('281', 'field', '130', 'en_us', ' header section legacy companies '),
 ('281', 'field', '81', 'en_us', ' a biotechnology company focused on discovery and development of small molecule therapeutics generated by its proprietary fragments of active structures fast medicinal chemistry platform '),
 ('281', 'field', '66', 'en_us', ' sgx transparent '),
 ('280', 'name', '0', 'en_us', ' principal '),
 ('280', 'slug', '0', 'en_us', ''),
 ('280', 'title', '0', 'en_us', ' principal '),
 ('281', 'field', '62', 'en_us', ' https www lilly com home aspx https www linkedin com company sgx pharmaceuticals '),
 ('281', 'field', '103', 'en_us', ' legacy investment '),
 ('281', 'slug', '0', 'en_us', ' sgx pharmaceuticals '),
 ('281', 'title', '0', 'en_us', ' sgx pharmaceuticals '),
 ('282', 'field', '63', 'en_us', ' https www lilly com home aspx '),
 ('282', 'field', '64', 'en_us', ' https www linkedin com company sgx pharmaceuticals '),
 ('282', 'slug', '0', 'en_us', ''),
 ('364', 'filename', '0', 'en_us', ' aileron_logo_4c png '),
 ('363', 'title', '0', 'en_us', ' triple care transparent '),
 ('363', 'slug', '0', 'en_us', ''),
 ('363', 'kind', '0', 'en_us', ' image '),
 ('284', 'field', '66', 'en_us', ' syntimmune logo '),
 ('284', 'field', '130', 'en_us', ' header section therapeutics '),
 ('284', 'field', '81', 'en_us', ' syntimmune is developing novel antibody therapies for inflammatory diseases and severe toxicities '),
 ('284', 'field', '61', 'en_us', ' syntimmune is developing novel antibody therapies for inflammatory diseases and severe toxicities syntimmune s lead program synt 001 specifically blocks fcrn igg interaction resulting in the rapid clearance of pathogenic igg important in a variety of antibody mediated diseases '),
 ('284', 'field', '62', 'en_us', ' http syntimmune com '),
 ('284', 'field', '103', 'en_us', ' therapeutics '),
 ('284', 'slug', '0', 'en_us', ' syntimmune '),
 ('284', 'title', '0', 'en_us', ' syntimmune '),
 ('285', 'field', '63', 'en_us', ' http syntimmune com '),
 ('285', 'field', '64', 'en_us', ''),
 ('285', 'slug', '0', 'en_us', ''),
 ('363', 'extension', '0', 'en_us', ' png '),
 ('363', 'filename', '0', 'en_us', ' triplecare_transparent png '),
 ('287', 'field', '66', 'en_us', ' tendyne transparent '),
 ('287', 'field', '130', 'en_us', ' header section legacy companies '),
 ('287', 'field', '81', 'en_us', ' exitedtendyne is focused on the development and commercialization of minimally invasive therapies for the treatment of mitral regurgitation '),
 ('287', 'field', '61', 'en_us', ' tendyne is focused on the development and commercialization of minimally invasive therapies for the treatment of mitral regurgitation tendyne s first product is a percutaneous transcatheter mitral valve prosthesis acquired by abbott august 2015 '),
 ('287', 'field', '62', 'en_us', ' http www tendyne com '),
 ('287', 'field', '103', 'en_us', ' therapeutics '),
 ('287', 'slug', '0', 'en_us', ' tendyne '),
 ('287', 'title', '0', 'en_us', ' tendyne '),
 ('288', 'field', '63', 'en_us', ' http www tendyne com '),
 ('288', 'field', '64', 'en_us', ''),
 ('288', 'slug', '0', 'en_us', ''),
 ('362', 'slug', '0', 'en_us', ''),
 ('362', 'title', '0', 'en_us', ' syntimmune logo '),
 ('362', 'kind', '0', 'en_us', ' image '),
 ('362', 'extension', '0', 'en_us', ' png '),
 ('290', 'field', '66', 'en_us', ' tokai pharmaceuticals logo pms '),
 ('290', 'field', '130', 'en_us', ' header section therapeutics '),
 ('290', 'field', '81', 'en_us', ' tokai tkai is developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases '),
 ('290', 'field', '61', 'en_us', ' tokai tkai is developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases the company is conducting a pivotal clinical trial of its lead drug candidate galeterone in patients with metastatic castration resistant prostate cancer mcrpc whose tumors express the ar v7 splice variant which is a truncated form of the androgen receptor associated with non responsiveness to commonly used oral therapies for mcrpc this trial is the first precision medicine based pivotal clinical trial in prostate cancer '),
 ('290', 'field', '62', 'en_us', ' http tokaipharmaceuticals com https www linkedin com company tokai pharmaceuticals inc '),
 ('290', 'field', '103', 'en_us', ' legacy investment '),
 ('290', 'slug', '0', 'en_us', ' tokai pharmaceuticals '),
 ('290', 'title', '0', 'en_us', ' tokai pharmaceuticals '),
 ('291', 'field', '63', 'en_us', ' http tokaipharmaceuticals com '),
 ('291', 'field', '64', 'en_us', ' https www linkedin com company tokai pharmaceuticals inc '),
 ('291', 'slug', '0', 'en_us', ''),
 ('362', 'filename', '0', 'en_us', ' syntimmunelogo png '),
 ('361', 'title', '0', 'en_us', ' braeburn transparent '),
 ('361', 'slug', '0', 'en_us', ''),
 ('293', 'field', '66', 'en_us', ' triple care transparent '),
 ('293', 'field', '130', 'en_us', ' header section healthcare services '),
 ('293', 'field', '81', 'en_us', ' triplecare provides acute hospital level care to patients residing in skilled nursing facilities snfs using state of the art telemedicine technology '),
 ('293', 'field', '61', 'en_us', ' triplecare provides acute hospital level care to patients residing in skilled nursing facilities snfs using state of the art telemedicine technology the company expands patient access to care after hours and on weekends by providing physicians equipment and software to snfs with the goal of treating patients in place the company presently operates across over thirty five facilities in six states '),
 ('293', 'field', '62', 'en_us', ' http triple care https www linkedin com company esnf ');
INSERT INTO `craft_searchindex` (`elementId`, `attribute`, `fieldId`, `locale`, `keywords`) VALUES
 ('293', 'field', '103', 'en_us', ' healthcare services '),
 ('293', 'slug', '0', 'en_us', ' triplecare '),
 ('293', 'title', '0', 'en_us', ' triplecare '),
 ('294', 'field', '63', 'en_us', ' http triple care '),
 ('294', 'field', '64', 'en_us', ' https www linkedin com company esnf '),
 ('294', 'slug', '0', 'en_us', ''),
 ('361', 'extension', '0', 'en_us', ' png '),
 ('361', 'kind', '0', 'en_us', ' image '),
 ('361', 'filename', '0', 'en_us', ' braeburn_transparent png '),
 ('296', 'field', '66', 'en_us', ' tusker transparent '),
 ('296', 'field', '130', 'en_us', ' header section medical devices '),
 ('296', 'field', '81', 'en_us', ' tusker medical is an early stage medical device company developing innovative ear nose and throat treatments '),
 ('296', 'field', '61', 'en_us', ' tusker medical is an early stage medical device company developing innovative ear nose and throat treatments tusker is currently developing a suite of pediatric focused technologies designed to enable placement of tubes within the comfort of an office environment eliminating the need for general anesthetics '),
 ('296', 'field', '62', 'en_us', ' http www tuskermed com https www linkedin com company tusker medical inc '),
 ('296', 'field', '103', 'en_us', ' medical devices '),
 ('296', 'slug', '0', 'en_us', ' tusker medical '),
 ('296', 'title', '0', 'en_us', ' tusker medical '),
 ('297', 'field', '63', 'en_us', ' http www tuskermed com '),
 ('297', 'field', '64', 'en_us', ' https www linkedin com company tusker medical inc '),
 ('297', 'slug', '0', 'en_us', ''),
 ('298', 'field', '66', 'en_us', ' vytronus transparent '),
 ('298', 'field', '130', 'en_us', ' header section medical devices '),
 ('298', 'field', '81', 'en_us', ' vytronus is a clinical stage company redefining ablation by using a next generation ultrasound based robotic catheter to treat complex cardiac arrhythmias including atrial fibrillation '),
 ('298', 'field', '61', 'en_us', ' vytronus is a clinical stage company redefining ablation by using a next generation ultrasound based robotic catheter to treat complex cardiac arrhythmias including atrial fibrillation the company has developed an endocardial ablation platform based on low intensity collimated ultrasound licu licu is capable of quickly producing high resolution maps of cardiac anatomy and allows for non contact energy delivery to create durable continuous linear lesions vytronus will help simplify the procedure and improve efficacy by leading to more predictable outcomes '),
 ('298', 'field', '62', 'en_us', ' http www vytronus com '),
 ('298', 'field', '103', 'en_us', ' medical devices '),
 ('298', 'slug', '0', 'en_us', ' vytronus '),
 ('298', 'title', '0', 'en_us', ' vytronus '),
 ('299', 'field', '63', 'en_us', ' http www vytronus com '),
 ('299', 'field', '64', 'en_us', ''),
 ('299', 'slug', '0', 'en_us', ''),
 ('300', 'field', '96', 'en_us', ' left '),
 ('300', 'slug', '0', 'en_us', ''),
 ('301', 'field', '94', 'en_us', ' materials '),
 ('301', 'field', '95', 'en_us', ' all materials are provided as is may not be relied upon for any purpose and are not subject to express or implied warranties of any kind in particular we make no representations or warranties with regard to the materials accuracy completeness non infringement or fitness for a particular purpose you should be aware that a significant portion of the materials include or consist of information that has been provided by third parties and has not been validated or verified by us in connection with our investment activities we often become subject to a variety of confidentiality obligations to funds investors portfolio companies and other third parties any statements we make may be affected by those confidentiality obligations with the result that we may be prohibited from making full disclosures without limitation on the effect of other warnings and disclaimers set forth in these terms you should interpret any statements we make on this website or otherwise in that context please ensure that your own computer security is comprehensive and up to date we accept no responsibility for viruses malware or other malicious or damaging software contained in the materials or otherwise '),
 ('301', 'field', '96', 'en_us', ' left '),
 ('301', 'slug', '0', 'en_us', ''),
 ('302', 'field', '94', 'en_us', ' third party sites '),
 ('302', 'field', '95', 'en_us', ' we accept no responsibility for third party sites available through this website via hyperlink or otherwise you are encouraged to review the terms of use applicable to those sites any access to or use of a third party site is solely at your own risk '),
 ('302', 'field', '96', 'en_us', ' left '),
 ('302', 'slug', '0', 'en_us', ''),
 ('303', 'field', '94', 'en_us', ' no offer solicitation or advice '),
 ('303', 'field', '95', 'en_us', ' nothing on this website is intended to constitute i an offer or solicitation of an offer to purchase or sell any security other asset or service ii investment advice or an offer to provide such advice or iii a basis for making any investment decision except as expressly stated by an apple tree partners entity in writing neither this website nor any of the materials make any effort to present a comprehensive or balanced description of apple tree partners or its investment activities '),
 ('303', 'field', '96', 'en_us', ' left '),
 ('303', 'slug', '0', 'en_us', ''),
 ('304', 'field', '94', 'en_us', ' restrictions on use no license '),
 ('304', 'field', '95', 'en_us', ' we reserve all rights with respect to the design and content of this website in particular you must not misappropriate the design or content of this website and you must not alter or deface such design or content in any way nothing on this website grants any license with respect to such design or content except that you may download and use materials solely for your own personal information '),
 ('304', 'field', '96', 'en_us', ' left '),
 ('304', 'slug', '0', 'en_us', ''),
 ('305', 'field', '94', 'en_us', ' ownership of trademarks etc '),
 ('305', 'field', '95', 'en_us', ' all text photos graphics logos content and other materials on this website are protected by united states and foreign copyright trademark and other applicable laws in particular all trademarks trade names and logos displayed on this website are proprietary to apple tree partners its affiliates or their respective owners and this website grants no license to them apple tree partners and our tree logo are among our trademarks in the united states and or other countries '),
 ('305', 'field', '96', 'en_us', ' left '),
 ('305', 'slug', '0', 'en_us', ''),
 ('306', 'field', '94', 'en_us', ' submitting a business plan '),
 ('306', 'field', '95', 'en_us', ' or other confidential information due to the large number of business plan ideas and related materials that we review and the similarity of many such plans and materials we cannot accept responsibility for protecting against misuse or disclosure any confidential or proprietary information or other materials in the absence of our express written agreement to do so any plans information and other materials you submit in connection with this website may be used or disclosed by us for any purpose and in any manner as we determine in our sole discretion please consider this carefully before sending us any information or other materials that you deem confidential or proprietary '),
 ('306', 'field', '96', 'en_us', ' left '),
 ('306', 'slug', '0', 'en_us', ''),
 ('307', 'field', '94', 'en_us', ' privacy policy '),
 ('307', 'field', '95', 'en_us', ' we reserve the right to track visitors to and usage of this website through cookies and similar techniques and to use any resulting information as we determine in our sole discretion '),
 ('307', 'field', '96', 'en_us', ' left '),
 ('307', 'slug', '0', 'en_us', ''),
 ('308', 'field', '94', 'en_us', ' limitation of liability '),
 ('308', 'field', '95', 'en_us', ' except as specifically agreed by an apple tree partners entity in writing no apple tree partners individual or entity shall have any liability based upon your use of or reliance upon this website or the materials some jurisdictions limit our ability to disclaim liability with regard to those jurisdictions our liability shall be limited to the greatest extent permitted by applicable law '),
 ('308', 'field', '96', 'en_us', ' left '),
 ('308', 'slug', '0', 'en_us', ''),
 ('309', 'field', '94', 'en_us', ' modification of these terms '),
 ('309', 'field', '95', 'en_us', ' we reserve the right to modify these terms at any time please check these terms periodically for changes your continued use of this website after the posting of changes constitutes your binding acceptance of such changes '),
 ('309', 'field', '96', 'en_us', ' left '),
 ('309', 'slug', '0', 'en_us', ''),
 ('310', 'field', '94', 'en_us', ' general information '),
 ('310', 'field', '95', 'en_us', ' this website is operated and controlled by apple tree venture management llc in the united states of america if it is illegal or prohibited in your country of origin to access or use this website then you should not do so those who choose to access this website outside the united states of america access it on their own initiative and are responsible for compliance with all local laws and regulations these terms and any disputes relating to these terms or your use of this website or the materials shall be governed in all respects by the laws of the state of new york without regard to conflicts of laws principles except as otherwise agreed in writing by the applicable apple tree partners entities any disputes relating to these terms shall be resolved exclusively in the state or federal courts located in new york new york these terms set forth the entire agreement between you and us with respect to the subject matter hereof and supersede all prior agreements relating to such subject matter all apple tree partners individuals and entities are intended third party beneficiaries of these terms our rights under these terms may be waived by us only in writing these terms are binding on you as well as your successors and permitted assigns in the event any provision of these terms is determined to be invalid or unenforceable such provision shall be deemed severed from the remainder of these terms and replaced with a valid and enforceable provision as similar in intent as reasonably possible to the provision so severed and shall not cause the invalidity or unenforceability of the remainder of these terms '),
 ('310', 'field', '96', 'en_us', ' left '),
 ('310', 'slug', '0', 'en_us', ''),
 ('312', 'field', '20', 'en_us', ' 2016 07 06 '),
 ('312', 'field', '22', 'en_us', ' left a high tech version of healthcare is becoming more and more popular it s called telemedicine and in many cases it helps keep people out of the hospital right now there s a big push to cut the rate of people who are re admitted to the hospital it not only saves money but it also lowers the risk for infection and other complication plus it helps keep patients more comfortable sue and charlie lake just celebrated their 60th wedding anniversary they both live at meadowood senior living because 91 year old mr lake has health problems he stays at the skilled nursing facility they demonstrated their new triplecare telemedicine system for us on nights weekends or holidays when there isn t a doctor in person at the center there s one available through cyberspace with nurses help a doctor can do a thorough examination the camera can zoom in to look for swelling lesions or discoloration the stethoscope is also connected what nurses hear the doctor hears at the same time it s like skype except that you have all the dimensions you have all the senses that the physician can hone in on said sally ann heckert bikin attorney and director of nursing at meadowood mrs lake tells action news she was skeptical about the new technology at first i say i don t think it s going to work you are going to lose the face to face she said but when her husband got sick on a sunday night with the help of triplecare they were able to diagnose and treat him in his room as opposed to being transported by ambulance to the hospital i went from saying it s not going to work to telling everyone this is such a great thing said sue so far we ve had 16 calls and out of 16 13 we were able to treat here in the patient s room said lynn plepis clinical informatics at meadowood mr lake was one of those 13 triplecare is also set up to keep up the information private and secure many other centers are using similar technology view the original news clip including the video '),
 ('312', 'field', '36', 'en_us', ''),
 ('312', 'slug', '0', 'en_us', ' high tech healthcare helps eliminate unnecessary hospital visits '),
 ('312', 'title', '0', 'en_us', ' high tech healthcare helps eliminate unnecessary hospital visits '),
 ('313', 'field', '25', 'en_us', ' a high tech version of healthcare is becoming more and more popular it s called telemedicine and in many cases it helps keep people out of the hospital right now there s a big push to cut the rate of people who are re admitted to the hospital it not only saves money but it also lowers the risk for infection and other complication plus it helps keep patients more comfortable sue and charlie lake just celebrated their 60th wedding anniversary they both live at meadowood senior living because 91 year old mr lake has health problems he stays at the skilled nursing facility they demonstrated their new triplecare telemedicine system for us on nights weekends or holidays when there isn t a doctor in person at the center there s one available through cyberspace with nurses help a doctor can do a thorough examination the camera can zoom in to look for swelling lesions or discoloration the stethoscope is also connected what nurses hear the doctor hears at the same time it s like skype except that you have all the dimensions you have all the senses that the physician can hone in on said sally ann heckert bikin attorney and director of nursing at meadowood mrs lake tells action news she was skeptical about the new technology at first i say i don t think it s going to work you are going to lose the face to face she said but when her husband got sick on a sunday night with the help of triplecare they were able to diagnose and treat him in his room as opposed to being transported by ambulance to the hospital i went from saying it s not going to work to telling everyone this is such a great thing said sue so far we ve had 16 calls and out of 16 13 we were able to treat here in the patient s room said lynn plepis clinical informatics at meadowood mr lake was one of those 13 triplecare is also set up to keep up the information private and secure many other centers are using similar technology view the original news clip including the video '),
 ('313', 'field', '26', 'en_us', ' left '),
 ('313', 'slug', '0', 'en_us', ''),
 ('314', 'field', '131', 'en_us', ' header section news '),
 ('314', 'field', '20', 'en_us', ' 2016 06 28 '),
 ('314', 'field', '22', 'en_us', ' left cure forward an online precision medicine platform for cancer patients and their care teams and novartis pharmaceuticals corporation today announced that cure forward s unique clinical trial exchange will support novartis in identifying potential patients for all of its current oncology trials the collaboration further validates cure forward s approach for real time patient sourcing in clinical trials by utilizing its patent pending clinical trial exchange cure forward facilitates connections between patients and drug development companies based on mutual criteria and preferences comparable to popular online dating platforms there is a significant efficiency gap in the clinical trial process today placing undue burden on patients and caregivers to navigate the vast complex landscape of medical research options often at stages in which their time is most valuable drug developers are concurrently developing investigational treatments but often struggle to find the right patients to receive these investigational treatments cure forward s platform empowers patients to govern their own care plans providing accurate easily accessible information to help drive individual choices today s patient is active in his or her care accessing data to make important treatment decisions said martin naley founder and chief strategy officer cure forward cure forward makes clinical trial enrollment easier and more accessible novartis bold approach of activating searches for oncology trials on our platform will help patients find possible investigational treatments for their care about cure forward left cure forward bridges the gap between patients and precision medicine beginning in cancer cure forward provides a simple to use platform that allows patients to obtain their genomic data and use it to identify treatment options including clinical trials solving critical business needs for diagnostic laboratories health care providers and clinical trial recruiters cure forward is based in cambridge massachusetts and was incubated and launched by apple tree partners new york city the company s platform is in beta release at www cureforward com '),
 ('314', 'field', '36', 'en_us', ''),
 ('314', 'slug', '0', 'en_us', ' cure forward announces first trial recruitment collaboration that will expand patient access to innovative treatments '),
 ('314', 'title', '0', 'en_us', ' cure forward announces first trial recruitment collaboration that will expand patient access to innovative treatments '),
 ('315', 'field', '25', 'en_us', ' cure forward an online precision medicine platform for cancer patients and their care teams and novartis pharmaceuticals corporation today announced that cure forward s unique clinical trial exchange will support novartis in identifying potential patients for all of its current oncology trials the collaboration further validates cure forward s approach for real time patient sourcing in clinical trials by utilizing its patent pending clinical trial exchange cure forward facilitates connections between patients and drug development companies based on mutual criteria and preferences comparable to popular online dating platforms there is a significant efficiency gap in the clinical trial process today placing undue burden on patients and caregivers to navigate the vast complex landscape of medical research options often at stages in which their time is most valuable drug developers are concurrently developing investigational treatments but often struggle to find the right patients to receive these investigational treatments cure forward s platform empowers patients to govern their own care plans providing accurate easily accessible information to help drive individual choices today s patient is active in his or her care accessing data to make important treatment decisions said martin naley founder and chief strategy officer cure forward cure forward makes clinical trial enrollment easier and more accessible novartis bold approach of activating searches for oncology trials on our platform will help patients find possible investigational treatments for their care '),
 ('315', 'field', '26', 'en_us', ' left '),
 ('315', 'slug', '0', 'en_us', ''),
 ('316', 'field', '23', 'en_us', ' about cure forward '),
 ('316', 'slug', '0', 'en_us', ''),
 ('317', 'field', '25', 'en_us', ' cure forward bridges the gap between patients and precision medicine beginning in cancer cure forward provides a simple to use platform that allows patients to obtain their genomic data and use it to identify treatment options including clinical trials solving critical business needs for diagnostic laboratories health care providers and clinical trial recruiters cure forward is based in cambridge massachusetts and was incubated and launched by apple tree partners new york city the company s platform is in beta release at www cureforward com '),
 ('317', 'field', '26', 'en_us', ' left '),
 ('317', 'slug', '0', 'en_us', ''),
 ('318', 'name', '0', 'en_us', ' heartware '),
 ('318', 'slug', '0', 'en_us', ''),
 ('318', 'title', '0', 'en_us', ' heartware '),
 ('319', 'field', '131', 'en_us', ' header section news '),
 ('319', 'field', '20', 'en_us', ' 2016 06 27 ');
INSERT INTO `craft_searchindex` (`elementId`, `attribute`, `fieldId`, `locale`, `keywords`) VALUES
 ('319', 'field', '22', 'en_us', ' left medtronic plc nyse mdt the global leader in medical technology and heartware international inc nasdaq htwr a leading innovator of less invasive miniaturized circulatory support technologies for the treatment of advanced heart failure today announced that the companies have entered into a definitive merger agreement under which medtronic will acquire heartware in a transaction valued at approximately $1 1 billion under the terms of the agreement medtronic will commence a tender offer for all outstanding shares of heartware common stock for $58 00 per share in cash the boards of directors of both medtronic and heartware have unanimously approved the transaction the acquisition is expected to close during medtronic s second fiscal quarter ending oct 28 2016 subject to the satisfaction of customary closing conditions medtronic s acquisition of heartware will expand medtronic s portfolio of diagnostic tools therapies and services for patients suffering from heart failure aligning with medtronic s mission of alleviating pain restoring health and extending life and is in line with the company s strategy to surround the physician with innovative products while focusing on patients and disease states heartware s flagship product the hvad system features the world s smallest full support ventricular assist device vad and is designed to reduce surgical invasiveness improve patient recovery times and enhance patient outcomes in addition heartware has multiple technologies in development designed to offer progressively less invasive mechanical circulatory support options for patients with end stage heart failure medtronic estimates that the global vad market is approximately $800 million currently and worldwide is expected to grow in the mid to high single digits for cy16 17 and accelerate to high single low double digits beyond cy17 the addition of heartware s innovative portfolio adds to our expanding portfolio of diagnostics therapeutics and services that address heart failure patients said mike coyle executive vice president and president of the cardiac and vascular group at medtronic the team at heartware has established excellent relationships with its hospital customers and built a strong position and reputation in the marketplace this transaction once closed will be a further important step toward medtronic offering a complete suite of solutions to address patient needs across the heart failure care continuum medtronic is the worldwide leader in cardiovascular device technologies its expansive expertise in the development of implantable systems and battery technologies patient monitoring manufacturing global regulatory policy and commercialization should help accelerate the development and introduction of our innovative pipeline products and will expand access to our therapies and offerings to the sizeable heart failure population said doug godshall president and chief executive officer heartware combining the unique capabilities of the heartware team which has been entirely focused on mechanical support technologies with the broad strength of the medtronic organization provides a unique opportunity to enhance growth in the mechanical circulatory support market all of our stakeholders including customers employees shareholders and most importantly patients will benefit meaningfully from this complementary combination heart failure also known as congestive heart failure is a condition or a collection of symptoms in which the heart isn t pumping enough blood to meet the body s needs heart failure usually develops slowly after an injury to the heart some injuries may include a heart attack too much strain on the heart due to years of untreated high blood pressure or a diseased heart valve among others heart failure remains a leading cause of hospitalization and death in the united states and its prevalence continues to increase affecting more than five million people in the u s alone the cost of heart failure is high healthcare expenditures in the u s on heart failure are estimated to be approximately $39 billion per year making it one of the largest expenses to the healthcare system with the aging of the population medtronic estimates that the number of patients with heart failure could exceed eight million by 2030 heartware s hvad system enhances the portfolio of our cardiac vascular group a team with a proven track record of executing and a demonstrated ability to scale early stage concepts into large sustainable end markets said omar ishrak chairman and chief executive officer of medtronic in addition from a financial perspective we are pleased to reach an agreement that meets our acquisition criteria of adding minimal to no net eps dilution in the near term while at the same time creating strong long term expected returns for our shareholders this acquisition supports medtronic s therapy innovation strategic priority in collaboration with leading clinicians researchers and scientists worldwide medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias the company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world this transaction is expected to meet medtronic s long term financial metrics for acquisitions medtronic does not intend to modify its fiscal year 2017 revenue outlook or earnings per share eps guidance as a result of this transaction although it is expected to provide increased confidence in the company s ability to deliver on its fy17 revenue growth outlook in addition medtronic expects minimal to no net eps dilution from this transaction for the first two years as the company intends to offset the expected dilutive impact the acquisition is expected to be earnings accretive in year three medtronic intends to report results from the acquired heartware business as part of its cardiac rhythm heart failure division within the cardiac vascular group medtronic s financial advisor for the transaction is j p morgan securities llc with ropes gray llp acting as legal advisor heartware s financial advisor is perella weinberg partners lp with shearman sterling llp acting as legal advisor about heartware international left heartware international inc www heartware com develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients around the world suffering from advanced heart failure dedicated to developing new minimally invasive technologies to revolutionize the treatment of patients with end stage heart failure heartware has multiple technologies in development to offer progressively less invasive mechanical circulatory support options heartware s corporate headquarters are located in framingham massachusetts and the company has technology operations manufacturing and distribution centers in miami lakes florida arden hills minnesota and hannover germany about medtronic left medtronic plc www medtronic com headquartered in dublin ireland is among the world s largest medical technology services and solutions companies alleviating pain restoring health and extending life for millions of people around the world medtronic employs more than 85 000 people worldwide serving physicians hospitals and patients in approximately 160 countries the company is focused on collaborating with stakeholders around the world to take healthcare further together '),
 ('319', 'field', '36', 'en_us', ''),
 ('319', 'slug', '0', 'en_us', ' medtronic to expand heart failure portfolio with acquisition of heartware international '),
 ('319', 'title', '0', 'en_us', ' medtronic to expand heart failure portfolio with acquisition of heartware international '),
 ('320', 'field', '25', 'en_us', ' medtronic plc nyse mdt the global leader in medical technology and heartware international inc nasdaq htwr a leading innovator of less invasive miniaturized circulatory support technologies for the treatment of advanced heart failure today announced that the companies have entered into a definitive merger agreement under which medtronic will acquire heartware in a transaction valued at approximately $1 1 billion under the terms of the agreement medtronic will commence a tender offer for all outstanding shares of heartware common stock for $58 00 per share in cash the boards of directors of both medtronic and heartware have unanimously approved the transaction the acquisition is expected to close during medtronic s second fiscal quarter ending oct 28 2016 subject to the satisfaction of customary closing conditions medtronic s acquisition of heartware will expand medtronic s portfolio of diagnostic tools therapies and services for patients suffering from heart failure aligning with medtronic s mission of alleviating pain restoring health and extending life and is in line with the company s strategy to surround the physician with innovative products while focusing on patients and disease states heartware s flagship product the hvad system features the world s smallest full support ventricular assist device vad and is designed to reduce surgical invasiveness improve patient recovery times and enhance patient outcomes in addition heartware has multiple technologies in development designed to offer progressively less invasive mechanical circulatory support options for patients with end stage heart failure medtronic estimates that the global vad market is approximately $800 million currently and worldwide is expected to grow in the mid to high single digits for cy16 17 and accelerate to high single low double digits beyond cy17 the addition of heartware s innovative portfolio adds to our expanding portfolio of diagnostics therapeutics and services that address heart failure patients said mike coyle executive vice president and president of the cardiac and vascular group at medtronic the team at heartware has established excellent relationships with its hospital customers and built a strong position and reputation in the marketplace this transaction once closed will be a further important step toward medtronic offering a complete suite of solutions to address patient needs across the heart failure care continuum medtronic is the worldwide leader in cardiovascular device technologies its expansive expertise in the development of implantable systems and battery technologies patient monitoring manufacturing global regulatory policy and commercialization should help accelerate the development and introduction of our innovative pipeline products and will expand access to our therapies and offerings to the sizeable heart failure population said doug godshall president and chief executive officer heartware combining the unique capabilities of the heartware team which has been entirely focused on mechanical support technologies with the broad strength of the medtronic organization provides a unique opportunity to enhance growth in the mechanical circulatory support market all of our stakeholders including customers employees shareholders and most importantly patients will benefit meaningfully from this complementary combination heart failure also known as congestive heart failure is a condition or a collection of symptoms in which the heart isn t pumping enough blood to meet the body s needs heart failure usually develops slowly after an injury to the heart some injuries may include a heart attack too much strain on the heart due to years of untreated high blood pressure or a diseased heart valve among others heart failure remains a leading cause of hospitalization and death in the united states and its prevalence continues to increase affecting more than five million people in the u s alone the cost of heart failure is high healthcare expenditures in the u s on heart failure are estimated to be approximately $39 billion per year making it one of the largest expenses to the healthcare system with the aging of the population medtronic estimates that the number of patients with heart failure could exceed eight million by 2030 heartware s hvad system enhances the portfolio of our cardiac vascular group a team with a proven track record of executing and a demonstrated ability to scale early stage concepts into large sustainable end markets said omar ishrak chairman and chief executive officer of medtronic in addition from a financial perspective we are pleased to reach an agreement that meets our acquisition criteria of adding minimal to no net eps dilution in the near term while at the same time creating strong long term expected returns for our shareholders this acquisition supports medtronic s therapy innovation strategic priority in collaboration with leading clinicians researchers and scientists worldwide medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias the company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world this transaction is expected to meet medtronic s long term financial metrics for acquisitions medtronic does not intend to modify its fiscal year 2017 revenue outlook or earnings per share eps guidance as a result of this transaction although it is expected to provide increased confidence in the company s ability to deliver on its fy17 revenue growth outlook in addition medtronic expects minimal to no net eps dilution from this transaction for the first two years as the company intends to offset the expected dilutive impact the acquisition is expected to be earnings accretive in year three medtronic intends to report results from the acquired heartware business as part of its cardiac rhythm heart failure division within the cardiac vascular group medtronic s financial advisor for the transaction is j p morgan securities llc with ropes gray llp acting as legal advisor heartware s financial advisor is perella weinberg partners lp with shearman sterling llp acting as legal advisor '),
 ('320', 'field', '26', 'en_us', ' left '),
 ('320', 'slug', '0', 'en_us', ''),
 ('321', 'field', '23', 'en_us', ' about heartware international '),
 ('321', 'slug', '0', 'en_us', ''),
 ('322', 'field', '25', 'en_us', ' heartware international inc www heartware com develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients around the world suffering from advanced heart failure dedicated to developing new minimally invasive technologies to revolutionize the treatment of patients with end stage heart failure heartware has multiple technologies in development to offer progressively less invasive mechanical circulatory support options heartware s corporate headquarters are located in framingham massachusetts and the company has technology operations manufacturing and distribution centers in miami lakes florida arden hills minnesota and hannover germany '),
 ('322', 'field', '26', 'en_us', ' left '),
 ('322', 'slug', '0', 'en_us', ''),
 ('323', 'field', '23', 'en_us', ' about medtronic '),
 ('323', 'slug', '0', 'en_us', ''),
 ('324', 'field', '25', 'en_us', ' medtronic plc www medtronic com headquartered in dublin ireland is among the world s largest medical technology services and solutions companies alleviating pain restoring health and extending life for millions of people around the world medtronic employs more than 85 000 people worldwide serving physicians hospitals and patients in approximately 160 countries the company is focused on collaborating with stakeholders around the world to take healthcare further together '),
 ('324', 'field', '26', 'en_us', ' left '),
 ('324', 'slug', '0', 'en_us', ''),
 ('14', 'field', '131', 'en_us', ''),
 ('325', 'name', '0', 'en_us', ' cure forward '),
 ('325', 'slug', '0', 'en_us', ''),
 ('325', 'title', '0', 'en_us', ' cure forward '),
 ('326', 'name', '0', 'en_us', ' braeburn '),
 ('326', 'slug', '0', 'en_us', ''),
 ('326', 'title', '0', 'en_us', ' braeburn '),
 ('327', 'field', '131', 'en_us', ' header section news '),
 ('327', 'field', '20', 'en_us', ' 2016 05 26 '),
 ('327', 'field', '22', 'en_us', ' left the u s food and drug administration today approved probuphine the first buprenorphine implant for the maintenance treatment of opioid dependence probuphine is designed to provide a constant low level dose of buprenorphine for six months in patients who are already stable on low to moderate doses of other forms of buprenorphine as part of a complete treatment program until today buprenorphine for the treatment of opioid dependence was only approved as a pill or a film placed under the tongue or on the inside of a person s cheek until it dissolved while effective a pill or film may be lost forgotten or stolen however as an implant probuphine provides a new treatment option for people in recovery who may value the unique benefits of a six month implant compared to other forms of buprenorphine such as the possibility of improved patient convenience from not needing to take medication on a daily basis an independent fda advisory committee supported the approval of probuphine in a meeting held earlier this year opioid abuse and addiction have taken a devastating toll on american families we must do everything we can to make new innovative treatment options available that can help patients regain control over their lives said fda commissioner robert m califf m d today s approval provides the first ever implantable option to support patients efforts to maintain treatment as part of their overall recovery program expanding the use and availability of medication assisted treatment mat options like buprenorphine is an important component of the fda s opioid action plan and one of three top priorities for the u s department of health and human services opioid initiative aimed at reducing prescription opioid and heroin related overdose death and dependence opioid dependence is the diagnostic term used for the more common concept addiction in the probuphine clinical trials addiction is defined as a cluster of behavioral cognitive and physiological phenomena that may include a strong desire to take the drug difficulties in controlling drug use persisting in drug use despite harmful consequences a higher priority given to drug use than to other activities and obligations as well as the possibility of the development of tolerance or development of physical dependence physical dependence is not the same as addiction newer diagnostic terminology uses the term opioid use disorder which includes both milder forms of problematic opioid use as well as addiction mat is a comprehensive approach that combines approved medications currently methadone buprenorphine or naltrexone with counseling and other behavioral therapies to treat patients with opioid use disorder regular adherence to mat with buprenorphine reduces opioid withdrawal symptoms and the desire to use without causing the cycle of highs and lows associated with opioid misuse or abuse at sufficient doses it also decreases the pleasurable effects of other opioids making continued opioid abuse less attractive according to the substance abuse and mental health services administration patients receiving mat for their opioid use disorder cut their risk of death from all causes in half scientific evidence suggests that maintenance treatment with these medications in the context of behavioral treatment and recovery support are more effective in the treatment of opioid use disorder than short term detoxification programs aimed at abstinence said nora volkow m d director of the national institute on drug abuse at the national institutes of health this product will expand the treatment alternatives available to people suffering from an opioid use disorder probuphine should be used as part of a complete treatment program that includes counseling and psychosocial support probuphine consists of four one inch long rods that are implanted under the skin on the inside of the upper arm and provide treatment for six months administering probuphine requires specific training because it must be surgically inserted and removed only a health care provider who has completed the training and become certified through a restricted program called the probuphine risk evaluation and mitigation strategy rems program should insert and remove the implants if further treatment is needed new implants may be inserted in the opposite arm for one additional course of treatment the fda is requiring postmarketing studies to establish the safety and feasibility of placing the probuphine implants for additional courses of treatment the safety and efficacy of probuphine were demonstrated in a randomized clinical trial of adults who met the clinical criteria for opioid dependence and were considered stable after prior buprenorphine treatment a response to mat was measured by urine screening and self reporting of illicit opioid use during the six month treatment period sixty three percent of probuphine treated patients had no evidence of illicit opioid use throughout the six months of treatment similar to the 64 percent of those who responded to sublingual under the tongue buprenorphine alone the most common side effects from treatment with probuphine include implant site pain itching and redness as well as headache depression constipation nausea vomiting back pain toothache and oropharyngeal pain the safety and efficacy of probuphine have not been established in children or adolescents less than 16 years of age clinical studies of probuphine did not include participants over the age of 65 probuphine has a boxed warning that provides important safety information for health care professionals including a warning that insertion and removal of probuphine are associated with the risk of implant migration protrusion expulsion and nerve damage resulting from the procedure probuphine must be prescribed and dispensed according to the probuphine rems program because of the risks of surgical complications and because of the risks of accidental overdose misuse and abuse if an implant comes out or protrudes from the skin as part of this program probuphine can only be prescribed and dispensed by health care providers who are certified with the rems program and have completed live training among other requirements probuphine implants contain a significant amount of drug that can potentially be expelled or removed resulting in the potential for accidental exposure or intentional misuse and abuse if the implant comes out of the skin patients should be seen during the first week after insertion and a visit schedule of no less than once monthly is recommended for continued counseling and psychosocial support probuphine is marketed by san francisco based titan pharmaceuticals inc and braeburn pharmaceuticals based in princeton new jersey the fda an agency within the u s department of health and human services protects the public health by assuring the safety effectiveness and security of human and veterinary drugs vaccines and other biological products for human use and medical devices the agency also is responsible for the safety and security of our nation s food supply cosmetics dietary supplements products that give off electronic radiation and for regulating tobacco products '),
 ('327', 'field', '36', 'en_us', ''),
 ('327', 'slug', '0', 'en_us', ' fda approves first buprenorphine implant for treatment of opioid dependence '),
 ('327', 'title', '0', 'en_us', ' fda approves first buprenorphine implant for treatment of opioid dependence '),
 ('328', 'field', '25', 'en_us', ' the u s food and drug administration today approved probuphine the first buprenorphine implant for the maintenance treatment of opioid dependence probuphine is designed to provide a constant low level dose of buprenorphine for six months in patients who are already stable on low to moderate doses of other forms of buprenorphine as part of a complete treatment program until today buprenorphine for the treatment of opioid dependence was only approved as a pill or a film placed under the tongue or on the inside of a person s cheek until it dissolved while effective a pill or film may be lost forgotten or stolen however as an implant probuphine provides a new treatment option for people in recovery who may value the unique benefits of a six month implant compared to other forms of buprenorphine such as the possibility of improved patient convenience from not needing to take medication on a daily basis an independent fda advisory committee supported the approval of probuphine in a meeting held earlier this year opioid abuse and addiction have taken a devastating toll on american families we must do everything we can to make new innovative treatment options available that can help patients regain control over their lives said fda commissioner robert m califf m d today s approval provides the first ever implantable option to support patients efforts to maintain treatment as part of their overall recovery program expanding the use and availability of medication assisted treatment mat options like buprenorphine is an important component of the fda s opioid action plan and one of three top priorities for the u s department of health and human services opioid initiative aimed at reducing prescription opioid and heroin related overdose death and dependence opioid dependence is the diagnostic term used for the more common concept addiction in the probuphine clinical trials addiction is defined as a cluster of behavioral cognitive and physiological phenomena that may include a strong desire to take the drug difficulties in controlling drug use persisting in drug use despite harmful consequences a higher priority given to drug use than to other activities and obligations as well as the possibility of the development of tolerance or development of physical dependence physical dependence is not the same as addiction newer diagnostic terminology uses the term opioid use disorder which includes both milder forms of problematic opioid use as well as addiction mat is a comprehensive approach that combines approved medications currently methadone buprenorphine or naltrexone with counseling and other behavioral therapies to treat patients with opioid use disorder regular adherence to mat with buprenorphine reduces opioid withdrawal symptoms and the desire to use without causing the cycle of highs and lows associated with opioid misuse or abuse at sufficient doses it also decreases the pleasurable effects of other opioids making continued opioid abuse less attractive according to the substance abuse and mental health services administration patients receiving mat for their opioid use disorder cut their risk of death from all causes in half scientific evidence suggests that maintenance treatment with these medications in the context of behavioral treatment and recovery support are more effective in the treatment of opioid use disorder than short term detoxification programs aimed at abstinence said nora volkow m d director of the national institute on drug abuse at the national institutes of health this product will expand the treatment alternatives available to people suffering from an opioid use disorder probuphine should be used as part of a complete treatment program that includes counseling and psychosocial support probuphine consists of four one inch long rods that are implanted under the skin on the inside of the upper arm and provide treatment for six months administering probuphine requires specific training because it must be surgically inserted and removed only a health care provider who has completed the training and become certified through a restricted program called the probuphine risk evaluation and mitigation strategy rems program should insert and remove the implants if further treatment is needed new implants may be inserted in the opposite arm for one additional course of treatment the fda is requiring postmarketing studies to establish the safety and feasibility of placing the probuphine implants for additional courses of treatment the safety and efficacy of probuphine were demonstrated in a randomized clinical trial of adults who met the clinical criteria for opioid dependence and were considered stable after prior buprenorphine treatment a response to mat was measured by urine screening and self reporting of illicit opioid use during the six month treatment period sixty three percent of probuphine treated patients had no evidence of illicit opioid use throughout the six months of treatment similar to the 64 percent of those who responded to sublingual under the tongue buprenorphine alone the most common side effects from treatment with probuphine include implant site pain itching and redness as well as headache depression constipation nausea vomiting back pain toothache and oropharyngeal pain the safety and efficacy of probuphine have not been established in children or adolescents less than 16 years of age clinical studies of probuphine did not include participants over the age of 65 probuphine has a boxed warning that provides important safety information for health care professionals including a warning that insertion and removal of probuphine are associated with the risk of implant migration protrusion expulsion and nerve damage resulting from the procedure probuphine must be prescribed and dispensed according to the probuphine rems program because of the risks of surgical complications and because of the risks of accidental overdose misuse and abuse if an implant comes out or protrudes from the skin as part of this program probuphine can only be prescribed and dispensed by health care providers who are certified with the rems program and have completed live training among other requirements probuphine implants contain a significant amount of drug that can potentially be expelled or removed resulting in the potential for accidental exposure or intentional misuse and abuse if the implant comes out of the skin patients should be seen during the first week after insertion and a visit schedule of no less than once monthly is recommended for continued counseling and psychosocial support probuphine is marketed by san francisco based titan pharmaceuticals inc and braeburn pharmaceuticals based in princeton new jersey the fda an agency within the u s department of health and human services protects the public health by assuring the safety effectiveness and security of human and veterinary drugs vaccines and other biological products for human use and medical devices the agency also is responsible for the safety and security of our nation s food supply cosmetics dietary supplements products that give off electronic radiation and for regulating tobacco products '),
 ('328', 'field', '26', 'en_us', ' left '),
 ('328', 'slug', '0', 'en_us', ''),
 ('329', 'field', '131', 'en_us', ' header section news '),
 ('329', 'field', '20', 'en_us', ' 2016 04 20 '),
 ('329', 'field', '22', 'en_us', ' left qualderm partners llc qdp a dermatology services company announced today it has raised $31 8 million in growth equity funding from apple tree partners atp and cressey company cressey the financing will enable qualderm to strengthen its comprehensive physician support services and accelerate expansion through partnerships with leading dermatology practices headquartered in brentwood tn qualderm provides physician support services through partnerships with best in class dermatology practices in the southeastern u s the company provides leadership growth resources and management services to skin surgeons pediatric and general dermatologists and mid level providers to alleviate the burden of the day to day administrative demands of running a business our investment in qdp aligns with atp s commitment to partner with exceptional management teams and build leading healthcare companies said diane daych partner of apple tree partners who joined qualderm s board of directors with extensive experience building and operating multi site provider businesses and deep knowledge in effective practice management strategy atp looks forward to supporting qdp s growth cressey company is excited to have additional resources from atp to support the continued professional success and clinical excellence of our existing partnership with qdp said david schuppan cressey partner and qdp board member under the leadership of bill southwick ceo qualderm partners with physicians to create high functioning teams through shared culture shared services and shared decision making qualderm is dedicated to expanding patient access to high quality care in secondary markets as well as other underserved areas where the nationwide dearth of dermatologists is particularly problematic we are pleased to partner with our investors who bring significant experience building healthcare companies and adding operational value this investment will facilitate qdp s mission to provide management growth and strategic services that enable high quality dermatology care while preserving physician autonomy in true partnership fashion said southwick the company s practice affiliates include the skin surgery center a full service multi site specialty group based in north carolina led by distinguished physicians drs barry leshin and john albertini as the platform practice for qdp we have been truly gratified by the sophistication and expertise of our management team and anticipate that atp s investment in both capital and strategic vision will synergize with cressey in a way that adds tremendous value as we expand our mission to provide high quality dermatologic care to the region and beyond about apple tree partners left apple tree partners atp is a venture capital firm that invests in pharmaceuticals biotech medtech and healthcare services founded in 1999 with a history of well known successes atp closed its current capital pool of $1 5 billion in 2012 and is actively funding healthcare innovation atp starts companies or invests in existing companies with commitments as high as $250 million the firm is headquartered in new york city with satellite offices in princeton nj cambridge ma and los altos ca for more information please visit www appletreepartners com about cressey company left based in chicago il and nashville tn cressey company is a private investment firm focused on building leading healthcare provider service and information technology businesses with a history spanning nearly 35 years the cressey company team is one of the most experienced and successful in the healthcare private equity field more information about cressey company is available at www cresseyco com about qualderm left based in brentwood tn qualderm partners provides strategic leadership and practice management services for dermatologists and skin care professionals the company strives to be the partner of choice for premier patient centric dermatology practices throughout the southeast for more information please visit www qualderm com '),
 ('329', 'field', '36', 'en_us', ''),
 ('329', 'slug', '0', 'en_us', ' dermatology services company qualderm unveils 31 8m growth investment '),
 ('329', 'title', '0', 'en_us', ' dermatology services company qualderm unveils $31 8m growth investment '),
 ('330', 'field', '25', 'en_us', ' qualderm partners llc qdp a dermatology services company announced today it has raised $31 8 million in growth equity funding from apple tree partners atp and cressey company cressey the financing will enable qualderm to strengthen its comprehensive physician support services and accelerate expansion through partnerships with leading dermatology practices headquartered in brentwood tn qualderm provides physician support services through partnerships with best in class dermatology practices in the southeastern u s the company provides leadership growth resources and management services to skin surgeons pediatric and general dermatologists and mid level providers to alleviate the burden of the day to day administrative demands of running a business our investment in qdp aligns with atp s commitment to partner with exceptional management teams and build leading healthcare companies said diane daych partner of apple tree partners who joined qualderm s board of directors with extensive experience building and operating multi site provider businesses and deep knowledge in effective practice management strategy atp looks forward to supporting qdp s growth cressey company is excited to have additional resources from atp to support the continued professional success and clinical excellence of our existing partnership with qdp said david schuppan cressey partner and qdp board member under the leadership of bill southwick ceo qualderm partners with physicians to create high functioning teams through shared culture shared services and shared decision making qualderm is dedicated to expanding patient access to high quality care in secondary markets as well as other underserved areas where the nationwide dearth of dermatologists is particularly problematic we are pleased to partner with our investors who bring significant experience building healthcare companies and adding operational value this investment will facilitate qdp s mission to provide management growth and strategic services that enable high quality dermatology care while preserving physician autonomy in true partnership fashion said southwick the company s practice affiliates include the skin surgery center a full service multi site specialty group based in north carolina led by distinguished physicians drs barry leshin and john albertini as the platform practice for qdp we have been truly gratified by the sophistication and expertise of our management team and anticipate that atp s investment in both capital and strategic vision will synergize with cressey in a way that adds tremendous value as we expand our mission to provide high quality dermatologic care to the region and beyond '),
 ('330', 'field', '26', 'en_us', ' left '),
 ('330', 'slug', '0', 'en_us', ''),
 ('331', 'field', '23', 'en_us', ' about apple tree partners '),
 ('331', 'slug', '0', 'en_us', ''),
 ('332', 'field', '25', 'en_us', ' apple tree partners atp is a venture capital firm that invests in pharmaceuticals biotech medtech and healthcare services founded in 1999 with a history of well known successes atp closed its current capital pool of $1 5 billion in 2012 and is actively funding healthcare innovation atp starts companies or invests in existing companies with commitments as high as $250 million the firm is headquartered in new york city with satellite offices in princeton nj cambridge ma and los altos ca for more information please visit www appletreepartners com '),
 ('332', 'field', '26', 'en_us', ' left '),
 ('332', 'slug', '0', 'en_us', ''),
 ('333', 'field', '23', 'en_us', ' about cressey company '),
 ('333', 'slug', '0', 'en_us', ''),
 ('334', 'field', '25', 'en_us', ' based in chicago il and nashville tn cressey company is a private investment firm focused on building leading healthcare provider service and information technology businesses with a history spanning nearly 35 years the cressey company team is one of the most experienced and successful in the healthcare private equity field more information about cressey company is available at www cresseyco com '),
 ('334', 'field', '26', 'en_us', ' left '),
 ('334', 'slug', '0', 'en_us', ''),
 ('335', 'field', '23', 'en_us', ' about qualderm '),
 ('335', 'slug', '0', 'en_us', ''),
 ('336', 'field', '25', 'en_us', ' based in brentwood tn qualderm partners provides strategic leadership and practice management services for dermatologists and skin care professionals the company strives to be the partner of choice for premier patient centric dermatology practices throughout the southeast for more information please visit www qualderm com '),
 ('336', 'field', '26', 'en_us', ' left '),
 ('336', 'slug', '0', 'en_us', ''),
 ('337', 'name', '0', 'en_us', ' syntimmune '),
 ('337', 'slug', '0', 'en_us', ''),
 ('337', 'title', '0', 'en_us', ' syntimmune '),
 ('338', 'field', '131', 'en_us', ' header section news '),
 ('338', 'field', '20', 'en_us', ' 2016 03 22 '),
 ('338', 'field', '22', 'en_us', ' left syntimmune inc a development stage company advancing novel treatments for igg mediated autoimmune diseases based on leading expertise in fcrn biology today announced that it has made important progress by achieving preclinical proof of concept and completing preclinical safety testing triggering a second $10 million tranche of the company s committed $26 million series a financing the series a financing is co led by apple tree partners and baxalta ventures the corporate venture capital arm of baxalta incorporated with participation by the partners innovation fund and additional investors funds from this tranche of the series a round will be used to complete the anticipated phase 1a clinical trial in healthy volunteers of syntimmune s lead candidate synt001 the company intends to submit an ind application to the food and drug administration for synt001 in mid 2016 to authorize initiation of the phase 1a study later this year synt001 is a biologic that blocks the fcrn igg interaction and is being developed for the treatment of igg mediated autoimmune diseases the closing of the second tranche in the series a affirms the progress syntimmune has achieved and reflects the importance of targeting fcrn as a breakthrough modality for treating igg mediated autoimmune diseases said laurence blumberg m d founder and coo of syntimmune since our founding just over two years ago syntimmune has made rapid progress in advancing its pipeline of candidates and progressing its lead program synt001 through ind enabling studies and toward the clinic synt001 is showing a promising preclinical safety profile and robust activity in unique in vivo preclinical models which we plan to present at appropriate peer reviewed forums the opportunity for synt001 is substantial stated david de graaf ph d venture partner at apple tree partners we are extremely happy with the progress the team has made on the lead molecule which has the potential to address a large number of autoimmune indications fcrn is a central mediator of igg related immunity and part of an important pathway that enables abnormal igg responses in a large number of clinical settings including autoimmune disease commented richard blumberg m d scientific founder of syntimmune and division chief of gastroenterology hepatology and endoscopy at brigham and women s hospital as well as co director of the harvard digestive diseases center and director of the brigham research institute while fcrn is a highly validated target and has attracted substantial industry interest there are no commercially available therapies designed to block igg fcrn interactions which underlie diseases that affect multiple organ systems and for which there are continuing substantial medical needs such as inflammatory bowel disease lupus erythematosus dermatomyositis and others i am thrilled with the progress of syntimmune and look forward to the advancement of the clinical program for synt001 about syntimmune left founded in 2013 syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal fc receptor fcrn fcrn is a well validated target for igg mediated autoimmune diseases and represents a central common pathway that enables abnormal igg responses syntimmune s lead candidate synt001 is a biologic progressing through ind enabling studies that specifically blocks the fcrn igg interaction and is being developed for the treatment of igg mediated autoimmune diseases syntimmune has two additional earlier stage therapeutic programs targeting other unique aspects of fcrn biology the syntimmune team has world class experience in the field of fcrn biology and has successfully pioneered and advanced biologics targeting fcrn including approved therapies currently on the market since its founding the company has received a total of $28 million in funding commitments from leading life sciences investors including apple tree partners baxalta ventures and partners innovation fund for more information on syntimmune please visit the company s website atwww syntimmune com '),
 ('338', 'field', '36', 'en_us', ' syntimmune '),
 ('338', 'slug', '0', 'en_us', ' syntimmune secures second tranche of 26 million series a financing '),
 ('338', 'title', '0', 'en_us', ' syntimmune secures second tranche of $26 million series a financing '),
 ('339', 'field', '25', 'en_us', ' syntimmune inc a development stage company advancing novel treatments for igg mediated autoimmune diseases based on leading expertise in fcrn biology today announced that it has made important progress by achieving preclinical proof of concept and completing preclinical safety testing triggering a second $10 million tranche of the company s committed $26 million series a financing the series a financing is co led by apple tree partners and baxalta ventures the corporate venture capital arm of baxalta incorporated with participation by the partners innovation fund and additional investors funds from this tranche of the series a round will be used to complete the anticipated phase 1a clinical trial in healthy volunteers of syntimmune s lead candidate synt001 the company intends to submit an ind application to the food and drug administration for synt001 in mid 2016 to authorize initiation of the phase 1a study later this year synt001 is a biologic that blocks the fcrn igg interaction and is being developed for the treatment of igg mediated autoimmune diseases the closing of the second tranche in the series a affirms the progress syntimmune has achieved and reflects the importance of targeting fcrn as a breakthrough modality for treating igg mediated autoimmune diseases said laurence blumberg m d founder and coo of syntimmune since our founding just over two years ago syntimmune has made rapid progress in advancing its pipeline of candidates and progressing its lead program synt001 through ind enabling studies and toward the clinic synt001 is showing a promising preclinical safety profile and robust activity in unique in vivo preclinical models which we plan to present at appropriate peer reviewed forums the opportunity for synt001 is substantial stated david de graaf ph d venture partner at apple tree partners we are extremely happy with the progress the team has made on the lead molecule which has the potential to address a large number of autoimmune indications fcrn is a central mediator of igg related immunity and part of an important pathway that enables abnormal igg responses in a large number of clinical settings including autoimmune disease commented richard blumberg m d scientific founder of syntimmune and division chief of gastroenterology hepatology and endoscopy at brigham and women s hospital as well as co director of the harvard digestive diseases center and director of the brigham research institute while fcrn is a highly validated target and has attracted substantial industry interest there are no commercially available therapies designed to block igg fcrn interactions which underlie diseases that affect multiple organ systems and for which there are continuing substantial medical needs such as inflammatory bowel disease lupus erythematosus dermatomyositis and others i am thrilled with the progress of syntimmune and look forward to the advancement of the clinical program for synt001 '),
 ('339', 'field', '26', 'en_us', ' left '),
 ('339', 'slug', '0', 'en_us', ''),
 ('340', 'field', '23', 'en_us', ' about syntimmune '),
 ('340', 'slug', '0', 'en_us', ''),
 ('341', 'field', '25', 'en_us', ' founded in 2013 syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal fc receptor fcrn fcrn is a well validated target for igg mediated autoimmune diseases and represents a central common pathway that enables abnormal igg responses syntimmune s lead candidate synt001 is a biologic progressing through ind enabling studies that specifically blocks the fcrn igg interaction and is being developed for the treatment of igg mediated autoimmune diseases syntimmune has two additional earlier stage therapeutic programs targeting other unique aspects of fcrn biology the syntimmune team has world class experience in the field of fcrn biology and has successfully pioneered and advanced biologics targeting fcrn including approved therapies currently on the market since its founding the company has received a total of $28 million in funding commitments from leading life sciences investors including apple tree partners baxalta ventures and partners innovation fund for more information on syntimmune please visit the company s website atwww syntimmune com '),
 ('341', 'field', '26', 'en_us', ' left '),
 ('341', 'slug', '0', 'en_us', ''),
 ('342', 'field', '131', 'en_us', ' header section news '),
 ('342', 'field', '20', 'en_us', ' 2016 02 22 '),
 ('342', 'field', '22', 'en_us', ' left braeburn pharmaceuticals and camurus announced today that the first patients have been dosed with cam2038 weekly and monthly subcutaneous buprenorphine injections in a pharmacokinetic study of opioid dependent patients with chronic pain the primary objective of this phase 2 study is to assess the steady state pharmacokinetics of buprenorphine after repeated doses in opioid dependent patients with chronic pain including effects of injection into different subcutaneous sites this study will also explore the effect of cam2038 on chronic pain along with evaluation of safety and tolerability this marks the fourth clinical study that has been started in the last five months for cam2038 including two phase 3 trials in opioid dependence the ability to use cam2038 in multiple injection sites would allow physicians the flexibility to personalize treatments said behshad sheldon president and ceo braeburn pharmaceuticals our goal is to provide a suite of best in class long acting treatment options tailored to the individual needs of patients suffering from opioid dependence and chronic pain patients that suffer from chronic pain and are also opioid dependent are a difficult population to treat said the principal investigator dr greg sullivan medical director at parkway medical center in birmingham alabama by using a long acting buprenorphine injectable these patients would no longer be required to take medication multiple times per day buprenorphine also guards against hyperanalgesia and opiate tolerance both of which are problems with conventional opiates cam2038 has the potential to offer effective and safe around the clock pain relief without risks of abuse and diversion the pharmacological properties of buprenorphine together with long acting release from the fluidcrystal formulation could also decrease risks of respiratory depression and overdose mortality associated with current opioid pain treatments said fredrik tiberg president and ceo camurus about braeburn pharmaceuticals left braeburn pharmaceuticals an apple tree partners company is a pill free pharmaceutical company delivering precision medicine in neuroscience in september 2015 the food and drug administration fda accepted for review braeburn s new drug application for its lead candidate probuphine a six month buprenorphine implant for treatment of opioid dependence the agency has set may 27 2016 as the target date for action long acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in these conditions which are often complicated by stigma and present significant public health challenges braeburn s investigational product pipeline consists of long acting implantable and injectable therapies for serious neurological and psychiatric disorders including opioid addiction pain and schizophrenia candidates include probuphine a six month buprenorphine implant for treatment of opioid addiction cam2038 weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain a risperidone six month implant for treatment of schizophrenia and a novel molecule ati 9242 for treatment of schizophrenia more information on braeburn can be found at https braeburnpharmaceuticals com about cam2038 left the investigational cam2038 buprenorphine subcutaneous injection products for treatment of opioid addiction and pain are being developed as once weekly and once monthly formulations each with multiple doses to cover all phases of treatment from initiation through maintenance the cam2038 products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion abuse misuse and accidental exposure the cam2038 products have been evaluated in three phase 1 2 clinical trials which evaluated the safety and tolerability as well as pharmacokinetic and pharmacodynamics properties of the products in a total of 176 individuals opioid dependent patients and healthy volunteers under naltrexone blockage the cam2038 products are also being developed for treatment of chronic pain combining the effective analgesic properties of buprenorphine with the long acting release provided by the fluidcrystal injection depot about camurus left camurus is a swedish research based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions new drug products with best in class potential are conceived based on the proprietary fluidcrystal drug delivery technologies and an extensive r d expertise camurus clinical pipeline includes products for treatment of cancer endocrine diseases pain and addiction developed in house and in collaboration with international pharmaceutical companies the company s share is listed on nasdaq stockholm under the ticker camx for more information visit www camurus com '),
 ('342', 'field', '36', 'en_us', ' braeburn '),
 ('342', 'slug', '0', 'en_us', ' braeburn and camurus announce initiation of a phase 2 study in opioid dependent patients with moderate to severe chronic pain '),
 ('342', 'title', '0', 'en_us', ' braeburn and camurus announce initiation of a phase 2 study in opioid dependent patients with moderate to severe chronic pain '),
 ('343', 'field', '25', 'en_us', ' braeburn pharmaceuticals and camurus announced today that the first patients have been dosed with cam2038 weekly and monthly subcutaneous buprenorphine injections in a pharmacokinetic study of opioid dependent patients with chronic pain the primary objective of this phase 2 study is to assess the steady state pharmacokinetics of buprenorphine after repeated doses in opioid dependent patients with chronic pain including effects of injection into different subcutaneous sites this study will also explore the effect of cam2038 on chronic pain along with evaluation of safety and tolerability this marks the fourth clinical study that has been started in the last five months for cam2038 including two phase 3 trials in opioid dependence the ability to use cam2038 in multiple injection sites would allow physicians the flexibility to personalize treatments said behshad sheldon president and ceo braeburn pharmaceuticals our goal is to provide a suite of best in class long acting treatment options tailored to the individual needs of patients suffering from opioid dependence and chronic pain patients that suffer from chronic pain and are also opioid dependent are a difficult population to treat said the principal investigator dr greg sullivan medical director at parkway medical center in birmingham alabama by using a long acting buprenorphine injectable these patients would no longer be required to take medication multiple times per day buprenorphine also guards against hyperanalgesia and opiate tolerance both of which are problems with conventional opiates cam2038 has the potential to offer effective and safe around the clock pain relief without risks of abuse and diversion the pharmacological properties of buprenorphine together with long acting release from the fluidcrystal formulation could also decrease risks of respiratory depression and overdose mortality associated with current opioid pain treatments said fredrik tiberg president and ceo camurus '),
 ('343', 'field', '26', 'en_us', ' left '),
 ('343', 'slug', '0', 'en_us', ''),
 ('344', 'field', '23', 'en_us', ' about braeburn pharmaceuticals '),
 ('344', 'slug', '0', 'en_us', ''),
 ('345', 'field', '25', 'en_us', ' braeburn pharmaceuticals an apple tree partners company is a pill free pharmaceutical company delivering precision medicine in neuroscience in september 2015 the food and drug administration fda accepted for review braeburn s new drug application for its lead candidate probuphine a six month buprenorphine implant for treatment of opioid dependence the agency has set may 27 2016 as the target date for action long acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in these conditions which are often complicated by stigma and present significant public health challenges braeburn s investigational product pipeline consists of long acting implantable and injectable therapies for serious neurological and psychiatric disorders including opioid addiction pain and schizophrenia candidates include probuphine a six month buprenorphine implant for treatment of opioid addiction cam2038 weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain a risperidone six month implant for treatment of schizophrenia and a novel molecule ati 9242 for treatment of schizophrenia more information on braeburn can be found at https braeburnpharmaceuticals com '),
 ('345', 'field', '26', 'en_us', ' left '),
 ('345', 'slug', '0', 'en_us', ''),
 ('346', 'field', '23', 'en_us', ' about cam2038 '),
 ('346', 'slug', '0', 'en_us', ''),
 ('347', 'field', '25', 'en_us', ' the investigational cam2038 buprenorphine subcutaneous injection products for treatment of opioid addiction and pain are being developed as once weekly and once monthly formulations each with multiple doses to cover all phases of treatment from initiation through maintenance the cam2038 products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion abuse misuse and accidental exposure the cam2038 products have been evaluated in three phase 1 2 clinical trials which evaluated the safety and tolerability as well as pharmacokinetic and pharmacodynamics properties of the products in a total of 176 individuals opioid dependent patients and healthy volunteers under naltrexone blockage the cam2038 products are also being developed for treatment of chronic pain combining the effective analgesic properties of buprenorphine with the long acting release provided by the fluidcrystal injection depot '),
 ('347', 'field', '26', 'en_us', ' left '),
 ('347', 'slug', '0', 'en_us', ''),
 ('348', 'field', '23', 'en_us', ' about camurus '),
 ('348', 'slug', '0', 'en_us', ''),
 ('349', 'field', '25', 'en_us', ' camurus is a swedish research based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions new drug products with best in class potential are conceived based on the proprietary fluidcrystal drug delivery technologies and an extensive r d expertise camurus clinical pipeline includes products for treatment of cancer endocrine diseases pain and addiction developed in house and in collaboration with international pharmaceutical companies the company s share is listed on nasdaq stockholm under the ticker camx for more information visit www camurus com '),
 ('349', 'field', '26', 'en_us', ' left '),
 ('349', 'slug', '0', 'en_us', ''),
 ('350', 'name', '0', 'en_us', ' corvidia '),
 ('350', 'slug', '0', 'en_us', '');
INSERT INTO `craft_searchindex` (`elementId`, `attribute`, `fieldId`, `locale`, `keywords`) VALUES
 ('350', 'title', '0', 'en_us', ' corvidia '),
 ('351', 'field', '131', 'en_us', ' header section news '),
 ('351', 'field', '20', 'en_us', ' 2016 02 17 '),
 ('351', 'field', '22', 'en_us', ' left corvidia therapeutics a biotechnology company focused on the development of precision cardiovascular therapies announced today that it has raised $26 million in a series a financing co led by seed investor sofinnova partners and apple tree partners concurrent with the financing corvidia has licensed a clinical stage compound from astrazeneca to develop and commercialize as its lead therapeutic cor 001 funds from the series a financing will be used to progress cor 001 into phase i ii clinical trials during 2016 as well as to advance the company s preclinical pipeline corvidia was co founded by serial entrepreneur and chief executive officer michael davidson m d dr davidson a recognized expert in the field of cardiology previously served as chief medical officer of sofinnova backed omthera pharmaceuticals and was instrumental in the successful acquisition of that company by astrazeneca in 2013 for $443 million joining dr davidson at corvidia are co founders rahul kakkar m d and matt devalaraja ph d both of whom previously worked in astrazeneca s emerging innovations unit where they developed the science behind genome guided cardiovascular therapies ram aiyar ph d mba an entrepreneur in residence at the national institutes of health and biohealth innovation completes corvidia s founding team commenting on today s news dr davidson stated our ability to complete this significant series a financing with such high quality investors is a testament to the promise of our technology and expertise of our management team positioning corvidia as a leader in the field of precision medicine as applied to cardiovascular diseases with these funds we aim to drive each of our assets through clinical trials and validate our precision medicine approach graziano seghezzi partner at sofinnova partners and corvidia s board member commented given omthera s success we were strongly in favor of teaming up once again with dr davidson the seed funding that sofinnova partners provided allowed for corvidia s inception for the pipeline crafting and for the eventual structuring of the series a we are pleased to continue to support corvidia and this latest financing represents a major step for the future advancement of novel cardiovascular therapeutics seth harrison m d managing partner of apple tree partners noted in our years of start up investing we have not seen a better team than the group that michael davidson has assembled from astrazeneca and the nih we are thrilled to be able to support corvidia with our capital resources and company building experience and look forward to working with sofinnova partners astrazeneca and management to create the first great precision cardiovascular medicine company cor 001 a monoclonal antibody initially developed by medimmune astrazeneca s global biologics research and development arm was previously in a phase 1 study for a different indication it was repurposed by astrazeneca s emerging innovations unit scientific partnering and alliances sp a prior to licensing to corvidia this is another example of the strong entrepreneurial culture within astrazeneca where we push the boundaries of science to explore new therapeutic uses for our compounds we will continue to divest or out license assets where we believe it will help accelerate the development of new medicines said kumar srinivasan vice president sp a innovative medicines unit astrazeneca in conjunction with the financing seth harrison and adrien lemoine executive director corporate development for astrazeneca will join graziano seghezzi and michael davidson on corvidia s board of directors about sofinnova partners left sofinnova partners is a leading european venture capital firm specialized in life sciences based in paris france the firm brings together 12 highly experienced investment professionals from all over europe the us and china the firm focuses on paradigm shifting technologies alongside visionary entrepreneurs sofinnova partners seeks to invest as a founding and lead investor in start ups and corporate spin offs and has backed nearly 500 companies over more than 40 years creating market leaders around the globe today sofinnova partners has over 1 5 billion under management for more information please visit www sofinnova fr about corvidia therapeutics left based in boston ma corvidia is a biotechnology company pioneering the next generation of cardiovascular therapies leveraging functional genomics the company s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations corvidia s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways potentially allowing for the rapid development of therapies targeting those pathways for more information please visit www corvidiatx com '),
 ('351', 'field', '36', 'en_us', ' corvidia '),
 ('351', 'slug', '0', 'en_us', ' corvidia therapeutics raises 26m in a series a financing led by sofinnova partners and apple tree partners '),
 ('351', 'title', '0', 'en_us', ' corvidia therapeutics raises $26m in a series a financing led by sofinnova partners and apple tree partners '),
 ('352', 'field', '25', 'en_us', ' corvidia therapeutics a biotechnology company focused on the development of precision cardiovascular therapies announced today that it has raised $26 million in a series a financing co led by seed investor sofinnova partners and apple tree partners concurrent with the financing corvidia has licensed a clinical stage compound from astrazeneca to develop and commercialize as its lead therapeutic cor 001 funds from the series a financing will be used to progress cor 001 into phase i ii clinical trials during 2016 as well as to advance the company s preclinical pipeline corvidia was co founded by serial entrepreneur and chief executive officer michael davidson m d dr davidson a recognized expert in the field of cardiology previously served as chief medical officer of sofinnova backed omthera pharmaceuticals and was instrumental in the successful acquisition of that company by astrazeneca in 2013 for $443 million joining dr davidson at corvidia are co founders rahul kakkar m d and matt devalaraja ph d both of whom previously worked in astrazeneca s emerging innovations unit where they developed the science behind genome guided cardiovascular therapies ram aiyar ph d mba an entrepreneur in residence at the national institutes of health and biohealth innovation completes corvidia s founding team commenting on today s news dr davidson stated our ability to complete this significant series a financing with such high quality investors is a testament to the promise of our technology and expertise of our management team positioning corvidia as a leader in the field of precision medicine as applied to cardiovascular diseases with these funds we aim to drive each of our assets through clinical trials and validate our precision medicine approach graziano seghezzi partner at sofinnova partners and corvidia s board member commented given omthera s success we were strongly in favor of teaming up once again with dr davidson the seed funding that sofinnova partners provided allowed for corvidia s inception for the pipeline crafting and for the eventual structuring of the series a we are pleased to continue to support corvidia and this latest financing represents a major step for the future advancement of novel cardiovascular therapeutics seth harrison m d managing partner of apple tree partners noted in our years of start up investing we have not seen a better team than the group that michael davidson has assembled from astrazeneca and the nih we are thrilled to be able to support corvidia with our capital resources and company building experience and look forward to working with sofinnova partners astrazeneca and management to create the first great precision cardiovascular medicine company cor 001 a monoclonal antibody initially developed by medimmune astrazeneca s global biologics research and development arm was previously in a phase 1 study for a different indication it was repurposed by astrazeneca s emerging innovations unit scientific partnering and alliances sp a prior to licensing to corvidia this is another example of the strong entrepreneurial culture within astrazeneca where we push the boundaries of science to explore new therapeutic uses for our compounds we will continue to divest or out license assets where we believe it will help accelerate the development of new medicines said kumar srinivasan vice president sp a innovative medicines unit astrazeneca in conjunction with the financing seth harrison and adrien lemoine executive director corporate development for astrazeneca will join graziano seghezzi and michael davidson on corvidia s board of directors '),
 ('352', 'field', '26', 'en_us', ' left '),
 ('352', 'slug', '0', 'en_us', ''),
 ('353', 'field', '23', 'en_us', ' about sofinnova partners '),
 ('353', 'slug', '0', 'en_us', ''),
 ('354', 'field', '25', 'en_us', ' sofinnova partners is a leading european venture capital firm specialized in life sciences based in paris france the firm brings together 12 highly experienced investment professionals from all over europe the us and china the firm focuses on paradigm shifting technologies alongside visionary entrepreneurs sofinnova partners seeks to invest as a founding and lead investor in start ups and corporate spin offs and has backed nearly 500 companies over more than 40 years creating market leaders around the globe today sofinnova partners has over 1 5 billion under management for more information please visit www sofinnova fr '),
 ('354', 'field', '26', 'en_us', ' left '),
 ('354', 'slug', '0', 'en_us', ''),
 ('355', 'field', '23', 'en_us', ' about corvidia therapeutics '),
 ('355', 'slug', '0', 'en_us', ''),
 ('356', 'field', '25', 'en_us', ' based in boston ma corvidia is a biotechnology company pioneering the next generation of cardiovascular therapies leveraging functional genomics the company s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations corvidia s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways potentially allowing for the rapid development of therapies targeting those pathways for more information please visit www corvidiatx com '),
 ('356', 'field', '26', 'en_us', ' left '),
 ('356', 'slug', '0', 'en_us', ''),
 ('357', 'field', '137', 'en_us', ' areas of expertise '),
 ('357', 'slug', '0', 'en_us', ''),
 ('9', 'field', '140', 'en_us', ' charting a trajectory '),
 ('375', 'kind', '0', 'en_us', ' image '),
 ('9', 'field', '141', 'en_us', ' partnerships '),
 ('376', 'name', '0', 'en_us', ' legacy investment '),
 ('376', 'slug', '0', 'en_us', ''),
 ('376', 'title', '0', 'en_us', ' legacy investment '),
 ('20', 'field', '142', 'en_us', ' meet the medical devices team '),
 ('21', 'field', '142', 'en_us', ' meet the healthcare services team '),
 ('22', 'field', '142', 'en_us', ''),
 ('377', 'filename', '0', 'en_us', ' icon_atp_logo white svg '),
 ('377', 'extension', '0', 'en_us', ' svg '),
 ('377', 'kind', '0', 'en_us', ' image '),
 ('377', 'slug', '0', 'en_us', ' icon atp logo white '),
 ('377', 'title', '0', 'en_us', ' icon atp logo white '),
 ('379', 'slug', '0', 'en_us', ''),
 ('379', 'field', '143', 'en_us', ' icon atp logo white '),
 ('380', 'filename', '0', 'en_us', ' coelacanthchemicalcorporation png '),
 ('380', 'extension', '0', 'en_us', ' png '),
 ('380', 'kind', '0', 'en_us', ' image '),
 ('380', 'slug', '0', 'en_us', ''),
 ('380', 'title', '0', 'en_us', ' coelacanth chemical corporation '),
 ('381', 'filename', '0', 'en_us', ' gala_logo png '),
 ('381', 'extension', '0', 'en_us', ' png '),
 ('381', 'kind', '0', 'en_us', ' image '),
 ('381', 'slug', '0', 'en_us', ''),
 ('381', 'title', '0', 'en_us', ' gala logo '),
 ('382', 'filename', '0', 'en_us', ' cyrano png '),
 ('382', 'extension', '0', 'en_us', ' png '),
 ('382', 'kind', '0', 'en_us', ' image '),
 ('382', 'slug', '0', 'en_us', ''),
 ('382', 'title', '0', 'en_us', ' cyrano '),
 ('383', 'name', '0', 'en_us', ' corvidia '),
 ('383', 'slug', '0', 'en_us', ''),
 ('383', 'title', '0', 'en_us', ' corvidia '),
 ('384', 'name', '0', 'en_us', ' braeburn '),
 ('384', 'slug', '0', 'en_us', ''),
 ('384', 'title', '0', 'en_us', ' braeburn '),
 ('385', 'name', '0', 'en_us', ' syntimmune '),
 ('385', 'slug', '0', 'en_us', ''),
 ('385', 'title', '0', 'en_us', ' syntimmune '),
 ('386', 'slug', '0', 'en_us', ''),
 ('386', 'title', '0', 'en_us', ' cleanslate '),
 ('24', 'field', '144', 'en_us', ' see the therapeutics portfolio '),
 ('25', 'field', '144', 'en_us', ' see the medical devices portfolio '),
 ('26', 'field', '144', 'en_us', ' see the healthcare services portfolio '),
 ('23', 'field', '144', 'en_us', ''),
 ('387', 'slug', '0', 'en_us', ''),
 ('387', 'title', '0', 'en_us', ' header section legal 1 '),
 ('79', 'field', '145', 'en_us', ' more press releases on our news page '),
 ('342', 'field', '146', 'en_us', ' braeburn and camurus announce initiation of a phase 2 study in opioid dependent patients with chronic pain '),
 ('338', 'field', '146', 'en_us', ' syntimmune secures second tranche of $26 million series a financing '),
 ('329', 'field', '146', 'en_us', ' dermatology services company qualderm unveils $31 8m growth investment '),
 ('327', 'field', '146', 'en_us', ' fda approves first buprenorphine implant for treatment of opioid dependence '),
 ('319', 'field', '146', 'en_us', ' medtronic to expand heart failure portfolio with acquisition of heartware international '),
 ('314', 'field', '146', 'en_us', ' cure forward announces first trial recruitment collaboration that expands patient access to innovative treatments '),
 ('312', 'field', '146', 'en_us', ' high tech healthcare helps eliminate unnecessary hospital visits '),
 ('52', 'field', '146', 'en_us', ' mass based addiction treatment center expands nationally as opioid epidemic rages on '),
 ('14', 'field', '146', 'en_us', ' cleanslate centers names gregory c marotta president ceo '),
 ('388', 'filename', '0', 'en_us', ' menu background png '),
 ('388', 'extension', '0', 'en_us', ' png '),
 ('388', 'kind', '0', 'en_us', ' image '),
 ('388', 'slug', '0', 'en_us', ''),
 ('388', 'title', '0', 'en_us', ' menu background '),
 ('111', 'field', '147', 'en_us', ' menu background '),
 ('389', 'field', '147', 'en_us', ' menu background '),
 ('389', 'slug', '0', 'en_us', '');



DROP TABLE IF EXISTS `craft_sections`;


--
-- Schema for table `craft_sections`
--
CREATE TABLE `craft_sections` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `structureId` int(11) DEFAULT NULL,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `handle` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `type` enum('single','channel','structure') COLLATE utf8_unicode_ci NOT NULL DEFAULT 'channel',
  `hasUrls` tinyint(1) unsigned NOT NULL DEFAULT '1',
  `template` varchar(500) COLLATE utf8_unicode_ci DEFAULT NULL,
  `enableVersioning` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_sections_name_unq_idx` (`name`),
  UNIQUE KEY `craft_sections_handle_unq_idx` (`handle`),
  KEY `craft_sections_structureId_fk` (`structureId`)
) ENGINE=InnoDB AUTO_INCREMENT=16 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_sections`
--

INSERT INTO `craft_sections` (`id`, `structureId`, `name`, `handle`, `type`, `hasUrls`, `template`, `enableVersioning`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('6', NULL, 'Home', 'home', 'single', '1', 'home', '1', '2016-06-14 15:24:07', '2016-06-14 15:25:35', '9b74b1cf-23fb-4ae9-ba02-356ce309e188'),
 ('7', NULL, 'Contact', 'contact', 'single', '1', 'contact', '1', '2016-06-14 15:24:20', '2016-06-14 15:24:20', '7da0bbe4-25fa-4565-a2f6-f10163895deb'),
 ('8', NULL, 'News', 'news', 'channel', '1', 'news/_entry', '1', '2016-06-14 15:25:04', '2016-06-21 19:39:23', '62b2adee-9fd3-48a7-839e-9290362176cf'),
 ('9', NULL, 'Team', 'team', 'single', '1', 'team', '1', '2016-06-14 15:25:54', '2016-06-15 17:12:51', '23b1479a-6138-40f7-910c-b633dd553880'),
 ('10', NULL, 'Portfolio', 'portfolio', 'single', '1', 'portfolio', '1', '2016-06-14 15:26:11', '2016-06-15 17:13:21', '9870e8af-60a1-49f1-bbbd-a097e3442c9b'),
 ('12', NULL, 'Team Member', 'teamMember', 'channel', '1', 'team/_entry', '1', '2016-06-14 15:27:43', '2016-06-14 15:27:43', 'ce1a2223-42bb-4112-b6a1-e4bf2c117433'),
 ('13', NULL, 'Company', 'company', 'channel', '1', 'portfolio/_entry', '1', '2016-06-14 15:28:12', '2016-06-21 19:39:15', '0bbd84cb-3bdf-4c74-83d7-b78f0640aecd'),
 ('14', NULL, 'Legal', 'legal', 'single', '1', 'legal', '1', '2016-06-27 16:01:14', '2016-06-27 16:01:30', '23ba1687-7f65-4cb7-8364-c322c19d845a'),
 ('15', NULL, 'Press', 'press', 'single', '1', 'press', '1', '2016-07-06 21:31:22', '2016-07-06 21:31:22', 'a7656485-368f-4ead-b3dd-19ff6d0e28c0');



DROP TABLE IF EXISTS `craft_sections_i18n`;


--
-- Schema for table `craft_sections_i18n`
--
CREATE TABLE `craft_sections_i18n` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `sectionId` int(11) NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `enabledByDefault` tinyint(1) unsigned NOT NULL DEFAULT '1',
  `urlFormat` text COLLATE utf8_unicode_ci,
  `nestedUrlFormat` text COLLATE utf8_unicode_ci,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_sections_i18n_sectionId_locale_unq_idx` (`sectionId`,`locale`),
  KEY `craft_sections_i18n_locale_fk` (`locale`)
) ENGINE=InnoDB AUTO_INCREMENT=16 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_sections_i18n`
--

INSERT INTO `craft_sections_i18n` (`id`, `sectionId`, `locale`, `enabledByDefault`, `urlFormat`, `nestedUrlFormat`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('6', '6', 'en_us', '1', '__home__', NULL, '2016-06-14 15:24:07', '2016-06-14 15:25:35', '8a6fe42c-4a25-4695-907b-e297800ca29d'),
 ('7', '7', 'en_us', '1', 'contact', NULL, '2016-06-14 15:24:20', '2016-06-14 15:24:20', 'b6613625-914e-461d-bc2a-9cc03e01300a'),
 ('8', '8', 'en_us', '1', 'news/{slug}', NULL, '2016-06-14 15:25:04', '2016-06-15 18:07:26', '181ba16e-af4f-4bb5-9ce0-7fc97a3ceb93'),
 ('9', '9', 'en_us', '1', 'team', NULL, '2016-06-14 15:25:54', '2016-06-14 15:25:54', '8b0ccb8a-dade-43b3-8184-74abe21d18b0'),
 ('10', '10', 'en_us', '1', 'portfolio', NULL, '2016-06-14 15:26:11', '2016-06-14 15:26:11', 'aacded57-aaf5-4336-8233-015487759a68'),
 ('12', '12', 'en_us', '1', 'team/{slug}', NULL, '2016-06-14 15:27:43', '2016-06-14 15:27:43', 'c2dbcc50-731e-41bb-bf82-7dd32a41aa8d'),
 ('13', '13', 'en_us', '1', 'portfolio/{slug}', NULL, '2016-06-14 15:28:12', '2016-06-21 19:39:15', 'b6a3d9a3-24a4-40a1-b415-bea219ed9f57'),
 ('14', '14', 'en_us', '1', 'legal', NULL, '2016-06-27 16:01:14', '2016-06-27 16:01:14', 'fa5f87e7-d0a3-4762-9485-f8d6a1e79205'),
 ('15', '15', 'en_us', '1', 'press', NULL, '2016-07-06 21:31:22', '2016-07-06 21:31:22', 'aa8273bb-bd1e-46d1-ad74-0b9d0f6acda9');



DROP TABLE IF EXISTS `craft_sessions`;


--
-- Schema for table `craft_sessions`
--
CREATE TABLE `craft_sessions` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `userId` int(11) NOT NULL,
  `token` char(100) COLLATE utf8_unicode_ci NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  KEY `craft_sessions_uid_idx` (`uid`),
  KEY `craft_sessions_token_idx` (`token`),
  KEY `craft_sessions_dateUpdated_idx` (`dateUpdated`),
  KEY `craft_sessions_userId_fk` (`userId`)
) ENGINE=InnoDB AUTO_INCREMENT=60 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_shunnedmessages`;


--
-- Schema for table `craft_shunnedmessages`
--
CREATE TABLE `craft_shunnedmessages` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `userId` int(11) NOT NULL,
  `message` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `expiryDate` datetime DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_shunnedmessages_userId_message_unq_idx` (`userId`,`message`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_structureelements`;


--
-- Schema for table `craft_structureelements`
--
CREATE TABLE `craft_structureelements` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `structureId` int(11) NOT NULL,
  `elementId` int(11) DEFAULT NULL,
  `root` int(11) unsigned DEFAULT NULL,
  `lft` int(11) unsigned NOT NULL,
  `rgt` int(11) unsigned NOT NULL,
  `level` smallint(6) unsigned NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_structureelements_structureId_elementId_unq_idx` (`structureId`,`elementId`),
  KEY `craft_structureelements_root_idx` (`root`),
  KEY `craft_structureelements_lft_idx` (`lft`),
  KEY `craft_structureelements_rgt_idx` (`rgt`),
  KEY `craft_structureelements_level_idx` (`level`),
  KEY `craft_structureelements_elementId_fk` (`elementId`)
) ENGINE=InnoDB AUTO_INCREMENT=4 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_structureelements`
--

INSERT INTO `craft_structureelements` (`id`, `structureId`, `elementId`, `root`, `lft`, `rgt`, `level`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('3', '2', NULL, '3', '1', '2', '0', '2016-07-05 21:14:44', '2016-07-05 21:14:44', 'e61cfe19-2df6-41fd-bb0a-442025f91ce2');



DROP TABLE IF EXISTS `craft_structures`;


--
-- Schema for table `craft_structures`
--
CREATE TABLE `craft_structures` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `maxLevels` smallint(6) unsigned DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=3 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_structures`
--

INSERT INTO `craft_structures` (`id`, `maxLevels`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('2', NULL, '2016-07-05 21:12:50', '2016-07-05 21:12:50', 'cb381fef-7c6b-4ee8-a140-0ea0aa5dae3a');



DROP TABLE IF EXISTS `craft_systemsettings`;


--
-- Schema for table `craft_systemsettings`
--
CREATE TABLE `craft_systemsettings` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `category` varchar(15) COLLATE utf8_unicode_ci NOT NULL,
  `settings` text COLLATE utf8_unicode_ci,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_systemsettings_category_unq_idx` (`category`)
) ENGINE=InnoDB AUTO_INCREMENT=2 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_systemsettings`
--

INSERT INTO `craft_systemsettings` (`id`, `category`, `settings`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', 'email', '{\"protocol\":\"php\",\"emailAddress\":\"jamesl@stinkdigital.com\",\"senderName\":\"Apple Tree Partners\"}', '2016-06-10 14:33:29', '2016-07-11 13:55:51', '27af415b-2299-4549-b2a4-80bab047b2f6');



DROP TABLE IF EXISTS `craft_taggroups`;


--
-- Schema for table `craft_taggroups`
--
CREATE TABLE `craft_taggroups` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `handle` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `fieldLayoutId` int(10) DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_taggroups_name_unq_idx` (`name`),
  UNIQUE KEY `craft_taggroups_handle_unq_idx` (`handle`),
  KEY `craft_taggroups_fieldLayoutId_fk` (`fieldLayoutId`)
) ENGINE=InnoDB AUTO_INCREMENT=7 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_taggroups`
--

INSERT INTO `craft_taggroups` (`id`, `name`, `handle`, `fieldLayoutId`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', 'Default', 'default', '108', '2016-06-10 14:33:29', '2016-06-23 18:57:25', 'cf28b422-c5ff-473d-81cb-6bb141cb56a7'),
 ('4', 'expertise', 'expertise', '141', '2016-06-28 15:57:34', '2016-06-28 15:57:34', '0730471a-131e-4cd3-9a57-22c501c8ba5e'),
 ('5', 'company', 'company', '144', '2016-06-28 16:24:38', '2016-06-28 16:24:59', 'e469975f-b428-4d3d-ac1f-a073015841ff'),
 ('6', 'News Tags', 'newsTags', '271', '2016-07-13 21:51:33', '2016-07-13 21:51:33', '64d3c752-be74-4abc-8b16-90535c63de66');



DROP TABLE IF EXISTS `craft_tags`;


--
-- Schema for table `craft_tags`
--
CREATE TABLE `craft_tags` (
  `id` int(11) NOT NULL,
  `groupId` int(11) NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  KEY `craft_tags_groupId_fk` (`groupId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_tags`
--

INSERT INTO `craft_tags` (`id`, `groupId`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('61', '1', '2016-06-21 15:51:04', '2016-06-21 15:51:04', '2454f5b7-7194-46ad-b1fb-87a8814a2847'),
 ('65', '1', '2016-06-23 18:55:51', '2016-06-23 18:55:51', '1ea5be84-9485-4946-9598-c28f273a5475'),
 ('70', '4', '2016-06-28 15:58:42', '2016-06-28 15:58:42', '19064fbe-0405-4b72-8f3e-5ce6ea46af7d'),
 ('71', '5', '2016-06-28 16:26:33', '2016-06-28 16:26:33', 'b93f7d7f-6d05-401d-bc38-cb3f69817b33'),
 ('72', '5', '2016-06-28 16:26:39', '2016-06-28 16:26:39', 'dacd90ab-de53-465f-9215-22b32e9ab1fd'),
 ('73', '5', '2016-06-28 16:28:32', '2016-06-28 16:28:32', '8ce67770-ae8e-419d-b5ff-3eee6e61c74c'),
 ('96', '4', '2016-07-11 19:00:38', '2016-07-11 19:00:38', 'b2da60ab-e843-490d-9444-0326f4df52aa'),
 ('97', '4', '2016-07-11 19:01:28', '2016-07-11 19:01:28', '4ca32ff5-689a-45ec-9c60-e07582a9621c'),
 ('98', '4', '2016-07-11 19:02:51', '2016-07-11 19:02:51', 'a0452b99-8b2b-4829-9c44-4311b1fed842'),
 ('100', '4', '2016-07-11 19:05:31', '2016-07-11 19:05:31', '841d957d-c205-4482-b69d-10d5fad3a952'),
 ('101', '4', '2016-07-11 19:06:46', '2016-07-11 19:06:46', '57b2cc9b-1106-4c2f-b4b7-650e08d397a0'),
 ('117', '4', '2016-07-11 20:54:41', '2016-07-11 20:54:41', 'c01ce3d1-7f27-4aa5-bcce-7add330209fe'),
 ('118', '4', '2016-07-11 20:54:46', '2016-07-11 20:54:46', 'e913ca48-2f09-4225-a175-a05ddfb27b6c'),
 ('119', '4', '2016-07-11 20:54:56', '2016-07-11 20:54:56', 'eb930bf3-199a-42e9-b700-028a4a2f436e'),
 ('120', '4', '2016-07-11 20:55:03', '2016-07-11 20:55:03', '735a6857-a88d-406e-b0c4-aae34275ed76'),
 ('121', '4', '2016-07-11 20:55:14', '2016-07-11 20:55:14', '54d00f98-6111-42d9-aed9-30f6e6a9de39'),
 ('122', '4', '2016-07-11 20:55:48', '2016-07-11 20:55:48', '70ccb188-11a3-4b45-b2f8-555c066b4f36'),
 ('124', '4', '2016-07-11 20:57:14', '2016-07-11 20:57:14', '0da0cf8c-bf74-4e1c-a0f6-9785ad6d30be'),
 ('129', '1', '2016-07-11 21:04:23', '2016-07-11 21:04:23', '9a43fe24-1519-430b-9fdc-afd15d3ce4f9'),
 ('227', '4', '2016-07-11 22:01:54', '2016-07-11 22:01:54', 'd1dad778-a56a-4c0e-bab7-37dfd2b84bb1'),
 ('228', '5', '2016-07-11 22:03:14', '2016-07-11 22:03:14', 'a8be13bd-421e-4f00-a37b-5b15d822b032'),
 ('232', '1', '2016-07-11 22:17:15', '2016-07-11 22:17:15', 'e049dcb4-8f2d-4856-93d0-76298f29a197'),
 ('233', '1', '2016-07-11 22:18:44', '2016-07-11 22:18:44', 'e26816d2-777e-4692-9a1c-1b101cb2e158'),
 ('238', '1', '2016-07-11 22:21:22', '2016-07-11 22:21:22', '1c47d94e-f483-47ae-84b4-f140d10e02ea'),
 ('255', '1', '2016-07-11 23:15:08', '2016-07-11 23:15:08', '7ab40152-98c5-400a-b200-10bc6ce14805'),
 ('256', '1', '2016-07-11 23:24:25', '2016-07-11 23:24:25', '1506941c-0819-44a8-be29-3de814f13c22'),
 ('257', '1', '2016-07-11 23:37:38', '2016-07-11 23:37:38', '8e0d4508-a7db-4f68-8403-24fea4d3e6b9'),
 ('266', '1', '2016-07-11 23:40:12', '2016-07-11 23:40:12', '56acf74a-4185-4b20-9de5-72e4332fb772'),
 ('280', '4', '2016-07-11 23:58:00', '2016-07-11 23:58:00', '8e5cfa17-3f71-481e-9e6e-5dcd6049472d'),
 ('311', '1', '2016-07-12 04:44:54', '2016-07-12 04:44:54', 'ee3909cd-ebe5-4b2c-bd9e-b5261515073a'),
 ('318', '1', '2016-07-12 04:49:55', '2016-07-12 04:49:55', '11ff6803-889c-4621-90ec-b67b554f76d7'),
 ('325', '1', '2016-07-12 04:50:44', '2016-07-12 04:50:44', '90d703d4-5944-44e3-a015-2ad7858dcfb1'),
 ('326', '1', '2016-07-12 04:52:34', '2016-07-12 04:52:34', '1ef42689-413a-468b-8249-c6909a6f5690'),
 ('337', '1', '2016-07-12 04:56:48', '2016-07-12 04:56:48', 'fbdd4f85-c1a6-4b31-9fe3-74c880f9a7b2'),
 ('350', '1', '2016-07-12 05:01:52', '2016-07-12 05:01:52', '371d6ef9-8a9b-46b3-bdde-ab1e42c92f3a'),
 ('376', '4', '2016-07-13 16:29:09', '2016-07-13 16:29:09', '57d6c531-2b4d-4f90-9465-c19ea06613b6'),
 ('383', '6', '2016-07-13 21:52:58', '2016-07-13 21:52:58', '1b387aa1-fab5-40f0-aa95-193fd0d36b2d'),
 ('384', '6', '2016-07-13 21:53:09', '2016-07-13 21:53:09', 'eb6c060b-8979-4690-9830-ac082f9b6bee'),
 ('385', '6', '2016-07-13 21:53:19', '2016-07-13 21:53:19', 'ccbcbeb8-2063-4b38-bc1d-9fcdb055d287'),
 ('386', '6', '2016-07-13 21:53:45', '2016-07-13 21:53:45', 'ea6611da-20d7-4bcb-a43b-83ea53c3afd0');



DROP TABLE IF EXISTS `craft_tasks`;


--
-- Schema for table `craft_tasks`
--
CREATE TABLE `craft_tasks` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `root` int(11) unsigned DEFAULT NULL,
  `lft` int(11) unsigned NOT NULL,
  `rgt` int(11) unsigned NOT NULL,
  `level` smallint(6) unsigned NOT NULL,
  `currentStep` int(11) unsigned DEFAULT NULL,
  `totalSteps` int(11) unsigned DEFAULT NULL,
  `status` enum('pending','error','running') COLLATE utf8_unicode_ci DEFAULT NULL,
  `type` varchar(150) COLLATE utf8_unicode_ci NOT NULL,
  `description` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `settings` mediumtext COLLATE utf8_unicode_ci,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  KEY `craft_tasks_root_idx` (`root`),
  KEY `craft_tasks_lft_idx` (`lft`),
  KEY `craft_tasks_rgt_idx` (`rgt`),
  KEY `craft_tasks_level_idx` (`level`)
) ENGINE=InnoDB AUTO_INCREMENT=43 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_templatecachecriteria`;


--
-- Schema for table `craft_templatecachecriteria`
--
CREATE TABLE `craft_templatecachecriteria` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `cacheId` int(11) NOT NULL,
  `type` varchar(150) COLLATE utf8_unicode_ci NOT NULL,
  `criteria` text COLLATE utf8_unicode_ci NOT NULL,
  PRIMARY KEY (`id`),
  KEY `craft_templatecachecriteria_cacheId_fk` (`cacheId`),
  KEY `craft_templatecachecriteria_type_idx` (`type`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_templatecacheelements`;


--
-- Schema for table `craft_templatecacheelements`
--
CREATE TABLE `craft_templatecacheelements` (
  `cacheId` int(11) NOT NULL,
  `elementId` int(11) NOT NULL,
  KEY `craft_templatecacheelements_cacheId_fk` (`cacheId`),
  KEY `craft_templatecacheelements_elementId_fk` (`elementId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_templatecaches`;


--
-- Schema for table `craft_templatecaches`
--
CREATE TABLE `craft_templatecaches` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `cacheKey` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `locale` char(12) COLLATE utf8_unicode_ci NOT NULL,
  `path` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `expiryDate` datetime NOT NULL,
  `body` mediumtext COLLATE utf8_unicode_ci NOT NULL,
  PRIMARY KEY (`id`),
  KEY `craft_templatecaches_expiryDate_cacheKey_locale_path_idx` (`expiryDate`,`cacheKey`,`locale`,`path`),
  KEY `craft_templatecaches_locale_fk` (`locale`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_tokens`;


--
-- Schema for table `craft_tokens`
--
CREATE TABLE `craft_tokens` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `token` char(32) COLLATE utf8_unicode_ci NOT NULL,
  `route` text COLLATE utf8_unicode_ci,
  `usageLimit` tinyint(3) unsigned DEFAULT NULL,
  `usageCount` tinyint(3) unsigned DEFAULT NULL,
  `expiryDate` datetime NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_tokens_token_unq_idx` (`token`),
  KEY `craft_tokens_expiryDate_idx` (`expiryDate`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_usergroups`;


--
-- Schema for table `craft_usergroups`
--
CREATE TABLE `craft_usergroups` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `handle` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_usergroups_users`;


--
-- Schema for table `craft_usergroups_users`
--
CREATE TABLE `craft_usergroups_users` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `groupId` int(11) NOT NULL,
  `userId` int(11) NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_usergroups_users_groupId_userId_unq_idx` (`groupId`,`userId`),
  KEY `craft_usergroups_users_userId_fk` (`userId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_userpermissions`;


--
-- Schema for table `craft_userpermissions`
--
CREATE TABLE `craft_userpermissions` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_userpermissions_name_unq_idx` (`name`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_userpermissions_usergroups`;


--
-- Schema for table `craft_userpermissions_usergroups`
--
CREATE TABLE `craft_userpermissions_usergroups` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `permissionId` int(11) NOT NULL,
  `groupId` int(11) NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_userpermissions_usergroups_permissionId_groupId_unq_idx` (`permissionId`,`groupId`),
  KEY `craft_userpermissions_usergroups_groupId_fk` (`groupId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_userpermissions_users`;


--
-- Schema for table `craft_userpermissions_users`
--
CREATE TABLE `craft_userpermissions_users` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `permissionId` int(11) NOT NULL,
  `userId` int(11) NOT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_userpermissions_users_permissionId_userId_unq_idx` (`permissionId`,`userId`),
  KEY `craft_userpermissions_users_userId_fk` (`userId`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

DROP TABLE IF EXISTS `craft_users`;


--
-- Schema for table `craft_users`
--
CREATE TABLE `craft_users` (
  `id` int(11) NOT NULL,
  `username` varchar(100) COLLATE utf8_unicode_ci NOT NULL,
  `photo` varchar(100) COLLATE utf8_unicode_ci DEFAULT NULL,
  `firstName` varchar(100) COLLATE utf8_unicode_ci DEFAULT NULL,
  `lastName` varchar(100) COLLATE utf8_unicode_ci DEFAULT NULL,
  `email` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `password` char(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `preferredLocale` char(12) COLLATE utf8_unicode_ci DEFAULT NULL,
  `weekStartDay` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `admin` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `client` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `locked` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `suspended` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `pending` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `archived` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `lastLoginDate` datetime DEFAULT NULL,
  `lastLoginAttemptIPAddress` varchar(45) COLLATE utf8_unicode_ci DEFAULT NULL,
  `invalidLoginWindowStart` datetime DEFAULT NULL,
  `invalidLoginCount` tinyint(4) unsigned DEFAULT NULL,
  `lastInvalidLoginDate` datetime DEFAULT NULL,
  `lockoutDate` datetime DEFAULT NULL,
  `verificationCode` char(100) COLLATE utf8_unicode_ci DEFAULT NULL,
  `verificationCodeIssuedDate` datetime DEFAULT NULL,
  `unverifiedEmail` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `passwordResetRequired` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `lastPasswordChangeDate` datetime DEFAULT NULL,
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `craft_users_username_unq_idx` (`username`),
  UNIQUE KEY `craft_users_email_unq_idx` (`email`),
  KEY `craft_users_verificationCode_idx` (`verificationCode`),
  KEY `craft_users_uid_idx` (`uid`),
  KEY `craft_users_preferredLocale_fk` (`preferredLocale`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_users`
--

INSERT INTO `craft_users` (`id`, `username`, `photo`, `firstName`, `lastName`, `email`, `password`, `preferredLocale`, `weekStartDay`, `admin`, `client`, `locked`, `suspended`, `pending`, `archived`, `lastLoginDate`, `lastLoginAttemptIPAddress`, `invalidLoginWindowStart`, `invalidLoginCount`, `lastInvalidLoginDate`, `lockoutDate`, `verificationCode`, `verificationCodeIssuedDate`, `unverifiedEmail`, `passwordResetRequired`, `lastPasswordChangeDate`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', 'atp_admin', NULL, '', '', 'jamesl@stinkdigital.com', '$2y$13$nKqJiydFXJE1zDZLd.KTc.qg/OqJQAeDtvRPZ5bQLuOieYX4U4Cae', NULL, '0', '1', '0', '0', '0', '0', '0', '2016-07-15 17:57:45', '127.0.0.1', NULL, NULL, '2016-07-11 21:14:47', NULL, NULL, NULL, NULL, '0', '2016-07-11 20:08:13', '2016-06-10 14:33:29', '2016-07-15 17:57:45', '12724961-5d10-4e8c-bdb4-fba6bfefbad2');



DROP TABLE IF EXISTS `craft_widgets`;


--
-- Schema for table `craft_widgets`
--
CREATE TABLE `craft_widgets` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `userId` int(11) NOT NULL,
  `type` varchar(150) COLLATE utf8_unicode_ci NOT NULL,
  `sortOrder` smallint(6) unsigned DEFAULT NULL,
  `colspan` tinyint(4) unsigned DEFAULT NULL,
  `settings` text COLLATE utf8_unicode_ci,
  `enabled` tinyint(1) unsigned NOT NULL DEFAULT '1',
  `dateCreated` datetime NOT NULL,
  `dateUpdated` datetime NOT NULL,
  `uid` char(36) COLLATE utf8_unicode_ci NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  KEY `craft_widgets_userId_fk` (`userId`)
) ENGINE=InnoDB AUTO_INCREMENT=8 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Data for table `craft_widgets`
--

INSERT INTO `craft_widgets` (`id`, `userId`, `type`, `sortOrder`, `colspan`, `settings`, `enabled`, `dateCreated`, `dateUpdated`, `uid`) VALUES
 ('1', '1', 'RecentEntries', '4', NULL, NULL, '1', '2016-06-10 14:33:32', '2016-06-14 16:25:56', '0a175559-0b15-493e-bdfa-b7f129ba3526'),
 ('2', '1', 'GetHelp', '5', NULL, NULL, '1', '2016-06-10 14:33:32', '2016-06-14 16:25:56', 'ba99761c-dd84-47b3-9775-0ffbf6702486'),
 ('3', '1', 'Updates', '3', NULL, NULL, '0', '2016-06-10 14:33:32', '2016-06-14 16:23:40', 'fe38e164-189e-4045-a68a-7a7f0fd1d729'),
 ('4', '1', 'Feed', '4', NULL, '{\"url\":\"https:\\/\\/craftcms.com\\/news.rss\",\"title\":\"Craft News\"}', '0', '2016-06-10 14:33:32', '2016-06-14 16:23:11', '4b344c09-d42c-4f1d-ba44-137994516e99'),
 ('5', '1', 'QuickPost', '3', '1', '{\"section\":\"13\",\"entryType\":\"\",\"fields\":[\"66\",\"61\",\"62\"]}', '1', '2016-06-14 16:22:54', '2016-06-14 16:25:56', '77e36b49-1e56-4c24-acb9-24a946345cd4'),
 ('6', '1', 'QuickPost', '1', NULL, '{\"section\":\"8\",\"entryType\":\"\",\"fields\":[\"21\",\"20\",\"22\",\"36\"]}', '1', '2016-06-14 16:23:28', '2016-06-14 16:25:56', 'f9de0f45-28e2-4a49-a120-4e4349a96c5d'),
 ('7', '1', 'QuickPost', '2', NULL, '{\"section\":\"12\",\"entryType\":\"\",\"fields\":[\"56\",\"57\"]}', '1', '2016-06-14 16:24:08', '2016-06-14 16:25:56', 'ee4d4e7f-96a9-4c35-b780-6b9ffe538783');


--
-- Constraints for tables
--


--
-- Constraints for table `craft_assetfiles`
--
ALTER TABLE `craft_assetfiles`
	ADD CONSTRAINT `craft_assetfiles_folderId_fk` FOREIGN KEY (`folderId`) REFERENCES `craft_assetfolders` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_assetfiles_id_fk` FOREIGN KEY (`id`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_assetfiles_sourceId_fk` FOREIGN KEY (`sourceId`) REFERENCES `craft_assetsources` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_assetfolders`
--
ALTER TABLE `craft_assetfolders`
	ADD CONSTRAINT `craft_assetfolders_parentId_fk` FOREIGN KEY (`parentId`) REFERENCES `craft_assetfolders` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_assetfolders_sourceId_fk` FOREIGN KEY (`sourceId`) REFERENCES `craft_assetsources` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_assetindexdata`
--
ALTER TABLE `craft_assetindexdata`
	ADD CONSTRAINT `craft_assetindexdata_sourceId_fk` FOREIGN KEY (`sourceId`) REFERENCES `craft_assetsources` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_assetsources`
--
ALTER TABLE `craft_assetsources`
	ADD CONSTRAINT `craft_assetsources_fieldLayoutId_fk` FOREIGN KEY (`fieldLayoutId`) REFERENCES `craft_fieldlayouts` (`id`) ON DELETE SET NULL;

--
-- Constraints for table `craft_categories`
--
ALTER TABLE `craft_categories`
	ADD CONSTRAINT `craft_categories_groupId_fk` FOREIGN KEY (`groupId`) REFERENCES `craft_categorygroups` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_categories_id_fk` FOREIGN KEY (`id`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_categorygroups`
--
ALTER TABLE `craft_categorygroups`
	ADD CONSTRAINT `craft_categorygroups_fieldLayoutId_fk` FOREIGN KEY (`fieldLayoutId`) REFERENCES `craft_fieldlayouts` (`id`) ON DELETE SET NULL,
	ADD CONSTRAINT `craft_categorygroups_structureId_fk` FOREIGN KEY (`structureId`) REFERENCES `craft_structures` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_categorygroups_i18n`
--
ALTER TABLE `craft_categorygroups_i18n`
	ADD CONSTRAINT `craft_categorygroups_i18n_groupId_fk` FOREIGN KEY (`groupId`) REFERENCES `craft_categorygroups` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_categorygroups_i18n_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_content`
--
ALTER TABLE `craft_content`
	ADD CONSTRAINT `craft_content_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_content_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_elements_i18n`
--
ALTER TABLE `craft_elements_i18n`
	ADD CONSTRAINT `craft_elements_i18n_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_elements_i18n_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_emailmessages`
--
ALTER TABLE `craft_emailmessages`
	ADD CONSTRAINT `craft_emailmessages_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_entries`
--
ALTER TABLE `craft_entries`
	ADD CONSTRAINT `craft_entries_authorId_fk` FOREIGN KEY (`authorId`) REFERENCES `craft_users` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_entries_id_fk` FOREIGN KEY (`id`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_entries_sectionId_fk` FOREIGN KEY (`sectionId`) REFERENCES `craft_sections` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_entries_typeId_fk` FOREIGN KEY (`typeId`) REFERENCES `craft_entrytypes` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_entrydrafts`
--
ALTER TABLE `craft_entrydrafts`
	ADD CONSTRAINT `craft_entrydrafts_creatorId_fk` FOREIGN KEY (`creatorId`) REFERENCES `craft_users` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_entrydrafts_entryId_fk` FOREIGN KEY (`entryId`) REFERENCES `craft_entries` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_entrydrafts_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE,
	ADD CONSTRAINT `craft_entrydrafts_sectionId_fk` FOREIGN KEY (`sectionId`) REFERENCES `craft_sections` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_entrytypes`
--
ALTER TABLE `craft_entrytypes`
	ADD CONSTRAINT `craft_entrytypes_fieldLayoutId_fk` FOREIGN KEY (`fieldLayoutId`) REFERENCES `craft_fieldlayouts` (`id`) ON DELETE SET NULL,
	ADD CONSTRAINT `craft_entrytypes_sectionId_fk` FOREIGN KEY (`sectionId`) REFERENCES `craft_sections` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_entryversions`
--
ALTER TABLE `craft_entryversions`
	ADD CONSTRAINT `craft_entryversions_creatorId_fk` FOREIGN KEY (`creatorId`) REFERENCES `craft_users` (`id`) ON DELETE SET NULL,
	ADD CONSTRAINT `craft_entryversions_entryId_fk` FOREIGN KEY (`entryId`) REFERENCES `craft_entries` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_entryversions_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE,
	ADD CONSTRAINT `craft_entryversions_sectionId_fk` FOREIGN KEY (`sectionId`) REFERENCES `craft_sections` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_fieldlayoutfields`
--
ALTER TABLE `craft_fieldlayoutfields`
	ADD CONSTRAINT `craft_fieldlayoutfields_fieldId_fk` FOREIGN KEY (`fieldId`) REFERENCES `craft_fields` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_fieldlayoutfields_layoutId_fk` FOREIGN KEY (`layoutId`) REFERENCES `craft_fieldlayouts` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_fieldlayoutfields_tabId_fk` FOREIGN KEY (`tabId`) REFERENCES `craft_fieldlayouttabs` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_fieldlayouttabs`
--
ALTER TABLE `craft_fieldlayouttabs`
	ADD CONSTRAINT `craft_fieldlayouttabs_layoutId_fk` FOREIGN KEY (`layoutId`) REFERENCES `craft_fieldlayouts` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_fields`
--
ALTER TABLE `craft_fields`
	ADD CONSTRAINT `craft_fields_groupId_fk` FOREIGN KEY (`groupId`) REFERENCES `craft_fieldgroups` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_globalsets`
--
ALTER TABLE `craft_globalsets`
	ADD CONSTRAINT `craft_globalsets_fieldLayoutId_fk` FOREIGN KEY (`fieldLayoutId`) REFERENCES `craft_fieldlayouts` (`id`) ON DELETE SET NULL,
	ADD CONSTRAINT `craft_globalsets_id_fk` FOREIGN KEY (`id`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_matrixblocks`
--
ALTER TABLE `craft_matrixblocks`
	ADD CONSTRAINT `craft_matrixblocks_fieldId_fk` FOREIGN KEY (`fieldId`) REFERENCES `craft_fields` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixblocks_id_fk` FOREIGN KEY (`id`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixblocks_ownerId_fk` FOREIGN KEY (`ownerId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixblocks_ownerLocale_fk` FOREIGN KEY (`ownerLocale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE,
	ADD CONSTRAINT `craft_matrixblocks_typeId_fk` FOREIGN KEY (`typeId`) REFERENCES `craft_matrixblocktypes` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_matrixblocktypes`
--
ALTER TABLE `craft_matrixblocktypes`
	ADD CONSTRAINT `craft_matrixblocktypes_fieldId_fk` FOREIGN KEY (`fieldId`) REFERENCES `craft_fields` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixblocktypes_fieldLayoutId_fk` FOREIGN KEY (`fieldLayoutId`) REFERENCES `craft_fieldlayouts` (`id`) ON DELETE SET NULL;

--
-- Constraints for table `craft_matrixcontent_areasofexpertise`
--
ALTER TABLE `craft_matrixcontent_areasofexpertise`
	ADD CONSTRAINT `craft_matrixcontent_areasofexpertise_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixcontent_areasofexpertise_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_matrixcontent_articlebody`
--
ALTER TABLE `craft_matrixcontent_articlebody`
	ADD CONSTRAINT `craft_matrixcontent_articlebody_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixcontent_articlebody_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_matrixcontent_companycontactmethods`
--
ALTER TABLE `craft_matrixcontent_companycontactmethods`
	ADD CONSTRAINT `craft_matrixcontent_companycontactmethods_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixcontent_companycontactmethods_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_matrixcontent_expertisesection`
--
ALTER TABLE `craft_matrixcontent_expertisesection`
	ADD CONSTRAINT `craft_matrixcontent_expertisesection_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixcontent_expertisesection_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_matrixcontent_footerlink`
--
ALTER TABLE `craft_matrixcontent_footerlink`
	ADD CONSTRAINT `craft_matrixcontent_footerlink_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixcontent_footerlink_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_matrixcontent_legalcopy`
--
ALTER TABLE `craft_matrixcontent_legalcopy`
	ADD CONSTRAINT `craft_matrixcontent_legalcopy_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixcontent_legalcopy_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_matrixcontent_locations`
--
ALTER TABLE `craft_matrixcontent_locations`
	ADD CONSTRAINT `craft_matrixcontent_locations_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixcontent_locations_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_matrixcontent_partnerships`
--
ALTER TABLE `craft_matrixcontent_partnerships`
	ADD CONSTRAINT `craft_matrixcontent_partnerships_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixcontent_partnerships_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_matrixcontent_pressmaterials`
--
ALTER TABLE `craft_matrixcontent_pressmaterials`
	ADD CONSTRAINT `craft_matrixcontent_pressmaterials_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixcontent_pressmaterials_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_matrixcontent_teammembercontactmethods`
--
ALTER TABLE `craft_matrixcontent_teammembercontactmethods`
	ADD CONSTRAINT `craft_matrixcontent_teammembercontactmethods_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixcontent_teammembercontactmethods_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_matrixcontent_teams`
--
ALTER TABLE `craft_matrixcontent_teams`
	ADD CONSTRAINT `craft_matrixcontent_teams_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixcontent_teams_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_matrixcontent_trajectories`
--
ALTER TABLE `craft_matrixcontent_trajectories`
	ADD CONSTRAINT `craft_matrixcontent_trajectories_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_matrixcontent_trajectories_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_migrations`
--
ALTER TABLE `craft_migrations`
	ADD CONSTRAINT `craft_migrations_pluginId_fk` FOREIGN KEY (`pluginId`) REFERENCES `craft_plugins` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_relations`
--
ALTER TABLE `craft_relations`
	ADD CONSTRAINT `craft_relations_fieldId_fk` FOREIGN KEY (`fieldId`) REFERENCES `craft_fields` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_relations_sourceId_fk` FOREIGN KEY (`sourceId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_relations_sourceLocale_fk` FOREIGN KEY (`sourceLocale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE,
	ADD CONSTRAINT `craft_relations_targetId_fk` FOREIGN KEY (`targetId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_routes`
--
ALTER TABLE `craft_routes`
	ADD CONSTRAINT `craft_routes_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_sections`
--
ALTER TABLE `craft_sections`
	ADD CONSTRAINT `craft_sections_structureId_fk` FOREIGN KEY (`structureId`) REFERENCES `craft_structures` (`id`) ON DELETE SET NULL;

--
-- Constraints for table `craft_sections_i18n`
--
ALTER TABLE `craft_sections_i18n`
	ADD CONSTRAINT `craft_sections_i18n_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE,
	ADD CONSTRAINT `craft_sections_i18n_sectionId_fk` FOREIGN KEY (`sectionId`) REFERENCES `craft_sections` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_sessions`
--
ALTER TABLE `craft_sessions`
	ADD CONSTRAINT `craft_sessions_userId_fk` FOREIGN KEY (`userId`) REFERENCES `craft_users` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_shunnedmessages`
--
ALTER TABLE `craft_shunnedmessages`
	ADD CONSTRAINT `craft_shunnedmessages_userId_fk` FOREIGN KEY (`userId`) REFERENCES `craft_users` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_structureelements`
--
ALTER TABLE `craft_structureelements`
	ADD CONSTRAINT `craft_structureelements_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_structureelements_structureId_fk` FOREIGN KEY (`structureId`) REFERENCES `craft_structures` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_taggroups`
--
ALTER TABLE `craft_taggroups`
	ADD CONSTRAINT `craft_taggroups_fieldLayoutId_fk` FOREIGN KEY (`fieldLayoutId`) REFERENCES `craft_fieldlayouts` (`id`) ON DELETE SET NULL;

--
-- Constraints for table `craft_tags`
--
ALTER TABLE `craft_tags`
	ADD CONSTRAINT `craft_tags_groupId_fk` FOREIGN KEY (`groupId`) REFERENCES `craft_taggroups` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_tags_id_fk` FOREIGN KEY (`id`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_templatecachecriteria`
--
ALTER TABLE `craft_templatecachecriteria`
	ADD CONSTRAINT `craft_templatecachecriteria_cacheId_fk` FOREIGN KEY (`cacheId`) REFERENCES `craft_templatecaches` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_templatecacheelements`
--
ALTER TABLE `craft_templatecacheelements`
	ADD CONSTRAINT `craft_templatecacheelements_cacheId_fk` FOREIGN KEY (`cacheId`) REFERENCES `craft_templatecaches` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_templatecacheelements_elementId_fk` FOREIGN KEY (`elementId`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_templatecaches`
--
ALTER TABLE `craft_templatecaches`
	ADD CONSTRAINT `craft_templatecaches_locale_fk` FOREIGN KEY (`locale`) REFERENCES `craft_locales` (`locale`) ON DELETE CASCADE ON UPDATE CASCADE;

--
-- Constraints for table `craft_usergroups_users`
--
ALTER TABLE `craft_usergroups_users`
	ADD CONSTRAINT `craft_usergroups_users_groupId_fk` FOREIGN KEY (`groupId`) REFERENCES `craft_usergroups` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_usergroups_users_userId_fk` FOREIGN KEY (`userId`) REFERENCES `craft_users` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_userpermissions_usergroups`
--
ALTER TABLE `craft_userpermissions_usergroups`
	ADD CONSTRAINT `craft_userpermissions_usergroups_groupId_fk` FOREIGN KEY (`groupId`) REFERENCES `craft_usergroups` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_userpermissions_usergroups_permissionId_fk` FOREIGN KEY (`permissionId`) REFERENCES `craft_userpermissions` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_userpermissions_users`
--
ALTER TABLE `craft_userpermissions_users`
	ADD CONSTRAINT `craft_userpermissions_users_permissionId_fk` FOREIGN KEY (`permissionId`) REFERENCES `craft_userpermissions` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_userpermissions_users_userId_fk` FOREIGN KEY (`userId`) REFERENCES `craft_users` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `craft_users`
--
ALTER TABLE `craft_users`
	ADD CONSTRAINT `craft_users_id_fk` FOREIGN KEY (`id`) REFERENCES `craft_elements` (`id`) ON DELETE CASCADE,
	ADD CONSTRAINT `craft_users_preferredLocale_fk` FOREIGN KEY (`preferredLocale`) REFERENCES `craft_locales` (`locale`) ON DELETE SET NULL ON UPDATE CASCADE;

--
-- Constraints for table `craft_widgets`
--
ALTER TABLE `craft_widgets`
	ADD CONSTRAINT `craft_widgets_userId_fk` FOREIGN KEY (`userId`) REFERENCES `craft_users` (`id`) ON DELETE CASCADE;

SET FOREIGN_KEY_CHECKS = 1;
